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Introduction 
Dear Friends and Colleagues, 
It is a great honor and pleasure for us to invite you cordially to participate in the 9th Congress 
on Trends in Medical Mycology (TIMM-9), which will be held in 11–14 October 2019 at Nice-
Acropolis Convention Center, Nice, France. TIMM-9 is the 9th in the series of TIMM mycological 
international meetings organized jointly by the European Confederation of Medical Mycology 
(ECMM) and the Infectious Diseases Group of the European Organisation for Research and 
Treatment of Cancer (EORTC-IDG). 
TIMM has become an important and essential meeting in the field of fungal infections, a forum 
in which researchers and clinicians from all over the world present the most important advances and 
research findings in clinical mycology. TIMM-9 will cover all aspects of mycology, with special focus 
on evidence-based and personalized approach to medical mycology, as well as diagnostic–
therapeutic integrative efforts in the quest to improve the present knowledge of epidemiology, 
diagnosis, clinical course, and pathophysiological mechanisms of fungal diseases. It would be the 
place to present recent innovations in medical mycology. 
The meeting is designed for medical microbiologists, medical mycologists, hematologists, 
oncologists, transplant physicians, intensivists, immunologists, and all those with interest in medical 
mycology. We expect TIMM-9 to be at least as successful as previous TIMM Congresses, which 
brought together around 1000 international delegates from all over the world. Therefore, we would 
like to invite you to TIMM-9 in Nice to enjoy with us excellent science in a stimulating environment. 
We look forward to greeting you in Nice! 
 
Jean-Pierre Gangneux 
Olivier Lortholary 
Oliver A. Cornely 
Livio Pagano 
 
TIMM-9 Executive Committee 
  
J. Fungi 2019, 5, 95 2 of 464 
 
COMMITTEES 
Executive Committee 
Jean-Pierre Gangneux, ECMM, France 
Olivier Lortholary, EORTC, France 
Livio Pagano, EORTC, Italy 
Oliver A. Cornely, ECMM, Germany 
 
Local Scientific Committee 
Hamdi Akan, EORTC, Turkey 
Valentina Arsić Arsenijević, ECMM, Serbia 
Sharon Chen, ECMM, Australia 
Raoul Herbrecht, EORTC, France 
Martin Hoenigl, ECMM, Austria 
Nikolai Klimko, ECMM, Rusland 
Katrien Lagrou, ECMM, Belgium 
Johan Maertens, EORTC, Belgium 
Jacques F. Meis, ECMM, the Netherlands 
Tony Pagliuca, EORTC, UK 
Zděnek Racil, EORTC, Czech Republic 
Esther Segal, ECMM, Israel 
Don Sheppard, ECMM, Canada 
Paul Verweij, EORTC, the Netherlands 
Thomas Walsh, ECMM, USA 
 
International Scientific Committee 
Jean-Pierre Gangneux, Rennes 
Olivier Lortholary, Paris 
Alexandre Alanio, Paris 
Jean-Philippe Bouchara, Angers 
Marie-Elizabeth Bougnoux, Paris 
Stephane Bretagne, Paris 
Christophe D’Enfert, Paris 
Jean-Paul Latgé, Paris 
Laurence Millon, Besançon  
J. Fungi 2019, 5, 95 3 of 464 
 
CONTENT 
Welcome Address           1 
Introduction to the Scientific Programme       5 
Scientific Programme           6 
Honorary Lectures           16 
Plenary Sessions            17 
Meet the Expert Sessions          29 
Symposia             31 
Poster Presentations           97 
J. Fungi 2019, 5, 95 4 of 464 
 
Introduction to the Scientific Programme 
Plenary Sessions: 
No session will be held in parallel to these sessions.  
Plenary sessions are indicated by the prefix: PS 
Symposia: 
Each day, symposia will convene renowned speakers from several continents, who will cover a wide 
range of recent developments in their fields.  
Symposia are indicated by the prefix: S 
A part of the symposia includes a selected submitted abstract. These abstracts are marked with an 
asterisk (*). 
Meet the Expert Sessions: 
The audience will actively participate in these small sessions.  
Meet the expert sessions are indicated by the prefix: M 
Poster Sessions: 
All poster boards are situated on the exhibition floor of the congress centre. The poster exhibition is 
open to all participants during the entire congress. The numbers on the poster boards correspond 
with the abstract numbers in this abstract supplement.  
All authors of odd poster numbers must be present at their poster on Saturday 12 October, from 11:30 
to 12:30. All authors of even poster numbers must be present at their poster on Sunday 13 October, 
from 11:30 to 12:30. 
All posters are indicated by the prefix: P 
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SCIENTIFIC PROGRAMME 
FRIDAY 11 OCTOBER 2019 
09:00   ECMM Council Meeting 
12:25   Welcome Address 
12:45–13:45  Plenary Session 1—Tropical 
Chairs: Jean-Pierre Gangneux, FECMM, France & Olivier Lortholary, France 
12:45  PS1.1  Histoplasmosis 
Matthieu Nacher, France 
13:15  PS 1.2  Emergomycosis 
Nelesh Govender, FECMM, South Africa 
13:45–15:15  Parallel Symposia 1–4 
Symposium 1 Water Quality (Mis-)Management—An Opportunity for Fungal 
Contamination 
Chairs: João Brandão, Portugal & Esther Segal, FECMM, Israel 
13:45  S01.1  Fungal Contaminants in Drinking Water Regulation? A Tale of Ecology,  
Exposure, Purification, and Clinical Relevance 
Monica Novak Babič, Slovenia 
14:05  S01.2  Hospital Environment: Water Supply and Containment of Aerosolised 
Fungal  
Particles 
How Far Must We Go in Times of Antimicrobial Resistance? 
Raquel Sabino, FECMM, Portugal 
14:25  S01.3  Potential Transmission Pathways of Clinically Relevant Fungi in Indoor  
Swimming Pool Facilities 
Ciska Schets, the Netherlands 
14:45  S01.4*  Study of Fungal Environmental Contamination in Nests of the Penguin  
Enclosure of a Large French Animal Zoo Park 
Guillaume Desoubeaux, France 
14:55   S01.5*  Spectrum of Indoor Fungi Isolated from Indoor Environments in Busia—Kenya 
Olga Mashedi, Kenya 
Symposium 2 Pneumocystis jirovecii, an Airborne Transmissible and Human-Derived 
Ascomycete Showing Strong Pulmonary Tropism 
Chairs: Philippe Hauser, Switzerland & Gilles Nevez, France 
13:45  S02.1  Pneumocystis jirovecii: An Obligate Parasite of Human Lungs with Unique  
Camouflage and Sex Strategies 
Philippe Hauser, Switzerland 
14:10  S02.2  High-Throughput Methodologies in Molecular Epidemiology of Pneumocystis  
Jirovecii Olga Matos, Portugal 
14:35  S02.3  Airborne Acquisition and Transmission of Pneumocystis jirovecii: An Update 
Gilles Nevez, France 
15:00  S02.5*  Does Pneumocystis jirovecii Infection Aggravate the Prognosis of Invasive  
Pulmonary Aspergillosis? Data from the RESSIF Network in France (2012–
2016) 
Florence Robert-Gangneux, France 
Symposium 3 Mucormycosis 
Chairs: Fanny Lanternier, FECMM, France & Arunaloke Chakrabarti, FECMM, 
India 
13:45   S03.1  Hospital-Related Mucormycosis 
Anna Skiada, Greece 
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14:00   S03.3  The New Treatment of Mucormycosis  
Livio Pagano, FECMM, Italy 
14:15   S03.4  Clinical Features Associated to Fungal Species 
Dea Garcia Hermoso, France 
14:30   S03.5  Molecular diagnosis 
Laurence Millon, France 
14:45   S03.6  Management of Mucormycosis in Low- and Middle-Income Countries 
Arunaloke Chakrabarti, FECMM, India 
15:00     Discussion 
Symposium 4 MSG Symposium (Trial Design in Clinical Mycology: Innovative 
Approaches) 
Chairs: Peter Pappas, USA & Sharon Chen, FECMM, Australia 
13:45   S04.1  Candidiasis 
Bart-Jan Kullberg, The Netherlands 
14:05   S04.2  Endemic Mycoses 
George Thompson, USA 
14:25   S04.3  Cryptococcosis 
David Boulware, USA 
14:45   S04.4  Aspergillosis and other molds 
Tom Patterson, USA 
15:05   S04.5*  The Lung Transplant Community Is Interested in a Clinical Trial to Determine  
the Optimal Strategy to Prevent Invasive Mold Disease 
Ricardo La Hoz, USA 
18:30 EDL E. Drouhet Lecture (ECMM) 
Chair: Martin Hoenigl, FECMM, Austria 
How to Convince European institutions that Medical Mycology is a Major 
Science 
Jean-Paul Latgé, France 
SATURDAY 12 OCTOBER 2019 
08:00–08:45  Meet the Expert Sessions 
08:00  M01  Hematology 
Malgorzata Mikulska, FECMM, Italy & Alessandro Busca, Italy 
08:00  M02  Peadiatrics 
Simone Cesaro, Italy & Adillia Warris, FECMM, UK 
08:00  M03  Candida in the ICU 
Matteo Bassetti, Italy & Jean-François Timsit, France 
08:00  M04  Diagnostics/Laboratory 
Alida Talento, Ireland & Michaela Lackner, FECMM, Austria 
08:00  M05  Tropical 
Arunaloke Chakrabarti, FECMM, India & Rita Oladele, FECMM, Nigeria 
09:00–10:00  Plenary Session 2—Highlights on Fungal Biology 
Chairs: Vishukumar Aimanianda, France & Don Sheppard, FECMM, Canada 
08:50   PS 2.1  Candida 
Christophe D'Enfert, France 
09:20  PS 2.2  Aspergillus 
Agostinho Carvalho, FECMM, Portugal 
09:50  PS 2.3*  Lineage-Specific Behavioural Differences in Isolates of Candida auris 
Andrew Borman, UK 
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10:30–11:30 Plenary Session 3—One World One Guideline ECMM MSG-ERC (EFISG) 
ISHAM Guidelines Initiative 
Chairs: Martin Hoenigl, FECMM, Austria & John Perfect, USA 
10:30   PS3.1  Mucormycosis 
Oliver Cornely, FECMM, Germany 
10:45   PS3.2  Endemic 
George Thompson, USA 
11:00   PS3.3  Rare Moulds 
Martin Hoenigl, FECMM, Austria 
11:15   PS3.4  Rare Yeasts 
Sharon Chen, FECMM, Australia 
11:30-12:30  Poster Session 
14:15-15:45  Parallel Symposia 5–9 
Symposium 5 Lung Transplantation 
Chairs: Shahid Husain, FECMM, Canada & Paolo Grossi, Italy 
14:15  S05.1  Pretransplant Assessment 
Blandine Rammaert, France 
14:35   S05.2  Pathophysiology and Epidemiology of Invasive Aspergillosis in Lung  
Transplant Recipients 
Claire Aguilar, France 
14:55   S05.3  Current Guidelines 
Shahid Husain, FECMM, Canada 
15:15   S05.4  Prophylaxis 
John Perfect, USA 
15:35   S05.5*  From the Lung to the Heart: Fatal Dissemination of Azole-Resistant Aspergillus  
Fumigatus in a Lung Transplant Patient 
Rose-Anne Lavergne, France 
Symposium 6 Prophylaxis during Hematology Malignancies 
Chairs: Livio Pagano, FEMCC, Italy & Oliver Cornely, FECMM, Germany 
14:15   S06.1  AML—in the Era of FLT3 Inhibitors 
Russel Lewis, Italy 
14:35   S06.2  ALL—There Is a Role for Prophylaxis 
Daniel Teschner, Germany 
14:55   S06.3  Personalized Medicine/Approach by Genetic Risk Factors 
Pierre-Yves Bochud, Switzerland 
15:15   S06.4  Baseline CT upon Diagnosis of Acute Leukemia 
Stefan Schwartz, Germany 
15:35   S06.5*  Investigating the Impact of Posaconazole Prophylaxis on Systematic Fungal  
Screening Using Galactomannan Antigen, Aspergillus qPCR and Mucorales  
qPCR 
Anne-Pauline Bellanger, France 
Symposium 7 Paediatric Mycology (EPMyN) 
Chairs: Emmanuel Roilides, FECMM, Greece & Roger Brüggemann, FECMM, The 
Netherlands 
14:15  S07.1  Fluconazole and Micafungin Dosing in Neonates 
Roger Brüggemann, The Netherlands 
14:35  S07.2  Antifungal Susceptibility of Pediatric Candidemia 
Zoi-Dorothea Pana, Greece 
14:55  S07.3  Primary Immunodeficiencies Characterized by Fungal Infections 
Fanny Lanternier, FECMM, France 
15:25  S07.5*  Isavuconazole use in pediatric hematoncologic patients: the Italian  
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Association of Pediatric Hematology Oncology (AIEOP) experience 
Nunzia Decembrino, Italy 
Symposium 8 Immunologic Markers for Diagnosis and Treatment Stratification in 
Invasive Mold Infection 
Chairs: Martin Hoenigl, FECMM, Austria & Agostinho Carvalho, FECMM, 
Portugal 
14:15  S08.1  Antimold Immune Response: the Impact of the Host, the Pathogen, and  
Translational Implications 
Agostinho Carvalho, FECMM, Portugal 
14:35  S08.2  Immunologic Markers for Diagnosis of Invasive Aspergillosis and Other  
Invasive Mold Infections 
Carol Garcia-Vidal, Spain 
14:55  S08.3  Immunologic Markers For Treatment Stratification in Invasive Mold Infection 
Philipp Köhler, FECMM, Germany 
15:15  S08.4  Fungal Translocation: From Persistent Inflammation to Non-AIDS Events 
Martin Hoenigl, FECMM, Austria 
15:35  S08.5*  Immunological Characteristics of Broncho Alveolar Lavage in Neutropenic  
Patients with Invasive Aspergillosis 
Claire Aguilar, France 
Symposium 9 Chronic Pulmonary Aspergillosis 
Chairs: David Denning, FECMM, United Kingdom & Aleksandra Barac, FECMM, 
Serbia 
14:15  S09.1  Effect of Patient Immunodeficiencies on the Diagnostic Performance of  
Serological Assays to Detect Aspergillus-Specific Antibodies in Chronic 
Pulmonary Aspergillosis 
Elizabeth Hunter, UK 
14:35  S09.2  Diagnosis of CPA. Where Do We Stand? 
Aleksandra Barac, FECMM, Serbia 
14:55  S09.3 Current Treatment Options for CPA 
David Denning, FECMM, UK 
15:15  S09.4  Future Directions 
David Denning, FECMM, UK 
15:25  S09.5*  Raised Amphotericin B MIC in Aspergillus fumigatus Isolates from Patients  
with Chronic Pulmonary Aspergillosis 
Fiona Lynch, UK 
16:15–17:45  Parallel Symposia 10–14 
Symposium 10 Sensing the Host 
Chairs: Muriel Cornet, France & Mihai Mares, FECMM, Romania 
16:15  S10.1  S10.1 Cell wall of Aspergillus fumigatus in murine lung tissue 
Thierry Fontaine, France 
16:45  S10.2  Hybrid Histidine Kinases: Major Sensing Proteins in Pathogenic Fungi 
Nicolas Papon, France 
17:15  S10.3  Adapting to the Host: How Candida Causes Bloodstream Infection 
Oliver Kurzai, Germany 
Symposium 11 The Antifungal Pipeline 
Chairs: David Denning, FECMM, United Kingdom & Oliver Cornely, FECMM, 
Germany 
16:15  S11.1 Olorofim—A Novel Mould-Active Antifungal (F2G) 
John Rex, FECMM, UK 
16:40  S11.2  Fosmanogepix: A Novel, Broad Spectrum Antifungal Therapy in Clinical  
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Development (Amplyx) 
Michael Hodges, USA 
17:05  S11.3  Ibrexafungerp (formerly SCY-078) (Scynexis) 
David Angulo, USA 
Symposium 12 Environment and Fungal Outbreaks 
Chairs: Jean-Pierre Gangneux, FECMM, France & Tom Chiller, USA 
16:15  S12.1  Frogs 
Matthew Fisher, UK 
16:35  S12.2  Cryptococcus gattii 
Ferry Hagen, FECMM, The Netherlands 
16:55  S12.3  Natural Disasters 
Tom Chiller, US 
17:15  S12.4  Genomic Sequencing 
Marie Desnos, France 
17:35  S12.5*  Outbreak of Fluconazole-Resistant Candida Parapsilosis in a Hospital Ward:  
Arguments for Clonal Transmission and Environmental Persistence 
Arnaud Fekkar, France 
Symposium 13 Fungal Respiratory Infections in Cystic Fibrosis (the ECMM/ISHAM 
Working Group Fri-CF) 
Chairs: Jean-Philippe Bouchara, France & Petr Hamal, Czech Republic 
16:15  S13.1  Rasamsonia Species and Other Emerging Fungi in CF 
Solène Le Gal, France 
16:35  S13.2  Immunodiagnosis of Scedosporium/Lomentospora Infection—Lessons from  
Immunoproteomic Studies 
Andoni Ramirez-Garcia, Spain 
16:55  S13.3  Bacterial/Fungal Interactions in the CF Mucus 
Françoise Botterel, France 
17:15  S13.4*  Morphology, Growth, and Biofilm Formation of the Black Yeast-Like Fungus  
Exophiala dermatitidis is Influenced by Pseudomonas aeruginosa under in 
Vitro Cystic Fibrosis Conditions 
Lisa Kirchhoff, Germany 
17:25  S13.6*  Study of Antigenic Markers for Serological Detection of Scedosporium spp.  
in Cystic Fibrosis Patients 
Leire Martin-Souto, Spain 
17:35    Discussion 
Symposium 14 Teaching Medical Mycology: What, How, to Whom and When 
Chairs: Patricia Muñoz, Spain & Esther Segal, FECMM, Israel 
16:15  S14.1  Mycology Teaching in Medical School—How Much, What to Choose, at 
What Level 
Peter Rath, FECMM, Germany 
16:35  S14.2  Mycology Teaching in Medical School—Is Student Demography Important 
  to What Should Be Taught? 
Ester Segal, FECMM, Israel 
16:55  S14.3  Specific Courses Outside the European Continent—The Indian Example 
Ruth Ashbee, United Kingdom 
17:15  S14.4  Teaching Clinical Laboratory Mycology—How and Who Is the Audience? 
Sevtap Arikan-Akdagli, FECMM, Turkey 
17:35  S14.5  The African Example 
Aude Sturny, France 
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SUNDAY 13 OCTOBER 2019 
08:00–08:45  Meet the Expert Sessions 6–10 
08:00  M06  Hematology—hematopoietic stem cell transplantation 
Nikolai Klimko, FECMM, Russia & Tony Pagliuca, UK 
08:00  M07  Molecular Diagnostics 
Maurizio Sanguinetti, Italy & Dieter Buchheidt, FECMM, Germany 
08:00  M08  Surgery/Transplantation 
Patricia Munoz, Spain & Paolo Grossi, Italy 
08:00  M09  Neonates 
Thomas Walsh, FECMM, USA & Emmanuel Roilides, FECMM, Greece 
08:00  M10  Meet Mr. and Mrs. Fungus 
Cornelia Lass-Flörl, FECMM, Austria & Neil Gow, FECMM, UK 
08:50–09:50  Plenary Session 4—Top 10 papers in Mycology 
Chairs: Maiken Arendrup, Denmark & Malcolm Richardson, FECMM, UK 
08:50  PS4.1  The Clinical and Translational Perspective 
Don Sheppard, FECMM, Canada 
09:20  PS4.2 The Microbiology Perspective 
Katrien Lagrou, FECMM, Belgium 
ECMM Academy and Excellence Centers: A Story of Success 
Chair: Martin Hoenigl, FECMM, Austria 
09:50    ECMM Academy 
Katrien Lagrou, FECMM, Belgium 
09:55    ECMM Excellence Centers 
Cornelia Lass-Flörl, FECMM, Austria 
10:30–11:30 Plenary Session 5—ICU—Candida Infections/Breaking News from 
Hematology and ICU 
Chairs: Johan Maertens, FECMM, Belgium / Maricela Valerio, Spain 
10:30   PS5.1  Abdominal Candidiasis in ICU Patients 
Philipp Köhler, FECMM, Germany 
10:45   PS5.2  Are the New Management Strategies Useful? 
Arnaldo Colombo, FECMM, Brazil 
11:00   PS5.3  CNS Infections 
Anna Candoni, Italy 
11:15   PS5.4  CMV and Aspergillosis in HSCT Patients 
Johan Maertens, FECMM, Belgium 
11:30–12:30  Poster Session 2 
11:30   Video Session 
11:30  V01  Subcutaneous Nodule Caused by Phaeoacremonium fuscum in a Non- 
Immunocompromised Patient 
Sofie Colman, Belgium 
11:40  V02  Trichosporon Diagnosis—The Right Path 
Thayanidhi Premamalini, India 
11:50  V03  Disseminated Rhinosporidiosis with Different Morphological Lesions  
Involving Various Anatomical Sites 
Jagdish Chander, India 
14:15–15:45  Parallel Symposia 15–19 
Symposium 15 Aspergillus in the ICU 
Chairs: Katrien Lagrou, FECMM, Belgium & Alessandro Pasqualotto, FECMM, 
Brazil 
14:15   S15.1  Influenza 
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Joost Wauters, Belgium 
14:35  S15.2  Invasive Aspergillosis in Patients with Underlying Liver Cirrhosis 
Juergen Prattes, Austria 
14:55   S15.3  Renal Failure 
Riina Richardson Rautema, FECMM, UK 
15:15   S15.4*  Fungal Pneumonia in Critically Ill Cirrhotics: Spectrum, Outcomes,  
Comparison of Diagnostic Methods and Biomarkers 
Pratibha Kale, India 
15:25   S15.5*  IPAFLU Survey: Invasive Aspergillosis among Patients with Severe  
Influenza in Intensive Care Units 
Joost Wauters, Belgium 
15:35   S15.6*  Trend of Candidemia with Bloodstream Infection in Intensive Care Units 
from  
2006 to 2017: Results from the Korean National Healthcare-Associated 
Infections Surveillance System 
Young Hwa Choi, Korea 
Symposium 16 Dermatology 
Chairs: Valentina Arsic Arsenijevic, ECMM, Serbia & Sevtap Arıkan Akdagli, 
FECMM, Turkey 
14:15  S16.1  Cutaneous Aspergillosis, Is It So Rare? 
Sevtap Arıkan Akdagli, FECMM, Turkey 
14:35  S16.2  Is Resistance a Problem for Dermatophytosis? 
Pietro Nenoff, Germany 
14:55  S16.3  Phaeohyphomycosis 
Teresa Martin, Spain 
15:15  S16.4  Blastomycosis 
Ilan Schwarz, Canada 
15:35  S16.5*  Galleria mellonella as a Novelty Model to Study Host—Pathogen Interaction  
in Malassezia furfur CBS 1878 
Adriana Marcela Celis Ramírez, Colombia 
Symposium 17 HIV-Associated Cryptococcal Meningitis 
Chairs: John Perfect, USA & Olivier Lortholary, France 
14:15  S17.1 Screening in Low-Resource Areas 
Elvis Temfack, Cameroon 
14:35  S17.2  Current Therapeutic Strategies 
Olivier Lortholary, France 
14:55  S17.3  Towards Having Antifungal Drugs in Low-Resource Areas 
Ida Kolte, UK 
15:15  S17.4  Early versus Delayed Antiretroviral Treatment in HIV-Positive People with  
Cryptococcal Meningitis 
Tihana Bicanic, FECMM, UK 
15:35  S17.5  Current and Future Clinical Trials on HIV-Associated Cryptococcal Meningitis 
Tom Harrison, UK 
Symposium 18 Antifungal Stewardship in the Era of Resistance 
Chairs: Paul Verweij, FECMM, The Netherlands & Souha Kanj, FECMM Lebanon 
14:15  S18.1  Antifungal Stewardship: A Practical Experience in a Tertiary Care Institution 
Maricela Valerio, Spain 
14:35  S18.2 Stewardship and Azole-Resistant Aspergillosis: A Challenge for Farmer or  
Physician? 
Paul Verweij, FECMM, The Netherlands 
14:55  S18.3  Rapid Diagnosis of Fungal Infections: Impact on Stewardship 
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Souha Kanj, FECMM, Lebanon 
15:15  S18.4  Mycology Laboratory Diagnostic Capabilities in Different Areas of the World 
Alessandro Pasqualotto, FECMM, Brazil 
15:35  S18.5*  Optimising Antifungal Stewardship: An Evaluation of Candidaemia Guideline  
Compliance and Clinical Outcome 
Laura Cottom, UK 
Symposium 19  Pneumocystis 
Chairs: Enrique Calderon, Spain & Stephane Bretagne, FECMM, France 
14:15  S19.1  Diagnosis 
Alexandre Alanio, FECMM, France 
14:40  S19.2  Pneumocystosis in HIV and Non-HIV Patients 
Joseph Kovacs, USA 
15:05  S19.4  Pneumocystosis in Neonates 
Enrique Calderon, Spain 
15:30  S19.5*  Evaluation of a Novel Commercial Loop-Mediated Isothermal Amplification  
(LAMP) Assay for Rapid Detection of Pneumocystis jirovecii 
Dirk Schmidt, Germany 
16:15–17:45  Parallel Symposia 20–24 
Symposium 20 Candida auris 
Chairs: Nelesh Govender, FECMM, South Africa & Anuradha Chowdhary, 
FECMM, India 
16:15  S20.1 Schizophrenic Gram-Negative Yeast Conquering the World 
Jacques Meis, FECMM, The Netherlands 
16:35  S20.2  In the US 
Tom Chiller, USA 
16:55  S20.3  Outbreak Control 
Alba Ruiz, Spain 
17:15  S20.4  In Resource-Limited Countries 
Anuradha Chowdhary, FECMM, India 
17:35  S20.5*  Understanding Echinocandin Activity towards Candida auris 
Milena Kordalewska, USA 
Symposium 21 Immunotherapy for Opportunistic Fungal Infections 
Chairs: Carol Garcia-Vidal, Spain & Dimitrios Kontoyiannis, FECMM, USA 
16:15  S21.1  CAR-T Cells, NK Cells 
Dimitrios Kontoyiannis, FECMM, USA 
16:35  S21.2  WBC Transfusions 
Livio Pagano, FECMM, Italy 
16:55  S21.3  Cytokines 
George Chamilos, Greece 
17:15  S21.4*  Novel Chimeric Antigen Receptor T Cells for Invasive Aspergillosis  
Immunotherapy 
Michelle Seif, Germany 
17:25  S21.5*  Comparison Of Circulating Lymphocyte Populations CD4+ and CD8+ T  
Cells, B and NK lymphocytes According to the Favorable or Worsening 
Evolution of Patients with Pneumocystosis 
Eléna Charpentier, France 
17:35  S21.6*  Glucosylceramides from Lomentospora prolificans Induce Cytokines  
Production and Increase the Microbicidal Activity of Macrophages 
Mariana Ingrid Dutra Silva Xisto, Brazil 
Symposium 22 NGS and Mycobiota 
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Chairs: Laurence Delhaes, France & Jean-Pierre Gangneux, FECMM, France 
16:15  S22.1  Bacterial–Fungal Interactions at the Airway Mucosa and Implications for  
Chronic Rhinosinusitis 
Emily Cope, USA 
16:35  S22.2  Respiratory Mycobiome—A Clinical Perspective 
Robert Krause, FECMM, Austria 
16:55  S22.3  Characterization of Indoor Dust Microbiota in Homes of Asthma and Non- 
Asthma Patients 
Jean-Pierre Gangneux, FECMM, France 
17:15  S22.4  Understanding the Role of the Gut Mycobiome in Health and Disease 
Maria Vehreschild, FECMM, Germany 
17:35  S22.5*  An ECMM-ESCMID Survey on Goals and Practices for Mycobiota  
Characterization Using Next-Generation Sequencing in European 
Laboratories 
Jean-Pierre Gangneux, FECMM, France 
Symposium 23 The Funny Life of C. albicans in the Oral Tract 
Chairs: Marie-Elisabeth Bougnoux, France & Anna Maria Tortorano, Italy 
16:15  S23.1  Within-Host Genomic Diversity of Candida albicans in Healthy Carriers 
Marie-Elisabeth Bougnoux, France 
16:35  S23.2  Activation of Oral Immune Responses by C. albicans 
Julian Naglik, UK 
16:55  S23.3  Modulation of the Fungal–Host Interaction by the Intraspecies Diversity of  
C. albicans 
Dominique Sanglard, Switzerland 
17:15  S23.4  Intestinal Th17 Drives Airway Inflammation in ABPA 
Petra Bacher, Germany 
17:35  S23.5*  Persistence of Clonal Azole-Resistant Isolates of Candida albicans from a 
Patient  
with Chronic Mucocutaneous Candidiasis in Colombia 
Andres Ceballos-Garzon, Colombia 
Symposium 24  Fungal Neglected Tropical Diseases 
Chairs: Flavio Queiroz-Telles, Brazil & Leila Lopes Bezerra, Brazil 
16:15  S24.1  Mycetoma 
Wendy van de Sande, FECMM, The Netherlands 
16:35  S24.2  Chromoblastomycosis 
Flavio de Queiroz-Telles, FECMM, Brazil 
16:55  S24.3  Sporotrichosis 
Leila Lopes Bezerra, Brazil 
17:15  S24.4  Novel Diagnostic and Treatment Strategies for the Southeast Asian Fungus  
Talaromyces marneffei 
Thuy Le, USA 
17:25    Discussion 
MONDAY 14 OCTOBER 2019 
08:00–8:45  Meet the Expert Sessions 11–15 
08:00  M11  HIV 
Blandine Denis, France & Nelesh Govender (FECMM), South Africa 
08:00  M12  Environment 
Ester Segal, FECMM, Israel & Raquel Sabino, FECMM, Portugal 
08:00  M13  Diagnostics/Imaging 
Frédéric Lamoth, FECMM, France & Christopher Thornton, UK 
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08:00  M14  Resistance 
Maiken Arendrup, Denmark & Lewis White, FECMM, UK 
08:00  M15  Registries 
Danila Seidel, Germany & Oscar Marchetti, Switzerland 
08:50–10:00  Plenary Session 6—Management of IFD in Pediatrics (EPMyN) 
Chairs: Adilia Warris, FECMM, United Kingdom & Andreas Groll, FECMM, 
Germany 
08:50  PS6.1  Biomarker-Based Diagnostic Work-Up of IFD in Immunocompromised  
Pediatric Patients 
Thomas Lehrnbecher, Germany 
09:20  PS6.2  Pre-Emptive Versus Empiric Antifungal Therapy in Children with Cancer 
Maria Elena Santolaya, Chile 
09:50  PS6.3*  Invasive Mucormycosis in Children with Hematological Malignancies and  
Solid Tumors: Report from the Infection Working Group of the Hellenic 
Society of Pediatric Hematology Oncology (2008–2017). 
Emmanuel Roilides, Greece 
10:30–11:15  Plenary Session 7—Superficial and Dermatology 
Chairs: Arnaldo Colombo, FECMM, Brazil & Yee-Chun Chen, Taiwan,  
Province of China 
10:30  PS7.1  When the Skin Is the Portal of Invasive Infections 
Yee-Chun Chen, Taiwan, Province of China 
11:00  PS7.2  When the Skin Talks for Systemic Infections 
Fanny Lanternier, FECMM, France 
11:15–12:30  Plenary Session 8—New (Antineoplastic) Drugs, New Risks 
Chairs: Livio Pagano, FECMM, Italy & Johan Maertens, FECMM Belgium 
11:30  PS8.1  In Hematology 
Alessandro Busca, Italy 
12:00  PS8.2  In Oncology 
Lubos Drgona, FECMM, Slovakia 
12:30   Closing TIMM-9 
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Honorary Lectures 
 
E. Drouhet lecture 
EDL 
How to convince European institutions that Medical Mycology is a major science 
J.-P. Latgé 
University of crete, Heraklion, Greece 
How to convince Europe that Medical Mycology is a major science 
Biochemistry; Molecular biology; Immunology 
There are many reasons for flying the flag of Medical Mycology in medicine but also in science in Europe. First, 
morbidity and mortality due to fungi is much higher than the one due to tuberculosis and malaria in Europe. 
Second, essential advances in immunology such as TLR or C-type lectins, had their root in the analysis of the host 
response against fungal infections. Fungi continue to be models of choice for deciphering new immunological 
pathways. Cell wall which is a unique feature of these eukaryotic microorganisms, has been instrumental on this 
medical theme but also on the finding of new essential enzymes in glycobiology. Third, Mycobiota is a majority 
underrecognized and understudied component of the microbiota which is more and more recognized as an 
important constituent of human health. Fourth, analysis of fungal biochemical and molecular pathways can help 
understanding human diseases or metabolic dysregulations or stem cell dormancy. Finally, more than other 
microbes, fungi have to be loved for their natural beauty. All these cases will be illustrated with examples taken 
from the study of Aspergillus fumigatus which has been my “baby” for the last 30 years. 
Ranking of importance: Medecine, Lobbying or Science? The three for sure. 
 
Plenary session 1—Tropical 
 
PS1.2 
Emergomycosis 
N. Govender 
National Institute for Communicable Diseases, Johannesburg, South Africa 
Five species of thermally-dimorphic fungi within a new genus Emergomyces cause a disseminated 
mycosis among immunocompromised persons. Distinct from the closely-related Emmonsia and 
Blastomyces genera, Emergomyces strains have only been isolated from human infections and all 
species produce yeast cells (usually <5 µ m diameter and with narrow-based budding) in the 
thermotolerant phase. The type species, Emergomyces pasteurianus was first described from a case in 
1992 and has an apparently cosmopolitan distribution with cases diagnosed in Europe, Africa and 
Asia. The other four species were described to have emerged over the last decade, coinciding with 
increasing use of molecular diagnostic techniques in clinical and research laboratories, and may be 
geographically restricted. Overall, Emergomyces africanus has been implicated in the largest number 
of reported cases of emergomycosis. Restricted to southern Africa and first described by Kenyon et 
al in 2013, E. africanus causes a multi-system disease among persons living with advanced HIV 
disease. Systemic infection is presumed to occur following inhalation of air-borne conidia from a soil 
reservoir, with a subsequent temperature-mediated phase transition to a yeast form and 
dissemination through the reticuloendothelial system among immunocompromised individuals. 
Most cases are diagnosed by conventional culture of blood, tissues and fluids and/or 
histopathological tissue examination, both of which require technical expertise. Limited pulmonary 
disease is probably under-diagnosed in resource-limited settings; this has only been described to 
occur in the single case of Emergomyces europaeus infection. The full spectrum of clinical infection and 
prevalence in different populations could potentially be determined by better use of non-culture-
based methods, including antigen and PCR assays, in clinical settings and for epidemiological 
surveillance. For instance, E. africanus is known to cross-react with a commercially-available 
Histoplasma galactomannan antigen assay and Emergomyces canadensis with a commercial DNA probe 
for Blastomyces dermatitidis. Although the attributable mortality has not been defined, the crude 
mortality in a South African case series was approximately 50%. Screening for emergomycosis among 
high-risk patients in endemic areas could detect active disease earlier and thus reduce mortality 
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associated with late presentation. Treatment recommendations for emergomycosis are the same as 
for patients with disseminated histoplasmosis and are based only on observational data. 
 
Plenary session 2—Highlights on fungal biology 
 
PS2.1 
Candida albicans genome diversity: mechanisms and consequences 
C. D’Enfert 
Fungal Biology and Pathogenicity, Institut Pasteur, INRA, Paris, France 
The fungal pathogen Candida albicans shows significant diversity at the genetic and phenotypic levels. 
Here, I will review our current knowledge of the C. albicans diploid genome and its variability, the 
genetic structure of the C. albicans population and the mechanisms that are involved in C. albicans 
genome dynamics, with a focus on the parasexual cycle and loss-of-heterozygosity events. I will 
further explore the impact of genetic diversity and genome dynamics on C. albicans phenotypic 
diversity. Finally, I will discuss how our current knowledge of C. albicans genetic diversity could be 
leveraged in the future in order to get insights in the mechanisms underlying important biological 
attributes that are subject to variations across C. albicans isolates. 
 
PS2.2 
Metabolic regulation of innate immunity to Aspergillus fumigatus 
S. Gonçalves, C. Cunha, A. Carvalho 
Life and Health Sciences Research Institute (icvs), University of Minho, Braga, Portugal 
The reprogramming of cellular metabolism was recently recognized as a fundamental mechanism 
through which innate immune cells meet the energetic and anabolic needs during host defense 
against invading pathogens. Sensing of microbial ligands by macrophages drives the upregulation of 
glycolysis, which delivers a rapid source of energy to support antimicrobial functions and the 
production of cytokines and other inflammatory mediators. The stimulation of immune cells with 
structural components of the fungal cell wall, such as β-1,3-glucan, has been demonstrated to 
promote the metabolic and functional reprogramming of immune cells during infection with the 
yeast Candida albicans. However, how the immune response to other fungi, such as Aspergillus 
fumigatus, is also regulated at the metabolic level and whether other cell wall constituents also 
participate in these signaling events remains unknow. Fungal melanin is a major virulence factor, 
endowing A. fumigatus with the ability to survive killing by phagocytes. By resorting to in vitro and 
in vivo models of infection and patients suffering from invasive pulmonary aspergillosis (IPA), and 
using different pharmacological and genetic tools to manipulate both the host and the pathogen, we 
reveal a novel mechanism whereby fungal melanin is perceived by the host to regulate adequate 
immunometabolic responses and susceptibility to infection. Specifically, we demonstrate that the 
host counters the immune inhibitory mechanisms deployed by fungal melanin, by “sensing” its 
removal during intracellular swelling inside the phagosome, and using these signals to rewire 
cellular metabolism towards enhanced glycolysis and promote antifungal immune responses. The 
contribution of glucose homeostasis to human antifungal immunity is further supported by genetic 
variation in glycolytic regulators that act as cytokine quantitative trait loci and predispose patients 
at-risk to IPA. Given the current limitations in diagnosis and therapy of fungal diseases as well as 
concerns over the emergence of antifungal resistance, these results may contribute towards the design 
of innovative therapeutic approaches or metabolic adjuncts to reorient host cells towards immune 
protection against IPA. 
 
PS2.3 
Lineage-specific behavioural differences in isolates of Candida auris 
A. Borman1, A. Szekely1, L. Majoros2, S. Lockhart3, G.S. De Hoog4, R. Ben-Ami5, E. Johnson1 
1Public Health England UK National Mycology Reference Laboratory, Bristol, United Kingdom, 
2Department Of Medical Microbiology, University of Debrecen, Debrecen, Hungary, 3Centres For 
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Disease Control and Prevention, Atlanta, United States of America, 4Westerdijk Institute, Utrecht, 
Netherlands, 5Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel 
Objectives: Candida auris is a serious nosocomial health risk, with widespread outbreaks in hospitals 
worldwide. Sequence analyses of outbreak isolates revealed that C. auris has simultaneously emerged 
as multiple distinct, geographically restricted clonal lineages. We previously reported multiple 
independent introductions of C. auris isolates from at least three of these lineages (S. Asia, S. Africa 
and Japan/Korea) into hospitals across the UK, and that isolates circulating in the UK displayed two 
different cell phenotypes which correlated with differences in virulence in Galleria mellonella. The 
present study aimed to more fully characterise clade-specific differences in the behaviour of Candida 
auris isolates. Methods: Multiple independent Candida auris isolates corresponding to 4 of the known 
geographically-restricted clonal lineages (S. Asia, S. Africa, S. America/Israeli and Japanese/Korean) 
were subjected to extensive phenotypic characterisation (cellular morphology, actidione tolerance, 
virulence in insect [Galleria mellonella] and mammalian [mouse] infection models, antifungal 
susceptibility profiles, antifungal drug-mediated morphological changes) using well-established 
methodologies. Results: Significant clade-dependent differences in C. auris isolate behaviour were 
noted with respect to all of the biological features examined, including cellular morphology, 
resistance to actidione, virulence, antifungal susceptibility and morphological responses to antifungal 
drug exposure. Several of these differences may be correlated with previously described differences 
in cellular aggregation capacity, ERG11 resistance mutations and gene copy numbers, biofilm 
formation and efflux pump activity. Conclusion: The present data demonstrate that “one size does 
not fit all for Candida auris” and that the behaviour of individual isolates is at least in part dependent 
on the clonal lineages from which they originate. Further studies will aim to elucidate whether such 
differences have clinical significance, and to attempt to establish why isolates of three of the principal 
clonal lineages (S. Asian, S. African, S. American/Israeli) have been reported from large scale 
nosocomial outbreaks but none to date have been attributed to isolates from the Japanese/Korean 
clade. 
 
Plenary session 3—One World One Guideline ECMM MSG-ERC (EFISG) 
ISHAM Guidelines initiative 
 
PS3.1 
Global guideline for the diagnosis and management of mucormycosis: An initiative of the 
European Confederation of Medical Mycology in cooperation with the Mycoses Study Group 
Education and Research Consortium 
O.A. Cornely1,2,3,4, A. Alastruey-Izquierdo5, D. Arenz1,3, S.C.-A. Chen6, E. Dannaoui7, B. Hochhegger8,9, 
M. Hoenigl10,11, H.E. Jensen12, K. Lagrou13, R. Lewis14, S. Mellinghoff1,3, M. Mer15, Z. Pana16, D. Seidel1,3, 
D.C. Sheppard17, R. Whaba18, A. Chakrabarti19, M. Akova20, A. Alanio21, A. Al-Hatmi22, S. Arikan-
Akdagli23, H. Badali24, R. Ben-Ami25, A. Bonifaz26, S. Bretagne21, E. Castagnola27, M. Chayakulkeeree28, 
A. Colombo29, D.E. Corzo-León30, L. Drgona31, A.H. Groll32, J. Guinea33, C.-P. Heussel34, A.S. Ibrahim35, 
S. Kanj36, N. Klimko37, M. Lackner38, F. Lamoth39, F. Lanternier40, C. Lass-Flörl38, D.-G. Lee41, T. 
Lehrnbecher42, B.E. Lmimouni43, M. Mares44, G. Maschmeyer45, J. Meis46, J. Meletiadis47, O. 
Morrissey48, M. Nucci49, R. Oladele50, L. Pagano51, A. Pasqualotto52, A. Patel53, Z. Racil54, M.D. 
Richardson55, E. Roilides16, M. Ruhnke56, S. Seyedmousavi24,57,58, N. Sidharthan59, N. Singh60, J. Sinko61, 
A. Skiada62, M. Slavin63,64, R. Soman65, B. Spellberg66, W. Steinbach67, B.H. Tan68, A.J. Ullmann69, J.-J. 
Vehreschild1,2, M.J.G.T. Vehreschild1,2,70, T. Walsh71, P.L. White72, N. Wiederhold73, T. Zaoutis74 
1Department I Of Internal Medicine, University Hospital of Cologne, Cologne, Germany, 2German 
Centre for Infection Research (DZIF) partner site Bonn-Cologne, Cologne, Germany, 3Cecad Cluster 
Of Excellence, University of Cologne, Cologne, Germany, 4Clinical Trials Center Cologne, University 
Hospital of Cologne, Cologne, Germany, 5Mycology Reference Laboratory, National Centre For 
Microbiology, Instituto de Salud Carlos III, Madrid, Spain, 6Centre For Infectious Diseases And 
Microbiology Laboratory Services, New South Wales Health Pathology, And The Department Of 
Infectious Diseases, Westmead Hospital, School of Medicine, University of Sydney, Sydney, 
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Australia, 7Unité De Parasitologie-mycologie, Service De Microbiologie, Université Paris-Descartes, 
Faculté de Médecine, APHP, Hôpital Européen Georges Pompidou, Paris, France, 8Radiology, 
Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, 
Brazil, 9Radiology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto 
Alegre, Brazil, 10Section Of Infectious Diseases And Tropical Medicine And Division Of 
Pulmonology, Medical University of Graz, Graz, Austria, 11Division Of Infectious Diseases, 
Department Of Medicine, University of California San Diego, San Diego, United States of America, 
12Faculty Of Health And Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 
13Department Of Microbiology, Immunology And Transplantation, Clinical Department Of 
Laboratory Medicine And National Reference Center For Mycosis, KU Leuven, University Hospitals 
Leuven, Leuven, Belgium, 14Infectious Diseases Clinic, Sant’Orsola-Malpighi Hospital, Department 
of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, 15Divisions Of Critical Care 
And Pulmonology, Department Of Medicine, Charlotte Maxeke Johannesburg Academic Hospital, 
Johannesburg, South Africa, 16Infectious Diseases Unit, 3rd Department Of Paediatrics, Faculty Of 
Medicine, Aristotle University School of Health Sciences, Hippokration General Hospital, 
Thessaloniki, Greece, 17Division Of Infectious Diseases, Department Of Medicine, Microbiology And 
Immunology, McGill University, Montreal, Canada, 18Department Of General, Visceral And Cancer 
Surgery, University Hospital of Cologne, Cologne, Germany, 19Department Of Medical Microbiology, 
Postgraduate Institute of Medical Education & Research, Chandigarh, India, 20Department Of 
Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey, 21Institut Pasteur, 
National Reference Center For Invasive Mycoses And Antifungals, Department Of Mycology, Cnrs 
Umr2000, Parasitology-mycology Laboratory, Fernand Widal Hospitals, Assistance Publique-
Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France, 22Directorate General Of Health 
Services, Ministry of Health, Ibri, Oman, 23Department Of Medical Microbiology, Hacettepe 
University School of Medicine, Ankara, Turkey, 24Department Of Medical Mycology/invasive Fungi 
Research Center (ifrc), School Of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, 
25Infectious Diseases Unit, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 
Tel Aviv, Israel, 26Dermatology Service & Mycology Department, Hospital General de México “Dr. 
Eduardo Liceaga”, Mexico City, Mexico, 27Infectious Diseases Unit, Istituto Giannina Gaslini 
Children's Hospital, Genova, Italy, 28Department Of Medicine, Faculty Of Medicine, Siriraj Hospital, 
Mahidol University, Bangkok, Thailand, 29Special Mycology Laboratory, Division Of Infectious 
Diseases, Department Of Medicine, Universidade Federal de São Paulo (UNIFESP), Sao Paulo, Brazil, 
30Department Of Epidemiology And Infectious Diseases, Hospital General Dr. Manuel Gea González, 
Mexico City, Mexico, 31Oncohematology Clinic, Faculty Of Medicine, Comenius University and 
National Cancer Institute, Bratislava, Slovak Republic, 32Infectious Disease Research Program, 
Department Of Paediatric Hematology/oncology And Center For Bone Marrow Transplantation, 
University Children's Hospital Münster, Münster, Germany, 33Clinical Microbiology And Infectious 
Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 34Diagnostic And 
Interventional Radiology, Thoracic Clinic, University Hospital Heidelberg, Heidelberg, Germany, 
35Division Of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor-University of 
California, Torrance, United States of America, 36Department Of Internal Medicine, Division Of 
Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon, 37Department Of 
Clinical Mycology, Allergology And Immunology, North Western State Medical University, St. 
Petersburg, Russian Federation, 38Division Of Hygiene And Medical Microbiology, Department Of 
Hygiene, Microbiology And Public Health, Medical University Innsbruck, Innsbruck, Austria, 
39Infectious Diseases Service, Department Of Medicine And Institute Of Microbiology, Lausanne 
University Hospital, Lausanne, Switzerland, 40Institut Pasteur, National Reference Center for 
Invasive Mycoses and Antifungals, Department of Mycology, CNRS UMR2000, Paris Descartes 
University, Necker-Enfants Malades University Hospital, Department of Infectious Diseases and 
Tropical Medicine, Centre, Paris, France, 41Division Of Infectious Diseases, Department Of Internal 
Medicine, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 
Seoul, Korea, Democratic People's Republic of, 42Division Of Paediatric Haematology And Oncology, 
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Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany, 
43School Of Medicine And Pharmacy, University Mohammed the fifth, Rabat, Morocco, 44Laboratory 
Of Antimicrobial Chemotherapy, Ion Ionescu de la Brad University, Iasi, Romania, 45Department Of 
Hematology, Oncology And Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany, 
46Department Of Medical Microbiology And Infectious Diseases, Centre Of Expertise In Mycology, 
Radboudumc/Canisius Wilhelmina Hospital, Nijmegen, Netherlands, 47Clinical Microbiology 
Laboratory, Attikon University Hospital, National and Kapodistrian University of Athens, 
Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Athens, 
Greece, 48Department Of Infectious Diseases, Alfred Health & Monash University, Melbourne, 
Australia, 49Department Of Internal Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 
Brazil, 50Department of Medical Microbiology & Parasitology, College of Medicine, University of 
Lagos, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United 
Kingdom, 51Department Of Hematology, Fondazione Policlinico Universitario A. Gemelli –irccs–, 
Universita Cattolica del Sacro Cuore, Rome, Italy, 52Federal University of Health Sciences of Porto 
Alegre, Hospital Dom Vicente Scherer, Porto Alegre, Brazil, 53Infectious Diseases Clinic, Vedanta 
Institute of Medical Sciences, Ahmeddabad, India, 54Department Of Internal Medicine, Hematology 
And Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic, 55UK NHS 
Mycology Reference Centre, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom, 56Department Haematology / Oncology, Paracelsus Klinik, Osnabrück, Germany, 57Center 
of Expertise in Microbiology, Infection Biology and Antimicrobial Pharmacology, Tehran, Iran, 
58Molecular Microbiology Section, Laboratory Of Clinical Immunology And Microbiology, National 
Institute Of Allergy And Infectious Diseases, National Institutes of Health, Bethesda, United States 
of America, 59Department Of Hemato Oncology, Amrita Institute Of Medical Sciences, Amrita Viswa 
Vidyapeetham University, Kochi, India, 60Division of Infecatious Diseases, University of Pittsburgh 
Medical Center and VA Pittsburgh Helthcare System, Infectious Diseases Section, University of 
Pittsburgh, Pittsburgh, United States of America, 61Infectious Diseases Unit, Szent Istvan and Szent 
Laszlo Hospital, Budapest, Hungary, 62Department Of Infectious Diseases, Laiko General Hospital, 
National and Kapodistrian University of Athens, Athens, Greece, 63University of Melbourne, 
Melbourne, Australia, 64The National Centre for Infections in Cancer, Peter MacCallum Cancer 
Centre, Melbourne, Australia, 65Dept. Of Medicine, P. D. Hinduja Hospital & Medical Research 
Centre, Mumbai, India, 66Los Angeles County + University of Southern California (LAC+USC) 
Medical Center, Los Angeles, United States of America, 67Division Of Pediatric Infectious Diseases, 
Department Of Pediatrics, Duke University Medical Center, Durham, United States of America, 
68Department Of Infectious Diseases, Singapore General Hospital, Singapore, Singapore, 
69Department For Internal Medicine Ii, University Hospital Würzburg, Würzburg, Germany, 
70Department Of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, Frankfurt, 
Germany, 71Departments Of Medicine, Pediatrics, Microbiology & Immunology, Weill Cornell 
Medicine, and New York Presbyterian Hospital, New York, United States of America, 72Public Health 
Wales Microbiology Cardiff, UHW, Cardiff, United Kingdom, 73Fungus Testing Laboratory, The 
University of Texas Health Science Center at San Antonio, San Antonio, United States of America, 
74Division Of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, United 
States of America 
Abstract: Background Mucormycosis is a difficult to diagnose rare disease with high morbidity and 
mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and 
medical intervention is lifesaving. Guidance on the complex multidisciplinary management has 
potential to improve prognosis, but approaches differ between health care settings. Methods from 
January 2018, authors from 33 countries in all United Nations regions analysed the published 
evidence on mucormycosis management and provided consensus recommendations addressing 
differences between the regions of the world as part of the “One World One Guideline” initiative of 
the European Confederation of Medical Mycology (ECMM). The author group based in 17 time 
zones, relied on electronic media including video tutorial on methodology, and central document 
repository with several daily updates. Results Signs and symptoms of mucormycosis depend on 
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organ patterns and underlying conditions. Diagnostic management does not differ greatly between 
world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to 
document extent of disease and is followed by strongly recommended surgical intervention. First-
line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous 
isavuconazole and intravenous or delayed release tablet posaconazole are recommended with 
moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B 
deoxycholate is recommended against, because of substantial toxicity, but may be the only option in 
resource limited settings. Conclusion Management of mucormycosis depends on recognising disease 
patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in 
low and middle income settings. Areas of uncertainty were identified and future research directions 
specified. 
 
PS3.3 
Rare moulds: Clinical Practice Guideline of the ECMM and the MSG-ERC 
M. Hoenigl1,2 
1Division of Infectious Diseases, University of California, San Diego, United States of America, 
2Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, Medical 
University of Graz, Graz, Austria 
Abstract: In the context of a growing population of immunocompromised patients at risk for 
opportunistic infections, prevalence of invasive mould infections, including moulds other than 
Aspergillus and Mucorales, are on the rise. While new diagnostic and therapeutic options are now 
available to tackle rare invasive mould infections, up to date guidance for the correct utilization in 
the clinical setting is urgently needed. On that background, ECMM together with MSG-ERC set out 
an unprecedented orphan diseases guidance initiative involving all disciplines involved in diagnosis 
and treatment of rare mould infections. Utilizing the global network of the ECMM Academy and the 
ECMM Excellence Centers, clinicians, microbiologists and other medical professionals from around 
the world will be invited by ECMM to contribute their expertise to the project "One World-One 
Guideline". The rare mould guideline covers diagnosis and treatment of infections caused by 
Fusarium, Lomentospora, Phaeohyphomycetes/dematiaceous fungi/black fungi, Rasamsonia, 
Scedosporium, Schizophyllum and other basidiomycetes, Scopulariopsis, Penicillium, and 
Talaromyces other than marneffei. The guideline will include taxonomy and epidemiology and give 
detailed recommendations regarding diagnosis and clinical management of these rare mould 
infections for adults and the pediatric population. The guideline follows the structure and definitions 
of the ESCMID/ECMM guidelines on invasive fungal infection, and the ECMM MSG-ERC guideline 
on mucormycosis, which are in accord with the GRADE and AGREE systems. 
 
Plenary session 5—ICU—candida infections/Breaking news from Hematology 
and ICU 
 
PS5.1 
Abdominal Candidiasis in ICU patients 
P. Köhler 
Department I for Internal Medicine, European Excellence Center for Medical Mycology (ecmm), 
Germany and Cecad Cluster of Excellence, University of Cologne, Cologne, Germany 
Abstract: With increased admission rates to intensive care unit and high morbidity and mortality in 
the presence of severe sepsis or septic shock abdominal candidiasis is a frequent complication in 
surgical patients. In the majority of cases Candida species are part of polymicrobial infections after 
upper gastrointestinal tract perforation, anastomotic leaks after bowel surgery, acute necrotizing 
pancreatitis or peritoneal dialysis. Further risk factors comprise premorbid conditions, total 
parenteral nutrition, and previous antibiotic therapy among others. Blood cultures are often negative 
and the serum beta-D-glucan assay can support diagnosis in patients with suspected intraabdominal 
candidiasis. The diagnosis is achieved by aspiration of fluid under ultrasound or CT guidance or at 
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the time of surgery. Current treatment strategies comprise both surgical intervention and antifungal 
therapy, preferably with an echinocandin. Therapy should continue for at least two weeks and often 
longer, until the abscess and all signs and symptoms of peritonitis are resolved. 
 
PS5.2 
Are the new management strategies useful? 
A. Colombo 
Medicine, Federal University of São Paulo, São Paulo, Brazil 
Abstract: Along the last decades, we faced a substantial progress in the clinical validation of new 
diagnostic and therapeutic tools for treating patients with invasive Candidiasis (IC). However, we 
still have several gaps in knowledge that may mitigate our results in the clinical management of 
complex patients with invasive candidiasis. We selected 3 main topics to be addressed along this 
presentation: (1) How Candida Biomarkers might be utilized in the clinics, (2) Should we continuous 
to order universal screening of eye infection and endocarditis for candidemic patients? (3) Concerns 
in the clinical management of neutropenic patients with candidemia. 
 
PS5.3 
Breaking news from Hematology and ICU: CNS infections. 
A. Candoni 
University Hospital, Asuiud, Division of Hematology and Stem Cells Transplantation, Udine, Italy 
Abstract: Fungal Infections of the Central Nervous System (IFI-CNS) are rare life-threatening 
infections in hematologic patients and their management remains a challenge despite availability of 
new diagnostic techniques and novel antifungal agents (1–4). In addition, analyses of large cohort of 
patients focusing on these rare IFIs, are still lacking. The most important causative agent remains 
Aspergillus species and a concomitant extra-CNS involvement (mainly lung) is common. Recent 
reports highlight that the fungal biomarkers in CSF could be highly informative reinforcing that 
diagnostic lumbar puncture should be performed when IFI-CNS is suspected, enabling diagnosis 
confirmation and prompt initiation of targeted therapy (2). Surgical approach of this complications 
is feasible only in a minority of cases (those with focal, cortical-subcortical lesions and no severe 
thrombocytopenia), and, even with a broad spectrum of antifungal drugs, overall response rate 
remains poor (less than 40%) with a 12-months survival probability less than 30% (1–4). Availability 
of new drugs, with better CNS permeability and less interaction with immunosuppressive agents 
and chemotherapy (such as Isavuconazole), and prompt diagnostic work-up (high diagnostic value 
of CSF biomarkers) can guide a rapid, specific and aggressive therapy (including combination 
antifungal therapy ± surgery) to further improve outcomes of IFI-CNS in hematologic patients (1–4). 
(1) Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic 
malignancy. Expert Rev Anti Infect Ther. 2005;3:775‒85. (2) Candoni A, Klimko N, Busca A, et al Fungal 
infections of the central nervous system and paranasal sinuses in onco-haematologic patients. 
Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases. 
Mycoses. 2019;62(3):252–260. (3) Schwartz S, Kontoyiannis DP, Harrison T, Runke M. Advances in the 
diagnosis and treatment of fungal infections of the CNS. Lancet Neurology. 2018;17:362–372. (4) 
McCarthy M, Rosengart A, Schuetz AN, et al. Mold Infections of the Central Nervous System. N Engl 
J Med. 2014; 10(371-2): 150–160. 
 
Plenary session 6—Management of IFD in paediatrics (EPMyN) 
 
PS6.1 
Biomarker based diagnostic work-up of IFD in immunocompromised paediatric patients 
T. Lehrnbecher 
Pediatric Hematology and Oncology, University of Frankfurt, Frankfurt, Germany 
Abstract: Immunocompromised pediatric patients such as children undergoing therapy for 
hematological malignancies or receiving allogeneic hematopoietic stem cell transplantation are at 
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high risk for invasive fungal diseases, which are a major cause of morbidity and mortality in these 
patient populations. Unfortunately, clinical signs and symptoms of invasive fungal disease are 
mostly unspecific, which makes early diagnosis difficult. However, early diagnosis and prompt 
treatment of invasive fungal disease is associated with better outcome. Non-invasive antigen-based 
assays such as galactomannan (GM) or β-D-glucan and molecular biomarkers in peripheral blood 
have the potential to indicate invasive fungal disease prior to the development of clinical symptoms, 
and may therefore be helpful in the decision to institute and choose antifungal compounds and also 
to guide duration of therapy. When GM in blood is used as a diagnostic test in neutropenic children 
with prolonged febrile neutropenia unresponsive to broad-spectrum antibiotics or in children with a 
pulmonary infiltrate in the CT scan, sensitivity and specificity of the assay do not significantly differ 
between children and adults. However, the utility of the assay is clearly limited by the poor positive 
predictive value and the fact that despite the high negative predictive value of the test, a negative 
GM assay does not rule out non-Aspergillus molds. Data on β-D-glucan in immunocompromised 
children are too limited to give a final recommendation on its use, and similarly, the results of PCR 
testing in blood are variable and do not allow a firm conclusion on its utility. However, despite these 
limitations, biomarkers in blood may help to plan invasive diagnostic procedures such as broncho-
alveolar lavage (BAL) or bioptic procedures. As compared to blood, both galactomannan and PCR 
testing in BAL lavage seem to be superior, but again, further studies in the pediatric population are 
warranted. Regarding the value of biomarker in CNS samples such as cerebrospinal fluid, little is 
known in both pediatric and adult patients. Further pediatric studies are warranted to evaluate 
whether the combination of diagnostic methods can improve sensitivity and specificity, but in 
addition, new diagnostic tools are needed that will improve the early and reliable diagnosis of 
invasive fungal disease in children. 
 
PS6.2 
Pre-emptive versus empiric antifungal therapy in children with cancer 
M.E. Santolaya 
Hospital de niños Dr. Luis Calvo Mackenna, Santiago, Chile 
Abstract: Invasive fungal disease (IFD) causes significant morbidity and mortality in paediatric 
cancer patients with high-risk febrile neutropenia (HRFN), along with high utilization of resources 
for prevention, diagnosis and treatment. Early diagnosis of IFD and prompt implementation of 
aggressive antifungal treatment have proven to be critical for patient survival. Nevertheless, early 
identification of the causal pathogen of an IFD continues to be difficult. The classic approach is 
currently based on clinical, imaging, microbiological (cultures from sterile sites) and histological 
studies. Major advances for early diagnosis of IFD have been made by the development of non-
culture assays such as detection of galactomannan (GM) antigen, (1-3)-b-D-glucan antigen detection 
and nucleic acid detection, by PCR techniques. Despite these advances, IFD diagnosis continues to 
be a challenge and current recommendations propose to initiate empirical antifungal therapy in IFD 
high-risk paediatric patients with persistent (96 h) fever and neutropenia that are unresponsive to 
broad-spectrum antibacterial agents. The downside of this approach is the overtreatment of patients 
meeting the above criteria but who do not have an IFD, leading to an increase in adverse events, 
prolonged hospitalizations and elevated costs associated with the use of antifungal drugs. A more 
reasonable approach in cancer subjects would be to consider early identification of patients at high 
risk of IFD, application of a complete screening diagnosis strategy followed by a rational approach 
to antifungal therapy based on results of this early and extensive diagnostic workup, adopting a more 
selective preemptive treatment strategy in patients with persistent fever and neutropenia. We 
performed a prospective, multicenter study in children with cancer and persistent HRFN, aimed to 
determine the efficacy of pre-emptive treatment compared with current standard empirical 
antifungal treatment. In our study, pre-emptive antifungal therapy was as effective as empirical 
antifungal therapy, with a significant reduction in antifungal use. A reduction of antifungal use, 
based on stringent diagnostic criteria, could favor the adoption of evidence-based management 
strategies in this population. This approach requires optimal laboratory support with rapid 
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turnaround response. Introduction of non-culture-based diagnostic techniques into clinical practice 
could contribute to better management of these patients, favoring the possibility of patient-based 
individualized therapy. Active monitoring and early diagnostic workup is a necessary step prior to 
proposing an evidence-based management strategy. In our experience, 58% of patients of the pre-
emptive group did not receive antifungal therapy, with similar clinical outcome to the empirical 
group, with the aim of reserving antifungal therapy for the subset of patients who have early evidence 
of IFD by careful clinical, laboratory, imaging and microbiological assessment. The main findings of 
our study lead us to propose a step forward in the rational approach to treating children with cancer 
focusing on one yet-unresolved issue in the management of the patients: adoption of a more selective 
pre-emptive antifungal treatment strategy in children with prolonged fever and neutropenia. 
 
PS6.3 
Invasive mucormycosis in children with hematological malignancies and solid tumors: Report 
from the Infection Working Group of the Hellenic Society of Pediatric Hematology Oncology 
(2008-2017). 
C. Antoniadi1, I. Lialias2, H. Tsipou3, N. Kazakou4, E. Iosifidis2, E. Papakonstantinou5, S. 
Polychronopoulou1, A. Kattamis3, E. Roilides2, A. Tragiannidis4 
1Department of Pediatric Hematology-oncology, "Agia Sofia" Children's Hospital, Athens, ATHENS, 
Greece, 23rd Pediatric Department, Aristotle University of Thessaloniki, Hippokration Hospital, 
THESSALONIKI, Greece, 3Pediatric Hematology-oncology Unit, 1st Pediatric Department, National 
and Kapodistrian University of Athens, "Agia Sofia" Children's Hospital, ATHENS, Greece, 
4Haematology-oncology Unit, 2nd Pediatric Department, Aristotle University of Thessaloniki, 
AHEPA Hospital, Thessaloniki, Greece, 5Department Of Pediatric Hematology-oncology, 
Hippokration Hospital, THESSALONIKI, Greece 
Objectives: Mucormycosis is an invasive, life-threatening fungal infection that mainly affects 
immunocompromised hosts. Zygomycetes can invade virtually any tissue or organ, resulting in a 
variety of clinical presentations. The Infection Working Group (IWG) of the Hellenic Society of 
Pediatric Hematology-Oncology (HELSPHO) collected and analyzed data of pediatric mucormycosis 
cases from 7 Hematology-Oncology Departments within 2008–2017. 
Methods: Six cases of proven invasive mucormycosis were reported retrospectively (female/male: 
2/4, median age: 9.6 years, range: 2–15 years) during chemotherapy for hematologic malignancies and 
solid tumors within 2008–2017. 
Results: Among the 6 children with invasive mucormycosis, three presented with acute 
lymphoblastic leukaemia (ALL), one with acute myeloid leukemia (AML), one with neuroblastoma 
and one child with brain tumor, as the primary underlying malignancy. In 4/6 children (66%), 
mucormycosis occurred within the first 20 days from the diagnosis of the underlying disease. One 
child with ALL developed mucormycosis 4 months since the initial diagnosis, with prior invasive 
aspergillosis two months earlier treated with voriconazole. Four out of 6 patients had received 
prolonged corticosteroid treatment and 3/6 had severe neutropenia with a neutrophil count <500 μL 
at the time of diagnosis. Four out of 6 patients (66%) had received intensive chemotherapy within the 
last 4 weeks and all patients had been hospitalized for at least 20 days. All patients presented with 
fever (100%), 4/6 with pain (66%), 3/6 with palpable mass (50%) (one at the left forearm and two at 
the orbit) and 3 patients presented with central nervous system symptoms (seizures, headache, and 
blur of vision) (50%). Primary infection sites were combined paranasal sinus with orbital involvement 
(2), central nervous system (1), occipital area (1), orbital involvement (1) and forearm (1). The 
diagnosis of mucormycosis was documented by histology and mycology (PCR or culture) in all 
patients (2 Rhizopus arrhizus,1 Mucor spp., 1 Absidia spp., 2 unidentified Mucorales). Dissemination 
was defined by clinical signs, imaging studies and histology in 4/6 (66%) patients. Four (4) out of 6 
patients had received prophylactic treatment with antifungal agents (2/4 patients received 
micafungin and 2/4 L-Amphotericin B). Therapeutically, all patients received L-Amphotericin B (L-
AmB) (median dose: 7.5mg/kg, range: 3-10 mg/kg). Two (2) patients received combined antifungal 
treatment with L-AmB and caspofungin, one (1) L-AmB and voriconazole, one (1) L-AmB and 
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posaconazole and one (1) L-AmB, voriconazole and caspofungin. Three (3) patients received 
maintenance treatment with posaconazole. Surgical excision was performed in 4/6 cases (66%). Two 
out of 6 patients (33%) died, after 6 and 12 months, respectively. 
Conclusion: Pediatric invasive mucormycosis mainly presents as paranasal sinus and orbital disease 
and is still related to high mortality rates. Our data demonstrated that the disease occurs early after 
initiation of intensive chemotherapy and febrile neutropenia and prolonged corticosteroids are the 
main predisposing factors. Early recognition and prompt intervention with combined prolonged 
antifungal and surgical treatment may rescue the patients and improve overall survival. 
 
Plenary session 8—New (antineoplastic) drugs, new risks 
 
PS8.1 
New antineoplastic drugs, new risks in hematology 
A. Busca 
Division of Hematology, AOU Citta della Salute e della Scienza, Torino, Turin, Italy 
Abstract: Over the last 10 to 15 years, therapeutic options for patients with hematologic malignancies 
have largely increased with the growth of new immunotherapeutic agents. At least two issues 
regarding invasive fungal infections (IFI) and the new immunotherapeutic agents should be 
addressed. First, there are relevant pharmacokinetic interactions of the new targeted therapies with 
coadministered mold active azoles, namely posaconazole and voriconazole that are strong inhibitors 
of CYP3A4. Awareness of these interactions is of paramount importance for optimization of the 
treatment of patients, since we are asked to monitor for potential toxicity, or to modulate the dose of 
the drugs or rather to avoid the combination and consider alternative therapy. Second, is the risk of 
IFI increased with the use of the new agents? For many of these, for instance monoclonal antibodies 
(MoAb), bcl-2 inhibitors (i.e. venetoclax) and tyrosine kinase inhibitors (TKI) (i.e. sorafenib and 
midostaurin) when used for the treatment of patients with acute leukemia, it is hard to realize 
whether they have an additive risk to the underlying disease: indeed, there are very few information 
respect the incidence of IFI based on the clinical trials published so far. By contrast, several studies 
raised concern that the Bruton’s tyrosine kinase inhibitor Ibrutinib may increase the risk for IFI in 
patients with lymphomas. In this respect, different mechanisms by which Ibrunitib may favor the 
occurrence of IFI have been described, including alveolar macrophage, neutrophil, T-cell, and platelet 
function as well as alterations of cytokine environment. A recent study of Ibrutinib treatment for 
primary CNS lymphoma reported a 39% rate of invasive aspergillosis in patients concurrently 
receiving steroids even in absence of neutropenia, while in other reports the incidence appears to be 
much lower in the 3–4% range. Conversely, the risk of IFI with the use of Idelalisib, another B-cell 
receptor inhibitor, seems to be restricted to Pneumocystis jirovecii pneumonia only. Until more detailed 
epidemiological data will be available, anti-mold prophylaxis is not recommended for patients 
receiving Ibrutinib or Idelalisib. Chimeric antigen receptor (CAR) T cell therapy is an innovative 
strategy to harness the immune system to treat patients with diffuse large B cell lymphoma (DLBCL). 
CAR-T cells are T lymphocytes genetically engineered to express a tumor-targeting receptor, 
directing T cells to bind to a tumor-associated antigen, namely the CD19 in the case of DLBCL. A 
recent study evaluated infectious complications in 133 patients with ALL and lymphomas treated 
with CD19 CAR-T cells: IFI occurred in 5% of the patients during the first 28 days after CAR-T cell 
infusion, all of whom had severe cytokine release syndrome (CRS) or neurotoxicity requiring 
tocilizumab and/or corticosteroids. CRS severity was the only factor after CAR-T cell infusion 
associated with infection in a multivariable analysis. In summary, the risk of IFI in patients receiving 
targeted therapies needs to be defined by further experience in clinical practice and ongoing research 
trials. Preventive strategies of IFI in patients managed long term with immunotherapy remain at the 
present a challenge. 
 
PS8.2 
In oncology 
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L. Drgona 
Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, 
Slovak Republic 
Abstract: The field of new antineoplastic therapeutical agents is increasing rapidly over the last 
decade. New drugs in oncology are basically considered as targeted ones due to their mechanism of 
action. These drugs directly target the cells or pathways involved in pathophysiology of neoplastic 
disease. Cell surface receptors, cytokines, immunoglobulines, intracellular enzymes are the most 
common targets involved in the therapy. Other drugs are focusing on the patient’s own immune 
system with the aim to boost the responsible cells to fight against the disease. The new drugs have 
different mechanisms of action resulted in less “classical“ toxicity known from chemotherapy agents. 
The adverse events after the targeted therapy are mainly caused by interaction with the immune 
system—targeted sites are often key elements of physiological processes like cell cycle control. This 
may have an influence on responses to acute infection or on control of latent/chronic infection. 
Theoretically, the potential of the new drugs to predispose to infection depends on their site of action. 
But this is simplification of the whole problem, because cancer patients are treated for months or 
years before the installation of the innovative therapy. Thus, an old, traditional risk factors for 
infectious complications should be added to the overall risk for the given patient. Invasive fungal 
diseases (IFDs) are associated with the treatment of cancer, patients with solid tumors have lower 
risk than majority of patients with hematological malignancies. The obvious risk factors for IFDs in 
patients with solid tumors are neutropenia, steroids, central venous catheter, progressive or 
refractory malignancy, gastrointestinal surgery with leak of anastomosis among others. Invasive 
candidiasis followed by invasive aspergillosis are the most common IFDs in this setting, other 
pathogens are less involved. With the advent of the new therapeutic approaches in oncology patients 
and physicians are challenged with the new spectrum of adverse events including infections. 
Generally, monoclonal antibodies, tyrosine kinase inhibitors, check point inhibitors and other 
targeted and biological agents are not associated with the increasing risk of IFDs in solid tumor 
patients. In special circumstancies patient undergoing such antineoplastic therapy may have an 
additional risk for IFDs. An example are the patients with melanoma or lung cancer treated with 
check point inhibitor developing an immune related adverse event. High dose steroids with or 
without anti -TNF blocker are recommended in the management of the serious toxicity; these patients 
are potentially at risk for IFD development due the supportive treatment of AE. Risk of IFD will be 
discussed in the patients with solid tumors reflecting the advances of antineoplastic treatment. 
Despite the relatively low risk for the development of IFDs and slowly growing experience some 
recommendations could be made. Anticipation, prediction and alertness are the pillars of action in 
this setting of cancer patients. 
 
Meet the expert sessions 
 
M04 
Novelties in the molecular diagnostics of fungal infections 
M. Lackner 
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, 
Austria 
The aim of this meet the expert session is to provide an overview on the most recent developed 
diagnostic kits in the field of medical mycology. We aim to present and compare novel diagnostic 
tools with established assay based on our personal experience and available literature. The 
presentation will be based on a literature review of the past 18 months and a web search for 
commercially available products. A mix of currently developed assays of research groups will be 
presented, as well as CE-IVD labelled commercial tests. The most promising innovative diagnostic 
assays will be presented and discussed. The audience is invited to share their experience with novel 
assays to enable a lively discussion and exchange of opinions. 
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M12 
Environment 
R. Sabino1, E. Segal2 
1Reference Unit for Parasitic and Fungal Infections, Infectious Diseases, National Health Institute Dr. 
Ricardo Jorge, Lisbon, Portugal, 2Sackler School of Medicine Tel-Aviv University, Tel-Aviv, Israel 
Abstract: Exposure to environmental fungi, whether this occurs indoors or outdoors, in leisure 
activities, in the workplace or in the home, is an everyday occurrence. Different types of environment 
may contain variable levels of fungal particles and include viable and non-viable yeasts, conidia, 
hyphal fragments, as well as fragments derived from the fungal cell wall. Mycotoxins and other 
volatile organic compounds should also be considered as environmental potential hazards. 
Recognition of the importance of the environment as a source of human infection has come about, at 
least in part, as result of the emergence of an unprecedented number of ubiquitous environmental 
fungi as major causes of disease. Exposure to environmental fungi is associated with high number of 
hospital admissions, and asthma related ailments. Allergic bronchopulmonary mycosis, 
rhinosinositis, asthma with fungal sensitization and hypersensivity pneumonitis are among the 
diseases more frequently associated with fungal exposure. In addition, immunocompromised 
patients are at higher risk for the development of invasive infections. Changes in environmental 
factors, including changing land-use patterns, use of antifungals in agriculture, and climate changes 
have led to epidemiological shifts. Therefore, special attention should be paid in regard to the isolated 
fungal species. Environmental fungal species such as Aspergillus spp., Mucorales, Candida spp., 
dermatophytes and dimorphic fungi will be discussed during this session; emphasizing their 
importance as etiological agents of fungal infections. 
 
M13 
Diagnostics/Imaging 
C. Thornton 
Biosciences, University of Exeter and ISCA Diagnostics Ltd., Exeter, United Kingdom 
Abstract: Bench-to-Bedside Diagnosis of Invasive Pulmonary Aspergillosis. Invasive pulmonary 
aspergillosis (IPA) is a life-threatening lung disease of haematological malignancy and bone marrow 
transplant patients caused by the air-borne mould Aspergillus. Current diagnostic tests for the disease 
lack sensitivity or specificity, and culture of the fungus from invasive lung biopsy, considered the 
gold standard for IPA detection, is slow and often not possible in critically ill patients. While 
Computed Tomography (CT) is a non-invasive diagnostic procedure, it has limited clinical utility for 
IPA diagnosis, but is nevertheless used as a trigger for commencing antifungal treatment in a number 
of centres. Innovative approaches to the diagnosis of IPA are needed to enable diagnostic-driven 
treatment with mould active drugs. In this talk, I will discuss the development of diagnostic 
technologies for IPA detection based on the Aspergillus-specific mouse monoclonal antibody JF5, 
including the CE-marked Aspergillus lateral-flow device (OLM Diagnostics), and CE-marked 
Aspergillus-ELISA (Euroimmun AG). In addition, I will describe the humanisation of mAb JF5 for 
PET/MR imaging of Aspergillus lung infections in vivo, and translation of the imaging technology to 
the clinical setting. I will finish by describing the recent development of a mAb, PD7, specific to A. 
fumigatus, and its use to detect a novel protein biomarker of IPA in urine. 
 
M14 
Resistance—Utilizing molecular methods 
P. White 
Microbiology, Public Health Wales Microbiology, Cardiff, United Kingdom 
Abstract: Until recently the identification of antifungal resistance has been based on the availability 
of a cultured organism to perform susceptibility testing to determine a MIC against a particular 
antifungal agent. The development of molecular techniques has provided an alternative option, by 
identifying genetic markers potentially associated with resistance or identifying species that may by 
inherently resistant, or have an increased likelihood of resistance to particular drugs. Indeed, 
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molecular assays offer the only alternative to culture dependent procedures, that themselves can 
suffer from limited sensitivity and delayed time to result. However, molecular approaches are not 
without limitations. PCR based methods targeting specific mutations (for example: single nucleotide 
polymorphisms and/or tandem repeats), by design have a limited detection range, missing existing, 
likely less prevalent mutations, but also the presentation of novel genetic mechanisms. PCR methods 
that identify species that are usually resistant to certain antifungal drugs will be reliant on the 
knowledge of local epidemiology and the subsequent susceptibility testing of relevant cultures to 
guide antifungal prescribing. The use of PCR-sequencing, but more so next generation sequencing, 
will help identify a wider range of polymorphisms in genes encoding the proteins targeted by 
antifungal therapy and also in promoter regions that may enhance up-regulation, but the detection 
of novel mutations may lack the necessary phenotypic evidence confirming associated resistance. In 
addition, PCR-sequencing is associated with a significant processing time and has only had limited 
evaluation of direct specimen testing, where sensitivity may be lacking when targeting single copy 
genes. As of yet none of these methods can be confidently associated with a specific MIC range, and 
the presence of well defined polymorphisms have been associated with typically susceptible MIC 
values. This presentation will describe the benefits and limitations of using molecular methods for 
determining antifungal resistance, while providing data on the clinical performance of assays, 
including those that are commercially manufactured. 
 
Symposium 1 Water quality (mis-)management—an opportunity for fungal 
contamination 
 
S01.1 
Fungal Contaminants in Drinking Water Regulation? A Tale of Ecology, Exposure, Purification 
and Clinical Relevance 
M. Novak Babič1, N. Gunde-Cimerman1, J. Brandão2 
1Department Of Biology, University of Ljubljana, Biotechnical Faculty, Ljubljana, Slovenia, 
2Department Of Environmental Health, National Institute of Health Doutor Ricardo Jorge, Lisbon, 
Portugal 
Safe drinking water is one of the fundamental human rights according to the Resolution 64/292 issued 
by the United Nations Human Rights Council [1]. Although the parameters for safe drinking water 
depend on the living conditions and vary between continents and countries, they strive for a common 
goal: drinking water is suitable for users when it does not contain dangerous chemical substances 
and microorganisms [2]. To achieve this, raw water from an underground or surface source is subject 
to various purification techniques before entering the distribution system. The processes usually 
include aeration, coagulation, flocculation, sedimentation, and ultrafiltration, depending on the 
location and quality of raw water [3]. Finally, water quality in Europe is controlled based on the 
parameters listed in Drinking Water Directive (98/83/CE). Water not reaching the required 
microbiological minimum is additionally subject to chemical treatment, mostly chlorination. Fungi 
are not listed in the current directive and are therefore not specifically monitored. Yet, their presence 
in fresh water is well documented and has been studied in at least 19 countries of Europe over the 
past 30 years [3]. More than 400 different species of fungi have been reported from water sources 
intended for human consumption, with prevailing presence of ascomycetous fungi of the genera 
Alternaria, Acremonium, Aspergillus, Aureobasidium, Candida, Cladosporium, Exophiala, 
Fusarium, Penicillium, Phoma, Sarocladium, Scopulariopsis, Sporothrix, Stachybotrys and 
Trichoderma, followed by Absidia, Mortierella, Mucor and Rhizopus from subphylum 
Mucoromycotina. Most commonly encountered yeasts were basidiomycetous genera Cystobasidium, 
Naganishia (formerly Cryptococcus) and Rhodotorula [3]. While water purification procedures 
remove 8–90% of fungal propagules, the remaining will ultimately form mixed biofilms inside the 
tap water distribution systems, later affecting the taste and odour of drinking water. Also, several 
water-related fungal species were recognised as opportunistic or emerging pathogens, although their 
transmission and effect on the health of drinking water consumers remains poorly investigated. 
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Besides drinking, consumers use potable water also for daily activities such as cooking, washing and 
personal hygiene. During these activities they are in constant contact with fungi and their metabolites 
directly with the skin while washing, the digestive system while drinking, and through the 
respiratory system by inhaling aqueous aerosols [3,4]. With increasing transitory and serious immune 
alterations among patients as well as an increase of azole-resistant fungal strains in recent years also 
a need for monitoring of fungi increased, not only in drinking water but also in relation to materials 
in contact with drinking water. References: [1] UN. Resolution adopted by the General Assembly on 
28 July 2010 64/292. The human right to water and sanitation. United Nations: New York, USA, 2010; 
p. 3. [2] WHO. Guidelines for Drinking Water Quality, 4th ed.; World Health Organization: Geneva, 
Switzerland, 2011; p. 564. [3] Novak Babič, M., et al. Fungal Contaminants in DrinkingWater 
Regulation? A Tale of Ecology, Exposure, Purification and Clinical Relevance. Int. J. Environ. Res. 
Public Health 2017, 14, 636. [5] DEFRA. A Review of Fungi in Drinking Water and the Implications 
for Human Health, 1st ed.; BIO Intelligence Service: Paris, France, 2011; p. 107. 
 
S01.2 
Hospital environment: water supply and containment of aerosolised fungal particles. How far 
must we go in times of antimicrobial resistance? 
R. Sabino 
Reference Unit for Parasitic and Fungal Infections, Infectious Diseases, National Health Institute Dr. 
Ricardo Jorge, Lisbon, Portugal 
Invasive fungal infections depend on the interplay between host susceptibility and environmental 
exposure. Therefore, hospital environment is one of the major concerns in the management of 
nosocomial fungal infections, especially in wards bearing immunocompromised patients. Particular 
attention should be paid to the environmental risks associated with water since fungi can be 
aerosolized at water taps and showers. This may lead to fungal exposure by inhaled and ingested 
droplets, or even by direct contact with mucosae. Studies report that filamentous fungi and yeasts 
are commonly found on water-pipe inner surfaces, even in the presence of free chlorine. Air levels of 
Fusarium and Aspergillus conidia were found to increase in hospital environments after running 
showers multiple times. Species of these two genera are described as the most frequently found in 
this setting due to their conidial dispersion mode, as well as their ability to form biofilms. Despite the 
intrinsic resistance found in some species of these two genera, fungal exposure to antifungal agents 
via medical or agricultural use of these compounds, appears to have a major impact on acquisition 
of resistance to azoles; namely in Aspergillus fumigatus. The isolation of this species in hospital water 
and water reservoirs is therefore an even bigger matter of concern. More recently, several reports on 
nosocomial outbreaks caused by Candida auris have been described. This species is resistant to several 
classes of antifungals and is associated with high mortality. Contamination of hospital environment 
or transient colonization of medical devices and equipment may display an important role in the 
transmission of this species. C. auris was already found in water samples and therefore this reservoir 
should not be excluded as possible source of infection. In conclusion, fungal counts and detection of 
potential pathogenic species in water were, until a few years ago, the major concern of clinical and 
scientific community towards the reduction of nosocomial fungal infections originating in water 
devices. The emergence of infections caused by fungal isolates with intrinsic or acquired antifungal 
resistance triggered new levels of alert in this field. 
 
S01.5 
Spectrum of indoor fungi isolated from indoor environments in Busia-Kenya 
O. Mashedi1, E. Amukoye2, C. Bii3, B. Kimani3, A. Chepchirchir4, S. Okoth5 
1Centre For Respiratory Dise Ases Research, Kenya Medical Research Institute, Nairobi, Kenya, 
2Centre For Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya, 
3Centre For Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya, 4School Of 
Health Sciences, University of Nairobi, Nairobi, Kenya, 5School Of Biological Sciences, University of 
Nairobi, Nairobi, Kenya 
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Objectives: The unplanned growth, rapid evolution of industrialization has deteriorated the ambient 
air quality. Anthropogenic indoor air pollution continues to be seen as an environmental and public 
health problem. Its seriousness lies in exposure to fungi that can trigger allergic reactions, 
hypersensitivity pneumonitis, allergic rhinitis, and some types of asthma. Very few studies in Kenya 
have been conducted to determine the possible types of indoor fungi allergens in indoor environment 
and to evaluate the relationship between allergen exposure in residential environments and 
respiratory morbidity. The aim of this study is to determine the prevalence of fungal indoor pollution 
in residential environments and to establish allergens which are associated with fungal pathogens. 
Methods: This was a cross-sectional study carried out in 60 households in Busia County. Sedimentary 
and Volumetric sample collection method was used on water, air, swabs of dust and surfaces from 
homes. Mycological procedures in identification and analysis were used in fungal characterization. 
Comprehensive questionnaires were administered to determine the risk factors associated with 
indoor fungi infestation. 
Results: 60 study participants were interviewed from Busia urban setting with mean age of 35.2 ± 7.7 
(SD) years where most 60.3% of them were aged between 40–49 years; while 19.0% were aged 20–29 
years. 68.4% of the respondents were females. As regard to education background, 61.4% of the 
respondents had primary education as the highest education level whereas 3.5% had tertiary level. 
43.1% of the households were occupied by more than 5 people. Filamentous and yeast fungi were 
both isolated. Candida albicans and Rhodotorula accounted for the 39% of the isolated yeast species. 
Among the filamentous fungi Fusarium had the highest prevalence of 79.7%, followed by 
Cladosporium spp, Alternaria spp, Acremonium Apergillus and Penicillium respectively. There was a 
significant association between Fusarium and Acremonium moulds and respiratory conditions. 
Acremonium species was significantly associated with itchy eyes allergies, p = 0.023. 
Conclusion: There is a need for the identification and monitoring of fungi in our home environment. 
Residential environment could potentially be considered an effective target for interventions aimed 
at reducing inciting fungi exposures to prevent upper respiratory allergies and infection in urban 
populations. 
 
Symposium 2 Pneumocystis jirovecii, an airborne transmissible and human 
derived ascomycete showing strong pulmonary tropism 
 
S02.1 
Pneumocystis jirovecii: an obligate parasite of human lungs with unique camouflage and sex 
strategies 
P. Hauser 
Institute of Microbiology, CHUV Hospital, Lausanne, Switzerland 
Abstract: Pneumocystis jirovecii is a fungus colonizing the human lungs. Should the immune system 
weaken, it can turn into an opportunistic pathogen causing severe pneumonia that can be fatal if not 
treated. A method of in vitro long-term culture for this pathogen is not available yet. Nevertheless, 
the advent of the high throughput DNA sequencing methods allowed sequencing the P. jirovecii 
genome out of the lung microbiome. The analysis of this genome revealed the loss of several synthesis 
pathways, demonstrating that this fungus is an obligate parasite. The presence of a fusion of the 
minus and plus mating-type loci suggested that its mode of sexual reproduction is primary 
homothallism (self-fertility). The sexuality of P. jirovecii proved to be obligatory with human lungs, 
which is compatible with asci and/or ascospores being the particles responsible for the transmission 
between humans by the air route. Long reads sequencing permitted characterizing six hypervariable 
gene families encoding surface antigens within the subtelomeres of all chromosomes. These gene 
families are responsible for surface antigenic variation allowing presumably escape from the human 
immune system, as well as for adhesion to host cells. The most abundant family is subject to mutually 
exclusive expression of a single gene, whereas each gene of the other families possesses its own 
promoter, suggesting independent expression. Recombinations between members of each family is 
thought to generate gene mosaicism that contribute to antigenic variation. The mechanisms involved 
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in P. jirovecii antigenic variation suggest that the infecting populations are antigenically 
heterogeneous, i.e., made of subpopulations displaying each a unique antigen of the most abundant 
family, as well as a minority of antigens of the other families. 
 
S02.2 
High-throughput methodologies in molecular epidemiology of Pneumocystis jirovecii 
O. Matos 
Medical Parasitology Unit, Group of Opportunistic Protozoa/hiv and Other Protozoa, Global Health 
and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 
Lisboa, Portugal 
Abstract: The microscopic fungus Pneumocystis jirovecii is a pathogen that can cause fatal pneumonia 
(PcP) in immunocompromised patients (AIDS, transplant recipients, patients with haematologic and 
solid malignancies, patients with rheumatoid conditions and connective tissue disorders, patients 
receiving immuno-modulatory therapies or with pre-existing chronic lung conditions) worldwide. In 
the absence of an in vitro culture system to isolate and maintain live organisms, previous efforts to 
understand transmission patterns to develop methods of intervention and management for PcP relied 
on PCR-based approaches. Several genotyping methods have been used so far to address the genetic 
heterogeneity of P. jirovecii, PCR of multiple loci followed by direct DNA sequencing (Sanger), 
restriction fragment length polymorphism (RFLP), single-strand conformation polymorphism 
(SSCP), short tandem repeat (STR) or single-base extension (SBE). These methodologies were 
followed by the introduction of next generation sequencing (NGS), which is considered a revolution 
in the field of DNA analysis. NGS has been applied in the assembly of P. jirovecii whole genome and 
in amplicon analysis, especially for outbreaks investigation. Here we will explore the advantages and 
disadvantages of these approaches applied in the expansion of knowledge of the epidemiology of P. 
jirovecii. 
 
S02.3 
Airborne acquisition and transmission of Pneumocystis jirovecii: an update 
G. Nevez1,2, P. Laurence1,2, S. Le Gal1,2 
1University of Brest, Brest, France, 2Host-Pathogen Interaction Study Group, SFR ICAT 4208, Univ 
Angers, Univ Brest, Institute of Biology in Health, IRIS, University Hospital Center, Angers, France, 
Angers Cedex, France 
Abstract: Airborne transmission of Pneumocystis sp. from host to host has been demonstrated in 
rodent models and several observations suggest that interindividual transmission occurs in humans. 
Moreover, it is accepted that the Pneumocystis organisms infecting each mammalian species are host 
specific. Thus, the hypothesis of an animal reservoir for Pneumocystis jirovecii (P. jirovecii), the human-
specific Pneumocystis species, can be excluded. An exosaprophytic form of the fungus cannot be 
strictly ruled out. Nonetheless, these data point out that: (i) the specific host may serve as its own 
reservoir (ii) Pneumocystis infection in humans is an anthroponosis with humans as a reservoir for 
P. jirovecii. This review highlights the main data on host-to-host transmission of Pneumocystis sp. in 
rodent models and in humans by the airborne route. Specifically, recent data on P. jirovecii exhalation 
by patients developing PCP or with pulmonary colonization in their surrounding environment are 
described. Taken together, these recent findings render it possible to provide a rationale for 
prevention of P. jirovecii acquisition and transmission within the hospitals. 
 
S02.5 
Does Pneumocystis jiroveci infection aggravate the prognosis of invasive pulmonary 
aspergillosis? Data from the RESSIF network in France (2012–2016) 
F. Robert-Gangneux1, G. Bouzille2, F. Dromer3, J.P. Gangneux4, T.H.E. French Mycoses Study Group5 
1Univ Rennes, CHU Rennes, Inserm, EHESP, IRSET UMR S_U1085, RENNES, France, 2Univ Rennes, 
CHU Rennes, Inserm, LTSI – UMR 1099, RENNES, France, 3National Reference Center For Invasive 
Mycoses & Antifungals, Molecular Mycology Unit, Cnrs Umr2000, Institut Pasteur, Paris, France, 
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4Laboratoire De Parasitologie-mycologie, CHU de Rennes, Rennes, France, 5National Reference 
Center For Invasive Mycoses & Antifungals, Molecular Mycology Unit, Cnrs Umr2000, Institut 
Pasteur, RENNES, France 
Objectives: Pneumocystis jiroveci pneumonia (PjP) is a frequent opportunistic infection in 
immunocompromised patients with various immune deficiency backgrounds, whereas invasive 
aspergillosis (IA) mostly occurs in patients with neutropenia or neutrophil impairment. Occasionally 
both fungi can be detected simultaneously. In that instance, Pj detection is sometimes considered as 
simple colonization, particularly when microscopic examination is negative and PCR is positive. In 
this study, we addressed the question of the presence of Pj as an aggravating factor during IA. 
Methods: We took advantage of the surveillance of invasive fungal infections (IFIs) implemented by 
the National Reference Center for Invasive Mycoses and Antifungals through the RESSIF network. 
All cases of IA and PjP recorded during a 5-year period (2012–2016) were analyzed. Multivariate 
analysis compared cases of IA and cases of IA+PjP co-infection, using Cox regression after multiple 
imputation of missing data. All cases with a follow-up of 90 days were taken into account, extra-
pulmonary aspergillosis was excluded. The following variable were included for analysis: age, sex, 
clinical background (hematological malignancy, allogeneic stem cell transplantation (allo-HSCT), 
auto-HSCT, graft versus host (GVH) disease, solid organ transplantation (SOT), cancer), 
corticotherapy or biotherapy, delay of AI onset, AI classification (proven, probable), and Aspergillus 
species. 
Results: 730 patients were included, of whom 701 had IA and 29 had IA+PjP. The mean age of patients 
with IA and IA+PjP was 58.5 and 61.3, respectively (p = 0.08). There were no statistical differences in 
the sex ratio, clinical background, type of SOT, corticotherapy or biotherapy exposure, time from 
transplantation to diagnosis, time from hospitalization to IA diagnosis, time to death, nor 
classification of IA, between the two groups. The mortality rate was higher in the group IA+PjP than 
in IA alone (65% versus 39%, respectively, p = 0.009). Species from the Fumigati section accounted for 
58.6% and 43.1% of cases in IA+PjP and IA, respectively (ns). In the multivariate analysis, the factos 
independently associated with death at 3 months were: age > 60 years (HR = 1.74 ; CI95% [1.4–2.2]), 
solid cancer (HR = 2.2 ; CI95% [1.1–4.6]), co-infection AI+PjP (HR = 1.9 ; CI95% [1.2–3.1]) and section 
Fumigati IA (HR = 1.65 ; CI95% [1.3–2.1]). 
Conclusion: Pj infection is an aggravating factor of IA, particularly in patients with solid cancer. No 
other associated risk factor was uncovered probably due to the limited number of co-infections 
recorded. We plan to extend the study period to increase the statistical power of the analysis. 
 
Symposium 3 Mucormycosis 
 
S03.1 
Hospital related mucormycosis 
A. Skiada 
1st Dpt. of Medicine, Laiko Hospital, Athens University, Athens, Greece 
Abstract: Mucormycosis is a rare invasive fungal infection due to fungi of the order Mucorales. The 
usual underlying diseases are hematological malignancies and diabetes mellitus, but a significant 
proportion of patients are immunocompetent. The main clinical presentations are rhinocerebral, 
pulmonary, cutaneous and disseminated. The agents of mucormycosis are ubiquitous in nature, and 
they are transmitted by inhalation, direct inoculation or ingestion. There have been multiple reports 
of healthcare associated mucormycosis, either as isolated cases or as outbreaks. In a publication from 
India, during an eighteen month period, 75 cases of mucormycosis were reported, of which 9% were 
nosocomial. Healthcare associated mucormycosis has been attributed to various exposures in the 
hospital environment, including: (a) Use of non-sterile products. This is the most commonly 
suspected cause of infection. Bandages, adhesives, nitroglycerin patches, contaminated linen, 
wooden tongue depressors, ostomy bags, probiotics, have all been implicated. There has even been a 
report of an outbreak due to allopurinol tablets and pre-packaged food. (b) Various procedures and 
medical devices, such as catheters, insulin pumps and finger sticks, as well as insertion of tubes, tooth 
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extractions and surgery. (c) Environmental factors may also be a source of infection. Molds may be 
found in the air, dust, water or any surfaces in the hospital. Construction works increase the risk of 
invasive fungal infections. Outbreaks have been linked to defective ventilation systems and water 
leakage. The clinical presentation varies, depending on the source of infection. Infections due to 
bandages, adhesives or contaminated wound dressings are mostly cutaneous. Percutaneous 
exposure in immunocompromised patients has led to disseminated disease. Inhalation leads to 
pulmonary and rhino-cerebral infection, while ingestion of tablets or food, as well as the use of tongue 
depressors, are responsible for gastrointestinal mucormycosis. Dialysis catheters have been linked to 
peritonitis. It is not easy to investigate a possible mucormycosis outbreak. The Centers of Disease 
Control of USA have recently published a guide to investigating suspected outbreaks due to 
mucormycosis. Due to the rarity of the disease, investigation is warranted even when it is unclear if 
there is a true outbreak. The first step is to verify the diagnosis and define a case. Histopathology and 
culture are the mainstay of diagnosis. In recent years, newer tools have been added to our diagnostic 
armamentarium. These include PCR, whole-genome sequencing and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The next step in the 
investigation of an outbreak is to describe the epidemiologic features of the cases, scrutinize patient 
care activities and determine environmental involvement. The management of outbreaks is multi-
disciplinary and should include treating physicians, hospital administration, workers in the 
microbiology laboratory and health departments. Rapid identification of cases and initiation of 
treatment is important, in order to decrease mortality of existing cases and prevent the emergence of 
new ones. 
 
S03.3 
The new treatment of mucormycosis 
L. Pagano 
Fondazione Policlinico Universitario A. Gemelli—IRCCS—Universita Cattolica del Sacro Cuore, 
Rome, Italy 
The antifungal drug that showed the best in vivo activity in the past has been deoxycolate 
Amphotericin B (d-AmB). Although this molecule, although extremely effective, has been 
characterized by an important series of side effects (i.e. renal insufficiency, hypokalemia) which have 
made its use disadvantageous. In more recent years, the introduction of new formulations of AmB in 
lipid formulations (L-AmB, ABCD, ABLC) have mitigated the unpleasant side effects without 
eliminating them completely but have made their use more manageable. Nowadays lipid 
formulations, and especially L-AmB, are considered by all the international guidelines as the first-
choice drugs for the treatment of mucormycosis. In recent years new azole formulations, first and 
second-generation azoles (i.e. posaconazole, isavuconazole) have shown considerable efficacy in the 
treatment of these molds even in highly immunocompromised patients such as those suffering from 
acute leukemia or undergoing bone marrow transplantation, whereas voriconazole and itraconazole 
show no effect on mucorales. Posaconazole was registered as a drug to be used as an alternative to 
liposomal amphotericin and often the availability of the oral solution alone has considerably limited 
its use. The oral-only route of posaconazole is anyway a great limitation, especially in hematologic 
patients, often inable to take drug per os or undergoing chemotherapy with subsequent high 
incidence of vomiting. However the availability of posaconazole in intravenous formulation and in 
coated tablets has favored a greater absorbability and, consequently, greater efficacy. Isavuconazole 
in registrative trial has shown a good efficacy in the treatment of this fungal complication and is now 
recognized as an excellent alternative. We must also take into account the possibility, supported in 
recent years by multiple studies in real life, to approach the most aggressive and disseminated forms 
of mucormycosis with the combination of multiple drugs. L-Amb combined with caspofungin would 
appear to be preferable due to the lack of negative interactions between the drugs used, however 
there are multiple reports showing that L-Amb plus posaconazole may have a positive role. 
 
S03.4 
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Clinical features associated to fungal species 
D. Garcia-Hermoso1, K. Sitbon1, C. Gautier1, F. Dromer2, T.H.E. French Mycoses Study Group2 
1National Reference Center for Invasive Mycoses & Antifungals, Molecular Mycology Unit, Cnrs 
Umr2000, Institut Pasteur, PARIS, France, 2National Reference Center for Invasive Mycoses & 
Antifungals, Molecular Mycology Unit, Cnrs Umr2000, Institut Pasteur, Paris, France 
Background Fungi of the order of Mucorales are ubiquitous saprobes that can be responsible for life-
threatening infections especially in immunocompromised patients but also in immunocompetent 
individuals. An increased incidence of mucormycosis has been reported mostly due to the rise of 
populations at risk and the use of better diagnostic tools. There are more than 20 pathogenic species 
involved in this type of infections, with some of them associated with specific body sites. The main 
localizations of mucormycosis are rhino-orbito-cerebral and pulmonary infections, depending on the 
underlying conditions of the patient. We present here a preliminary analysis aiming to dissect the 
association between clinical manifestations and Mucorales species using the active surveillance 
system (RESSIF) implemented in France at the NRCMA since 2012.  
Methods Three-hundred cases of probable and proven mucormycosis were so far collected through 
RESSIF. The isolates were characterized using phenotypic analysis by morphological methods, and 
antifungal susceptibility testing of 8 antifungal drugs done using EUCAST microdilution method. In 
addition, a multi-locus sequencing based on LSU, ITS, TEF-1 was performed.  
Results Among those 300 cases of invasive mucormycosis, lung involvement was the main 
presentation (52%) followed by rhinocerebral (18%) and cutaneous (15%) involvement. Deep 
infections occurred most often in patients with hematological malignancies. Six major species of 
Mucorales were identified with Rhizopus arrhizus being the most frequent fungus. Our current data 
expand previous findings showing that distribution of these 6 major species depended on the body 
site localizations and underlying condition of the patient. 
 
S03.5 
Molecular diagnosis of mucormycosis 
L. Millon 
Parasitology—Mycology—Umr6249 Cnrs Chrono-environnement, University Hospital Besançon, 
Besançon, France 
Molecular techniques have provided a new understanding of the epidemiology of mucormycosis. 
Several factors may explain the growing incidence of mucormycosis, especially the increase in the 
number of susceptible people and the change in antifungal practices (which may have altered the 
relative frequency of mucormycosis and aspergillosis among patients at risk for both infection). In 
addition, the routine use of molecular techniques has helped to accurately identify Mucorales fungi 
in tissue samples when cultures are negative. As a result, the number of mucormycosis cases 
diagnosed in the last 10 years has increased. The use of molecular techniques has also improved the 
therapeutic management of mucormycosis. Indeed, mucormycosis and aspergillosis have similar 
underlying conditions, and similar radiological and clinical signs, but their antifungal treatments are 
different. For each of these infections, early diagnosis and early initiation of directed treatment are 
essential to improving patient outcome Molecular techniques may help to provide fast, effective 
treatment by accurately identifying the causative fungi. PCR amplification and sequencing were first 
applied to better identify isolates grown from cultures of biopsies or bronchalveolar lavage samples 
collected in patients with Mucorales infection. Molecular techniques have also been used to identify 
the fungus directly from the tissue samples when cultures were negative. The first technical approach 
for detection fungi in tissue samples consists of using panfungal primers, targeting ITS regions, 
followed by sequencing. The second possible approach consists of using Mucorales-specific primers. 
Diverse PCR techniques were tested and were successful, and several studies confirmed that PCR 
results were better in fresh/ frozen samples than in formalin-fixed paraffin-embedded samples. 
Molecular detection of fungi on hyphal positive biopsy samples is now strongly recommended (AII) 
by the European ESMID and ECMM joint clinical guidelines. Recent studies confirmed that 
Mucorales quantitative PCR (qPCR) applied on bronchoalveolar lavage fluid could provide 
J. Fungi 2019, 5, 95 34 of 464 
 
additional arguments favoring earlier initiation of specific antifungal therapy, thus improving the 
outcome of pulmonary mucormycosis patients. However, these tools require invasive sampling 
(biopsy, bronchoalveolar lavage), which is not feasible in patients in poor condition in Hematology 
or Intensive Care units. QPCR-based procedures to detect Mucorales DNA in non-invasive samples 
such as plasma or serum have proved successful in diagnosing mucormycosis early (as early as 8 
days before mycological diagnosis and 3 days before imaging in patients with hematological 
malignancies). The test can be performed in all patients, even those who cannot endure a biopsy or 
bronchoalveolar lavage. The Mucorales qPCR performed on serum or plasma is becoming essential 
to improve the management of at-risk patients. The main problem at the moment is a lack of 
standardization, because of the use of multiple in-house assays. Efforts from the Fungal PCR 
Initiative (FPCRI)/Mucorales Lab working group of the International Society for Human and animal 
Mycology (ISHAM) are currently ongoing to improve standardization and provide 
recommendations, as was previously done for Aspergillus PCR assays by the European Aspergillus 
PCR Initiative (EAPCRI) working group. 
 
S03.6 
Management of mucormycosis in low and middle income countries 
A. Chakrabarti 
Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research, 
Chandigarh, India 
The epidemiology of mucormycosis is different in low and middle income countries (LMIC) from 
developed nations. In LMIC the number of mucormycosis cases is alarmingly high in diabetic 
patients, the spectrum of causative agents is wide with lack of knowledge on antifungal susceptibility 
of the new agents. Occasional unusual clinical presentation baffles the clinicians about diagnosis, and 
delay in seeking healthcare by patients leads to poor outcome of the disease. Additionally, the lack 
of awareness of the disease among clinicians, the lack of availability of appropriate diagnostic 
facilities, poor availability and affordability of antifungal agents pose serious challenge in the 
management of the disease. In a recent descriptive study covering 465 mucormycosis cases from 13 
centres in India, it was noted that 24% patients could not complete or start antifungal therapy due to 
affordability issue and nearly 20% patients were treated with amphotericin B deoxycholate. In 4.2% 
patients the therapy was shifted from liposomal to deoxycholate preparation of amphotericin B after 
certain period due to financial constraints, and improper antifungal therapy was prescribed in 7% 
patients. Due to those challenges, 90-day mortality was 52.0%, though majority (78.2%) of the patients 
had rhino-cerebral or cutaneous mucormycosis, which were not difficult for early diagnosis. 
Deferasirox of label use was also noted in certain number of patients. 
 
Symposium 4 MSG symposium (Trial Design in Clinical Mycology: Innovative 
Approaches) 
 
S04.5 
The Lung Transplant Community is Interested in a Clinical Trial to Determine the Optimal 
Strategy to Prevent Invasive Mold Disease 
R. La Hoz1, C. Jones2, G. Mcgwin3, T. Patterson4, P. Pappas3, J. Baddley3, O. Morrissey5 
1Internal Medicine, UT Southwestern Medical Center, Dallas, United States of America, 2The Ohio 
State University, Columbus, United States of America, 3University of Alabama at Birmingham, 
Birmingham, United States of America, 4University of Texas Health Science Center at San Antonio, 
San Antonio, United States of America, 5Monash University, Melbourne, Australia 
Objectives: The objectives of this survey were to: (1) describe the strategies used to prevent invasive 
mold disease in lung transplant recipients, (2) quantify the interest in participating in a clinical trial 
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to determine the optimal prophylactic strategy for invasive mold disease in lung transplant recipients 
and (3) to describe the design types and factors that influence willingness to participate in the clinical 
trial. 
Methods: We invited transplant providers to participate in an anonymous cross-sectional web-based 
survey via email between December 2018 and February 2019. The 139-item survey was hosted on the 
University of Alabama at Birmingham Research Electronic Data Capture (REDCap) server. The 
contact list was generated from a variety of sources. The study was approved the University of 
Alabama at Birmingham Institutional Review Board. 
Results: Of the 238 practitioners contacted, 50 (21.0%) responded to the survey. Responses were 
mainly from the United States 85.7% (36/42) and were transplant infectious diseases physicians 65.2% 
(30/43). The number of transplants performed at the responder’s centers during 2016 was less than 
20 in 44.4% (16/36), 21 to 50 in 19.4% (7/36) and more than 50 in 36.1% (13/16). Most responders, 81.0% 
(30/37), had a mold prevention protocol at their program. Universal prophylaxis was the most 
common prevention strategy 75.7% (28/37), followed by pre-emptive prophylaxis 10.8% (4/37), and 
targeted prophylaxis 5.4% (2/37). A quarter of the responders (7/34) used prophylaxis for <3 months, 
58.8% (20/34) for 3 to 6 months, 11.8% (4/34) for 6 to 12 months and 8.8% (3/27) for more than 12 
months. The majority of the responders, 84.6% (22/26) were interested in participating in a clinical 
trial to assess the optimal prophylactic strategy for mold infections in lung transplant recipients. 
Almost a quarter of the participants were willing to participate of the clinical trial with a universal 
prophylaxis study design of new azole formulation to mold active azole (Figure 1). The study design 
arms and the anti-fungals selected for the study arms were the factors that had the most influence in 
study participation (Figure 2).  
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Conclusion: Universal prophylaxis was the most common strategy to prevent invasive mold disease 
in lung transplant recipients. The majority of the responders were interested in a clinical trial to 
determine the optimal strategy to prevent mold disease in lung transplant recipients. The study 
design arms and the anti-fungals selected for the study arms were the factors that had the most 
influence in study participation. 
 
Symposium 5 Lung transplantation 
 
S05.1 
Pre-transplant assessment 
B. Rammaert1,2,3 
1Infectious Diseases, CHU Poitiers, Poitiers, France, 2U1070, INSERM, Poitiers, France, 3Faculté De 
Médecine Et Pharmacie, Université de Poitiers, Poitiers, France 
All the three main chronic pulmonary diseases leading to lung transplantation are at risk for fungal 
respiratory tract colonization: cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), 
and interstitial lung diseases (ILD). Aspergillus and Scedosporium species are the two main molds 
found in the lower respiratory tract of lung transplant candidates. Colonization in CF patients could 
be explained by impairment of muco-ciliary clearance, and in COPD and ILD patients by use of 
inhaled or systemic corticosteroids that alter pulmonary immunity. Mortality due to invasive fungal 
diseases in post-transplantation can reach 60% depending on the causal species. Therefore, fungal 
colonization of the lower respiratory tract is on the list of relative contraindications for lung 
transplantation. Although passage from colonization to infection is not well understood, fungal 
spores could remain quiescent in the lungs, and secondarily reactivate once patients have received 
immunosuppressive drugs. Donor-derived fungal infection is one of the best examples of this 
reactivation. Pre-transplant colonization is not considered predictive for fungal invasive disease in 
post-transplantation. However, the timing and bronchoalveolar lavage protocols for fungal screening 
in respiratory tract before lung transplantation are heterogeneous between centers. In addition, 
culture of lower respiratory tract specimens has to be done on specific media such as Sabouraud 
glucose agar or yeast extract-peptone-dextrose-agar (YPDA), which could miss out on some fungi. 
Utilization of culture media supplemented with antibiotics has increased the number of CF patients 
culture-positive for fungi in their respiratory specimens from 18% to 78%. Scedosporium specific media 
such as Scesel+ increase the detection of Scedosporium spp. compared to Sabouraud glucose agar. 
Active screening for fungal colonization during the pre-transplant period is consequentley crucial 
not only in patients on a waiting list, but also in donors. There is an urgent need for bronchoalveolar 
lavage and fungal culture standardization in the different mycological laboratories dealing with 
lower respiratory tract specimens before focusing on pre-transplant fungal colonization. 
 
S05.5 
From the lung to the heart: fatal dissemination of azole-resistant Aspergillus fumigatus in a lung 
transplant patient 
R.-A. Lavergne1,2, T. Lepoivre3, T. De Groot4, F. Jeddi2, D. Boutoille5, I. Danner-Boucher6, F. Morio1,2, 
J. Meis7, P. Le Pape1,2 
1Ea1155 Parasitology And Mycology Department, Nantes University, Nantes, France, 2Parasitology 
And Mycology Laboratory, Nantes University Hospital, Nantes, France, 3Thoracic Transplantation 
Intensive Care Unit, Nantes University Hospital, Nantes, France, 4Medical Microbiology And 
Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands, 5Tropical Infectious 
Diseases, University Hospital of Nantes, Nantes, France, 6Pneumology Unit, Nantes University 
Hospital, Nantes, France, 7Department Of Medical Microbiology And Infectious Diseases, Excellence 
Center For Medical Mycology (ECMM), Canisius Wilhelmina Hospital, Nijmegen, Netherlands 
Azole resistance in Aspergillus fumigatus has emerged as a worrisome problem since the last ten years. 
Patients suffering from cystic fibrosis (CF) are at risk of being colonized with azole-resistant isolates. 
At our CF reference center hospital, prevalence of azole resistance in A. fumigatus reached 6.8% in 
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2015. Though resistance is increasingly described, its impact in CF patients is yet poorly known. Here, 
we describe the case of a CF patient having long-term colonization of the respiratory tract with a non-
cyp51A mediated azole-resistant Aspergillus fumigatus isolate, prior to lung transplantation. Then, 
proven azole-resistant invasive aspergillosis and mucormycosis were diagnosed in the first days after 
transplantation and treated with liposomal amphotericin B. Two years later, azole-resistant 
Aspergillus fumigatus mitral-aortic endocarditis was diagnosed. Despite surgery and multiple 
antifungal regimens, the patient died with intracerebral hematoma. Objectives: The aim of the study 
was to investigate the genetic relationship between isolates collected at the time of transplantation 
and those from the native valve. Methods: Five isolates were retrospectively investigated for azole 
susceptibility to itraconazole (ITR), voriconazole (VOR), posaconazole (POS) and isavuconazole (ISA) 
(EUCAST method). Identification of A. fumigatus sensu stricto was confirmed using partial beta-
tubulin sequencing. Molecular mechanisms leading to resistance (nucleotide sequencing of cyp51A 
gene and its promotor) and STRAf genotypes were determined. Results: Two isolates were collected 
at time of transplantation (bronchial secretion (n = 1) and postoperative wound (n = 1)) and three 
isolates were collected during endocarditis episode (respiratory tract (n = 2) and mitral valve (n = 1)). 
All isolates were identified as Aspergillus fumigatus and were pan-azole resistant (MIC ITR: > 8 mg/L, 
VOR: 4 to 16 mg/L, POS: 0.5 to 1 mg/L, ISA: 8 to >16 mg/L). Sequencing of the cyp51A gene and its 
promotor (4 isolates) showed wildtype cyp51A and promotor. All isolates shared the same STRAf 
genotype (M2: 26-20-8 M3: 35-9-7 M4: 9-10-20) confirming dissemination of this isolate from the lung 
tissue to the heart. Conclusion: This case report highlights the need for regular screening for azole 
resistance in CF patients especially for those awaiting lung transplantation. Physicians should keep 
in mind that azole-resistant colonizing isolates could be a possible source of life threatening invasive 
infection after lung transplantation. Yet, antifungal treatment of Aspergillus endocarditis is based on 
voriconazole or lipid formulation of amphotericin B but no data are available in case of azole-resistant 
isolate. 
 
Symposium 6 Prophylaxis during hematology malignancies 
 
S06.1 
AML—in the era of FLT3 inhibitors 
R. Lewis1,2 
1Infectious Diseases Clinic, Sant’Orsola-Malpighi Hospital, Department of Medical and Surgical 
Sciences, University of Bologna, Bologna, Italy, 2Department Of Medical And Surgical Sciences, 
University of Bologna, Bologna, Italy 
FLT3 mutations are among the most common genetic mutations in acute myeloid leukemia (AML) 
associated with increased risk of disease relapse and poorer survival. A number of small molecule 
tyrosine kinase inhibitors (TKI) of FLT3 signalling have shown promise for reducing relapse of FLT3+ 
AML. One TKI, midostaurin, received fast-track approval in 2017 for the treatment of FLT3 positive 
AML on the basis of data demonstrating, for the first time in over 45 years, improved survival 
compared to standard induction 7+3 (cytarabine/anthracycline) chemotherapy. The use of FLT3 
inhibitors, however, is problematic in patients who require antifungal prophylaxis or treatment with 
triazole antifungals. In general FLT3 inhibitors are extensively metabolized by CYP3A4 to active 
metabolites with high potency and potential off-target effects. When coadministered with triazoles, 
FLT3 exposures may increase between 1.3 to 10 fold and alter production of active metabolites 
essential for FLT3 inhibition or increase off-target effects. Indeed, higher rates of pulmonary toxicity 
including fatal events, were observed among patients receiving midostarin with azole antifungals. 
Currently, the midostaurin SmPC does not recommend the co-administration of strong CYP3A4 
inhibitors such as voriconazole or posaconazole; although this recommendation is not practical for 
many patients especially with active fungal disease. Unfortunately, second-generation FLT3 
inhibitors currently in clinical studies (e.g., quizartinib) also appear to have similar risks as 
midostaurin as well as greater risk for dose-limiting myelotoxicity and QTC prolongation. It is clear 
that striking the balance between optimal antifungal prophylaxis vs. optimal FLT3 inhibition will 
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become a major challenge in the management of AML in the coming decade. This presentation will 
discuss the pros and cons of possible strategies for managing drug-drug interactions with FLT3 
inhibitors and antifungals in the absence of clearly-defined guidance. 
 
S06.4 
Baseline CT upon diagnosis of acute leukemia 
S. Schwartz 
Charité Berlin, Berlin, Germany 
Computed tomography (CT) is a routine diagnostic procedure in immunocompromised patients (i.e. 
patients with long-lasting neutropenia) with suspected fungal pneumonia. Particular radiological 
appearances of lung infiltrates (e.g. halo-sign) have been associated with lung infections caused by 
molds and findings have been incorporated into the well acknowledged definitions of invasive fungal 
infections developed by the EORTC/MSG (1). A conventional chest X-ray is usually performed in 
immunocompromised patients with fever, but the value of a conventional chest X-ray has been 
questioned due to its poor diagnostic yield and most recommendations advocate CT (2). A baseline 
chest CT in asymptomatic patients scheduled for therapies resulting in a profound 
immunosuppression (e.g. induction chemotherapy for acute leukemia) appears meaningful, but 
published data about this are limited. In a prospective study, 198 adult patients scheduled for 
hematopoietic stem cell transplantation or intensive chemotherapy were evaluated with a baseline 
CT (3). Overall, 72 (36%) patients showed lung abnormalities. Of these, 19 exhibited disease-defining 
lesions according to the EORTC/MSG definitions (nodules, halo sign, cavitation) and 53 patients 
showed other abnormalities (most frequently consolidations or ground-glass opacifications). Nine 
patients in each group were subsequently categorized as having proven or probable invasive mold 
infections. The risk of developing an invasive pulmonary mold infection was significantly higher 
among patients with disease-defining lesions according to the EORTC/MSG definitions or, less 
pronounced, with other abnormalities compared to patients with a normal baseline CT. In another 
study, 145 baseline CT scans from patients with acute leukemia scheduled for their first induction 
therapy were assessed retrospectively (4). Remarkably, the majority of baseline CT scans disclosed 
abnormalities (127; 88%) with nodules in 71 (49%) patients. Cavitations or lesions with a halo- or an 
air-crescent-sign were not present in this patient series. However, an independent radiological review 
and results from a comprehensive diagnostic evaluation were not available from this study. The high 
frequency of lung lesions at baseline, including disease-defining lesions associated with invasive 
mold infections, in patients scheduled for intensive chemotherapy or hematopoietic stem cell 
transplantation is striking. A baseline CT scan in these patients appears reasonable, but the overall 
benefit of this diagnostic approach in asymptomatic patients should be explored further in future 
studies. It would be desirable to evaluate in more detail other underlying, infectious/non-fungal and 
non-infectious, conditions (e.g. opacities associated with hyperleukocytosis) associated with lung 
lesions (5). Literature 1. de Pauw B, et al. Clin Infect Dis 2008;46(12): 1813–21. 2. Maschmeyer G. Curr 
Opin Oncol 2001;13: 229-35. 3. Ceesay MM, et al. Br J Haematol 2018;182: 723–27. 4. Vallipuram J, et 
al. Leuk Lymphoma 2017;58: 834–41. 5. Stefanski M, et al. Medicine 2016;95: e5285. 
 
S06.5 
Investigating the impact of posaconazole prophylaxis on systematic fungal screening using 
galactomannan antigen, Aspergillus qPCR and Mucorales qPCR. 
A.-P. Bellanger1, N. Tatoyan1, A. Berceanu2, H. Gbaguidi-Haore3, T. Monnot4, D. Bichard4, L. Millon1 
1Mycology, University Hospital Jean Minjoz, Besancon, France, 2Hematology, University Hospital 
Jean Minjoz, BESANCON, France, 3Infectious Risk Control, University Hospital Jean Minjoz, 
BESANCON, France, 4Pharmacy, University Hospital Jean Minjoz, BESANCON, France 
Objectives: At the University Hospital of Besancon, a systematic panel of fungal biomarkers is 
applied systematically to screen for invasive fungal infection (IFI) highly immunocompromised 
patients of the Hematology Department. This panel of biomarkers does include the galactomannan 
antigen (GM), Aspergillus qPCR and Mucorales qPCR. Most of the stem cell transplant (SCT) 
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recipients receive now posaconazole prophylaxis. The pertinence of systematic fungal screening has 
been discussed in the literature for patients under active antifungal prophylaxis, especially the 
realization of the GM. In this context, our main objective was to investigate retrospectively if the 
posaconazole prophylaxis influenced the numeric value of the GM. Our secondary aims were to 
assess the contribution of Aspergillus qPCR and Mucorales qPCR as well as the prevalence of IFI 
under active antifungal prophylaxis. 
Methods: The results of systematic fungal screening (GM, Aspergillus and Mucorales qPCR) were 
collected for all the SCT recipients, treated with posaconazole as prophylaxis treatment for more than 
8 days, from January 2015 to December 2016. Similarly, results of systematic fungal screening were 
collected for patients without posaconazole as prophylaxis treatment (induction chemotherapy-
January 2010 to December 2015). The statistical analysis of data was performed using the Stata 2 
software. 
Results: For the group of patients receiving posaconazole prophylaxis: 60 patients were included, 
with a mean period of prophylaxis of 107 days and a total 916 fungal screenings. The mean value of 
the GM was 0.17 (±0.32), the frequency of positive GM was 4.37%, the frequency of positive 
Aspergillus qPCR was 0.68% and the frequency of positive Mucorales qPCR was 3.66%. The 
frequency of IFI in this group was estimated at 5%. For the control group: 38 patients were included 
with a total of 392 fungal screenings. The mean value of the GM was 0.22 (±0.64), the frequency of 
positive GM was 5.61%, the frequency of positive Aspergillus qPCR was 12.35% and the frequency 
of positive Mucorales qPCR was 5.33%. The frequency of IFI in this group was estimated at 13%. The 
statistical analysis showed that posaconazole prophylaxis did not affect significantly neither the 
numeric value nor the frequency of positivity of the GM. A significant decrease of the frequency of 
positive Aspergillus qPCR was observed (0.68 vs 12.35, p = 0.015). A tendency of decreased frequency 
of IFI was also observed (5% vs 13%, p = 0.076). 
Conclusion: Our study did not demonstrate any negative effect of the posaconazole prophylaxis on 
the GM. This study highlights the high efficacy of the posaconazole prophylaxis, especially when 
using the tablet form, which was supported by a significant decreased frequency of positive 
Aspergillus qPCR and relatively lower frequency of IFI. The current screening strategy combining 
GM and fungal qPCRs is of high interest, even if the posaconazole prophylaxis is efficient, in a context 
of emerging infection with azole resistant strains of Aspergillus fumigatus and risk of A. fumigatus-
Mucorales mixed infections. 
 
Symposium 7 Paediatric Mycology (EPMyN) 
 
S07.5 
Isavuconazole use in pediatric hematoncologic patients: the Italian Association of Pediatric 
Hematology Oncology (AIEOP) experience 
N. Decembrino1, K. Perruccio2, A. Colombini3, E. Calore4, P. Muggeo5, E. Soncini6, A. Comelli7, M. 
Molinaro8, B.M. Goffredo9, S. De Gregori8, I. Giardini8, S. Cairoli9, L. Scudeller10, M. Zecca1, S. Cesaro11 
1Pediatric Hematology/oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 
2Division of Pediatric Hematology, University Hospital of Perugia, Perugia, Italy, 3Pediatric 
Hematology/oncology, Fondazione Monza e Brianza per il Bambino e la Mamma, Monza, Monza, 
Italy, 4Clinic Of Pediatric Hemato- Oncology, Department Of Women’s And Children’s Health, 
University Hospital of Padova, Padova, Italy, Padova, Japan, 5Department Of Pediatric Oncology 
And Hematology, University Hospital of Policlinico, Bari, Italy, Bari, Italy, 6Pediatric 
Hematology/oncology, Spedali Civili, Brescia, Italy, Brescia, Italy, 7Department Of Infectious And 
Tropical Diseases, Spedali Civili, Brescia, Italy, Brescia, Italy, 8Clinical And Experimental 
Pharmacokinetics Lab, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 9Metabolic 
Pathology Lab, Ospedale Pediatrico Bambino Gesù, Roma, Roma, Italy, 10Clinical Epidemiology And 
Biometric Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 
11Pediatric Hematology/oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy, 
Verona, Italy 
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Objectives: Isavuconazole (ISA) is a new triazole approved for invasive aspergillosis and 
mucormycoses treatment in adults only. Advantages are activity against both moulds and yeasts spp, 
excellent bioavailability after oral administration without relevant food or gastric pH effect, a water-
soluble prodrug without nephrotoxic excipients, poor drug-drug interactions. We analyzed ISA use, 
safety and efficacy in immunocompromised children. 
Methods: Italian Association Paediatric Hematology Oncology (AIEOP) multicentric retrospective 
analysis of pediatric hematoncologic patients who received ISA asinvasive fungal disease (IFD) 
treatment or prophylaxis. Due to the lack of recommended dosing in children and of PK/PD target 
value, therapeutic monitoring (TDM) was applied by a validated liquid chromatography-tandem 
mass spectrometry (HLPC-MS/MS) assay technique. ISA trough plasma concentrations (C0) and 3 
hours after drug intake (C3h) were measured. 
Results: Twenty-nine patients were included, (M/F 20/9); median age: 14.5 years (range 3–18), median 
bodyweight 47 kg (range 15–80). Ten patients only received chemotherapy, 19 patients received 
allogeneic hematopoietic stem cell transplantation (HSCT). Donors were haploidentical in 9 patients, 
matched-sibling in 4, allogenic-unrelated in 4 cases. ISA was used as prophylaxis in 5 patients, as IFD 
treatment in 24 cases: 20 for previous therapeutic failure (7 L-AMB, 4 Voriconazole, 5 combination 
therapy, 1 Posaconazole, 3 Caspofungin), 4 as first line therapy. According to EORTC criteria, IFD 
was proven in 5 patients (1 Aspergillus spp, 1 Aspergillus flavus, 1 Aspergillus fumigatus, 1 Penicillium 
spp. and 1 Mucor spp), probable in 9 and possible in 10 patients. Lungs were the main localization (18 
cases), liver was involved in 2 cases, 3 patients had sinus involvement (2 with central nervous system 
localizations), 1 had a disseminated infection. Patients under 30 kg bodyweight received half ISA 
dose, the others received adult schedule (200 mg TID loading dose on days 1 and 2, 200 mg/die 
maintenance); only 13 patients received loading dose. Ten patients only received oral therapy, in the 
others IV route was switched to oral during treatment. ISA was administered for a median of 75.5 
days (range 6–523 day), in combination with other antifungals in 7 patients (Caspofungin in 3 cases, 
L-AMB in 4). Overall response rate was 70.8%. IFD complete remission was achieved in 12 cases, 
partial remission in 5. Treatment failure was experienced by 5 patients, in 3 cases fungal lesions 
remained stable. No breakthrough infections were registered in prophylaxis group. TDM was 
applied to 17 patients including 1with severe veno-occlusive disease and 1 with renal failure 
secondary to thrombotic-microngiopathy. Overall median ISA Ctroughss concentration observed was 
4.91 mg/L (2.15–8.54); Conc/Dose (kg) ratio was 1.13 (0.47–3.42). In 6 cases a 12h-PK profile was 
carried out and median AUC0–12h of 153,16 mgxh/L (range 86.31–169.45) was obtained. CTAE grade 
II-III toxicity was observed in 6 patients, with increased transaminase and/or creatinine levels which 
resolved after temporary ISA withdrawal. We did not observe drug-drug interactions in the patients 
receiving immunosuppressant as graft versus host disase prophylaxis (5 cyclosporine, 2 sirolimus, 1 
tacrolimus). 
Conclusion: Isavuconazole may be useful and safe in the pediatric population with hematoncologic 
diseases, even in the HSCT setting. Prospective studies are warranted. 
 
Symposium 8 Immunologic markers for diagnosis and treatment stratification in 
invasive mold infection 
 
S08.3 
Immunologic Markers for Treatment Stratification in Invasive Mold Infection 
P. Köhler 
Department I Of Internal Medicine, University Hospital of Cologne, Cologne, Germany 
The two major entities, invasive aspergillosis and mucormycosis account for the majority of fungal 
mould infections in haematology and oncology. With increased hospital admission rates and 
admission to intensive care unit and high morbidity and mortality the need for prompt identification 
and outcome prediction is needed. Current in vitro diagnostic approaches comprise direct 
observation of fungi in biopsy or bronchoalveolar lavage samples, blood cultures and detection of 
diagnostic antigens such as galactomannan. New immunologic markers for diagnosis and treatment 
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stratification have been recently published. Fungus-reactive CD4 T cells, interleukin profiling and 
inflammation parameters will be discussed with regard to treatment stratification depending of 
response of invasive mould infections. Possible developments could lead to algorithms incorporating 
measurement of these biomarkers at admission and throughout initial treatment for the purpose of 
identifying patients who warrant more aggressive treatment. 
 
S08.4 
Fungal Translocation: from persistent inflammation to non-AIDS events 
M. Hoenigl1,2 
1Division Of Infectious Diseases, Department of Medicine, UCSD, San Diego, United States of 
America, 2Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, 
Medical University of Graz, Graz, Austria 
Abstract: 1,3-β-D-glucan is a fungal cell wall polysaccharide produced by ascomycete fungi including 
Candida albicans and other yeast that colonize the GI tract. Recently we and others have shown that 
in the absence of an invasive fungal infection blood 1,3-β-D-glucan levels may serve as a marker of 
microbial translocation in patient populations with hypoperfusion of the gut and those with 
persistent inflammation, including patients with advanced liver cirrhosis, sepsis or HIV infection, 
where blood 1,3 β-D-glucan have been shown to be elevated compared to HIV negative controls and 
to correlate with other biomarkers of microbial translocation, with markers of immune activation and 
with lower Lactobacillales proportion (i.e. less protective) in the gut microbiome. In animal models 
1,3-β-D-glucan has been shown to decrease Dectin-1 (innate pattern recognition receptor essential for 
the control of fungal infections), and also NKp30 (NK receptor mediates direct fungal recognition 
and killing) on monocytes and NK cells respectively, and induced pro-inflammatory cytokines 
secretion, indicating a potential role in pathogenesis of clinical events. Going one step further, studies 
have shown clear correlations between blood 1,3-β-D-glucan levels and non-AIDS events, including 
cardiopulmonary morbidity, and neurocognitive impairment. Only few studies to date have 
evaluated a potential benefit of antifungal treatment for tackling fungal translocation and reducing 
blood 1,3-β-D-glucan levels. In vitro model of mixed rat neuronal cultures that screened more than 
2000 compounds, half of which were US Food and Drug Administration approved drugs for putative 
neuroprotective effects against oxidative stress-mediated neuronal injury not only paroxetine, a 
selective serotonin reuptake inhibitor, but also fluconazole, protected hippocampal neurons. In 
another study, the combination of paroxetine and fluconazole protected macaques from simian 
immunodeficiency virus–associated neurodegeneration. However, a phase 1/2, randomized, double-
blind, placebo-controlled study for the treatment of HIV-associated neurocognitive impairment did 
not show an improvement of neurocognitive outcomes among the 9 participants randomized to 
fluconazole treatment alone, indicating that more research and larger studies are needed on how to 
prevent/treat fungal translocation. 
 
S08.5 
Immunological characteristics of Broncho alveolar lavage in neutropenic patients with invasive 
aspergillosis 
C. Aguilar1, S. Moshkelgosha2, W. Gohir1, K. Yee3, A. Schimmer3, M. Minden3, A. Schuh3, C. Ryan4, S. 
Juvet2, S. Husain1 
1Transplant Infectious Diseases, University Health Network, Toronto, Canada, 2Lung Transplant 
Program, University Health Network, Toronto, Canada, 3Hematology Department, University 
Health Network, Toronto, Canada, 4Respirology, University Health Network, Toronto, Canada 
Objectives: Invasive aspergillosis (IA) is a major complication in patients with acute leukemia 
receiving high dose chemotherapy. Diagnosis of IA classically relies on radiological criteria 
associated with direct and/or indirect microbiological tests, which have some limitations. some 
limitations. Antifungal immunity involves phagocytic cells including neutrophils and macrophages, 
as well a dendritic cells presenting antigen to T-CD4+ T cells. Antigen presentation leads to 
differentiation of CD4+ T cells into Th1 and Th17 cells, under the influence of cytokinic environment. 
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Those cells secrete cytokines and amplify effector functions of phagocytic cells in order to kill the 
fungus. The triggering of those mechanisms relies on the recognition of fungal patterns by receptors 
of innate immunity, both soluble (such as PTX-3) and membrane bound (such as Dectin-1 and Dectin-
2). In this study we aimed to assess the immunological parameters of broncho alveolar lavage (BAL) 
fluid of neutropenic patients with or without IA. 
Methods: We included acute myeloid leukemia patients who were neutropenic after receiving high 
dose chemotherapy and who underwent a bronchoscopy for diagnosis of pneumonia. Ten milliliters 
of BAL fluid were collected for the research study. Supernatant and cell pellet were separated and 
frozen until use. The level of 35 cytokines (EGF, Eotaxin, FGF basic, G-CSF, GM-CSF, HGF, IFN-α, 
IFN-γ, IL1-ra, IL-1α, IL1-β, IL-2, IL-2r, IL-3, IL-4, IL-5, IL-6, IL-7, IL-7, IL-8, IL-9, IL-10, IL-12 (p40/p70), 
IL-13, IL-15, IL-17A, IL-17F, IL-22, IP-10, MCP-1/CCL2- MIG, MIP-α, RANTES, TNF-α, and VEGF) 
was measured in BAL supernatant using Luminex technology. PTX-3 level in BAL supernatant was 
measured by Enzyme-linked immunosorbent assy. The cell pellet was analyzed by flow cytometry 
for expression of CD45, CD206, CD163, Dectin-1 and Dectin-2. 
Results: Forty three patients were included in the study. Seven patients were diagnosed with 
probable IA and 20 with possible IA. One patient had mucormycosis diagnosed on lung biopsy and 
1 patient had fusariosis. While PTX-3 level was not significantly different in patients with probable 
IA compared to patients without IA, IL-6, IL-8 land GM-CSF levels were higher in patients with 
probable IA compared to patients without invasive fungal infection. Flow cytometry could be 
performed on 31 BAL cell pellets. The proportion of alveolar macrophages (CD163+ CD206+) among 
CD45 positive cells was similar in all groups. Dectin-1 and Dectin-2 expression on alveolar 
macrophages (CD163+ CD206+ cells) was similar in patients with and without invasive fungal 
infection. 
Conclusion: Neutropenic patients with probable IA exhibit higher IL-8, IL-6 and GM-CSF levels in 
BAL supernatant compared to neutropenic patients without any fungal infection. The cellular 
expression of membranar receptors Dectin-1 and Dectin-2, as well as the level of soluble PTX-3 were 
not significantly modified in patients with IA. Further studies are needed to assess the role of 
immunological parameters, especially cytokines profile, in the panel of tests used for the diagnosis 
of IA in immunocompromised patients. 
 
Symposium 9 Chronic Pulmonary Aspergillosis 
 
S09.2 
Diagnosis of CPA. Where do we stand? 
A. Barac 
Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Belgrade, Serbia 
Abstract: Chronic pulmonary aspergillosis (CPA) is an uncommon, slowly destructive pulmonary 
disease characterized by progressive cavitation, fibrosis, and pleural thickening. CPA is usually seen 
in immunocompetent individuals with underlying respiratory disorders. Estimates suggest that up 
to 3 million people are affected worldwide causing high rates of morbidity and mortality. Diagnosis 
of CPA is often challenging and delayed and should be based upon a combination of characteristics. 
Patients are present with indolent, non-specific symptoms such as fatigue, weight loss, sweats, cough, 
dyspnea, or hemoptysis. The disease often remains undiagnosed for years, resulting in progression. 
A high index of suspicion is required in patients with predisposing factors such as previous 
tuberculosis (TB) with residual cavities, severe chronic obstructive pulmonary disease, previous 
treatment for lung cancer, or nontuberculous mycobacteria. The most important diagnostic finding 
is changes on chest imaging, usually CT scan. The most common presentation is one or more cavities, 
characteristically with an irregular or thick wall, but occasionally thin-walled, with or without 
intracavitary material or well-formed aspergilloma. Cavities tend to affect the upper lobes and often 
cause para-cavitary or adjacent pleural fibrosis. In early stages, nodules may be present, which may 
develop into cavitary disease over time. Differential diagnosis includes mycobacterial infection, 
bacterial abscess, cancer, or vasculitis. Expertise of the reporting radiologist is essential in 
J. Fungi 2019, 5, 95 44 of 464 
 
highlighting the possibility of CPA. In addition to compatible radiological findings, microbiological 
and/or serological evidence of Aspergillus infection is required, in addition to ruling out alternative 
diagnoses. Direct microscopy for hyphae, fungal culture of respiratory secretions and histology are 
all recommended for diagnosis of CPA. Sensitivity of sputum or bronchoalveolar lavage (BAL) 
culture remains moderate at best, even when specific fungal media are used. Culturing a higher 
volume of sputum may lead to increased sensitivity. Sensitivity is significantly higher with the high-
volume culture, which in addition detected azole-resistant isolates that could be missed with 
conventional culture. When microscopy and cultures are negative, molecular markers like 
Aspergillus polymerase chain reaction (PCR), as well as beta D-glucan, galactomannan (GM) testing 
in BAL samples can be used to increase sensitivity. In addition, using these tests in combination may 
result in better PPV. The usefulness of testing GM in sputum is not clear in a cohort of patients with 
CPA and ABPA. Therefore, sputum GM cannot be recommended for the diagnosis of CPA at present. 
Serological methods can contribute to the diagnosis of CPA. Aspergillus precipitins were used 
previously but have been supplanted by more sensitive serologic assays. Several assays detecting 
Aspergillus-specific immunoglobulin G (IgG) are commercially available. In summary, clinical and 
radiological findings, along with microbiological and serological tests are used in combination to 
diagnose CPA. There is no individual reference-standard test as all tests are characterized by 
suboptimal sensitivity and specificity. A high index of suspicion is needed, along with the need to 
rule out alternative diagnoses like TB or lung cancer. 
 
S09.5 
Raised amphotericin B MIC in Aspergillus fumigatus isolates from patients with Chronic 
Pulmonary Aspergillosis 
F. Lynch1,2, C. Moore2,3, R. Rautemaa-Richardson1,2,4 
1Infectious Diseases, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 
2National Aspergillosis Centre, Manchester, United Kingdom, 3Mycology Reference Centre 
Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 4Division 
Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, United 
Kingdom 
Objectives: Chronic pulmonary aspergillosis (CPA) is a fungal infection of the lung caused by 
Aspergillus species, which usually affects patients with an underlying respiratory condition. The 
mainstay of treatment is prolonged antifungal therapy to improve symptoms and prevent disease 
progression. Aspergillus fumigatus with elevated minimum inhibitory concentrations (MIC) for 
amphotericin B (AMB) have been isolated. The aim of this study is to investigate the emergence and 
clinical relevance of elevated AMB MICs in A. fumigatus. 
Methods: Patients with CPA reported with AMB resistant (MIC > 4 mg/L) A. fumigatus were 
identified from the Mycology Reference Centre Manchester databases. All A. fumigatus isolates 
reported from these patients were included in the analyses. The date of sampling and resistance 
patterns of the isolates were analysed against the antifungal history of each patient. EUCAST 
antifungal breakpoints were used to determine sensitivity. Clinic letters and dispensing records were 
used to determine medical history, antifungal therapy and clinical outcomes. 
Results: Nine patients reported with one or more AMB resistant A. fumigatus isolates and a total of 
148 isolates from these patients were identified. Of the isolates, 34 (22%) were resistant to AMB; 13 
(38%) had an MIC of 4 mg/L, five (15%) had an MIC of 8 mg/L and 16 (47%) had an MIC of >8 mg/L. 
In addition, 18 (12%) isolates were reported as intermediate to AMB (MIC = 2 mg/L). Five of the nine 
patients had prior exposure to AMB (IV AmBisome). Patients received 3-5 mg/kg once daily and 
different treatment regimens were used; one patient had one 3-week course, two patients had two 3-
week courses and two patients received long term therapy three times weekly (for up to 3 years). 
Four patients had no exposure to AMB. Of the 5 patients exposed to AMB, 4 developed resistance 
during therapy, and 1 patient first showed resistance 5 years after their 3-week course. All patients 
had prior azole exposure, and the duration of azole exposure prior to AMB resistance was from 8 
months to 5 years. All AMB resistant isolates showed some level of azole resistance and 27 (82%) 
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were pan-azole resistant. Example patient timeline  
 
Conclusion: All patients reported with A. fumigatus with elevated MIC for AMB had previously been 
treated with azole antifungals and developed resistance against one or more azoles. Many AMB 
resistant isolates were pan-azole resistant suggesting a link between AMB and azole resistance. 
Antifungal drug resistance can have significant implications on patient care due to limited treatment 
options. A better understanding of the development, genetic mechanism, and clinical relevance of 
AMB resistance is needed. Therefore, all isolates identified in this study will next be sequenced and 
typed. 
 
Symposium 10 Symposium 10 Sensing the host 
 
S10.2 
Hybrid histidine kinases: major sensing proteins in pathogenic fungi 
N. Papon1, S. Kabbara1, A. Hérivaux1, B. Bidon1, J. Kilani1, Y. Le Govic1, A. Gastebois1, T. Dugé De 
Bernonville2, M. Clastre2, V. Courdavault2, S. Le Gal1, G. Nevez1, J.-P. Bouchara1 
1Host-Pathogen Interaction Study Group, SFR ICAT 4208, Univ Angers, Univ Brest, University 
Hospital Center, Angers, France, 2Ea2106 “biomolécules Et Biotechnologies Végétales”, Université de 
Tours, Tours, France 
Protein phosphorylation is one of the most extensively used modifications in signal transduction 
pathways in both prokaryotic and eukaryotic cells. Prominent families of enzymes that perform these 
protein phosphorylations encompass serine/threonine kinases, tyrosine kinases, and histidine 
kinases (HKs). While HKs dominate prokaryotic signaling pathways, they are less prevalent in 
eukaryotes, and most importantly, absent in animals. Historically, a small number of eukaryotic HKs 
have been studied in plants, yeasts, filamentous fungi, and slime molds. Recent studies have 
expanded characterization of HKs in other eukaryotic lineages and archaea, allowing a broader 
assessment of the types of signaling systems mediated by HKs, their phylogenetic distribution and 
evolution. HKs are central to regulatory systems that impact agriculture, the environment, and both 
beneficial and pathogenic interactions of microbes with humans and other animals. Their great 
diversity, versatility, and broad distribution make them attractive targets for therapeutics, 
biotechnological interventions, and also as building blocks for engineered biosensor systems. From a 
structural perspective, fungal HKs are commonly composed of three main regions. The first region 
referred to as the “sensing domain” corresponds to a highly variable N-terminal sequence that 
determines the stimulus perceived. The central “transmitter region” is made of two conserved 
domains: a dimerization histidine phosphotransfer (DHp) domain and a catalytic ATP-binding (CA) 
domain. The DHp domain includes an H-box, usually containing the phosphorylatable histidine 
residue, and an X-box. The CA subdomain includes four distinct sequence motifs: the N-, G1-, F-, and 
G2-boxes. In contrast to prokaryotic HKs, most eukaryotic HKs harbor an additional C-terminal 
receiver domain (REC) that includes a phosphorylatable aspartate residue. Thus, eukaryotic HKs are 
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generally called “hybrid HKs” (HHKs). From a mechanistic point of view, HHKs constitute in fungal 
cells the initial sensing proteins of a four-step phosphorelay signaling pathway involving 
phosphorylation events of two downstream effectors, i.e. histidine phosphotransfer shuttle proteins 
(Hpts) and response regulators (RRs) (Figure 1). The perception of a stimulus induces the trans-
autophosphorylation of a conserved His residue in the DHp domain by the CA catalytic part of the 
HHK. The phosphate of this histidine is then transferred to the conserved Asp residue in the REC 
domain prior to transfer to the Hpt domain, and finally to the conserved aspartate residue of the 
protein belonging to the RR family. The phosphorylation state of this RR orchestrates subsequent 
molecular events underlying the response to the input signal. 
 
Here, we review the distinct genetic approaches carried out over the last fifteen years and that 
allowed the elucidation of the function of several HKs in prominent fungal pathogens. However, 
because their roles in regulating fundamental cellular processes are still largely obscure in fungi, we 
will discuss the major challenges that remain to improve our knowledge about the function of HKs 
in fungi and to design specific inhibitors for future therapeutic development. 
 
S10.5 
The analysis on the genes related to the biofilm formation of Candida glabrata 
X. Chen1, T.W. Widiyanto1, H. Chibana2, S. Kajiwara1 
1School Of Life Science And Technology, Tokyo Institute of Technology, Yokohama, Japan, 2Medical 
Mycology Research Center, Chiba University, Chiba, Japan 
Objectives: Candida glabrata is capable of developing biofilm on the surface of host cells and medical 
materials. The biofilm formation is considered as one of pathogenic factors on infection to the host, 
which shows increase in the resistance to antifungals and host immune defense compared to the 
planktonic cells. Until now, the mechanism of biofilm formation of C. glabrata has not been studied 
well compared with C. albicans. Therefore, the aim of our study was to isolate and characterize some 
genes related with the biofilm formation of C. glabrata. Methods: The in vitro model of biofilm 
formation was constructed by using multi-well plates and the metabolic activity were detected by 
XTT assay. The susceptibility of biofilm formation was also detected towards different antifungals. 
Gene expression was analyzed by qPCR. Vacuolar morphology was observed by staining with FM4-
64 fluorescent dye. The growth fitness was detected in buffered media with different pH and 
intracellular pH was measured with flow cytometry. Results: Upon the result of a genetic 
comprehensive screening by using C. glabrata mutant library, two gene mutants decreased metabolic 
activity of biofilms drastically and the transcriptional expressions of these two genes in biofilm 
formation showed more than two times higher than those of planktonic cell growth. One gene 
showed high homology with Saccharomyces cerevisiae SYN8 gene, then was named as CgSYN8. S. 
cerevisiae Syn8p was identified as a SNARE protein, acting in membrane fusion of vesicles. C. 
glabrata syn8Δ mutant was defective in both the metabolic activity and the biomass of the biofilm. 
Deletion of SYN8 also led to decrease in the adhesion ability during the biofilm formation, which 
may link to the repression of two adhesin genes, EPA10 and EPA22. Additionally, C. glabrata syn8Δ 
mutant revealed the abnormal vacuolar morphology. Therefore, it was suggested Syn8p is not only 
required for the normal vacuolar function but also influence the biofilm formation of C. glabrata. 
Another gene related to the biofilm formation of C. glabrata was named as CgQDR2. QDR (quinidine 
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drug resistance) family genes in S. cerevisiae belong to MFS (Major Facilitator Superfamily) 
transporters, which mediate the ability of membrane transport to actively efflux the drug out of the 
cell. C. glabrata qdr2Δ mutant exhibited significant reduction in the biofilm formation and 
fluconazole drug susceptibility during biofilm formation. In addition, our results suggested QDR2 
deletion caused an impaired ability of C. glabrata to maintain pH homeostasis, then might lead to the 
reduction of cell growth at neutral-basic pH conditions. These results may explain how the QDR2 
gene affect the biofilm susceptibility and drug efflux towards antifungal drugs in C. glabrata. 
Conclusion: CgSYN8 and CgQDR2 were suggested to be involved in biofilm formation of C. glabrata. 
These findings provide more understanding on the biofilm formation of this fungus and more 
information for the development of clinical treatment in future. 
 
Symposium 12 Environment & fungal outbreaks 
 
S12.1 
‘Once is a misfortune, twice is carelessness…’: Lessons to be learnt from pandemic fungal 
infections of amphibians 
M. Fisher 
Department Of Infectious Disease Epidemiology, Imperial College London, London, United 
Kingdom 
Abstract: Discovering that chytrid fungi cause the disease chytridiomycosis in amphibians 
represented a paradigm shift in our understanding of how emerging infectious diseases contribute 
to global patterns of biodiversity loss. In this lecture I describe how the use of multidisciplinary 
biological approaches has been essential to pinpoint the origins of pathogenic chytrids, to time their 
emergence and pathways of spread and to identify the core mechanisms that underpin their 
pathogenicity. I will discuss the potential for using bioinformatics toolkits and experimental methods 
to allow a fuller understanding of these chytrids biology in order to leverage emerging technologies 
aimed at their control. The impacts of infectious diseases in wild populations are not restricted to 
wild animals and plants; they also threaten public health through the attrition of ecosystem services 
as well acting as reservoirs and amplifiers of disease inocula. I will argue that the lessons learnt from 
tracking amphibian chytrid fungi are also of relevance to understanding and tackling emerging 
patterns of fungal disease in humans. Paraphrasing Oscar Wilde, ‘to allow one fungal pandemic is 
misfortune, to allow two is carelessness, to allow three…’. 
 
S12.2 
The Cryptococcus gattii species complex 
F. Hagen1,2,3 
1Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, Netherlands, 2Medical 
Microbiology, University Medical Center Utrecht, Utrecht, Netherlands, 3Department Of 
Dermatology, Jining No. 1 People's Hospital, Jining, China 
Abstract: The Cryptococcus gattii species complex placed itself in the spotlights of the medical 
mycology community with the unprecedented and ongoing outbreak that emerged in the temperate 
climate of Vancouver Island (British Columbia, Canada) during the late 1990s. A few years thereafter 
the outbreak was found to have spread to the Canadian mainland and the Pacific Northwest of the 
U.S.A. This pathogenic yeast, at that time named Cryptococcus neoformans variety gattii, was mostly 
known as being a tropical or subtropical pathogen that caused disease among apparently 
immunocompetent subjects. It was observed that the outbreak in Canada and the U.S.A. was due to 
an until then rare genotype named AFLP6/VGII, mostly known from Australia and the South 
American continents. Subsequent molecular typing showed that the outbreak was caused by a major 
(AFLP6A/VGIIa) and a minor (AFLP6B/VGIIb) genotype that had different virulence properties. In 
2002 C. neoformans variety gattii was raised to species level as Cryptococcus gattii. Using several 
molecular techniques five lineages were recognized, nowadays known as molecular types 
(genotypes) VGI (AFLP4), VGII (AFLP6), VGIII (AFLP5) and VGIV (AFLP7), the fifth lineage is 
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extremely rare and known as genotype AFLP10/VGIIIc. Although C. gattii was just proposed as being 
a separate species, the debate was already ongoing whether or not to further differentiate it into more 
species related to the molecular defined lineages. A further refinement for a taxonomic revision was 
supported by the availability of more molecular, phenotypic, antifungal sensitivity, geographic 
distribution and predilection for certain hosts. In 2015 a proposal was made to raise the five lineages 
to species level: C. gattii sensu stricto (AFLP4/VGI), C. bacillisporus (AFLP5/VGIII), C. deuterogattii 
(AFLP6/VGII), C. tetragattii (AFLP7/VGIV) and C. decagattii (AFLP10/VGIIIc). Due to the outbreak 
with C. deuterogattii in North America most of the focus was on this species, but what do we know 
about the other members of the C. gattii species complex in terms of environmental distribution and 
clinical relevance? 
 
S12.4 
Whole genome sequencing: a valuable tool to study outbreaks due to uncommon yeast species 
M. Desnos-Ollivier 
National Reference Center For Invasive Mycoses & Antifungals, Molecular Mycology Unit, Cnrs 
Umr2000, Institut Pasteur, Paris, France 
Abstract: Rapid genotyping tools such as Multi Locus Sequence Typing (MLST) and Variable 
Number Tandem Repeat (VNTR) are frequently used for common yeast species involved in invasive 
human infection (Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, 
Pichia kudriavzevii, Cryptococcus neoformans/gattii complex). These methods are very useful to 
determine potential link between clinical and/or environmental isolates but 
implementation/validation requires a large number of unrelated isolates. Grouped-cases of infection 
or colonization due to uncommon or emerging pathogenic yeast species are usually considered to be 
due to a single strain. Since there is no genotyping method for these uncommon species and 
considering that origin of the infection can be endogenous and/or exogenous, this hypothesis should 
be verified. Whole genome sequencing (WGS) has become relatively simple, fast and inexpensive but 
analysis remains time-consuming and requires bioinformatic expertise. Since 2012 and the first 
French outbreak due to Saprochaete clavata, we started using WGS to study relationship between 
isolates involved in grouped cases and belonging to uncommon yeast species. Different approaches 
involving different parts of the genome can be considered. For S. clavata, alignment of whole genome 
allowed to identify different clades, one of which was responsible for the national epidemic with 
specific Single Nucleotide Polymorphism positions (SNP). Then, some SNPs were selected to design 
a real time PCR with allele-specific oligonucleotide (ASO) which allowed us to rapidly detect isolate 
belonging to the epidemic clade. Another approach was the use of WGS data of Yarrowia lipoytica 
to identify intergenic regions highly polymorphic and usable as molecular tool. Finally, the alignment 
of SNPs positions localized all over the genome was used to study genomic diversity of Trichosporon 
asahii and Magnusiomyces capitatus population. Although the presence of a rare species in several 
patients in the same hospital over a short period of time suggest a common source of infection, this 
is not always the case especially for species that are supposed to be part of the normal biota of skin 
and/or gastrointestinal tract. Our data confirm the importance of data and isolate centralization in a 
Reference Laboratory for molecular epidemiology. The routine WGS as a typing method for 
uncommon yeasts requires prior validation with varied sampling together with bioinformatics 
experts and mycologists to avoid misinterpretation. 
 
S12.5 
Outbreak of fluconazole-resistant Candida parapsilosis in a hospital ward: arguments for clonal 
transmission and environmental persistence 
A. Fekkar1,2, A. Bougle3, A.C. Normand1, M. Palous1, R. Piarroux1, S. Imbert1 
1Laboratoire De Parasitologie-mycologie, APHP La Pitié Salpétrière, PARIS, France, 2Sorbonne 
Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, F-75013, 
PARIS, France, 3Réanimation Chirurgie Cardiaque, La Pitie Salpetriere Hospital, Paris, France 
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Objectives: The emergence of multidrug-resistant fungal agent is a threat for human health. In recent 
years, breakthroughs of infections due to fluconazole-resistant Candida parapsilosis isolates have been 
increasingly reported in different countries. We have recently faced with invasive infections due to 
resistant isolates and have decided to further investigate this phenomenon. 
Methods: We conducted a monocentric study at La Pitié-Salpêtrière Hospital, a tertiary care center 
in Paris, France. All Candida parapsilosis isolates collected between January 2012 and April 2019 for 
which sensitivity to antifungal agents had been determined were analyzed. Antifungal susceptibility 
testing was performed using Etest (Biomerieux) method and confirmed according the EUCAST broth 
microdilution reference method. Minimal Inhibitory Concentrations were determined for azoles 
drugs (i.e. fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole). For fluconazole 
resistant isolates and a random selection of susceptible isolates, the erg11gene was sequenced and 
isolates were genotyped by a microsatellite method based on 6 markers. 
Results: 193 isolates (193 patients) sampled between 2012 and 2019 were analyzed. We observed an 
increase of fluconazole resistance rate among Candida parapsilosis isolates (MIC > = 8 µg/mL) between 
the periods 2012-2016 (3/97, 3.1%) and January 2017-April 2019 (10/96, 10.4%) (p<0.05 by Fisher's 
Exact test) : three fluconazole-resistant isolates were detected in 2012-2013, none in 2014-2016 and 10 
between January 2017 and April 2019. All the resistant isolates presented the previously described 
A395T mutation in the erg11 gene that confers the amino acid change Y132F. This mutation was 
absent in azole-sensitive isolates. Genotyping showed 4 different microsatellite profiles for resistant 
isolates (R1, R2, R3 and R4) while susceptible isolates were not related each other’s and showed a 
greater diversity (Figure 1). 
 
Two resistant clusters (R1 and R3) were related to grouped cases in a single intensive care unit (ICU). 
Isolates belonging to the R3 profile (n = 7) were detected since November 2017, were responsible of 7 
deep infections and presented the highest MICs to fluconazole (> 64 mg/L) and a cross resistance with 
voriconazole (MIC > 0.5 mg/L). Epidemiological and chronological analyses furnish clues for a 
patient-to-patient transmission but also suggest an ability of resistant isolates to persist in the ward 
environment. Indeed, two isolates of the same genotype R1 were detected 4 years apart in the same 
ICU. 
Conclusion: Our work shows an increase of the incidence of fluconazole-resistant Candida parapsilosis 
isolates in intensive care units in relation to the clonal spread of few strains. Our results provide 
evidence of i. patient-to-patient transmission and ii. persistence of resistant clone over time in the 
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same unit. Our study urges for a better investigation of fungal resistance and improved eradication 
measures to limit the spread of this resistant emerging pathogen. 
 
Symposium 13 Fungal respiratory infections in cystic fibrosis (the 
ECMM/ISHAM working Group Fri-CF) 
 
S13.1 
Rasamsonia species and other emerging fungi in CF 
S. Le Gal1,2, G. Nevez1,2, L. Favennec3,4, J.-P. Bouchara5,6 
1Laboratory of Parasitology-Mycology, University Hospital Center, Brest, France, Brest, France, 
2Host-pathogen Interaction Study Group Ea3142, University of Brest - University of Angers, BREST, 
France, 3Laboratoire De Parasitologie-mycologie, CHU de Rouen, Rouen, France, 4Protozooses 
Transmises Par L’alimentation, University of Rouen - University of Reims, Rouen, France, 5Host-
Pathogen Interaction Study Group, SFR ICAT 4208, Univ Angers, Univ Brest, Institute of Biology in 
Health, IRIS, University Hospital Center, Angers, France, Angers Cedex, France, 6Laboratory of 
Parasitology-Mycology, University Hospital Center, Angers, France, Angers, France 
Abstract: Cystic fibrosis (CF) is the most common genetic inherited disease in the European 
Caucasian population. The disease is caused by mutations in the gene CFTR (Cystic Fibrosis 
Transmembrane conductance Regulator) which encodes a membrane transporter involved in 
electrolytic exchanges across the apical membrane of epithelial cells. Several organs are therefore 
affected by these mutations, but the clinical picture is dominated by respiratory infections. Indeed, 
because of the resulting thickening of the bronchial mucus, the respiratory tract is often colonized by 
microorganisms, leading to respiratory infections which are the major cause of morbidity and 
mortality in patients with CF. Bacteria, mainly Staphylococcus aureus and Pseudomonas aeruginosa, 
are the major cause of these infections. However, several yeasts and filamentous fungi may also 
colonize the airways of patients with CF, sometimes leading to pulmonary infections and to severe 
disseminated infections after lung transplantation. Moreover, even in the absence of clinical signs, 
this fungal colonization could contribute to the inflammatory reaction and thus to the progressive 
deterioration of the lung function. If the epidemiology and pathophysiology of fungal infections still 
remain largely unknown, the frequency of these infections increases together with life expectancy of 
CF patients. Aspergillus fumigatus ranks first among the filamentous fungi colonizing the airways 
of patients with CF, followed by Scedosporium species, Exophiala dermatitidis, Lomentospora 
prolificans (formerly Scedosporium prolificans), and Aspergillus terreus. The prevalence of these 
fungi varies from one study to another because of: i) differences in patient recruitment (age, CFTR 
genotype); ii) lack of standardization of the procedures used for mycological examination of 
respiratory secretions; iii) geographical and climatic variations. In addition, other fungal species have 
been increasingly reported during the past decade, such as the yeasts Candida blankii, 
Trichomonascus ciferrii and Blastobotrys adeninivorans / Blastobotrys raffinosifermentans. These 
yeasts share the capability to use diamines, such as putrescine, which may explain that they multiply 
in the bronchial mucus during pulmonary exacerbations since the concentration of putrescine 
increases in this context. Likewise, some filamentous fungi including Arthrographis kalrae and 
species of the Rasamsonia argillacea complex (formerly Geosmithia argillacea, but first reported in 
CF as Penicillium emersonii) seem to be emerging in CF. Although it is usually well tolerated, the 
chronic colonization of the airways by these fungi should not be disregarded since it constitutes a 
risk factor for disseminated infections in the case of lung transplantation. The emergence of these 
fungi could be explained at least in part by improvements in diagnostic methods, or by selection 
pressure caused by repeated antifungal cures. Our knowledge of the ecology of these filamentous 
fungi still remains in infancy; nevertheless, regarding species of the Rasamsonia argillacea complex, 
some observations suggest that they could be xylophagous fungi that have spread in Europe since 
the end of the last century as a consequence of global warming and of the many storms that have 
crossed Europe since the end of the nineties. 
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S13.2 
Immunodiagnosis of Scedosporium/Lomentospora infection - lessons from immunoproteomic 
studies 
A. Ramirez-Garcia1, L. Martin-Souto1, L. Aparicio-Fernandez1, I. Buldain1, A. Antoran1, J.-P. 
Bouchara2, M.T. Martin-Gomez3, A. Rementeria1, F.L. Hernando1 
1Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), Leioa, 
Spain, 2Laboratory of Parasitology-Mycology, University Hospital Center, Angers, France, Angers, 
France, 3Microbiology, Vall d'Hebron Universitary Hospital, Barcelona, Spain 
Abstract: The detection and diagnosis of Scedosporium/Lomentospora still relays on traditional methods 
and, in spite of being the second most common etiological agent among filamentous fungal infections, 
very few advances have been achieved in this field during the last decades. This fact is especially 
worrying in Cystic Fibrosis (CF) patients, whose characteristics favor the microbial presence. In these 
patients, the fungal detection does not mean that an infection is occurring, but it may increase the 
risk of suffering from it or other health problems. Therefore, it would be interesting to dispose an 
easy, rapid and non-invasive detection method for monitoring these patients and study the evolution 
of the fungus. With this purpose, some groups are focusing their efforts on finding new approaches 
to design a serologic system. In fact, techniques such as counterimmunoelectrophoresis or ELISA 
using recombinant proteins of some well-described virulence factors are being used by some 
laboratories, which design their own assays. Our research group addressed this problem using 
different immunoproteomics-based approaches. First, four different Scedosporium boydii protein 
extracts were studied by ELISA to select the most useful one for IgG detection in CF patients. The 
extracts used were a whole-cell extract, fungal cell-surface extract, conidia cell surface extract and 
secreted extract, all of them being able to discriminate acceptably the Scedosporium/Lomentospora-
infected patients from Aspergillus-infected and non-infected patients. However, the best results were 
obtained with the whole-cell extract, which showed specificity, sensitivity, predicted positive and 
negative values comparable with commercial kits for other fungal diagnosis purposes. In spite of the 
excellent results obtained, to increase the specificity and avoid the problems derived from the use of 
a complex extract, the immunoreactivity of a collection of sera from CF patients infected with 
Scedosporium/Lomentopora against S. boydii was also studied in comparing with sera from CF patients 
infected with Aspergillus or without fungus. The analysis, made by 2-DE and WB, allowed the 
identification of antigens specifically detected by CF patients with Scedosporium/Lomentopora, two of 
them being identified because of their promising results. In addition, to shed light on the problematic 
of whether the fungal presence in CF patients is a colonization or an infection, we used sera from 
mice infected intravenously with different species of Scedosporium/Lomentospora to detect infection-
related antigens of S. boydii. Interestingly, all the sera showed a very similar immunorecognition 
patterns, but different from the recognized by sera from Aspergillus-infected mice. Therefore, we 
purified six antigens and tested their interest for diagnosis analyzing their immunoreactivity by WB 
against sera from CF patients, two of them showing interesting results. Altogether, these results 
obtained by immunoproteomics-based techniques open up door in the looking for a serologic test for 
the detection of Scedosporium/Lomentospora in CF patients, as well as the monitoring of the fungal 
presence. Specifically, although the results have to be further studied and standardized, the ELISA 
test using whole-cell extract appears to be a very useful, and the antigens identified seems to be 
interesting candidates to be include in the diagnostic procedure. 
 
S13.4 
Morphology, growth and biofilm formation of the black yeast-like fungus Exophiala dermatitidis 
is influenced by Pseudomonas aeruginosa under in vitro cystic fibrosis conditions. 
L. Kirchhoff1, P.-M. Rath1, J. Steinmann1,2 
1Institute Of Medical Microbiology, University Hospital Essen, Essen, Germany, 2Institute Of Clinical 
Hygiene, Medical Microbiology And Clinical Infectiology, Klinikum Nuernberg, Nuremberg, 
Germany 
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Objectives: Exophiala dermatitidis, belonging to the melanized fungi, is frequently colonizing the 
respiratory tract of cystic fibrosis (CF) patients in rates up to 19 %. It was recently reported that E. 
dermatitidis is capable to form biofilms in a strain-dependent manner. However, little is known about 
E. dermatitidis behavior in co-culture with other CF-relevant pathogens, e.g. one of the most prevalent 
bacterial species, Pseudomonas aeruginosa. Growth, biofilm formation capabilities and morphology of 
E. dermatitidis in an artificial sputum medium (ASM), mimicking the CF sputum conditions, were 
assessed in mono- and in co-culture with P. aeruginosa. 
Methods: P. aeruginosa (PA07 & PA14, including PA14 ΔlasR and ΔrhlR) and E. dermatitidis (clinical 
isolate) were analyzed in growth experiments over a period of 48 hours at 36°. Growth was 
determined by colony forming unit (CFU) counts. Biofilm, formed on polystyrene surfaces under 
standard protocols, was determined after 24 and 48 hours of incubation at 36°C without agitation by 
stain with crystal violet, by CFU counts after biofilm detachment using 0.1% dithiothreitol, for 
species-specific cell counts and by confocal laser scan microscopy determining the thickness of 
extracellular matrix (ECM). Morphology of the dimorphic E. dermatitidis was monitored in light 
microscopy. Lengths of fungal hyphae were estimated and compared. 
Results: P. aeruginosa showed growth inhibiting effects on E. dermatitidis. Cell count of the fungus 
was decreasing in co-culture with P. aeruginosa. In contrast, E. dermatitidis biofilm formation was 
induced after 24 h and reduced after 48 h in co-culture with P. aeruginosa. A lack of P. aeruginosa 
quorum sensing (QS) systems lasR and rhlR resulted in induced fungal biofilm formation. At the 
same time, presence of lasR and rhlR lacking mutants caused an increased amount of E. dermatitidis 
hyphal structures whereas co-cultivation with the P. aeruginosa wildtype resulted in decreased 
hyphae amounts, compared to mono-culture. 
Conclusion: Interactions between P. aeruginosa and E. dermatitidis result in altered growth, biofilm 
formation capabilities and morphology of the fungus in an in vitro CF model. A role of P. aeruginosa 
QS systems in these interactions is suggested. 
 
S13.6 
Study of antigenic markers for serological detection of Scedosporium spp. in Cystic Fibrosis 
patients 
L. Martin-Souto1, M. Areitio1, L. Aparicio-Fernandez1, I. Buldain1, A. Antoran1, J.-P. Bouchara2, M.T. 
Martin-Gomez3, A. Rementeria4, F.L. Hernando4, A. Ramirez-Garcia4 
1Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), Leioa, 
Spain, 2CHU d'Angers, Angers, France, 3Microbiology, Hospital Universitari Vall d’Hebron, 
Barcelona, Spain, 4Immunology, Microbiology And Parasitology, University of the Basque Country 
(UPV/EHU), Leioa, Spain 
Objectives: Cystic fibrosis (CF) is the major genetic disorder among the Caucasian population. CF 
patients produce a thick and sticky bronchial mucus in their respiratory tract, which facilitates the 
growth of airborne pathogens. In addition to bacteria, several fungi colonize the respiratory tracts of 
these patients. Species of Scedosporium and Lomentospora genera are emergent fungal pathogens 
ranking the second, only behind Aspergillus spp., among filamentous fungi causing a chronic 
colonization of the airways of CF patients. This may lead to chronic inflammation or even to life-
threatening invasive disease in cases of severe immunosuppression. Detection of 
Scedosporium/Lomentospora relies upon low sensitivity and specificity non-standardized procedures. 
To contribute to the finding of new diagnostic methods, this work aims to characterize some 
molecular targets and to study their usefulness for serological detection of infections caused by 
Scedosporium spp. in CF patients. 
Methods: A total of 191 CF patients’ sera were used in this study. First, we classified these sera into 
3 groups: patients with positive sputum cultures for Scedosporium (S+), for Aspergillus (A+), and 
patients with negative fungal cultures (Ctrl). A serological study of the sera was carried out to detect 
specific IgG response against Scedosporium boydii total protein extract by ELISA. In the search of 
diagnostic markers that allow the discrimination between colonization and infection, we performed 
an in vivo infection in a murine model to obtain sera that allow the detection of antigens associated 
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with a disseminated infection by two dimensional western blot. These antigens were electroeluted 
from protein gels and blotted individually against CF patients’ sera to observe the immunological 
response. 
Results: The ELISA assay provided good specificity, and positive and negative predictive values to 
discriminate among S+, A+ and Ctrl patients. However, the sensitivity was influenced by differences 
in the humoral response of the S+ group. This suggests different levels of fungal presence, from 
colonization to infection, among S+ patients. To solve this problem, we looked for S. boydii antigens 
associated with a disseminated infection in a murine model selecting the six proteins with the highest 
immunoreactivity. Two of them were specifically recognized by most of S+ sera, especially by those 
that were more reactive in the ELISA assay. 
Conclusion: Two proteins of S. boydii resulted to be potential diagnostic markers for the detection of 
the infection caused by Scedosporium spp. in CF patients. The use of them in combination with an 
ELISA using S. boydii total protein extract might help in the detection of Scedosporium spp. in CF 
patients and the monitoring of the fungal presence. 
 
Symposium 14 Teaching Medical Mycology: what, how, to whom and when 
 
S14.2 
Mycology teaching in Medical School - Is student demography important to what should be taught 
E. Segal 
Sackler School Of Medicine, Clinical Microbiology And Immunology, Tel Aviv University, Tel Aviv, 
Israel 
Abstract: Mycology which is the discipline devoted to the study of fungi, is one of the four parts 
comprising Microbiology, the basis for understanding infectious diseases. Medical Mycology is the 
part of Mycology which focuses on those fungi known to cause or potentially can cause infections in 
human hosts. As such, study of Medical Mycology is an integral part of the education of physicians 
and is included in the curriculum of Medical Schools. One of the questions associated with the 
teaching of Medical Mycology is at which level should Medical Mycology be taught: at the basic 
sciences level, with other parts of Microbiology, or at a later stage in the frame of Infectious Diseases, 
as part of Internal Medicine. The answer to this dilemma may vary among different Medical Schools. 
Another question associated with teaching Medical Mycology in Medical Schools is as to the content 
of the subject: should it reflect the specific geographic–climatic conditions of the given Medical School 
or should a more general, broader approach be used. An additional dilemma regarding teaching of 
Medical Mycology in Medical Schools is whether the specific student demography should affect what 
is taught and to what extent. The latter is the subject of the following presentation. In the presentation 
different teaching possibilities will be demonstrated and discussed, as to pro- or contra- of the impact 
of student demography on what is taught. Examples of different approaches to the dilemma will be 
shown and discussed. Participation of the audience in the discussion will be encouraged. 
 
S14.3 
Specific courses outside European Continent – The Indian Example 
R. Ashbee 
University of Leeds, Leeds, United Kingdom 
HR Ashbee, RD Sahni & JS Michael Teaching medical mycology in the Indian setting presents some 
unique challenges and opportunities. The diversity of mycoses seen is extensive and presentations 
can be unusual with disease sometimes occurring in patients not traditionally ‘at risk’. Whilst 
dermatophytosis and superficial candidosis is often neither diagnosed nor treated, fungal keratitis 
and sinusitis, subcutaneous and systemic mycoses represent a significant burden on the healthcare 
system. In combination with this, diagnostic facilities vary from virtually nil to fully equipped 
laboratories with well-trained staff. The Christian Medical College Hospital in Tamil Nadu, south 
India has had a mycology laboratory since the 1950’s, has highly skilled staff and a massive number 
of clinical samples – hence it is ideally suited to deliver comprehensive mycology training. The first 
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course in 2007 was aimed at technical staff working in laboratories and junior faculty, primarily 
focusing on basic medical mycology and identification of fungal pathogens. The course was attended 
by 30 participants from all over India, some traveling for 30 hours by train to take part in the course. 
The need for training was apparent and further courses were planned The current course has been 
re-designed and is run in two parts. The first 3-day part is aimed at registrars/residents in 
microbiology and provides an integrated approach to teaching with clinicians presenting cases and 
the laboratory aspects taught in practical, hands-on sessions after the cases. The full range of diseases 
are covered, including the superficial mycoses, subcutaneous mycoses, candidosis, cryptococcosis, 
mucormycosis, aspergillosis and endemic mycoses. Hands-on practical sessions also cover setting up 
of antifungal susceptibility tests and their interpretation. The second part of the course held over 2 ½  
days is for consultant microbiologists and this includes a full day of practical molecular mycology, 
including DNA extraction, setting up PCR and trouble-shooting molecular assays, use of 
commercially available assays, as well as molecular detection of antifungal resistance. Antifungal 
susceptibility testing is taught in another full day practical session with participants taken through 
the whole CLSI method, from making up the medium, preparing antifungal dilutions, making up 
plates and preparing the inoculum, to reading and interpreting results. Other methods such as E-test 
and disc diffusion are also taught. The practicals take place in small groups so every participant can 
get hands-on experience of each technique. Discussion sessions make up the remainder of the time 
with ample opportunity for participants to ask questions and clarify any problems. Participants are 
also encouraged to maintain contact after the workshop and help is provided with testing or fungal 
identification by CMC staff if required. The courses represent a significant investment of time and 
resources by the staff of CMC and overseas faculty but feedback has been extremely good and 
demonstrates that provision of high quality, comprehensive mycology training is both very much 
needed but also very well received. 
 
S14.4 
Teaching Clinical Laboratory Mycology : How and who is the audience? 
S. Arikan-Akdagli 
Medical Microbiology, Mycology Laboratory, Hacettepe University Medical School, ANKARA, 
Turkey 
Expertise in Clinical Laboratory Mycology requires hands-on experience and in-depth basic 
knowledge. Challenges regarding teaching Clinical Laboratory Mycology are numerous. First, the 
number of invasive fungal infections is increasing with more infections due to rare and less-
recognized species and the education for management of this growing problem is yet inadequate. 
Second, Mycology education was rather less emphasized until recent years. Teaching for Clinical 
Laboratory Mycology practices is usually limited during training of a Clinical Microbiologist and the 
numbers of well-equipped Clinical Mycology Laboratories and experts are also relatively limited 
worldwide. Third, the characteristics of Y (and Z) generation(s) are unique. The members of 
generation Y are primarily among the current audience and they are largely influenced by 
technology. Therefore, broader training and diverse teaching methods are required to meet all these 
challenges. Clinicial Laboratory Mycology training is a part of speciality/subspeciality, PhD or Master 
of Science training programs in Medical Microbiology/Mycology. Also, Infectious Diseases/Infectious 
Diseases and Clinical Microbiology Joint Training, and Pathology Training Programs include training 
in Mycology at required levels. For Medical Faculty students, on the other hand, basic Clinical 
Laboratory Mycology teaching is incorporated in the program at some institutions in order to 
integrate the previously taught theoretical knowledge with that on mycological diagnosis in the last 
year(s) of education. Laboratory technicians are also among the audience for teaching Clinical 
Laboratory Mycology at required and specifically technical level. Combining conventional teaching 
methods with digital technologies is needed for contemporary high quality Clinical Laboratory 
Mycology education. The common approach for teaching requires expert(s), a well-equipped 
Mycology Laboratory, and reliable basic information sources, including physical books or e-books. 
In lack of these facilities or for advancement for higher levels, in-person courses and workshops are 
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very beneficial. However, they are costly and require qualified instructors and resources. E-learning 
courses, webinars, and educational websites are also very helpful in expanding the trained audience. 
Teaching Clinical Laboratory Mycology is a difficult task and requires dedicated Mycologists. 
 
S14.5 
Capacity building for invasive fungal infections in Africa: concrete examples through mycology 
courses and the DREAMM implementation project 
A. Sturny Leclère1, D. Garcia-Hermoso2, T. Boyer-Chammard1, I. Kolte3, F. Dromer4, A. Alanio5, O. 
Lortholary6, A. Loyse3 
1Molecular Mycology, IP Paris, Paris, France, 2National Reference Center For Invasive Mycoses & 
Antifungals, Molecular Mycology Unit, Cnrs Umr2000, Institut Pasteur, PARIS, France, 3Institute Of 
Infection And Immunity, St. George’s University of London, London, United Kingdom, 4National 
Reference Center For Invasive Mycoses & Antifungals, Molecular Mycology Unit, Cnrs Umr2000, 
Institut Pasteur, Paris, France, 5Paris-diderot, Sorbonne Paris Cité University, Institut Pasteur, 
Molecular Mycology Unit, Cnrs Cmr2000, Parasitology-Mycology Laboratory, Lariboisière Saint-
Louis Fernand Widal Hospitals, Assistance Publique-Hôpitaux de Paris, Paris, France, 6Infectious 
Diseases, APHP, Hopital Necker-Enfants malades, Paris, France 
Across the world, fungal pathogens are omnipresent in the environment, affect over a billion and kill 
more than 1,5 million people. Despite these figures, invasive fungal infections (IFIs) do not gather as 
much press coverage as tuberculosis or malaria. AIDS represents one of the major risk factors for IFIs 
together with other acquired immunodeficiencies. Invasive fungal infections should be a concern 
everywhere by their incidence, severity and high burden. Worldwide IFIs are not recognized due to 
lack of surveillance systems together with a lack of mandatory reporting, limited teaching in medical 
schools and therefore limited awareness and expertise of clinicians and biologists, lack of reliable 
diagnostic procedures for many IFIs, and limited number of commercialized antifungal drugs. In 
resource limited countries, the lack of basic laboratory equipment and poor access to essential 
medicines are additional major barriers. Outcomes of cryptococcal meningitis, a leading cause of 
HIV-related death, are still poor despite updated WHO guidelines. The DREAMM project aims to 
reduce the mortality of cryptoccocal meningitis in resource limited settingsby providing rapid 
diagnostic tests, essential medicines and reinforcing basic and mycology trainings for all staff 
members involved (technicians, nurses, physicians, biologists). Through this program, a better 
awareness of all IFIs is expected and results are already visible. 
 
Symposium 15 Aspergillus in the ICU 
 
S15.1 
Influenza-associated aspergillosis in ICU: when the flu get mouldy 
J. Wauters 
Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium 
Worldwide, 3-5 million people develop severe influenza every year, leading to 50.000-100.000 deaths 
annually in the European Union and the USA. Of the patients hospitalized, 5-10% needs ICU 
admission due to severe illness. Patients with severe illness initially present with typical influenza 
symptoms, but are rapidly evolving into respiratory deterioration due to bacterial superinfection but 
also influenza in itself can cause severe acute respiratory distress syndrome (ARDS), the latter being 
associated with a mortality of 14% to 41%. Although bacterial co-infection is already known for 
decades, influenza-associated aspergillosis (IAA) was recently found to be a frequent and severe 
complication of influenza pneumonia in critically ill patients. Classically, invasive pulmonary 
aspergillosis (IPA) typically occurs in a severely immunocompromised host. Influenza-associated 
aspergillosis (IAA) was occasionally described decades ago and several small case series were 
reported recently. 65% of the reported cases did not have classic host factors for IPA as defined by 
the EORTC/MSG. Recently, we published a large multicentre case-control study within the Dutch-
Belgian Mycosis Study Group (7 Belgian and Dutch ICUs, 2009-2016) including 432 severe influenza 
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patients (positive influenza polymerase chain reaction (PCR)), 315 of them being EORTC negative. 
As a control group, 315 influenza negative and EORTC negative patients, admitted to the ICU with 
severe community-acquired pneumonia (CAP), were selected. In the 432 severe influenza patients, 
IPA was diagnosed in 19% (83/432), a median of 3 (IQR 0-7) days after ICU admission. The IPA 
incidence in the 117 immunocompromised (EORTC positive) influenza patients was as high as 32% 
(38/117), while 14% (45/315) of the non-immunocompromised (EORTC negative) influenza patients 
developed IPA. In contrast, only 5% (16/315) of the non-immunocompromised influenza-negative 
controls developed IPA (p<0·0001). The 90-day mortality in influenza patients with and without IPA 
was 51% and 28%, respectively (p<0·0001). Moreover, in this retrospective cohort study, influenza 
was found to be independently associated with IPA (aOR 5·2, 95% CI 2·6-10·3, p<0·0001), besides a 
higher APACHE II score, male sex and use of corticosteroids. Though awareness of IAA is rising, it 
remains unclear why patients with severe influenza infection develop IPA. Influenza-induced 
necrosis of the bronchial tree might provide a gateway for Aspergillus infection. Further, severe 
influenza might alter innate and adaptive host facilitating fungal infection and genetic variation 
might also influence the susceptibility to IPA. Finally, corticosteroid (CS) therapy is a known 
independent risk factor for the development of IPA at the ICU. In summary, IAA is an early and 
frequent complication of influenza pneumonia and increases the probability of death with a factor 2 
to 3 in critically ill patients with severe influenza. An aggressive diagnostic approach should be 
pursued, but early diagnosis is difficult due to unspecific clinical and radiological presentation. 
Future studies should evaluate whether a faster diagnosis and/or antifungal prophylaxis could 
improve outcome of influenza-associated aspergillosis. Reference: Schauwvlieghe AFAD, Rijnders 
BJA, Philips N et al. Dutch-Belgian Mycosis study group. Invasive aspergillosis in patients admitted 
to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 
2018;6(10):782-792. 
 
S15.2 
Invasive aspergillosis in patients with underlying liver cirrhosis 
J. Prattes 
Section Of Infectious Diseases And Tropical Medicine, Medical University of Graz, Graz, Austria 
Abstract: Invasive aspergillosis (IA) has increasingly reported in critical ill patients without classical 
risk factors like hematological malignancy, neutropenia or solid organ transplantation. Liver cirrhosis 
represents the main underlying disease in some of these patients, highlighting the relevance of 
cirrhosis as a risk factor for IA development. Whereas the overall incidence of IA in patients with 
liver cirrhosis is very low (<1%), the risk for IA increases when liver function deteriorates and patients 
are in need for intensive care. Reasons for susceptibility of cirrhotic patients for developing IA are 
diverse. Cirrhosis-associated immune dysfunction summarizes both, systemic inflammation due to 
cirrhosis and cirrhosis associated immunodeficiency. The latter one may be due to systemic 
glucocorticoid treatment but also due to alterations of the innate as well as adaptive immune 
functions. Impaired expression of Fcγ –receptor on neutrophils, impaired neutrophil mobilization, 
phagocytic activity, chemotaxis, bacterial phagocytosis and killing are present in cirrhotic patients. 
However, the degree of immune dysfunction correlates with the stage of the liver disease putting 
patients with end stage liver disease at highest risk for IA development. Awareness for IA in cirrhotic 
patients has to be warranted as diagnosis may be challenging. Blood biomarkers, like galactomannan 
and beta-d-glucan, lack sensitivity and clinical presentation may be atypical. In case of IA suspicion 
early chest CT scan and bronchoscopy may be needed. 
 
S15.3 
Aspergillus in the ICU – Management of IA in Renal Failure 
R. Rautemaa-Richardson1,2,3,4 
1Division Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, 
United Kingdom, 2Mycology Reference Centre, Excellence Center For Medical Mycology (ecmm), 
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
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Kingdom, 3National Aspergillosis Centre, Manchester, United Kingdom, 4Department Of Infectious 
Diseases, Manchester University NHS Foundation Trust, Manchester, United Kingdom 
Abstract: Renal failure is a common complication in critically ill patients. In addition, angioinvasive 
aspergillosis is associated with renal lesions and renal failure. The challenge is that the main 
intravenous drugs used to manage invasive aspergillosis (IA), namely amphotericin B and 
voriconazole (with cyclodextrin) are nephrotoxic. Also, in critically ill patients with multi organ 
failure, the pharmacodynamics and pharmacokinetics are highly variable, which results in a 
significant risk for toxicity as well as suboptimal dosing and treatment failure. The impact of renal 
failure on the management of IA depends on whether the patient is on renal replacement therapy 
(RRT) or not. Once on RRT, the main consideration is the risk for suboptimal drug levels until the 
system is saturated with the drug. However, it is important to keep in mind that the initiation of RRT 
does not remove the risk for further or permanent drug-induced kidney injury. Once the patient starts 
to respond to the treatment, their haemodynamics stabilise and their kidney function improves, there 
is a risk for both toxicity and subtherapeutic levels. Therefore, in the case of azoles, critically ill 
patients on intensive care unit (ICU) require regular therapeutic drug monitoring (TDM) and 
repeated dose adjustments. This also applies to azoles not associated with kidney toxicity 
(isavuconazole). Whilst TDM is an important part of monitoring the safety and efficacy of antifungal 
treatment, microbiological diagnostics are another important tool in patient management. Sputum 
high-volume culture, PCR and galactomannan measurements can be used to monitor treatment 
response whereas blood galactomannan is less useful in non-neutropenic setting. However, it is not 
rare that these tests remain positive for prolonged periods despite good clinical response. 
 
S15.4 
Fungal pneumonia in critically ill cirrhotics: Spectrum, Outcomes, Comparison of diagnostic 
methods and Biomarkers 
P. Kale1, V. Khillan1, S.K. Sarin2 
1Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi, India, 2Hepatology, 
Institute of Liver and Biliary Sciences, New Delhi, India 
Objectives: Liver cirrhosis causes immune dysregulation and increased susceptibility to fungal 
infections. Futher there are associated co-morbidities like diabetes mellitus, renall impairment and 
malignancy which predispose to fungal infections. Hence early diagnosis of fungal infections and 
initiation of appropriate empiric or pre-emptive antifungal is essential to reduce morbidity and 
mortality associated with it. We studied the epidemiology, spectrum, risk factors of fungal infections 
and antifungal susceptibility pattern for guiding empiric therapy. We also compared the rapid 
diagnostic methods and biomarkers for early diagnosis fungal pneumonia in critically ill cirrhotics. 
Methods: Single-center, prospective cohort study of 100 critically ill cirrhotics with fungal 
pneumonia between January to September 2018. All patients met the diagnostic criteria for liver 
cirrhosis by clinical, biochemical, and ultrasonography findings. Respiratory samples were processed 
for fungal culture and real time PCR. Antifungal susceptibility testing was done by Broth 
microdilution method in accordance with CLSI guidelines. Biomarkers; bronchoalveolar lavage 
(BAL) and serum Galactomannan, and serum procalcitonin measured on day 1, 3 7. Mortality within 
one month of diagnosis or discharge was analyzed. 
Results: Aspergillus flavus was the most common species (70/100,70%). Risk factors for fungal 
pneumonia included neutropenia (p 0.03), steroids prior to ICU admission (p 0.02), prolonged (>21 
days) hospitalization (p<0.05). Culture positivity was 80%. Culture was not inferior to real time PCR 
for diagnosis of fungal pneumonia. Antifungal susceptibility testing revealed, all A.flavus and 
A.fumigatus isolates sensitive to azoles, amphotericin B and echinocandins. BAL galactomannan was 
early prognostic marker with median rise >3.5 over the index value. Median PCT level was higher 
from day 1in the fungal pneumonia non-survivor than survivor group (3.29 vs. 0.8ng/ml), with higher 
30-day mortality (72%). Baseline PCT at admission to ICU was higher in non- survivors; levels on D3 
and D7 were persistently higher. Higher PCT level was associated with bacterial co-infection (48%), 
antibiotic (74%) and antifungal therapy and renal failure and mortality. 
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Conclusion: Cirrhotics who are neutropenic, have prolonged hospitalization and exposed to steroids 
have a high risk of fungal pneumonia. Aspergillus flavus predominate as in consensus with Asian 
epidemiology. Culture methods are reliable and combination of molecular test with BAL 
galactomannan is useful for rapid diagnosis. However the cutoff should be defined with 
epidemiological correlation. High serum procalcitonin level is an independent prognostic biomarker 
of mortality risk in fungal pneumonia which reaches nearly 70%. In our study the baseline PCT at 
admission to ICU was higher in non- survivor group, levels on D3 and D7 were persistantly higher. 
High index of suspicion and early detection is required in advanced cirrhosis 
 
S15.5 
IPAFLU survey: Invasive Aspergillosis among Patients with Severe Influenza in Intensive Care 
Units 
M. Holtappels1, C. Jacobs1, T. Chiller2, J. Fortenberry3, B. Jackson4, K. Lagrou5, M. Toda4, F. Van De 
Veerdonk6, P.E. Verweij7, J. Wauters8 
1Laboratory For Clinical Infectious And Inflammatory Disorders, KU Leuven, Leuven, Belgium, 
2Mycotic Diseases Branch, Centre for Disease Control, Altanta, United States of America, 3Pediatric 
Critical Care, Children's Healthcare of Atlanta, Atlanta, United States of America, 4Mycotic Diseases 
Branch, Centre for Diseases Control, Altanta, United States of America, 5Department Of 
Microbiology, Immunology And Transplantation, KU Leuven, Leuven, Belgium, 6Infectieziekten, • 
Afdeling Interne Geneeskunde, Nijmegen, Netherlands, 7Medical Microbiology, RadboudUMC, 
Nijmegen, Netherlands, 8Medical Icu, UZLeuven, Leuven, Belgium 
Objectives: Invasive aspergillosis usually occurs in people with weakened immune systems. 
However, several reports describe fatal Aspergillus pulmonary infections in previously healthy 
patients who were hospitalized with a severe influenza virus infection. Recently, a retrospective 
cohort study, conducted at seven intensive care units (ICUs) in Belgium and the Netherlands during 
2009–2016, found that invasive pulmonary aspergillosis occurred in 19% of patients with severe 
influenza requiring admission to the ICU. We conducted an international survey to determine 
broader knowledge and awareness of influenza-associated aspergillosis (IAA), as well as the 
diagnostic use of galactomannan (GM) in bronchoalveolar lavage (BAL) and serum in critically ill 
patients with severe influenza. 
Methods: Members of the Extracorporeal Life Support Organization (ELSO), the Society of Critical 
Care Medicine (SCCM), and the European society of intensive medicine (ESICM) network (n = 20,093 
) were invited to participate in an online 11-question survey. Participants were asked about their roles 
in the ICU, ICU size, number of patients with influenza admitted to the ICU per influenza season, 
use of neuraminidase inhibitors (NAIs), frequency of obtaining lower respiratory specimens and GM 
testing on serum and BAL samples, and their knowledge on the occurrence of IAA. 
Results: A total of 468 (2.3%) members responded, with 225 (48%) residing in the United States, 151 
(32%) in Europe, and 92 (20%) in other countries, including Australia and countries in South America, 
Asia and Africa. Most (89%) participants were critical care physicians. Large ICU departments were 
more common in the United States compared with Europe. The majority of participants reported <30 
influenza cases per season, and NAIs were the preferred antiviral treatment (92%). European 
participants reported obtaining lower respiratory specimens and determining GM on BAL and serum 
more commonly than U.S. participants (p < 0.001) (Figure 1). Globally, 66% (n = 303) of respondents 
denied hearing of or seeing IAA cases in the past five years (Figure 2). However, 57% of European 
participants reported seeing ≥1 patient with IAA compared with only 17% of U.S. participants (p < 
0.001) and 36% of participants in other countries (p = 0.007). 
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Conclusion: More participants in Europe reported having seen IAA cases in compared with the 
United States and other countries. Although the observed differences in IAA cases could be explained 
by true variation in IAA prevalence, the condition might be underdiagnosed outside Europe. The 
results suggest that such underdiagnosis might partly explain the differences in IAA awareness in 
Europe compared with the United States and other countries. 
 
S15.6 
Trend of Candidemia with Bloodstream infection in Intensive care units from 2006 to 2017: Results 
from the Korean National Healthcare-associated Infections Surveillance System 
Y.H. Choi1, E.J. Kim1, Y.G. Kwak2, H.M. Yoo3, J.Y. Choi4, M.J. Shin5, S.R. Kim6, S.-Y. Yoo7, N.-H. Cho8 
1Department Of Infectious Diseases, Ajou University School of Medicine, Suwon-si, Gyeonggi-do, 
Korea, Republic of, 2Department Of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, 
Korea, Republic of, 3Infection Control Office, Inje University Sanggye Paik Hospital, Seoul, Korea, 
Republic of, 4Infection Control Unit, Chung-Ang University Healthcare System, Seoul, Korea, 
Republic of, 5Infection Control Office, Seoul National University Bundang Hospital, Seongnam, 
Korea, Republic of, 6Infection Control Office, Korea University Guro Hospital, Seoul, Korea, Republic 
of, 77adjunct Assistant Professor, College of Nursing, The Catholic University of Korea, Seoul, Korea, 
Republic of, 8Department Of Infection Control, Gangnam severance hospital, Yonsei university, 
Seoul, Korea, Republic of 
Objectives: Candidemia is an important healthcare-associated infections (HAIs) in intensive care 
units (ICUs). The incidence trend and distribution of candidemia over a 12-year period through the 
Korean National Healthcare-associated Infections Surveillance System (KONIS) data were analyzed. 
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Methods: The KONIS system was established in 2006, and has performed prospective surveillance 
for HAIs including bloodstream infection (BSI) and causative pathogen in ICU. We evaluated yearly 
trends of the frequencies of the causative pathogens and candidemia. All statistical analyses were 2-
sided and performed the Cochran-Armitage test for trend and the Cochran–Mantel–Haenszel mean 
score test, by use of SAS software. 
Results: From 2006 until 2017, 2,248 candidemia cases occurred in 9,184,264 patients-days. For BSI, 
the proportion of candidemia gradually increased (for BSI from 15.2% in 2006 to 16.6% in 2017, P < 
0.05) (Figure 1). The pooled mean incidence rate of candidemia was 0.24 per 1,000 patient days. Most 
frequent pathogen for BSI was Staphylococcus aureus from 2006 to 2012, however, candida species 
emerged as the most frequent pathogen since 2013. Candida albicans (39.9%) was the most frequent 
pathogen for candidemia, followed by C. tropicalis (20.2%) and C. parapsilosis (18.2%) (Figure 2). There 
was no significant change in the distribution of candida species by year (P = 0.29). Central-line 
associated BSI were the majority (92.5%). In subgroup analysis, there was a significant association 
with the increase in the proportion of candidemia by year in the presence of organ transplant wards 
(from 18.9% in 2006 to 21.1% in 2017), hospitals with less than 500 beds (from 2.7% in 2006 to 13.6% 
in 2017), or surgical ICUs (from 16.2% in 2006 to 21.7% in 2017) (P < 0.05).
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Conclusion: The proportion of candida as nosocomial pathogen for BSI has increased in Korea. 
Especially, the proportion in hospitals with less than 500 beds and surgical ICUs is increasing, so 
appropriate infection control program is needed. This work was supported by the Research Program 
funded (M2018A060000011) by the Korea Centers for Disease Control and Prevention. 
 
Symposium 16 Dermatology 
 
S16.1 
Cutaneous Aspergillosis: Is it so rare? 
S. Arikan-Akdagli 
Medical Microbiology, Mycology Laboratory, Hacettepe University Medical School, ANKARA, 
Turkey 
Abstract: Invasion of skin by Aspergillus is an uncommonly encountered clinical picture. Primary 
cutaneous aspergillosis (PCA) indicates lesions due to direct inoculation of the fungus at the 
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otherwise injured site. The lesions usually develop following trauma, surgery or burn wounds. One 
significant feature of PCA is that it may be observed in immunosuppressed as well as 
immunocompetent individuals. Premature neonates also constitute a unique group of predisposed 
hosts due to skin fragility. PCA may disseminate and be lethal particularly in immunocompromised 
patients. Secondary cutaneous aspergillosis (SCA), on the other hand, develops either due to 
hematogenous spread or direct invasion of the skin from adjacent infected structures, such as 
paranasal sinuses. Skin and visceral involvement or multiple skin lesions in two or more 
noncontiguous areas suggest disseminated Aspergillus infection. It is estimated that skin involvement 
in invasive aspergillosis occurs at rates of 1-5%. The skin lesions in CA appear to have variable 
presentations, including macule, papule, plaque, subcutaneous nodule, ulceration with necrosis, and 
hemorrhagic bulla. The exact prevalence of CA is unknown and there are limited number of 
dedicated series and case reports. Cases of CA are probably underdiagnosed and underreported due 
also to difficulties in diagnosing fungal infections in general. In addition, the affected patient 
population is heterogeneous and complex with multiple comorbidities and this further complicates 
the issue. For optimal management of patients with CA, skin biopsy should immediately be taken 
from suspected lesions particularly in predisposed individuals for histopathological and direct 
microscopic examinations and mycological culture. 
 
S16.2 
Is resistance a problem for dermatophytosis? 
P. Nenoff1, M. Monod2, S.B. Verma3, A. Burmester4, A. Ebert1, A. Singal5, S. Gupta6, C. Wiegand4, U.-
C. Hipler7, F. Wittig1, C. Krüger1, D. Koch1, R. Vasani8, A. Saraswat9, R. Madhu10, S. Panda11, A. Das11, 
M. Kura12, A. Jain13, Y. Graeser14, S. Uhrlaβ1 
1Partnership Dr. C. Krueger & Prof. P. Nenoff, Laboratory of medical microbiology, Roetha OT 
Moelbis, Germany, 2Dermatology Service, Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland, 3"Nirvan” and “In Skin” Clinics, Vadodara, India, 4Klinik Für Hautkrankheiten, 
Universitätsklinikum Jena, Jena, Germany, 5Department Of Dermatology & Std, University College 
of Medical Sciences & GTB Hospital (University of Delhi), Delhi, India, 6Department Of Dermatology 
And Venereolgy, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, 
India, 7Klinik Für Hautkrankheiten, Universitätsklinikum, Jena, Germany, 8Bhojani Clinic, Mumbai, 
India, 9Dermatology, Indushree Skin Clinic, Lucknow, India, 10Department Of Dermatology 
(mycology), Madras Medical College,, Chennai, India, 11Department Of Dermatology, KPC medical 
college, Kolkata, India, 12Department Of Dermatology, Grant Medical College, Mumbai & Sir JJ 
Group of Hospitals, Mumbai, India, 1312415, Doctor's Nest, New Rajeev Gandhi Nagar, Kota, India, 
14Institut Für Mikrobiologie Und Hygiene, Universitätsmedizin – Charité, Berlin, Germany 
Objectives: Resistance of dermatophytes against antifungal agents was not perceived as a problem 
for decades. Therapy failure in onychomycosis or tinea capitis was never related to a reduced in vitro 
susceptibility of the causative species of dermatophytes. The situation has changed dramatically. The 
starting point, was, most likely, India. An incredible increase in chronic recalcitrant dermatophytoses 
over the past few years has been noted in India. The main causative pathogen is the zoophilic 
dermatophyte Trichophyton (T.) mentagrophytes ITS genotype VIII.  
Patients and methods: Three epidemiologic exercises, for the purpose of speciation and also to look 
into the possibility of antifungal resistance were undertaken with cooperation from nine Indian 
centers with German and Swiss mycologists. A total of 291 isolates (278 T. mentagrophytes VIII, and 
13 T. rubrum) were included in the terbinafine antifungal susceptibility testing and genetic point 
mutation analysis of the squalene epoxidase (SQLE) gene. Itraconazole and voriconazole minimal 
inhibitory concentrations (MICs) were determined.  
Results: High resistance rates of 66.7% (T. mentagrophytes VIII), and 27.3% (T. rubrum) to terbinafine 
were found in the first multicentric study from India. 76.0% T. mentagrophytes VIII and 57.1% T. 
rubrum strains of two further studies (New Delhi and Mullana) showed in vitro resistance to 
terbinafine. The T. mentagrophytes VIII strains collected from multiple geographic regions of India 
showed high frequency of single point mutations in the SQLE gene leading to terbinafine resistance. 
J. Fungi 2019, 5, 95 63 of 464 
 
All resistant T. mentagrophytes strains (200) harboured missense mutations with subsequent amino 
acid substitutions, most frequently Phe397Leu (90.0%), either as a single substitution or in combination 
with Ala448Thr. On the other hand, terbinafine sensitive strains (78) showed almost exclusively a 
SQLE wild type (23.1%) or a single Ala448Thr substitution (73.1%). Substitutions less commonly 
encountered included Leu393Phe, Leu393Ser, Ser395Pro, Gln408Leu, His440Tyr and Ser443Pro. The number 
of terbinafine resistant dermatophytes in Northern India has increased significantly from 2017 to 2019 
(69.0% in 2017; 72.0% in 2018; 78.0% in 2019). Additionally, we noted a rise in SQLE double mutants, 
which shows a selection advantage for this genotype combination.  
Conclusion: The dramatic increase in terbinafine resistant T. mentagrophytes ITS VIII from all over 
India within such a short period of time underscores the issue of development of resistance in patients 
with chronic dermatophytoses. A strong association was found between in vitro terbinafine resistance 
of T. mentagrophytes and the occurrence of single point mutations of the SQLE gene and distinct amino 
acid substitutions, respectively. Alterations at position Phe397Leu, Leu393Ser, Leu393Phe, Gln408Leu, 
His440Tyr, of the SQLE were associated with terbinafine resistance. Increasing number of patients in 
Europe (Germany, Finland, Estonia) and from United States have been seen to be presenting with 
chronic recalcitrant dermatophytosis due to terbinafine-resistant T. mentagrophytes VIII from India. 
Transmission of the Indian T. mentagrophytes VIII to other countries due to travel, migration and in 
general, globalization, appears to be a serious issue even from a public health perspective. Further 
studies are the need of the day to understand this phenomenon better and find answers to combat it. 
 
S16.4 
Blastomycosis 
I.S. Schwartz 
University of Alberta, Edmonton, Canada 
Abstract: Among the main endemic mycoses of North America, blastomycosis is least understood. 
Until recently, blastomycosis was thought to be a single clinical disease caused by a single pathogen, 
Blastomyces dermatitidis. However, recent re-analyses of isolates from North American and global 
collections have revealed substantial genetic and phenotypic diversity in Blastomyces. Classical 
blastomycosis, now known to be caused by B. dermatitidis and the cryptic species B. gilchristii, is 
limited primarily to eastern and midwestern parts of North America. In addition, B. helicus, a species 
morphologically and physiologically distinct from B. dermatitidis species complex, has been described 
as the cause of atypical, disseminated blastomycosis in immunocompromised hosts from western 
and mountainous parts of the United States and Canada. Moreover, blastomycosis from Africa and 
the Middle East - long recognized to have clinical differences from the disease in North America - has 
been determined to be primarily caused by B. percursus and an additional novel species. Clinicians 
and microbiologists should be aware of these additional species, how they differ from B. dermatitidis, 
and the clinical and epidemiological spectrum of blastomycosis. 
 
S16.5 
Galleria mellonella as a novelty model to study host – pathogen interaction in Malassezia furfur 
CBS 1878 
A.M. Celis Ramírez1, C.M. Parra Giraldo2, E.N. Pinzón Pineda1 
1Biological Sciences, Universidad de los Andes, Bogotá, Colombia, 2Microbiology, Pontificia 
Universidad Javeriana, Bogotá, Colombia 
Objectives: Malassezia furfur is a lipid-dependent yeast that is part of the animal and human skin 
mycobiota. This species can cause dermatological infections in the immunocompetent host until 
fungemia in immunosuppressed patients and neonates with parental lipid nutrition. However, 
aspects related to virulence traits and antifungal resistance is not entirely understood. Thus, the 
establishment of a model to study host-pathogen interaction has been a matter of attention in the last 
decade. The silkworm Galleria mellonella is a useful animal model characterized by its tolerance to a 
wide range of temperatures, including human temperature 37 ◦C; also, the immune response against 
pathogens is similar to the innate immunity in humans. Hence, this exciting model has been used for 
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the large-scale screening of fungal pathogens such as Candida spp., Cryptococcus neoformans, and the 
activity of antifungal drugs in dermatophytes. This study aim to evaluate the feasibility of using G. 
mellonella larvae as an invertebrate model for infection with Malassezia furfur CBS 1878 
Methods: M. furfur CBS 1878 (Westerdijk institute, Utrecht, The Netherlands) was used for all 
experiments. An inoculum was adjusted to four different concentrations (1,5 x 10 9 UFC/mL to 1,5 x 
10 6 UFC/mL) and 10 μl were injected in the last pro leg of G. mellonella. Survival analysis was 
performed for statistical processing using Prism software (GraphPad Software, Inc.). Infected larvae 
and controls were maintained at 33°C and checked daily. Hemolymph analysis was conducted to 
evaluate the capacity of phagocytosis of hemocytes. Experiments to corroborate the fungal load were 
also conducted. Each treatment was conducted in triplicate (technical replicates), and the whole 
experiment was repeated three times (biological replicates). Statistical analysis were performed using 
R package. 
Results: Survival test reveals that at least all silkworms injected with M. furfur CBS 1878 at 
1,5x109UFC/mL died within five days, whereas all silkworms injected with saline were alive. Fungal 
load data were in agreement with the inoculums tested. Besides, activation of the immune system of 
G. mellonella and the interaction between the yeast with different cells of the hemolymph was 
observed. 
Conclusion: This study is the first approach to the implementation of an invertebrate model Galleria 
mallonella to the future study of the host-pathogen interaction and the antifungal activity in M. furfur 
CBS1878. We demonstrated that injection of this yeast into silkworm hemolymph killed silkworms. 
We found the most effective inoculum was 1,5x109UFC/mL with a short time of survival on average 
of five days. This model promise to be an efficient infection model to conduct easy and reliable 
approaches that perform to underpin our knowledge in Malassezia genus. 
 
Symposium 17 HIV associated cryptococcal meningitis 
 
S17.3 
Towards having antifungal drugs in low-resource areas 
I. Kolte1, A. Sturny Leclère2, T. Boyer-Chammard2, S. Lesikari Kivuyo3, S. Mfinanga3, C. Kanyama4, C. 
Kouanfack5, O. Lortholary6, F. Dromer7, T. Bicanic1, S. Molloy1, T. Harrison1, A. Loyse1 
1Infection & Immunity, St Georges University of London, London, United Kingdom, 2Molecular 
Mycology, IP Paris, Paris, France, 3National Institute for Medical Research, Dar es Salaam, Tanzania, 
4UNC Project-Malawi, Lilongwe, Malawi, 5Hôpital Central de Yaoundé, Yaoundé, Cameroon, 
6Infectious Diseases, APHP, Hopital Necker-Enfants malades, Paris, France, 7National Reference 
Center For Invasive Mycoses & Antifungals, Molecular Mycology Unit, Cnrs Umr2000, Institut 
Pasteur, Paris, France 
Abstract: The results of the ACTA trial underpinned the development of new 2018 WHO guidance 
for the treatment of cryptococcal meningitis with short course amphotericin B deoxycholate (AmBd) 
+ flucytosine (5FC) becoming the new gold standard for resource limited settings. The alternative 
recommended regimen is a two-week oral course of 5FC and fluconazole. However, access to key 
diagnostic tests such as the cryptococcal antigen lateral flow assay (CrAg LFA) and essential 
antifungal medicines including 5FC for the treatment of HIV-related cryptococcal meningitis is 
severely lacking in African low-and middle-income countries (LMICs) where disease burden and 
mortality is highest. This talk will highlight longstanding advocacy and implementation efforts to 
ensure access to these lifesaving tools and train frontline healthcare workers (HCWs) working on 
their optimal use so as to effectively reduce mortality in resource limited settings. We will focus in 
particular on illustrating the respective work of the cryptococcal meningitis action group 
(cryptoMAG), the DREAMM project, and outline the recently announced Unitaid/CHAI project on 
advanced HIV disease. The cryptoMAG group is an international group of stakeholders including St 
George’s University of London (SGUL), Centers for Disease Prevention & Control (CDC), WHO, 
Médecins sans Frontières (MSF) and Institut Pasteur amongst notable others that has been advocating 
for access to diagnostic tests and essential medicines for cryptococcal meningitis since 2013. 
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DREAMM (Driving REduced AIDS-associated Meningo-encephalitis Mortality) is an 
implementation project currently ongoing in Tanzania, Cameroon and Malawi. It uses mixed 
methodology including co-designed training programs and local health system strengthening 
centred around African leadership to effectively and sustainably reduce mortality linked to HIV-
related meningitis, a leading cause of advanced HIV disease. Lastly, in January 2019 Unitaid 
announced its program on AHD in partnership with the Clinton Health Access Initiative (CHAI). 
This program will enable access to the CrAg LFA and essential antifungal medicines including 5FC 
in 7 African LMICs, cryptococcal meningitis being a leading cause of death from advanced HIV 
disease. 
 
S17.4 
Fluconazole resistance in cryptococcal meningitis 
T. Bicanic 
Infection & Immunity, St Georges University of London, London, United Kingdom 
In much of sub-saharan Africa, where Cryptococcus is the most common cause of community 
acquired meningitis, the gold standard treatment of Amphotericin B with flucytosine is not available, 
and fluconazole monotherapy is the norm for all phases of CM treatment: induction, consolidation 
and maintenance. Even at higher doses of 800-1200 mg/d, fluconazole is slow to clear Cryptococcus 
from CSF. Although primary resistance is rare in global surveys using MIC testing, the intrinsic 
mechanism of fluconazole resistance, reversible disomy of chromosome 1, is unstable: in the absence 
of drug pressure, it occurs in only a very small subpopulation of colonies and will be missed by 
conventional MIC testing. In a study in Tanzania in patients with HIV-associated cryptococcal 
meningitis, we performed serial lumbar punctures in 20 patients receiving fluconazole monotherapy 
versus fluconazole combined with flucytosine, plotting the rate of clearance of the total population 
and subpopulation able to grow on fluconazole, and saving colonies for subsequent whole genome 
sequencing. Fluconazole heteroresistance was detectable in all clinical Cryptococcal isolates.from 
CSF of all patients prior to initiation of therapy. The proportion of resistant colonies in CSF increased 
during the first two weeks of treatment in all patients receiving Fluconazole at 800-1200mg/d, but 
was suppressed in those receiving combination with flucytosine. Genomic analyses revealed high 
rates of aneuploidy in heteroresistant colonies, as well as in clinical isolates from patiets experiencing 
relapse. The predmonant mechanism in human infectionwas disomy of chromosome 1 (containing 
the drug target gene ERG11 and the efflux pump AFR1) and heteroresistance positively correlated 
with in vitro drug efflux pump activity. We also undertook fluconazole PK analyses in CSF for a 
subpopulation of patients: Monte Carlo simulations from the clinical PK/PD model predicted that 
only a minority of patients (13%) receiving doses of fluconazole at 1200 mg/d sterilise their CSF after 
2 weeks, with 83% having a persistant subpopulation resistant to fluconazole. Our findings 
demonstrate that fluconazole when used alone is a sub-optimal agent for treating cryptococcal 
meningitis due to rapid selection of a resistant sub-population which comes becomes predominant 
within 2 weeks. Efforts are underway to make the combination oral therapy of cluconazole with 
flucytosine more widely available and implementable in Africa. 
 
S17.5 
Current and future clinical trials on HIV-associated cryptococcal meningitis. 
T. Harrison 
Centre For Global Health, Institute Of Infection And Immunity, St George's University of London, 
London, United Kingdom 
The ACTA trial demonstrated that in centres in Sub-Saharan Africa, an induction regimen of 1 week 
amphotericin B (AmB) and flucytosine (5FC), followed by fluconazole (FLU) 1200 mg/d in the second 
week, was associated with reduced 10-week mortality compared with the then internationally 
recommended regimen of 2 weeks of AmB+5FC. 2 weeks of the oral combination of FLU plus 5FC 
was non-inferior to this standard; and 5FC was superior to FLU, as the partner drug given with AmB. 
The results have been further supported through 12-month outcome and economic analyses, and 
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have driven both a change in WHO guidelines for the treatment of HIV-associated cryptococcal 
meningitis, and increasing access to 5FC through a Unitaid programme. The ongoing AMBITION-
CM trial is testing single high dose (10mg/kg) liposomal amphotericin B (L-AmB), given with a 2-
week oral FLU+5FC backbone, against the new standard of 1 week AmB+5FC. A randomized phase 
II study had shown non-inferior early fungicidal activity (EFA) with single high dose L-AmB vs daily 
L-AmB at 3 mg/kg/d for 14 days. The hope is that the L-AmB arm will be at least as effective and 
better tolerated and easier to deliver than one week of AmB deoxycholate. The trial includes a pre-
planned health economic evaluation. Over 300 participants have been enrolled. Any further 
improvements in treatment may depend on introduction of new drugs into induction regimens, or 
novel host-directed or mechanical strategies. Viamet-1598, a fungal Cyp51 inhibitor, and a compound 
series from Amplyx Pharmaceuticals that target Gwt1, an enzyme required for fungal cell wall 
localization of GPI-anchored mannoproteins, are 2 promising candidates, and it is hoped both can 
advance to phase II EFA studies. Immunotherapeutic approaches should be further investigated but 
will need to be carefully targeted based on rapid assays of patient specific immunity. Investigators at 
Duke University are exploring the possibility of using neurapheresis to filter fungal cells from the 
CSF and rapidly reduce the organism load. Meanwhile efforts continue to prevent the development 
of clinical cryptococcal infection in patients with advanced HIV disease, and improve the results of 
the cryptococcal antigen (CrAg) screen and pre-emptive treatment strategy for patients with low CD4 
cell counts. Despite pre-emptive fluconazole, mortality for those screening CrAg positive is 
significantly higher than for those who are CrAg negative; many of those with high CrAg titre have 
evidence of sub-clinical meningitis; and fluconazole failures have been increasingly well 
documented. A study looking at single high dose L-AmB to treat CrAg positive patients in screening 
will take place in Uganda, and a trial to test the oral FLU+5FC combination against FLU alone for 
CrAg positive patients identified at screening is planned in South Africa and Tanzania. 
 
Symposium 18 Antifungal stewardship in the era of resistance 
 
S18.1 
Stewardship and azole resistant aspergillosis: a challenge for farmer or physician? 
P.E. Verweij 
Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the Netherlands 
Aims of antibiotic stewardship include treating infectious diseases with the appropriate drug, 
preventing overuse and minimizing resistance selection. These goals are frustrated by the emergence 
of azole resistance in Aspergillus fumigatus. Recent studies showed that voriconazole-treated 
patients with invasive aspergillosis have a 20% lower survival when the infection was caused by a 
voriconazole-resistant isolate compared with voriconazole-susceptible infection. Appropriate initial 
therapy is thus critical but diagnosis of resistance is slow when based on fungal culture and MIC-
testing. To ensure appropriate initial antifungal therapy combination antifungal therapy is 
recommended if resistance frequencies exceed 10%. The Dutch guideline for management of invasive 
aspergillosis indeed recommends voriconazole/isavuconazole in combination with an echinocandin 
of liposomal amphotericin B is the azole-susceptibility is unknown as resistance surveillance 
indicated a resistance rate of 15%. Therefore, many patients are exposed to increased toxicity and 
drug interactions, while the majority still have an infection due to an azole-susceptible isolate. To 
improve antifungal stewardship programs accurate resistance surveillance is required as well as 
rapid and sensitive diagnostic resistance tests. As the main driver of resistance to medical azoles in 
A. fumigatus is azole fungicide use in the environment, interventions are needed to reduce the 
burden. Recent studies have identified specific conditions that facilitate resistance selection and the 
next step is to design and evaluate interventions that preclude resistance selection in the 
environment. 
The azoles represent an important class for both medical treatments and food production. 
Maintaining this class for both application is therefore critical and requires investment in rapid 
diagnostic tests and stewardship programs. 
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S18.2 
Rapid diagnosis of fungal infections: Impact on stewardship 
S. Kanj 
Department Of Internal Medicine, Division Of Infectious Diseases, American University of Beirut 
Medical Center, Beirut, Lebanon 
Invasive fungal infections (IFI) remain a challenge to the treating physician because of difficulty in 
diagnosis and high rates of morbidity and mortality associated with these infections, which occur 
predominantly in the immunosuppressed and critically ill patients. The incidence of invasive fungal 
infections, especially candidiasis, aspergillosis, and mucormycosis, continues to rise. With the 
excessive use of azole antifungal agents, we have witnessed a global shift of fungal population to 
more resistant species and genera. In addition, the increased consumption of antifungal agents in 
agriculture have selected for resistant Aspergillus species. There is a wide variation in the 
epidemiology of fungal infections worldwide. It is no longer acceptable to manage IFI without 
identifying the species of the infecting organism and its susceptibility profile to the various antifungal 
agents. Neighboring countries might have a different epidemiology depending on antifungal 
practices in humans and the environment. Whereas guidelines can be of great help in the 
management of patients, making the correct diagnosis is of paramount importance. Studies have 
shown that delay in the initiation of appropriate antifungal therapy is associated with a significant 
increase in mortality. Therefore, there is an urgent need to make a prompt diagnosis of IFI. In the 
past, histopathology, fungal cultures, and Candida scores in the right clinical setting guided the 
diagnosis and therapy of IFI. More recently, the availability of newer diagnostic tools such as 
Aspergillus galactomannan, β-D glucan, and polymerase chain reaction, has been of great help in 
speeding the diagnosis of IFI. These tools have also been used for screening and guiding pre-emptive 
therapy in high-risk patients. Studies have shown that combining these new tools increases the 
sensitivity and specificity with an impact on fungal infection-free survival in some patients and 
allows for early discontinuation. More recently, the development of new molecular tools such as 
Matrix-Assisted Laser Desorption/Ionization – Time of Flight, FilmArray, Light Cycler, T2Candida 
assay, and others, allows the rapid detection of fungal pathogens and determines resistance markers 
with a turnaround time of only a few hours. Investigational tools such as Proximity Ligation Assay, 
Breath Fungal Secondary Metabolite Signature, and Siderophore-based Molecular Infection Imaging 
are also promising in facilitating the diagnosis of IFI in the future. In addition, the development of 
point-of-care testing is helpful, especially in diagnosing cryptococcal meningitis in some developing 
countries where access to microbiology laboratory is limited, or in diagnosing invasive Aspergillosis 
using Lateral Flow Devices. All these new diagnostic tools have a tremendous impact on antifungal 
stewardship as they allow physicians to discontinue antifungal agents earlier when not needed or to 
de-escalate them to narrower-spectrum agents. These efforts will ultimately translate into decreasing 
antifungal resistance and reducing costs to healthcare, which are essential elements of stewardship. 
 
S18.5 
Optimising antifungal stewardship: An evaluation of candidaemia guideline compliance and 
clinical outcome 
L. Cottom1, B. Jones2 
1Department Of Medical Microbiology, Glasgow Royal Infirmary, NHS Greater Glasgow & Clyde, 
Glasgow, United Kingdom, 2Department Of Medical Microbiology, Glasgow Royal Infirmary, 
Glasgow, United Kingdom 
Objectives: Candidaemia remains an important cause of nosocomial infection, associated with 
significant morbidity and mortality. Over the last decade there has been a growing awareness that 
improvements to stewardship and robust surveillance is needed to ensure the judicious use of 
antifungal therapy. A guideline should never be construed or serve as a standard of care, rather 
recommendations should always be interpreted alongside individual patient findings and be guided 
by local epidemiology and antifungal susceptibility knowledge. The aim of this study was to evaluate 
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compliance with the current 2016 Infectious Diseases Society of America (IDSA) guidelines and assess 
the impact on clinical outcome. Adherence to management recommendations was assessed using the 
EQUAL Candida Score of the European Confederation of Medical Mycology (ECMM). A secondary 
aim was to assess clinical outcome (30 day, 90 day and all-cause mortality) with an echinocandin 
compared to fluconazole as the initial treatment (primary therapy) for candidaemia. 
Methods: A retrospective analysis was performed over 18-months (January 2017 to June 2018). Data 
was analysed from five large university teaching hospitals within Greater Glasgow and Clyde; the 
largest NHS organisation in Scotland serving a population of 1.2 million. Patients were identified 
using our laboratory information management system and electronic clinical record systems. Only 
cases where a diagnosis of candidaemia had been confirmed and the patient had been actively treated 
were included for analysis. The source of infection and antifungal management was reviewed for 
each patient. The EQUAL candida score was calculated for each case. The 30-day, 90-day and all-
cause mortality rate was determined for the study population. 
Results: A total of 131 patients were identified as having a candidaemia. The most common Candida 
species isolated was C.albicans (40%; 53/131) followed by C.glabrata (27%; 35/131). An echinocandin 
was initiated as primary therapy in 52% (68/131) of cases. In 62% of cases the patient had an 
indwelling line that was attributed as the direct source/nidus of infection. 21% of cases were related 
to a urinary tract source and/or urological instrumentation. The mean EQUAL Candida Score was 
found to be 13 (range 9-17), with the maximum score for guideline adherence being 16 for non-CVC 
patients and 19 for CVC carrier (score adjusted as initial blood culture volume was not known for 
study population). No statistically significant difference in clinical outcome (30 day mortality) was 
found when comparing an EQUAL Candida Score of ≤13 with > 13 (chi-square calculation; p-value 
0.76). For the study population, a statistically significant difference in clinical outcome (30 day 
mortality) was found when comparing fluconazole to an echinocandin as initial treatment/primary 
therapy with a survival benefit being found in favour of fluconazole (chi-square calculation; p-value 
0.039). 
Conclusion: Our study provides a valuable evaluation of compliance. Interesting, increased 
compliance was not found to improve clinical outcome. Furthermore, the results from our study 
suggest that fluconazole as initial therapy was non-inferior to an echinocandin for the treatment of 
candidaemia, with a survival benefit being observed. This study supports the importance of an 
effective program of surveillance to promote antifungal stewardship and the judicious use of 
antifungal agents. 
 
Symposium 19 Pneumocystis 
 
S19.1 
Recent diagnostic strategies in Pneumocystis pneumonia 
A. Alanio 
Paris-diderot, Sorbonne Paris Cité University, Institut Pasteur, Molecular Mycology Unit, Cnrs 
Cmr2000, Parasitology-Mycology Laboratory, Lariboisière Saint-Louis Fernand Widal Hospitals, 
Assistance Publique-Hôpitaux de Paris, Paris, France 
Pneumocystis jirovecii pneumonia (PCP) is one of the most commonly diagnosed opportunistic 
infection in HIV-positive patients. In addition, the rising number of immunocompromised HIV-
negative patients at risk of P. jirovecii infection (immunosuppressive therapies, allogeneic bone 
marrow or solid organ transplantation) is an emerging concern. PcP is difficult to diagnose in HIV-
negative patients owing to the non-specific pulmonary symptoms and signs associated. Microscopic 
visualization of cysts or trophic forms in respiratory specimens based on immunofluorescence 
stainings is the most sensitive microscopic method and still considered as the gold-standard test to 
diagnose this infection. Bronchoalveolar lavage fluids are the most sensitive specimen type, since P. 
jirovecii is an organism associated to lung alveoli. PCR-based methods play an increasing role in the 
lab, initially developed to circumvent decreased fungal load in HIV-negative patients and detection 
in upper respiratory specimens. Real-time quantitative PCR (qPCR) is definitely the only format 
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adapted to detect P. jirovecii since the risk of contamination is minimal and quantification is possible. 
A negative qPCR in BAL, but not in non-invasive respiratory specimens, allows to rule out PCP 
diagnosis. Quantitative results have been used for years to try to discriminate PCP (high fungal load) 
from carriage/colonization (low fungal load). However, these methodologies have limited use since 
intermediate fungal load are inconclusive. Recent advances in the comparison of the performances 
of the different qPCR assays showed that standardization is certainly one of the clues to move 
forward with this question. In parallel, the combination with (1-3)-b-D-Glucan (BG) detection in 
serum helps but do not completely resolve the problem. BG detection has a high sensitivity and a 
high negative predictive value for diagnosis of PcP in immunocompromised HIV-positive and -
negative patients, but a positive result may also indicate the presence of other invasive fungal 
infections. The clinical utility of these diagnostic tests and the diagnostic strategies in HIV or non-
HIV patients should be further assessed in prospective, randomized interventional studies.In the 
meantime, the status of the host should be better defined with regard to the evolution of P. jirovecii 
carriage. New screening and prophylaxis strategies to prevent transmission in hospital settings 
should be proposed and discussed 
 
S19.2 
Management of Pneumocystis Pneumonia in HIV-infected Patients 
J. Kovacs 
Associate Clinical Professor of Medicine, The George Washington University School of Medicine and 
Health Sciences, Washington, DC, United States of America 
Pneumocystis pneumonia (PCP) remains one of the most common life-threatening opportunistic 
infections in HIV-infected patients, despite the tremendous benefits seen with combination 
antiretroviral therapies. PCP continues to be seen in the current era primarily because at-risk patients 
are unaware of their HIV infection or are not in continuous medical care. Infection appears to 
represent recent acquisition in many cases rather than reactivation of latent infection. Primary clinical 
manifestations include fever, shortness of breath, and a non-productive cough. CXR will typically 
show diffuse infiltrates though it may be normal in 10-20% of cases; chest CT scans will almost 
invariably be abnormal, however. Diagnosis is based on detection of the organism in respiratory 
samples such as induced sputum or BAL. Because the organism cannot be cultured, organism 
detection relies on colorimetric or immunofluorescent staining, or PCR assays. The latter are highly 
sensitive but less specific than the former, in part because PCR can identify colonization or subclinical 
infection not requiring therapy. Assays to measure (1-3)-β-D-glucan levels have poor specificity and 
should not be relied on as the exclusive diagnostic modality. The preferred first-line drug for 
treatment is trimethoprim-sulfamethoxazole, which targets 2 steps in Pneumocystisfolate metabolism. 
Alternatives for patients with mild to moderate disease (A-a O2 gradient <45 mm Hg) include 
clindamycin-primaquine, trimethoprim plus dapsone, and atovaquone. Alternatives for patients 
with more severe disease requiring parenteral therapy include clindamycin-primaquine (primaquine 
is available only for oral administration) and pentamidine. Caspofungin should not be used as a 
single agent since it affects only the cyst form and not the more numerous trophic form of the 
organism; further, there are no controlled studies evaluating its efficacy. Corticosteroids should be 
administered in patients with PaO2 <70 mm Hg or (A-a) O2 gradient >35 mm Hg, ideally within 3 days 
of starting therapy, and be continued using a tapering regimen while anti-Pneumocystis therapy is 
administered. Although there are no randomized trials, meta-analyses suggest that clindamycin-
primaquine is more efficacious than pentamidine. For patients failing therapy, there are no 
randomized trials to address optimal management, and whether it is better to add drugs or to change 
regimens. PCP can be effectively prevented in at-risk patients (e.g. CD4 <200 cells/mm3) by using 
trimethoprim-sulfamethoxazole, or alternatively dapsone, dapsone-pyrimethamine, atovaquone, or 
aerosol pentamidine. In patients recovering from an episode of PCP, secondary prophylaxis should 
be initiated after completion of therapy. Prophylaxis can be discontinued after the immune system 
has reconstituted to CD4 >200 cells/mm3 for at least 3 months. In patients with poor immune 
reconstitution (CD4 >100 but <200 cells/mm3) but with HIV suppression to below detection limits of 
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commercial assays (typically <20 copies/ml) for 3-6 months, prophylaxis can also be discontinued. 
Prophylaxis should be continued in patients with CD4 <100 cells/mm3 even with HIV suppression. 
Mutations have been identified in the dihydropteroate (DHPS) gene of Pneumocystis, the target of 
sulfamethoxazole and dapsone, primarily in patients receiving those drugs for prophylaxis. 
Although these mutations appear to confer at least low level resistance, their clinical significance is 
uncertain. 
 
S19.4 
Pneumocystosis in neonates 
E. Calderon 
Instituto de Biomedicina de Sevilla and CIBER de Epidemiología y Salud Pública, Seville, Spain 
Pneumocystosis has been well recognized as a severe pulmonary disease and an important cause of 
morbidity and mortality in premature infants or debilitated neonates since the mid-twentieth century 
when Pneumocystis was acknowledged as the causing agent of interstitial plasma cell pneumonia. 
This form of pneumocystosis was observed before, during and after World War II in Europe, where 
it reached epidemic proportion with more than 500 cases confirmed by autopsy. Unexpectedly, this 
epidemic pneumocystosis disappeared in the same manner it had been emerged in Europe. Although 
data on pediatric Pneumocystis pneumonia (PcP) from developing countries are scarce mostly based 
on small series of cases, PcP in infants seem to remain as an important medical problem in those 
areas. Nowadays, the interest in Pneumocystis infection goes beyond PcP because a new spectrum of 
Pneumocystis-related disease seems to emerge in immunocompetent infants. Serological studies and 
use of molecular techniques to identified Pneumocystis jirovecii have shown that this microorganism 
probably is one of the more frequent infectious agents faced by humans in everyday life and that the 
first exposition to this pathogen happen in most children early in life, probably in the neonatal period. 
However, primary Pneumocystis infection currently goes unrecognized because it has been presumed 
to be an asymptomatic or mild nonspecific disease. However, recent reports indicate that it can 
present clinically as a self-limiting upper or lower acute respiratory tract infection. Pneumocystis 
infection was identified by specific PCR in 24% of infants with bronchiolitis from France and in 29.4% 
of Cuban infants and toddlers with whooping cough. In another study of 422 children hospitalized 
with acute respiratory tract infection, Pneumocystis was detected in 16% of infants. However, a 
marked difference occurred in the age distribution, as the prevalence was 48% in infants ages 50 to 
112 days, 13% in infants ages 113 to 265 days, and 2% in in infants younger than 49 days. In a study 
carried out in Santiago de Chile, Pneumocystis DNA was detected in specimens from 51.7% of infants 
who died unexpectedly in the community, but only 15% had pneumonia. This study also showed 
that Pneumocystis infection is more frequent than viruses before the age of 6 months, and that it has a 
consistent peak between 2 and 5 months of age. The significance of these findings is unclear but shows 
the high prevalence of Pneumocystis infection in infants. Recently, in Spain, a high prevalence of 
Pneumocystis infection has been described in preterm neonates and this infection was associated to 
higher risk to develop neonatal respiratory distress syndrome. Increasing evidence suggests that the 
most common respiratory infection-affecting infants is the mild and sneaky, primary infection by 
Pneumocystis. This infection goes currently unrecognized and has been neglected as a subclinical 
irrelevant infection by contrast with the severe PcP affecting the immunocompromised patients. 
However, compelling new evidence suggests that this infection may be pathogenic to certain infant 
age groups and that microbiome host interactions in early life may condition the development of 
altered immune responses in older infants or adults. 
 
S19.5 
Evaluation of a Novel Commercial Loop-mediated Isothermal Amplification (LAMP) Assay for 
Rapid Detection of Pneumocystis jirovecii 
D. Schmidt, U. Scharmann, J. Buer, P.-M. Rath 
Institute Of Medical Microbiology, University Hospital Essen, Essen, Germany 
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Objectives: Pneumocystis jirovecii pneumonia (PCP) is an increasing problem in 
immunocompromised patients. Detection of P. jirovecii in respiratory samples is usually based on 
microscopy or PCR. Both methods require experienced technical personnel and are either insensitive 
or time-consuming. In this study, a prototype of the eazyplex Pneumocystis jirovecii assay (Amplex 
Diagnostics, Germany) was established. The assay is based on LAMP technique (loop-mediated 
isothermal amplification). It requires minimal hands on time for sample manipulation (below 5 
minutes) and performance of the assay itself (25 minutes) and could be a reliable technique to detect 
P. jirovecii. 
Methods: In total, 145 respiratory samples from 134 critically ill patients (65% male, median age = 64 
years) were investigated, using the LAMP assay in comparison with the RealStar Pneumocystis 
jirovecii PCR 1.0 (altona Diagnostics, Germany). For the LAMP assay 25µl of sample were mixed with 
125µl RALF buffer (resuspension and lysis fluid, Amplex) and incubated for 3 minutes at 99°C. 25µl 
of this suspension were added to the wells of the test strip afterwards. The LAMP assay was 
performed in a Genie II Mk2 device (Amplex). For qPCR, 300µl of sample were extracted using the 
Maxwell16 nucleic acid extraction platform (Promega, Germany). 10µl of DNA were used for qPCR 
according to the manufacturer ś recommendations. QPCR was performed on a RotorGeneQ cycler 
(Qiagen, Germany) in a final volume of 30µl. To determine the detection limit of the LAMP assay, 
compared to the qPCR, tenfold serial dilution of extracted P. jirovecii DNA and of a high positive P. 
jirovecii respiratory sample were investigated in both assays. Additionally, for each serial dilution 
time-to-positivity of the LAMP assay was plotted against cycle threshold values (ct values) of the 
qPCR. For quantification of the fungal load the quantification standards of the RealStar qPCR were 
used (1x104 -1x101 copies/µl). 
Results: The LAMP assay detected 17 of 19 qPCR positive samples and 117 of 117 qPCR negative 
samples. The assay was invalid in nine samples that were negative by qPCR. Time-to-positivity of 
the LAMP assay ranged from 11-22 minutes in patient samples. Detection limit of the assay was 
approximately 15-20 copies of genomic DNA/µl in patient samples and in extracted DNA which 
corresponded with ct values of 28-29 in the qPCR. 
Conclusion: The LAMP assay is an accurate and time saving tool for the detection of P. jirovecii in 
respiratory samples. Two samples that were positive by qPCR were not detected by the assay which 
is probably due to the significantly lower sample volume and the crude extraction method the assay 
uses. Nevertheless, the convenience of the performance of the assay and interpretation of the results 
allows laboratories with less experience and less technical equipment to perform molecular assays 
on a high standard. 
 
Symposium 20 Candida auris 
 
S20.1 
Schizophrenic gram negative yeast conquering the world 
J. Meis 
Department Of Medical Microbiology And Infectious Diseases, Excellence Center For Medical 
Mycology (ECMM), Canisius Wilhelmina Hospital, Nijmegen, Netherlands 
Candida auris has been named as the new “fungal superbug” which poses a significant threat to public 
health during outbreaks. C. auris was first named and described only 10 years ago. Follow-up 
genomic analysis has revealed that C. auris has emerged almost simultaneously in this short period 
on 3 different continents. At present 4 major clades have been identified and last month a fifth clade 
was discovered. In the beginning C. auris was often mistaken for other Candida or yeast species when 
using phenotypic assimilation/fermentation identification tests. Wide introduction of MALDI-TOF 
technology has significantly improved accurate identification in the past few years and is now the 
gold standard in addition to molecular sequencing. C. auris has also shown resistance to several 
different antifungal drugs and classes of drugs. While its resistance profile varies geographically, this 
new yeast pathogen has acquired resistant to fluconazole, a key drug in the azole class of antifungal 
drugs. C. auris spreads in healthcare facilities in a similar way as bacteria while the occurrence and 
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niche in the environment is elusive. Infections have been reported in a range of countries across 
continents, but current estimates are probably inaccurate. Impervious to both antiseptics and the 
three major classes of anti-fungal medications, C. auris has been quietly transmitted within hospitals 
and nursing homes in at least 37 countries such as the UK, Spain, India, Pakistan, Middle East, South 
Africa, Latin America and parts of the USA. Patients can be colonised with C. auris without becoming 
sick, but the pathogen seems to prefer to colonise patients who are already sick or 
immunocompromised (eg, cancer or transplant patients), and the very young or very old among 
hospitalised inpatients. Among at-risk patients who have C. auris candidemia or invasive candidiasis, 
depending on the world region, high mortality rates (~ 30–60%) have been observed. But because 
infection typically occurs when a person is already very sick, it may be difficult to disentangle the 
attributable mortality. It is important to realize that C. auris is predominantly a healthcare-associated 
infection. Prior broad-spectrum antibiotics and antifungal use can influence the risk of infection. 
Finally an important question is still unanswered C. auris: Unde venis et quo tendis? Reference Meis JF, 
Chowdhary A. Candida auris: a global fungal public health threat. Lancet Infect Dis. 2018;18(12):1298-
1299 
 
S20.3 
Outbreak control: "Controlling a multidrug-resistant Candida auris outbreak" 
A. Ruiz-Gaitan1,2 
1Severe Infection Research Group, Medical Research Institute La Fe, Valencia, Spain, 2Department Of 
Clinical Microbiology, La Fe University and Polytechnic Hospital, Valencia, Spain 
Background: Candida auris is an emerging, multidrug-resistant yeast causing hospital outbreaks. The 
outbreaks by C. auris described in Spain as well as in other countries with large outbreaks, are 
characterized by an exponential increase in the number of cases in a short period, suggesting a high 
transmission rate. Objectives We report the first 24 months of the ongoing C. auris outbreak in a 
tertiary hospital in Spain. The epidemiological, clinical and microbiological characteristics of 
candidemia episodes and environmental samples by C. auris were also analyzed. Results: 228 
patients were involved in the case–control study (114 colonized/candidemia and 114 controls). All 
candidemia episodes were observed in adult patients (21–81 years old) and 87.8% of them were 
admitted to SICU. The most common underlying condition observed in both colonized and 
candidemia patients was polytrauma (n = 13, 32%) followed by cardiovascular disease (n = 10, 25%) 
and cancer (n = 7, 17%). Indwelling CVC (odds ratio {OR}, 13.48), parenteral nutrition (OR, 3.49), and 
mechanical ventilation (OR, 2.43) were the more frequently invasive procedures observed in these 
two groups and remained significant predictors of C. auris colonization/candidemia. All C. auris 
isolates were resistant to fluconazole (MICs >64 mg/L) and had significantly reduced susceptibility 
to voriconazole (GM, 1.8 mg/ L). All isolates were susceptible to itraconazole, posaconazole, 
isavuconazole, and echinocandins. Environmental sampling showed presence of the C. auris on 
sphygmomanometer cuffs (25%) patient tables (10.2%), keyboards (10.2%), and infusion pumps 
(8.2%). Conclusions: - Predictor conditions to C. auris colonization/candidemia are similar to other 
Candida species. C. auris colonizes multiple patient’s environment surfaces. All isolates are resistant 
to fluconazole and had significant reduced susceptibility to voriconazole. - Due to its high 
transmissibility and survival in the hospital environment, C. auris can cause long duration outbreaks 
that are difficult to detect in early stages, and it makes it difficult to control and eradicate. - The 
implementation of early and strict surveillance and control measures is essential to preventing the 
spread of the outbreak representing a significant risk to critical patients. - Immediate notification of 
C. auris to clinical and infection control teams, as well as to health authorities and institutions, is 
essential to implementing infection control precautions at all levels in a timely way, to prevent 
transmission inside and outside the hospital and to prevent the development of infections in patients 
who are already colonized. - This report is intended to demonstrate not only the complexity of 
handling and containing a C. auris outbreak, but also how, with the use of a series of effective infection 
prevention measures, the spread of this pathogen can be successfully controlled. 
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S20.4 
Candida auris: in developing world  
Anuradha Chowdhary 
Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India  
Candida auris a multidrug-resistant(MDR) yeast that exhibits resistance to fluconazole and markedly 
variable susceptibility to other azoles, amphotericin B, and echinocandins has globally emerged as a 
nosocomial pathogen that can cause invasive infections. Candida auris was first described in 2009 by 
Satoh et al. as a novel Candida species, in the Candida haemulonii complex(Metchnikowiaceae), from 
a patient in Japan after its isolation from the external ear canal. Subsequent to the first nosocomial 
outbreak in South Korea in 2011, several hospitals associated outbreaks have been reported in 
developing world especially in India, Pakistan and Africa. Alarmingly, in less than a decade this 
yeast, which is difficult to treat, has become widespread across several countries causing a broad 
range of healthcare associated invasive infections that display clonal inter- and intra-hospital 
transmission. C. auris in routine microbiology laboratories remains an unnoticed pathogen as 90% of 
the isolates characterized by commercial biochemical identification systems such as API 20C, Vitek 2 
(bioMérieux), Phoenix (BD), and MicroScan (Beckman Coulter), misidentify as a range of other 
Candida species. Most commonly, these isolates have been misidentified as C. haemulonii, but also 
C. famata, C. sake, Rhodotorula glutinis, Rhodotorula mucilaginosa, and Saccharomyces species. 
Rarely, C. auris has been identified as C. catenulate, C. lusitaniae, C. guilliermondii, or C. 
parapsilosis. However, MALDI-TOF MS is considered a more rapid and robust diagnostic technique 
for C. auris identification. Mass spectra can be easily added to the MALDI-TOF MS database, leading 
to accurate identification of C. auris to the species level. Sequencing of genetic loci, including D1/D2, 
RPB1, RPB2, and internal transcribed spacer (ITS) domains of the rRNA, has proven useful in the 
identification of C. auris, but it is not routinely used. 
However, in the routine microbiology laboratories this yeast remains unidentified especially in 
developing world due to lack of fully equipped mycological diagnostic facilities. Further, the true 
burden of C. auris remains unexplored as effective surveillance of Candida spp is not available in 
several countries in the developing world. Antifungal susceptibility data for C. auris is of primary 
concern as C. auris exhibit consistently high fluconazole MICs and variable susceptibility to the other 
azoles, echinocandins and amphotericin B. No antifungal clinical breakpoints reported for C. auris. 
Studies examining the susceptibility of this organism to antifungals have used a variety of methods, 
including Clinical and Laboratory Standards Institute (CLSI) broth microdilution, Etest, and the Vitek 
2 yeast susceptibility system. Regarding azole resistance mutations in Erg11 associated with the 
development of fluconazole resistance in C. albicans have also been detected in C. auris isolates. The 
fact that this yeast exhibit MDR clonal strains which are nosocomially transmitted is unusual in other 
Candida species. Therefore, the possible threat of its rapid spread in affected countries and its 
emergence in unaffected countries will not only challenge clinicians for its effective therapeutic 
management but will also bring high economic burden to countries especially in resource limited 
settings where modern identification facilities and access to antifungals other than FLU are limited. 
 
S20.5 
Understanding Echinocandin Activity Towards Candida auris 
M. Kordalewska1, A. Lee1, R. Garcia-Rubio1, S. Park1, I. Berrio2, A. Chowdhary3, Y. Zhao1, D.S. Perlin1 
1Center For Discovery And Innovation, Hackensack Meridian Health, Nutley, United States of 
America, 2Hospital General de Medellín “Luz Castro de Gutiérrez” ESE, Medellin, Colombia, 
3Department Of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, 
India 
Objectives: Candida auris is a recognized cause of invasive infections and health care associated 
outbreaks around the world. Development of echinocandin resistance has been documented in C. 
auris isolates recovered from patients treated with these drugs. Thus, a thorough understanding of 
C. auris echinocandin susceptibility profiles and resistance mechanisms is crucial for improved 
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management. In this study, we performed a comprehensive analysis of C. auris echinocandin 
susceptibility and molecular resistance determinants. 
Methods: A total of 106 C. auris isolates (Colombia, India, AR Bank) were investigated in this study. 
Antifungal susceptibility testing (AFST) with echinocandins (anidulafungin, caspofungin, 
micafungin) was performed in accordance with CLSI document M27‐A3. FKS1 gene, encoding the 
target enzyme for echinocandin class antifungal drugs, was amplified and sequenced. Mutation 
prevention concentration (MPC) determination assay was performed for echinocandin-susceptible 
(micafungin MIC range 0.03-0.5 mg/l), FKS1 wild-type C. auris, C. albicans and C. glabrata control 
strains. Isolates were cultured in RPMI-1640 containing 2-fold increasing concentrations (0.03 to 128 
mg/l) of micafungin, then culture aliquots were plated onto YPD plates and number of surviving cells 
were calculated. Recovered colonies were screened for the presence of FKS1 mutations. Moreover, in 
vivo drug response of C. auris isolates to caspofungin was assessed in a murine model of invasive 
candidiasis. 
Results: Four Indian isolates from a total of 106 isolates (3.8%) exhibited highly elevated MICs ≥4 
mg/l at 24 h and were considered presumptively resistant to all tested echinocandins. These isolates 
were found to harbor an S639F amino acid substitution in Fks1. The remaining 102 echinocandin-
sensitive isolates presented wild-type genotype. Micafungin was the most potent echinocandin 
(MIC50 = 0.125 mg/l). We encountered a significant challenge obtaining an accurate MIC readout for 
caspofungin since all tested isolates exhibited an Eagle effect (paradoxical growth effect), with the 
intensities of the Eagle effect varying among the isolates. In MPC determination assay with 
micafungin, C. auris isolates did not present a classical bi-modal killing pattern characteristic for 
fungicidal drugs activity against other Candida species. Response of C. auris to micafungin differed 
between isolates, but micafungin did not reach the fungicidal endpoint for any of the isolates, even 
when high drug concentrations (128 mg/L) were tested. Since no FKS1 mutation was revealed by 
sequencing, we hypothesize the presence of extreme tolerance mechanism in C. auris. Echinocandins 
were effective in vivo in the treatment of invasive murine candidiasis caused by FKS1 wild-type C. 
auris isolates (significant (P < 0.05) ~1 log10 CFU/g kidney burden reduction upon caspofungin 
treatment relative to vehicle controls), despite the presence of the Eagle effect in vitro. Mice challenged 
with fks1 S639F mutants failed to respond to the drug and their kidney burdens were not much 
different between caspofungin treated and untreated groups. 
Conclusion: Without established breakpoints for C. auris, AFST results interpretation and 
conclusions regarding resistance, especially when testing caspofungin, should be made with caution. 
The high echinocandin tolerance of C. auris observed in vitro should be further explored. Presently, 
the only validated determinant impacting C. auris pharmacodynamic response to echinocandins is 
the FKS1 genotype. 
 
Symposium 21 Immunotherapy for opportunistic fungal infections 
 
S21.1 
CAR T cell and NK cell therapy of invasive mycoses 
D. Kontoyiannis 
Ut Md Anderson Cancer Center, 1515 Holcombe, Houston, United States of America 
Invasive fungal infections remain a major threat to the survival of immunocompromised patients and 
no curative therapies are currently available to treat drug resistant opportunistic fungi. In this brief 
talk, I will provide a conceptual overview of recent developments to use specific chimeric antigen 
receptor (CAR) expressing T cells and NK cells as adoptive immunotherapy. CAR T cells have been 
successfully used to treat B-cell malignancies. To render CAR T cell therapy specific for fungi, we 
designed a CAR which combines the carbohydrate-binding domain of Dectin-1 with T cell signaling 
domains, designated as Dectin-1-CAR (D-CAR). The pattern recognition receptor Dectin-1 was 
selected based on its property to bind selectively to β-1,3-glucan present on the cell wall of life 
threatening fungal species. I will be discussing our efforts to manufacture clinical grade D-CAR+ T 
cells and to increase T cell persistence. However, allogeneic CAR T cells carry a significant risk of 
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graft-versus-host disease, and logistical problems of rapid and robust production remain. As the role 
of natural killer (NK) cells in fungal immunity has been increasingly deciphered, I will be discussing 
the potential benefits of cord-blood derived NK cells as an attractive, allogeneic, off-the-self source 
for future, logistically feasible immunotherapeutic approaches to treat invasive mycoses. 
 
S21.2 
WBC transfusions Granulocyte Transfusions As Adjunctive Treatment Of Invasive Fungal Diseases 
In Neutropenic Patients 
L. Pagano 
Fondazione Policlinico Universitario A. Gemelli - IRCCS - Universita Cattolica del Sacro Cuore, 
Rome, Italy 
The degree and duration of neutropenia are crucial prognostic factors in hematological patients (pts) 
with invasive fungal infections (IFIs). Since the introduction of granulocyte colony stimulating factor 
(G-CSF), there has been a renewal of interest in granulocyte transfusions (GTX). Granulocyte 
transfusions (GTX) are seldom used as a life-saving therapy for neutropenic patients with severe 
infections. Despite several compelling evidences of GTX efficacy in retrospective and prospective 
case series, no study has been successful in demonstrating a definite advantage for recipients in 
controlled clinical trials. Some specific issues relevant to the efficacy of this therapeutic approach, 
such as the primary infection, the delivered doses and schedules, and the immunological effects of 
GTX, are still subject to discussion today. Importantly, the awareness of biological effects 
accompanying the transfusion of neutrophils might support their use at standardized doses and may 
definitely convey significant advantages to the recipient patients. At present, despite statistical 
evidences are lacking, GTX are still perceived as a lifesaving tool to support neutropenic patients 
with life threatening IFIs until their bone marrow recovery. Sharing procedures for donor 
identification and cell mobilization, pursuing common criteria to identify which patients will benefit 
of GTX during febrile neutropenia and define indications and therapeutic cell doses are absolutely 
urgent to pinpoint the true advantage of using GTX. On the other hand, adopting equal end points 
and outcomes to evaluate both clinical response to treatment and biological functions of neutrophils 
and chemokines during IFI, need to be clarified. 
 
S21.4 
Novel chimeric antigen receptor T cells for invasive aspergillosis immunotherapy 
M. Seif1, T. Nerreter1, M. Machwirth1, F. Ebel2, H. Einsele1, M. Hudecek1, J. Löffler1 
1Medizinische Klinik Und Poliklinik Ii, Universitätsklinikum Würzburg, Würzburg, Germany, 
2Institut Für Infektionsmedizin Und Zoonosen, Ludwig-Maximilians-Universität München, 
München, Germany 
Objectives: Immunocompromised patients are susceptible to invasive fungal infections mainly 
caused by Aspergillus fumigatus (Af). Adoptive transfer of Aspergillus-specific T cells has been shown 
to reduce the burden of invasive aspergillosis. Such T cells are hard to isolate and expand. An 
alternative option is the use of T cells modified to express a chimeric antigen receptor (CAR). CARs 
are recombinant receptor constructs composed of an extracellular targeting element linked to an 
intracellular signaling module. A recent study using Dectin 1 as targeting element proved the 
applicability for antifungal CAR T cells in vitro and in vivo. One main limitation of Dectin 1 is the 
differential expression of its target β-glucan on Af morphotypes cell wall. β-glucan is mainly exposed 
on the surface of swollen conidia and early germ tubes but less on hyphae. Thus, better specificity 
would be highly valuable. Here we propose a highly specific and effective way of redirecting T cells 
towards Af. 
Methods: For the construction of AF-specific CARs, we fused an scFv, derived from an antibody 
directed against the Af hyphal cell wall, to extracellular IgG4-Fc spacer domains of different lengths 
followed by CD28 and CD3-ζ signaling domains. We non-virally expressed the CARs on the surface 
of primary human CD4+ and CD8+ T cells using the Sleeping Beauty retrotransposon system and co-
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cultured CAR T cells with Af germ tubes to evaluate specific T cell activation and direct hyphal 
damage. 
Results: We could show that our CAR T cells are specific for Aspergillus fumigatus, as no cross-
reactivity with other Aspergilli was observed. Activated CD8+ CAR T cells secreted mainly Th1-
related cytokines (IFN-γ, TNFα, IL-8 and GM-CSF) and chemokines (mainly CCL3 and CCL4), and 
only one Th2 cytokine (IL-13). Similarly, CD4+ CAR T cells secreted mostly Th1 cytokines and 
chemokines, but also some Th2 cytokines (mainly IL-13 and IL-4). CARs equipped with a long 
extracellular spacer containing the full hinge-CH2-CH3-motif conferred superior T cell activation as 
compared to CARs having a short "hinge-only" spacer. Noteworthy, mainly CAR T cells containing 
a long spacer underwent proliferation upon activation. Upon binding to the target, the cytolytic 
machinery of CD8+ CAR T cells was activated, leading to the release of perforin and granzyme B and 
up to 45% hyphal damage. Furthermore, when cocultured with macrophages, both CD4+ or CD8+CAR 
T cells enhanced antifungal activity of macrophages. 
Conclusion: Taken together, our results show that we successfully redirected CD4+ and CD8+ CAR T 
cells against Af hyphae and that fine-tuning of CAR constructs might allow the control of fungal 
infections in high-risk patients. 
 
S21.5 
Comparison of circulating lymphocyte populations CD4+ and CD8+ T cells, B and NK 
lymphocytes according to the favorable or worsening evolution of patients with pneumocystosis 
E. Charpentier1,2, C. Marques1, S. Menard1, N. Blanchard1, P. Chauvin2, E. Guemas1, S. Cassaing2, J. 
Fillaux2, A. Valentin2, A. Berry1,2, X. Iriart1,2 
1Center for Pathophysiology of Toulouse Purpan - INSERM UMR 1043, Toulouse, France, 
2Parasitology And Mycology, CHU de Toulouse, Toulouse, France 
Objectives: Pneumocystosis is a severe opportunistic disease in which the host inflammatory 
response to the infection is decisive for the disease evolution. Although a reduced count of CD4+ T 
lymphocytes has been associated to a major risk of pneumocystosis, especially in HIV-positive 
subjects, little is known about other lymphocyte populations (CD8+ T cells, B and NK lymphocytes) 
or about CD4+ and CD8+ T cells subpopulations. This study aimed to compare circulating 
lymphocyte populations in patients suffering from pneumocystosis according to the patient 
evolution. 
Methods: Levels of circulating lymphocyte populations were evaluated in the blood of 24 patients 
diagnosed with a pneumocystosis at Toulouse Teaching Hospital between 2016 and 2018. Among 
them, five were solid organ transplant (SOT) recipients, seven had a haematological malignancy 
(HM), five had a solid cancer (SC), three had an inflammatory disease (ID) and four were HIV-
positive. CD4+ and CD8+ T cells, B lymphocytes and NK cells were evaluated with flow cytometry 
as well as Th1, Th2, Th17, Treg and naive, effector, memory subpopulations. The lymphocyte 
populations were compared between patients with favorable evolution (n = 16) and deceased patients 
(n = 8; 2 SOT, 2 HM, 3 SC, 1 HIV). 
Results: Interestingly, the most significant results concerned CD8+ T cell subpopulations. Although 
there was no difference in global CD8+ T lymphocyte count, the proportions of memory CD8+ T 
lymphocytes (both central memory and effector memory) were lower in deceased subjects. At the 
opposite, the proportions of naive and effector CD8 lymphocytes were increased in this group. 
Effector memory CD8+ lymphocytes of deceased patients harboured less CD127 (IL7 receptor that 
induces lymphocyte survival and proliferation) whereas their CD8+ effector cells contained more 
CD127+ CD25+ (IL2 receptor and activation marker) cells in comparison to the CD8+ effector cells of 
surviving patients. These differences in CD8+ T cells were associated with reduced Th1 CD4 
subpopulation and Th1/Th2 ratio in deceased patients. NK cells were also reduced in this group. 
There was no significant difference, either in CD4+ T cells count or in other CD4 subpopulations (Th2, 
Th17, Treg, naive, effector, memory) or in B cells count. Patients age, fungal load and CMV presence 
or absence were not significantly different in the two groups. 
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Conclusion: The implication of CD8+ T cells in pneumocystosis is currently a controversial topic with 
a discussed role of these cells in the fungus clearance and a suspected association with alveolar 
lesions. According to this study, high CD8+ memory subpopulations would be associated with a 
better evolution of the disease, along with Th1 CD4+ T cells. However, high naive and effector CD8 
populations would be associated to a worsening evolution of the patient. The disparity of CD8+ 
lymphocytes subpopulations might be related to a difference of immunity stimulation by 
Pneumocystis jirovecii antigens or it could be connected with a difference of CD8+ subpopulations 
homeostasis possibly affected by some therapeutics or living conditions. Despite the dogma that 
establishes CD4+ T lymphocytes as the center of pneumocystosis pathogenesis, CD8+ T cells may also 
have an important role in the disease pathogenesis. 
 
S21.6 
Glucosylceramides from Lomentospora prolificans Induce Cytokines Production and Increase the 
Microbicidal Activity of Macrophages 
M.I.D.S. Xisto1, J.E. Muñoz2, L.S. Dias3, G.M.P. Santos2, R.O.R. Calixto1, M.C. Bernardino1, C.P. 
Taborda4, E. Barreto-Bergter1 
1Instituto De Microbiologia Paulo De Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 
Brazil, 2Instituto Biomédico, Departamento De Microbiologia E Parasitologia, Universidade Federal 
Fluminense, Niterói, Brazil, 3Department Of Pediatric, School Of Medicine And Public Health, 
University of Wisconsin-Madison, Madison, United States of America, 4Institute Of Biomedical 
Sciences, department Of Microbiology, University of São Paulo, São Paulo, Brazil 
Objectives: Lomentospora prolificans is an emerging opportunistic fungus with a high resistance to 
antifungal agents and it can cause localized infections in immunocompetent patients and 
disseminated infections with a high mortality rate in immunosuppressed patients. 
Glucosylceramides (GlcCer) are synthetized in the majority of known fungal pathogens. They are 
bioactive molecules presenting different functions such as involvement in fungal growth and 
morphological transitions in several fungi. In this study, we report the characterization of GlcCer 
species in L. prolificans and the role of these molecules in the activation of the innate immune response. 
Methods: GlcCer species were isolated from mycelium and conidia forms of L. prolificans and their 
chemical structures were elucidated by mass spectrometry (ESI-MS). The reactivity of L. prolificans 
GlcCer species to anti-GlcCer Mab was analyzed by ELISA. The GlcCer distribution on the surface of 
L. prolificans was analyzed by immunofluorescence using anti-GlcCer Mab. The cytokine analysis was 
performed by the GlcCer injection in BALB/c mice and the cytokines were quantified by ELISA 
according to the manufacturer’s instructions. Recruitment of Cells to the Peritoneum Cavity was 
analyzed FACS. 
Results: GlcCer purified from both forms presented a major species at m/z 750 that corresponds to 
N-2-hydroxyhexadecanoyl-1-β-D-glucopyranosyl-9-methyl-4,8-sphingadienine. Monoclonal 
antibodies against GlcCer could recognize L. prolificans GlcCer species from mycelium and conidia, 
suggesting a conserved epitope in fungal GlcCer. In addition, in vivo assays showed that purified 
GlcCer species from both forms was able to induce a high secretion of pro-inflammatory cytokines 
by splenocytes. GlcCer species also promote the recruitment of polymorphonuclear, eosinophils, 
small peritoneal macrophage (SPM) and mononuclear cells to the peritoneal cavity. GlcCer species 
were also able to induce the oxidative burst by peritoneal macrophages with NO and superoxide 
radicals production, and to increase the killing of L. prolificans conidia by peritoneal macrophages. 
Conclusion: Our results indicate that GlcCer species from L. prolificans are potent immune response 
activators. These molecules induce a strong production of NO in peritoneal macrophages with a high 
killing activity. In vivo, GlcCer species induce an immune response composed by a Th1 and Th17 
cytokine profile, with recruitment of inflammatory cells to the peritoneum cavity. In this way, we 
believed that these molecules are very important to the immune response against L. prolificans, and 
could be used to produce antibodies, vaccines or as an adjuvant. 
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S22.1 
Bacterial-Fungal Interactions at the Airway Mucosa and Implications for Chronic Rhinosinusitis 
E. Cope, O. Kask, S. Kyman, I. Zhang, K. Lee 
The Pathogen And Microbiome Institute, Northern Arizona University, Flagstaff, United States of 
America 
Emerging studies of the human microbiome (the trillions of bacteria, fungi, viruses, and archaea that 
inhabit the human body) have demonstrated the myriad of ways that host-associated microbial 
communities contribute to host health. In the airways, the composition and diversity of the mucosal 
microbial communities are related to health status. However, the relationship between airway 
microbiota and inflammation is not well understood. Chronic rhinosinusitis (CRS) is a significant 
healthcare issue; current estimates suggest that CRS is responsible for 5% of the total healthcare costs 
in the US and affects up to 16% of the population. In a prior study of the bacterial microbiota of CRS 
patients, we’ve shown that CRS patients have decreased sinonsasal bacterial diversity compared to 
healthy individuals. CRS patients were characterized by enrichment of one of four bacterial 
pathobionts, including Staphylococcaceae or Pseudomonadaceae. The objectives of this study were to 
determine whether bacterial and fungal microbiota interact in the airways to influence host immune 
response. We used ITS2 sequencing in a cohort of 100 CRS patients and healthy controls and found 
that, although bacterial community composition is variable across CRS patients, Malassezia is the 
predominant fungal genus in the upper airways of healthy individuals and CRS patients. We then 
hypothesized that species-specific bacterial-fungal interactions differentially influence host mucosal 
immune response. Thus, we investigated in vitro and in vivo interactions between Malassezia 
sympodialis, P. aeruginosa, and S. aureus. In vitro interactions were evaluated using the modified Kirby-
Bauer Assay and Crystal Violet assay for biofilm quantification. A murine model of acute sinusitis 
was used to investigate relationships with the host immune response. S. aureus and P. aeruginosa were 
intranasally instilled in the presence or absence of M. sympodialis. 16S rRNA gene sequencing and 
FungiQuant were used to evaluate changes in microbiota composition and burden, and host immune 
response was measured using quantitative real-time PCR (qRT-PCR). In vitro, late stage planktonic 
and biofilm P. aeruginosa inhibited M. sympodialis growth. Co-infection of mice with M. sympodialis 
and P. aeruginosa or S. aureus differently influenced the immune response. In co-infected mice, 
expression of fungal sensing receptors (Dectin-1), allergic responses (IL-5 and IL-13) and 
inflammation (IL-10, and IL-17) in the murine sinonasal cavity depended on the bacterial species that 
was co-instilled with M. sympodialis (p<0.05, Mann Whitney). Mice infected with M. sympodialis alone 
did not have increased Th1, Th2, or Th17 gene expression, suggesting that this taxon can act as a 
commensal. However, mice that were co-infected with M. sympodialis and S. aureus had increased IL-
5 gene expression (p = 0.01, Mann Whitney) compared to M. sympodialis or S. aureus alone. These 
results show that species-specific interactions in airway associated microbiota relate to distinct host 
immune response. These interactions may be implicated in some subsets of CRS disease. Our 
understanding of the role of bacterial-fungal interactions in CRS will contribute to development of 
novel therapies toward manipulation of the airway microbiota. 
 
S22.3 
Characterization of indoor dust microbiota in homes of asthma and non asthma patients 
J.P. Gangneux1, M. Sassi1, P. Le Cann2, P. Lemire2 
1Laboratoire De Parasitologie-mycologie, CHU de Rennes, Rennes, France, 2Inserm Irset- Umr 1085, 
EHESP, Rennes, France 
Objective: The exposure of occupants of housing to indoor air pollutants has increased in recent 
decades. Among microbiological contaminants, bacterial and fungal aerosols remain poorly studied 
and the debate on the impact of these aerosols on respiratory health is still opened. This study aimed 
to assess the diversity of indoor microbial communities in relationship with the health of occupants. 
Methods: Measurements were taken from dwellings of 2 cohorts in Brittany (France), one with 
children without any pathology and the other with children and adults with asthma. Thirty dust 
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samples were analyzed by next generation sequencing with a 16S and 18S targeted metagenomics 
approach. Analysis of sequencing data was performed using qiime 2, and univariate and multivariate 
statistical analysis using R software and phyloseq package. Dust samples were collected by 
vacuuming the floor in the child's bedroom using a Dustream Collector (Indoor biotechnologies, 
United Kingdom) sampler-fitted vacuum cleaner (40 μm mesh nylon filter, domestic vacuum 
cleaner). 
Results: A total of 2,637 prokaryotic (589 at genus level) and 2,153 eucaryotic taxa were identified 
(856 fungal taxa (39%) and 573 metazoa (26%)). Among Fungi, only 136 taxa were identified at genus 
level. The four main bacterial phyla were identified: Proteobacteria (53%), Firmicutes (27%), 
Actinobacteria (11%), Bacteroidetes (8%). The three main fungal phyla identified were: Ascomycota 
(84%), Basidiomycota (12%) and Mucoromycota (3%). No bacterial nor fungal taxa were significantly 
associated with asthma versus control group. 
A trend of over representation in Asthma group versus control was observed for Corynebacterium (p-
value = 0.013, adj. p-value = 0.09) and Streptococcus (p-value = 0.025, adj. pvalue = 0.112) genus. No 
correlations between the populations of fungi and the asthma conditions as well as the habits of the 
occupants/the characteristics of the dwellings or other environmental characteristic were observed. 
Conclusion: Our findings provide evidence that dust samples harbor a high diversity of human-
associated bacteria and fungi. Molecular methods such as NGS are reliable tools for identifying and 
tracking the bacterial and fungal diversity in dust samples, a less easy strategy for the detection of 
eucaryots at least using18S metagenomics approach. This study showed that the detection of some 
bacteria may be associated to indoor air of asthmatic patients. Regarding fungi, a higher number of 
samples and sequencing with more depth could allow to reach significant signatures. 
 
S22.5 
An ECMM-ESCMID survey on goals and practices for mycobiota characterization using Next 
Generation Sequencing in European laboratories 
J.P. Gangneux1, H. Guegan1, L.-E. Vandenborght2, S. Buffet-Bataillon1, R. Enaud3, L. Delhaes4, F. The 
Esghami-Efisg (Escmid) And ecmm NGS Study Group1 
1Laboratoire De Parasitologie-mycologie, CHU de Rennes, Rennes, France, 2Genoscreen, Lille, France, 
3University of Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CHU de 
Bordeaux, CRCM Pédiatrique, CIC 1401, Bordeaux, France, 4Parasitology Mycology, Univeristy of 
Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33000, Bordeaux, France, 
Bordeaux, France 
Objectives: Although substantial efforts have been made to investigate about the composition of the 
microbiota, fungi that constitute the mycobiota play a pivotal role in maintaining microbial 
communities and physiological processes in the body. Next generation sequencing (NGS) techniques 
have clearly renewed methodology to characterize host-associated microbiota in a more 
comprehensively way, and have consequently revealed a much more diverse microbiota than was 
previously thought to exist. 
Methods: We constituted a panel of experts from the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID-ESGHAMI and -EFISG study groups) and the European Confederation 
of Medical Mycology (ECMM) to address an international-survey focusing on laboratory’s current 
procedures regarding their goals and practices of mycobiota characterization using NGS. 
Results: The laboratories reported their main reason of using NGS to study the mycobiota primary 
to understand the pathophysiology of a dysbiosis (n = 20), at a second level, to contribute to a 
diagnosis (n = 16) to implement a therapeutic strategy (n = 12), or to evaluate the exposome 
(environmental studies)(n = 10). Respiratory tract represented the most studied site, followed by the 
digestive tract, Sample originated in half of the laboratories from sputum (n = 14), or from stool (n = 
12), broncho-alveolar lavage (n = 11), environmental (n = 6), oral wash (n = 4) and skin (n = 1). Target 
used for mycobiota analysis was equal among 18S rRNA (n = 11), ITS1 (n = 11) and ITS2 (n = 11), while 
some centers used the shotgun approach (n = 5). When asked about data analysis, database used for 
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alignment were mostly UnitE (n = 8 labs), and both Genebank and CBS databases (n = 7 labs). Other 
details will be presented. 
Conclusion: We can therefore report a photography of mycobiota analysis in 28 laboratories from 19 
countries, affiliated to working groups from ESCMID and ECMM and draw some conclusions of the 
diversity of approaches. NGS to study mycobiota is a great challenge for understanding 
pathophysiological questions in experimental studies as well as for driving diagnostic strategies. 
Techniques will rapidely develop, moving from targeted NGS to shotgun approaches and whole 
genome sequencing will also be very useful in the next years in the field of mycology, but also for an 
holistic reasoning. 
 
Symposium 23 The funny life of C. albicans in the oral tract 
 
S23.3 
Modulation of the Fungal-Host Interaction by the Intra-Species Diversity of C. albicans. 
A. Kannan1, G. Laval2, M.-E. Bougnoux3, C. D'Enfert4, D. Sanglard1 
1Microbiology Institute, University Hospital Lausanne, University of Lausanne, Lausanne, 
Switzerland, 2Center For Bioinformatics, Institut Pasteur, Paris, France, 3Laboratoire De Parasitologie 
Mycologie, APHP Hôpital Necker-Enfants-Malades, Paris, France, 4Fungal Biology And 
Pathogenicity, Institut Pasteur, INRA, Paris, France 
Candida albicans clinical isolates intrinsically display high diversity in their population genetic 
structure. Regulation of several host factors and development of C. albicans diseases can be influenced 
by diverse genetic backgrounds of the fungus. Using a collection of 96 genome-sequenced isolates, 
we aim here to understand by so-called Expression Quantitative Trait Loci (eQTLs), the influence of 
C. albicans genome diversity on fungal transcriptomic profiles in contact with human keratinocytes 
(TR146 cells). The impact of the fungal genomes on the host transcriptome can thus be probed. Pilot 
experiments using 5 distinct commensal clinical isolates (including the reference isolate SC5314) in 
contact with TR146 cells at different time points (0.3-, 1-,2- and 6h) revealed distinct transcriptional 
differences between the isolates. After 6h co-culture, only 194 C. albicans genes were found to be 
commonly differentially regulated (2-fold threshold) as compared to SC5314 in all four isolates. These 
data suggest a heterogeneous response between these different isolates, even with a small number of 
isolates. This heterogeneous response underpins the large genome diversity existing between the 
different C. albicans clades. Based on the overall summary of top 200 variable C. albicans genes among 
all the five isolates, we observed that the isolate CEC3665 most varied from SC5314 upon infection. 
This isolate differed from the others principally by genes involved in hyphal development and 
adherence. Consistently, CEC3665 exhibited low adherence to TR146 cells as compared to the others. 
The use of these 5 initial isolates allowed the optimization of several other experimental parameters 
(optimal exposure time to TR146 cells, variations within biological triplicates) that was used for 
probing the transcriptional profiles of the entire 96 genome-sequenced collection. The current state 
of the 96 genome-sequenced collection analysis will be presented. 
 
S23.4 
Intestial Th17 drives airway inflammation in ABPA 
P. Bacher 
Institute of Clinical Molecular Biology & Institute of Immunology, Kiel, Germany 
Th17 cells provide protection at barrier tissues but may also contribute to immune pathology. The 
relevance and induction mechanisms of pathologic Th17 responses are poorly understood. In 
humans, Th17 responses are particularly important against Candida albicans, a mucocutaneous 
fungal pathobiont. In contrast, the role of Th17 cells for other pathogenic fungal species is unclear. 
We used antigen-reactive T cell enrichment (ARTE) for the ex vivo analysis of human T helper cell 
responses against 30 common members of the human mycobiome. We identified the mucocutaneous 
pathobiont Candida albicans as the major direct inducer of human anti-fungal Th17 cells. Th17 cells 
directed against other fungal species are induced by T cell cross-reactivity to C. albicans. Intestinal 
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inflammation expands total C. albicans- and cross-reactive Th17 cells. Strikingly, Th17 cells cross-
reactive to the airborne fungus Aspergillus fumigatus are selectively activated and expanded in 
patients with airway inflammation, such as asthma, COPD and cystic fibrosis and especially during 
acute allergic bronchopulmonary aspergillosis (ABPA), suggesting their specific contribution to lung 
pathology. This indicates a direct link between protective intestinal Th17 responses against C. 
albicans and lung inflammation caused by airborne fungi. We identified heterologous immunity to a 
single, ubiquitous member of the mycobiota as a central mechanism for systemic induction of human 
anti-fungal Th17 responses and as a risk factor for pulmonary inflammatory diseases. 
 
S23.5 
Persistence of clonal azole-resistant isolates of Candida albicans from a patient with Chronic 
Mucocutaneous Candidiasis in Colombia 
A. Ceballos-Garzon1,2, L.M. Wintaco3, C. Hernández Padilla4, A. De La Hoz4, S.L. Valderrama Beltrán4, 
C. Alvarez Moreno4, P. Le Pape1, J. Ramirez3, C.M. Parra-Giraldo2, N. Velez2 
1Department Of Parasitology And Medical Mycology Of The University Of Nantes., Universite de 
Nantes, Nantes, France, 2Unidad de Proteómica y Micosis Humanas, Grupo de Enfermedades 
Infecciosas Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, 
Bogotá D.C, Colombia, Bogota, Colombia, 3Grupo De Investigaciones Microbiológicas-ur (gimur), 
Universidad del Rosario, bogota, Colombia, 4Grupo De Investigación En Enfermedades Infecciosas, 
Unidad De Infectología, Hospital Universitario San Ignacio (husi) Pontificia Universidad Javeriana, 
Hospital Universitario San Ignacio, bogota, Colombia 
Objectives: To evaluate and to characterize phenotypically and molecularly clinical Candida albicans 
isolates, obtained from a patient with Chronic Mucocutaneous Candidiasis. 
Methods: sixteen C. albicans were isolated from a 25-year-old male with several recurrent fungal 
infections and admitted to the San Ignacio Hospital in Bogota, Colombia. The isolates were recovered 
during four-year from a different anatomical sites. The isolates were typified by MultiLocus Sequence 
Typing, and evaluate for susceptibility to triazoles, Caspofungin and Amphotericin B by 
microdilution method (CLSI). Their pathogenic capacity was evaluated in the Galleria mellonella 
model. 
Results: Genotyping of all clinical isolates showed the persistence of the same Diploid Sequence Type 
(DST). Isolates changed their susceptibility profile over time acquiring resistance to azole drugs. In 
Contrast there were no significant statistical differences in pathogenicity during the period. 
 
Figure 1. Characteristics of Candida spp isolates A. Antifungal treatment over time B. Antifungal 
susceptibility results. 
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Figure 2. Survival curve of average according to anatomical origin. Kaplan-Meier plots of G. mellonella 
survival after infection with C. albicans 3x105 UFC/ml. Inside the brackets the number of samples. 
Conclusion: The 16 samples collected, allow us to identify the same DST918 which belongs to Clade 
9, being this DST widely reported worldwide. It is important to highlight that among the isolates 
reported to date with the same DST, none had been previously associated with Chronic 
Mucocutaneous Candidiasis (CMC). The persistent clonal strain C. albicans strain (DST 918) in a 
patient with CMC, showed changes in its susceptibility profile after several antifungal treatments 
acquiring gradual resistance to the azole drugs, which did not affect their pathogenicity. 
 
Symposium 24 Fungal neglected tropical diseases 
 
S24.1 
Updates on mycetoma 
W. Van De Sande 
Department Of Microbiology And Infectious Diseases, Erasmus Medical Center, Rotterdam, 
Netherlands 
Abstract: Mycetoma is a subcutaneous inflammatory and infectious disease of mainly the foot. It is 
endemic in tropical and subtropical regions where it causes a high morbidity. It was the first fungal 
infection recognized as a Neglected Tropical Disease by the World Health Organization by resolution 
WHA69.21 in 2016. Within this resolution, endemic regions were encouraged to assess the burden of 
mycetoma and the scientific community was encouraged to develop tools for early diagnosis and to 
improve treatment of mycetoma. It is now more than 3 years since this resolution and within these 
three years new information became available on all these subjects. In terms of assessing the burden 
of infection, case reports and single center studies were published from different regions in the world. 
Studies from Brazil, China, India, Mexico, the Philippines, Senegal, Sudan and Togo. Also reports 
from non-endemic regions such as Italy, Spain, Switzerland and the United States of America 
demonstrated that immigrants and refugees can also take mycetoma to their new homelands where 
they often cause problems in diagnosis due to lack of awareness. Within these reports it became 
evident that there are still new mycetoma causative agents discovered every year. To identify the 
causative agents, morphological identification and/or histology often leaded to misidentification 
demonstrating the need for more reliable diagnostic tools. To speed up diagnosis and make it more 
reliable, techniques were developed to isolate DNA directly from mycetoma grains and novel PCR 
primers were developed to be able to identify more causative agents. Isothermal alternatives were 
also explored and for histology sections an in situ hybridization probe was developed. For 
identification on cultures, a Maldi-Tof database was generated. To optimize treatment, an open 
source drug discovery platform was founded (MycetOS) which identified the fenarimols as a new 
class of potent anti-mycetoma drugs and other classes such as the orotomides were tested in vitro for 
their activity against mycetoma causative agents. Based on the in vitro potency of ravuconazole, the 
first ever clinical trial on a new drug was started at the mycetoma research centre in Khartoum. It is 
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obvious that since the recognition as a Neglected Tropical Disease the mycetoma field has moved 
forward and will continue as such in the upcoming future. 
 
S24.2 
Chromoblastomycosis: A true neglected tropical disease 
F. Queiroz-Telles 
Public Health, Federal University of Parana, Curitiba, Brazil 
Several infectious diseases, including helminthic, protozoal, bacterial, and viral infections but not 
fungal diseases other than mycetoma and chromoblastomycosis, are currently defined as “neglected 
diseases” by the WHO. After sporotrichosis, chromoblastomycosis is the second most prevalent 
implantation mycosis in the world. Chromoblastomycosis (CBM) is defined as a chronic and indolent 
granulomatous fungal disease caused by the transcutaneous inoculation of propagules from several 
species of melanized fungi from the Herpotrichiellaceae family. The most prevalent species causing 
chromoblastomycosis are Fonsecaea pedrosoi, F. monophora, and Cladophialophora carrionii. Advances in 
molecular taxonomy have shown that the biodiversity of the CBM agents has increased without 
substantial correlation with specific type of lesions or severity of the disease and response to therapy. 
Because several CBM sibling etiologic agents are found in soil and plant microbiota, this disease is 
strongly associated with cutaneous macro or micro traumas during diverse outdoor activities, such 
as agro pastoralism, hunting, eco-tourism, etc. Chromoblastomycosis mainly occurs in tropical and 
subtropical zones in Latin America, Africa, Asia and Oceania. According to recent data, the the 
highest incidence density of CBM (number of reported cases /10 million), occurs in the Dominican 
Republic (50.1), Madagascar (26.4), Gabon (23.5), Congo and Costa Rica (11.8), respectively (Santos 
DW, PhD Thesis) Melanized cell wall, muriform cell architecture, hydrophobicity and cell adhesion 
are considered virulence factors leading to increased pathogenicity, a key point for disease 
development. After an uncertain period of incubation, the initial lesion starts at the site of inoculation. 
With time, these can evolve to polymorphic cutaneous lesions. The clinical forms of the disease might 
be associated with cytokine cellular-mediated response and in severe cases, the production of TNF α 
and interleukin 10 has been detected. To confirm diagnosis, the visualization of pathognomonic 
muriform (sclerotic) cells is the most simple, inexpensive, rapid and 100% sensitive method. In 
culture, the organisms are fastidious. Molecular methods are mandatory for species identification, 
but they remain expensive and are not important for therapeutic guidelines. Although serologic tests 
(immunodiffusion and ELISA) have been validated, they are not commercially available. The 
therapeutic options, for CBM, include physical methods and chemotherapy. Without a doubt, 
excisional surgery is the best method for the treatment of CBM but only for initial small and well-
delimitated cutaneous lesions. According to a few open non-comparative clinical studies, 
itraconazole (ITZ) is currently the best therapeutic option for CBM, at the daily dose of 200 to 400 mg 
from 8 to 36 months. The success rate ranges from 15 to 80%. The duration and cure rates are related 
to the severity of the disease, ITZ gut absorption and the etiologic agent. Terbinafine (TBF) at the 
daily dose of 250 to 500 mg is the second most used drug. For refractory cases, posaconazole may be 
used as well as the combination of ITZ with TBF or 5-flucytosine. The only way to prevent CBM is to 
avoid trauma Individual under occupational risk should use protective equipment such as adequate 
clothes, shoes and gloves. Similarly, to other implantation mycoses, there are no available 
immunoprophilaxis for CBM. 
 
S24.3 
Sporotrichosis: past and future 
L. Lopes Bezerra 
CIETEC/USP, São Paulo, Brazil 
The description of new cryptic species with different pathogenic potentials has changed the 
perspectives on sporotrichosis. The Pathogenic Clade of the Sporothrix genus has four pathogenic 
species: S. schenckii, S. brasiliensis, S. globosa and S. lurei. The new emerging pathogen, S. brasiliensis, 
shows higher virulence and is mainly related to zoonotic transmission while S. schenckii and S. globosa 
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are sapronotic agents. After 20 years of the zoonotic outbreak of sporotrichosis in Brazil the challenges 
to manage the disease caused by S. brasiliensis are enormous, including clinical-epidemiological 
aspects, treatment and diagnosis. The cat-transmitted disease has already spread from the South to 
the Northeast of Brazil with impressive number of cases in either humans or felines being reported 
every year. The increment of cases reported by Centers of Zoonotic Control account for over 500% 
between 2016 and 2018. For this reason, a national effort among scientists, clinicians and veterinaries 
was established to propose a guideline for the management of S. brasiliensis infection. This group of 
experts from several endemic areas is working since 2018. The data and conclusions achieved by the 
Feline and Human Brazilian Working Groups will be presented. 
 
S24.4 
Novel diagnostic and treatment strategies for the Southeast Asian fungus Talaromyces marneffei 
T. Le 
Duke University School of Medicine, DURHAM, United States of America 
 Novel diagnostic and treatment strategies for the Southeast Asian fungus talaromyces marneffei – 
Thuy Le, MD DPhil Talaromyces marneffei (Tm) is one of seven endemic human fungal pathogens that 
causes substantial global morbidity and mortality. Over just two decades, Tm has emerged as a 
leading cause of opportunistic infection and death in adults and children with advanced HIV disease 
in southern China and Southeast Asia. The mortality on antifungal therapy in both HIV and non-HIV 
infected patients is as high as 30%. The current diagnosis still relies on microscopy of skin lesions 
(which is a late manifestation and is absent in 40% of patients) and on cultures of the pathogen which 
takes up to 14 days. Late diagnosis is the most challenging clinical problem and drive mortality from 
24% to 50%. The current treatment options are suboptimal. Intravenous amphotericin B deoxycholate 
is recommended for induction therapy but has serious side effects and is still not widely available. 
Itraconazole tablets are cheap and are widely available, but has low oral bioavailability, variable 
pharmacokinetics and is inferior to amphotericin B in efficacy. This talk presents new data on the 
comparative performance of real-time PCR assays versus antigen detection assays for rapid diagnosis 
of talaromycosis. Both assays have excellent specificity of >95%; however, the antigen tests are 
significantly more sensitive than the real-time PCR tests (>90% compared to 70-80%). Tm antigen can 
be detected up to 16 weeks prior culture positivity in symptomatic hospitalized AIDS patients, and 
Tm antigen independently predicts 12-month mortality in patients with a CD4 cell count <100 starting 
antiretroviral therapy. This talk will also present results of the IVAP trial, a multi-center clinical trial 
comparing amphotericin B and itraconazole for induction therapy in Vietnam, which demonstrated 
a 50% mortality reduction in the amphotericin B group. The trial showed that 98% of patients in the 
amphotericin B group cleared fungemia within 8 days of therapy, paving the road for a planned 
phase II clinical trial testing short courses of liposomal amphotericin B therapy to reduce toxicity. 
Efforts to test novel antifungal compounds are ongoing and should offer new and less toxic treatment 
options in the coming years. 
 
S24.5 
Urban sporotrichosis: neglected micro-epidemia in the State of Minas Gerais, Brazil 
M.A. Resende Stoianoff, D.B. Silva Navarro, D.L. Silva, D. Assis Santos 
Dept. Of Microbiology, Federal University of Minas Gerais, Belo Horizonte MG, Brazil 
Objectives: Sporotrichosis is a subcutaneous mycosis caused by dimorphic fungus of the Sporothrix 
complex that can affect both humans and other animals, being more common and severe in cats, and 
occurring more frequently in regions of tropical climate, as is the case in Brazil. Because it is not a 
compulsory notification disease in most Brazilian states, the true incidence of the disease is unknown. 
The aim of this study was to report the occurrence of cases of human sporotrichosis in the state of 
Minas Gerais, Brazil. Methods: The secretions of the ulcerated lesions were collected with the aid of 
sterile swab and the material was subjected to Gram staining, as well as to the culture at 28°C and 
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37°C. It was confirmed by the micromorphological examination that the samples belong to the genus 
Sporothrix. The molecular identification of the species is underway and the patients were referred 
for treatment. Results: It was reported the occurrence of 11 cases of human sporotrichosis between 
August 2018 and May 2019, nine of them from the city of Ribeirão das Neves and two from Belo 
Horizonte, state of Minas Gerais, Brazil. Among the patients, nine belonged to the female gender and 
two to the male. The patients' ages ranged from two to 61 years and all of them reported contact with 
sick cats. The mean time between contact with the animals and the appearance of the lesions was 15 
days. Nine patients presented lymphocutaneous form and two presented fixed cutaneous form. The 
patients presented lesions in the arms, forearms, fingers or in the heel. The Gram staining revealed 
presence of yeasts of elongated and/or rounded form, sometimes with single bud. The thermal 
dimorphism and the micromorphology confirmed the identification of Sporothrix spp. Conclusion: 
The results suggest that there may be a sporotrichosis microepidemia in the municipality of Ribeirão 
das Neves, with marked importance of the zoonotic transmission of the disease. According to official 
information, the conditions of infrastructure and sanitation are precarious in this region. The 
notification of this disease and studies that relate the socio-environmental and behavioral conditions 
that can determine the variation in sporotrichosis transmission are of great importance, in order to 
adopt the appropriate prevention and control measures. The contact of individuals with cats at home 
environment may be increasing in the last years, a fact that contributes to the increase of the 
possibility of infection of the population. The control of the source of infection is fundamental in this 
situation, with priority being given to the investigation of factors involved in the transmission 
dynamics of the disease, to assist in the surveillance and control measures necessary to contain its 
growth. Key words: Sporotrichosis, Sporothrix spp., Urban sporotrichosis Financial Support: CNPq, 
CAPES 
 
 
Posters 
P001 
induction of antifungal resistance exerted by the exposure of paclobutrazol to Aspergillus 
fumigatus 
E. Marques De Araujo1,2, P. Le Pape2, R. Gonçalves De Lima-Neto1, T. Gonçalves1, N. Buarque De 
Gusmao1 
1Biologia De Fungos, universidade federal de pernambuco, Recife, Brazil, 2Ea1155 Iicimed, Nantes 
University Hospital, NANTES, France 
Objectives: The resistance of Aspergillus fumigatus to azolic drugs occurs mainly through two 
routes: in vivo as a consequence of antifungal therapy, and in the enviroment as a consequence of the 
use of fungicides in agriculture. Placobutrazol is a plant growth retardant used in agriculture, which 
inhibits cellular growth and hormones composition. Since it is excessively applied and presents 
chemical stability, paclobutrazol accumulates in the soil and can affect the existing microbiota.The 
present study aimed to induce to the resistance and consequently the induction of CYP51 gene 
mutation on azoles-susceptible isolates of Aspergillus fumigatus after exposition against 
paclobrutazol. 
Methods: he A. fumigatus (2 from environmental origin and 1 ATCC) were submitted to antifungal 
susceptibility testing by the microdilution method (MIC-EUCAST) to prove that all strains were 
sensitive at concentrations of 32 μg/mL of paclobrutazol and 0.5 μg/mL of voriconazole and 
itraconazole. For the resistance induction test, these fungi were exposed to paclobrutazol for five 
weeks in RPMI culture medium at 37°C in initial concentration of 4 μg/mL, and increasing to a 
concentration of 64 μg/mL, it was also checked whether concentration progression influenced 
induction using the same method, without elevation in concentration of the molecule in the medium. 
Over the five weeks of the test, the MIC was verified through the micro dilution method established 
by EUCAST and the yeastone sensitrite commercial method in order to evidence the elevation of MIC 
after exposure. 
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Results: he MICs obtained over the five weeks of the test showed a decreasing of sensitivity in all 
strains (100%) against antifungals used in the hospital routine after exposure to the paclobrutazol. 
Conclusion: Thus, is possible to affirm the exposure of the Aspergillus fumigatus to drugs used on 
agriculture may induce resistance against azoles usually prescribed. These finds demonstrating the 
need of a better and more rigid regulation in the use of this molecule in agriculture. The next steps in 
this research are to confirm that placobutazol exposure may induce a permanent mutation on 
resistance gene. 
 
P002 
Oral Candidiasis in HIV Infected Patients and its Antifungal Susceptiblity Pattern by Disc 
Diffusion Method. 
P. Chaudhary 
Microbiology, Sagarmatha chaudhary eye hospital, lahan, siraha, Nepal 
Objectives: Oropharyngeal candidiasis (OPC) is an opportunistic fungal infection that is commonly 
found in (Human Immunodeficiency Virus) HIV infected patients. Acquired Immunodeficiency 
syndrome (AIDS), a disease of human immune system caused by HIV, has emerged as a global crisis 
since its discovery in summer of 1981 in United States. The low absolute CD4+ T-lymphocyte count 
has traditionally been cited as the greatest risk factor for the development of OPC and current 
guidelines suggest increased risk once CD4+T-lymphocyte counts fall below 200 cells/mm³.Hence, a 
cross-sectional study was conducted in Sukraraj Tropical and Infectious Disease Hospital (STIDH), 
Teku, Kathmandu over 3 months period with a primary objective, to isolate and identify Candida 
species among HIV infected patients and susceptibility pattern of isolates by disc diffusion method 
and secondary objective, to estimate the frequency of oral candidiasis according to age, sex, and other 
factors (CD4+ count, tobacco consumption, URTI, recent antibiotic consumption) in HIV infected 
patients. 
Methods: A total of 408 throat swab samples were collected from patients with and without active 
lesion visiting ART center of STIDH. Flow chart for sample processing and identification of isolates 
is shown below. 
Results: 114 isolates were obtained from total sample processed. Among them, 65 isolates were 
Candida species and remaining 49 was bacterial flora and other yeasts. Based on various phenotypic 
methods, Candida albicans, 53 (81.5%), was the most commonly isolated organism followed by Candida 
tropicalis 3 (4.6%), Candida krusei 2 (3.1%), Candida glabrata 1 (1.5%) and 6 (9.2%) were other Candida 
species. Of the 65 yeast isolates from HIV seropositive individuals, 26 patients had CD4+ ≤ 200 
cells/mm³ and 39 patients had CD4+ ˃200 cells/mm³. 14 patients exhibited severe immune 
suppression with CD4+ count less than 100 cells/mm³. There was a significant association between 
oral Candida carriage and CD4+ cell count ≤ 200 cells/mm³ (p<0.001). Antifungal susceptibility test of 
Candida species showed highest sensitivity with Amphotericin B and resistance with Fluconazole 
respectively. Table below depicts about the susceptibility pattern of the Candida spp. 
Conclusion: C. albicans was the predominant species for oral yeast colonization in our study. 
Different isolates presented different susceptibility to various antifungal agents. Among the 
antifungal discs tested, Fluconazole was found to show resistance in most of the isolates and 
Amphotericin B was the most sensitive drug which is an excellent antifungal to control Candida spp. 
since it showed the best result among all antifungal tested. Oral yeast colonization was associated 
with low CD4+ count (<200 cells/mm³). Thus, oral lesion serves as early marker for HIV infection. The 
increase incidence of oral candidiasis in HIV patients may be due to low CD4+ count, URTI and recent 
antibiotic consumption. 
 
P003 
The validation of VIPcheck™ plates to screen Aspergillus fumigatus isolates for phenotypic 
resistance to triazole antifungal agents in St. James’s Hospital, Dublin. 
 
A. Griffin 
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Microbiology, St. James's Hospital, Dublin, Dublin, Ireland 
 
Objectives: Triazole resistance is an emerging problem in Aspergillus fumigatus (AF) resulting in 
failure of azole therapy. Triazole resistant AF is acquired through one of two routes - previous 
exposure to triazole therapy or an environmental source. In vitro antifungal susceptibility testing 
(AFST) on all AF strains isolated in a microbiology laboratory would be both labour intensive and 
impractical. A method to screen for triazole resistance would be more favourable. The objective was 
to validate VIPcheck™ plates (Mediaproducts BV, Groningen, Netherlands) in SJH to investigate 
whether they would be a suitable screening method for triazole resistance in AF clinically isolated 
from patients in a large tertiary hospital with a significant cohort of immunocompromised patients. 
Methods: A total of 18 retrospective isolates (clinical and environmental) of AF were tested using the 
VIPcheck™ plates (n=2 wild type, n=16 resistant to ≥ 1 triazole drug as previously determined by 
AFST and/or molecular methods). VIPcheck™ plates are a simple agar based screening method, each 
4 well plate containing a growth control (GC) well and 3 wells containing itraconazole (4mg/L), 
voriconazole (2mg/L) and posaconazole (0.5 mg/L). Briefly, 25ul of a 0.5-2McF suspension AF is 
inoculated into each well and plates are read after 48hrs incubation at 37◦C. Any growth in a triazole 
containing well is suggestive of resistance prompting full AFST be carried out. 
Results: A total of 18 isolates (clinical and environmental) of AF were tested using the VIPcheck™ 
plates as described above. The wild type isolates showed growth only in the GC well while the 
resistant strains all showed growth in one or more of the triazole containing wells. 
Conclusion: VIPcheck™ plates are not intended to give an exact MIC; the preparation of the 
inoculum has a broad McFarland range of 0.5-2 and only one concentration of each azole drug is 
included in the plates. Rather, they are useful as a screening method to determine the need for further 
AFST and/or molecular testing and more importantly for earlier detection of triazole resistance in 
patients who will require treatment. Currently in SJH, AFST is carried out using gradient strips 
(Liofilchem™) and results are interpreted using EUCAST breakpoints We validated the VIPcheck™ 
plates with the intention to include this screening method as part of our AFST for AF isolated from 
clinical samples and our results suggest that they provide a reliable screening method for triazole 
resistance. 
 
P004 
In vitro susceptibility to isavuconazole of Fusarium clinical isolates; comparison between eucast and 
etest methods 
A. Broutin1, J. Bigot1, A.C. Normand2, Y. Senghor3, A. Moreno3, M. Hendrickx4, J. Guitard1, C. 
Hennequin3 
1Parasitology-mycology, APHP, hôpital St Antoine, Paris, France, 2Parasitology-mycology, APHP, 
Hôpital Pitie-Salpêtrière, Paris, France, 3Parasitology-mycology, APHP, Hôpital St Antoine, Paris, 
France, 4Mycology, Scientific Institute of Public Health, Brussels, Belgium 
 
Objectives: To evaluate the in vitro susceptibility to isavuconazole of a panel of precisely identified 
clinical Fusarium isolates and to assess the value of Etest as an alternative method in this indication. 
Methods: We randomly selected 75 clinical isolates previously identified as Fusarium sp. The strains 
were identified using MALDI-TOF technology (MSI System). They were then tested comparatively 
against isavuconazole (ISA) either using the broth microdilution method proposed by the Eucast 
consortium according to the recent document E.DEF 9.1 and the Etest technique as recommended by 
the manufacturer (Liofilchem). 
Results: All strains could be identified at the cryptic species-level revealing the existence of 14 
different species in the panel (Table 1). F. solani (FSSC), F. oxypsorum (FOSC) and F. fujikuroi 
(FFSC) were the species complexes the most frequent, encompassing 22, 17 and 31 strains, 
respectively. Overall, ISA exhibited a limited activity against the Fusarium strains with MICs90 >16 
µg/ml whatever was the species complex. Strains of the FOSC appeared a little bit more susceptible 
with a geometric mean at 9.41 µg/ml versus 14.02 µg/ml and 13.68 µg/ml for FSSC and FFSC, 
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respectively. Considering the diversity of species, it was not possible to test a possible difference in 
susceptibility between the cryptic species within a given complex. Finally, we observed MIC between 
2 to >16 µg/ml for strains of the single species of the FOSC, suggesting that precise identification may 
not be enough to predict the susceptibility to ISA. The concordance between Etest and Eucast results 
was calculated at 100% within an interval +/- 2 dilutions. The Intraclass Correlation Coefficient was 
calculated at 0.91, indicative of a strong concordance between the 2 methods. 
 
 
Table 1 : Isavuconazole MICs distribution against 75 clinical isolates of Fusarium 
Conclusion: ISA exhibits a limited in vitro activity against clinical isolates of Fusarium, with few 
variations between the species complexes. In the case the drug should be used, Etest appears a 
valuable alternative to Eucast for evaluating the in vitro susceptibility of the infecting strain. 
 
 
P005 
Species Distribution and Antifungal Susceptibility of Candida Ear Isolates from a Hospital in 
Korea 
J.H. Shin, Y.J. Kwon, S.A. Byun, M.J. Choi, E.J. Won, S.H. Kim 
Department Of Laboratory Medicine, Chonnam National University Medical School, Gwangju, 
Korea, Republic of 
Objectives: Candida auris was first isolated from the ears of Japanese and Korean patients. However, 
the prevalence of Candida species from ear cultures and their antifungal susceptibility profiles in these 
nations are unclear. 
Methods: We assessed Candida isolates recovered from cultures of ear specimens from a university 
hospital in Korea over the 4-year period from January 2014 to December 2017. Species identification 
was performed by matrix-assisted laser desorption/ionization time of flight mass spectrometry 
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and/or sequence analysis. Antifungal minimal inhibitory concentrations (MICs) were determined by 
the broth microdilution method (M27A) of the Clinical and Laboratory Standards Institute. 
Results: Candida species were isolated from the ears of 80 patients (75 adult and 5 pediatric patients). 
Most of these patients suffered from chronic otitis media (83.8%), and had a history of antibiotic use 
(73.8%) and ear surgery (60.0%). Among 80 non-duplicate isolates from ear cultures, Candida 
parapsilosis was the most frequently detected Candida species (35.0%), followed by C. auris (28.8%), 
Candida metapsilosis (10.0%), Candida orthopsilosis (8.8%), Candida albicans (7.5%), and other species 
(11.1%). The MICs of the isolates were 0.125 to > 64 μg/mL, ≤ 0.03 to 4 μg/mL, 0.25 to 1 μg/mL, 0.125 
to 1 μg/mL, and ≤ 0.03 to 2 μg/mL for fluconazole, voriconazole, amphotericin B, caspofungin, and 
micafungin, respectively. Of the 80 isolates, 43.8% (35/80) showed decreased susceptibility to 
fluconazole (MIC ≥ 4 μg/mL). Of 23 C. auris isolates, 19 (82.6%) had a fluconazole MIC of ≥ 32 μg/mL. 
None of the isolates showed resistance to amphotericin B or echinocandins. 
Conclusion: C. parapsilosis complex and C. auris were the Candida species identified most frequently 
in ear cultures and exhibited a high rate of fluconazole non-susceptibility, particularly C. auris. 
 
P006 
Epidemiological pattern of Malassezia, its phenotypic identification and anti-fungal 
susceptibility profile to azoles by broth micro-dilution method. 
N. Romald1, A.J. Kindo2, M. Veeraragavan3 
1Department Of Microbiology, Sri Ramachandra Institute of Higher Education and Research, 
Chennai, India, 2Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, 
Chennai, India, 3Dermatology, Sri Ramachandra Medical College and Research Institute, Chennai, 
India 
Objectives: Analyse the epidemiological pattern of disease with regards to age ,sex and site of 
predilection To Speciate Malassezia phenotypically. To study the anti-fungal susceptibility (AFST) 
pattern of Azoles to pathogenic Malassezia species by recording their MIC values (MIC50 & MIC90) 
using Broth Micro dilution method in accordance with CLSI M27-A3. To identify resistant 
drug/drugs to Malassezia species. . 
Methods: Prospective study was done from August 2016-October2018 with sample size of 150 
Sample collection-Hyper/hypo pigmented skin lesions by Skin scrapings and swabs Microscopic 
examination with 10%KOH Those showing meat ball and spaghetti appearances were included in the 
study. Culture Samples inoculated into Sabourauds Dextrose Agar (SDA), SDA with olive oil overlay 
(SDA-O) and Modified Dixon’s agar (MDA) containing chloramphenicol and incubated at 32o C upto 
3 weeks. Phenotypic Identification Done by colony growth characteristics, gram staining, urease test, 
catalase test, bile esculin with tween 60 hydrolysis and tween assimilation AFST AFST was performed 
by the broth micro-dilution method, according to the Clinical and Laboratory Standard Institute 
(CLSI) guidelines M27-A3 (2008) Systemic anti-fungals used-Fluconazole, Itraconazole, 
Voriconazole Topical Anti-fungals used-Clotrimazole, Miconazole, Luliconazole Since Malassezia 
are lipid dependant yeast RPMI 1640 was supplemented with glucose, peptone, ox bile, malt extract, 
glycerol, tween 80, tween 40 and Chloramphenicol Culture-Malassezia isolates grown on MDA for 72 
h at 32°C± 2°C were used for inoculum preparation. Anti-fungal stock solutions of drugs were 
prepared and stored at - 700C Quality Control-Each microtitre plate included growth control well with 
inoculum and supplemented RPMI -1640 medium without the antifungal agent. Candida krusei ATCC 
6258 was used as a quality control strain for antifungal susceptibility testing. Incubation and Reading 
Results-The microtitre plates were incubated at 32˚C.Results read after 24hrs for candida isolate and 
after 72-96 hours for Malassezia isolates. The minimum inhibitory concentration (MIC90) (reduction of 
90% growth compared to growth control well) and MIC50 (50% reduction of growth compared to 
growth control well) were recorded. 
Results:  
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Age distribution- The most common age affected was 20 to 30yrs (36%), followed by 30-40yrs (21%) 
and 10-20yrs (19%) extremes of age showed lower incidence. Sex distribution-The incidence among 
male and female was almost equal, showing little female predominance Site of infection - Among the 
total 150, the most common site was back (47 samples), followed by neck and shoulder (31 samples), 
and scalp (27 samples). Skin lesions-Both hypo and hyperpigmented skin scrapings were collected. 
But more of hypopigmented lesions were noted in our study ANTI-FUNGAL SUSCEPTIBILITY 
PATTERN-fig 
Conclusion: Among 150 samples only 95(62%) yielded growth on both SDA with olive oil and MDA. 
Growth on MDA was soon than SDA with olive oil Overlay. All organisms were urease and catalase 
positive. Among the 95 samples grown the predominant species was Malassezia sympodialis-29(33%) 
followed by M.globosa-26(29.5%), M.furfur-21(23%), M.obtusa-12(13%) by conventional method. The 
systemic anti-fungal with the least MIC values were Itraconazole and Voriconazole. Fluconazole 
shows resistant Pattern with high MIC values The most effective topical anti-fungal was Clotrimazole 
with low MIC values Malassezia sympodialis responded to anti-fungal better than other species isolated 
 
P007 
Prevalence and genotype distribution of fluconazole-resistant Candida parapsilosis bloodstream 
isolates from a neonatal intensive care unit during a 14-year period 
J.H. Shin1, I.J. Hwang2, E.J. Won1, M.J. Choi1, S.-I. Jung3, E.S. Song2, Y.Y. Choi2 
1Department Of Laboratory Medicine, Chonnam National University Medical School, Gwangju, 
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Korea, Republic of, 2Paediatrics, Chonnam National University Medical School, Gwangju, Korea, 
Republic of, 3Chonnam National University Medical School, Gwangju, Korea, Republic of 
Objectives: Candida parapsilosis bloodstream infection (BSI) is a significant problem in neonatal 
intensive care units (NICUs). C. parapsilosis is usually susceptible to azole antifungals; however, some 
recent reports have indicated the emergence of BSIs caused by fluconazole-resistant (FR) C. 
parapsilosis isolates. We investigated the prevalence and genotype distribution of FR C. parapsilosis 
BSI isolates recovered from a NICU during a 14-year period. 
Methods: We assessed a total of 64 C. parapsilosis BSI isolates comprising 22 non-duplicate isolates 
from 22 neonates and 42 isolates from 21 neonates (two isolates from each neonate obtained on the 
first and the last days of C. parapsilosis-positive culture). All isolates were obtained at the same NICU 
between 2002 and 2015. In vitro antifungal susceptibility testing for fluconazole, amphotericin B, 
caspofungin, and micafungin was performed using the Clinical and Laboratory Standards Institute 
(CLSI) M27-A3 microdilution method. All isolates were genotyped via microsatellite typing using 
four specific microsatellite markers (CP1, CP4, CP6, and B). Clonal strains were defined as the 
isolation of two or more strains with identical genotype as determined by microsatellite typing. 
Results: Of the 64 C. parapsilosis BSI isolates, 11 (17%) obtained from eight patients were FR 
(fluconazole minimal inhibitory concentration [MIC] ≥ 8 mg/L). All 64 isolates were susceptible to 
amphotericin B, caspofungin, and micafungin. Based on microsatellite typing, the 64 isolates yielded 
19 different genotypes, including 12 genotypes unique to a single isolate and seven genotypes shared 
by 49 isolates (77%). All 11 FR isolates shared two genotypes (1 and II) that displayed closer genetic 
relatedness than other isolates examined in the microsatellite analysis, according to as an unweighted 
pair group method with arithmetic mean (UPGMA) tree. Of these two genotypes, type I strains (three 
patient isolates) were isolated within a 6-month period, whereas type II strains (five patient isolates) 
were isolated over a 4-year period. Among 21 patients showing more than one C. parapsilosis isolate 
on 2 or more separate days, two sequential strains from each patient had identical types in 76% (16/21) 
of patients and different types in 24% (5/21). No difference in antifungal susceptibility was detected 
between two sequential isolates from the same patient. Among eight patients with FR C. parapsilosis 
isolates, 88% had no known prior antifungal exposure. We detected no significant difference in the 
overall 30-day mortality of C. parapsilosis BSI due to FR strains, or in that of BSI due to fluconazole-
susceptible (FS) strains (25 vs. 20%). 
Conclusion: The results of the present study suggest that clonal transmission may occur frequently 
among both FS and FR blood isolates of C. parapsilosis in a NICU setting. Increased incidence of BSI 
due to the FR C. parapsilosis strain in this NICU may be associated with clonal transmission rather 
than prior antifungal exposure. 
 
P008 
Bloodstream Isolates of Azole-Resistant Candida glabrata in Korean hospitals: Resistance 
Mechanisms and Clinical Features 
J.H. Shin1, E.J. Won1, S.-I. Jung2, I.J. Hwang3, M.J. Choi1, S.A. Byun2, S.H. Kim1, Y.-J. Park4, M.-N. Kim5 
1Department Of Laboratory Medicine, Chonnam National University Medical School, Gwangju, 
Korea, Republic of, 2Chonnam National University Medical School, Gwangju, Korea, Republic of, 
3Paediatrics, Chonnam National University Medical School, Gwangju, Korea, Republic of, 4The 
Catholic University of Korea College of Medicine, Seoul, Korea, Republic of, 5University of Ulsan 
College of Medicine and Asan Medical Center, Seoul, Korea, Republic of 
Objectives: Candida glabrata has recently become the most common non-albicans Candida species 
causing bloodstream infection (BSI) in South Korea, and the occurrence of azole-resistant C. glabrata 
isolates has been observed. We investigated the azole resistance mechanisms and clinical features of 
patients with azole-resistant C. glabrata BSI isolates recovered from multicenter surveillance in Korea. 
Methods: In total, 248 C. glabrata BSI isolates comprising 43 azole-resistant (fluconazole minimum 
inhibitory concentration [MIC], ≥ 64 μg/mL and voriconazole MIC, ≥ 1 μg/mL) and 205 non-azole-
resistant (non-AR) isolates (fluconazole MIC, ≤32 μg/mL and voriconazole MIC, ≤ 0.5 μg/mL) were 
analyzed. The isolates were collected from 10 university hospitals over 8 years (2009–2017). The PDR1 
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genes of the isolates were sequenced to identify mutations. Expression levels of CDR1, CDR2, and 
ERG11 genes after fluconazole exposure were quantified by real-time PCR. The clinical features 
related to risk factors for BSI and the mortality rates were compared. Risk factors for BSI caused by 
AR isolates and survival rates in patients were assessed using multivariate logistic regression. 
Results: Pdr1 mutations were identified in 42 of 43 azole-resistant isolates, while no Pdr1 mutation 
was found in 201 of 205 non-AR isolates. Azole-resistant isolates of C. glabrata had higher mean 
expression levels of CDR1 (8.3-fold) gene than non-AR isolates (P <0.05). However, there were no 
significant differences in the mean expression levels of CDR2 and ERG11 between two groups. 
Previous azole exposure (odds ratio [OR], 6.369; 95% confidence interval [CI], 2.434-16.664; P < 0.001), 
central venous catheter use (OR, 11.406; 95% CI, 2.462-52.837; P = 0.00211), and total parenteral 
nutrition (OR, 4.042 95% CI, 1.381-11.828; P = 0.011) were the independent risk factors for BSI caused 
by AR C. glabrata. C. glabrata BSIs caused by AR isolates resulted in a higher 30-day mortality rate 
(55.8%, 24/43) than BSIs caused by non-AR strains (36.6%, 75/205) (P = 0.019). In multivariate analyses, 
severe sepsis (OR, 5.592; 95% CI, 2.689-11.630; P < 0.001), a high age-adjusted Charlson comorbidity 
index (ACCI) score (OR, 1.131; 95% CI, 1.012-1.263; P = 0.03), lack of antifungal therapy (OR, 5.213; 
95% CI, 2.487-10.930; P < 0.001), and azole-resistance in C. glabrata BSI isolates (OR, 2.856; 95% CI, 
1.161-7.025; P = 0.022) were independent predictors of the 30-day mortality among the 248 patients. 
Conclusion: This study provides that Pdr1 mutation with overexpression of CDR1 may be the main 
resistance mechanism of C. glabrata in Korea, and that azole-resistance in C. glabrata BSI isolates is 
independent predictor of 30-day mortality, and is associated with antifungal exposure, central 
venous catheter, and total parenteral nutrition use. 
 
P009 
A case of urinary tract candidosis: a risky business 
R. Barton, K. Sethi 
Microbiology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom 
Case Report: A 62 year old man with a history of psoriasis treated with methotrexate, poorly 
controlled type 2 diabetes, and chronic obstructive pulmonary disease had a laparoscopic 
cholecystectomy for cholecystitis and repair of a cholecystoduodenal fistula. He then presented with 
severe dysuria, polyuria and complained of passing cloudy urine ever since the surgery. Following 
a series of urine samples which were positive for yeasts which were not identified and a course of 
fluconazole (details not available), he was seen at a haematuria clinic with continued dysuria, 
frequency and urgency, and a flexible cystoscopy showed a "snowstorm" appearance within bladder, 
and an ultrasound revealed mobile echogenic debris. He was then put on a 14/7 course of 200mg oral 
fluconazole, pending a cystoscopy and bladder biopsy which revealed erosive cystitis. A subsequent 
urine sample was identified as Candida glabrata which was resistant to fluconazole (MIC >256mg/L) 
but sensitive to flucytosine (MIC 0.06mg/L). Despite a further 14 day course of 800mg fluconazole, 
signs and symptoms of Candida cystitis were not resolved. The patient was then referred to a urologist 
at our hospital and various treatment choices were discussed with oral flucytosine and IV 
Amphotericin deoxycholate being the main two options, associated with the risk of resistance and 
toxicity respectively. It was decided to treat with a 7 day course of 25mg/kg of oral flucytosine (levels 
were not monitored due to the short course) but follow up urine samples 9 days after completing the 
flucytosine course were still positive for C. glabrata resistant to both fluconazole (MIC >256mg/L) and 
flucytosine (MIC >64mg/L). Approximately 2 weeks after completing the course of flucytosine, the 
patient was admitted via Accident and Emergency with suspected sepsis relating to a biliary source, 
and a new ultrasound showed that the left kidney was moderately hydronephrotic, the bladder was 
filled with echogenic debris. A nephrostomy was performed and blood cultures taken which grew C. 
glabrata with identical sensitivities to that from the most recent urine sample. The patient was 
prescribed a 2 week course of Anidulafungin (200mg loading dose then 100mg 24-hourly IV) to 
combat the systemic candidosis, and a 7 day course of intravenous Amphotericin deoxycholate at 
0.6mg/kg/day. During the Amphotericin B deoxycholarte treatment, renal function was not markedly 
affected, though increases in alkaline phosphatase levels led to the treatment being stopped at 6 days. 
J. Fungi 2019, 5, 95 93 of 464 
 
Subsequent blood and urine cultures remained negative, CRP declined from 150 to 5.8 mg/L and 
symptoms resolved. This case is one of the examples of how the significance of the presence of yeasts 
in urine of patients is not clearly understood by the clinicians. Our patient presented here highlights 
the increasing prevalence of C.glabrata in funguria and non-albicans candidaemia in at risk settings, 
the challenges in its management, the risks and drug related factors which need to be assessed when 
treating fluconazole resistant urinary tract candidosis. 
 
P010 
Effects of efflux pump modulators on the azole antifungal susceptibility of Microsporum canis  
C. Aneke, W. Rhimi, D. Otranto, C. Cafarchia 
Veterinary Medicine, University of Bari, Aldo Moro, Bari, Italy 
Objectives: This study investigated the effect of efflux pump modulators, EPMs (i.e. haloperidol-
HAL and promethazine-PTZ) and their inhibiting activity on the minimum inhibitory concentrations 
of itraconazole (ITZ) and fluconazole (FLZ), against selected M. canis strains. 
Methods: M. canis strains with low (≤ 1mg/ml itraconazole and <64mg/ml fluconazole) and high 
(>1mg/ml itraconazole and ≥64 μg/ml fluconazole) azole MIC values were tested, and data analyzed 
using the model‐fractional inhibitory concentration index (FICI) method. 
Results: The MIC values of ITZ and FLZ of M. canis decreased in the presence of sub‐inhibitory 
concentrations of HAL and PTZ, the latter being more effective with a greater increased 
susceptibility. Synergism was observed in all strains with high azole MICs (FICI<0.5) and no 
synergism in the strains with low azole MICs. 
Conclusion: These results suggest that the drug efflux pumps are involved in the defense 
mechanisms to azole drugs in M. canis strains. The synergism might be related to an increased 
expression of efflux pump genes, eventually resulting in azole resistance phenomena. Additionally, 
the most effective double combinations were those of PTZ with either FLZ or ITZ as this had a greater 
increase in azole susceptibility. Complementary studies on M. canis resistance are advocated in order 
to investigate the molecular mechanisms of this phenomenon. 
 
P011 
Antifungal resistance pattern of Candida species isolated from women of child-bearing age in 
Nsukka Nigeria suffering from different clinical conditions. 
A. Mgbeahuruike 
Department Of Veterinary Pathology And Microbiology, Faculty Of Veterinary Medicine,, University 
of Nigeria, Nsukka, Nsukka, Enugu, Nigeria 
Objectives: To isolate and identify Candida species in child bearing women suffering from malaria, 
typhoid and diabetes To investigate the resistance partarn of the identified Candida species using 
conventional azoles and plant extracts To trace the evolutionary relatedness of the isolated fungi 
using phylogenetic analysis 
Methods: High vaginal swabs were analyzed for Candida presence in women of child bearing age 
suffering from malaria, typhoid and diabetes using Chromogenic agar. Evolutionary relatedness of 
the Candida species was inferred using phylogenetic reconstruction. Growth rate assay was done 
using Sabourand Dextrose medium supplemented with NaCl and glucose. The resistance pattern of 
the Candida species was tested using fluconazole and extracts (methanol and ethyl) from Byrsocarpus 
coccineus. 
Results: Out of the 79 fungal samples analyzed, 21 (26.6%) were C. tropicalis, 25 (31.6%) were C. krusei, 
10 (12.7%) were C. parapsilosis and 8 (10.1%) were C. albicans. C. tropicalis was highest in the malaria 
patients, C. albicans dominated in the typhoid patients while C. krusei was more in the diabetic 
patients. The healthy women presented a very low percentage (8.9%) of Candida species. 
Phylogenetically, the sequenced Candida species was more closely related to C. tropicalis. High 
concentration of glucose (1g/ml) and NaCl (0.5M) decreased the growth of the fungus. . From the 
study, fluconazole showed a higher activity than the two extracts (methanol and ethyl acetate). 
J. Fungi 2019, 5, 95 94 of 464 
 
Conclusion: In conclusion, although fluconazole showed a higher activity than the two extracts 
(methanol and ethyl acetate), the plant extracts demonstrated very high activity and can be used as 
potential antifungal agents. C. tropicalis and C. krusei were the most abundant Candida species found 
in this study. 
 
P012 
Colistin and isavuconazole interact synergistically in vitro against Aspergillus nidulans and 
Aspergillus niger 
P. Schwarz1,2, E. Dannaoui3,4 
1Department Of Internal Medicine - Respiratory And Critical Care Medicine, University Hospital 
Marburg, Marburg, Germany, 2Center For Invasive Mycoses And Antifungals, Philipps University 
Marburg, Marburg, Germany, 3Hôpital Européen Georges Pompidou, Laboratoire de Parasitologie-
Mycologie, Paris, France, 4Working Group Dynamyc, Faculté de Médecine, Hôpital Henri Mondor, 
Créteil, France 
Objectives: Invasive aspergillosis is a devastating disease in immunocompromised patients. It 
mostly affects patients with hematological malignancies, especially those with severe and prolonged 
neutropenia. Colistin is a polypeptide antibiotic from the class of polymyxins. Polymyxins bind to 
lipopolysaccharides and phospholipids of the outer cell membrane of gram-negative bacteria. 
Binding leads to competitive displacement of divalent cations from the phosphate groups of the 
membrane lipids, leading to bactericidal action by disruption of the outer cell membrane and leakage 
of intracellular contents. Colistin has also shown in vitro activity against some fungi. The aim of the 
present study was to assess the in vitro interaction of the broad-spectrum azole isavuconazole with 
colistin against the most important Aspergillus species responsible for human disease. 
Methods: A panel of 31 Aspergillus isolates belonging to 5 species responsible for human invasive 
aspergillosis was used for the experiments (10 Aspergillus fumigatus, 5 Aspergillus flavus, 5 Aspergillus 
terreus, 6 Aspergillus nidulans, and 5 Aspergillus niger). Combinations of isavuconazole with colistin 
were tested by a broth microdilution checkerboard technique based on the EUCAST reference 
methodology. Plates were read spectrophotometrically, and ninety percent of inhibition was used as 
an endpoint for both, the drugs alone and in combination. Results were interpreted with the fractional 
inhibitory concentration index (FICI). Drug interactions were defined as synergistic (FICI≤0.5), 
indifferent (FICI>0.5≤4) or antagonistic (FICI>4). 
Results: Isavuconazole MICs ranges from 0.5 to 16 µg/ml. When tested alone, colistin exhibited no 
antifungal activity with MICs of 128 µg/ml for all isolates. Combination of isavuconazole with colistin 
was synergistic for 100 and 60% of the A. nidulans, and A. niger isolates, respectively (Table). All other 
interactions were indifferent. Antagonism was never seen.
 
Conclusion: Combination of colistin with isavuconazole showed strong synergy against all tested A. 
nidulans isolates and synergy for the majority of the tested A.niger isolates. In vitro interaction of 
colistin and isavuconazole will be further evaluated by checkerboard and gradient concentration 
strips against a larger panel of A. nidulans and A.niger isolates. 
 
P013 
Update 2016-2018 of the nationwide Danish fungaemia surveillance study: epidemiologic changes 
in a 15-year perspective 
M. Risum1, R. Datcu1, H.K. Johansen2, H.C. Schønheyder3, F.S. Rosenvinge4, I.J.D. Knudsen5, B.L. 
Røder6, V.S. Antsupova7, J.B. Gertsen8, L. Kristensen8, J.K. Møller9, R. Hare1, K.M.T. Astvad1, K.M. 
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Objectives: The objectives of this study was to provide nationwide contemporary data on the 
epidemiology of candidaemia, often a serious complication of hospital stay with a crude 30-day 
mortality rate of about 40% despite recent advantages in diagnosis and management. The motivation 
was that outcome depend on early appropriate therapy necessitating knowledge on susceptibility 
pattern of involved species. Moreover, epidemiological changes reflect current practises in 
prophylactic, empirical and pre-emptive use of antifungals and therefore are also informative 
regarding the need for adjustment of antifungal stewardship programmes or treatment guidelines. 
Methods: As part of an active national surveillance programme, fungal isolates from blood culture 
were referred to Statens Serum Institut (Copenhagen) for confirmatory species identification and 
EUCAST E.Def 7.3.1 susceptibility testing. A total of 1452 unique isolates (same patient and species 
isolates were regarded unique if more than 21 days apart or with different susceptibility) were 
included. 13 isolates (0.9%) were not referred. When MICs for echinocandins were above the clinical 
breakpoints, FKS sequencing of the isolates was performed. An isolate was deemed echinocandin 
resistant if the MIC was above anidulafungin breakpoint and/or if the isolate had a known FKS 
hotspot-mutation. Results were compared to previous data in a 15-year perspective. 
Results: The mean incidence rate during 2016-2018 was 8.13/100.000 inhabitants. Candidaemia was 
more frequent in males than females (60% vs 40%) as in accordance with previous years. In 
comparison to previous data, the fungaemia rate was stable (8.64, 9.03 and 8.38 per 100.000 
inhabitants in 2004-7, 2008-11 and 2012-15 respectively). In the years 2016-2018 C. albicans accounted 
for 42.1% of all unique isolates with a decline in 2017 to below 40%. C. glabrata accounted for 32.1%. 
The proportion of candidaemia in 2018 involving C. albicans decreased by a third from 64% in 2004 
(P<0.0001), and C. glabrata almost doubled from 17% in 2004 (P<0.0001) (Figure). We found a 
fluconazole susceptibility rate across all Candida species of 59% of isolates which has decreased since 
2004-7 from 69% (P = 0.02). Echinocandin resistance was detected in 18/1294 isolates (1.4%) including 
11/459 (2.4%) in C. glabrata specifically. No echinocandin resistance was detected in 2004-7. FKS-
mutations were identified in the following species C. glabrata: two L630Q/S663F, four F659S, one 
L662W, three S663F and one S663P; C. krusei: four L701M, two S659F and one S659S/F; C. albicans one 
P1354P/S; C. dubliniensis one S645P; and for Candida lusitaniae one H657Y/L1243F/I283V. 
H657Y/L1243F/I283V, P1354P/S and L701M are outside the hot spot, and L701M is not associated as 
a molecular cause of echinocandin resistance.  
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Conclusion: We report a stable incidence rate of candidaemia, but the proportion of C. glabrata 
continues to rise at the expense of C. albicans which accounted for less than 40% in 2017. The 
consequent decrease in fluconazole susceptibility along with the presence of FKS-mutations 
particularly in C. glabrata raises concern for future perspectives in the treatment of candidaemia. 
 
P014 
In vitro potpourri: Aspergillus terreus and the activity of amphotericin B 
R. Vahedi Shahandashti 
Division Of Hygiene And Medical Microbiology, Medical University of Innsbruck, Innsbruck, 
Austria 
Objectives: Invasive aspergillosis caused by intrinsically resistant non-fumigatus Aspergillus species 
displays a poor outcome in immunocompromised patients. Aspergillus terreus holds an exceptional 
position within the aspergilli due to its intrinsic resistance against the polyene amphotericin B (AmB). 
Till now, the exact mode of action in polyene resistance is not well understood. Micro-environmental 
factors at the infection site influence the growth of fungal pathogens and most likely also the efficacy 
of antifungal drugs. The purpose of this study was to evaluate the impact of hypoxia versus normoxia 
on the in vitro activity (fungistatic and fungicidal) of AmB against A. terreus. 
Methods: In total, 100 clinical strains of Aspergillus section terrei, collected from 21 various countries 
were analyzed in detail. Antifungal susceptibility testing was carried out according to EUCAST 
guideline, with normoxic (20% oxygen/5% carbon dioxide/75% nitrogen) and hypoxic (1% oxygen/5% 
carbon dioxide/94% nitrogen) conditions. Final drug concentrations used for AMB were 0.03–16 
μg/ml. Minimum inhibitory concentration (MIC) was defined as the lowest drug concentration 
showing no fungal growth and minimum fungicidal concentrations (MFCs) was taken as the first 
well with ≥90% killing of fungi. MFC was determined by agar and broth-based (flash microbicide 
method) methods. MICs (μg/ml) and colony forming units were determined after 48h at 37°C. Testing 
was performed in duplicates. 
Results: AmB MICs of A. terreus section terrei ranged from 0.125-2 µg/ml for hypoxia, and from 0.5-8 
µg/ml for normoxia. These data indicate that some strains were more susceptible to AmB in hypoxic 
conditions compared to normoxia (Figure 1). The majority of strains showed that AmB had no 
fungicidal effect against tested A. terreus under any methods and atmospheric conditions (Figure 2). 
A. terreus representing lower MICs (n = 41, ≤0.5 μg/ml) did not result in modest MFCs (≥90% killing 
in 1-2 µg/ml). Fig.1. In vitro susceptibility to AMB of 100 A. terreus isolates in normoxia versus 
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hypoxia, measured by EUCAST
 
Fig.2.a. The effect of oxygen on MFC distributions of AMB, agar-based method measured by colony 
forming units. 
 
Conclusion: Simulating the host environment in in vitro susceptibility testing will contribute to a 
better understanding of how these conditions influence antifungal activity. Hypoxic conditions had 
a marginal influence on the in vitro antifungal susceptibility pattern of A. terreus species to AmB. A 
slight reduction of MICs was demonstrated, however, A. terreus did not turn to be classified as AmB 
susceptible (AmB MICs < 0.125 µg/ml) under hypoxic conditions. Remarkably, AmB lacked any 
fungicidal activity in the majority of examined strains; comparing with MICs, MFC seems to be 
related more with in vivo outcome and might partially explain the high failure rate of AmB therapy 
in vivo. 
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In vitro activity of active ingredients of disinfectants against drug-resistant fungi 
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Objectives: Prevention of immunosuppressed patients against fungal pathogens is essential in times 
of emergence of antifungal-resistant yeasts and moulds. Therefore, the use of fungicidal disinfectants 
is an important measure preventing infections. In this study, the fungicidal activity of common 
microbial agents of chemical disinfectants against antifungal-resistant and antifungal-susceptible 
yeasts and moulds was tested in comparison to the reference strains Candida albicans, Candida 
tropicalis, Aspergillus brasiliensis and Aspergillus niger. 
Methods: In total, nine clinical isolates from the fungal collection of the University Hospital Essen 
and four reference strains were included. Species identification was performed by morphological 
methods and sequencing of the internal transcribed spacer region (ITS). The antifungal susceptibility 
testing was performed via microdilution assay according to EUCAST standard 9.3 for moulds and 
7.3.1 for yeasts. The sensitivity of clinical yeasts and moulds isolates in comparison to the reference 
isolates was tested in a quantitative suspension test against peracetic acid and ethanol as the common 
active ingredients of chemical disinfectants. 
Results: Ethanol was sufficiently active with a log10 reduction factor of ≥ 4.0 against all yeasts in a 
concentration of 50 % v/v within 1 min and against all moulds as 80 % solution within 1 min. Peracetic 
acid was active as 0.25 % solution in 5 min against all yeasts and as 0.5 % solution in 5 min against all 
moulds. Compared to the reference strains the clinical isolates showed similar or higher sensitivity 
to the active ingredients. In addition, antifungal-resistant strains exhibited equivalent sensitivity in 
vitro against ethanol and peracetic acid compared to the susceptible ones. 
Conclusion: Clinical fungal isolates including multidrug resistant ones did show a similar or higher 
sensitivity to active ingredients of disinfectants than the reference strains. 
 
P016 
In vitro susceptibility of olorofim against 1,682 clinical Aspergillus isolates 
J. Buil1, J. Oliver2, M. Birch2, D. Law2, J. Rex2, M. Tehupeiory-Kooreman1, H. Van Der Lee1, W. 
Melchers1, P.E. Verweij1 
1Medical Microbiology, Radboudumc, Nijmegen, Netherlands, 2F2G Ltd, Manchester, United 
Kingdom 
Objectives: Olorofim (OLO) is a novel antifungal agent with potent activity against filamentous fungi 
such as Aspergillus spp., Scedosporium spp. and Lomentospora prolificans. We included OLO in our 
routine MIC-panel for filamentous fungi and analysed the in vitro susceptibility of OLO against 
clinical Aspergillus isolates received in our laboratory between May 2017 and March 2019. 
Methods: The in vitro activity of OLO was tested against 1,682 clinical Aspergillus isolates (987 azole 
susceptible A. fumigatus isolates, 414 azole-resistant A. fumigatus, 72 A. flavus species complex (SC), 
32 A. nidulans SC, 110 A niger SC, 21 A. terreus SC, 7 A. versicolor SC, 39 other species). OLO 
susceptibility was determined using broth microdilution based on EUCAST guidelines. Isolates were 
identified to the SC level using microscopy and growth characteristics. 
Results: The olorofim MICs of all clinical A. fumigatus, A. flavus species complex, A. terreus species 
complex, A. niger species complex, A. versicolor species complex were found to be uniformly <1 mg/L. The 
MIC50 and MIC90 of species with >10 different isolates are displayed in the table. No significant 
differences were found in the OLO MICs of azole-susceptible A. fumigatus isolates compared to azole-
resistant A. fumigatus isolates. Isolates of some cryptic species within the Aspergillus aspergillus species 
complex (A. hollandicus, n = 1 A. glaucus, n = 4 and A. chevalieri n = 1) were found to have elevated 
MIC’s: 1 isolate (A. glaucus) with a MIC of 1 mg/L and the remainder with a MIC of >2 g/L).  
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Conclusion: OLO showed potent in vitro activity against a large collection of clinical Aspergillus 
species, including 1401 A. fumigatus isolates, with many of these resistant to one or more azoles. 
Interestingly, OLO was less potent against a small number of isolates belonging to the Aspergillus 
aspergillus SC (formerly Eurotium). 
 
P017 
Detection and Typing of Fluconazole Resistance on Candida albicans with Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass 
M. Delavy, M. Corthesy, G. Greub, D. Sanglard, A.T. Coste 
Microbiology Institute, University Hospital Lausanne, University of Lausanne, Lausanne, 
Switzerland 
Objectives: Candida albicans causes life-threatening systemic infections in immunosuppressed 
patients. These infections are commonly treated with fluconazole, an antifungal agent targeting the 
ergosterol biosynthesis pathway. Current Antifungal Susceptibility Testing (AFST) methods take 
time and are often subjective. An alternative to the classical AFST methods could use Matrix-Assisted 
Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass spectrometry (MS). This tool, 
already used in clinical microbiology for microbial species identification, has already offered 
promising results to detect antifungal resistance and could be used to detect specific peaks associated 
with fluconazole resistance. 
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Methods: We analyzed MALDI-TOF MS spectra acquired, with the Bruker microflex device, from 21 
C. albicans clinical strains isolated from 9 patients. Those strains were exposed for 3h to 3 fluconazole 
concentrations (256, 16, 0μg/mL). We optimized a protein extraction protocol that allowed the 
acquisition of high-quality spectra. Two steps of quality controls were implemented. First, the quality 
of the spectrum was assessed through its identification score. Second, the variability of the biological 
and technical replicates was evaluated, and outliers were removed. We then developed an R pipeline 
to identify MALDI-TOF MS signature peaks associated with fluconazole resistance or with TAC1 or 
ERG11 mutations known to affect C. albicans susceptibility level, and we designed score-based 
diagnostic tests with these signature peaks. Finally, we evaluated the effects of adding a protein 
standard (Bacterial Testing Standard, BTS, Bruker) to the proteins extracts to reduce the variability of 
the peaks position. And then we tested the effect of the tolerance inhibitor cyclosporin A on the 
susceptible strains’ spectra quality. 
Results: Up to now, in absence of cyclosporin A or BTS, we identified a 4480 m/z peak, whose 
intensity after exposition to 16 μg/mL fluconazole, was inversely proportional correlated with 
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fluconazole resistance. The intensity of the peak seems to be more inversely proportional correlated 
with TAC1 gain-of-function mutation than with ERG11 mutations. Since only a single peak was 
identified, it is likely that the trailing effect of fluconazole might hide other interesting peaks. We thus 
decide to inhibit fluconazole tolerance using cyclosporin A in further experiments. In addition, the 
main challenge of this first analysis was to reproducibly align the spectra. To circumvent this issue, 
we decided to introduce a protein standard (BTS) to the fungal proteins extracts to be analyzed. 
Effects of BTS or cyclosporin A are currently under investigation. 
Conclusion: This study acts as a proof-of-concept for the use of MALDI-TOF MS for the typing of 
fluconazole resistance in C. albicans and currently offer promising results. 
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Azole resistance in Aspergillus. The first six months data from the Danish nationwide surveillance 
study 
M. Risum1, R. Hare1, F.S. Rosenvinge2, J.B. Gertsen3, L. Kristensen3, J. Bangsborg4, B.L. Røder5, E.S. 
Marmolin6, S. Sulim7, K.M.T. Astvad8, M. Pedersen8, R. Datcu1, M.C. Arendrup1,9,10 
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Herlev Hospital, Herlev, Denmark, 5Department Of Clinical Microbiology, Slagelse Sygehus, 
Slagelse, Denmark, 6Department Of Clinical Microbiology, Vejle Sygehus, Vejle, Denmark, 
7Department Of Clinical Microbiology, Å lborg University Hospital, Å lborg, Denmark, 8Department 
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Objectives: Azole resistance (azole-R) in Aspergillus has been increasingly reported worldwide. The 
use of azole fungicides has been proposed to contribute to the emergence of azole-R A. fumigatus, and 
isolates harbouring the resistance mechanisms TR34/L98H or TR46/Y121F/T289A have been dominant 
among azole-R A. fumigatus in azole naïve patients and environmental samples. These two resistance 
genotypes have been sporadically found in clinical and environmental samples in Denmark, but the 
size of the problem remains unknown. The purpose of this study was to establish a nationwide 
surveillance programme of azole-R Aspergillus in Denmark and to report the data from the first six 
month’s study period. 
Methods: Unique Aspergillus isolates were included from all Danish clinical microbiological 
departments in the period October-2018 to March-2019. Isolates from same patients were defined as 
unique if 1) found >30 days apart, 2) confirmation of another species or 3) different susceptibility 
pattern. Inclusion criteria were: a) Aspergillus isolates regarded clinically significant, or b) any 
Aspergillus isolate detected on a Monday regardless of clinical significance. Referral practices varied 
depending on local mycology skills. Most laboratories referred all moulds or all Aspergillus isolates 
which then underwent species ID and susceptibility testing at the reference lab (SSI). One laboratory 
(Aarhus University Hospital) reported the species identification for Aspergillus (n = 214) and only 
referred part of the isolates. Thus susceptibility was performed for 46/138 A. fumigatus isolates from 
AUH at the time of writing. Referred Aspergillus isolates were identified to the complex level except 
A. fumigatus which was identified sensu stricto using thermotolerance testing. A. fumigatus isolates 
underwent screening for azole-R following the EUCAST E.Def 10.1 method and using VIPcheck azole 
agar plates (Mediaproducts BV, Grönningen, NL). Screening positive A. fumigatus isolates and all 
non-fumigatus Aspergillus isolates underwent EUCAST E.Def 9.3.1 susceptibility testing. Isolates were 
deemed intermediate when classified as such for >1 azole. Isolates with azole MIC(s) above the 
EUCAST BP(s) underwent CYP51A sequencing. Duplicates within 30 days were excluded. 
Results: A total of 695 Aspergillus isolates were included of which 503 were A. fumigatus. 
Susceptibility testing was performed for 411 A. fumigatus isolates from 319 patients at time of writing 
(Table 1). For A. fumigatus, 92.7% isolates were azole susceptible, 1.7% intermediate and 5.6% azole-
R. Nineteen out of 319 patients harboured an A. fumigatus which was azole-R (6%). Among these 
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18/19 (95%) harboured an isolate with a CYP51A mutation (Table 2), and 14/19 (73.7%) a CYP51A 
mutation derived from the environment. Furthermore, 2/9 patients harboured three azole resistant 
A. terreus isolates, each with a CYP51A mutation (Table 2). 
 
 
Conclusion: We report a nationwide azole-R rate of 6% in A. fumigatus at the patient level. The 
underlying resistance mechanisms was target gene mutations in all but one case and notably, the vast 
majority were of environmental origin linked to the use of azole fungicides. The fact that such isolates 
have increasingly been found in Denmark since 2009 is concerning and suggests that a one-health 
approach involving human and environmental azole management is necessary to limit further rise 
in azole-R A. fumigatus 
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Multicentre study to determine the Etest® epidemiological cut-off values of antifungal drugs in 
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Bourgeois9, B. Bouteille10, S. Houzé11, E. Dannaoui12, H. Guegan2, E. Charpentier3, F. Persat13, L. 
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Objectives: To determine the specific Etest® -based epidemiological cut-off values (ECVs) for the 
main antifungal agents used in clinical practice, against the most frequent Candida spp. and 
Aspergillus fumigatus species complex (SC), in order to harmonise the interpretation of the Etest®  
minimum inhibitory concentrations (MICs) results in daily routine. 
Methods: For each antifungal agent, the Etest®  MICs in Candida spp. and A. fumigatus SC isolated 
from routine specimen cultures were retrospectively collected from 2004 to 2018 from the laboratories 
of 12 French university hospitals. To ensure that robust and comparable data were included for the 
ECV estimation, basic requirements and criteria have been fulfilled during the selection of MIC data: 
aberrant individual distributions were excluded, MIC data were pooled only if there are generated 
by at least three independent laboratories, and a minimum of 100 MIC values were required after 
data pooling for each species-antifungal agent combinations. The ECVs were then calculated using 
the iterative statistical method with a 97.5% cut-off. 
Results: Forty-eight Etest®  ECVs were determined for amphotericin B, caspofungin, micafungin, 
anidulafungin, fluconazole, voriconazole, posaconazole and itraconazole, after pooling and 
analysing the MICs of 9,654 Candida albicans, 2,939 Candida glabrata SC, 1,458 Candida parapsilosis SC, 
1,148 Candida tropicalis, 575 Candida krusei, 518 Candida kefyr, 241 Candida lusitaniae, 131 Candida 
guilliermondii, and 1,526 A. fumigatus SC isolates. The ECV results were identical (17/32 ECVs) or 
within one two-fold dilution (15/32 ECVs) to the previously reported Etest® -based ECVs. They were 
comparable to the Clinical and Laboratory Standards Institute (CLSI) ECVs in 76.1% (similar or 
within one two-fold dilution: 35/46 ECVs) and strictly identical in 39.1% of cases (18/46 ECVs). They 
were comparable to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
ECVs in 81.2% of cases (similar or within one two-fold dilution: 26/32 ECVs) and strictly identical in 
28% (9/32 ECVs). 
Conclusion: On the basis of these and other previous results, we recommend the determination of 
method-dependent ECVs. As Etest®  is the most widely used commercial method in French 
laboratories, the goal of this study was to calculate specific ECVs for this method and harmonise the 
interpretation of the Etest®  MICs results in daily routine. Etest®  ECVs should not be used in place of 
breakpoints but may identify non-WT isolates with a potential resistance to antifungal agents and 
suggest that an isolate may not respond as expected to the standard treatment. 
 
P020 
Human cell cultures exposed to antibiotic amphotericin B: toxicity and defence 
E. Grela1, M. Piet2, R. Luchowski1, W. Grudzinski1, R. Paduch2, W. Gruszecki1 
1Biophysics, Maria Curie-Sklodowska University, Lublin, Poland, 2Virology And Immunology, Maria 
Curie-Sklodowska University, Lublin, Poland 
Objectives: Amphotericin B (AmB) is a polyene antifungal antibiotic, which is synthetized by the 
bacteria Streptomyces nodosus. AmB is a “gold standard” in treatment of systemic fungal infections, 
due to its broad spectrum of action, high effectiveness and rare pathogens resistant to this drug. 
Unfortunately due to the low selectivity of the action of this antibiotic, it is very toxic for patients. 
Although, the exact mechanism of action of AmB is still unknown, it is used as a lifesaving medicine. 
Understanding the mechanism of action of AmB would enable to minimize its toxic side effects, and 
possibly increase its therapeutic effects. The aim of this study was to get to know the toxicity 
mechanism of action of AmB. 
Methods: To understand molecular mechanism underlying the toxicity of AmB, human normal colon 
epithelial cells CCD 841 CoTr (ATCC No. CRL-1807) and human colon adenocarcinoma cells HT-29 
(ATCC No HTB-38) were exposed to the drug and were imaged using Fluorescence Lifetime Imaging 
Microscopy (FLIM) and Raman scattering spectroscopy. Cultures were incubated for 24 h with AmB. 
Fluorescence lifetime imaging was carried out on MicroTime 200 (Picoquant GmbH, Germany) 
linked with Olympus IX71 inverted microscope. The cell samples were excited by 405 nm pulsed 
laser. Fluorescence lifetimes and fluorescence anisotropy values were analyzed. Raman spectral 
analysis and imaging on a microscale was carried out with inVia Reflex confocal Raman microscope 
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(Renishaw, UK) with Cobolt o8-NLD 405 nm laser (power at a sample 0.2 mW). Obtained results 
were analyzed by DCLS spectral deconvolution. 
Results: The results confirmed high toxicity of antibiotic AmB for both human cell lines but lower for 
HT-29 cells. The results show that AmB incorporates to the lipid membrane containing cholesterol. 
The cell defense mechanism against the action of antibiotic was also observed, which is based on 
removing AmB from the membrane in the form of sterol-deficient exosomes. 
Conclusion: The lower toxicity of AmB observed for HT-29 cells, may be associated with high 
proliferation rate or different membrane composition of adenocarcinoma cells compared to CCD 841 
CoTr cells. AmB binds to the bilayer in the form of small aggregates, which can cause uncontrolled 
ion-leakage and lead to the cell death.  
 
 
P021 
African ST173 Cryptococcus deuterogattii strains are commonly less susceptible to fluconazole : a 
tricky mechanism of resistance 
V. Bellet1, F. Roger1, T. Gouveia1, P. Drakulovski1, F. Kassi2, H. Menan2, D. Krasteva1, S. Bertout1 
1Laboratoire De Parasitologie Et Mycologie Médicale Umi 233, University of Montpellier, 
Montpellier, France, 2CEDRES CHU de Treichville, Abidjan, Côte d'Ivoire 
Objectives: Fluconazole, alone or in association, is often administered during cryptococcosis 
treatment especially in Sub-Saharan Africa. Its intensive use leads to the emergence of resistant 
strains. The mechanisms underlying resistance are poorly documented for yeasts belonging to the C. 
gattii species complex. Literature suggests that resistance could be due to mutations and/or 
surexpression of ERG11 gene and overexpression of efflux pumps, like MDR or AFR. 
Methods: In Ivory Coast, we highlighted the presence of strains with a rare subtype in the molecular 
type VGII associated with high minimum inhibitory concentrations to FCZ compared to VGII strains 
originating from the Pacific Northwest. We investigated the mechanisms of fluconazole resistance of 
18 ivorian clinical strains of C. deuterogattii with high MIC to FCZ compared to 10 strains with low 
MIC to FCZ. 
Results: We demonstrated that (i) these strains exhibited no mutation in the ERG11 gene, (ii) some 
strains had an increased in ERG11 and MDR1 mRNA expression while AFR1 and AFR2 were not 
overexpressed in high MIC to FCZ strains versus the low MIC to FCZ strains and (iii) exposure to 
FCZ in strains with high MIC to FCZ induced AFR1 mRNA overexpression. 
Conclusion: We demonstrated that the FCZ-resistant mechanism commonly described in 
Cryptococcus neoformans or in Cryptococcus gattii from the Pacific Northwest were not responsible for 
the resistance to FCZ in this rare sub-type strains. 
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Novel Technique to Measure Susceptibility to Lipid-Associated Antifungals 
M. Frenkel1, Y. Yunik1, E. Segal2 
1Tel Aviv University, Tel Aviv, Israel, 2Sackler School Of Medicine, Clinical Microbiology And 
Immunology, Tel Aviv University, Tel Aviv, Israel 
Objectives: Lipid associated antifungals, such as polyenes, are extensively used for therapy in 
patients with invasive fungal infections. Thus, susceptibility of fungi to the lipid- associated 
antifungals is of importance. The most reliable method used in susceptibility testing is the broth 
micro-dilution technique. However, visual- or spectral- assessment of the antifungal activity is 
difficult, and possibly unreliable, in lipid-associated drugs, due to turbidity caused by the lipid. 
Hence, the objective of this study was to adapt a method for spectral measurement of susceptibility 
of fungi to lipid-associated antifungal drugs. 
Methods: The technique was adapted for Amphotericin B- Intralipid (AMB-IL) and Nystatin- 
Intralipid (NYT-IL) in comparison to AMB and NYT. Drug preparation: AMB-IL was prepared by 
adding to 5 mg/ml of AMB 20% Intralipid in DDW to a final concentration of 0.2 mg/ml AMB and 
shaken at 280 rpm for 18 h at 240 C. Intralipid in DDW was used as control. NYT-IL was prepared 
similarly, by adding to 20 mg/ml nystatin 20% Intralipid in DMSO to a final concentration of 0.8 
mg/mL NYT and shaken at 280 rpm for 18 h at 240 C. Intralipid in DMSO was used as control. 
Susceptibility test: Susceptibility of the Candida albicans strains to AMB, NYT, AMB-IL, and NYT-IL 
was assessed by the micro-broth dilution assay using micro-titer plates. Susceptibility was evaluated 
using spectral readings in an EMax+ Microplate Reader at 560nm and 650nm, for the standard (AMB, 
NYT) and experimental Intralipid-associated polyene formulations (AMB-IL, NYT-IL), respectively. 
For AMB-IL or for NYT-IL the drug solutions and the relevant controls were diluted in RPMI. Each 
well contained the same concentration of RPMI, IL, DDW or DMSO, and serial dilutions of the 
antifungal drugs (AMB, NYT). 
Results: The validity of the test was evaluated by testing susceptibility of 40 C. albicans isolates: 20 
from human mucosal infections (M strains) and 20 from candidemia patients (S strains) vs. a control 
strain C. albicans CBS-562, for which susceptibility data were available. We determined 50, 90 & 100% 
MIC values by spectral readings (see an example of tests with the control stain – CBS 562–Fig.1). The 
spectral readings were compared to visual readings of the micro-titer plates using an inverted 
microscope. In addition, minimal fungicidal concentration (MFC) for each strain was determined 
((Fig.2). Fig. 1: Spectral readings of Control strain –CBS 562 treated with AMB-IL & NYT-IL 
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Figure 2: Spectral readings vs. Visual assessment of M and S Candida albicans strains . 
 
Conclusion: This study presents a spectral method for measuring susceptibility of yeasts to lipid 
associated polyenes which deals with the difficulties of visual assessment of susceptibility to lipid 
associated antifungals. 
 
P023 
Antifungal activity of antimicrobial peptides against clinical and environmental Aspergillus 
fumigatus isolates. 
E. Ballard1, R. Yucel2, W. Melchers3, A. Brown1, P.E. Verweij3, A. Warris1 
1Mrc Centre For Medical Mycology,, University of Aberdeen, Aberdeen, United Kingdom, 2Ifcc, 
University of Aberdeen, Aberdeen, United Kingdom, 3Medical Microbiology, RadboudUMC, 
Nijmegen, Netherlands 
Objectives: Antimicrobial peptides (AMPs) are a key defence against invading microorganisms. The 
activity of AMPs against human fungal pathogen Aspergillus fumigatus remains poorly understood. 
We characterised the anti-Aspergillus activity of specific human AMPs and determined whether in-
host adaption could lead to resistance to specific AMPs. 
Methods: The antifungal activity of lysozyme, histones, lactoferrin, β-defensin-1 and LL-37, was 
tested against 15 clinical isolates (from patients with cystic fibrosis, chronic and acute invasive 
aspergillosis), 5 environmental isolates and 13 isogenic A. fumigatus isolates obtained from a single 
patient over 2 years showing in-host acquired azole resistance. Hyphae grown from 5x104 conidia 
and incubated with individual AMPs at various concentrations for 2 h at 37oC, after which metabolic 
activity was determined by XTT. Aspergillus conidia (1x105 per well) were incubated for 10 h at 37oC 
with specific AMPs and fixed in 4% paraformaldehyde fixing solution. Analysis of hyphal length was 
performed using the Amnis ImageStreamX MK II Imaging Flow Cytometer (Luminex, USA). Data 
analysis was performed using IDEAS software. 
Results: Dose-dependent decreases in hyphal metabolic activity in all isolates were shown for 
lysozyme (20-80 µM; 31-65% and 5-25% decrease respectively; p<00001) and histones (50-100 ug/ml; 
35-66% and 6-45% decrease respectively; p<0.0001). No effect was observed for lactoferrin (10-40 µM), 
β-defensin-1 (1-10 µM) and LL-37 (5-50 µM). Imaging flow cytometry revealed that incubation with 
histones (100 μg/ml), β-defensin-1 (10 µM) or lactoferrin (40 µM) resulted significantly fewer cells in 
the hyphae gate (p<0.0001, p = 0.04 and p = 0.003, respectively). No significant differences were 
observed with lysozyme (80 µM) or LL-37 (12.5 µM). 
Conclusion: Lysozyme and histones show dose dependent antifungal activity against A. fumigatus 
hyphae, irrespective of the isolate’s azole resistance profile. In addition, histones, lactoferrin and β-
defensin-1 display inhibitory activity against germinating conidia. No differences were observed in 
the susceptibility to AMPs between the groups of A. fumigatus isolates used. We did not identify any 
trends indicating increased resistance to AMPs as a result of in-host adaptation. 
 
P024 
Characterization of I1380T a new FKS1 polymorphism in Candida parapsilosis that confers high-
level echinocandin resistance when associated to P660A 
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I. Accoceberry1, S. El-Kirat-Chatel2, F. Quilès2, N. Biteau1, T. Noël1 
1Cnrs Umr5234, University of Bordeaux, Bordeaux, France, 2Cnrs Umr 7564, Université de Lorraine, 
Villers-lès-Nancy, France 
Objectives: The aim of this study was to determine the impact on echinocandin resistance of a new 
mutation identified in a FKS1 allele of a clinical isolate of C. parapsilosis. 
Methods: To assess the role of mutations potentially implicated in echinocandin resistance, a C. 
lusitaniae strain specially engineered for the expression of a single chromosomal copy of FKS1 was 
used for the expression of I1380T and P660A FKS1 alleles. The echinocandin susceptibility of the 
mutants, as well as their growth rates and phenotypes of interaction with murine macrophages, were 
evaluated in the absence or in the presence of caspofungin. Atomic force microscopy (AFM) was used 
to observe the morphological changes induced by caspofungin exposition. Finally, infrared 
spectroscopy in attenuated total reflection mode (IR-ATR) spectroscopy was used to detect and 
quantify the biochemical signatures of the cell wall before and after caspofungin treatment. 
Results: A caspofungin-resistant C. parapsilosis bloodstream isolate was recovered from a patient who 
underwent allogeneic bone marrow hematopoietic stem-cell transplantation (HSCT) for an idiopathic 
medullary aplasia with positive PNH clone. Full-length nucleotide sequencing of the FKS1 gene 
showed that the strain harboured the heterozygous mutation I1380T (isoleucine at position 1380 
replaced by threonine) located 4 amino acids beyond the HS2 region (amino acids 1369 to 1376), 
compared to Fks1p of the C. parapsilosis reference strain CBS 604, in addition to the naturally 
occurring P660A polymorphism responsible for increased echinocandin MICS in this species. To 
characterize the impact of each mutation on caspofungin resistance, FKS1 alleles bearing I1380T 
associated or not to P660A were genetically engineered and expressed in Candida lusitaniae. When 
compared to a wild type allele bearing no mutation, I1380T conferred a 12-fold MIC increase, P660A 
a 6-fold MIC increase and the combination of both mutations a ≥ 256-fold MIC increase. Measuring 
the cellular interactions between C. lusitaniae FKS1 mutants and murine macrophages showed that, 
in the presence of caspofungin, I1380T enhanced yeast phagocytosis but had no effect on 
intramacrophagic yeast survival rates. AFM analysis of FKS1 mutants showed that caspofungin 
treatment impacts the cell surface topography in both susceptible and resistant strains, and that the 
single I1380T mutation leads to morphological changes even in the absence of caspofungin treatment. 
Infrared spectroscopy in attenuated total reflection mode (IR-ATR) showed that under high drug 
concentration exposure, the FKS1 I1380T mutants exhibited a massive β-glucan synthesis inhibition 
that was not proportionally compensated by chitin synthesis. 
Conclusion: We have identified I1380T, a new mutation located close to the HS2 region of the FKS1 
gene of a clinical isolate of C. parapsilosis. We demonstrated that the high caspofungin MIC for this 
isolate was depending on the combination of I1380T with the naturally occurring P660A 
polymorphism. Further characterization at the cell wall level suggested a potential fitness cost caused 
by I1380T. 
 
P025 
Azole resistant Aspergillus fumigatus: surveillance from flowered patios to departments with at-
risk patients 
C. Godeau, E. Scherer, A. Laboissière, C. Léchenault-Bergerot, G. Reboux, L. Millon, S. Rocchi 
Mycology - Umr6249 Cnrs Chrono-environnement, University Hospital Besançon, Besançon, France 
Objectives: The University Hospital of Besançon is geographically located in a highly agricultural 
area (wood, vegetables, cereals, fruit and vines), and is very concerned by the emergence of azole 
resistance in Aspergillus fumigatus (ARAf), having an increasing number of cases especially amongst 
cystic fibrosis patients. For more than 20 years, the University Hospital of Besançon has been taking 
weekly samples (n = 25) to assess fungal air contamination in the 3 departments of hematology and 
corridors. Since 2015, the number of ARAf found in corridors has been increasing. This study aimed 
to determine whether plant, tree and flowerbeds within or near the hospital are sources of ARAf and 
to assess their spread into the hospital. 
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Methods: Four soil sampling areas within the hospital and in the surrounding environment have 
been identified. Zone A corresponds to an outdoor relaxation area within the hospital, zone B consists 
of flowerbeds in front of the hospital entrance, zone C (inside) corresponds to pots containing trees 
below the hospital reception area and finally zone D corresponds to an outdoor area at level -1 below 
the zone A. From January 2019, external samples were taken using a homemade dust vane sensor 
equipped with 2 wipes, placed on a terrace at second floor, to capture the prevailing wind. Dust 
aspiration was also achieved using a filter placed at the end of a vacuum cleaner, towards the 
emergency door of the department of hematology, in the corridor along zone A, then in hematology 
consultation department. Soils and dust (wipes and aspiration) samples were seeded on medium 
containing itraconazole and voriconazole (2mg/L). The usual weekly air samples taken in the 
hematology departments and corridors from January 2019 were also analyzed. Resistance of A. 
fumigatus growing on azole media was tested using EUCAST method and cyp51A gene of ARAf were 
sequenced. 
Results: From the 85 soils samples, 137 colonies were isolated on azole medium from zones A, B and 
D, grew on azole media. Resistance of 90 A. fumigatus isolates was evaluated with EUCAST method. 
Other strains (zone B) were Neosartorya fisheri. Moreover, 71% (64/90) of A. fumigatus isolates were 
resistant to at least one azole. So far, 20 strains have been sequenced and all harbored the TR34/L98H 
mutation. 59 ARAf were found in pots containing tulips coming from Netherlands and 5 in soil pots 
containing trees. Three isolates were detected on azole media with dust vacuum and 2 (hematology 
department and corridor along zone A) were resistant with TR34/L98H mutation. No resistant strains 
were collected with the external sensor. Four ARAf with the TR34/L98H mutation were also isolated 
from air of corridors. 
Conclusion: Patios containing Dutch tulips in particular, had a significant number of ARAf. On the 
other hand, samples taken upstream of the esplanades, in relation to the prevailing wind, did not 
present any ARAf. Addionally, ARAf were also found in hospital corridors and to emergency exits, 
but not in hematology departments. Genotyping analyses will be carried out to confirm that tulips 
can be a source of ARAf found inside the hospital. 
 
P026 
Triazole-resistant Aspergillus fumigatus: Evaluation of the Fungiplex® Aspergillus and Azole-R 
kits 
S. Rocchi, E. Scherer, A. Laboissière, C. Léchenault-Bergerot, C. Godeau, A.-P. Bellanger, G. Reboux, 
L. Millon 
Mycology - Umr6249 Cnrs Chrono-environnement, University Hospital Besançon, Besançon, France 
Objectives: Cases of Aspergillosis with azole resistant Aspergillus fumigatus are increasingly 
described. Some resistance mechanisms, with two major mutations on the cyp51A gene (TR34/L98H 
and TR46/Y121F/T289A), are linked to the unintended impact of triazole fungicides in agriculture. At 
the University Hospital of Besançon, 216 resistant strains have been isolated since 2012 and 142 
sequenced for beta-tubulin: 52% from professional environments, 28% from clinical samples, 10% 
from hospital corridors, 7% from the inside garden of the Hospital and 3% from patients' homes. 
Given the seriousness of resistant infections, it is important to detect cases of resistance as soon as 
possible. It is in this context that we proposed to test to Fungiplex ®  (Aspergillus et Azole R) kits 
(Bruker). 
Methods: The Fungiplex®  Aspergillus Azole-R kit was retrospectively evaluated on DNA extracts 
from a collection for which cyp51A gene sequencing and genotyping was previously performed. 
According to the instructions, the Azole-R kit is made for the identification of azole resistance 
markers in Aspergillus positive species directly from serum, plasma and bronchoalveolar lavage. We 
are evaluating the kits for the routine testing of cystic fibrosis patients working from isolated strains 
and directly on sputum. We also are testing the performance of the kits to detect 1) Aspergillus 
fumigatus strains 2) resistant strains directly in soil samples. To do this, we worked on inoculated soils 
with increasing concentrations of resistant strains (from 5 to 50 000 spores/mL with 200µL sprayed 
on 250 mg of soil) and directly on soils containing resistant strains. 
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Results: 97 resistant strains previously characterized by sequencing techniques (beta-tubulin and 
cyp51A) were analyzed: 82 TR34/L98H, 2 TR34/L98H/S297T/F495I, 9 TR46/Y121F/T289A and 4 other 
resistant strains. Results showed that 99% of strains carrying one of the two mutations are detected. 
The first prospective results (22 resistant strains in Etest, analysed directly with the kits) made it 
possible to detect 22 A. fumigatus with the TR34/L98H mutation. Verification sequencing is in progress. 
Sputum analysis and tests with cryptic species are also in progress. Tests on inoculated soils show 
that resistant strains can be detected even for the smallest inoculated quantities (200 µL of solution 
concentrated at 5 spores/mL). Real soil tests provide a signal for Aspergillus but not for the TR34 and 
TR46 mutations. Internal reaction controls are also not detected, suggesting a problem with DNA 
extraction and inhibitors rather than poor kit performance. Different methods for extracting DNA 
directly from the soil are under evaluation. 
Conclusion: The kits show ease of use and very good reliability on retrospective analyses with 99% 
of the strains tested validated. The performance of the Aspergillus kit will also be evaluated on cryptic 
species of A. fumigatus (Neosartorya fisherii, A. oerlinghausenensis, Neosartorya hiratsukae, A. lentulus). If 
performance is equally good in ongoing prospective analyses, these kits will be promising to improve 
early diagnosis. 
 
P027 
Relation between hanseniasis and superficial mycoses: prevalence, fungal identification and 
antifungal susceptibility. 
M.L. Scroferneker1, D. Heidrich2, R. Vettorato2,3, L. Eidt4, A. Carvalho Ribeiro1, D. Pagani5, A.H. Da 
Silva Hellwig2, T. Amaro3 
1Department Of Microbiology, Immunology And Parasitology, Universidade Federal do Rio Grande 
do Sul, Porto Alegre, Brazil, 2Postgraduate Program In Medicine: Medical Sciences, Universidade 
Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Serviço de Dermatologia do complexo Hospitalar 
Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil, 4Ambulatório de Dermatologia 
Sanitária de Porto Alegre, Porto Alegre, Brazil, 5Postgraduate Program In Agricultural And 
Environmental Microbiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil 
Objectives: The aim of this study was to evaluate superficial mycoses in patients with hanseniasis in 
relation to the prevalence of fungal species causing mycoses and susceptibility to antifungals. 
Methods: A cross-sectional study was carried out with patients who were seen between May and 
October 2017 at the Hanseniasis Service of the Sanitary Dermatology Ambulatory in the city of Porto 
Alegre, Brazil. The samples collected were submitted to direct (DME) and cultural (CME) mycological 
examinations at the G post of the Santa Clara Hospital in Porto Alegre, were identified by region 
sequencing specified for each genus of fungus and traced sensitivity profile to clinical antifungals 
using protocols M38-A2 and M27-A3 from the Clinical and Laboratory Standards Institute. 
Results: A total of 91 hanseniasis patients were evaluated and 37 presented suspicion mycosis. Of 
these, 23 had DME positive and 14 CME cultures were identified, with eight dermatophytes (seven 
Trichophyton interdigitale and one Epidermophyton floccosum), two isolates of Fusarium keratoplasticum, 
two Acremonium sp., one Candida albicans and one Arthrinium arundinis. Three patients had claws, 
caused by hanseniasis, at the mycosis site, indicating a relation of the two diseases (3/5 patients with 
claw). Terbinafine presented the lowest minimum inhibitory concentrations (MICs) for 
dermatophyte isolates (0.0078-0.06 μg / mL), while fluconazole MICs were the highest (4-> 64μg / 
mL). Fusarium keratoplasticum and Acremonium sp. have higher MICs than all antifungal agents than 
dermatophytes. 
Conclusion: This is the second onychomycosis caused by Arthrinium arundinis from the literature and 
showed low sensitivity to antifungals. Itraconazole had higher MICs for dermatophytes isolated from 
patients with hanseniasis (0.25-1μg / mL) than without the disease cited in the literature, indicating a 
relation of susceptibility to antifungals between mycosis and hanseniasis. 
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Prevalence of azole-resistant Aspergillus fumigatus isolates from respiratory specimens of patients 
from Lyon and exploration of resistance mechanisms 
L. Simon1, R. Kramer2, D. Dupont3, T. Déméautis4, H. Garnier5, B. Lina6, M. Rabodonirina7, M. 
Wallon3, F. Persat8, J. Menotti4 
1Parasitology And Medical Mycology, Hospices Civils de Lyon / CHU de Nice, Nice, France, 
2Parasitology And Medical Mycology, And Virology, Hospices Civils de Lyon / EUPHEM, Lyon, 
France, 3Parasitology And Medical Mycology / Umr 5292, Université Lyon 1 / Hospices Civils de 
Lyon, Lyon, France, 4Parasitology And Medical Mycology / Ea7426 Inflammation And Immunity Of 
The Respiratory Epithelium, Université Lyon 1 / Hospices Civils de Lyon, Lyon, France, 5Parasitology 
And Medical Mycology, Hospices Civils de Lyon, Lyon, France, 6Virology / U1111, Université Lyon 
1 / Hospices Civils de Lyon, Lyon, France, 7Parasitology And Medical Mycology / U1111, Université 
Lyon 1 / Hospices Civils de Lyon, Lyon, France, 8Parasitology And Medical Mycology, Université 
Lyon 1 / Hospices Civils de Lyon, Lyon, France 
Objectives: Resistance of Aspergillus fumigatus strains to triazole antifungals is increasingly reported 
in Europe. The main mechanisms of resistance described are mutations in the cyp51A gene encoding 
a lanosterol 14-α-demethylase or its promoter. As few data are available in Southern France, our 
objective was to assess the burden of Aspergillus isolates with azole resistance from clinical specimens 
in Lyon University Hospitals 
Methods: In this retrospective cross-sectional study, 203 consecutive A. fumigatus isolates were 
identified during a seven-month period from February to September 2017 from respiratory 
specimens from 182 patients attending the inpatient and outpatient wards of the Pulmonary 
Medicine Departments of Lyon University Hospitals. Morphological identification was confirmed by 
sequence analysis of the β-tubulin gene. Minimum inhibitory concentrations were determined using 
E-test reagent strips for itraconazole, voriconazole, posaconazole, and isavuconazole. Resistance was 
defined according to the 2018 EUCAST clinical breakpoints. The molecular resistance mechanisms 
were searched for by sequence analysis of the cyp51A gene and its promoter region, as well as by 
gene expression analysis of the cyp51 genes and genes encoding several efflux transporters. 
Results: PCR and sequence analysis of the β-tubulin gene confirmed the identification of Aspergillus 
fumigatus for the 203 isolates. Four isolates presented with azole resistance: two isolates against 
itraconazole/posaconazole/isavuconazole and another two against all four triazoles. Out of these four 
strains, three presented silent polymorphisms in an intronic part of cyp51A and one presented 
simultaneously the F46Y, M172V and E427K mutations. No mutation was identified in the cyp51A 
promoter, but significant inductions of cyp51A and cyp51B gene expression were observed for all 
four isolates and three isolates, respectively. Significant inductions of atrF and crd1B gene expression 
were observed for two and three isolates, respectively. No significant induction of MDR1-4, MFS56 
and M85 gene expression was observed. 
Conclusion: The prevalence of azole resistance in our study population was 2.2% (95% CI 0.9-5.6). 
Only polymorphisms were found in the cyp51A gene and no mutation was found in its promoter. 
Nevertheless, significant inductions of the expression of the cyp51 genes and two genes encoding 
efflux transporters were evidenced, underlying the diversity of resistance mechanisms to be 
explored. 
 
P029 
Antifungal activity of a mastoparan analog peptide: mode of action and in vivo evaluation in a 
Galleria mellonella model 
J. Singulani1, M.C. Galeane1, M. Dorisse Ramos1, P.C. Gomes1, C. Santos1, B. Monson De Souza2, M.S. 
Palma2, A.M. Fusco Almeida1, M.J. Soares Mendes Giannini1 
1Clinical Analysis, UNESP, Araraquara, Brazil, 2Biology, UNESP (Sao Paulo State University), Rio 
Claro, Brazil 
Objectives: The purpose of this work was to evaluate the antifungal activity and toxicity of a peptide 
analog of mastoparan class from wasps (MK58911) under both in vitro and in vivo conditions. 
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Methods: Firstly, MK58911 was tested against Cryptococcus neoformans ATCC 90112 using the 
microdilution susceptibility test according to the CLSI M27-A3 (2008). In addition, the mechanism of 
action on fungal membrane, death cell events (apoptosis and necrosis) and reactive oxygen species 
(ROS) was evaluated by flow cytometry. Secondly, the peptide toxicity tests on lung fibroblasts 
(MRC5) and glioblastoma cells (U87) were performed. Finally, the efficacy and toxicity of the peptide 
were evaluated in vivo using a Galleria mellonella model. 
Results: The results showed a promising activity of the peptide with minimal concentration 
inhibitory (MIC) of 31.2 μg/mL and low toxicity in MRC and U87 cells (IC50 > 500 μg/mL). Taken 
together, these results demonstrated that the peptide has a high selectivity by fungal cells compared 
to mammal cells (selectivity index - SI > 16). The peptide presented a mechanism of action on plasma 
membrane, leading to death of the fungus mainly by the necrosis process and without production of 
reactive oxygen species. Finally, the peptide showed no toxic effects on G. mellonella and significantly 
enhanced the survival rates and decreased the fungal burden of larvae infected with C. neoformans. 
These effects were independent of an immunomodulatory activity. 
Conclusion: The results showed the peptide as a potential new antifungal drug against 
cryptococcosis. "This study was supported by the Fundação de Amparo à Pesquisa do Estado de São 
Paulo (FAPESP grants no. 2017/06658-9 and 2016/16212-5)." 
 
P031 
Screening for Triazole resistance in clinically significant Aspergillus species from Pakistan 
A. Zafar, S. Moin, K. Jabeen, J. Farooqi, S. Laiq 
Pathology And Laboratory Medicine, Aga Khan University, Karachi, Pakistan 
Objectives: To determine the frequency of triazole (itraconazole, voriconazole, posaconazole) 
resistance in clinically significant Aspergillus species isolated at a tertiary care centre, Karachi, 
Pakistan. 
Methods: A descriptive cross-sectional study was conducted in the Department of Pathology and 
Laboratory Medicine, Microbiology Section of the Aga Khan University Clinical Laboratories, 
Karachi, Pakistan from September 2016 to May 2019. One hundred and fourteen, clinically significant 
Aspergillus isolates [A.fumigatus (38; 33.3%), A.flavus (64; 56.1%), A.niger (9; 7.9%) and A.terreus (3; 
2.6%)] were included in the study. They were assessed for their clinical significance. The clinical 
spectrum ranged from Invasive Aspergillosis (IA) (n = 25; 21.9%), further divided into proven 
invasive extrapulmonary aspergillosis (n = 8; 7%), proven invasive pulmonary aspergillosis (IPA) (n 
= 6; 5.3%), putative/probable IPA (n = 11; 9.6%) according to the AspICU and 2008 EORTC criteria, to 
Chronic Pulmonary Aspergillosis (CPA) (n = 58; 50.9%), Allergic Bronchopulmonary Aspergillosis 
(ABPA) (n = 4; 3.5%), Severe Asthma with Fungal Sensitization (SAFS) (n = 4; 3.5%) and saprophytic 
tracheobronchial aspergillosis (n = 23; 20.2%). Screening for triazole resistance was performed by 
antifungal agar screening method as described by Mortenssen et al. The minimum inhibitory 
concentration (MIC) of 41 representative isolates [A.flavus (n = 15; 13.2%), A.fumigatus (n = 15; 13.2%), 
A.niger (n = 8; 7%), A.terreus (n = 3; 2.6%)] representing a clinical spectrum of extrapulmonary IA (n = 
7; 6.1%), IPA (n = 4;3.5%) putative/probable IPA (5; 4.4%), CPA (n = 18;15.8%), ABPA (n = 3; 2.6%), 
SAFS (n = 1; 0.9%), and saprophytic tracheobronchial aspergillosis (n = 3; 2.6%) were tested according 
to the CLSI broth microdilution method. 
Results: All the isolates were categorized as triazole-susceptible based on the triazole antifungal agar 
screening. The MICs of the three azole antifungals for 41 representative isolates tested were found to 
be ≤1 ml/L and hence according to CLSI breakpoints, all the isolates tested were found to be triazole-
susceptible. The MIC 90 of itraconazole, voriconazole and posaconazole of the representative 
aspergillus isolates was 1mg/L, 1mg/L and 0.5mg/L respectively. 
Conclusion: This study may set precedence for future periodic antifungal resistance surveillance 
studies in our region on Aspergillus isolates causing invasive disease, as well as other syndromes 
requiring long term antifungal therapy. 
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Antifungal susceptibility profile of invasive Candida glabrata isolates (2009-2019) from a tertiary 
care hospital laboratory in Pakistan 
J. Farooqi1, S. Memon2, S. Laiq1, F. Naqvi1, A. Zafar1, K. Jabeen3 
1Pathology And Laboratory Medicine, Aga Khan University, Karachi-KHI, Pakistan, 2Microbiology, 
Karachi University, Karachi, Pakistan, 3Pathology And Laboratory Medicine, Aga Khan University, 
Karachi, Pakistan, Pakistan 
Objectives: Candida glabrata invasive infections are increasingly associated with antifungal resistance 
and poor clinical outcomes. The objective of this study was to evaluate antifungal resistance and 
distribution of minimum inhibitory concentrations (MICs) against invasive C. glabrata isolates (200-
2019) at Aga Khan University (AKU) at Karachi, Pakistan. This laboratory, through its network of 
satellite collection centers receives specimens from more than 100 major cities and towns of the 
country. 
Methods: 162 Candida glabrata strains were isolated from blood (101), body fluids (26), pus and 
wounds (21) tissue (4) and others (10). Isolates were identified by conventional method using API 
20C AUX, gross morphology on chromogenic and microscopic morphology on corn meal agar. MICs 
were determined using colorimetric broth microdilution (YeastOne Sensititre, Trek diagnostics). 
Susceptibilities were interpreted according to Clinical Laboratory standard Institute breakpoints 
mentioned in “Performance Standard for Antifungal Susceptibility Testing of Yeasts M60-ED1:2017”. 
Results: Out of 1917 archived invasive candida, 162 (8.4%) were C.glabrata 76% of these isolates were 
from patients admitted at AKU. Male to female ratio was 1.4 and 62% of the isolates were from ages 
18-64 year. MIC90 of these strains against fluconazole was 64 µg/ml, voriconazole 2µg/ml, itraconazole 
1µg/ml and posaconazole 2µg/ml. Among echinocandins, MIC90 was 0.12µg/ml for caspofungin, 
0.06µg/ml for anidulafungin and 0.03µg/ml for micafungin. MIC90 for amphotericin B was 0.5µg/ml. 
Conclusion: Antifungal sensitivity testing for invasive candidiasis is essential in the face of emerging 
resistance as empiric therapy may not have reliable outcomes. Surveillance data of antifungal 
resistance among common Candida species with potential for developing antifungal resistance, like 
C. glabrata, should be monitored closely for identifying resistant strains in circulation. 
 
P033 
Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in 
hematological malignancy (CLARITY) – a multicenter study 
D. Seidel1, O.A. Cornely2, P. Köhler1,3, J. Meis4, M. Zarrouk3, J. Salmanton-Garcia3, D. Arenz5, O. 
Blennow6, D. Buchheidt7, J.-J. Vehreschild3, N. Alakel8, A. Bergeron9, G. Desoubeaux10, I. Falces-
Romero11, N. Klimko12, K. Lagrou13, C. Lass-Flörl14, Y. Le Govic15, J. Maertens16, A. Ostojic17, J. Prattes18, 
Z. Racil19, A. Reséndiz Sharpe16, E. Schalk20, M. Stanzani21, J. Steinmann22, W. Melchers23, M.J.G.T. 
Vehreschild24, P.E. Verweij23 
1Department I Of Internal Medicine, Ecmm Excellence Centre Of Medical Mycology, Cologne 
Excellence Cluster On Cellular Stress Responses In Aging-associated Diseases (cecad), University 
Hospital Cologne, Cologne, Germany, 2Department I Of Internal Medicine, Ecmm Excellence Centre 
Of Medical Mycology, Cologne Excellence Cluster On Cellular Stress Responses In Aging-associated 
Diseases (cecad), German Centre For Infection Research, Partner Site Bonn-cologne, Clinical Trials C, 
University Hospital Cologne, Cologne, Germany, 3Department I Of Internal Medicine, University 
Hospital of Cologne, Cologne, Germany, 4Department Of Medical Microbiology And Infectious 
Diseases, Excellence Center For Medical Mycology (ecmm), Canisius Wilhelmina Hospital, 
Nijmegen, Netherlands, 5Department I For Internal Medicine, Excellence Center For Medical 
Mycology (ecmm), University of Cologne, Cologne, Germany, 6Karolinska University Hospital, 
Stockholm, Sweden, 7Mannheim University Hospital, Heidelberg University,, Mannheim, Germany, 
8University Hospital Dresden, Dresden, Germany, 9Université Paris Diderot, APHP Saint-Louis 
Hospital, Paris, France, 10Cepr Inserm U1100, Université de Tours, Tours, France, 11Hospital 
Universitario La Paz, Madrid, Spain, 12Department Of Clinical Mycology, Allergology And 
Immunology, North-Western State Medical University n.a. I.I. Mechnikov, Saint-Petersburg, Russian 
Federation, 13Clinical Bacteriology And Mycology, Katholieke Universiteit Leuven, Leuven, Belgium, 
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14Div Hygiene & Med. Microbiology, Med. Univ. Innsbruck, Innsbruck, Austria, 15Groupe d'Etude 
des Interactions Hôte Pathogène (GEIHP), Université d'Angers, Angers Cedex , France, 16KU Leuven, 
Leuven, Belgium, 17University Hospital Centre Zagreb, Zagreb, Croatia, 18Section Of Infectious 
Diseases And Tropical Medicine, Medical University of Graz, Graz, Austria, 19Department Of Internal 
Medicine - Hematology And Oncology, University Hospital Brno, Brno, Czech Republic, 20Otto-von-
Guericke University, Magdeburg, Germany, 21"Lorenzo e Ariosto Seràgnoli" S'Orsola-Malpighi 
Hospital, University of Bologna, Bologna, Italy, 22Institute Of Clinical Hygiene, Medical Microbiology 
And Clinical Infectiology, Klinikum Nuernberg, Nuremberg, Germany, 23Medical Microbiology, 
RadboudUMC, Nijmegen, Netherlands, 24Uniklinikum Frankfurt, Med. Klinik II, Infektiologie, 
Frankfurt, Germany 
Objectives: In recent years, survival of patients with invasive aspergillosis (IA) has improved mainly 
due to availability of extended spectrum triazoles. These advances are jeopardized by the emergence 
of azole resistance in Aspergillus fumigatus, the most common causative pathogen of IA. Despite 
several studies suggesting high probability of azole treatment failure in patients with azole-resistant 
isolates, the clinical implications of azole-resistant IA compared to azole-susceptible IA remain 
unclear. Thus, we seek to describe the epidemiology and determine the efficacy of antifungal therapy 
in patients with documented azole-resistant IA compared to azole-sensitive IA in patients with 
hematological malignancy. 
Methods: In patients with hematological malignancies, cases of proven or probable IA (EORTC/MSG 
2008) caused by A. fumigatus are registered. Retrospective data are documented, comprising 
demographics, diagnosis, treatment, response and outcome. Participating sites provided 
susceptibility results or isolates. Provided isolates were analyzed in a central laboratory. 
Results: Since January 2018, 51 sites in 15 countries worldwide enrolled 154 cases diagnosed with IA 
between 2010 and 2019, of which 23 (14.9%) had azole-resistant IA. Of 44 cases, the respective clinical 
fungal isolate was analyzed in the central laboratory. A mixed fungal infection was reported for 34 
patients (22.1%), 1 (2.9%) in the azole-resistant group; most were related to non-fumigatus Aspergillus 
species (n = 12, 35.3%) and non-Aspergillus molds (n = 10, 29.4). Most patients were male (n = 98, 
63.6%); 19 (82.6%) in the azole-resistant group, 79 (60.3%) in the azole-susceptible group. Age was 
documented in categories instead of the exact age. Median age group was 50-69 years in both groups 
(ranging from 7-11 to 70-89 years for azole-resistant cases, 1-12 months to 70-89 years for azole-
susceptible cases). Underlying disease and survival are shown in the table. 
 
Conclusion: A worldwide network of investigators contributes to the CLARITY registry study. 
Completion of recruitment and subsequent data analysis are planned for 2019. Further sites may be 
added if azole resistant cases are encountered. 
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Sensitivity of isolated dermatophyte strains to antifungal drugs in the Russian Federation 
M. Manoyan, V. Sokolov, A. Gursheva, N. Gabuzyan, A. Panin 
Veterinary Mycology, The All-Russian State Center for Quality of Animal Medicines and Feeds, 
Moscow, Russian Federation 
Objectives: The spread of dermatophytosis is a veterinary problem; the spread of dermatophytosis 
pathogens in the human population is a social problem. In the Russian Federation immunobiological 
preparations, as well as external agents in the form of suspensions or shampoos are used for a 
treatment of animals dermatophytosis. As a rule, such agents contain azoles (clotrimazole, 
miconazole, enilconazole) or terbinafine as an active substance. They are often used unsystematically 
and can trigger the emergence of resistant strains. Recently, there have been increasing reports about 
dermatophytoses strains, resistant to antifungal drugs: M. canis strains resistant to terbinafine and 
azoles, and T. rubrum strains resistant to terbinafine. 
Methods: For comparison, the strains of dermatophytes - M. canis and T. mentagrophytes, earlier 
collected and freshly isolated from cats and dogs, were chosen. Collection strains, stored in a 
lyophilized form, were isolated from animals between 1970 and 2000. For the study there were 
selected ten strains of M. canis and T. mentagrophytes. Freshly isolated strains were collected from 
animals between 2015 and 2018, they also were stored in the laboratory's collection in a lyophilized 
form; we also selected ten strains of M. canis and T. mentagrophytes. The choice of antifungal drugs 
spectrum, for which MIC was determined, was dictated by the data on the use of antifungal drugs in 
the Russian Federation: for terbinafine there was evidence of resistant strains; ketoconazole and 
enilconazole were used for animal fungal infections treatment and prevention. Cultures were isolated 
on Saburo medium with chloramphenicol and cycloheximide, pure cultures for determining MIC 
were cultivated on Saburo medium without additives for 7 days at +28°C. A method based on 
EUCAST E.def 9.3.1 was used to determine the MIC (inoculum density was 1.0E+5 CFU/ml, the 
incubation time was 4days . 
Results: MIC studies of terbinafine, ketoconazole and enilconazole for strains isolated between 1970 
and 2000 showed following. One of ten M. canis strains was resistant to the action of terbinafine (MIC> 
32 μg / ml), there was no detected any strain resistant to ketoconazole and enilconazole. None of the 
ten T. mentagrophytes strains was resistant to the action of terbinafine, ketoconazole or enilconazole. 
MIC studies of terbinafine, ketoconazole and enilconazole for strains isolated between 2015 and 2018 
showed following. Four of the ten M. canis strains were resistant to the action of terbinafine (MIC> 32 
μg / ml); one strain was resistant to the action of enilconazole (MIC> 16 μg / ml); and we did not find 
a ketoconazole resistant strain. Four of the ten T. mentagrophytes strains were resistant to the action of 
terbinafine (MIC> 32 μg / ml); one strain was resistant to ketoconazole (MIC> 16 μg / ml); 2 strains 
were resistant to the action of enilconazole (MIC> 16 µg / ml). We did not find strains of M. canis or 
T. mentagrophytes, resistant to two or three drugs. 
Conclusion: The number of antifungal resistant dermatophyte strains was higher among those 
isolated for a later period. This may indicate the emergence of resistant dermatophytosis pathogens 
strains in the Russian Federation. 
 
P035 
Evaluation of the in vitro susceptibility testing of dermatophytic isolates: preliminary comparison 
of four methods 
A.-M. Markantonatou, K. Samaras, E. Zachrou, T.-A. Vyzantiadis 
First Department Of Microbiology, Medical School, Aristotle University of Thessaloniki, 
Thessaloniki, Greece 
Objectives: Superficial infections caused by dermatophytes affect a high percentage of the 
population. Antifungal susceptibility testing (AST) of these pathogens may offer information about 
their susceptibility profiles, documentation of the appropriate treatment and reduction of the cost. 
However, there are two factors that could delay and affect the performance of the AST: the slow 
growth rate of these fungi and their poor sporulation. The proposed methods by the CLSI or the 
EUCAST are both laborious for the everyday routine. Though, there are alternative applications that 
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propose the use of an inoculum consisting of a conidia-mycelium mixture or even from plain mycelia, 
as well as the use of resazurin in order to facilitate the reading. The aim of this study was to compare 
these approaches to the EUCAST method in order to evaluate their performance. 
Methods: Three alternative methods of dermatophytic AST were compared to the EUCAST proposed 
methodology for conidia forming moulds. The methods under evaluation were a) a fragmented 
mycelia method, b) the EUCAST method with the addition of resazurin sodium salt solution and c) 
the fragmented mycelia method with the addition of resazurin sodium salt solution. The 
susceptibility of twenty dermatophytic isolates (8 Trichophyton interdigitale, 6 T. rubrum and 6 M. canis) 
was tested against the antifungal agents of griseofulvin, terbinafine, fluconazole and itraconazole. 
Results: After the measurement of the MICs by all four different methods, the essential agreement 
between them was calculated in percentages. Data analysis revealed sufficient overall essential 
agreement of the methods with the addition of resazurin to the initial “uncoloured” ones (98.5% and 
97.2% for the EUCAST and the fragmented mycelia method respectively). The fragmented mycelia 
method exhibited a relatively sufficient overall essential agreement to the EUCAST method (88.9%) 
but not a satisfactory correlation between the MIC values. The mean MICs (by the EUCAST method, 
in μg/mL) for the twenty isolates were 1.78 for griseofulvin, 0.034 for terbinafine, 25.2 for fluconazole 
and 0.57 for itraconazole. 
Conclusion: The addition of resazurin sodium salt solution facilitates the reading and provides a 
more objective evaluation. The fragmented mycelia method could serve as an alternative in cases of 
poor or no sporulating dermatophytes. 
 
P037 
Distribution of azole minimal inhibitory concentration (MIC) values and Erg11 amino acid 
substitutions among Candida auris isolates from different geographic clades 
M. Kordalewska1, K.R. Healey2, C. Jimenez-Ortigosa1, A. Singh3, B. Williamson2, A. Wilk2, I. Berrio4, 
A. Chowdhary3, D.S. Perlin1 
1Center For Discovery And Innovation, Hackensack Meridian Health, Nutley, United States of 
America, 2Department Of Biology, William Paterson University, Wayne, United States of America, 
3Department Of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, 
India, 4Hospital General de Medellín “Luz Castro de Gutiérrez” ESE, Medellin, Colombia 
Objectives: Candida auris isolates are often characterized with reduced susceptibility to fluconazole 
(FLC) and other azole class drugs: voriconazole (VRC), posaconazole (POS), itraconazole (ITC), and 
isavuconazole (IVC). Such a situation is extremely worrying, since azoles are a mainstay in the 
treatment of Candida infections and antifungals other than fluconazole might be unavailable in 
resource-limited countries. Moreover, no antifungal clinical breakpoints are available for C. auris. 
CDC provides guidance for C. auris MIC interpretation, based on information gathered for related 
Candida species and expert opinion. Tentative epidemiological cut off values (ECVs) were proposed 
only for C. auris isolates from India. The aim of this study was to analyze distribution of azole minimal 
inhibitory concentration (MIC) values for isolates belonging to different geographic clades together 
with the data regarding molecular resistance determinants. 
Methods: A total of 108 C. auris isolates representing four geographic clades (I – South Asian; II – 
East Asian; III – South African; IV – South American) were investigated in this study. Antifungal 
susceptibility testing (AFST) with azoles (FLC, ITC, IVC, POS, VRC) was performed in accordance 
with CLSI document M27‐A3. The ERG11 gene, encoding the target for azole antifungal drugs, was 
amplified and sequenced. All identified ERG11 alleles were cloned onto a low-copy vector (pRS416) 
and expressed within a haploid strain of Saccharomyces cerevisiae (BY4741). Azole susceptibilities were 
then determined for the transformed strains of S. cerevisiae. 
Results: The results of C. auris AFST and ERG11 sequencing are presented in Table 1. Expression of 
ERG11 alleles in S. cerevisiae revealed that triazole resistance was induced only upon expression of 
pCauErg11-V125A/F126L, pCauErg11-Y132F, and pCauErg11-K143R, but not pCauErg11-WT, 
pCauErg11-K177R/N335S/E343D, pCauErg11-I466M, or pCauErg11-Y501H. 
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Conclusion: Differences in the distribution of MIC values and resistance-conferring ERG11 
mutations between isolates from different geographic clades underscore the need for an extreme 
caution when categorizing isolates as sensitive/resistant on a basis on AFST results. Only 
V125A/F126L, Y132F and K143R Erg11 amino acid substitutions identified in C. auris isolates directly 
mediate resistance and may be used as diagnostic markers for C. auris azole resistance. Mechanisms 
other than ERG11 mutations may also contribute to reduced azole susceptibility in C. auris, although 
this remains to be determined. 
 
P038 
To study the profile of conventional and newer antifungal agents against dermatophytes in a 
tertiary care hospital in South India 
A.J. Kindo1, H. Veena1, A. Subramanian2, A. Krishnan2 
1Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India, 
2Dermatology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India 
Objectives: 1.Speciation of dermatophytes from the clinical isolates 2.To study the antimicrobial 
pattern of frequently used antifungal agents 3.To compare the antifungal profile with the newer 
antifungal agents 
Methods: Clinically diagnosed dermatophytic patients were sampled for microscopy and culture, 
grown dermatophytes were subjected to phenotypic identification by conventional method. 
Antifungal susceptibility testing was done by broth microdilution method according to CLSI M38-
A2 document guidelines. Trichophyton mentagrophytes ATCC 4439 was included in each run of 
susceptibility testing as a quality control. Final drug concentration in the microdilution plates ranged 
from 64 to 0.25 µg/ml for fluconazole and Amphotericin B and from 16 to 0.06 µg/ml for 
Itraconazole,Voriconazole, Griesofulvin ,Terbinafine, Sertaconazole,Luliconazole, Fenticonazole 
tested. 
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Results: 
 
Out of the 100 clinical isolates tested, 58 of them were identified as Trichophyton mentagrophytes , 40 
were Trichophyton rubrum. and the remaining two isolates were identified as Epidermophyton 
Floccosum and Microsoprum nanum Antifungal susceptibility testing was carried out for 100 isolates of 
Trichophyton species against 9 antifungal agents. All isolates showed detectable growth after 4-5days 
of incubation. MICS for Trichophyton mentagrophytes ATCC 4439 were within the established range. 
Conclusion: In this study Trichophyton mentagrophytes was the most common cause of 
dermatophytosis .The most challenging task is not the diagnosis but the treatment , compliance and 
recurrence. Since it requires a long term treatment, the management with appropriate and responsive 
drug is the need of the hour. Currently this study suggests that the overall activity of Luliconazole, 
Fenticonazole, Sertaconazole, as topical agent and Itraconazole , Voriconazole (systemic) are 
significantly effective against dermatophytes. Current solution to this could be to maintain skin 
hygiene , prudent use of antifungals appropriate dosing and duration, performing antifungal 
susceptibility testing ,usage of conventional drugs or topical keratolytic agents in combination with 
newer drugs in appropriate dosages and combination therapy. 
 
P039 
Terbinafine resistant Trichophyton mentagrophytes genotype VIII, Indian type, isolated in 
Finland 
H. Järv1, S. Uhrlass2, T. Simkin1, P. Nenoff2, E. Alvarado Ramirez3, E. Chryssanthou3, M. Monod4 
1SYNLAB Estonia, Tallinn, Estonia, 2Laboratory For Medical Microbiology, Mölbis, Mölbis, Germany, 
3Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden, 4Department Of 
Dermatology, Lausanne University Hospital, Chexbres, Switzerland 
Objectives: Objective We are reporting first four isolates of Trichophyton mentagrophytes representing 
novel Indian genotype VIII in Finland potentially resistant to terbinafine. Our study points out the 
need for antifungal susceptibility testing of dermatophytes as a new issue in microbiology 
laboratories. The roles of classical mycological culture vs DNA-based diagnostics for laboratory 
diagnostics of dermatophytosis will be discussed. 
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Methods: Primary fungal cultures were made on Sabouraud dextrose and 2% malt extract agar. 
Identification of fungal isolates was made by micromorphological appearance in SYNLAB laboratory 
in Estonia and by sequencing the ITS region of rDNA and TEF1-alpha gene in clinical microbiology 
laboratory in Mölbis, Germany. The genotyping of squalene oxidase gene was made in dermatology 
department of Vaudoise, Lausanne, Switzerland. The minimal inhibitory concentration (MIC) to 
terbinafine was determined by broth microdilution method in microbiology laboratory of Karolinska 
Hospital, Sweden. MIC was detected spectrophotometrically after 5 days incubation at 28˚C. 
Results: We describe four cases of extensive tinea cutis glabrae caused by T. mentagropytes. All cases 
were diagnosed from January to April of 2019 and occurred in geographically distinct regions of 
Finland. Three of four of T. mentagrophytes sub-type VIII (Indian sybtype) strains have high MIC 
values of terbinafine from 4 mg/L to >8 mg/L. 
Conclusion: Dermatophytosis has taken epidemic dimensions in India during the last 5 to 6 years. 
Unusual clinical presentation of dermatophytosis and corticosteroid modified lesions are making 
diagnosis challenging. Indian experts panel ECTODERM India has published new treatment 
guidelines in 2018. Nenoff et al have demonstrated in a recently published study from different 
geographical locations from India that 93.25% of the dermatophytes isolated from patients suffering 
from dermatophytosis correspond to a special genotype (VIII) of T. mentagrophytes . Singh with co-
workers have published data about alarming terbinafine resistance of T. interdigitale strains in India. 
Trichophyton spp isolates with Indian origin have demonstrated high MICs to terbinafine, up to 32 
mg/L, and also to azoles. Terbinafine is considered to be the most effective drug for treatment of 
Trichophyton spp infections. In general, we know that pathogens and resistant strains follow the 
human migration routes. The lack of data about presence of this novel genotype in European 
countries is because most clinical laboratories do not use multilocus sequencing for routine 
identification of dermatophytes. SYNLAB Estonia uses classical culture-based diagnostics and DNA-
based diagnostics (in house PCR) for dermatophytes, handling approx. 10000 sample per year. We 
are not able to identify 1/5 of dermatophytes on species level. Most of commercial diagnostic DNA 
panels for dermatophytes do not discriminate T. mentagrophytes and T. interdigitale. In the light of new 
data diagnostic laboratories need to put more effort to identify all dermatophytes on species level by 
molecular methods. It will help to map the changing epidemiological situation of dermatophytosis 
in Europe. 
 
P040 
An emerging clone of Candida tropicalis bloodstream isolates with ERG11 gene mutations and 
overexpression conferring reduced activity of isavuconazole 
P.-Y. Chen, Y.-C. Chuang, U.-I. Wu, H.-Y. Sun, J.-T. Wang, W.-H. Sheng, Y.-C. Chen, S.-C. Chang 
National Taiwan University Hospital, Taipei, Taiwan 
Objectives: In Asia, in vitro activity of isavuconazole (ISA) against clinical Candida isolates are 
seldomly reported, especially a rising concern that azole-resistant Candida tropicalis is common (≥10%) 
in this region. Also, few studies characterized molecular mechanisms of reduced isavuconazole 
activity against C. tropicalis. 
Methods: Sixty-four non-duplicated C. tropicalis bloodstream isolates were prospectively collected in 
National Taiwan University Hospital in 2017. In vitro susceptibility to antifungal agents was 
performed by using the microdilution colorimetric Sensititre YeastOne panel and the results were 
interpreted by the Clinical and Laboratory Standards Institute. ISA MICs were determined using the 
EUCAST E.def 7.3.1 method. Wild-type upper limit (wtUL) was defined as two two-fold dilutions 
above the MIC50. Isolates with reduced ISA activity (RIA) were defined as their ISA MICs above 
wtUL. The ERG11 gene was sequenced for all isolates, and the results were compared to the ERG11 
wild-type sequence from C. tropicalis reference strain ATCC 750 (Genbank accession M23673). 
Quantitative realtime reverse transcription-polymerase chain reaction (ERG11, CDR1, and MDR1) 
were performed. Multilocus sequencing types were analyzed by the eBURST to determine putative 
relationships between isolates. 
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Results: Among sixty-four C. tropicalis bloodstream isolates, the resistant/ non-wild type rates of 
fluconazole, voriconazole, posaconazole or itraconazole were 21.5%, 30.7%, 64.6%, and 13.9%, 
respectively. The proportions of RIA was 18.8% (n = 12). ISA MICs correlated with other azoles MICs 
by calculating with nonlinear regression fits. The R2 values were in the following orders: 
posaconazole (0.74) < itraconazole (0.82) < voriconazole (0.86) < fluconazole (0.88). The mean 
percentage of ISA trailing was 27.4%. A total of 8 nucleotide mutations were detected in ERG11 gene 
of all isolates. Only 2 (A395T/W and C461T/Y) belonged to missense mutations resulting in amino 
acid substitutions (Y132F and S154F). There were fourteen isolates with one or two these mutations 
all resistant to fluconazole. Twelve of them had RIA, all of which belonging to the same clone. Gene 
relative expression levels among three groups (isolates with low and high ISA trailing, and those 
with RIA) are shown Figure. Only ERG11 expression levels demonstrated significant difference (P < 
0.001), and neither did CDR1 nor MDR1 (P > 0.05). Those with RIA showed the highest mean ERG11 
relative expression level (3.51 ± 0.59 [S.D.]) with statistically significance, while the mean ERG11 
levels between high and low ISA trailing group were not statistically different (1.08 ± 0.69 and 0.93 ± 
0.66, respectively). Figure 
 
Conclusion: C. tropicalis bloodstream isolates in our report showed an emerging clone with pan-azole 
resistance, including RIA. Fluconazole MICs best correlated to ISA MICs. Combined ERG11 gene 
missense mutations and ERG11 overexpression conferred RIA. 
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Comparative genomics of Aspergillus fumigatus and the influence of agriculture on ecology and 
azole resistance 
A.E. Barber1,2,3, J. Born4, T. Sae-Ong2, I. Schliebner4, K. Kang2, G. Walther2,3, G. Panagiotou2, H.B. 
Deising4, O. Kurzai1 
1University of Wuerzburg, Wuerzburg, Germany, 2Leibniz HKI Jena, Jena, Germany, 3National 
Reference Center for Invasive Fungal Infections, Jena, Germany, 4Martin Luther University Haale-
Wittenberg, Halle (Saale), Germany 
Objectives: Aspergillus fumigatus is an environmentally ubiquitous saprophyte capable of causing 
life-threatening invasive infections and allergic bronchopulmonary disease and current management 
strategies rely on the azoles. Unfortunately, over the last decade there has been a global emergence 
in resistance to the azoles in A. fumigatus and the dominant resistance mechanism is of environmental 
origin, suggesting that resistance is emerging through a selective pressure applied by the widespread 
usage of azoles in agriculture. 
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Methods: To examine the link between the use of azoles in agriculture and the emergence of clinical 
resistance, systematic soil sampling was performed over a three year period on seven conventional 
agricultural sites in Germany utilizing azole fungicides and on six organic sites withholding these 
compounds. Conventional sites were evaluated both before and after azole application. We also 
performed WGS on 250 environmental and 50 clinical isolates. 
Results: In total, 2875 soil samples were analyzed between 2016 and 2018. We observed a high degree 
of variation in the abundance of A. fumigatus across sites, however, fields with high A. fumigatus 
density tended to be consistently so from year to year. Strikingly, we observed a significant reduction 
in the abundance of A. fumigatus on conventional fields following azole treatment – a finding that 
was not repeated on an organic agriculture control field – indicating that the application of azoles is 
imposing a bottleneck on A. fumigatus. We detected a low overall resistance frequency amongst 
agricultural isolates, with only 1-5% of isolates from 2016-2018 showing medical azole resistance – a 
rate lower than the 15-20% resistance frequency observed by the German National Reference Center 
for Invasive Fungal Infections during the same time period. Susceptibility to commonly-applied 
agricultural azoles was also assessed and isolates resistant to medical azoles almost always had 
elevated MICs to these agricultural azoles, suggesting cross resistance. Importantly, we observed an 
increased tolerance to both agricultural and medical azoles in the samples taken after the growing 
season and application of azoles. At the genome level, isolates from different regions and types of 
agriculture did not cluster separately, indicating a lack of population structure in the fungus. 
Comparison of environmental isolates with clinical isolates revealed several subgroups present in the 
environment that were not represented among clinical samples. We also observed differences in the 
distribution of resistance mutations between environmental and clinical isolates. Resistant 
environmental isolates were exclusively either wild type at the cyp51a loci or carried the 
environmentally-derived TR34/L98H mutation. Clinical isolates, in contrast, showed a much wider 
range mutations, including substitutions at positions F219, M220, S297, F495, and G448.Ongoing 
work is focused on defining fungal determinants critical for human infection as well as genetic 
mechanisms associated with cyp51a-independent azole resistance. 
Conclusion: We observed a marked reduction in A. fumigatus fields following azole application and 
increased azole tolerance after the growing season and azole exposure. No population structure was 
observed among environmental isolates, but whole genome phylogeny identified genetic 
backgrounds enriched for among clinical isolates. 
 
P042 
MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and 
anidulafungin and thirty-five uncommon pathogenic yeast species from the UK determined using 
the CLSI broth microdilution method 
A. Borman, J. Muller, J. Walsh-Quantick, A. Szekely, Z. Patterson, M. Palmer, M. Fraser, E. Johnson 
Public Health England UK National Mycology Reference Laboratory, Bristol, United Kingdom 
Objectives: Epidemiological cut-off values and clinical interpretive breakpoints have been developed 
for a number of antifungal agents with the most common Candida species which account for the 
majority of infections due to pathogenic yeasts species. However, less common species for which 
susceptibility data are limited are increasingly reported in high risk patients and breakthrough 
infections. 
Methods: The UK National Mycology Reference Laboratory performs routine antifungal 
susceptibility testing of clinical isolates of pathogenic yeast submitted from across the United 
Kingdom. Between 2002 and 2016, in excess of 32 000 isolates representing 94 different yeast species 
were referred to the laboratory. Here we present antifungal susceptibility profiles generated over this 
15 year period for amphotericin B, fluconazole, voriconazole, itraconazole, anidulafungin and 
flucytosine against 35 species of uncommon yeast. Minimum inhibitory concentrations (MICs) were 
obtained using CLSI broth microdilution methodologies, and MIC data was interpreted against 
epidemiological cut-off values and clinical breakpoints developed with Candida albicans, in order to 
identify species with unusually skewed MIC distributions that potentially indicate resistance. 
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Results: Potential resistance to at least one antifungal agent (>10% of isolates with MICs greater than 
the epidemiological cut-off or clinical breakpoint) was evidenced for 29/35 species examined here. 
Four species exhibited elevated MICs with all of the triazole antifungal drugs against which they 
were tested, and 21 species exhibited antifungal resistance to agents from at least 2 different classes 
of antifungal agent. 
Conclusion: The current study highlights the importance of rapid and accurate yeast identification, 
and provides data to aid clinicians in deciding which antifungal regimens are appropriate when 
confronted with infections with rarer yeasts. 
 
P043 
Case-series of Candida albicans and glabrata echinocandin-resistant candidemia in Switzerland 
A.T. Coste1, J. Li1, N. Khanna2, D. Goldenberger3, C. Garzoni4, Z. Zhender5, K. Boggian6, D. Neofytos7, 
A. Riat8, D. Bachmann1, D. Sanglard1, F. Lamoth9,10 
1Microbiology Institute, University Hospital Lausanne, University of Lausanne, Lausanne, 
Switzerland, 2Division Of Infectious Diseases And Hospital Epidemiology, University Hospital of 
Basel, Basel, Switzerland, 3University Hospital Basel, Clinical Microbiology Laboratory Medicine, 
Basel, Switzerland, 4Riva Caccia 1b, Lugano, Switzerland, 5SYNLAB Suisse SA, Bioggio, Switzerland, 
6Department Of Infectious Diseases, Cantonal Hospital of Saint Gallen, Saint Gallen, Switzerland, 
7Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland, 8Geneva University 
Hospitals, Service of Laboratory Medicine, Geneva, Switzerland, 9Microbiology Institute, University 
Hospital Lausanne, Lausanne, Switzerland, 10Infectious Diseases Service, CHUV, Lausanne, 
Switzerland 
Objectives: Echinocandin drugs (anidulafungin, caspofungin, micafungin) represent first-line 
therapy of candidemia. Echinocandin resistance, due to hotspot mutations in the target FKS gene, has 
emerged among C. glabrata and C. albicans, which is associated with poor outcome. Therefore, 
national surveillance programs of echinocandin resistance are mandatory. The aims of this study 
were: i) to assess the epidemiology of echinocandin resistance among C. albicans/glabrata in 
Switzerland, ii) to describe the characteristics of candidemic episodes due to echinocandin-resistant 
isolates, and iii) to assess the efficacy of high-dose echinocandin against echinocandin-resistant C. 
albicans in an invertebrate model of infection. 
Methods: Cases of candidemia attributed to C. albicans/glabrata resistant to echinocandins (CLSI 
criteria) were identified by: i) screening of a collection of Candida bloodstream isolates from the 
Fungal Infection Network of Switzerland (FUNGINOS) including all candidemic episodes from 26 
hospitals in Switzerland from 2004 to 2013, and ii) screening of the microbiology databases of the 
most important university hospitals from 2014 to 2018. Echinocandin-resistant Candida isolates were 
sent to the reference laboratory for antifungal susceptibility testing (CLSI protocol) and sequencing 
of FKS hotspots. Clinical data of candidemia were collected. In order to assess a possible efficacy of 
high-dose echinocandins against these isolates, we tested the efficacy of escalating anidulafungin 
doses in a Galleria mellonella model of invasive candidiasis with a C. albicans FKS mutant (S645P) 
compared to the wild-type SC5314 strain. 
Results: Seven cases of candidemia due to echinocandin-resistant C. albicans/glabrata were identified: 
2 from the 2004-2013 cohort (incidence 0.1%) and 5 from the microbiological database screening from 
2014 to 2018. Four infections were due to C. albicans and 3 to C. glabrata. Candidemia originated from 
urine (2 cases), intravascular catheter (2), gastro-intestinal tract (1) and primary bloodstream infection 
(1). All patients received previous echinocandin therapy with a median duration of 18 days (range 
11-60). Overall mortality was 43%. One patient (C. glabrata infection) was cured by caspofungin 
therapy despite in vitro resistance. Minimal inhibitory concentrations (MIC) ranges for anidulafungin, 
caspofungin and micafungin were: 2-4, 1->16 and 1-4 µg/mL, respectively. The following hotspot 
mutations were identified in C. albicans: S645P (n = 3) and R1361G (n = 1). Among C. glabrata, 2 isolates 
displayed the S663P mutation in FKS2, while no hotspot FKS mutation was recovered from one pan-
echinocandin resistant isolate. Because anidulafungin displayed some in vitro activity against C. 
albicans S645P mutant (MIC 2 µg/mL), we assessed its in vivo activity in a Galleria mellonella model of 
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infection (Figure 1). While a dose-dependent response was observed in C. albicans wild-type strain-
infected larvae, no effect was observed against the C. albicans FKS mutant despite high anidulafungin 
doses (12 mg/kg). 
 
Conclusion: Our analysis suggests an increase in echinocandin resistance among C. albicans/glabrata 
in Switzerland with 5 cases identified within the last 5 years, while only two cases were reported in 
a cohort including all candidemias from 2004 to 2013. Previous echinocandin exposure was observed 
in all cases. Our invertebrate model suggests that high-dose echinocandins are ineffective against C. 
albicans FKS mutants despite some level of in vitro activity. 
 
P044 
Aspergillus isolates from patients with chronic pulmonary aspergillosis mycologically and 
clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078) 
R. Rautemaa-Richardson1,2, C. Moore1,2, K. Rawson2, L. Novak-Frazer1,2, D. Angulo3, S. Barat3, M.D. 
Richardson1,2 
1Division Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, 
United Kingdom, 2Mycology Reference Centre, Excellence Center For Medical Mycology (ECMM), 
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom, 3Scynexis Inc, New Jersey, United States of America 
Objectives: Ibrexafungerp (formerly MK-3118, SCY-078) is a novel and structurally distinct 
triterpenoid glucan synthase inhibitor whose oral availability and efficacy has already been 
demonstrated against a wide spectrum of Candida species. Currently the drug is being evaluated for 
efficacy in invasive and chronic pulmonary aspergillosis. Ibrexafungerp has been shown to be 
effective in vitro and in vivo against a broad range of Aspergillus species, including drug-resistant 
strains. In vitro activity is an important efficacy indicator of therapeutic success or failure. The 
objective of this study was to determine the activity of Ibrexafungerp against a panel of Aspergillus 
strains isolated from the respiratory tract of patients unresponsive to or failing azole therapy, and 
which were previously shown to be resistant to one or more azole antifungals (itraconazole, 
voriconazole, posaconazole and isavuconazole) using the EUCAST E.Def 10.1 standard. 
Methods: Patients failing azole therapy for chronic pulmonary aspergillosis were identified in the 
weekly departmental multi-disciplinary team meetings and their isolates selected for Ibrexafungerp 
sensitivity testing. Twenty-two Aspergillus fumigatus complex, three A. flavus complex and one A. 
niger complex strains with varying degrees of resistance to one or more azole antifungals were tested 
by measuring the minimum effective concentration (MEC) for Ibrexafungerp following the EUCAST 
E.Def 10.1 standard. Where required, isolates were sequenced (using primers to the internal 
transcribed spacers (ITS), beta-tubulin (bt) and calmodulin (cal) genes) to identify to the species level. 
Results: The Ibrexafungerp MEC range for the 26 Aspergillus spp. isolates was 0.008 to 0.25 mg/l. 
Isolates that were deemed to be resistant to all azoles had an Ibrexafungerp MEC of 0.015 to 0.25 mg/l. 
One isolate that was resistant to all azoles and amphotericin B was sensitive to Ibrexafungerp (MEC 
0.125 mg/l). 
Conclusion: The exquisite in vitro activity of Ibrexafungerp against Aspergillus fumigatus, A. flavus 
and A. niger isolated from patients with chronic pulmonary aspergillosis suggests that this new 
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compound has potential for treating patients with this condition and similar manifestations of 
pulmonary aspergillosis. 
 
P045 
Analysis of the susceptibility pattern among Aspergillus isolates against the commonly used 
Antifungal agents in a tertiary care centre in South India. 
U. Almas Fathima1, A.J. Kindo1, S. Prasanna Kumar2, M. Thirunarayan3, V. Lakshmi Sree4 
1Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India, 2Ent, 
Sri Ramachandra Institute of Higher Education and Research, Chennai, India, 3Microbiology, Apollo 
Hospitals, Chennai, India, 4Microbiology, Apollo Speciality Hospital, Chennai, India 
Objectives: To do in vitro susceptibility testing and analyse the difference in the Antifungal 
susceptibility profile of Aspergillus isolates by Broth Microdilution method. 
Methods: Aspergillus grown from various clinical samples (Ear swab, Bronchial wash, Endotracheal 
Aspiration, Paranasal sinus, BAL, Sputum) was subcultured on Sabouraud’s Dextrose Agar/Oat meal 
Agar. Tease mount/Slide culture was done to study the morphological features of the hyphae, size , 
shape and arrangement of the conidia. Antifungal susceptibility testing(AFST) was done according 
to CLSI guidelines M38-A2 2008 documented reference method for Broth Microdilution Antifungal 
susceptibility of Filamentous fungi. Antifungal stock solutions of AmphotericinB, Voriconazole, 
Posaconazole, Itraconazole and Caspofungin was prepared in di-methyl sulfoxide and stored at -700 
C. RPMI medium was prepared , adjusted to pH 7 and filter sterilized. Sterility was checked and 
stored at 40 C. Dilution of the stock solution was done as per the guidelines. Inoculum was prepared 
by adjusting conidial suspension in sterile distilled water to 0.5 McFarland Turbidity standard; to 100 
µ l of drug solution, 100 µl of inoculum in RPMI 1640 medium was added. Test micro-titre plate was 
incubated for 48hrs at 350 C. Growth and sterility control wells were included in each test. AFST-
READING RESULT: For AmphotericinB, Voriconazole, Posaconazole, Itraconazole - MIC is the first 
well without visible growth. For Echinocandins, eg. Caspofungin- MEC is the point (lowest value) 
where a visible change in growth as compared to the positive growth is noted. 
Results: A total of 30 Aspergillus isolates were collected-Aspergillus niger(14), Aspergillus flavus(9), 
Aspergillus fumigatus(6) & Aspergillus terreus(1). The result was compiled based on mean MIC values 
of 21 isolates are as follows. 
 
The MIC values of other isolates and Amphotericin B is yet to be completed. 
Conclusion: The common Aspergillus species was Aspergillus niger which was obtained from Ear 
swab. The susceptibility profile showed high MIC for Itraconazole in case of Aspergillus niger and 
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high MIC for Itraconazole, Voriconazole and Posaconazole in case of Aspergillus flavus. For Aspergillus 
fumigatus no such high MIC was recorded. In case of Aspergillus terreus, being resistant in nature the 
low MIC is recorded only with Caspofungin. Due to less susceptibility of Aspergillus to the common 
Antifungal agents, it is important to perform antifungal susceptibility testing to reduce the morbidity 
and mortality in patients especially with Invasive Aspergillosis. 
 
P046 
CRISPR-Cas9 as a tool box to investigate antifungal resistance 
F. Morio1, L. Lombardi2, U. Binder3, C. Loge1, E. Robert1, C. Lass-Flörl3, G. Butler2, P. Le Pape1 
1Ea1155 Iicimed, Nantes University Hospital, NANTES, France, 2School Of Biomolecular And 
Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland, 3Department Of 
Hygiene, Microbiology And Public Health, Division of Hygiene and Medical Microbiology, Medical 
University Innsbruck, Innsbruck, Austria 
Objectives: Antifungal resistance in human pathogenic fungi is increasingly reported and a public 
health issue. Deciphering the mechanisms underlying drug resistance strongly relies on genetic 
manipulation techniques such as generating mutant strains carrying specific mutations or gene 
deletions. However, these processes have often been time-consuming and cumbersome in fungi. Over 
the last decade, the groundbreaking discovery of Clustered Regularly Interspaced Short Palindromic 
Repeats and the associate protein Cas9 (CRISPR-Cas9) revolutionized genome editing. We evaluated 
the potential of a CRISPR-Cas9 method, as a tool to perform precise genome editing of the ERG11 
gene in the context of azole resistance. 
Methods: A new plasmid-based and marker-less CRISPR-Cas9 genome-editing method, recently 
developed for Candida parapsilosis (1), was used to investigate the potential contribution to azole 
resistance of two different single nucleotide polymorphisms (G1126A and G1372A), leading to amino 
acid substitutions (L376I and G458S, respectively) in the ERG11 gene, identified in an azole-resistant 
clinical isolate of Candida orthopsilosis. These mutations were introduced by homology directed 
recombination (HDR) using a donor template into a fluconazole-susceptible C. orthopsilosis 
background isolate. In vitro susceptibility of the transformants displaying the expected mutations 
(two clones for each engineered mutation) to azoles was then performed. 
Results: This approach allowed us to engineer both mutations in the fluconazole-susceptible 
background isolate. Though engineering L376I was straightforward, editing G458S required the 
addition of silent mutations within the core of the Cas9 recognition site to prevent Cas9 from recutting 
again. Eventually, in vitro susceptibility testing of the corresponding transformants demonstrated 
that G458S, but not L376I, confers resistance to fluconazole (MIC increased by 8-fold by introducing 
the homozygous mutation) and also affected voriconazole susceptibility. Importantly, after 3 
passages on YPD at 30°C, transformants were not resistant to nourseothricin (selection marker) 
anymore, showing the rapid loss of the plasmid containing all the CRISPR-Cas9 components, thus 
proving that it did not integrate in the genome. 
Conclusion: Our work supports the contribution of G458S but not L376I in fluconazole and 
voriconazole resistance in C. orthopsilosis (2). Besides these findings, this study highlights CRISPR-
Cas9 genome editing as a powerful tool to streamline the study of antifungal resistance in human 
pathogenic fungi. Though critical points should be considered (e.g. HDR drops with cut-to-mutation 
distance), this approach paves the way for an easier screening approach of any SNP, occurring in any 
gene suspected to be involved in antifungal resistance. 1-Lombardi et al., Plasmid-Based CRISPR-
Cas9 Gene Editing in Multiple Candida Species. mSphere. 2019 Mar 13;4(2). pii: e00125-19. doi: 
10.1128/mSphere.00125-19. 2-Morio et al., Precise genome editing using a CRISPR-Cas9 method 
highlights the role of CoERG11 amino acid substitutions in azole resistance in Candida orthopsilosis. J 
Antimicrob Chemother. 2019 May 18. pii: dkz204. doi: 10.1093/jac/dkz204. 
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Changes in the lipid microenvironment of β-(1,3)-D-glucan synthase of Aspergillus fumigatus is a 
new clinically important echinocandin resistance mechanism 
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S. Satish1, C. Jimenez-Ortigosa1, Y. Zhao1, M.H. Lee1, E. Dolgov1, T. Kruger2, S. Park1, D. Denning3, O. 
Kniemeyer2, A. Brakhage2, D.S. Perlin1 
1Center For Discovery And Innovation, Hackensack Meridian Health, Nutley, United States of 
America, 2Leibniz Institute for Natural Product Research and Infection Biology (HKI), Jena, Germany, 
3University of Manchester, Manchester, United Kingdom 
Objectives: Aspergillus fumigatus is a leading cause of opportunistic invasive fungal infections. 
Resistance to first-line triazole antifungals has led to therapy with echinocandin drugs. Recently, we 
identified several high Minimum Effective Concentration (MEC) A. fumigatus clinical isolates from 
patients failing echinocandin therapy. Echinocandin resistance in Candida is known to arise from 
amino acid substitutions in β-(1,3)-D-glucan synthase encoded by the fks1 gene. Yet, these clinical 
isolates did not contain mutations in fks1, indicating an undefined resistance mechanism. The 
objective of this study was to explore a novel mechanism of echinocandin resistance independent of 
fks1 mutations. 
Methods: To explore this new mechanism, we used a lab-derived strain, RG101, which does not 
contain fks1 mutations but is resistant to caspofungin (CAS). Inhibition of glucan synthase enzyme 
isolated from RG101 grown in the absence and presence of CAS was determined in vitro using 
radioactive substrate and IC50 (drug concentration required for 50% reduction of activity) values were 
measured. Post-translational modifications (PTMs) potentially leading to resistance was explored by 
evaluating enzyme derived from RG101 grown in the absence and presence of CAS (1 µg/mL) using 
nano LC-MS/MS. A comprehensive lipidomics analysis was also performed to compare lipid profiles 
of glucan synthase containing fractions derived from RG101 grown in the absence and presence of 
CAS (1 µg/mL) using LC-MS/MS. To measure Reactive Oxygen Species (ROS) levels induced by 
different echinocandins, a 2’,7’-dichlorofluorescin diacetate (DCFDA)-based fluorescence assay was 
used, and ROS levels measured after one hour of drug exposure. 
Results: Glucan synthase isolated from RG101 was fully sensitive to echinocandins. Yet, exposure of 
RG101 to CAS during growth yielded a modified enzyme that was drug insensitive (4 log-orders) in 
kinetic inhibition assays, and this insensitivity was also observed for enzymes isolated from clinical 
isolates. To understand this alteration, we analyzed whole enzyme post-translational modifications, 
but found none linked to resistance. However, analysis of the lipid microenvironment of CAS-
induced resistant enzyme revealed a prominent increase in abundance of dihydrosphingosine 
(DhSph) and phytosphingosine (PhSph). Exogenous addition of DhSph and PhSph to sensitive 
enzyme recapitulated the drug insensitivity of the CAS-derived enzyme. Further analysis 
demonstrated that CAS induces mitochondrial-derived ROS, and dampening ROS formation by 
antimycin A or thiourea eliminated drug-induced resistance. 
Conclusion: We conclude that CAS-induces cellular stress, promoting formation of ROS, triggering 
an alteration in the composition of plasma membrane lipids within the local environment of glucan 
synthase, rendering it insensitive to echinocandins. We have discovered a new mechanism of 
resistance in A. fumigatus independent of the well-characterized FKS mutation mechanism observed 
in Candida. This study also identifies an off-target effect of CAS, ROS production in A. fumigatus, and 
integrates oxidative stress and sphingolipid alterations into a novel mechanism of resistance. This 
stress-induced response has implications for drug resistance and/or tolerance mechanisms in other 
fungal pathogens. 
 
P048 
In vitro activity of fluconazole in combination with magnolol against Candida auris 
I. De-La-Fuente1, A. Matilla-Gutiérrez1, A. Guridi1, E. Sevillano1, J. Pemán2, E. Eraso1, G. Quindós1 
1Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), 
Bilbao, Spain, 2Servicio De Microbiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain 
Objectives: Candida auris is an emerging pathogen that causes outbreaks worldwide. This fungus is 
responsible for severe infections such as invasive candidiasis that present a high overall mortality. 
Treatment of these infections suppose a clinical challenge due to the high levels of multidrug-
resistance in C. auris, which makes the finding of new therapeutic alternatives an important issue. 
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Combination of fluconazole with different natural compounds has shown to be effective against 
fluconazole-resistant Candida isolates. For this reason, the aim of this study was to assess the in vitro 
interaction between fluconazole and magnolol, a polyphenol extracted from Magnolia officinalis, or 
epigallocatechin gallate (EGCG), a polyphenol obtained from Camellia sinensis, against clinical isolates 
of C. auris. 
Methods: We studied 21 C. auris isolates from different clinical specimens (seven from blood, seven 
from oropharynx and six from urine). Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 
were used as quality controls. Different fluconazole combinations with magnolol or EGCG were 
studied. Fluconazole concentrations were selected according to the minimum inhibitory 
concentration (MIC) determined by the European Committee on Antibiotic Susceptibility Testing 
(EUCAST) EDef 7.3.1 document. MIC was defined as the lowest drug concentration causing 50% 
growth reduction after 24 h of incubation. Magnolol and EGCG concentrations ranged from 0.125 to 
64 μg/mL. The interaction between fluconazole and magnolol or EGCG were assessed by a 
checkerboard microdilution method. In vitro interactions of drug combinations were interpreted in 
terms of fractional inhibitory concentration index (FICI) as follows: FICI ≤ 0.5, synergistic; 0.5 < FICI 
≤ 1, additive; 1 < FICI ≤ 4, indifferent and FICI > 4 antagonistic. 
Results: Fluconazole MIC range against C. auris was 64 to > 64 μg/mL and magnolol MIC range 16 to 
> 64 μg/mL; however, combination of both drugs reduced the concentrations necessary for inducing 
50% reduction in the growth of the isolates. The effect of the combination of fluconazole with 
magnolol against seven isolates (33.3%) was interpreted as additive. The effect against the other 14 
isolates was interpreted as indifferent, although the fluconazole MICs decreased to 1-16 μg/mL. The 
combination of fluconazole with EGCG was indifferent against all isolates and did not have any 
influence in the MICs of fluconazole. 
Conclusion: The combination of fluconazole with magnolol significantly reduced the fluconazole 
MICs against all of the C. auris isolates, showing additive effect in seven of them. The combination of 
fluconazole with EGCG showed indifferent effect. Funding: This work was co-supported by the 
Consejería de Educación, Universidades e Investigación (GIC15/78 IT-990-16) of Gobierno Vasco-
Eusko Jaurlaritza. 
 
P049 
Resistance to medical importance antifungals in environmental yeasts 
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S. Rios3, D. Heidrich4, A. M. Fuentefria2, P. Valente Da Silva2 
1Department Of Microbiology, Immunology And Parasitology, Universidade Federal do Rio Grande 
do Sul, Porto Alegre, Brazil, 2Postgraduate Program In Agricultural And Environmental 
Microbiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Federal University 
of Rio Grande do Sul, Porto Alegre, Brazil, 4Postgraduate Program In Medicine: Medical Sciences, 
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil 
Objectives: The aim of the study was to investigate the presence of potentially pathogenic yeasts 
from a lagoon in South America. 
Methods: The lagoon was sampled in the summer of 2019. The water samples were inoculated in 
acidified YM agar medium (1% glucose, 0.5 % peptone, 0.3 % malt extract, 0.3 % yeast extract, 2 % 
agar) and incubated at 25 ºC for 30 days. Representative yeast colonies were selected and stored in 
YM medium with 30 % of glycerol at -20 ºC and in GYMP agar medium (2 % glucose, 2 % malt extract, 
0.5 % yeast extract, 0.2 % monobasic sodium phosphate, 2 % agar) agar slants coated with mineral 
oil, maintained at 4 °C. We tested 8 environmental yeast strains. The antifungal susceptibility test was 
performed according to CLSI protocol, to select yeasts with possible resistance to clinical importance 
antifungals. The yeasts were tested in the antifungal concentrations established for Candida species 
against fluconazole, caspofungin and amphotericin B. 
Results: Four isolates had MIC ≥ 64 μg/mL to fluconazole, none of them were susceptible to 
caspofungin, with MIC ≥ 2 μg/mL. To amphotericin B, six strains had MIC ≥ 1μg/mL. Three isolates 
were considered resistant to all tested antifungals, following the guidelines for Candida species. 
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Conclusion: The preliminary findings feature this lagoon environment as a possible resistance genes 
reservoir and fungal infection source. Further studies are needed to have a better understanding of 
this environment and the fungal resistance. 
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A natural substitution in FksB Hot Spot 2 of Saprochaete capitata probably related to reduced 
susceptibility to echinocandins 
P. Menéndez-Manjón1, I. Arrieta-Aguirre1, M.S. Cuétara2, L. López-Soria3, J.C. García-Ruiz4, M.D. 
Moragues1 
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Ochoa, Leganés, Madrid, Spain, 3Microbiologia, Hospital Universitario Cruces, Barakaldo, Spain, 
4Biocruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain 
Objectives: Saprochaete capitata is an emerging opportunistic pathogen reported in patients with 
haematological malignancies. Antifungal clinical breakpoints are not established and therapy 
remains empirical. S. capitata shows reduced susceptibility to echinocandins, which inhibit the 
enzyme β-1,3-D-glucan synthase (Fks) involved in the cell wall synthesis. Resistance to echinocandins 
is linked to mutations in two highly conserved regions of Fks, Hot Spot 1 (HS1) and Hot Spot 2 (HS2). 
We already reported a natural substitution F-to-L in Fks-HS1 that might be linked to this fungus low 
susceptibility to echinocandins (Arrieta-Aguirre et al., 2018). Mutations in HS2 have also been related 
to reduced susceptibility to echinocandins. Therefore, we resolved to sequence HS2 of S. capitata and 
search for mutations that could be related to echinocandin resistance. 
Methods: DNA of 11 strains of S. capitata was extracted by mechanical cell disruption and purified 
with the DNeasy Plant Mini Kit (Qiagen). Since HS1 and HS2 are around 2500 bp apart, we applied 
a primer walking strategy of smaller fragments sequencing to locate them. With a specific primer 
from the HS1 sequence and a degenerate primer designed for the HS2 region, we obtained an 
amplicon for one of the strains that allowed us to design downstream specific primers that led us to 
HS2. Finally, we designed specific primers to sequence HS2 in the rest of the strains and the sequences 
were compared with other fungal species. 
Results: The alignment of Fks-HS2 of S. capitata and other species revealed a natural substitution R-
to-Q in the fourth position of HS2. The recently published genome of S. capitata reveals two Fks, FksA 
and B. Our sequence corresponds to FksB, which is more similar to Fks2 than Fks1 of other species. 
In C. glabrata, when R in the fourth position of Fks2-HS2 is modified it results in a deep decrease in 
the susceptibility to echinocandins (Jensen, 2016). Therefore, the natural substitution R-to-Q in FksB-
HS2 of S. capitata could be related to resistance. 
Conclusion: S. capitata has at least two natural substitutions (F-to-L in Fks-HS1 and R-to-Q in Fks-
HS2) that may be involved in its reduced susceptibility to echinocandins. However, the effect of both 
substitutions still needs to be verified empirically. This work contributes to understanding the 
molecular basis of antifungal resistance of this fungus and may help to improve its treatment. 
Financial support: Grupos de Investigación Consolidados of the Basque Government (GIC15/103; 
IT913-16) and Grant FPI of the Basque Government to PM-M. 
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Fluconazole resistance in Candida tropicalis blood stream isolates collected from 16 Brazilian 
Medical Centers 
A. Melo1, D. Da Matta1, L. Favarello1, C. Oliveira2, T. Sukiennik3, F. Telles4, M. Nucci5, A. Colombo1 
1Medicine, Federal University of São Paulo, São Paulo, Brazil, 2Medicine, Hospital Universitário do 
Oeste do Paraná, Cascavel, PR, Cascavel, Brazil, 3Medicine, Santa Casa de Porto Alegre, Porto Alegre, 
RS, Porto Alegre, Brazil, 4Medicine, Hospital de Clínicas da Universidade Federal do Paraná UFPR, 
Curitiba PR, Curitiba, Brazil, 5Medicine, Hospital Universitário da Universidade Federal do Rio de 
Janeiro, Rio de Janeiro RJ, Rio de Janeiro, Brazil 
Objectives: C. tropicalis is highly prevalent among episodes of candidemia in Latin America. The 
progressive use of fluconazole and other triazoles in regimens of prophylaxis and empirical therapy 
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in high-risk patients has led to selective pressure and emergence of secondary resistance among 
Candida spp. The aim of this study was to check for temporal trends in the rates of azole resistance 
among C. tropicalis blood stream isolates collected from patients assisted at 16 Brazilian medical 
centers at any time within 2007 and 2018. 
Methods: We selected isolates of C. tropicalis stored at the culture collection of Laboratório Especial 
de Micologia (LEMI) – Universidade Federal de São Paulo, Brazil, that were obtained from 
candidemic patients admitted in 16 medical centers along the period of study. The isolates were 
identified at species level by Matrix-Assisted Laser Desorption Ionization-Time of Fligh Mass Spectrometry 
(MALDI TOF MS). In vitro antifungal susceptibility tests to fluconazole and voriconazole were 
evaluated by the Clinical & Laboratory Standards Institute (CLSI ) microbroth method (documents 
M27-A3 and M27-S4). For quality control of in vitro assays we used the reference strains C. parapsilosis 
ATCC 22019, C. krusei ATCC 6258 and C. tropicalis ATCC 750. 
Results: In order to check for historical trends of azole resistance among C. tropicalis isolates, we 
compared the MIC values generated with fluconazole and voriconazole against 200 blood stream 
isolates collect at any time within two different periods: P1 (2007-2012) versus P2 (2013-2018). 
Statistical differences were checked by student T Test. After testing all 200 isolates, 3.5% of C. tropicalis 
strains were considered to be non-susceptible to azoles. As illustrated bellow, we found resistance 
rates of C. tropicalis against fluconazole of 1.9% and 3.2% in P1 and P2, respectively (p>0.05). In regard 
to voriconazole, resistance rates of 0 and 1% were documented in P1 and P2, respectively (p>0.05). 
Conclusion: After testing 200 blood stream isolates of C. tropicalis we identified a rate of 3.5% of 
isolates exhibiting limited susceptibility (SDD/R) to fluconazole and/or voriconazole. Otherwise, we 
were not able to demonstrate any historical trend in terms of increasing rates of azole resistance 
among C. tropicalis isolates collected along the 2 periods of study. 
 
P053 
Evaluation of spectrophotometric reading of EUCAST antifungal susceptibility testing of 
Aspergillus fumigatus 
G. Jan1, L. Kristensen2, I. Bach Bentsen2, M. Nielsen2 
1Department Of Clinical Microbiology, Aarhus University Hospital, Aarhus N, Denmark, 
2Department Of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark 
Objectives: The rise in azole resistance in Aspergillus fumigatus1 highlights the importance of 
antifungal susceptibility testing. While azole containing agar plates have been shown to have 
excellent sensitivity and specificity in detecting azole resistance2, access to MIC testing is still 
important. As commercially available methods have serious limitations reference broth microdilution 
is the only feasible option at present. The EUCAST method for antifungal susceptibility testing of 
moulds relies on visual reading of MICs which is laborious and time-consuming. A recent study3 
suggests that spectrophotometric determination of MICs of azoles may improve objectivity and allow 
automatisation of the EUCAST E.Def 9.3 method. The scope of this study is to evaluate the 
spectrophotometric metod in our center using seven antifungal drugs. 
Methods: 22 clinical isolates from A. fumigatus species complex were selected for the study. 9 isolates 
were resistant to at least one azole while 13 were wild type. All isolates were tested against 
itraconazole, voriconazole, isavuconazole, posaconazole, amphotericin B, natamycin and terbinafine 
using EUCAST E.Def 9.3. Visually determined MICs were read at complete inhibition of growth. 
Spectrophotometric reading was performed using a Thermo Multiskan FC microplate reader with a 
492 nm filter. The OD values of the negative control wells were subtracted from all wells and MICs 
were determined as the lowest concentration corresponding to either 5% growth compared to the 
drug free control or as 0.02 OD values above background. 
Spectrophotometrically determined MICs were compared to visually determined MICs. For all drugs 
the quantitative agreement within 0, 1 and 2 two-fold dilutions was calculated. For itraconazole, 
voriconazole, isavuconazole, posaconazole and amphotericin B categorical agreement was calculated 
using EUCAST Clinical breakpoints for fungi v. 9.0. 
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Results: 
Results are shown in Table 1. When using the 5% growth endpoint we found a high level of essential 
agreement (95-100%) for all drugs and a high level of categorical agreement (86-95%) for itraconazole, 
voriconazole, isavuconazole, posaconazole and amphotericin B. Of importance no major or very 
major errors was observed. When using the 0.02 OD values above background endpoint however we 
found only 64% essential agreement for terbinafine and a categorical agreement of 68% for 
posaconazole including 5% very major errors. 
Conclusion: Spectrophotometric determination of MICs using the EUCAST E-Def 9.3 for A. 
fumigatus species complex appears to be a promising method for all tested drugs. Highest agreement 
between visual and spectrophotometric MICs is obtained using the 5% growth endpoint. References 
1. van der Linden J et al. Prospective Multicenter International Surveillance of Azole Resistance in 
Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041-1044. 2. Arendrup MC et al; Multicentre 
validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-
resistant Aspergillus fumigatus, Journal of Antimicrobial Chemotherapy, Volume 72, Issue 12,Pages 
3325–3333 3. Meletiadis, J. et al., Spectrophotometric reading of EUCAST antifungal susceptibility 
testing of Aspergillus fumigatus, Clinical Microbiology and Infection, Volume 23, Issue 2, 98 - 103 
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Molecular mechanism and frequency of olorofim resistance in Aspergillus fumigatus 
J. Buil1, J. Oliver2, D. Law2, M. Tehupeiory-Kooreman1, J. Rex2, M. Hokken1, W. Melchers1, M. Birch2, 
P.E. Verweij1 
1Medical Microbiology, Radboudumc, Nijmegen, Netherlands, 2F2G Ltd, Manchester, United 
Kingdom 
Objectives: Olorofim (OLO) is a new antifungal agent with a novel mechanism of action, targeting 
dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway. It is active 
against both azole-susceptible and azole-resistant strains of Aspergillus fumigatus. Thus, OLO may be 
an important treatment option in patients with Aspergillus disease, including azole-resistant cases. 
Azole resistance selection occurs in >10% of patients with chronic pulmonary aspergillosis during 
itraconazole (ITZ) therapy. In this study, we analysed the frequency of resistance mutation induction 
of OLO in A. fumigatus in three different strains using two different methods. The underlying OLO 
resistance mechanism was also investigated. 
Methods: Method 1: From two A. fumigatus isolates, AZN 8196 and V139-36, 10 single colonies were 
separately inoculated onto Sabouraud agar and incubated at 37°C for 96h. From each culture 1 x 108 
conidia were applied to 6 RPMI agar plates containing either 0.5 mg/L OLO or 8 mg/L ITZ.. Plates 
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were incubated at 37°C for up to 7 days. Colonies growing on drug-containing plates were 
subcultured on RPMI agar containing 0.5 mg/L OLO or 8 mg/L ITZ to confirm resistance. Method 2: 
Spore stocks of A. fumigatus strain Af293 were prepared and inoculated onto yeast nitrogen base with 
glucose agar (YNBG) containing 0.25 mg/L OLO. A total of 8 x 109 spores were inoculated into 12 x 
100 ml YNBG-OLO agar plates that were subsequently incubated for 5 days at 35°C. Colonies 
growing on drug-containing plates were subcultured on YNBG-OLO to confirm resistance. The mean 
rate of resistance was calculated for each isolate. The pyrE gene which codes for DHODH was 
sequenced for initial OLO-susceptible strains and -resistant progeny isolates and analysed for 
mutations. 
Results: Method 1: The resistance rate of OLO was 1 in 5 x 107 (frequency of 2 x 10-8) for AZN 8196 
compared to 1 in 5 x 106 (2 x 10-7) for ITZ. For V139-36 the resistance rate of OLO was 1 in 9 x 107 (1.1 
x 10-8) while the rate for ITZ was 1 in 8 x 106 (1.3 x 10-7) Method 2: Resistance to OLO in Af293 occurred 
at a rate of 1 in 6 x 108 (frequency of 1.7 x 10-9). Sequencing of pyrE revealed a hotspot for resistance 
mutations in the pyrE gene for OLO resistance in A. fumigatus at locus Gly119. Four amino acid 
substitutions were found; G119V, G119C, G119S and G119A. A single OLO-resistant mutant was 
obtained that carried the wild type DHODH sequence, but this mutant was slow growing compared 
with parent. 
Conclusion: We demonstrate that OLO resistance can be selected in A. fumigatus and can be mediated 
by mutations in the pyrE gene at locus G119. The frequency of resistance varied from approximately 
2 x 10-8 to 1.7 x 10-9 for spontaneous mutations. The resistance rate of OLO was 5 to 10-fold lower 
compared to ITZ. The low resistance rate found in these experiments indicates that resistance 
selection may be less frequent in patients with Aspergillus diseases treated with OLO. 
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Comparison of killing activity of rezafungin, anidulafungin, caspofungin and micafungin against 
Candida auris in the presence and absence of serum 
Z. Tóth1, L. Forgács1, J.B. Locke2, G. Kardos1, F. Nagy1, R. Kovács1, A. Borman3, L. Majoros1 
1Department Of Medical Microbiology, University of Debrecen, Debrecen, Hungary, 2Cidara 
Therapeutics, San Diego, United States of America, 3Public Health England UK National Mycology 
Reference Laboratory, Bristol, United Kingdom 
Objectives: Candida auris is an emerging, difficult-to-treat multiresistant pathogen against which 
echinocandins are the recommended standard-of-care treatment. Rezafungin is a next-generation 
echinocandin with similar in vitro activity to existing echinocandins yet it attains much higher in vivo 
concentrations and exposures due to its extended half-life and front-loaded dosing paradigm. 
Because in vitro killing data with existing echinocandins are limited against C. auris and are lacking 
for rezafungin, we compared rezafungin to anidulafungin, caspofungin,and micafungin in time-kill 
assays against C. auris isolates in standard RPMI-1640 medium and also investigated the impact of 
serum on in vitro killing trends. 
Methods: Two C. auris clinical isolates from each clade (Japanese/Korean, South Asian/Indian and 
South African, obtained from the National Mycology Reference Laboratory, UK) were tested. Both 
South African isolates were autoaggregative. MICs in RPMI-1640 +/-50% human serum were 
determined using the standard broth macrodilution method (CLSI M27 Ed4). Time-kill studies with 
the four echinocandins were performed from 0.25 to 32 mg/L in both media, and killing rates were 
compared. Positive k values indicate killing; negative values indicate growth. 
Results: MIC values were higher in 50% serum than in RPMI-1640 alone (Table 1). In RPMI-1640, at 
1xMIC or higher concentrations all four echinocandins showed only fungistatic effect. The highest k 
value with rezafungin (1.34 1/h) was at 32 mg/L against isolate 209. However, none of the 
echinocandins produced any CFU decrease against aggregating isolates (k values in cases of isolates 
2 and 204 were always negative). Similar results were found in cases of caspofungin and micafungin 
against isolates 12, 15 and 27, and isolate 15, respectively. Re-growth was frequently observed for all 
four echinocandins. In 50% serum, growth rates were significantly lower. At 1xMIC or higher 
concentrations, echinocandins showed concentration-dependent killing activity, however, this CFU 
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reduction never reached the fungicidal threshold. The highest k values were 0.34, 0.33, 0.34 and 0.29 
1/h for rezafungin, anidulafungin, caspofungin and micafungin, respectively. However, k values 
were always negative at 1-32 mg/L, in the case of isolate 2 (an autoaggregative isolate) for all 
echinocandins and in cases of isolates 27 and 204 for caspofungin. Table 1. MIC values for rezafungin 
and echinocandin comparators against C. auris strains in the presence and absence of 50% serum 
 
Conclusion: Killing activity in RPMI-1640 alone was less consistently positive than in 50% serum and 
only fungistatic activity was detected. Aggregating isolates were less susceptible to echinocandins 
than non-aggregating isolates. Rezafungin showed the same or better activity than anidulafungin 
and micafungin at clinically attainable concentrations. The trend towards stronger killing activity in 
the presence of serum helps to account for the disconnect between the modest time-kill activity of 
echinocandins in vitro versus their strong efficacy against C. auris in vivo, as rezafungin has previously 
demonstrated in animal models. 
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Frequency of paradoxical and trailing effects with rezafungin, anidulafungin, caspofungin and 
micafungin against Candida species 
L. Forgács1, Z. Tóth1, J.B. Locke2, F. Nagy1, B. Balázs1, E. Prépost1, G. Kardos1, R. Kovács1, A. Szekely3, 
A. Borman3, L. Majoros1 
1Department Of Medical Microbiology, University of Debrecen, Debrecen, Hungary, 2Cidara 
Therapeutics, San Diego, United States of America, 3Public Health England UK National Mycology 
Reference Laboratory, Bristol, United Kingdom 
Objectives: Currently, echinocandins are the first-line agents for treatment of invasive Candida 
infections. Echinocandins demonstrate excellent efficacy and fungicidal activity against Candida 
species in vivo. However, echinocandins can exhibit some disconnected growth phenomena in vitro, 
such as paradoxical effect (PE) where activity decreases at higher drug concentrations and the trailing 
effect (TE) where complete growth inhibition is never achieved or occurs at dilutions well above the 
50% endpoint used to determine MIC values. PE and TE can significantly alter the 
determination/interpretation of MIC values and impact other in vitro assays. Rezafungin is a next-
generation echinocandin capable of attaining high concentrations and exposures in vivo, exceeding 
those measured for the three approved echinocandins, due to its long half-life and front-loaded 
dosing regimen. Given the relevance of evaluating higher drug concentrations for rezafungin and 
that rezafungin PE/TE trends have not yet been characterized, herein we compared the occurrence of 
PE and TE for rezafungin with data generated in parallel for caspofungin, micafungin and 
anidulafungin against clinically important Candida species. 
Methods: We tested 365 non-duplicate Hungarian clinical isolates belonging to 13 species (see Table). 
Isolates were collected between 2005 and 2018 and were identified with MALDI Biotyper (Bruker, 
Bremen, Germany). C. auris were obtained from National Mycology Reference Laboratory, UK. MICs 
were determined by BMD method according to CLSI (M27 Ed4) in RPMI-1640. Concentration ranges 
of antifungals were 0.06-32 mg/L. PE was defined as visible growth occurring at higher but not at 
lower supra-MIC concentrations. TE was defined when yeasts show reduced but observable growth 
in supra-MIC concentrations. 
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Results: The percentages of isolates showing PE or TE after 48 hours are shown in the Table. 
Cumulative percentage of PE plus TE was the highest for caspofungin (47.7%), followed by 
anidulafungin (35.9%), micafungin (25.8%) and rezafungin (17.7%). PE was observed most frequently 
for caspofungin (31.4%) but was uncommon for rezafungin (3.1%). PE with caspofungin, micafungin 
or anidulafungin occurred most frequently in cases of C.tropicalis, C. albicans, C. orthopsilosis and C. 
inconspicua but was never found incase of C. krusei. The majority of C. auris and C. dubliniensis isolates 
showed TE for all four echinocandins. Table. Percentages of Candida spp. isolates demonstrating 
paradoxical effect (PE) or trailing effect (TE)
 
Conclusion: PE or TE was widely observed among Candida species and were echinocandin- and 
species-dependent. PE was frequently found with caspofungin, micafungin and anidulafungin but 
not with rezafungin. This study is the first to characterize PE and TE trends for rezafungin and helps 
to inform future in vitro work with this novel echinocandin. 
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In vitro antifungal susceptibility testing of cryptic species of Aspergillus: a multi-centre study 
S. Imbert1, A.C. Normand2, F. Gabriel3, C. Bonnal4, L. Lachaud5, D. Costa6, S. Cassaing7, L. Hasseine8, 
L. Kristensen9, C. Schuttler10, H. Raberin11, S. Brun12, R. Piarroux1, A. Fekkar1 
1Laboratoire De Parasitologie-mycologie, APHP La Pitié Salpétrière, PARIS, France, 2Ap-hp, Groupe 
Hospitalier Pitié-salpêtrière, Service de Parasitologie Mycologie, Paris, France, 3Parasitology 
Mycology, CHU de Bordeaux, Bordeaux, France, 4Laboratoire De Parasitologie Mycologie, Hôpital 
Bichat-Claude Bernard, 46 rue Henri Huchard, PARIS, France, 5Laboratoire De Parasitologie-
mycologie, CHU de Montpellier, Montpellier, France, 6Laboratoire De Parasitologie-mycologie, CHU 
de Rouen, Rouen, France, 7CHU de Toulouse, Toulouse, France, 8Laboratoire De Parasitologie 
Mycologie, CHU DE NICE, NICE, France, 9Department Of Clinical Microbiology, Aarhus University 
Hospital, Aarhus, Denmark, 10Laboratoire BioParisOuest, Levallois Peret, France, 11CHU Saint 
Etienne, Saint Etienne, France, 12Parasitology-mycology, Avicenne Hospital, Bobigny, France 
Objectives: In recent years, Aspergillus species taxonomy has been revolutionized with the 
introduction of the concepts of cryptic species and species complex. However, these “new” species 
remain usually rare and their characteristics, including antifungal susceptibility, are little known. 
Thus, the aim of this study was to collect a large number of isolates per cryptic species and to assess 
their antifungal susceptibility. 
Methods: From September 2017, users of the MSI application, a free online MALDI-TOF mass-
spectrometry database, were asked to send to our University Hospital, isolates they identified as 
cryptic species of Aspergillus. Identification at the species level was confirmed by sequencing a part 
of beta-tubulin and calmodulin genes. Antifungal susceptibility for azole drugs (itraconazole, 
voriconazole, posaconazole and isavuconazole) and amphotericin B was assessed by EUCAST broth 
microdilution reference method. 
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Results: During the study period, 192 isolates were collected from 11 centers in France and Denmark 
and were assessed for antifungal susceptibility. According to sequence-based identification, isolates 
corresponded to 43 species, belonging to 6 species complexes. Nidulantes species complex was the 
most represented (53 isolates, 12 species), followed by the species complexes Circumdati (43 isolates, 
10 species) and Fumigati (40 isolates, 8 species). The last species complexes represented were Usti (23 
isolates, 4 species), Flavi (19 isolates, 5 species) and Terrei (14 isolates, 4 species). Regarding the 3 main 
species complexes, diversity in antifungal susceptibility between cryptic species was observed. 
Indeed, inside the Fumigati complex A. thermomutatus, A. lentulus, A. udagawae, A. fischeri and (15, 7, 
3 and 3 isolates respectively) showed pan-azole high minimal inhibitory concentrations (MICs), 
whereas A. hiratsukae (8 isolates) showed low MICs. All these species had low MICs for amphotericin 
B, except A. lentulus with MICs ³4 mg/L. Regarding the Circumdatispecies complex, A. westerdijkiae (12 
isolates) showed the highest MICs for amphotericin B (> 16 mg/L), whereas A. sclerotiorum (17 
isolates) showed lower MICs (MIC50 = 4 mg/L). In contrast A. sclerotiorum showed pan-azole high 
MICs, whereas azole MICs where much lower for A. westerdijkiae. Finally, inside the 
Nidulantescomplex, all species showed low MICs for all drugs, except A. creberand A. unguis (6 and 2 
isolates respectively) which showed high MICs (> 8 mg/L) for itraconazole only. MICs regarding the 
3 other species complexes studied are shown in table 1. 
 
Conclusion: This study brings evidence on the diversity of antifungal susceptibility pattern inside 
the same species complex. However, including more isolates is needed to confirm these preliminary 
results. Nevertheless, this underline the importance of an accurate and easy-to-perform identification 
of Aspergillus at the species level for the management of Aspergillus diseases and the conduct of 
epidemiological studies. 
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France, 12Laboratoire BioParisOuest, Levallois Peret, France, 13Parasitology-mycology, APHP, hôpital 
St Antoine, Paris, France, 14Laboratoire Parasitology Mycology, CHU Dijon, Dijon, France, 
15Dianalabs, Geneve, Switzerland, 16synlab, Lucerne, Switzerland, 17Department Of Clinical 
Microbiology, Aarhus University Hospital, Aarhus, Denmark, 18Laboratory Of Mycology And 
Parasitology, University Hospital of Lille, Lille Cedex, France, 19Clinical Microbiology, Karolinska 
University Hospital, karolinska Institutet, Stockholm, Sweden, 20AZ Roeselare, Roeselare, Belgium, 
21Mycology, Scientific Institute of Public Health, Brussels, Belgium 
Objectives: Fungi belonging to the genus Fusarium are responsible of a large number of infections 
that may be difficult to treat because of a low susceptibility to antifungal drugs available. However, 
in recent years, fungal taxonomy has been revolutionized with the introduction of the concepts of 
cryptic species and species complex. This is particularly true for the genus Fusarium, which taxonomy 
remains partially unclear. In consequence, pathogenicity and antifungal susceptibility specific to each 
Fusarium species is largely unknown. Thus, the aim of this study was to collect a large number of 
isolates per species, to collect clinical data on their pathogenicity and to assess their antifungal 
susceptibility. 
Methods: During 1 year (January-December 2018), users of the MSI application, a free online MALDI-
TOF mass-spectrometry database, were asked when they identified a Fusarium sp. to send 
prospectively to our University Hospital laboratory the isolates and to collect clinical data. 
Identification at the species level was confirmed by sequencing a part of TEF1α gene. Antifungal 
susceptibility for azole drugs (voriconazole, posaconazole and isavuconazole), terbinafin and 
amphotericin B was assessed by measuring minimal inhibitory concentrations (MICs) by EUCAST 
broth microdilution reference method. 
Results: During the study period, 145 isolates from 20 centers in 6 European countries were collected. 
According to sequence-based identification, 23 species were identified and were distributed in 6 
species complexes (SC) whose main ones are Fusarium oxysporum SC (FOSC, 54 isolates),Fusarium 
solani SC (FSSC, 48 isolates) and Fusarium fujikoroi SC (FFSC, 36 isolates). Regarding these 3 main 
species complexes, minimal inhibitory concentrations which inhibited 50% of our isolates (MIC50) 
were high for all azole drugs, FSSC showing the highest MICs for voriconazole. For amphotericin B, 
MIC50 were not high (1 mg/l) and no differences were observed between complexes. Finally, 
terbinafine susceptibility seemed to be related to the species complex. Indeed, FOSC and FSSC 
showed the highest MICs (MIC50 = 16 mg/l) whereas FFSC showed lower MICs (MIC50 = 2 mg/l). 
MICs results are shown in Table 1. 
 
Among isolates collected, clinical data were available for 117 isolates. They were responsible for 11 
invasive/disseminated infections, 19 keratitis and 40 superficial infections (34 onychomycosis and 6 
intertrigo). Sixteen isolates were considered as pulmonary airways colonization, whereas 31 were 
considered as culture contaminants. The three main species complexes identified in the study were 
represented in each category. 
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Conclusion: This study brings evidence on the diversity of Fusarium species implicated in human 
diseases and their differences in terms of in vitro antifungal susceptibility, mainly for terbinafin. This 
underlines the importance of an accurate and easy identification of Fusarium species, at least at the 
complex level, to improve therapeutic management of Fusarium-related diseases. 
 
P059 
Tacrolimus and not cyclosporin A or sirolimus interacts synergistically in vitro with isavuconazole 
against Aspergillus species 
P. Schwarz1,2, E. Dannaoui3,4 
1Department Of Internal Medicine - Respiratory And Critical Care Medicine, University Hospital 
Marburg, Marburg, Germany, 2Center For Invasive Mycoses And Antifungals, Philipps University 
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Mycologie, Paris, France, 4Working Group Dynamyc, Faculté de Médecine, Hôpital Henri Mondor, 
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Objectives: Invasive aspergillosis is a devastating disease in immunocompromised patients. It 
mostly affects patients with hematological malignancies, especially those with severe and prolonged 
neutropenia, but is also encountered in solid organ transplant recipients. Immunosuppressive agents 
are used as anti-rejection drugs in organ transplant patients, but besides their immunosuppressive 
activity, these drugs also possess intrinsic antifungal activity. The aim of the present study was to 
assess the in vitro interaction of the broad-spectrum azole isavuconazole with the calcineurin 
inhibitors (e.g. tacrolimus or cyclosporin A) or the mTOR pathway inhibitor (e.g. sirolimus) against 
the most important Aspergillus species responsible for human disease. 
Methods: A panel of 30 Aspergillus isolates belonging to 5 species responsible for human invasive 
aspergillosis was used for the experiments (10 Aspergillus fumigatus, 5 Aspergillus flavus, 5 Aspergillus 
terreus, 5 Aspergillus nidulans, and 5 Aspergillus niger). Combinations of isavuconazole with 
cyclosporine A, tacrolimus or sirolimus were tested by a broth microdilution checkerboard technique 
based on the EUCAST reference methodology. Plates were read spectrophotometrically, and 90% of 
inhibition was used as an endpoint for both, the drugs alone and in combination. Results were 
interpreted with the fractional inhibitory concentration index (FICI). Drug interactions were defined 
as synergistic (FICI≤0.5), indifferent (FICI>0.5≤4) or antagonistic (FICI>4). 
Results: Isavuconazole MICs ranged from 0.25 to 16 µg/ml. When tested alone, immunosuppressive 
drugs showed poor activity with MICs < 16 µg/ml for only 2, and 3 isolates for tacrolimus and 
cyclosporin A, respectively. Combinations of isavuconazole with tacrolimus, cyclosporine A or 
sirolimus were synergistic for 53, 20, and 10% of the tested isolates, respectively. There were some 
differences between species (Table). Antagonism was never seen. 
 
Conclusion: Calcineurin is a key enzyme in the calcium-dependent signal transduction pathways of 
eukaryotes. Antifungal drug resistance and virulence of several pathogenic fungi, including 
Aspergillus species, is regulated by this pathway. Results of the present study showed synergistic 
interactions between isavuconazole and tacrolimus and underline the role of the calcineurin pathway 
as a target for the development of new antifungal drugs. 
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Synergistic antifungal effect of fluconazole combined with pure culture extract of Candida 
albicans against Trichophyton mentagrophytes 
T. Lemes1, B. De Almeida2, M. Caetano3, C.R. Polaquini4, L.O. Regasini5, T. Maschio-Lima3, N. 
Brizzotti1,6, E. Castilho6, J.P. Siqueira7, M. Marques6, M. Almeida8 
1Microbiologia, Unesp, São José do Rio Preto, Brazil, 2Unesp, São José do Rio Preto, Brazil, 3UNESP, 
São José do Rio Preto, Brazil, 4São Paulo State University - Institute of Biosciences, Humanities and 
Exact Sciences (UNESP - IBILCE), São José do Rio Preto, Brazil, 5Chemistry And Environmental 
Sciences, UNESP (Sao Paulo State University), São José do Rio Preto, Brazil, 6FAMERP, São José do 
Rio Preto, Brazil, 7Infeciosas Disease, FAMERP, São José do Rio Preto, Brazil, 8Infectious Disease, 
Medical School, sao jose do rio preto, Brazil 
Objectives: The present study evaluated the synergistic interaction between a pure culture extract of 
Candida albicansand fluconazole againstTrichophyton mentagrophytes. 
Methods: This study used clinical strains of C. albicansfrom the Laboratory of Microbiology of the 
Medical School in São José do Rio Preto (FAMERP), Brazil. A 500-mL Inoculum prepared in 
Sabouraud Dextrose Broth was filtered through a 0.2 μm millipore membrane and separated using 
ethyl acetate as a counter-phase. The ethyl acetate phase was completely dried using a rotary 
evaporator and subsequently solubilized in sterile distilled water with 10% dimethyl sulfoxide 
(DMSO). Minimal Inhibitory Concentration (MIC) tests were performed for T. mentagrophytesstrains 
following the Clinical and Laboratory Standards Institute (CLSI) M38-A2 guidelines. After obtaining 
the extract’s MIC, a checkerboard trial with fluconazole was performed to evaluate the synergistic 
interaction with the extract based on the calculation of the fractional inhibitory concentration index 
(ICIF) = (MIC fluconazole in the mix / MIC fluconazole alone) + MIC extract in the mix / MIC extract 
isolated). The synergistic interaction was classified using the method described by Kumar et al., 
where values ≤ 0.5 indicate significant interactions. 
Results: The results obtained for the C. albicansextract’s MIC against the T. mentagrophytesstrain and 
fluconazole in isolation were 1000 μg/mL and 16 μg/mL, respectively. However, when the extract 
was used in combination with fluconazole, the MIC value was 0,001 μg/mL and of fluconazole it was 
2 μg/mL with an ICIF value of 0,01. 
Conclusion: The extract of C. albicansin isolation shows antifungal activity against T. mentagrophytes, 
which may influence the laboratory diagnosis of mixed infections. Furthermore, the action of this 
extract is greater in association with an azole derivative, thus proving synergy. In the future, the 
isolation and identification of extract compounds may allow new therapeutic approaches in the 
control of fungal infections. 
 
P061 
Screening of antifungal susceptibility of Malassezia pachydermatis isolates from dogs using disk 
diffusion test 
S. Hadina1, I. Benvin2, Z. Štritof1, J. Habuš1, V. Stevanović1, M. Perharić1, K. Martinković1, V. Mojčec1, 
L. Barbić1, Z. Milas1, V. Starešina1, N. Turk1, L. Pinter1 
1Department Of Microbiology And Infectious Diseases With Clinic, Faculty of Veterinary Medicine, 
The University of Zagreb, Zagreb, Croatia, 2Faculty of Veterinary Medicine, The University of Zagreb, 
Zagreb, Croatia 
Objectives: Malassezia pachydermatis is lipophilic yeast commonly seen in skin and ear diseases of 
dogs. Lately, different studies are describing the appearance of reduced susceptibility of M. 
pachydermatis strains. In addition, reports about its zoonotic potential and emerged number of 
Malassezia yeast resistance in human medicine, highlight the need for study of its antifungal 
susceptibility. The problem of surveillance of potential resistance is lying in no established reference 
method for antifungal susceptibility testing and no interpretative criteria for this yeast. Various 
studies used different methodologies and interpreted obtained results based on different 
recommendations. Modified microdilution method is considered the most accurate, but at the same 
time more expensive and technically demanding to perform in clinical laboratories. Recent study 
demonstrated good correlation of results obtained by modified CLSI M44-A2 disk diffusion and 
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broth microdilution method, indicating its suitability for in vitro susceptibility testing of M. 
pachydermatis in epidemiological studies (Pasquetti et al., 2015.). The aim of this study was to screen 
antifungal susceptibility of M. pachydermatis for miconazole (MCZ) and clotrimazole (CTZ) using disk 
diffusion method. 
Methods: A total of 96 isolates of M. pachydermatis were recovered from animals with clinical signs 
of otitis. Identification was based on their ability to grow on Sabouraud dextrose agar and typical 
macroscopic and microscopic appearance. Two antifungal tablets containing most commonly azole 
derivatives used for topical therapy were tested: MCZ and CTZ (10 µg, Neo-Sensitabs, Rosco, 
Denmark). Disk diffusion test was performed using Mueller-Hinton agar supplemented with 2% 
glucose and 0.5 μg/l methylene blue. Inoculum of M. pachydermatis was prepared in sterile saline from 
3 days old cultures, with addition of the lipid source, containing approximately 1-5x107 CFU/mL. 
Readings were performed 72 hours after incubation at 37°C, and interpreted according to guidelines 
provided by manufacturer. 
Results: Out of 96 tested, all isolates demonstrated good susceptibility to CTZ with variations of 
inhibition zones from 34 to 73 mm (mean ± SD: 56 ± 8,06 mm). Susceptibility testing against MCZ 
resulted with the range of inhibition zones from 14 to 65 mm (mean ± SD: 41 ± 6,77 mm) and good 
sensitivity of 95 strains, while one isolate demonstrated intermediate sensitivity. Comparison of the 
size of the zones showed that CTZ had larger zones of inhibition than MCZ indicating its higher 
antifungal activity. 
Conclusion: Screening of antifungal susceptibility of M. pachydermatis using disk diffusion method 
resulted with identification of one strain with reduced susceptibility to MCZ. However, taking into 
consideration that there are no standardized interpretative criteria for Malassezia yeast, follow up 
study using broth microdilution assay is needed, in order to check if this isolate could be categorized 
as potentially resistant. Reference: Pasquetti, M., E. Chiavassa, P. Tizzani, P. Danesi, A. Peano (2015): 
Agar diffusion procedures for susceptibility testing of Malassezia pachydermatis: Evaluation of 
Mueller-Hinton agar plus 2% glucose and 0.5 µg/mL methylene blue as the test medium. 
Mycopathologia 180, 153-158. 
 
P062 
Susceptibility to voriconazole of Aspergillus spp. strains, isolated from patients in Russia 
N. Vasilyeva1, I. Vybornova2, T. Bogomolova1 
1Kaschkin Research Institute Of Medical Mycology. Department Of Medical Microbiology, North-
Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 
2Kaschkin Research Institute Of Medical Mycology, North-Western State Medical University named 
after I.I. Mechnikov, Saint-Petersburg, Russian Federation 
Objectives: Azole resistance of aspergillosis etiologic agents is an emerging problem in Europe and 
other parts of the world. The aim of the study: to determine susceptibility to voriconazole of 
Aspergillus spp. strains isolated from patients with aspergillosis in Saint Petersburg, Russia. 
Methods: Fungal species identification was done using morphological and molecular methods. A 
total of 230 strains of Aspergillus spp. isolated from biological samples of patients with different 
clinical forms of aspergillosis (invasive, chronic and allergic) in Saint Petersburg during 2014 – 2019 
yrs. have been tested by standard disk diffusion method according to CLSI M51A Document. For 34 
strains MICs of voriconazole have been determined according to EUCAST Document E Def 9.3.1. 
Results: Species distribution among Aspergillus spp. isolates was as follows: A. fumigatus – 68%, A. 
niger – 16%, A. flavus – 13%, rare species – 3% (A. terreus – 4 strains, A. calidoustus – 2, A. ustus – 1, A. 
sydowii – 1). By disk diffusion method no voriconazole resistant isolates were found among common 
species: A. fumigatus , A. niger, A. flavus. Only 4 resistant strains were revealed among rare species: A. 
terreus – 1, A. calidoustus – 2, A. ustus – 1 (inhibition zone diameter < 17 mm). Voriconazole MICs for 
A. fumigatus, A. flavus, A. niger strains ranged from 0,125 to 0,5 mg/L. Only A. calidoustus showed high 
MIC – 4 mg/L. 
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Conclusion: Resistance to voriconazole among etiologic agents of aspergillosis in Saint Petersburg, 
Russia was found only among rare fungal species (A. calidoustus, A. ustus, A. terreus). Future 
surveillance is necessary to monitor antifungal resistance. 
 
P064 
Antifungal susceptibility testing of Malassezia furfur 
T. Bogomolova1, T. Bogdanova2, N. Vasilyeva1, A. Alexeyev1, V. Spiridonova3 
1Kaschkin Research Institute Of Medical Mycology. Department Of Medical Microbiology, North-
Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 
2Department Of Medical Microbiology, North-Western State Medical University named after I.I. 
Mechnikov, Saint-Petersburg, Russian Federation, 3Kaschkin Research Institute Of Medical 
Mycology, North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, 
Russian Federation 
Objectives: Malassezia spp. may be etiologic agents of superficial and invasive mycoses. There are no 
standard protocols for evaluation of antifungal susceptibility of these yeasts. The aim of the study 
was to determine Malassezia furfur isolates susceptibility to antifungal agents by two different 
methods. 
Methods: Disk diffusion method CLSI M44A2 was modified by addition of lipids to the Muller-
Hinton agar. Commercial test panels Sensititre Yeast One were also supplemented by fatty acid RPMI 
1640. 
Results: We tested 11 strains of M. furfur isolated from blood of pediatric patients. Both methods 
showed resistance to fluconazole and voriconazole. By Sensititre Yeast One panels the following 
MICs were obtained: amphoterecin B – 1 mg/L, fluconazole > 64 mg/L, caspofungin >8 mg/L, 
voriconazole – 1-8 mg/L, anidulafungin >8 mg/L, micafungin >8 mg/L, 5-fluorocytozne - > 256 mg/L, 
itraconazole - < 0,015, mg/L, pozaconazole – 0,03-0,06 mg/L. 
Conclusion: Disk diffusion method may be used for screening antifungal resistance in Malassezia spp. 
isolates. Itraconazole and pozaconazole demonstrated highest activity against M. furfur. 
 
P065 
Evaluation of the efficacy of antifungals against invasive aspergillosis in an invertebrate animal 
model 
J. Sana1, É. Melloul1, J. Guillot1, F. Botterel1,2, E. Dannaoui1,3 
18 Rue Du General Sarrail, DYNAMYC, Creteil, France, 2Laboratoire De Parasitologie-mycologie, 
APHP Hôpital Henri Mondor, Créteil, France, 3Hôpital Européen Georges Pompidou, Laboratoire de 
Parasitologie-Mycologie, Paris, France 
Objectives: Evaluation of new therapeutic strategies for the treatment of invasive aspergillosis is 
needed due to emergence of azole-resistance in Aspergillus fumigatus. Animal models in rodents are 
generally used but are costly and their use is limited by ethical considerations. For these reasons, 
evaluation of antifungal efficacy in mini-host models such as Galleria mellonella is a promising 
alternative. The aim of our study was to develop an invasive Aspergillus infection in larvae of Galleria 
mellonella to evaluate the efficacy of antifungals. 
Methods: Three clinical strains of Aspergillus fumigatus (HEGP064, HEGP4017 and HEGP2666) have 
been used. Minimum inhibitory concentration for voriconazole (VRZ) was 0.5, 0.5 and 8µg/mL for 
HEGP064, HEGP4017 and HEGP2666 respectively. Inoculum finding experiments (with spore 
suspensions at 105 to 108 conidia/mL) have been performed to determine the concentration that gave 
90% mortality at seven days post-infection (LD90). The presence of an invasive infection has been 
demonstrated by direct examination of tissues stained with Gomori-Grocott (GG) and by 
histopathology (H&S staining). In a first set of experiments, groups of 10 larvae were infected with 
the LD90 and treated with monotherapy by voriconazole (VRZ, [Vfend® ] at 0.5, 1, 2, 4, and 8 μg/larva), 
amphotericin B (AMB, [Fungizone®], or caspofungin (CSP, [Cancidas®] at 0.2, 0.4 and 0.8 μg/larva). 
Subsequently, HEGP4017 or HEGP2666 infected larvae were treated after two hours by VRZ at 
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4µg/ml alone and in combination with CSP at 4, 2 or 1µg/larvae. The mortality was estimated daily 
for 7 days. 
Results: After infection, an invasive aspergillosis was obtained as shown by the presence of hyphae 
in tissues. The LD90 values for the HEGP064, HEGP4017 and HEGP2666 strains were 4.38×107,9.59×107 
and 1×108 CFU/ml respectively. In infected and untreated groups, mortality was at least 90% on day 
7 post-infection. The mortality decreased with increasing doses of amphotericin B. At 4 µg/larvae, the 
mortality was on average 20% for the 3 strains. In animals treated with VRZ, the mortality rates on 
day 7 post-infection were 35%, 40% and 60% for HEGP064 and were 55%, 65% and 95% for HEGP4017 
and 85%, 95% and 95% for 8, 4 and 2 μg/larva, respectively (p = 0.0001 compared to control). VRZ at 
8, 4 and 2 μg/larva was statistically more effective for the treatment of larvae infected with HEGP064 
or HEGP4017 compared to those infected by HEGP2666. Administration of VRZ 4 did not decreased, 
significantly, the mortality of HEGP2666 infected larvae (p = 0.304) in contrast to those infected by 
HEGP4017 (p = 0.0082). The bitherapy VRZ 4µg/larvae and CSP 4µg/larvae lead to a more significant 
decrease in mortality compared to monotherapy (VRZ 4µg/larvae) and control group infected by 
HEGP4017(p = 0.026) and HEGP2666 (p = 0.005) strain. 
Conclusion: G. mellonella is a reliable model for inducing invasive aspergillosis. There was a clear 
dose-response when animals were treated with VRZ and AMB. This model could be used for 
screening and evaluation of different therapeutic strategies against Aspergillus spp. 
 
P066 
Analysis of the efflux-pump activity against resistant Sporothrix schenckii complex isolates 
M.L. Scroferneker1, T.R. Pinheiro2, G. Seibert2, A.L.R. Poletto3, J.V. Prade3, C.D.O. Stopiglia3 
1Department Of Microbiology, Immunology And Parasitology, Universidade Federal do Rio Grande 
do Sul, Porto Alegre, Brazil, 2Universidade Federal do Pampa, Uruguaiana, Brazil, 3Universidade 
Federal do Pampa, Uruguaiana, RS, Brazil 
Objectives: The present study aims to assess the efflux-pump activity in the resistant Sporothrix 
schenkii complex strains. 
Methods: The minimum inhibitory concentration (MIC) of itraconazole (0.03125-16 µg/mL) was 
determined through broth microdilution method, as described by protocol M38-A2 of the Clinical and 
Laboratory Standards Institute (CLSI, 2008). Ten clinical isolates of Sporothrix schenckii complex were 
prepared from 7-day-old cultures grown on potato dextrose agar at 28◦C. The inocula were adjusted 
to a final concentration of 0.5–2.5×103 cells/mL. The microdilution plates were incubated at 35◦C for 
72h. The MIC of itraconazole was defined as the lowest drug concentration capable of inhibiting total 
of growth. For the analysis of the efflux-pump activity, the resistant Sporothrix schenckii complex 
strains (04/10) were tested against two efflux-pump inhibitors, promethazine and verapamil by broth 
microdilution method. Posteriorly, susceptibility test was performed with itraconazole and sub-
inhibitory concentrations of promethazine (MIC/8 = 24 µg/mL) and verapamil (MIC/8 = 100µMol). 
Results: There were no reduction of MIC for itraconazole in the presence of the verapamil and 
prometazine inhibitors. 
Conclusion: Thus, the present study suggests that the mechanism of resistance of the isolated 
evaluated isn’t the presence of efflux pumps. 
 
P067 
Terbinafine resistant Trichophyton mentagrophytes ITS genotype VIII from India in Germany 
P. Nenoff1, A. Süβ2, A. Ludes3, A. Schuller4, E. Fischer5, S. Dessoi6, W. Hofmann6, S. Schmidt7, S.B. 
Verma8, M. Monod9, K. Salamin9, C. Krueger1, A. Ebert1, S. Uhrlass1 
1Partnership Dr. C. Krueger & Prof. P. Nenoff, Laboratory of medical microbiology, Roetha OT 
Moelbis, Germany, 2Hautärztin, Gemeinschaftspraxis Allgemeinmedizin und Dermatologie, 
Wittlich, Germany, 3Allgemeinmedizinische Praxis Dr. med. Alfons Ludes und Thorsten Koech, 
Leiwen, Germany, 4Hautarztpraxis, Halle/Saale, Germany, 5Hautarztpraxis Dr. med. Gunhild 
Kratzsch, Leipzig, Germany, 6Hautzentrum Nordwest, Frankfurt am Main, Germany, 
7Hautarztpraxis im MVZ Friedrichstadt, Dresden, Germany, 8"Nirvan” and “In Skin” Clinics, 
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Vadodara, India, 9Dermatology Service, Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland 
Case Report: Objectives: In India, a dramatic increase of chronic recalcitrant dermatophytoses due 
to Trichophyton (T.) mentagrophytes genotype VIII is on the rise. Due to travelling and migration, 
globalization of the mostly terbinafine resistant strains of the causative agent from India to other parts 
of the world is assumed. First strains of T. mentagrophytes genotype VIII have reached Germany, now. 
Patients: 1) A 6 months-old-female infant from Bahrain visiting Germany with her family for a 
holiday was seen for extensive dermatophytosis of the back, buttocks, chest and groins. Topical 
treatment by terbinafine for over 2 months was not successful. 2) A 28 years old male from Libya, 
living for 3 years in Germany, suffered from tinea cruris and tinea faciei involving the left upper and 
lower eyelids. Treatment by oral fluconazole and by terbinafine failed. His German girlfriend was 
affected by the dermatomycosis, too. Her child was free of signs of a dermatophytosis. The patient 
had no contact to India and Indians or Arabs, he did not visit Libya in the last years. The man, 
however, regularly goes to the gym. 3) After a trip to Saudi Arabia, a pregnant German woman 
suffered from tinea cruris and tinea corporis (trunk). Her husband was affected, too. 4) An Indian 
male, living in Germany, was treated because of a dermatomycosis of the buttocks and groins by oral 
terbinafine, without improvement. 5) A couple from Iraq, living for long time in Germany, suffered 
from chronic recalcitrant dermatophytosis of the groins for at least 1.5 years. Repeated topical 
treatments by „Combo Creams“ failed. Antifungal topical preparations (ciclopirox olamine, 
sertaconazole) for 5-6 weeks acted very slowly, progression of the dermatomycoses lead to therapy 
break-off. Oral itraconazole 200 mg daily was started. Results: Mycological examination of skin 
scrapings from all 5 patients revealed the detection of T. mentagrophytes. Four out of the five 
dermatophyte isolates were subject to sequencing of the “internal transcribed spacer” (ITS) region of 
the fungal rDNA. All these 4 strains belonged to the newly described genotype VIII of T. 
mentagrophytes. The until now investigated point mutations revealed for patient 1) TTC/TTA 
mutation of the squalene epoxidase (SQLE) gene which is closely associated with Phe397Leu amino 
acid substitution of the enzyme. T. mentagrophytes isolates of patient 2) and 3) were in vitro sensitive 
to terbinafine. The T. mentagrophytes strain of patient 3) showed GCT/ACT mutation (Ala448Thr). The 
above mentioned Phe397Leu and Ala448Thr substitutions are indicative of in vitro resistance of the 
dermatophyte against terbinafine. Conclusion: Transmission of the here found Indian ITS genotype 
VIII of T. mentagrophytes to other countries due to globalization is a serious issue to be considered. 
Moreover, a significant percentage of these Indian T. mentagrophytes strains are resistant to terbinafine 
both in vitro and due to point mutations in the SQLE gene. Some strains are also found to be partially 
resistant against itraconazole and voriconazole. The here described patients represent the first reports 
on an infection due to terbinafine-resistant T. mentagrophytes of the ITS genotype VIII from India in 
Germany. 
 
P068 
Comparison of two antifungal susceptibility tests for Malassezia yeasts 
A. Abdillah1, A. Packeu2, S. Khelaifia3, M. Hendrickx4, S. Ranque1 
1Vitrome, Aix Marseille Univ, IRD, AP-HM, SSA, Marseille, France, 2Mycology & Aerobiology, 
Sciensano, Brussels, Belgium, 3Culturomics, IHU Méditerranée Infection, Marseille, France, 4Service 
Of Mycology And Aerobiology, Bccm/ihem Fungal Collection, Sciensano, Brussels, Belgium 
Objectives: The lipid-dependent Malassezia spp. yeast are members of the normal human skin 
microbiota that are occasionally involved in various skin diseases or in blood stream infections in 
immunocompromised and neonates patients. A better knowledge of the antifungal susceptibility 
testing (AFST) profiles of these yeast is pivotal to enhance antifungal treatment strategies. This study 
aimed to compare two broth microdilution assays for the in vitro AFST of Malassezia spp. 
Methods: A total of 19 strains of the BCCM /IHEM collection, including 4 Malassezia species: (n = 6) 
M. furfur, (n = 4) M. pachydermatis, (n = 5) M. sympodialis and (n = 4) M. slooffiae were tested against 
ketoconazole, voriconazole, terbinafine and fluconazole using the broth microdilution method (CLSI 
- M27-A2). Two different media were used as diluent, modified Dixon broth (mDIXB) and FastFung 
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broth, a new medium derived from the Schaedler agar. MIC values were visually read after 48 h of 
incubation at 30°C. The essential agreement (EA) (±1 or 2 dilution) of the MIC values between both 
media was estimated. The inter-laboratory reproducibility between Marseille and Brussels was 
tested. 
Results: Ketoconazole, voriconazole and terbinafine MICs (mg/l) were low, with MIC90 values of 0.06 
to 0.5, 0.03 to 0.125, and 0.125, in mDIXB, and of 0.03 to 0.25, 0.03 to 0.125, and 0.06 to 1, in FastFung 
broth, respectively. Fluconazole displayed the highest MIC values. The EAs varied from 84.2 to 100% 
for ±1 dilution while EAs of 100% were observed for ±2 dilution. The inter-laboratory EAs (±2 
dilutions) ranged from 73.8 to 100% and 94.7 to 100% in mDIXB or FastFung broth, respectively. 
Conclusion: Our findings showed that both media performed similarly, with relatively higher EAs 
(>60%), except for terbinafine. The FastFung broth can be used as alternative medium for Malassezia 
in vitro AFTS. 
 
P075 
The effect of farnesol on Candida auris biofilms, virulence and azole susceptibility 
F. Nagy1, Z. Tóth1, L. Forgács1, A. Borman2, L. Majoros1, B. Balázs1, R. Kovács1 
1Department Of Medical Microbiology, University of Debrecen, Debrecen, Hungary, 2Public Health 
England UK National Mycology Reference Laboratory, Bristol, United Kingdom 
Objectives: Farnesol is a fungal quorum-sensing molecule, which has a pivotal role in regulation of 
fungal morphogenesis. The aim of our study was to examine the effect of farnesol on biofilms, azole 
susceptibility (fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole) against Candida 
auris clinical isolates as well as in vivo tissue fungal burden in a murine bloodstream infection model. 
Methods: The effect of farnesol on C. auris cells was tested in three experiments: i) biofilm forming 
ability of cells pre-treated with farnesol for 24-hours prior to biofilm formation, ii) biofilm forming 
ability of cells continuously exposed to farnesol for 24-hours during biofilm formation, iii) effect of 
farnesol on one-day-old biofilms. Farnesol concentrations tested were 10, 50, 100, 300 μM in all 
experiments. Metabolic activity of sessile cells was determined at 0, 2, 4, 6, 8, 10, 12 and 24 hours 
using XTT-assay. One-way ANOVA with Dunnett’s post-testing was used to analyze the metabolic 
activity change exerted by different farnesol concentrations compared to untreated control. 
Interactions between farnesol and azoles were examined against one-day-old biofilms by broth 
microdilution checkerboard method. The tested concentrations were 1.17-300 μM and 0.125-512 mg/L 
for farnesol and azoles, respectively. Fractional inhibitory concentration index (FICI) was used to 
assess the nature of interactions. Synergy was specified if the FICI was ≤0.5, between >0.5 and 4 was 
indifferent and as antagonistic if the FICI was >4. MICs were determined as at least 50% reduction of 
metabolic activity compared to control in case of individual drugs and isoeffective combinations. 
Farnesol pre-exposed (75 μM) cells were inoculated intravenously into immuncompromised female 
BALB/c mice to examine the day six fungal burden in kidneys, heart and liver. 
Results: The one-day-long farnesol pre-exposure (50-300μM) led to formation of biofilms with 
significant metabolic activity inhibition after 24 hours (p<0.01). Biofilms formed under farnesol 
exposure showed significantly decreased metabolic activity in first the 12, 12, 10 and 8 hours for 300, 
100, 50 and 10 μM farnesol, respectively (p<0.05-0.001). In case of one-day old biofilms treated with 
farnesol after formation, only the highest farnesol concentration caused significant inhibition at 24 
hours (p<0.001).The median MIC values of azoles and farnesol against sessile C. auris clinical isolates 
are showed in Table 1. Based on FICI values, farnesol was synergistic with all tested azoles (FICIs 
ranged from 0.061 to 0.375) (Table 1). Fungal tissue burdens caused by farnesol pre-exposed C. auris 
were significantly higher in all examined organs compared to organs infected by farnesol-unexposed 
fungal cells at sixth day postinoculation. 
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Conclusion: Farnesol inhibited the biofilm forming ability of C. auris and significantly reduced the 
metabolic activity of C. auris biofilms in a concentration-dependent manner; in addition, it showed a 
remarkable synergistic effect with azoles. On the other hand, farnesol pre-exposure led to increased 
tissue fungal burdens. In summary, though its systemic usage may be hindered by a potential 
enhancement of fungal virulence, farnesol may be a useful addition to therapy where biofilm 
formation is important, e.g. in catheter-lock therapy against C. auris. 
 
P076 
Transcriptional and physiological effect exerted by tyrosol on Candida parapsilosis cells 
 
R. Kovács1, Á . Jakab2, Z. Tóth1, F. Nagy1, T. Emri2, I. Pócsi2, L. Majoros1 
1Department Of Medical Microbiology, University of Debrecen, Debrecen, Hungary, 2Department Of 
Molecular Biotechnology And Microbiology, University of Debrecen, Debrecen, Hungary 
Objectives: Tyrosol has a potent antifungal activity against Candida species; however, the 
background of its antifungal mechanism is still poorly understood.We examined the effect of tyrosol 
at supraphysiological concentration on growth, biofilm formation, redox homeostasis, virulence as 
well as on fluconazole susceptibility to reveal the background of its antifungal effect. To gain further 
insights into the physiological consequences of tyrosol treatment we examined the caused genome 
wide gene expression changes using RNA-Seq. 
Methods: CLIB 214 Candida parapsilosis (sensu stricto) strain was used and 15 mM tyrosol 
concentration was applied to examine physiological and transcriptional changes. Following 4 hours 
incubation of C. parapsilosis precultures, we added 15 mM tyrosol to the cultures then growth was 
examined at 1-hour intervals by determination of cell density both by means of measuring of the 
absorbance (at 640 nm) and by counting the living cells. Reactive species were measured in the 
presence or absence of tyrosol by a technique that converts 2’,7’dichlorofluorescin-diacetate to 2’,7’–
dichlorofluorescein. One-day-old biofilm formation ability in the presence of tyrosol was determined 
by quantitative CFU determination of adhered cells. Interaction between fluconazole and tyrosol was 
evaluated by two-dimensional broth microdilution chequerboard assay. Afterwards, the nature of 
interaction was analyzed using Fractional Inhibitory Concentration Index determination. Tyrosol 
induced effect on virulence was examined in immuncompromised systemic BALB/c mouse model.To 
obtain global transcriptome data regarding tyrosol treatment, high-throughput mRNA sequencing 
was performed on Illumina NextSeq sequencing platform. 
Results: Fifteen mM tyrosol caused significant growth inhibition within two hours of the addition of 
tyrosol (p<0.01). Tyrosol increased the production of reactive oxygen species (p<0.001) and it was 
associated with elevated superoxide dismutase, glutathione peroxidase and catalase activities 
J. Fungi 2019, 5, 95 143 of 464 
 
(p<0.05). Biofilm formation ability was comparable in the presence or absence of 15 mM tyrosol in 
terms of living fungal cells.The interaction between fluconazole and tyrosol was antagonistic (FICI 
4.5). Fifteen mM daily treatment decreased the fungal tissue burden in the kidneys compare with 
untreated control (p<0.01).Tyrosol exposure resulted in 1,462 differentially expressed genes. Out of 
them, 261 and 181 genes with at least 1.5-fold increase or decrease in expression, respectively, were 
selected for further investigations (Figure 1). Genes involved in ribosome biogenesis showed down-
regulation, while genes related to later biofilm events, oxidative stress response and ethanol 
fermentation were up-regulated. In addition, tyrosol treatment up-regulated the expression of certain 
fluconazole efflux pump genes including MDR1 and CDR1 and down-regulated the FAD2 and FAD3 
virulence genes belonging to desaturated fatty acid formation. 
 
Figure 1 Up-regulated (red) and down-regulated (dark blue) genes were defined as differentially 
expressed genes (p<0.05) where log2(FC)>0.585 or log2(FC)<–0.585, respectively, and FC stands for 
fold change FPKM (fragments per kilobase per million mapped fragments) value. 
Conclusion: Tyrosol exposure enhanced oxidative stress response and efflux pumps, while inhibited 
growth and ribosome biogenesis as well as virulence. Metabolism was modulated towards glycolysis 
and ethanol fermentation. Primer adherence was inhibited, and rather later biofilm events was 
enhanced. Our findings suggest that tyrosol may be a potential locally active and/or adjuvant agent 
in the development of alternative treatments targeting quorum-sensing in the future. 
 
P077 
Nonyl 3,4-dihydroxybenzoate as a potent anti-biofilm compound for the treatment of 
dermatophytosis 
 
C. Orlandi1, R.H. Pires2, N.M. Bila1, A. Serafim-Pinto1, J.L. Bonatti1, L. Scorzoni1, J. Singulani1, C. 
Santos1, C.R. Andrade3, P. Silva4, M. Chorilli4, L.O. Regasini5, A.M. Fusco Almeida1, M.J. Soares 
Mendes Giannini1 
1Clinical Analysis, UNESP (Sao Paulo State University), Araraquara, Brazil, 2Health Promotion, 
UNIFRAN (University of Franca)), Araraquara, Brazil, 3Physiology And Pathology, UNESP (Sao 
Paulo State University), ARARAQUARA, Brazil, 4Drugs And Pharmaceuticals, UNESP (Sao Paulo 
State University), Araraquara, Brazil, 5Chemistry And Environmental Sciences, UNESP (Sao Paulo 
State University), São José do Rio Preto, Brazil 
Objectives: This study aimed to verify the in vitro susceptibility of nonyl 3,4-dihydroxybenzoate 
against planktonic cells and biofilms of dermatophytes. In addition, efficacy and toxicity were tested 
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in a murine model of dermatophytosis. The compound was incorporated into nanostructured lipid 
systems (NLS) in order to prove whether the incorporation was able to maintain its antifungal activity 
as well as, reduce toxicity in human cell lines and alternative models. In addition, the probable 
mechanism of action was evaluated. 
Methods: The preformed biofilms and planktonic cells of Trichophyton rubrum and T. mentagrophytes 
were treated with different concentrations of synthetic antifungal drugs and nonyl 3,4-
dihydroxybenzoate. The metabolic activities were determined using the XTT reduction assay. The 
effects of the treatments on biofilms structures were visualized by scanning electron microscopy 
(SEM). The efficacy of the compound was evaluated in wild type (WT) C57BL/6 mice by determining 
the fungal burden and histopathological analysis. Hepatic and renal toxicity were assessed by blood 
analysis in the equipment Vitros 250 chemistry analyzer. After incorporation into NLS, susceptibility 
tests were conducted according the document M38-A2, proposed by the CLSI (2008). The toxicity of 
incorporation was evaluated in HaCaT cell lines by the sulforhodamine B method and in 
Caenorhabditis elegans model. Finally, the damage of cell ultrastructure was evaluated by transmission 
electron microscopy (TEM). 
Results: Both biofilms and planktonic cells were susceptible to nonyl compound in concentrations 
ranging from 125 – 250 mg/L. T. rubrum and T. mentagrophytes biofilms were significantly more 
resistant to fluconazole, griseofulvin and terbinafine than planktonic cells (p<0.05). Fluconazole, 
griseofulvin, terbinafine and nonyl were able to prevent biofilm formation in all reference strains and 
clinical isolates tested (p<0.05). SEM results revealed that the antifungal drugs caused minor or no 
damage to the structure of the biofilms, and in some cases, stimulated the development of resistance 
structures. In contrast, the biofilms treated with the nonyl compound were seriously damaged. The 
fungal burden was significantly reduced after treatment and histopathological analysis showed 
complete tissue regeneration. In addition, there was no systemic toxicity after treatment in mice. 
Nonyl incorporated to NSL formed by the surfactant Brij® 98 Epikuron®  (98-I) presented the best 
results of minimum inhibitory concentration (MIC), with values between 1.98 and 3.9 mg/L. 
Cytotoxicity tests indicated that the incorporation resulted in cell viability greater than 80% at all 
tested concentrations. These results corroborated with in vivo testing in C. elegans model, which 
indicated that the incorporation of nonyl significantly increased the survival of larvae. Finally, TEM 
results indicated that the compound might have more than one mechanism of action in the 
dermatophytes, causing enlargement of the vacuoles, besides derangement and formation of pores 
in the plasma membrane, similar to amphotericin B. 
Conclusion: These findings show that nonyl 3,4-dihydroxybenzoate may be a promising antifungal. 
Funding: CNPq, Capes and FAPESP Process # 2018/02785-9; 2017/18388-6. 
 
P078 
Anti-dermatophyte biofilm activity of photodynamic therapy using 2-chalcone as photosensitizer 
 
N.M. Bila1,2, C. Orlandi1, L.C. Gonçalves1, C.O. Vaso1, C. Santos1, P. Silva3, M. Chorilli3, L.O. Regasini4, 
F.L. Primo5, C.R. Fontana1, A.M. Fusco Almeida1, M.J. Soares Mendes Giannini1 
1Clinical Analysis, UNESP (Sao Paulo State University), Araraquara, Brazil, 2Para-clinics, UEM 
(Eduardo Mondlane University), Maputo, Mozambique, 3Drugs And Pharmaceuticals, UNESP (Sao 
Paulo State University), Araraquara, Brazil, 4Chemistry And Environmental Sciences, UNESP (Sao 
Paulo State University), São José do Rio Preto, Brazil, 5Bioprocess And Biotechnology, UNESP (Sao 
Paulo State University), Araraquara, Brazil 
Objectives: This study aimed to evaluate the anti-dermatophytic and anti-biofilm activity of 2-
chalcone alone and combined with photodynamic therapy (PDT). 
Methods: Strains of Trichophyton rubrum, T. mentagrophytes and one clinical isolate of Microsporum 
canis were used. Susceptibility tests were conducted according to the M38-A2 document proposed by 
CSLI. Planktonic cells, biofilms with 24 h (initial stage) and 72- 96 h of growth (mature) were formed 
in RPMI-1640 medium and placed in contact with different concentrations of 2-chalcone (1 - 500 mg 
/ L), fluconazole (1,25 - 512 mg / L) and terbinafine (0.002 – 32 mg / L). The metabolic activities after 
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the treatments were quantified using the tetrazolium salt (XTT) reduction method. The topographies 
of initial and mature biofilms with or without treatment were visualized by scanning electron 
microscopy (SEM). For the PDT assay, 2-chalcone was used a photosensitizer and a blue led as a 
source of light with a dose of 150 J.cm-2. 
Results: All the strains, in the planktonic form, were inhibited by treatment with 2-chalcone (MIC = 
3,9 - 7.8 mg/L), terbinafine (MIC = 0.008 - 0.03 mg/L) and fluconazole (1-64 mg/L). The substance 2- 
chalcona eradicated the 24 hour biofilm of all strains tested at the concentration of 15.6 mg / L, 
terbinafine ranging from 0.06 to 16 mg / L, and fluconazole inhibited only the formation of T. 
mentagrophytes biofilm in the concentration of 32 mg / l. Regarding mature biofilms, only 2-chalcone 
was able to reduce the metabolic activities in the concentration of 31.2 mg/L. Mature biofilms were 
resistant to both antifungal drugs tested. When planktonic and biofilms (initial and mature) were 
treated with PDT using 2-chalcone as photosynthesizer, the inhibitory concentrations were reduced 
by 4 times (2 – 8 mg/L). The SEM of biofilms treated with 2-chalcone showed a total collapse of the 
cell walls, resulting from a probable extravasation of cytoplasmic content. 
Conclusion: The substance 2-chalcone is a promising antifungal drug. Funding: CNPq, IBE process 
150/2017, Capes and FAPESP Process # 2018/02785-9; 2017/18388-6. 
 
P079 
Antifungal activity of voriconazole and micafungin against the biofilms and planktonic cells of 
Candida albicans and Aspergillus fumigatus in vitro 
 
D. Shi1, W. Liu2 
1Jining No. 1 People's Hospital, Jining, China, 2Institute of Dermatology, Chinese Academy of Medical 
Sciences & Peking Union Medical College, Nanjing, China 
Objectives: Candida albicans and Aspergillus fumigatus are among the most common invasive 
opportunistic pathogens known to have high morbidity and mortality. Micafungin (MCF) and 
voriconazole (VOR) are the most commonly used first-line therapies for these fungi. However, to our 
knowledge, there are few data comparing the efficacy of MCF and VOR on biofilm and planktonic 
cells on both fungi. 
Methods: We have carried out an in vitro study to evaluate the efficacy of VOR and MCF against 
biofilm development and inhibition of fungal viability within biofilm formed by these two 
pathogenic fungi. 
Results: We find that, when compared with planktonic cells, the corresponding fungal biofilm 
magnificently decreases drug sensitivities. To inhibit more than 50% of cell viability within a mature 
biofilm, the concentration of each drug must increase by at least 5 to 10 MIC – depending on the 
specific drug and fungus combination. With specific regard to biofilm formation itself, we find that 
MCF is more effective than VOR against developing biofilm in C. albicans, whereas VOR is more 
effective at high concentration against developing biofilm in A. fumigatus. We also find that the earlier 
the therapeutic intervention, the greater the biofilm inhibition that will be achieved. The critical time 
window for biofilm inhibition is 12h for A. fumigatus and 8h for C. albicans; beyond those points in 
time safe and effective drug intervention is almost impossible. 
Conclusion: Our results provide a few clinical hints that may help in choosing antifungal agents 
when treating common fungal infections. 
 
P080 
Contribution of Galleria mellonella model to understand interactions between Aspergillus 
fumigatus and Stenotrophomonas maltophilia: study of human, animal and environmental 
strains. 
 
M.-F. Durieux1,2, É. Melloul2, L. Roisin2, P.-L. Woerther2,3, V. Risco2,4, J. Guillot2,4, M.-L. Dardé1, E. 
Dannaoui5, J.-W. Decousser2,3, F. Botterel2,6 
1Hopital Dupuytren, Laboratoire de Parasitologie-Mycologie, Limoges, France, 2Dynamyc, Créteil, 
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France, 3Microbiology, Hôpital Henri-Mondor, Créteil, France, 4École Nationale Vétérinaire D’alfort, 
Unité de Parasitologie-Mycologie, Maisons-Alfort, France, 5Hôpital Européen Georges Pompidou, 
Laboratoire de Parasitologie-Mycologie, Paris, France, 6Laboratoire De Parasitologie-mycologie, 
APHP Hôpital Henri Mondor, Créteil, France 
Objectives: Clinical and environmental strains of Aspergillus fumigatus (Af) and Stenotrophomonas 
maltophilia (Sm) can colonize the respiratory tract of patients with chronic lung diseases such as cystic 
fibrosis, specially in biofilm form. The interactions between these two pathogens are not well known 
(1, 2). For a decade, insect model Galleria mellonella (Gm) can be used to screen microorganism 
pathogenicity. The aim of this study was to compare several associations of Af – Sm strains of 
different origin in a Gm model to determine the virulence of these associations. 
Methods: An in vivo infection model with human, animal and environmental strains of Af and Sm, 
alone and associated, was developed using larvae of Gm. Several couples were tested using different 
strains of Sm and Af, especially human reference clinical strains (Af13073 and Sm13637). Virulence 
was analysed by survival curves at 7 days and histology method. 
Results: Mortality rate with Af alone showed no significant difference between human, animal and 
environmental strains. For Sm, mortality rates showed variations depending on the strains. The 
association between reference clinical strains Sm13637 and Af13073 showed a synergistic effect in Gm 
(60% of mortality at 7 days) versus Sm 13637 alone (10% mortality) and Af13073 alone (30% 
mortality). This effect was not observed with the other co-infections. Gomori-Grocott coloration of 
histological sections showed fungal nodules disseminated in the larvae and a Gram coloration 
demonstrated the presence of the bacteria, validating our infection model (3). 
Conclusion: For the first time, we described a coinfection of Af and Sm in a Gm model with an 
interesting synergistic effect between human clinical strains. This effect did not exist for 
environmental and animal strains showing a particular fitness between the human strains. These 
preliminary results provide complementary data to the in vitro data already obtained. The Gm model 
has demonstrated its relevance for the study of mixed infections, which remains to be improved (2). 
Indeed, the extracellular matrix could not be identified in Gm, which could validate the presence of 
mixed biofilm. (1, 2) Melloul et al. 2016 and 2018 (3) Société Française de Mycologie Médicale price 
of the best oral communication, 2019. 
 
P081 
Antifungal susceptibility of Lictheimia corymbifera biofilms to Amphotericin B formulations and 
Posaconazole 
A. Vikelouda1, M. Simitsopoulou1, C. Antachopoulos1, L. Skoura2, A. Chatzimoschou1, I. Stamouli1, 
E. Roilides1 
13rd Department Of Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece, 
2Department Of Microbiology,, Aristotle University, Thessaloniki, Greece 
Objectives: Mucormycosis is an emerging life-threatening opportunistic fungal infection that affects 
patients with underlying immunosuppressive conditions, such as hematological malignancies, 
trauma, hematopoietic stem cell transplantation and diabetes mellitus. The ability of Mucorales to 
form biofilms, structures with reduced susceptibility to antifungal agents, has recently been 
demonstrated., Lictheimia Corymbifera is the second most common clinically significant Mucorales 
species and is related mostly to pulmonary and trauma infections. We investigated the antifungal 
activity of deoxycholate amphotericin B (D-AMB), liposomal amphotericin B (L-AMB), posaconazole 
(POS) against planktonic cells and mature biofilms of Lichteimia corymbifera. Additionally, we 
investigated the combinational activity of L-AMB with POS against mature biofilms. 
Methods: Three L. corymbifera clinical strains, were isolated from bronchial secretions and incubated 
at 10^5 cfu/ml in 96-well microtiter plates at 37οC for 48h. Biofilm formation was assessed by 1% 
safranin staining and measured spectrophotometrically at 490 nm. In order to determine the MIC, 
two-fold dilutions of D-AMB, L-AMB and POS (0.007-256 mg/l) were incubated with biofilms or 
planktonic cells (2x10^5 cfu/ml) for 24h (n = 9). XTT metabolic reduction assay was used to assess 
biofilm damage compared to controls. MIC50 was determined as ≥50% biofilm damage. The activity 
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of the combination of L-AMB (0.5-32 mg/l) with POS (0.125-64 mg/l) against biofilms was determined 
using a checkerboard microdilution method (n = 10). Drug interactions were analyzed using Bliss 
independence model. The combination effect was defined as synergistic, antagonistic or indifferent 
when the observed biofilm damage was significantly higher, lower or equal to the expected damage, 
respectively. 
Results: All L. corymbifera strains exhibited strong biofilm formation. Biofilm MIC50 of D-AMB, L-
AMB and POS were 2, 4 and >256 mg/l, respectively, as compared to 0.007, 0.03 and 0.03 mg/l for 
planktonic cells. Synergistic effects were observed at 1-2 mg/l of L-AMB combined with 8-16 mg/l of 
POS (mean ΔE value of significant interactions:19% [range: 17% to 21%]; mean SE:1% [range: 1% to 
3%]). None of the combinations exhibited antagonism. 
Conclusion: L. corymbifera can produce strong biofilms that possess comparable susceptibility 
profiles to D-AMB and L-AMB, but are resistant to POS. The combination of L-AMB with POS at 
super-therapeutic concentration ranges exhibits synergistic activity against mature L. corymbifera 
biofilms. 
 
P082 
Biofilm formation by Histoplasma capsulatum in different culture mediums and oxygen 
atmospheres 
L.C. Gonçalves1, C. Orlandi1, N.M. Bila1,2, C.O. Vaso1, R.A. Moraes Da Silva1, M.L. Taylor3, M.J. 
Soares Mendes Giannini1, A.M. Fusco Almeida1 
1Clinical Analysis, UNESP (Sao Paulo State University), Araraquara, Brazil, 2Para-clinics, UEM 
(Eduardo Mondlane University), Maputo, Mozambique, 3Microbiology And Parasitology, UNAM 
(Autonomous University of Mexico), México, D.F., Mexico 
Objectives: This work aimed to study Histoplasma capsulatum biofilms, by checking the influence of 
different culture media and oxygen atmospheres in the development of these communities. 
Methods: The biofilm formation by two strains (ATCC 26029 – G186A and EH315) was 
characterized in different nutrient conditions [Brain Heart Infusion (BHI), Roswell Park Memorial 
Institute (RPMI) with 2% of glucose, Dulbecco's Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum and nutrient medium HAM-F12 (HAM-F12) supplemented with 
glucose (18.2 g / L), glutamic acid (1 g / L), HEPES (6 g / L), and L-cysteine (8.4 mg / L)] and 
atmospheres of oxygen (aerobic and microaerophilic). Optical microscopy techniques, XTT 
reduction assay, as well as crystal violet and safranin staining, and scanning electron microscopy 
(SEM) were performed. 
Results: The results indicated that, although all the culture media stimulated the maturation of the 
communities, the nutrient-rich culture media, such as HAM-F12, provided a better biomass and 
extracellular matrix development when compared to the others. In addition, microaerophilic 
conditions were the most favorable than aerobic. The topographies observed in SEM showed yeasts 
surrounded at several points by an exuberant amount of extracellular matrix. However, the 
biofilms formed in BHI, RPMI and DMEM presented a reversal yeast for significant filamentation, 
which needs better investigation. 
Conclusion: The results obtained so far represent significant advances for the field of biofilms and 
open new possibilities for the study of virulence and Histoplasma-host interaction. Funding: FAPESP 
(Fundação de Amparo à Pesquisa do Estado de São Paulo Process # 2016/11836-0); CNPq (Conselho 
Nacional de Desenvolvimento Científico e Tecnológico Process # 130018/2018-0) and Capes 
(Coordenação de Aperfeiçoamento de Pessoal de Nível Superior). 
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Combined treatment of experimental paracoccidiodomycosis with Itraconazole and low-level 
LASER therapy 
E. Burger1, J.C. Grisolia1, L.A. Santos1, N.A. Dias1, L.C.C. Malaquias1, A.M. Rodrigues2, Z.P.D. 
Camargo2 
1Department Of Microbiology And Immunology, Federal University of Alfenas, Alfenas, Brazil, 
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2Department Of Microbiology, Immunology And Parasitology, Federal University of Sao Paulo, 
Alfenas, Brazil 
Objectives: Paracoccidioidomycosis (PCM) is a systemic mycosis caused by the fungus 
Paracoccidioides brasiliensis (Pb), requiring long treatment, justifying studies that amplify the 
therapeutic options. Itraconazole (Itra) is effective for PCM and requires shorter therapy than other 
drugs. We propose to study a shorter treatment model with fewer side effects through the activation 
of neutrophils by the simultaneous administration of the antifungal drug Itraconazole and adjuvant 
therapy with Low Level LASER Therapy (LLLT) to provide better control in the early stages of the 
infection, leading to a more efficient and protective immune response, resulting in the control or cure 
of this disease. 
Methods: We used a highly purified PMNs preparation by inoculating Pb in subcutaneous air 
pouches of mice. We evaluated the effect of Itraconazole (Itra) therapy and/or LLLT therapy on their 
size, cellular composition, mitochondrial activity, protein metabolism, production of reactive oxygen 
(ROS) and nitrogen (NO) species, production of IL-10, INF-y and TNF-α cytokines, and on tissue 
architecture and number of viable fungi. 
Results: The viability of air pouch cells was always greater than 70%, therefore, none of the 
treatments had adverse effects, and about 80% of the cells were PMN. Mitochondrial activity and cell 
counts differed significantly between LLLT-treated and controls and between mice treated with 
different Itra concentrations, with or without LLLT. Cells from 10mg/mL Itra-treated mice produced 
the highest levels of ROS followed by those of 3mg/mL. When Itra was associated with LLLT 
treatment, we found an increase in NO production in the 3mg/mL group. Total protein levels were 
higher when Itra was used, compared to the untreated group or to the group treated with LLLT alone, 
in which LLLT increased protein production in the 3mg/mL group and decreased in the 10mg/mL 
group. LLLT increased the production of cytokines IL-10, INF-y and TNF-α, and the use of antifungal 
decreased their production at all doses, both using only Itra treatments and in combination with 
LLLT. The highest dose of Itra (50mg/mL) resulted in a significant reduction of air pouch size, volume 
and weight. The intensity of the inflammatory process and the number of vessels and neovas 
decreased when the concentration of Itra in combination with LLLT increased. The numbers of viable 
Pb were significantly reduced when Itra was administered in a dose-response way and more 
markedly when used in combination with LLLT. 
Conclusion: Pb numbers decreased significantly when Itra was given at all concentrations, and this 
effect increased when used in combination with LLLT. Itra at 50 mg/mL caused a significant 
reduction in air pouch, indicating a dose-response control. Our results strongly suggest that the 
efficiency of Itra is enhanced by LLLT. Therefore, we could detect a possible additive or synergistic 
effect of PMNs, the antifungal drug Itra and LASER therapy, suggesting a new, more effective 
treatment for PCM. Grants: CNPq 305216/2016-3 and FAPEMIG APQ 012941-16. J.C.Grisolia and L.A. 
Santos are recipients of CAPES scholarships. 
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Clinical outcome of chronic pulmonary aspergillosis patients managed surgically 
F. Setianingrum1,2, R. Rautemaa-Richardson1,3,4, R. Shah4,5, D. Denning1,3,4 
1Division Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, 
United Kingdom, 2Department Of Parasitology, Universitas Indonesia, Jakarta, Indonesia, 3National 
Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 
4Manchester Academic Health Science Centre, Manchester, United Kingdom, 5Department Of 
Cardiology And Cardiothoracic Surgery, Manchester University NHS Foundation Trust, 
Wythenshawe Hospital, Manchester, United Kingdom 
Objectives: Surgery is one of the treatment options for chronic pulmonary aspergillosis (CPA), 
especially for single aspergilloma, for those with recurrent haemoptysis despite bronchial artery 
embolisation or with the unilateral azole-resistant disease. This study aims to evaluate the outcomes 
of patients managed surgically and the correlation between Aspergillus Immunoglobulin G (IgG) 
levels and response to treatment. 
J. Fungi 2019, 5, 95 149 of 464 
 
Methods: This was a retrospective cohort study evaluating CPA patients who were treated at 
National Aspergillosis Centre, Manchester, UK over an 11-year period (2007-2018). Clinical variables 
including antifungal therapy and Aspergillus-IgG (Thermo Fisher/Phadia) were recorded and 
correlated with surgical success or relapse. Aspergillus-IgG were analysed based on 37 patients with 
complete serology database. 
Results:  
 
61 patients with CPA underwent surgery with a mean duration of follow-up of 36 months. The mean 
age was 52.8 (+ 14.3) years. The most common presenting symptoms pre-operatively were cough (n 
= 41, 67%), haemoptysis (n = 24, 39%), dyspnea (n = 23, 38%) and 5 patients (8%) were asymptomatic. 
Failed medical therapy (n = 31, 51%) and presumed malignancy (n = 23, 38%) were the most common 
indications for surgery. The most common sign of failed medical therapy was recurrent haemoptysis 
(n = 19, 31%). Twenty-six patients (43%) had single aspergilloma, 23 patients (38%) showed chronic 
cavitary pulmonary aspergillosis (CCPA) while 19 patients (31%) had one or more Aspergillus nodule. 
Main underlying diseases were chronic obstructive pulmonary disease (n = 19, 31%), asthma (n = 18, 
30%), bronchiectasis (n = 14, 23%) and previous pneumothorax (n = 13, 21%). The procedures included 
lobectomy (n = 39, 64%), wedge resection (n = 17, 28%), segmentectomy (n = 3, 5%), pneumonectomy 
(n = 3, 5%) and decortication (n = 2, 3%). Main surgical complications were pleural infection (n = 7, 
12%), prolonged air leak (n = 3, 5%) and persistent pneumothorax (n = 3, 5%). Assessed 6-8 months 
after surgery, 21 patients were asymptomatic (34%), 23 experienced cough (38%), 6 patients (10%) 
had haemoptysis, and the frequency of these symptoms reduced significantly after surgery (p< 0.05). 
Relapse occurred in 25 patients (41%) while the rest of the patients (n = 36, 59%) showed no sign of 
relapse. Haemoptysis, cough and dyspnea decreased significantly in the non-relapse group, whereas 
only haemoptysis was initially less frequent in relapse group (p<0.05). In this relapse group, 6 (24%) 
patients received antifungal before surgery compared to 23 (64%) in the non-relapse group (p = 0.002). 
Perioperative antifungal therapy was administered to 5 (20%) patients who relapsed and 19 (53%) 
who did not (p = 0.01). The median Aspergillus-IgG in the non-relapse group (n = 12, 32.4%) before 
surgery was 75 mg/L decreasing to 52 mg/L in the end of follow-up (p = 0.003). The median survival 
time (free-relapse) was 88 months in patients with antifungal therapy before surgery and 31 months 
in patients without antifungal therapy before surgery (p = 0.002). 
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Conclusion: Surgery in these selected CPA patients resulted in favourable outcomes with a decrease 
in clinical symptoms and the Aspergillus-IgG level of the non-relapse group of CPA. Pre and 
perioperative antifungal therapy reduced the likelihood of CPA relapse, but confounding factors may 
contribute to this. The diagnosis of CPA before surgery is important to optimise pre and perioperative 
antifungal therapy in patients to improve prognosis. 
 
P087 
The all new, updated antifungal drug interaction database at www.aspergillus.org.uk The all new, 
updated antifungal drug interaction database at www.aspergillus.org.uk The all new, updated 
antifungal drug interaction database at www.aspergillus.org.uk 
S. Niazi-Ali1, D. Denning2,3, G. Atherton2,3, M. Walczak3,4 
1Fungal Interaction Trust, Macclesfield, United Kingdom, 2University of Manchester, Manchester, 
United Kingdom, 3National Aspergillosis Centre, Manchester University NHS Foundation Trust, 
Manchester, United Kingdom, 4Manchester Academic Health Science Centre, Manchester University 
NHS Foundation Trust,, Wythenshawe, United Kingdom 
Objectives: A drug-drug interaction describes the influence of one drug upon another or the change 
in a drug’s effect on the body when the drug is taken together with a second drug. A drug-drug 
interaction can delay, decrease, or enhance absorption or metabolism of either drug. The antifungal 
drug interaction database was first launched in 2012. It is available as web 
(www.aspergillus.org.uk/content/antifungal-drug-interactions) and app versions to allow 
information on potential drug interactions with antifungals with a version for patients and another 
for health professionals. New drugs are constantly being launched and approved. In this era, with 
the requirement of speed and accurate information due to pressures on all healthcare professionals, 
a new and updated database with apps (on Apple and Android platforms) has been created. This 
allows all of the above with the added benefit of real time updates in a more time efficient manner. 
Methods: Horizon scanning documents were reviewed from 2017, 2018 and 2019 to date. Drugs that 
were not in the current database were identified and interactions determined using the Summary of 
Product Characteristics together with further exploration, as needed, with review of papers. CYP 
P450 and p-glycoprotein are the major interaction pathways where antifungal drugs are involved. 
However other pathways like OATP1B1 and BCRP were also explored, as there is new and emerging 
information on the effect of these pathways with drug-drug interactions. 
Results: 
 
134 new preparations were identified to April 2019 leading to updated information. 16 classed as red 
(severe interactions with some antifungals), 29 as amber (moderate interactions where co-
administration is possible and guidance on any management required) and 89 as green (interaction 
unlikely). These were added to the database together with references to ensure the user is able to, 
refer and, find references with ease to validate their decisions. Of 16,324 possible interactions for 
drugs licensed by the end of 2018, 507 are potentially severe (3.1%), 1080 (6.6%) moderate and 809 
mild interactions (4.9%). The antifungals with the least interactions are anidulafungin (n = 3 mild) 
and micafungin (n = 4 moderate & 8 mild) which contrasts with voriconazole with 459 interactions 
(140 severe) and itraconazole with 404 interactions (134 severe). 
Conclusion: The new and revised version of the web and smartphone app-based database of these 
drug interactions with antifungal agents is now available. This will allow clinicians to effectively 
evaluate the use of antifungals with all the new drugs on the market and allow the best outcome for 
their patients. It will also enable them to make the most effective and evidence-based decisions for 
those drugs that are co-administered and require a little more clinical management to provide the 
most successful treatment for the wellbeing of their patients. 
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P088 
Posaconazole Serum Drug Levels Associated with Hypertension and Hypokalemia: The 
Syndrome of Pseudohyperaldosteronism 
M.-V. Nguyen1, M. Davis1, R. Wittenberg1, I. Mchardy1, J. Baddley1, B. Young1, A. Odermatt2, G. 
Thompson1 
1Infectious Disease, University of California at Davis, Davis, United States of America, 2Toxicology, 
University of Basel, Basel, Switzerland 
Objectives: Posaconazole tablets are well tolerated and efficacious in the prophylaxis and treatment 
of aspergillosis, mucormycosis, and other invasive fungal infections There have been case reports of 
posaconazole-induced pseudohyperaldosteronism, however, its occurrence and association with 
serum posaconazole drug levels has not previously been investigated. 
Methods: In this single-center retrospective observational study, we examined the occurrence of 
posaconazole-induced pseudohyperaldosteronism (PIPH) in outpatients newly starting 
posaconazole and evaluated differences in serum posaconazole concentrations and clinical 
characteristics between those with and without this syndrome. 
Results: Sixty-nine patients receiving posaconazole were included, of whom 16 (23.2%) met the 
definition of PIPH. Patients with PIPH were significantly older (61.1 vs 44.7 years, P = 0.007) and 
more frequently had hypertension prior to starting posaconazole (68.8% vs 32.1%, P = 0.009). Patients 
with PIPH had a significantly higher median serum posaconazole level than those without PIPH (3.0 
vs 1.2 µg/mL, P< = 0.0001). There was a positive correlation between serum posaconazole levels and 
changes in systolic blood pressure (r = .37, P = 0.01), a negative correlation between serum 
posaconazole levels and changes in serum potassium (r = -.39, P = 0.006), and a positive correlation 
between serum posaconazole levels and serum 11-deoxycortisol (r = .69, P<0.0001). 
Conclusion: Posaconazole is associated with secondary hypertension and hypokalemia, consistent 
with pseudohyperaldosteronism, and development is associated with higher serum posaconazole 
concentrations, older age, and baseline hypertension. 
 
P089 
A case of primary joint infection caused by Candida pelliculosa 
S.-H. Kim1, K.Y. Song2, J.-H. Choi1 
1Department Of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, 
Korea, Republic of, 2Department Of Orthopaedic Surgery, College of Medicine, The Catholic 
University of Korea, Seoul, Korea, Republic of, Seoul, Korea, Republic of 
Case Report: Candida joint infection is most often due to hematogenous seeding during an episode of 
candidemia in immunocompromised patients. Exogenous inoculation after trauma or surgical 
procedures also can lead to infection, but primary joint infection caused by Candida species is 
extremely rare. Until now, some Candida joint infections by Candida albicans, Candida krusei, Candida 
lusitaniae, Candida parapsilosis, and Candida tropicalis have been reported. Herein, we report the first 
case of primary knee joint infection caused by Candida pelliculosa without predisposing factors. A 75-
year-old woman came to our hospital with a 3-year history of pain and swelling of the left knee, with 
the pain particularly aggravated for the past 1 month. The patient had undergone a left total knee 
arthroplasty (TKA) for incapacitating knee pain at a local hospital 32 months ago. At that time, C. 
pelliculosa was isolated from the tissue taken by intraoperative biopsy, but no antifungal treatment 
was performed. One year after TKA, C. pelliculosa was repeatedly isolated from left knee synovial 
fluid and the patient was treated with intravenous amphotericin B deoxycholate (0.5 mg/kg/day) for 
4 weeks, then intravenous fluconazole (6 mg/kg/day) for 3 weeks, followed by oral fluconazole (4 
mg/kg/day) for 2 weeks. However, progressive bone loss around prosthetic components was seen on 
follow-up radiographs and the patient was referred to tertiary hospital. The patient had no other 
significant medical history. The patient was admitted to our hospital and arthrocentesis of the left 
knee was performed. Results of synovial fluid analysis were as follows: leukocyte, 608 cells/μL 
(neutrophil, 54%); protein, 5.9 g/dL; glucose, 7 mg/dL. Magnetic resonance imaging showed a large 
abscess around the antero-lateral aspect of the left knee. Fungal culture of synovial fluid reported as 
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C. peilliculosa susceptible to amphotericin B (minimum inhibitory concentration [MIC], ≤0.25 mg/L), 
caspofungin (MIC, ≤0.25 mg/L), fluconazole (MIC, 2 mg/L), micafungin (MIC, ≤0.06 mg/L), and 
voriconazole (MIC, ≤0.12 mg/L) by Vitek 2 yeast identification system. The isolate was confirmed as 
C. pelliculosa using Internal transcribed spacer 1 and 4 region PCR and sequencing. At 2 weeks of 
micafungin (100 mg/day) therapy, the patient underwent prosthesis resection with debridement of 
soft tissue and bone, total synovectomy, and placement of an antibiotic-impregnated spacer. 
Operative findings showed infected granulation tissue in whole joint space and bony fistula extended 
to the anterolateral aspect of the lateral tibial component. Postoperatively, the patient was given 
micafungin for 4 weeks, followed by oral fluconazole (6 mg/kg/day). There were no signs of infection 
around the left knee and the patient was discharged from the hospital. Oral fluconazole will be given 
for at least 6 months and implantation of new prosthesis is planned at 3 months after the stage 1 
procedure. Rare Candida species could be a causative organism of primary joint infection. Even a 
single colony of Candida on synovial fluid or bone biopsy should be considered as pathogenic, and 
the patient should be treated with antifungal agents. A high index of suspicion is required to establish 
the diagnosis. 
 
P090 
Transdiaphragmatic Mucormycosis 
P. Köhler1, R. Reimer2, R. Whaba3, B. Schömig-Markiefka4, O.A. Cornely1 
1Department I For Internal Medicine, European Excellence Center For Medical Mycology (ecmm), 
Germany And Cecad Cluster Of Excellence, University of Cologne, Cologne, Germany, 2Department 
Of Diagnostic And Interventional Radiology, University Hospital Cologne, Cologne, Germany, 
3Department Of General, Visceral And Cancer Surgery, University Hospital Of Cologne, University 
of Cologne, Cologne, Germany, 4Institute Of Pathology, University Hospital Cologne, Cologne, 
Germany 
Objectives: Introduction Mucormycosis is a life-threatening infection in immunocompromised 
patients and in haematological malignancy patients in particular. Objectives To report the 
phenomenon of transdiaphragmatic mucormycosis and to raise concerns with regard to the extent of 
imaging studies in patients with mucormycosis. 
Methods: Retrospective chart review was performed on patients with Mucormycosis treated at the 
University Hospital of Cologne between January 2011 and January 2019. 
Results: In a series of three patients we observed a previously unreported contiguous disease pattern, 
where the pulmonary type of disease contiguously spread through the diaphragm into abdominal 
organs, mostly liver or spleen. Patient 1, a 53-year-old women with history of B-NHL, ASCT and 
chronic renal disease developed mucormycosis of the lungs with continuous growth through the 
diaphragm into the liver. Histology showed invasive growth of fungal hyphae of the Mucorales order 
in liver and diaphragm. Patient 2, a 35-year-old man with history of AML and no further underlying 
conditions developed mucormycosis of the lungs with continuous growth through the diaphragm 
into the spleen. Splenectomy was performed and histology showed invasive growth of fungal 
hyphae. Fungal cultures of the surgical sample remained negative, but panfungal PCR resulted in 
Rhizomucor spp. Patient 3, a 42-year-old man with history of poorly controlled IDDM and injection 
drug use developed mucormycosis of the lungs with continuous growth through the diaphragm into 
the liver. Fungal culture of BAL fluid showed growth and PCR positivity of Rhizopus microsporus. 
Conclusion: This is the first report of the clinical observation of transdiaphragmatic mucormycosis 
in 3 patients. We observed this phenomenon in 11% (3/27) of patients, raising concerns with regard 
to the extent of imaging studies in patients with mucormycosis. Clinicians should become aware of 
this new-described entity. 
 
P091 
Baseline predictors influencing the prognosis of invasive aspergillosis in adults 
P. Köhler1, J. Salmanton-Garcia2, S. Gräfe3, F. Köhler3, S. Mellinghoff4, D. Seidel1, A. Steinbach5, O.A. 
Cornely6 
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1Department I Of Internal Medicine, Ecmm Excellence Centre Of Medical Mycology, Cologne 
Excellence Cluster On Cellular Stress Responses In Aging-associated Diseases (cecad), University 
Hospital Cologne, Cologne, Germany, 2Department I For Internal Medicine, European Excellence 
Center For Medical Mycology (ecmm), Germany And Cecad Cluster Of Excellence, University of 
Cologne, Cologne, Germany, 3Cologne Excellence Cluster on Cellular Stress Responses in Aging-
Associated Diseases (CECAD), Cologne, Germany, 4Department I Of Internal Medicine, Ecmm 
Excellence Centre Of Medical Mycology, Cologne Excellence Cluster On Cellular Stress Responses In 
Aging-associated Diseases (cecad), German Centre For Infection Research, Partner Site Bonn-cologne, 
University Hospital Cologne, Cologne, Germany, 5Cologne Excellence Cluster on Cellular Stress 
Responses in Aging-Associated Diseases (CECAD), German Centre for Infection Research, Partner 
Site Bonn-Cologne, Cologne, Germany, 6Department I Of Internal Medicine, Ecmm Excellence Centre 
Of Medical Mycology, Cologne Excellence Cluster On Cellular Stress Responses In Aging-associated 
Diseases (cecad), German Centre For Infection Research, Partner Site Bonn-cologne, Clinical Trials C, 
University Hospital Cologne, Cologne, Germany 
Introduction: Invasive aspergillosis (IA) is a serious hazard to hematological and critical care 
patients.  
Objectives: To understand prognostic variables we analyzed original articles identifying baseline 
factors that predict treatment outcome in patients with IA. 
Methods: PubMed database was searched for publications since database inception until May 2018. 
Inclusion criteria were published baseline prognostic factors present at the diagnosis of IA. 
Results: In total, 58 studies from 267 centers reported 7,320 patients with IA, and 40 different 
predictors. Unfavorable predictors in medical history were kidney (7.4%, 10/136) and liver failure 
(3.7%, 5/136), ICU admission (3.7%, 5/136), and uncontrolled underlying disease (3.7%, 5/136). 
Regarding state of immunosuppression, negative outcome predictors were prolonged neutropenia 
(12.5%, 17/136), corticosteroid treatment (8.1%, 11/136), and graft-versus-host disease (3.7%, 5/136). 
On the pathogen side, relevant predictors were galactomannan positivity (8.1%, 11/136), Aspergillus 
terreus infection (2.2%, 3/136), and lack of amphotericin B susceptibility (1.5%, 2/136). IA-specific 
predictors were disseminated disease (5.1%, 7/136) and CNS involvement (2.9%, 4/136). Imaging 
results associated with negative outcome were multiple consolidations (2.9%, 4/136), bipulmonary 
lesions (2.2%, 3/136), and pleural effusion (2.2%, 3/136). 
Conclusion: At diagnosis of IA, most frequently identified predictors of outcome were neutropenia, 
corticosteroid use, elevated galactomannan, renal failure, and disseminated disease. 
 
P092 
EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure 
QUALity of the clinical management of invasive pulmonary aspergillosis 
O.A. Cornely1, P. Köhler2, D. Arenz3, S. Mellinghoff2 
1Department I For Internal Medicine, Excellence Center For Medical Mycology (ecmm), Cecad 
Cluster Of Excellence, Clinical Trials Centre Cologne (zks Köln), University of Cologne, Cologne, 
Germany, 2Department I For Internal Medicine, Excellence Center For Medical Mycology (ecmm), 
Cecad Cluster Of Excellence, University of Cologne, Cologne, Germany, 3Department I For Internal 
Medicine, Excellence Center For Medical Mycology (ecmm), University of Cologne, Cologne, 
Germany 
Introduction: Invasive pulmonary aspergillosis is a serious threat to immunocompromised and 
critical care patients. Recent detailed guidelines and treatment algorithms lead microbiologists and 
clinicians in diagnosis and treatment of invasive aspergillosis.  
Objectives: Currently, there is no tool available that allows to measure guideline adherence and 
quality of managing invasive pulmonary aspergillosis. 
Methods: To develop such a tool, we reviewed current guidelines provided by 5 scientific societies: 
European Society for Clinical Microbiology and Infectious Diseases, European Confederation of 
Medical Mycology, the European Respiratory Society, Infectious Diseases Society of America (IDSA), 
and Infectious Diseases Working Party of the German Society for Hematology and Medical 
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Oncology. We selected the strongest recommendations for management as key components for our 
scoring tool, broke down guidelines, and grouped recommendations into 3 groups: diagnosis, 
treatment, follow-up. First, we selected “AI” and “AII” recommendations. Then, we added aspects 
that are part of a complete work-up, but are either recommended with a lower grade of evidence or 
not specifically recommended in current guidelines. In a last step, we allocated score points according 
to levels of evidence and clinical importance. 
Results: We developed the EQUAL Aspergillosis Score 2018 to measure the quality of clinical 
management of invasive pulmonary aspergillosis. We integrated diagnostic measures (chest 
computed tomography, bronchoalveolar lavage with galactomannan, fungal culture, fungal 
polymerase chain reaction analysis, species identification, and susceptibility testing; histology with 
silver stain, Periodic acid–Schiff staining, and molecular diagnostics), treatment (antifungal choice 
and therapeutic drug monitoring), and follow-up computed tomography. For ease of use, we have 
summarized the EQUAL scores on laminate pocket cards, which will be translated in 15 different 
languages. The EQUAL Aspergillosis Score 2018 can be used to evaluate guideline adherence in daily 
clinical practice and thus aims to support antifungal stewardship. 
Conclusion: The EQUAL Aspergillosis Score 2018 aggregates and weighs the components 
recommended in the ideal management of invasive pulmonary aspergillosis and provides a tool 
supporting antifungal stewardship and quantifying guideline adherence. 
 
P093 
EQUAL Mucormycosis Score 2018: An ECMM Score Derived From Current Guidelines to Measure 
QUALity of Mucormycosis Management in Hematology 
P. Köhler1, S. Mellinghoff1, A. Alanio2, D. Arenz3, M. Hoenigl4, K. Lagrou5, C. Lass-Flörl6, J. Meis7, 
M.D. Richardson8, O.A. Cornely9 
1Department I For Internal Medicine, Excellence Center For Medical Mycology (ecmm), Cecad 
Cluster Of Excellence, University of Cologne, Cologne, Germany, 2Paris-diderot, Sorbonne Paris Cité 
University, Institut Pasteur, Molecular Mycology Unit, Cnrs Cmr2000, Parasitology-Mycology 
Laboratory, Lariboisière Saint-Louis Fernand Widal Hospitals, Assistance Publique-Hôpitaux de 
Paris, Paris, France, 3Department I For Internal Medicine, Excellence Center For Medical Mycology 
(ecmm), University of Cologne, Cologne, Germany, 4Division Of Infectious Diseases, Department Of 
Medicine, UCSD, San Diego, United States of America, 5Laboratory Of Clinical Bacteriology And 
Mycology, Department Of Microbiology And Immunology, Excellence Center For Medical Mycology 
(ecmm), KU Leuven, Leuven, Belgium, 6Division Of Hygiene And Medical Microbiology, Excellence 
Center For Medical Mycology (ecmm), Med. Univ. Innsbruck, Innsbruck, Austria, 7Department Of 
Medical Microbiology And Infectious Diseases, Excellence Center For Medical Mycology (ecmm), 
Canisius Wilhelmina Hospital, Nijmegen, Netherlands, 8Mycology Reference Centre, Excellence 
Center For Medical Mycology (ecmm), Wythenshawe Hospital, Manchester University NHS 
Foundation Trust, Manchester, United Kingdom, 9Department I For Internal Medicine, Excellence 
Center For Medical Mycology (ecmm), Cecad Cluster Of Excellence, Clinical Trials Centre Cologne 
(zks Köln), University of Cologne, Cologne, Germany 
Introduction: Mucormycosis is a serious infectious threat to immunocompromised patients in 
general and in hematological malignancy in particular. Detailed standards and treatment algorithms 
guide microbiologists and clinicians in the diagnosis and treatment of mucormycosis.  
Objectives: Currently, there is no tool available that allows the measurement of guideline adherence 
and the quality of managing mucormycosis. 
Methods: To develop such a tool, we reviewed current guidelines provided by four scientific 
societies: the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the 
European Confederation of Medical Mycology (ECMM), the European Conference on Infections in 
Leukemia (ECIL), and the Infectious Diseases Working Party of the German Society for Hematology 
and Medical Oncology. We selected the strongest recommendations for management as key 
components for our scoring tool, broke down guidelines, and grouped recommendations into three 
groups: diagnosis, treatment, follow-up. First, we selected “AI” and “AII” recommendations. Then 
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we added aspects that are part of a complete work-up, but are either recommended with a lower 
grade of evidence or not specifically recommended in current guidelines. In a last step, we allocated 
score points to the various levels of evidence and clinical relevance of diagnostic and therapeutic 
procedures. 
Results: We developed the EQUAL Mucormycosis Score 2018 to measure the quality of 
mucormycosis management. We integrated diagnostic measures (chest computed tomography, 
bronchoalveolar lavage with fungal culture, fungal polymerase chain reaction analysis, species 
identification, susceptibility testing, histology with silver stain, Periodic acid–Schiff staining, and 
molecular diagnostics), treatment (antifungal choice, surgical debridement and therapeutic drug 
monitoring), and follow-up computed tomography. For ease of use, we have summarized the 
EQUAL scores on laminate pocket cards, which will be translated in 15 different languages. The 
EQUAL Mucormycosis Score 2018 can be used to evaluate guideline adherence in daily clinical 
practice and thus aims to support antifungal stewardship. 
Conclusion: The EQUAL Mucormycosis Score 2018 aggregates and weighs recommendations for 
management of mucormycosis and provides a tool supporting antifungal stewardship and 
quantifying guideline adherence. 
 
P094 
Compliance with recurrent vulvovaginal candidiasis guidelines – An audit of RVVC referrals 
L. Brown1, R. Rautemaa-Richardson1,2 
1Faculty Of Biology, Medicine And Health, University of Manchester, pl, United Kingdom, 2Division 
Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, United 
Kingdom 
Objectives: Recurrent vulvovaginal candidiasis (RVVC) is a debilitating, chronic condition which 
affects over 138 million (6%) women of reproductive age annually. It is defined as four or more 
episodes in a 12-month period. Symptoms include vulval itch, soreness and discharge. Diagnosis is 
often difficult, as it is based on a combination of these non-specific clinical symptoms and detection 
of Candida by high vaginal swab (HVS) microscopy, which is part of the normal vaginal flora in many 
women. A number of other infectious and non-infectious conditions can present similarly. Treatment 
of RVVC comprises of vulval skin care with the use of emollients for personal hygiene and antifungal 
treatment combined with long-term antifungal suppression for 6 months or longer. The British 
Association for Sexual Health and HIV (BASHH) has published guidelines on the management of 
RVVC. The aim of our study is to evaluate the compliance of referring doctors to the current 
guidelines. 
Methods: This retrospective audit was undertaken in the Infectious Diseases (ID) department of 
Wythenshawe Hospital, Manchester from October 2017 to May 2019. All patients referred to the 
tertiary clinic with suspected RVVC were included in the analyses. Electronic patient records were 
analysed to determine whether appropriate investigations and treatments had been offered prior to 
referral. The type and pattern of recorded symptoms were assessed against the typical clinical picture 
of RVVC and whether alternative differentials should have taken precedence. 
Results: Patient records from a total of 47 RVVC referrals were analysed. Patient age at the time of 
referral ranged from 17-66 years with a mean age of 37.7 years. Symptom duration prior to referral 
ranged from 4 months to 24 years, with an average duration of 6.7 years. “Dry”, “sensitive” skin or 
“eczema” were mentioned in 36% of the cases. RVVC was the final diagnosis in 80% of cases. 19% of 
referrals were deemed inappropriate due to repeatedly negative HVS for Candida and lack of 
response to antifungal therapy, or reported symptoms not fitting with RVVC. 57% of patients had a 
secondary diagnosis, the most common being vulvodynia and vulval dermatitis. 94% of the patients 
were appropriately investigated by high vaginal swab (HVS) microscopy or culture prior to referral. 
Appropriate antifungal regimens, including long term suppression, were trialled in 53% of patients 
prior to referral. Only 11% patients were practicing appropriate vulval skin care before attending 
clinic. Excessive or otherwise inappropriate personal hygiene likely to irritate vulval skin, including 
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the use of soap and shower gel, was mentioned in 21% of cases. MBL deficiency was diagnosed in 
28% of the patients. 
Conclusion: RVVC is often complicated by coexisting vulval pathologies and vulval symptoms 
labelled as RVVC are often due to alternative diagnoses. Education on vulval skin care is the mainstay 
of RVVC management and prevention but healthcare professionals are failing to deliver this. Also, 
there is lack of awareness of the efficacy and safety of long term antifungal suppression. The 
morbidity related to this debilitating condition could be easily reduced by following the principles 
summarised in the BASHH guidelines. 
 
P095 
Validation of a clinical decision rule for selecting empiric treatment for invasive aspergillosis in 
a setting with high triazole resistance. 
R. Van De Peppel, R. Van Grootveld, B. Hendriks, J. Van Paassen, J. Koopmans, P. Von Dem Borne, 
M. Van Der Beek, M. De Boer 
Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands 
Objectives: World-wide, increasing triazole resistance complicates treatment of invasive 
aspergillosis (IA). In case of detected triazole resistance, the first choice treatment is replaced by 
lipid formulations of Amphotericin B (LAmB). In settings with substantial (>10%) prevalence of 
triazole resistance, empiric combination therapy with both a triazole and LAmB has been 
suggested. However, the expected benefits of this strategy need to be weighed against a higher rate 
of serious adverse events associated with combination therapy, as well as higher costs. To evade 
unnecessary toxicity while optimizing outcome, a clinical decision rule guiding to monotherapy 
with either voriconazole or LAmB was designed and validated. 
Methods: In 2015, all medical specialties involved in the diagnosis and treatment of patients with 
IA participated in constructing a treatment algorithm that provided rationale for empiric 
monotherapy with either voriconazole or LAmB (figure 1). The designed algorithm was approved 
by the institution’s antimicrobial steering committee. Protocolized CT-scanning and 
bronchoalveolar lavage (BAL) were performed upon suspicion of IA. BAL samples were examined 
by direct microscopy, culture, galactomannan assay (cut off at 0.5 OD) and from 2017 onwards also 
by PCR. Triazole resistance was routinely tested by four well agar plate. All adult patients 
diagnosed with IA and treated for this condition in the Leiden University Medical Center from 2015 
to 2019 were included. Data about underlying diseases, age, gender, results of diagnostic tests and 
outcomes, were extracted from the hospital’s electronic patient files and anonymized. Primary 
outcomes were 30- and 100-day crude- and attributable mortality rates. 
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Results: At first evaluation, 102 patients had been treated for IA with monotherapy according to the 
designed algorithm and 3 patients received off-protocol treatment regimens (figure 2). In the period 
of study, prevalence of voriconazole resistance in all Aspergillus isolates varied per year between 
16.3% and 24%. Of included patients, 65 (64%) were male; the median age was 64 (range 18-82), and 
80 (78%) patients were treated for an underlying hematological malignancy. Fifty-nine patients (58%) 
were started on voriconazole and 43 (42%) were started on LAmB. Cultures were positive in 16 
(15.7%) patients and phenotypical voriconazole resistance was detected in 7/16 (44%). Upon clinical 
evaluation of empiric therapy and/or resistance data if available, a switch was made to LAmB in 23/59 
(39%) of patients started on voriconazole. Crude mortality rates per treatment stratum are listed in 
figure 2. Later adaptation of antifungal therapy to LAmB was not associated with a higher crude 
mortality rate (p = 0.73). Definite therapy consisted of voriconazole in 41 (40%) and of LAmB in 61 
(60%) of cases.  
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Conclusion: By applying a comprehensive clinical decision algorithm in our area with high triazole-
resistance rates, 58% of patients were empirically treated with monotherapy voriconazole, without 
excess crude mortality even if a later switch to LAmB was needed. In 40% of patients therapy with 
LAmB could be safely avoided during the entire course of treatment. As treatment allocation was not 
randomized, and confounding by indication plays a role, it remains unclear whether patients directed 
to initial LAmB monotherapy would have benefited from the addition of a triazole. 
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Multicenter study on antifungal prophylaxis in high risk hematology patients - The SAPHIR 
Study 
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1Laboratoire De Parasitologie-mycologie, CHU de Rennes, Rennes, France, 2Pharmacy Department, 
CHU de Martinique, Fort-de-France, France, 3Clinical Haematology Department, CH Lyon-Sud, 
Pierre-Bénite, lyon, France, 4MSD France, courbevoie, France, 5ClinSearch, Malakoff, France, 6Saint-
Louis Hospital, APHP, Paris, France, 7CHRU Lapeyronie de Montpellier, Montpellier, France, 8CHU 
de Nantes, Nantes, France, 9Hospital group Haut Leveque de Pessac, Pessac, France 
Objectives: The main objective of the SAPHIR study was to describe the diagnostic and therapeutic 
management of hematology patients at high risk of Invasive Fungal Disease (IFD) under antifungal 
prophylaxis (AFP) in France. The secondary objectives were the description of (1) parameters and 
diagnostic procedures concomitant to AF therapy management and (2) preventive procedures 
adopted in French hematology services. 
Methods: SAPHIR was an observational, prospective, multicenter, non-comparative French study. 
The included patients were ≥18 years, in a context of myelosuppressive chemotherapy for acute 
myeloid leukemia (AML) and initiated an AF prophylactic treatment. 
Results: The 23 participating hematology services included 404 patients, whose mean age was 
56.4±14.0 years and of whom 51.2% were male. Duration between AML diagnosis and inclusion was 
65.4±178 days with 65.6% being newly diagnosed. A previous chemotherapy had been undergone by 
26.7%. The index chemotherapy, was started 1.06±4.49 days before inclusion and its nature was either 
induction 79.0%, consolidation 12.6% or relapse 8.4%. Among the 404 patients, 91.6% had 
experienced a profound neutropenia period with 1.08±0.51 periods per patient and a duration of 
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23.3±16.6 days. For 373 patients (92.4%), the initially prescribed AFP was posaconazole tablets (90.6%) 
or suspension (1.73%). Considering all patients, 8.17% changed AFP between 1 and 3 times, with the 
first change 17.3±23.9 days after inclusion mostly due to absorption issues (65.0%). The mean AFP 
period was 24.2±32.1 days after which 267 patients (66.8%) stopped because they were at the end of 
the high-risk period and 126 (31.2%) switched to a non-prophylactic AF treatment (2/3 empirical, 1/3 
preemptive/curative), mainly because of fever (67.1%). A total of 18/404 patients (4.46%) have 
received a curative treatment based on positive mycological exams, imaging, antifungal sensitivity 
tests and/or blood cultures. Among them, 9/404 (2.23%) were true probable IFDs: 5 probable invasive 
aspergillosis, 2 pulmonary pneumocystosis, 1 mucormycose and 1 fungemia due to Saccharomyces sp. 
At 7-15 days after AFP discontinuation, 365/387 patients (94.3%) showed no signs and symptoms of 
infection. In the course of the study, 20 patients (5.0%) had deceased within 57.6±50.3 days after 
inclusion. Of those, 7 patients (35.0%) showed signs and symptoms of infection and the death of 3 
patients was directly linked to IFD infections (1 candidiasis and 2 aspergillosis). In order to prevent 
IFD, additionally to AFP, French haematology services provide the patient with sterile/protected food 
(94.3%), digestive decontamination (35.8%), and accommodation in a sterile/isolated area (93.5%). To 
gain a better understanding of the patient characteristics possibly indicating the necessity for a 
consecutive empirical/preemptive/curative AF treatment, data of patients with and without such a 
consecutive treatment were compared. Several parameters proved to be significantly different, for 
instance: cytogenetics and molecular biology prognosis, AML onset, previous chemotherapy 
treatment but also duration between chemotherapy initiation and inclusion and the type of current 
chemotherapy cycle used. 
Conclusion: AF prophylactic treatment is frequently prescribed in French hematology services. Only 
few prophylactic treatment changes are necessary which reflects treatment tolerance and 
effectiveness regarding decreased numbers of intercurrent infections and mortality. 
 
P097 
EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived 
From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management 
A. Spec1, C. Mejia-Chew1, W. Powderly1, P. Köhler2,3, O.A. Cornely2,4 
1Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, United 
States of America, 2Department I For Internal Medicine, European Excellence Center For Medical 
Mycology (ecmm), Germany And Cecad Cluster Of Excellence, University of Cologne, Cologne, 
Germany, 3Department I Of Internal Medicine, Ecmm Excellence Centre Of Medical Mycology, 
Cologne Excellence Cluster On Cellular Stress Responses In Aging-associated Diseases (cecad), 
University Hospital Cologne, Cologne, Germany, 4German Centre For Infection Research, Partner 
Site Bonn-cologne, Cologne, Germany And Clinical Trials Centre Cologne (zks Köln), University of 
Cologne, Cologne, Germany 
Objectives: Cryptococcocis is an opportunistic fungal infection with high morbidity and mortality. 
Guidelines to aid clinicians regarding diagnosis, management, and treatment can be extensive and 
challenging for clinicians. Currently, there is no tool available that allows the measurement of 
guideline adherence and the quality of cryptococcosis management. 
Methods: We reviewed current guidelines from the Infectious Diseases Society of America, the World 
Health Organization, the American Society of Transplantation and recent significant publications to 
select the strongest recommendations as vital components of our scoring tool. 
Results: Items included diagnostic tests (blood, tissue, and cerebrospinal fluid cultures, Cryptococcus 
antigen, India ink, histopathology with special fungal stains, central nervous system imaging), 
pharmacological (amphotericin B, flucytosine, azoles) and nonpharmacological treatments 
(intracranial pressure management, immunomodulation, infectious disease consultation), and 
follow-up of central nervous system complications. For ease of use, we have summarized the EQUAL 
scores on laminate pocket cards, which will be translated into 15 different languages. 
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Conclusion: The EQUAL Cryptococcus Score 2018 weighs and aggregates the recommendations for 
the optimal management of cryptococcosis, providing a tool that could measure guideline adherence 
or facilitate clinical decision-making. 
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An ongoing malady, mucormycosis from a tertiary care centre at Chandigarh, India. 
J. Chander1, A. Bhagat1, N. Gulati1, N. Singla1, R.P.S. Punia2, D. Agarwal3, A.K. Attri4, A. Dass5 
1Microbiology, Government Medical College Hospital, Chandigarh, India, 2Pathology, Government 
Medical College Hospital, Chandigarh, India, 3Pulmonary Medicine, Government Medical College 
Hospitaln, Chandigarh, India, 4General Surgery, Government Medical College Hospital, Chandigarh, 
India, 5Ent, Government Medical College Hospital, Chandigarh, India 
Objectives: Mucormycosis is an emerging necrotizing angioinvasive infection caused by commonly 
encountered filamentous fungi of the class Mucormycetes. In our institution, as the awareness is 
gradually increasing, newer and newer species causing mucormycosis are being recognized. In this 
very reference a study was undertaken to further enhance our knowledge on risk factors, species 
distribution and their antifungal susceptibility testing. 
Methods: The study was conducted on forty-four cases of mucormycosis over a period of eighteen 
months from January 1, 2017 to June 30, 2018. The samples were subjected to microbiological 
examination like KOH/CFW wet mount and fungal culture and histopathology. The isolates obtained 
were identified phenotypically and confirmed by DNA sequencing of internal transcribed spacer 
region.The antifungal susceptibility testingwas done for amphotericin B, posaconazole, itraconazole 
and terbinafine by microbroth dilution as per CLSI Reference Method.Study performed by 
Almyroudis, et al, was referred to define susceptibility for some of the breakpoints for Mucorales. 
Results: The mean age of patients of mucormycosis was 48.89 ± 17.1 years. The proportion of female 
patients (54.5%) was slightly more than male patients (45.5%). Rhino-orbito-cerebral mucormycosis 
(ROCM) was the commonest presentation (61.4%, 27) followed by pulmonary (20.4%, 9) and 
cutaneous (15.9%, 7). One case of mucormycosis of the middle ear was also seen. The most common 
risk factor associated with mucormycosis was diabetes mellitus (77.3%, 34/44), which was found to 
be statistically significant (P = .003). Tooth extraction was seen as a risk factor in 18.5% (5/27) of ROCM 
cases. The commonest isolate was Rhizopus arrhizus(32.3%, 10), followed by Rhizopus microsporus(29%, 
9) and Apophysomyces variabilis (12.9%, 4). Rhizopus homothallicus was isolated from two cases, one of 
middle ear and other from pulmonary mucormycosis. A case of cutaneous mucormycosis caused by 
Thamnostylum piriforme, which is the second case of this genus and first of this species, is being 
reported. Amphotericin B was the most effective drug with an MIC range of 0.0313-4 µg/ml giving 
94.7 % isolates as sensitive. The only isolate resistant was Rhizopus homothallicuswith an MIC of 4 
µg/ml. Posaconazole gave an MIC range of 0.0625-4 µg/ml with 68.4% isolates as sensitive. Dual 
management with surgery and antifungals proved to be significantly better (P< 0.001) than 
amphotericin B alone. Treatment with liposomal amphotericin B (LAmB) was associated with a 
higher survival rate (81%), compared to 28.6% survival when patients were treated with conventional 
amphotericin B deoxycholate. Twelve (27.3%) patients either left against medical advice or were 
referred. A total of 12 patients expired giving a mortality rate of 27.3% and 37.5% among the treated 
patients. 
Conclusion: India has second largest diabetic population globally with nearly 70% being found with 
uncontrolled diabetes leading to high incidence of mucormycosis. Due to an ever-growing 
population at risk and the fatal outcome, need for more prospective studies in this field are 
emphasized. Increased awareness among clinicians, timely diagnosis and prompt treatment are the 
key to the successful management. 
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A. Kumari1, K. Singh2 
1Animal Mycology Laboratory, Zoology, Mmv, Banaras Hindu University, Varanasi, India, 2Animal 
Mycology Laboratory, Zoology, Mmv, Banaras Hindu University, VARANASI, India 
Objectives: Cinnamaldehyde is a natural product obtained from cinnamon and has been reported to 
have insecticidal, antimicrobial, anti-inflammatory, immunomodulatory, anticancer, anti-angiogenic 
and potential anti-fungal effects. The present study investigated the possible protective effect of 
cinnamaldehyde against tenuazonic acid-induced mycotoxicity in murine model. Tenuazonic acid 
(TeA), a toxin produced by Alternaria alternata is a common contaminant in tomato and tomato based 
products. 
Methods: The in-vivo experimental plan was as follows. 
 
All the experimental groups were administered with TeA for 8 weeks. After 2 weeks, the prophylactic 
group was administered with cinnamaldehyde along with TeA for the next 6 weeks. Haematological 
(differential leukocyte count), histopathological (haematoxylin and eosin), biochemical (superoxide 
dismutase, catalase, malondialdehyde, alanine aminotransferase, aspartate aminotransferase) and 
cell apoptotic factor (caspase-3) analyses of the experimental and control mice were performed. 
Results: Behavioral observations- Unlike mycotoxicosis induced groups, no behavioural 
abnormalities were observed in the animals who received cinnamaldehyde as prophylactic agent. 
Weights of the mice of the prophylactic group showed reduced body weight gain as compared to 
that of the mycotoxicosis induced groups. Morphological observations- Hair loss indicating 
mycotoxicosis was not observed in the prophylactic groups. Anatomical observations- 
Spleenomegaly, hepatomegaly and gross lesions on liver and kidney were noted on autopsy in the 
mycotoxicosis induced groups. On the other hand, the prophylactic groups showed normal weights 
of liver and spleen. The body:organ weight indices of all the organs remained at par to control group 
in the prophylactic groups except for the lungs and brain where the weights of the organs were 
significantly high. Haematological analysis- Neutrophilia was observed in IP (mycotoxicosis 
induced) while neutropenia was observed in the oral (mycotoxicosis induced) group while the 
differential leukocyte count of the prophylactic groups were found to lie in normal range. 
Biochemical analyses- Acute intoxication of mice with TeA showed elevated malondialdehyde 
(MDA), reduced catalase (CAT) and superoxide dismutase (SOD) production; abnormal levels of 
aspartate transaminase (AST) and alanine transaminase (ALT). Treatment with cinnamaldehyde 
reversed TeA-induced alterations of antioxidant defense enzyme activities. Histological 
observations- Histopathological changes characterised by non alcoholic fatty liver, nuclear pyknosis 
and infiltration of immune cells were observed in the mycotoxicosis induced groups while 
cinnamaldehyde significantly prevented the TeA-induced organ damage. Cell apoptosis factor- 
Reduced activity of caspase-3 enzyme was noted in the mycotoxicosis induced groups while 
significantly high activity of the enzyme was observed in the prophylactic groups. 
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Conclusion: Thus, from the present study we concluded that, cinnamaldehyde showed therapeutic 
effects and toxicity reduction in TeA induced mycotoxicosis. 
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Candi-SoL: A multi-site retrospective audit and analysis of Candidaemia across three South 
London Teaching Hospitals 
C. Logan1, A. Fife2, A. Goodman3, C. Ward2, T. Bicanic1 
1Infection & Immunity, St Georges university, London, London, United Kingdom, 2Department Of 
Microbiology, Kings College Hospital, London, United Kingdom, 3Department Of Infection, Guy's & 
St Thomas' Hospital, London, United Kingdom 
Objectives: Candidaemia is associated with high mortality, particularly in critical care and 
immunocompromised patients. Emergence of multi-resistant candida species, notably C. glabrata and 
C. auris, pose further challenges in treatment. This retrospective surveillance and audit study reviews 
both adult and paediatric candidaemia cases between January 2012- December 2018 across three 
Tertiary South London Trusts; St George’s Hospital in London, Kings College hospital London and 
Guys & St Thomas’ Hospital. Collectively these trusts have over 3500 beds, including over 220 ICU 
beds (adult surgical, neurological, cardiac and general ICUs and paediatric and neonatal ICU) and 
onsite specialist surgical, cardiothoracic and medical services, including liver, bone marrow and renal 
transplant. The aims of this study were to assess trends in candidaemia epidemiology across the 
South London region, categorise at risk groups, antifungal therapy used and review clinical 
outcomes. 
Methods: Blood cultures for adults and children isolating Candida species between January 2012-
December 2018 were retrospectively identified from the Microbiology database. Species and 
antifungal susceptibility were reviewed. Persistent candidaemia (identical Candida sp. isolated ≤ 
30days after the initial blood culture) was analysed as a single episode. Demographics (age, sex); 
location; risk factors; focus of candidaemia; antifungal treatment received and duration; ECHO 
performed and outcome; ophthalmology performed and outcome; line removal and culture result; 
length of stay; 30-day and in-hospital mortality was collected from electronic patient records. 
Analyses were conducted in Microsoft Excel 2013 and GraphPad Prism V7. 
Results: Between January 2012 – December 2018, 509 candidaemia episodes were identified across 
the three Trusts. In total 42% were C. albicans, 30% C. glabrata, 12% C. parapsilosis and 1% of cases were 
due to C. auris following an outbreak in 2016. There was no significant trend towards an increasing 
proportion of non-albicans species over the 7-year period (Chi-squared test for trend, p = 0.22). 
Regarding age at the time of candidaemia, 4% were neonates (< 1 month), 9% were children (aged 1 
month - <18 years), and 86% were adults (> 18 years). Patients on an intensive care unit (adult, 
paediatric or neonatal) accounted for 43% of cases. Clinical data regarding the candidaemia foci, the 
ECHO and ophthalmology findings, antifungal therapy and duration, B-D-glucan result if available, 
length of stay and mortality will also be presented. Susceptibility profile of isolates will be 
interrogated and presented to assess if there has been a change over time across the three trusts. 
Conclusion: This retrospective audit of candidaemia across three large South London Trusts 
illustrates the changing regional candida epidemiology, with non-albicans species accounting for 
over half of all isolates and highlights the emergence of multi-drug resistant species such as C. auris 
in the London. The remaining analyses of this large dataset will highlight which are the dominant 
causes of candidaemia across the South London Trusts and examine clinical outcomes with 
candidaemia over a diverse group of patients. 
 
P102 
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Experimental Exserohilum rostratum Meningitis and Therapeutic Monitoring with CSF (1→3)-β-
D-glucan: A Preclinical Paradigm for Treatment of CNS Phaeohyphomycosis 
V. Petraitis, R. Petraitiene, E. Naing, B.B.W. Maung, A. Garcia, P. Kavaliauskas, T.J. Walsh 
Infectious Diseases/medicine, Weill Cornell Medicine of Cornell University, New York, United States 
of America 
Objectives: Phaeohyphomycosis of the central nervous system (CNS) is a life-threatening infection 
with serious morbidity and mortality. Treatment options for CNS phaeohyphomycosis are limited. 
This severity of CNS phaeohyphomycosis was tragically illustrated in the contamination of a 
corticosteroid injection preparation that resulted in epidemic Exserohilum rostratum meningitis 
(ERM), resulting in meningoradiculitis, brain abscess, neurologic deficits, and death despite 
antifungal therapy with voriconazole with or without liposomal amphotericin B (LAMB). We 
hypothesized that isavuconazole may be an alternative approach for patients with ERM and other 
causes of CNS phaeohyphomycosis, particularly those with severe infection or intolerance to initially 
high dosages of voriconazole therapy. We therefore investigated the in vitro antifungal activity of 
isavuconazole with or without LAMB followed by treatment in a new model of experimental ERM. 
Methods: Clinical isolates of E. rostratum recovered from patients suffering from ERM were used 
in all experiments. Broth microdilution methodology was used to prepare an inoculum for each of 
five clinical isolates of E. rostratum. Combination checkerboard plates were used to test the activity 
of isavuconazole and LAMB, either alone or in combination. Minimum inhibitory concentrations 
(MICs), minimal lethal concentrations (MLCs) and fractional inhibitory concentration (FIC) indices 
were determined. For in vivo therapeutic studies, E. rostratum were inoculated intracisternally 
with 1.0x106 microconidia to anesthetized rabbits. Immunosuppression was produced with 
cytarabine-induced profound persistent neutropenia and methylprednisolone. Study groups 
consisted of isavuconazole, 60 mg/kg/d, LAMB at 5.0, 7.5, and 10 mg/kg/day and untreated controls 
(UC). 
Results: As there were no in vitro additive, synergistic, or antagonistic interactions for combinations 
of isavuconazole plus LAMB against the E. rostratum isolates, in vivo studies in the rabbit model 
of ERM were conducted with isavuconazole and LAMB as monotherapies. Isavuconazole 60 mg/kg/d 
and LAMB at 5.0, 7.5, and 10 mg/kg/day demonstrated significant reductions of the residual fungal 
burden of E. rostratum in cerebrum, cerebellum, spinal cord, and paravertebral muscle (p<0.01) in 
comparison to those of UC. Reduction of the residual fungal burden correlated with significant 
reduction of CSF (1→3)-β-D-glucan levels in comparison to those of UC (P<0.05). 
Conclusion: Isavuconazole alone or LAMB alone significantly reduced residual fungal burden in 
parallel with reduction of CSF (1→3)-β-D-glucan levels in treatment of experimental E. rostratum 
meningitis and may serve as alternative regimens for treatment of CNS phaeohyphomycosis. 
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Pulmonary mucormycosis caused by Lichtheimia ornata (experimental model) 
N. Vasilyeva1, I. Bosak2, T. Bogomolova1, I. Vybornova2, A. Stepanova2, Y. Avdeenko2, G. Chilina2, O. 
Aak2, G. Solovyeva1 
1Kaschkin Research Institute Of Medical Mycology. Department Of Medical Microbiology, North-
Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 
2Kaschkin Research Institute Of Medical Mycology, North-Western State Medical University named 
after I.I. Mechnikov, Saint-Petersburg, Russian Federation 
Objectives: Lichtheimia ornata (A.K. Sarbhoy) Alastr. – Izq. & Walter due to the prevalence and 
virulence is one of three most common species causing mucormycosis. This species was revealed 
among the agents of invasive mucormycosis in Russia. The purpose of the present research was to 
develop a murine experimental model of pulmonary mucormycosis caused by L. ornata. 
Methods: For the infection of mice we used the strain RCPF-1507 of L. ornata, isolated from the tissue 
of accessory sinuses of nose from a patient with lymphatic leukemia. For modeling the pulmonary 
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mucormycosis we used outbred mice, males, with body weight 18-20 g. For inducing the condition 
of neutropenia we intraperitoneally injected cyclophosphamide at the dose 150 mg/kg four times (-3, 
0, 4 and 8 days). From fungal culture grown on Sabouraud glucose agar for 3 days at 37° C we made 
the spore suspension in sterile 0.85% NaCl solution at the concentration 1·107 CFU/ml. Infection of 
animals was carried out by intranasal injection of 50 μl of fungal spores suspension to a narcotized 
mouse. 
Results: Data on mice lethality and results of cultural and histological investiga-tions of murine lungs 
with invasive mucormycosis were obtained. Death of animals was observed from 8 to 18 days after 
infection. No mice survived. Culturing of lung tissue from all dead mice revealed growth of L. ornata. 
During the histological investigation of murine lungs taken after eight days from the beginning of 
infection the different area of localization of hyphal cells were found. Hyphae were wide (10-12 µm), 
with rare branching at right angle. Hyphal cells in the lung parenchyma generally were located 
densely and in parallel relatively each other that is characteristic of tissue forms of mucormycetes. In 
lungs vessels massive aggregation of densely and chaotically oriented fungal hyphae were revealed. 
Also we observed the hyphal aggregation in gleams of bronchial tubes and an interstitium. The 
inflammatory process due to a mycotic infection was poorly expressed, provided by poor 
neutrophilic and lymphocytic infiltration, alteration processes prevailed. 
Conclusion: The scheme of immunosuppression used in this work (intra-peritoneal introduction of 
cyclophosphamide) showed efficiency for producing infection in mice by L. ornata. Data on survival 
of the infected animals and also results of cultural and histological investigations confirm existence 
of mycotic damage of lungs at the infected animals. The developed model of invasive pulmonary 
mucormycosis can be used for future scientific research, testing of new antifungal drugs and 
diagnostic methods. 
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Case of successful treatment of chronic pulmonary aspergillosis in a patient with polycystic 
disease 
O. Shadrivova1, V. Kuznetsov2, E. Desyatik2, Y. Borzova2, S. Ignatyeva2, T. Bogomolova2, N. 
Vasilyeva2, N. Klimko1 
1Department Of Clinical Mycology, Allergy And Immunology, North-Western State Medical 
University named after I.I.Mechnikov, St. Petersburg, Russian Federation, 2Kashkin Research 
Institute Of Medical Mycology, North-Western State Medical University named after I.I.Mechnikov, 
St. Petersburg, Russian Federation 
Case Report: Background. Publications onchronic pulmonary aspergillosis (CPA) in patients with 
polycystic diseaseare limited.  
Objection: We present a case of successful treatment of CPA in a patient with polycystic disease.  
Methods:Diagnosis of CPA was made in accordance with the criteria ESCMID/ECMM/ERS, 2016.  
Result: Patient V., 70 years old, was admitted to the mycological clinic with complaints of productive 
cough and dyspnea in September 2018. It is known that in 2015 lesions in left lung lower lobe were 
detected on chest CT scan. The CPA diagnosis was made on the basis of chest CT scan (multiple 
aspergillomas in left lung S6), elevated serum Aspergillus IgG level, and A. fumigatus and A. niger in 
BAL culture. The patient was treated with itraconazole 400 mg/day for 2 weeks. In October 2018, the 
patient underwent surgery removal of the left lung lower lobe, and CPA diagnosis was confirmed 
with histology. Therapy with itraconazole 400 mg/day was continued for 1 month. At the end of 
treatment, there was no data for active CPA: no specific lesions on chest CT scan, with negative BAL 
microscopy and culture, and serum Aspergillus IgG level. On the Pubmed website, we did not find a 
case reports of CPA in patients with polycystic disease.  
Conclusions: Polycystic disease can be underlying disease of chronic pulmonary aspergillosis. 
Combinations of antimycotic therapy and surgical treatment are necessary for the successful 
treatment of chronic pulmonary aspergillosis in patients with polycystic disease. 
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Chronic pulmonary aspergillosis in patients with idiopathic pulmonary fibrosis 
O. Shadrivova1, M. Tarasova1, E. Desyatik2, N. Nikolaeva3, Y. Borzova2, S. Ignatyeva2, T. 
Bogomolova2, N. Vasilyeva2, N. Klimko1 
1Department Of Clinical Mycology, Allergy And Immunology, North-Western State Medical 
University named after I.I.Mechnikov, St. Petersburg, Russian Federation, 2Kashkin Research 
Institute Of Medical Mycology, North-Western State Medical University named after I.I.Mechnikov, 
St. Petersburg, Russian Federation, 3North-Western State Medical University named after 
I.I.Mechnikov, St. Petersburg, Russian Federation 
Case Report: Introduction: Publications onchronic pulmonary aspergillosis (CPA) in patients with 
idiopathic pulmonary fibrosis are limited.  
Objective: We present a case of successful treatment of CPA in a patient with idiopathic pulmonary 
fibrosis.  
Materials and methods: Diagnosis CPA performed in accordance with the criteria EORTC/MSG, 
2008.  
Results: Patient V., 78 years old, was admitted to the mycological clinic with complaints of productive 
cough, exertional dyspnea in February 2018. It is known that the patient was diagnosed with 
idiopathic pulmonary fibrosis in 2017. He did not receive basic therapy. On chest CT scan for the first 
time was detected a cavity of 43x68x29 mm with the soft-tissue formation 12x14 mm in the apex 
region of the right lung. A positive titer the IgG to Aspergillus fumigatus1: 3200 was determined. 
Aspergillus fumigatusgrow in the sputum culture was revealed. The patient received itraconazole with 
400 mg per day with a positive clinical effect. Decrease of cough and exertional dyspnea was noted. 
Duration of antifungal treatment was 3 months. In July 2018, the chest CT scan showed a decrease in 
the size of the cavity and reducing of the soft-tissue formation in the right lung. The IgG titer to 
Aspergillus fumigatuswas decreased to 1: 800. No fungi were found in sputum culture. The patient 
received antimycotic therapy for another 3 months. In October 2018, the CT scan of the chest showed 
stabilization of changes. IgG titer to Aspergillus fumigatusdecreased to 1: 400. The culture study of 
sputum was negative. Antimycotic therapy was stopped. When analyzing the literature on the 
Pubmed site, we found 5 cases of aspergillosis with idiopathic pulmonary fibrosis. 1 case where the 
disease is associated with the intake of glucocorticosteroids, 1 case associated with primary 
immunodeficiency, 1 case with the influenza B virus and 2 cases in non-immunocompromised 
patients. Conclusion: Idiopathic pulmonary fibrosis can be an additional “background” disease of 
chronic pulmonary aspergillosis. Prolonged antimycotic therapy is necessary for successfully 
treatment of chronic pulmonary aspergillosis in patients with idiopathic pulmonary fibrosis. 
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The performance of the BALF later-flow device test in the rapid diagnosis of nonneutropenic 
invasive pulmonary aspergillosis 
L. Liu, Y. Wang, Y. Gu, S. Li, B. Chen, K. Shen, X. Su 
Jinling Hospital, Medical School of Nanjing University, Nanjing, China, nanjing, China 
Objectives: The Aspergillus lateral-flow device (LFD) is a new method to test for Aspergillus antigen. 
We performed this study to evaluate the value of the LFD test in diagnosing nonneutropenic invasive 
pulmonary aspergillosis. 
Methods: A total of 136 bronchoalveolar lavage fluid (BALF) samples from 136 suspected invasive 
pulmonary aspergillosis (IPA) patients were finally divided into 2 groups: the aspergillosis group 
and the non-aspergillosis group. We performed both the LFD and glactomannan (GM) tests on 80 
BALF samples and only the LFD test on the remaining 58 BALF samples. 
Results: After systematic clinical diagnosis, all 136 patients were divided into an aspergillosis group 
(n = 41, proven (n = 8) and probable (n = 33) diagnosis) and a non-aspergillosis group (n = 95, 
pneumonia, tuberculosis and others). The sensitivity, specificity, positive predictive value, and 
negative predictive value of LFD for diagnosing pulmonary aspergillosis in all 136 BALF samples 
were 69.7%, 72.6%, 87.3% and 46.9%,respectively. When comparing the GM and LFD test results for 
the 80 samples, the sensitivity (75.8% vs 74.1%, P = 0.769) was similar. The specificity of the GM test 
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was higher than that of the LFD test (83.0% vs 66.0%, P = 0.058), but there was no significant difference 
between the tests. The sensitivity and specificity of the combination of the positive results of both 
theLFD and GM tests were 63.6%and 89.4%, respectively, and the sensitivity and specificity of either 
LFD or GM positive results or both LFD and GM positive results were 90.9% and 59.6%, respectively. 
Conclusion: LFD is a promising alternative diagnostic method to the GM test fortheearly detection 
of patients with nonneutropenic pulmonary aspergillosis. 
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High rates of misidentification of uncommon Candida species fungemia with conventional 
phenotypic methods 
W.-L. Liu1,2, Y.-S. Huang3, F.-D. Wang4, M.-H. Hsieh5, I.-M. Hii6, Y.-L. Lee6, M.-W. Ho7 
1School Of Medicine, College Of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, 
2Emergency & Critical Care Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan, 
3Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 4Medicine, Taipei Veterans 
General Hospital, Taipei, Taiwan, 5Internal Medicine, Kaohsiung Medical University Hospital, 
Kaohsiung Medical University, Kaohsiung, Taiwan, 6Internal Medicine, Changhua Christian 
Hospital, Changhua, Taiwan, 7Internal Medicine, China Medical University Hospital, Taichung, 
Taiwan 
Objectives: Candidemia caused by uncommon Candida species is increasing. Correct identification 
of Candida isolates to species level is important for optimizing antifungal choice. In this study, we 
aimed to evaluate the accuracy of species-level identification of conventional methods and MALDI-
TOF MS system in patients with candidemia due to the uncommon Candida species. Sequencing of 
the internal transcribed spacer (ITS) was performed for comparison and determination of accuracy. 
Methods: From July 2011 to December 2014, uncommon Candida species identified by conventional 
phenotypic methods from candidemic patients were prospectively collected at 6 hospitals in Taiwan. 
Identification of theses uncommon Candida isolates were performed using MALDI-TOF MS and DNA 
sequencing of the fungal internal transcribed spacer (ITS). Susceptibility of the non-duplicate isolates 
were determined using SensititreTM YeastOneTM and were interpreted with cut-off values 
recommended by the CLSI. 
Results: A total of 85 uncommon Candida isolates reported by conventional methods were included. 
By conventional methods, the most frequently reported uncommon Candida species were C. 
guilliermondii (n = 39), C. sake (n = 7), and C. famata (n = 4). Using ITS sequencing analysis as standard, 
none of the C. sake and C. famata identified by conventional methods was correct, while MALDI-TOF 
MS correctly identified 10 of the 11 isolates. With the exclusion of the one unspecified Candida isolate 
reported by ITS sequencing, the accuracy of conventional methods and MALDI-TOF MS in the 
identification of 84 Candida isolates were 64.3% and 86.9%, respectively (p = 0.001). Eight isolates were 
confirmed to be non-Candida yeast species. Compared with other Candida species, C. guilliermondii 
showed elevated MIC values of echinocandins. Based on our results, an identification algorithm for 
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uncommon Candida species was proposed (Figure 1). 
 
Conclusion: Conventional methods could lead to high rate of misidentification of uncommon 
Candida species, especially C. sake and C. famata. MALDI-TOF MS assisted with DNA-sequencing 
based methods should be considered for identification of uncommon Candida species. 
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Cross-sectional study of respiratory Aspergillus spp. colonization or infection in patients with 
various stages of Chronic Obstructive Pulmonary Disease (COPD) using culture vs non-culture 
based technique. 
S. Waqas1,2, K. Dunne2, A. Fe Talento3,4,5, G. Wilson1, I. Martin-Loeches1, J. Keane1,2, T. R Rogers1,2 
1St. James's Hospital, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3Our Lady Of Lourdes 
Hospital, Drogheda, Ireland, 4Royal College of Surgeons Ireland, Dublin, Ireland, 5Beaumont 
Hospital, Dublin, Ireland 
Objectives: (*1st and 2nd Authors are equal contributors) COPD patients are now recognized to be 
at increased risk of colonization by Aspergillus spp. which may progress to invasive pulmonary 
aspergillosis (IA). Published data on the frequency of Aspergillus detection in COPD are limited. The 
objective of this study was to determine frequency of Aspergillus colonization or infection in COPD 
patients. 
Methods: A cross-sectional study was undertaken to determine Aspergillus colonization or infection 
in COPD patients undergoing bronchoscopy for any indication.Culture as well as galactomannan 
antigen (GM) and Aspergillus nucleic acid detection (PCR) were performed on bronchoalveolar lavage 
fluid (BAL). 
Results: One hundred and fifty patients were included (44.7 % female, mean age 68.2 years). 21.3% 
were inpatients, 74.7% outpatients and 4% were ICU patients. Investigation of lung masses was the 
most common indication (43.3%) for bronchoscopy. Most patients (81.3 %) were either GOLD stage 
1 or 2 COPD. Cancer was the most frequent co-morbidity (60.48%). 12 % and 48.7 % were on systemic 
and inhaled steroids respectively. Lung mass was the most common (28.43%) CT imaging finding. 
Seventeen patients (11.3%) had a positive result for Aspergillus (Culture +Galactomannan + PCR). 
76.4% out of these seventeen were in the early stages (GOLD stage 1 or 2) of COPD. 
Conclusion: Aspergillus sp. was detected in 3.3% of patients by culture, which increased to 11.3% if 
culture was combined with either a positive GM or PCR result. Overall the frequency of Aspergillus 
detection in this population of COPD patients was low which may reflect the predominance of Gold 
stages 1 and 2 among the study population. 
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Evaluation of new multiplex PCR-based blood assays for detection of candidemia 
M. Jobstmann1,2, J. Prattes2, E. Stelzl1, C. Zurl1, M. Hoenigl3, J. Rabensteiner1, R. Krause2, H. Kessler1 
1Medical University of Graz, Graz, Austria, 2Section Of Infectious Diseases And Tropical Medicine, 
Medical University of Graz, Graz, Austria, 3Division Of Infectious Diseases, University of California, 
San Diego, United States of America 
Objectives: Blood cultures have been considered as diagnostic gold standard for candidemia. 
Compared to cultures, assays based on polymerase chain reaction (PCR) may be useful to shorten the 
time to diagnosis of invasive candidiasis and to initiation of antifungal therapy. Recently, the new 
CandID®  and CandID PLUS®  kits (OLM Diagnostics, Newcastle Upon Tyne, England) for molecular 
detection of different Candida spp. have been developed. In this study, the analytical and clinical 
performance of the new kits was investigated. Reference material and clinical specimens were used. 
Methods: Nucleic acid extraction was performed on the EMAG®  platform (bioMérieux, Marcy-
l Étoile, France) using the specific B protocol. Real-time PCR (qPCR) and detection with the CandID®  
and CandID PLUS®  kits were performed on the Light Cycler®  480 II CE/IVD instrument (Roche 
Diagnostics, Penzberg, Germany). Both of the kits are based on multiplex qPCR providing detection 
of three different Candida spp. each and an internal control: Candida albicans, Candida glabrata, Candida 
parapsilosis with the CandID®  and Candida tropicalis, Candida krusei, Candida dubliniensis with the 
CandID PLUS® . The accuracy of the new kits was determined utilizing the Quality Control for 
Molecular Diagnostics (QCMD) 2018 Candida spp. EQA Programme. The panel consisted of 10 
members including Candida albicans, Candida auris, Candida glabrata, Candida krusei, and vials without 
Candida spp. The clinical performance of the new kits was determined with specimens obtained from 
three groups of patients: patients with culture-proven candidemia (n = 23; EDTA whole blood 
samples), patients with bacteremia (n = 31; plasma samples), and healthy controls (n = 25; EDTA 
whole blood samples). Whole blood samples from candidemic and bacteremic patients were drawn 
at the same day as the corresponding blood cultures. 
Results: With the quality control program, all panel members were correctly identified by the new 
PCR assays. With the clinical study, 2 EDTA whole blood samples obtained from patients with 
candidemia and 7 EDTA whole blood samples obtained from healthy controls were found to be 
inhibited and thus excluded from further analysis. In patients with candidemia (mean age, 67 years, 
range 20 to 89 years), 14 of 21 samples (67%) gave a positive result when employing the new PCR 
assays. In patients with bacteremia (mean age, 62 years, range 23 to 91 years), 1 of 31 samples gave a 
false-positive result with the CandID assay. All healthy controls (mean age, 57 years, range 45 to 66 
years) remained negative with the new PCR assays. All Candida spp. from candidemic patients were 
correctly identified with the PCR assays. 
Conclusion: When compared to blood culture, two thirds of samples obtained from patients with 
candidemia were found positive with the new CandID®  or CandID PLUS®  kits. While in samples 
obtained from patients with bacteremia one false-positive result was observed with the new PCR 
assays, results of samples obtained from healthy controls were all found to be correct. 
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Development of a New Quantitative Real-Time PCR Assay for the Detection and Identification of 
Aspergillosis and Mucormycosis Infections 
S. Godichaud1, J. Verrier1, R. Boisson1, G. Lagardere1, P. Flori2 
1ADEMTECH, PESSAC, France, 2CHU ST ETIENNE, ST ETIENNE, France 
Objectives: Mucormycosis is associated with high mortality rates, especially in haematological 
patients, and remains difficult to diagnose. The early distinction with invasive aspergillosis is of 
importance because the antifungal treatment for each is different. Unfortunately, the underlying 
conditions of both infections are similar. Moreover, detection of circulating antigens such as 
galactomannan and β-D-glucan provides no help for diagnosing mucormycosis, and cultures are 
often delayed or negative, preventing early management. Delayed directed antifungal treatment 
impacts the outcome of mucormycosis. The goal of this study is to evaluate a new quantitative PCR 
assay allowing the simultaneous detection of Aspergillus spp. and Mucorales spp. 
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Methods: The MycoGENIE Aspergillus-Mucorales spp. real-time PCR kit (Ademtech, France) is a 
triplex PCR assay targeting specifically Aspergillus spp., Mucorales spp. (including Lichtheimia, Mucor, 
Rhizomucor, Rhizopus and Cunninghamella species), and an exogenous Internal Control. This study 
was performed on a reference panel of 30 biopsy specimen, including 10 positive for Aspergillus spp. 
and 12 positive for Mucorales spp. previously identified by direct examination and culture. Twenty 
negative serum samples were also included in this study to evaluate the specificity of the assay. DNA 
extraction was performed using the MycoGENIE DNA Extraction kit (Ademtech, France) and 10 µL 
of pure DNA was used as a template for the PCR assay. Mucorales-infected samples were also 
evaluated with other external laboratory-developed PCR tests targeting only Mucor, Rhizomucor, 
Rhizopus and Lichtheimia species. 
Results: On the 30 samples, the MycoGENIE Aspergillus-Mucorales spp. PCR kit successfully 
detected 19 Aspergillus-positive samples including A. fumigatus, A. niger and A. nidulans identified by 
culture. Mucorales spp. were also detected in 18 samples. Notably, the PCR assay efficiently detected 
Aspergillosis-Mucormycosis co-infections in 9 samples. All serum samples returned negative. 
Conclusion: This new CE-IVD compliant real-time PCR assay, combined with an automated DNA 
extraction process is a sensitive and specific molecular diagnostic tool for the diagnosis of 
aspergillosis and mucomycosis infections in biopsy samples. The possibility to efficiently detect 
aspergillosis/mucormycosis co-infections is highlighted in this study and is of importance for a better 
therapeutic management. 
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Comparison of multiplex nested PCR and Maldi tof to identify clinically isolated candida from 
Sénégal, a preliminary study 
A. Badiane, A. Sene, A. Gaye, K. Diongue, M.C. Seck, M. Ndiaye, J.P. Gangneux, D. Ndiaye 
Parasitology And Mycology, Universite Cheikh Anta Diop de Dakar, Dakar, Senegal 
Objectives: The objective of this study is to compare the identification of clinically isolated candida 
species using Maldi tof and a multiplex nested PCR. 
Methods: A total of 38 clinically isolated strains of Candida from superficial mycosis and vaginal 
infection were conserved in brain heart broth additioned with 15 % glycerol and stored at – 20 °C. 
The strains were then sub cultured in CHROMagar™ candida (Becton Dickinson), incubate at 37 °C 
for 24 to 48 hours and identified using Maldi tof (Bruker) at University of Rennes / France. A 
multiplex nested PCR were performed directly from the conservative media at Cheikh anta Diop 
University of Dakar/ Senegal. 
Results: Thirty five (35) samples gave interpretable results for both methods. 51.43 % of the samples 
showed the same result with Maldi tof and multiplex PCR, among which Candida albicans (45.71 %) 
and C. parapsilosis (2.85%). The species identified by both methods were C. albicans, C. tropicalis and 
C. parapsilosis. C. albicans alone or mix with other species was identified 71.73 % by Maldi tof and 
61.70% by PCR nested multiplex. C. tropicalis alone or mix with other species was identified 13.04 % 
with Maldi tof and 8.51% with multiplex nested PCR. C. parapsilosis alone or mix with other species 
was identified 2.17 % with Maldi tof and 23.40% with multiplex nested PCR. C. glabrata, C. pintolepesii, 
C. orthopsilosis and C. pararugosa were identified only by Maldi tof. C. lusitania and C. kefyr were only 
identified by Mutiplex nested PCR. Seven (7) mix species were identified with multiplex nested PCR 
and five (5) with Maldi tof. Among the samples, identified as C. albicans using multiplex PCR three 
were identified as C. tropicalis by Maldi Tof. C. parapsilosis genotype 2 identified by multiplex PCR 
has been identified as C. orthopsilosis with Maldi tof. Threes strains identified as C. albicans by 
multiplex PCR were identified as C. tropicalis by Maldi tof. 
Conclusion: The multiplex nested PCR and the Maldi tof identified the most prevalent Candida 
species, but there is discordance for the identification of the non albicans species. The multiplex PCR 
identified more multiple strains infections than the Maldi tof. The differences observed between these 
two methods could be due to the absence of these strains in the Maldi tof database and the subculture 
of predominant strains. Also genetically close species might not be differentiated using PCR. 
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Utilization of MALDI-TOF MS for identification of filamentous fungi: a comparative study 
A. Vavrova1, L. Svobodova1, J. Mrazek2, P. Hamal1 
1Department Of Microbiology, Palacký University, Faculty of Medicine and Dentistry and University 
Hospital Olomouc, Olomouc, Czech Republic, 2Department Of Bacteriology And Mycology, Institute 
of Public Health in Ostrava, Ostrava, Czech Republic 
Objectives: Identification of filamentous fungi based on morphological characteristics is the most 
simple and available approach used in diagnostic clinical mycology laboratories. In many cases, 
however, it requires considerable experience of the rater and the ability of strains to produce spores. 
For its rapidity and accuracy, MALDI-TOF mass spectrometry is invaluable for identification of 
microorganisms including fungi. It is more challenging to use this method for identification of 
filamentous fungi than bacteria or yeasts given differences in cell wall structures and a limited 
spectrum of species in the database. The study aimed to find the optimal way of identifying 
filamentous fungi in mycology laboratories using MALDI-TOF MS. 
Methods: The tested group of moulds comprised 193 isolates obtained from clinical specimens. The 
identification started with morphological assessment (appearance of colonies, micromorphology 
from slide culture). Then isolates were identified using MALDI-TOF, both directly from culture and 
following culture in liquid media with extraction; in the latter case, both supernatant and sediment 
were tested. Finally, all the methods were compared as to the rate of agreement. Subsequently, a 
small sample of selected isolates was identified by sequencing. 
Results: Based on morphological criteria, 17 genera were identified; due to a lack of sporulation, 
another 5 isolates could not be identified. Further, 13 species were identified, mostly within the genus 
Aspergillus. With MALDI-TOF MS performed directly from culture, nine isolates were identified to 
the genus level and 184 were identified to the species level, with a total of 75 species being noted. 
With MALDI-TOF MS after culture in liquid media with extraction, 190 isolates were identified to 
the species level, with 43 species being noted; in only three cases, identification of filamentous fungi 
was limited to genera. Comparison of identification from supernatant and sediment showed that 
identical results were always obtained at both the genus and species level and there were only 
minimal differences in identification scores. The rates of agreement between isolate identification 
using morphology and MALDI-TOF MS from culture were 58.55% at the genus level and 22.24% at 
the species level. The rates of agreement between isolate identification using morphology and 
MALDI-TOF MS after culture in liquid media with extraction were 84.97% at the genus level and 
46.11% at the species level. Based on disagreeing results of the above identification methods, 20 
isolates from the sample were selected to be identified by sequencing. The highest agreement rate 
(70%) was found for identification with MALDI-TOF MS after culture in liquid media with extraction 
and only 35% using MALDI-TOF MS directly from culture. 
Conclusion: The results suggest that the optimal approach to identification of filamentous fungi in 
diagnostic medical mycology laboratories is a combination of morphological characteristics and 
MALDI-TOF MS. For species identification of morphologically typical isolates, assessing the 
appearance of colonies and slide cultures is sufficient; in the other cases, MALDI-TOF MS after 
culture in liquid media with extraction is recommended. If identification with the above combination 
is ambiguous or impossible to perform, molecular genetic methods need to be used, in particular 
sequencing. 
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Risk Factors for Candidemia: A Prospective Matched Case-Control Study 
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Cedex, France, 4Division Of Infectious Diseases And Hospital Epidemiology, University Hospital of 
Basel, Basel, Switzerland, 5Department Of Infectious Diseases, Cantonal Hospital of Saint Gallen, 
Saint Gallen, Switzerland, 6Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland, 
7Infectious Diseases Department, University Hospital of Lille, Lille Cedex, France, 8Hematological 
Disorders Department, University Hospital of Lille, Lille Cedex, France, 9Digestive Intensive Care 
Department, University Hospital of Lille, Lille Cedex, France, 10Intensive Care Department, 
University hospital of Lausanne, Lausanne, Switzerland, 11Infectious Diseases Department, 
University Hospital of Lausanne, Lausanne, Switzerland, 12Laboratory Of Mycology And 
Parasitology, University Hospital of Lille, Lille Cedex, France, 13Microbiology Institute, University 
Hospital of Lausanne, Lausanne, Switzerland 
Objectives: Candidemia is an opportunistic infection associated with high morbidity and mortality 
in hospitalized patients, both inside and outside intensive care units (ICUs). Identification of patients 
at risk for preemptive approach and early detection is crucial. Prospective control-matched studies 
and comparison between ICU and non-ICU patients are lacking in this field. We aim to identify and 
compare specfic risk factors in ICU and non ICU patients. 
Methods: This was a prospective multicenter matched case-control study assessing risk factors for 
candidemia and death in candidemic patients, both outside and inside ICUs from 6 teaching hospitals 
in Switzerland and France. Controls were matched to cases based on age, hospitalization ward, 
hospitalization duration and, when applicable, type of surgery. Risk factors were analyzed by 
univariate and multivariate conditional regression models, as a basis for a new scoring system for 
prediction of candidemia. 
Results: The study included 183 cases and 378 matched controls. 44% were hospitalized inside ICU 
and 56% outside. Independent risk factors for candidemia within the ICU population included total 
parenteral nutrition (TPN) (OR = 9.24, 95%CI 3.39-25.2, p<0.001), acute kidney injury (OR = 6.48, 
95%CI 2.39-17.6, p<0.001), solid cancer (OR = 4.59, 95%CI 1.23-17.2, p = 0.02), heart disease (OR = 4.26, 
95%CI 1.37-13.3, p = 0.01), invasive mechanical ventilation (OR = 3.37, 95%CI 1.17-9.67, p = 0.02), 
exposure to fluoroquinolones (OR = 3.05, 95%CI 1.14-8.16, p = 0.03) and exposure to aminoglycosides 
(OR = 2.47, 95%CI 1.07-5.69, p = 0.03). Independent risk factors for candidemia within the non-ICU 
population included central venous catheter (CVC) (OR = 10.20, 95%CI 3.87-27.2, p<0.001), TPN (OR 
= 3.37, 95%CI 1.53-7.41, p = 0.003), exposure to glycopeptides (OR = 4.10, 95%CI 1.57-10.7, p = 0.044), 
and to nitroimidazoles (OR = 5.14, 95%CI 1.59-16.6, p = 0.006). The weighted ICU-score was as follows 
: TPN, +2; AKI, +2; heart disease, +1.5; solid cancer, +1.5; invasive mechanical ventilation, +1.0; 
fluroquinolone: +1.0. aminoglycoside : +1. AUC of the ROC curve was 0.773. The optimal cut-off was 
≥5 (sensitivity = 76%, specificity = 64%). The bestl cut-off to optimize specificity was ≥7 (sensitivity = 
23%, specificity = 95%). The weighted non-ICU score was as follows : CVC : +3.5; nitroimidazole : 
+2.5; TPN, +2; Glycopeptide : +2.0. AUC of the ROC curve was 0.717. The optimal cut-off was ≥4 
(sensitivity = 83%, specificity = 49%). The best cut-off to optimize specificity was ≥6 (sensitivity = 49%, 
specificity = 82%). Independent factors for death in candidemic patients in the whole population were 
septic shock (OR = 7.17, 3.06-16.8, p<0.001), acute kidney injury (OR = 5.04, 2.16-11.8, p<0.001), number 
of antibiotics (OR = 1.42, 1.15-1.75, per unit, p<0.001). After stratification between ICU and non-ICU 
patients, only septic shock (OR = 4.49, 1.53-13.1, p = 0.006), acute kidney injury (OR = 3.13, 1.02-9.17, 
p = 0.04), the number of antibiotics to which patients were exposed before candidemia (OR = 1.35, 
1.05-1.75 per unit, p = 0.02) remain significantly and independently associated with death in ICU 
patients. For non-ICU patients, acute kidney injury (OR = 10.7, 2.16-52.5, p = 0.004) and septic shock 
(OR = 10.50, 2.80-39.7, p<0.001) were the only variables significantly associated with death 
Conclusion: Risk factors for candidemia are variable in the ICU versus non-ICU setting, including 
different patterns of antibiotic exposure. Weighted scores predictive of candidemia can be built based 
on these risks, with better performances for ICU-patients. An improved prediction of the risk of 
candidemia may contribute to guide targeted preventive and therapeutic antifungal strategies. 
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Inter-laboratory robustness of screening tests for the detection of Aspergillus antibodies for 
chronic aspergillosis: finding from a French External Quality Assessment 
F. Persat1,2, D. Dupont3, J.-C. Eynard2, B. Poggi2, M. Wallon3 
1Parasitology And Medical Mycology, Hospices Civils de Lyon / Université Lyon 1, Lyon, France, 
2Association Pro.Bio.Qual, Lyon, France, 3Parasitology And Medical Mycology / Umr 5292, 
Université Lyon 1 / Hospices Civils de Lyon, Lyon, France 
Objectives: Six million people worldwide are estimated to have chronic aspergillosis or/and allergic 
broncho pulmonary aspergillosis. Serum Aspergillus assay is an important parameter to detect and 
follow the immune host response against this fungus. Reliable tests are crucial for patients’ care but 
also to perform much needed multicentre-studies. However, the current tests are not standardized 
and may lack in robustness. We have analysed the results of a French External Quality Assessment 
(EQA) programme to assess the inter-laboratory robustness of four Aspergillus antibody techniques 
among those recommended in France as first-line screening tests. 
Methods: The study was based on the answers provided by 40 laboratories that took part at least 
once to the EQA organised by ProBioQual between 2013 to 2018 for Aspergillus serology. A total of 24 
sera were tested over this time period, 18 positive from patients with chronic or allergic 
bronchopulmonary aspergillosis and six negative sera from blood donors. The results of the 
following techniques were analysed: 1) PlateliaTMAspergillus IgG EIA (Bio-Rad, France); 2) ELISA 
ClassicTMA. fumigatus IgG (Virion/Serion, Germany); 3) ELISA Aspergillus fumigatus IgG (Bordier 
Affinity Products, Switzerland) since 2014; 4) Aspergillose Fumouze indirect hemagglutination 
(Biosynex Fumouze, France). 
Results: reported by the participants for the Bio-Rad test were all negative for five of the six negative 
sera and all positive for 14 of 18 positive sera. Those reported for the Virion/Serion ELISA were all 
negative for four of the six negative sera and all positive for 10 of the 18 positive sera. The results 
reported for the Bordier test were all concordant but only based on five positive sera and one negative 
serum. Results provided with the hemagglutination test were all negative on all negative sera, but 
none of 18 positive sera were found by all laboratories to be positive, and 10 of the positive sera were 
even found by all laboratories to be negative. 
Conclusion: Hemagglutination technique appears lacking too much in sensitivity to be used as single 
screening test, compared to the ELISA techniques, probably explaining its decreasing use. ELISA Bio-
Rad appeared as more robust than Virion/Serion ELISA. The potentially better performances of 
ELISA Bordier have to be confirmed. 
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Usefulness of conventional PCR through induced sputum to diagnoses Pneumocystis pneumonia 
in HIV infected patients 
O.J. Chagas1, R. Buccheri2, G. Naves1, P.L. Silva Pinto3, V.L. Pereira Chioccola4, G. Benard1, G.M.B. 
Del Negro1 
1Laboratório De Investigações Médicas 53, Insituto de Medicina Tropical, São Paulo, Brazil, 2Hospital 
Ward, Instituto de Infectologia Emílio Ribas, São Paulo, Brazil, 3Intitution: Intituto Adolfo Lutz - 
Núcleo de Enteroparasitas, São Paulo, Brazil, 4Intituto Adolfo Lutz - Laboratório de Biologia 
Molecular de Parasitas e Fungos do Centro de Parasitologia e Micologia, São Paulo, Brazil 
Objectives: The present study aims to determine the usefulness of conventional PCR in induced 
sputum to diagnoses Pneumocystis pneumonia in HIV infected patients. 
Methods: Study design was of a prospective-cohort with systematic collection of data. Ninety-five 
HIV-infected patients presenting cough and dyspnoea for more than 7 days were included. They 
should not have received antiretroviral therapy (ART) or a history of inadequate treatment. Induced 
sputum, obtained through concentrated saline solution (NaCl 3%-5%) inhalation, was obtained at 
admission and submitted to O-toluidine staining and conventional PCR for Pneumocystis. Clinical, 
laboratorial, imaging records and clinical outcome from PCR positive and PCR negative patients 
were compared. We also compared these data in PCR positive patients and confirmed pulmonary 
tuberculosis (TB) (presence of bacillus-acid-alcohol-resistant or positive rapid-molecular-test). 
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Results: PCR was positive in 34/95 (35.7%) of the patients. This group presented higher rates of dry 
cough (55.8% X 22.9%, P = 0.003), interstitial infiltrate on chest X-ray (94.1% X 61%, P = 0.001), ground 
grass on chest tomography (CT) (89.2% X 42.8%, P = 0.0002) and higher lactate dehydrogenase (LDH) 
levels (488U/L x 329U/L, P<0.0001), when comparing with the PCR negative patients. PCR positive 
patients had also more non-invasive ventilation (NIV) (47% X 15%, P = 0.002) and more admissions 
at the intensive care unit (ICU) (35.2% X 13.5%, P = 0.02). Both groups did not differ regarding n. of 
days with symptoms, PaO2, HIV viral load (VL) and Candida infection during hospitalization. There 
were 32 PCR positive patients without TB and 11 patients with confirmed pulmonary TB. TB was 
associated with CT budding tree (57,1% X 0, P = 0.0005), CT micronodules (85,7% X 23%, P = 0.008); 
trend toward higher CD4 cell count (129 X 47 cell/mm³, P = 0.01) and lower use of NIV (6,2% X 50%,P 
= 0.0417), and less CT ground grass (14,2% X 92,3%, P = 0.0001). There was no difference between 
LDH, PaO2, HIV VR, and ICU hospitalization between the two groups. Of note, 5/34 (14.7%) of the 
PCR positive patients did not receive any antimicrobial treatment for PCP during hospitalization but 
improved their initial symptoms, hence the difficult to differentiate between colonization and 
infection solely based on the conventional PCR. In addition, only two PCR positive patients did not 
display ground grass at CT: both had pulmonary consolidation. 
Conclusion: Our PCR assay was useful to define a subgroup of patients with clinical, laboratorial 
and imaging aspects related to PCP. Besides it, pulmonary CT is a fundamental tool, since suggestive 
alterations in this exam strongly contribute to the diagnosis, helping to differentiate the pulmonary 
involvement of PCP from that of TB, the main differential in our country, where TB is highly prevalen. 
Of note, five PCR positive patients did not receive specific treatment during hospitalization, pointing 
to either the existence of false-positive cases or to P. jiroveci colonization. The possibility that 
differentiation between these patients could be achieved by quantitative real-time-PCR remains an 
open question, since the literature is controversial, due mainly to the different primers and techniques 
employed. Another discriminatory assay would be the β-D-Glucan test, which, combined with PCR 
assay, would be able to discriminate colonized from infected patients. 
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Performance characteristics of the MucorGenius® real-time PCR assay for the detection of 
clinically relevant Mucorales species 
G. Gaajetaan, T. Kampermann, D. Van Tegelen, G. Dingemans 
PathoNostics, Maastricht, Netherlands 
Objectives: Determine the performance characteristics of the commercially available MucorGenius®  
real-time PCR assay for the detection of clinically relevant Mucorales species. For this purpose, 
several verification studies were performed including sensitivity, specificity and EQA evaluation. 
Methods: The analytical sensitivity or limit of detection (LOD) was determined by testing serial 
dilutions of all reference Mucorales culture extracts including Rhizopus oryzae, Rhizopus microsporus, 
Cunninghamella bertholletiae, Lichtheimia corymbifera, Rhizomucor pusillus, Mucor hiemalis and 
Rhizomucor miehei on various real-time PCR instruments. The LOD dilution of a Mucorales species 
was accepted if at least 19 out of 20 reactions were detected. This dilution was finally quantified for 
each species by using droplet digital PCR (ddPCR). Analytical specificity was determined by testing 
multiple high concentrations of bacterial and fungal DNA strains that can be present in the 
respiratory tract. The seven serum samples of the FPCRI Muc Panel (2018-1) were tested with the 
MucorGenius®  PCR after DNA-extraction with the NucliSENS®  easyMag system (bioMérieux). 
Results: The LOD was successfully determined for all seven Mucorales targets on 5 different real-
time cyclers. All results of the LOD study are listed in table 1. Table 1. Overview of MucorGenius® LOD 
results.  
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No cross-reactivity was observed with any of the clinically relevant fungal or bacterial strains. 
Mucorales DNA was successfully detected in 6 out of 7 serum DNA- extracts from the FPCRI panel. 
All samples showed an internal control signal indicating reliable DNA-extraction performance. These 
results were in agreement with the data of the FPCRI. 
Conclusion: The MucorGenius®  real-time PCR assay can detect all Mucorales species at low DNA-
concentrations of 1-2 copies/µ l which corresponds with high Ct-values (Ct 31-43). This indicates 
reliable analytical sensitivity. No cross-reactivity was observed for any of the tested fungal or 
bacterial strains, reducing the chance of a false positive result. Although 100% agreement was 
obtained with the FPCRI Muc Panel, this is a limited data set and only provides an indication of the 
performance. Clinical validation studies are now ongoing on different sample types to determine the 
clinical performance and suitability for routine diagnostics. 
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Objectives: Central venous catheters (CVCs) significantly increase the risk of candidemia, and 
inversely, candidemia is often associated with intravascular catheters. Most guidelines for 
candidiasis management recommend removal of existing intravascular catheters, if feasible. 
Although the recommendation is strong, various authors have recommended a re-consideration of 
CVC removal on an individual basis. Practically, one must consider the possible deleterious 
consequence of CVC removal, especially in patients who require long-term CVC for treatment or 
nutrition. This raises the question of systematic early removal of CVC in the management of 
candidemia since some authors did not report differences, knowing that patients who cannot tolerate 
CVC removal have often a worse prognosis. Time to positivity (TTP) and differential time to 
positivity (DTTP) between central and peripheral blood cultures are commonly used for bacteremia 
to evaluate the likelihood of CVC related bloodstream infection. Few studies have addressed the 
application of these approaches to candidemia. This study aimed to evaluate TTP and DTTP to assess 
CVC-related candidemia (CVC-RC). 
Methods: We retrospectively analyzed the results from 105 adult patients with incident candidemia, 
with CVC removed and cultured, collected from 2010 to 2017. The bottles were incubated in a 
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BioMérieux bact/ALERT 3D and kept for at least 5 days. Patients with CVC removed and cultured at 
the time of fungemia were divided into two groups as previously proposed: (i) CVC-related 
candidemia (CVC-RC) when the same yeast species was recovered from at least one BC and from the 
CVC culture; (ii) non-CVC-related candidemia (NCVC-RC) when a yeast species was recovered from 
at least one BC, and the CVC culture was negative or yielded a different species. 
Results: Of the 105 patients included, most were oncology patients (85.7%) and had of long-term 
CVC (79.6%); 32 (30.5%) had a positive CVC tip with the same species as in BC, defined as CVC-RC. 
The main species involved were C. albicans (46%), C. parapsilosis (19%), C. glabrata (15%), and C. 
tropicalis (9%), with no statistical difference between NCVC-RC and CVC-RC. Considering all species, 
the median TTP of the first bottle collected from CVC was statistically shorter in the CVC-RC group 
(16.8 h [9.7-28.6]) compared to the NCVC-RC group: median (29.4 h [20.7–41.3], p = 0.001, Figure 1). 
When analyzing TTP regarding the Candida species, a significant shorter TPP was only observed in 
C. albicans with a median of 12.9 h [10.0–22.7] vs. 32.3 h [24.4–41]) for CVC-RC and NCVC-RC, 
respectively (p = 0.001, Figure 1). A TTP < 10 h had the best positive likelihood ratio (21.5), although 
the sensitivity was only 28%. DTTP was available for 52 patients. A DTTP > 5 h had a sensitivity of 
100% and a specificity of 71%. 
  
Conclusion: Even if some cut-offs supported the diagnosis of CVC-RC, they did not allow the prompt 
decision on CVC removal, since the median TTP was 17 h. More rapid methods for detecting infected 
catheters should be tested to avoid withdrawal of non-infected CVC (69.5% of CVCs in our study). 
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Diagnostic value of immunological markers of allergic bronchopulmonary aspergilosis in patients 
with asthma 
Y. Kozlova1, E. Frolova2, A. Uchevatkina3, L. Filippova1, G. Solovjeva1, A. Sobolev1, N. Vasilyeva1, N. 
Klimko1 
1Department Of Clinical Mycology, Allergology And Immunology, 1.North-Western State Medical 
University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2Department Of 
Clinical Mycology, Allergology And Immunology, North-Western State Medical University n.a. I.I. 
Mechnikov, Saint-Petersburg, Russian Federation, 3North-Western State Medical University n.a. I.I. 
Mechnikov, Saint-Petersburg, Russian Federation 
Objectives: Allergic bronchopulmonary aspergillosis (ABPA) is a severe lung disease caused by 
hypersensitivity to Aspergillus spp. The study of the role of different immunological mediators in the 
formation of chronic allergic inflammation in patients with ABPA is necessary to identify potential 
targets for therapeutic intervention and timely diagnosis of the disease. To study of the role of 
immunological mediators in the development of allergic bronchopulmonary aspergillosis in patients 
with asthma. 
Methods: A prospective study conducted 58 patients with severe asthma (median of age - 45 years, 
men - 13, women - 45). The control group consisted of 16 apparently healthy people without allergic 
disease in history (median age - 24 years old, male - 4 women - 12). All patients underwent 
allergological (skin tests with fungal allergens, determination of serum levels of total IgE 
(“Polygnostus”, Russia) and specific IgE (sIgE) for fungal allergens (“AlcorBio”, Russia). Computed 
tomography of the chest was performed according to the indications. Diagnostic criteria of ABPA 
2013 [R. Agarwal et al] were used. The concentration of TARC (“R&D Systems”, USA), TSLP (“R&D 
Systems”, USA), IL-8 (“Vector-Best”, Russia) in the serum were determined by ELISA. All patients 
were performed respiratory function and used the AST questionnaire (Asthma Control Test). The 
obtained data was processed using the STATISTICA 10 software system. 
Results: ABPA patients demonstrated significantly lower scores on the questionnaire AST and worse 
lung function FVC and FEV1 compared to patients with asthma. The analysis of the content of TSLP 
in serum did not establish statistically significant differences between patients with ABPA 13.0 (9.70 
÷ 24.70) and asthma 19.0 (15.0 ÷ 29.0), and data from the control group 10.5 (9.0 ÷ 25.0) pg/ml. It was 
revealed that the level of IL-8 in patients with ABPA 35.0 (23.0 ÷ 49.0) was significantly higher than 
in patients with asthma 22.0 (14.4 ÷ 28.0; p = 0.002) and in healthy individuals (12.0 (4.5 ÷ 15.5); p = 
0.000) pg/mg. The content of TARC was higher in patients with ABPA 733.5 (599.0 ÷ 909.0) compared 
with asthma patients 336.1 (208.0 ÷ 571.3; p = 0.000) and control 224.5 (184.0 ÷ 265.0; p = 0.000) pg/mg. 
The importance of TARC in the development of allergic inflammation in patients with fungal 
sensitization was confirmed by a positive correlation of the content of the proinflammatory 
chemokine with the levels of total IgE (r = 0.35, p <0.05), sIgE to A.fumigatus (r = 0.39, p <0.05), the 
number of eosinophils (r = 0.34, p <0.05) and a negative correlation with the indicators of the 
respiratory function of FEV1 (r = -0.44; p <0.05). The high content of TARC and IL-8 suggests a mixed 
eosinophilic-neutrophilic type of inflammatory response in patients with ABPA. 
Conclusion: An increase in serum TARC can serve as a diagnostic biomarker for the development of 
ABPA in patients with asthma. 
 
P124 
Comparison of serum beta-D-glucan levels obtained by Fungitell Assay and Wako beta-Glucan 
Test 
I. Mareković, S. Pleško, V. Rezo Vranješ, M. Jandrlić 
Department Of Clinical And Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, 
Croatia 
Objectives: Fungitell Assay (FA) is the most widely used test for determining serum beta-D-glucan 
(BDG) levels in Europe. However, the disadvantage of this test is the need for samples' cummulation 
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to collect appropriate number of samples assuring optimal test usability. It poses a problem in 
laboratories with limited number of samples because of prolonged turnaorund-time and 
questionable impact on the diagnostic process and antifungal treatment of invasive fungal infections 
(IFI). Wako β-Glucan Test (WBG), recently launched in Europe, offers the possibility of individual 
sample testing. The objective of this study was to compare serum beta-D-glucan levels obtained by 
these two assays in patients with suspected IFI. 
Methods: The study was performed at the University Hospital Centre Zagreb, Department of Clinical 
and Molecular Microbiology. The Fungitell Assay (Associates of Cape Cod Inc.) and Wako β-Glucan 
Test (FUJIFILM Wako Chemicals Europe Gmbh) were performed on patients' sera and the results 
were interpreted according to manufacturers' instructions. Two to three serum samples were tested 
in each patient on two or three consecutive days. Discrepant results between two tests were explained 
and commented in the context of patients' clinical data. 
Results: Forty-four serum samples in 24 patients were tested. FA was positive in 13 and WBG in 9 
patients. The results obtained with two different tests regarding positivity and negativity were 
correspondent in 83,3% (20/24) of patients. In 16,7% (4/24) of patients, the results were discordant, 
with positive FA and negative WBG result. Results for four patients with discordant FA and WBG 
results are shown in Table 1. When cut-off value for WBG was lowered from manufacturer's cut-off 
value of 11 pg/mL to 3,8 pg/mL, as suggested in a recent publication, all the results, except one result 
in Patient 1, were concordant. Moreover, in Patient 1 diagnosis of IFI was excluded after diagnostic 
work-up as well as in Patient 2. In Patient 3, with a recent heart transplant, chest HR-CT was done 
eight days after last serum sample tested with both tests, demonstrated pulmonary infiltrates 
suspected by radiologist to be of fungal etiology and subsequently determined levels of BDG with 
FA only showed further increase. Aspergillus fumigatus grew in a culture of sputum and patient was 
treated with voriconazole. Patient 4 had a cystic fibrosis with A. fumigatus isolated in sputum and 
treated with voriconazole. In Patients 1, 2, and 4 the highest level of BDG determined with WBG was 
5,1 pg/mL, while in a Patient 3 the highest level was 9.62. 
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Conclusion: In our study FA was more frequently positive in comparison to WBG test. Among 
patients with positive FA and negative WBG was a also a patient with IFI. This is in concordance with 
so far conducted studies showing superior sensitivity of FA. Therefore, cut-off value for WBG should 
be reconsidered. As the results of any of these tests should be evaluated in the context of clinical 
picture and microbiological and radiological findings, WBG test remains a useful alternative for 
laboratories with low number of samples. 
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An immunonanodiagnostic approach for Pneumocystis pneumonia at point-of-care 
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Objectives: Pneumocystis jirovecii is an ubiquitous opportunistic fungus capable of causing fatal 
pneumonia (PcP) in immunocompromised patients worldwide. The diagnosis relies on microscopic 
visualization of the P. jirovecii organisms or on DNA detection, in respiratory specimens obtained by 
invasive and costly techniques. Thus, the search for a specific serological biomarker and for a faster, 
cost-effective and less-invasive diagnostic approach is an old ambition of the scientific community. 
This work aims to develop a point-of-care strip-based platform for anti-P. jirovecii antibodies 
detection in human serum specimens, applying the innovative association of recombinant synthetic 
antigens (RSA) technology with functionalized gold nanoparticles (AuNPs). 
Methods: P. jirovecii’s surface proteins such as the major surface glycoprotein (Msg) and kexin-like 
serine protease (Kex1) present highly reactive antigenic properties. Thus, newly recombinant 
synthetic (multi-epitope) antigens from these proteins were designed based on immunogenicity of 
their sequences. After synthesis and purification by immobilized metal affinity chromatography, 
these RSA were applied in ELISA tests as biomarkers of the disease to identify circulating anti-P. 
jirovecii antibodies in serum specimens of patients previously classified in distinct clinical groups. 
After confirming their applicability as biomarkers of infection, these RSA were conjugated with 
spherical AuNPs previously functionalized with mercaptoundecanoic acid. The interaction of such 
RSA-AuNP bionanoconjugates with specific anti-P. jirovecii antibodies in patient’s sera, was 
characterized by agarose gel electrophoresis (AGE). The same RSA-AuNP bionanoconjugates were 
then utilized in two strip-based lateral flow immunoassays (LFIA) prototypes, projected to detect the 
presence of human IgM reactive to each of the P. jirovecii’s RSA. These prototypes were optimized 
and tested with positive and negative clinical samples. 
Results: A synthetic antigen with three reactive Msg epitopes and another with three Kex1 reactive 
epitopes were produced. ELISA results with both RSA showed that IgM anti-P. jirovecii levels were 
significantly increased in patients with PcP compared with patients colonized by P. jirovecii (p = 0.002 
with Kex1 RSA; p<0.001 with Msg RSA) or patients without P. jirovecii infection (p≤0.001 with both 
RSA). AGE assays with the RSA-AuNPs bionanoconjugates confirmed that these bionanoconjugates 
reacted with anti-P. jirovecii antibodies present in patient’s serum. The LFIA prototypes developed 
were tested with sera pools from patients with active PcP (positive sample) and from patients without 
P. jirovecii infection (negative sample). Both samples showed the expected performance, namely, test 
and control colored lines with the positive sample and only a control colored line with the negative 
sample. 
Conclusion: Our results support the possibility to diagnose PcP and distinguish active disease from 
colonization using RSA as biomarkers of the disease and IgM anti-P. jirovecii antibodies as targets for 
immunonanodiagnosis. Further improvement and validation of the LFIA prototypes developed will 
help in the global effort to reduce high costs of medical diagnosis and consequently treatment of PcP. 
This applies not only to more economically advanced regions, but can also be a huge contribution, in 
terms of public health and economy, in communities with low-income and scarce access to 
technology. 
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Interest of Aspergillus fumigatus Western Blot assay for differential diagnostic between IgE 
sensitization and Allergic Broncho Pulmonary Aspergillosis. 
R. Piarroux1, J.-C. Dubus2,3, M. Reynaud-Gaubert3,4, M. Gouitaa5, S. Ranque6,7, J. Vitte8 
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Marseille Université AP-HM Hôpital Nord, Marseille, France, 5Clinique Des Bronches Et Allergies 
Du Sommeil, Aix-Marseille Université AP-HM, Marseille, France, 6IHU-Méditerranée Infection, 
Marseille, France, 7Vitrome, Aix Marseille Univ, IRD, AP-HM, SSA, Marseille, France, 8Ihu 
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Objectives: Diagnosis of Allergic Broncho Pulmonary Aspergillosis (ABPA) is complex and based on 
a multi-criteria definition. One of the major ABPA criteria, the detection and quantification of 
immunoglobin E (IgE) responses to Aspergillus fumigatus (Af), is also associated with Af-sensitization. 
In the past few years, a novel approach assaying IgE responses to molecular antigens enhanced the 
discrimination between Af sensitization and ABPA, but without allowing for a clear-cut distinction 
between these two diseases. We recently reported that a Western Blot detecting Af-specific IgE 
antibodies could be helpful in separating those two entities. This work aimed to strengthen the 
evaluation of the Af IgE WB assay as a differentiating tool between Af-sensitization and ABPA. 
Methods: 221 sera with known sIgE reactivity (21 ABPA, 200 Af-sensitized) were assayed with the 
LDBIO Asp II WB. Sera were collected 2014-2018 and previously assayed with ImmunoCap®  to Af 
extract and molecular antigens. We evaluated the ability of WB LDBIO to detect Af sensitization and 
to discriminate between ABPA and Af-sensitized patients, relying on ImmunoCap®  and clinical chart 
conclusions as a reference. 
Results: Samples displayed 0 to 10 bands in the 10-37 kDa range. Among those bands, four (16, 18-
20, 22 and 30 kDa) were most frequent and therefore considered as major bands, while the others 
were considered as minor bands. Af IgE WB positivity was defined by the presence of at least 2 major 
bands. The Af IgE WB was positive in 21/21 ABPA and 115/200 Af-sensitization sera (61% sensitivity). 
Af IgE WB positivity was strongly correlated to IgE level and was positive in 95% (75/79) of the sera 
with IgE to Af >2kUa/l. Band patterns formed various profiles for discrimination between ABPA and 
Af-sensitization. Of those profiles, one (5 detectable bands, regardless of minor/major classification) 
had 100% sensitivity (21/21) and 91% specificity (201/221) for ABPA diagnostic. However, by using a 
more specific profile with 2 major bands and 2 minor bands outside of the 16-30 kDa range, the WB 
yielded 90% (19/21) sensitivity and 96% (211/221) specificity. 
Conclusion: This study shows the potential of WB in the work-up of IgE responses to Af in asthmatics 
and cystic fibrosis patients: Af IgE WB was able to discriminate between ABPA and Af-sensitized 
patients, with a sensitivity of 90% and a specificity of 96%. In comparison, the ISHAM criteria 
(tIgE>1000 kUI/l and Af IgE>0.35 kUa/l) had 48% sensitivity (10/21) and 98.2% specificity (217/221) in 
the same population Noteworthy, among the Af IgE WB negative patients, 4 were sensitized to 
another mould (Alternaria alternata), thus Af IgE WB could avoid unnecessary diagnostic difficulties 
due to such cross-reactivity. A multicenter evaluation is now needed to confirm those results, but Af 
IgE WB shows a great potential for second-line diagnostic tool when ABPA is suspected. 
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Rapid Identification of Candida spp. from positive blood cultures 
V. Ö zenci, K. Ininbergs, C. Gronfors Seeth, K. Jansson, M. Ullberg 
Clinical Microbiology, Karolinska University Hospital, karolinska Institutet, Stockholm, Sweden 
Objectives: Candidemia is related to high mortality, morbidity. Rapid and reliable identification of 
Candida spp. and antifungal susceptibility testing is essential for early appropriate antifungal 
treatment. The aim of the present study was to evaluate two rapid methods for identification of 
Candida spp. from blood cultures (BC) using matrix assisted laser desorption ionization (MALDI-
TOF MS). The methods tested were (i) the Sepsityper kit and (ii) short-term culture followed by 
MALDI-TOF MS. The effect of using Bact/ALERT FA Plus and BACTEC Mycosis-IC/F blood culture 
bottles were compared for the performance of both of the rapid methods. The performance of short-
term culture on faster antifungal susceptibility testing was also analyzed. Conventional identification 
and antifungal susceptibility testing methods were used as reference. 
Methods: In total, 52 clinical Candida spp. were inoculated in two types of BC bottles and incubated 
in respective BC systems. Each bottle was inoculated with 8 mL human blood from a healthy donor 
which had been spiked with ~ 125 colony forming units (CFU) per mL. When the BC bottles signaled 
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positive, the samples were analyzed directly from BC bottles by the Sepsityper kit as well as after 6h 
short-term incubation on sabouraud agar and chrome plates followed by MALDI-TOF MS if growth 
in 6h was observed. 
Results: Overall, the Sepsityper kit and short-term culture method performed similarly and could 
identify Candida spp. in 66/101 (65.3%) and 63/85 (74.1%), respectively (NS). Mycosis-IC/F had higher 
identification rates than FA Plus BC bottles using the Sepsityper kit 39/51 (77%) and 27/50 (54%), 
respectively (p<0.05). Similarly Mycosis-IC/F performed better than FA Plus BC bottles using the 
short-term culture method 38/43 (88%) and 25/42 (60%), respectively (p<0.01). Six hours short term 
culture followed by Sensititre YeastOne method was tested on ten positive BC bottles. On average 
the MIC levels for antifungal agents were within one titre difference compared to conventional 
Sensititre method which was performed after overnight culture plates for both BC bottles (NS). 
Conclusion: The present data shows that Sepsityper kit and short-term culture method can be used 
in rapid identification of Candida spp. from blood cultures. Mycosis-IC/F has higher performance in 
identification of yeast with both methods compared to FA Plus BC bottles. Preliminary data suggest 
that six hours short term culture followed by Sensititre Yeast One method can be used as a reliable 
rapid antifungal susceptibility testing method for positive blood cultures. 
 
P128 
Comparison of Bactec Mycosis IC/F and BacT/Alert FA plus bottles in laboratory diagnosis of 
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Stockholm, Sweden 
Objectives: The aim of the present study was to compare the clinical performance of Bactec Mycosis 
IC/F and BacT/Alert FA blood culture bottles in detection and time to detection of Candida spp. over 
eight years period in a tertiary care hospital setting. 
Methods: During a period of eight years, all blood samples that were concurrently taken from 
patients with suspected candidemia and cultured paralleled in Bactec Mycosis IC/F, BacT/Alert FA, 
and BacT/Alert FN blood culture bottles were included in the study. Data collection was retrieved 
from the laboratory information system and from the respective blood culture system. Bottles that 
did not signal positive in 10 days in the blood culture system were regarded as negative. Time to 
growth was counted from the time that the incubation occurred until the time the system gave a 
positive signal. Results analyzed with use of R, conducting a mixed linear model and Chi-square test. 
Results: In total, 2,748 positive blood cultures with Candida spp. i.e Bactec Mycosis IC/F, BacT/Alert 
FA Plus, and BacT/Alert FN Plus bottles from 810 patients were analyzed. Triplicates of blood culture 
bottles that were taken in 24 h were included. There were 274 blood cultures from 261 patients with 
all three blood culture bottle types. The BacT/Alert FN bottles had too few positives and excluded 
from further analysis. The Bactec Mycosis IC/F Bottles could detect Candida spp. in 216 (78.83%) of 
274 samples, whereas BacT/Alert FA aerobic bottles were able to detect in 233 (85%) of 274 samples. 
The Mycosis IC/F and BacT/ Alert FA aerobic Bottles did not differ in detection of Candida spp. (NS). 
There was no species-specificity difference between the two bottles in growth of different Candida 
spp (NS). There was no difference in to time to detection between the two bottles (NS). 
Conclusion: The present study shows that the performance of Bactec Mycosis IC/F and BacT/ Alert 
FA blood culture bottles in detection of Candida spp. are similar. Further analysis of the discrepant 
results and the patient characteristics will be performed. 
 
P129 
Direct identification of 81% of candidemia from blood culture bottles by MALDI –TOF MS 
M. Vannini, E. Chandemerle, A. Landreau, L. Simon, C. Pomares, L. Hasseine 
Laboratoire De Parasitologie Mycologie, CHU DE NICE, NICE, France 
J. Fungi 2019, 5, 95 182 of 464 
 
Objectives: Candidemia are associated with high mortality rate (40%). Rapid yeast species 
identification is crucial to introduce as soon as possible appropriate treatment which is associated 
with an increase of patients survival rate. Because of the emergence of echinocandin resistance, 
strategies that allow targeted use of antifungals are essential, notably to reduce the duration of 
echinocandins exposition . With the conventional method, 24 to 48 hours are required to obtain 
enough fungal colonies for species identification. In this study, we developed a method to directly 
identify yeast from blood cultures bottles within one hour. In the context of Laboratory Accreditation 
we performed method validation according to the ISO 15189 norm. 
Methods: This work was done in the laboratory of parasitology and mycology at the University 
Hospital Center of Nice, France. We used 37 positive blood cultures obtained from 25 patients from 
4th January 2019 to 28 Mars 2019. 1.3 ml of positive blood cultures was transferred into 1.5 ml 
microtube and each sample was extracted according to the SDS lysis-based protocol (Jeddi et al 2017). 
Supernatants were spotted four times on the target plates that were read by the MADLI-TOF mass 
spectrometer (Bruker®). We validated species identification when a log (score) from Bruker either ≥ 
1.6 or ≥ 1.1 three-times repeatable was found, since we did not observe any species misidentification 
above these thresholds. In case of failure, spectra were analyzed online with the MSI-Users®  database 
(Mass Spectrometry Identification, Normand et al 2017) and identifications were validated when the 
score was ≥ 17%. We compared our results with the conventional culture and identification methods. 
Results: 30 blood cultures (81%) were correctly identified with both databases. Only 68 % with Bruker 
database and 73 % with MSI User database. This method is reproducible and reliable. We tested two 
mixed infections but they were not totally identified. 
Conclusion: Our study shows that direct identification of candidemia from blood culture with the 
SDS protocol allows rapid identification of the causative yeast in 81% of cases. It allows early 
identification of yeast species and thus appropriate antifungal treatment. This will improve patient’s 
healthcare in the context of candidemia. Mycological culture remains necessary when our protocol 
doesn’t work and in case of mixed infections. 
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The Use Of Coffee Agar As An Alternative Medium For The Presumptive Identification Of 
Cryptococcus neoformans In Resource – Limited Settings. 
P. Chidebelu, E. Nweze 
Microbiology, University of Nigeria, Nsukka., Enugu, Nigeria 
Objectives: Cryptococcus neoformans is presumptively identified by its characteristic brown - black 
colonies on media containing caffeic acid (Katiyar et al., 2011). In low income regions, neither the 
conventional identification media nor their basic component(s) is readily affordable and available. 
We proposed an alternative coffee agar media made of coffee which is rich in caffeic acid, for 
differential recovery of C.neoformans colonies from mixed cultures of various sample sources. 
Methods: The coffee agar media which is a modification of caffeic acid agar was composed with 
coffee as follows: ammonium sulphate (5.0g), glucose (5.0g), yeast extract (2.0g), dipotasium 
phosphate (0.8g), magnesium sulphate (0.7g), coffee (18.5g), chloramphenicol (0.05g), ferric citrate 
solution (4.0ml), agar (15.0g). The final pH of the solution in 1 litre of de-ionized water was adjusted 
to 6.5 ± 0.3. After sterilization at 121ºC and 15psi pressure for 15 minutes, the solution was cooled at 
45ºC, dispensed in Petri dishes and stored at refrigeration temperature until use. Test isolates (n = 12) 
of Cryptococcus neoformans VNI (ST32) identified by MALDITOF MS and MLST, were streaked on 
the Coffee agar plates and monitored for pigmentation. Reference strains of Cryptococcus 
neoformans var. grubii VNI H99 and Candida albicans SC5314 were cultured parallel as the control. 
A set of the plates was incubated at 30ºC, and the other at 37ºC for up to 1 week. 
Results: The colonies of Cryptococcus neoformans (both the test and reference strains) turned brown 
- black on the coffee agar plates, while Candida albicans SC5314 remained as cream – white colonies. 
Melanization was more conspicuous at 30ºC after 5 days of incubation. 
Conclusion: The brown - black pigmentation observed for C. neoformans indicated that coffee is rich 
in caffeic acid and thus, provided the substrate for the phenoloxidase enzyme laccase, which is absent 
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in C. albicans. Expression of melanin especially at 30ºC remains integral for Cryptococcus’ 
environmental survival. After the necessary validation, we suggest that coffee agar can provide an 
alternative detection media especially in resource – limited settings where absence and cost of 
conventional identification media pose a barrier to research and diagnostic studies of Cryptococcus 
neoformans and Candida albicans. 
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Objectives: The detection of serum (1→3)-β-D-glucan (BDG), an antigen common to several fungi, is 
part of the definition of invasive fungal infections (IFI). The turbidimetric or the colorimetric 
detection is the basis of two different commercial kits, the Fungitell assay (FA) and the Wako assay 
(WA), respectively. The FA has been used in Europe since the 2000’s, whereas the WA has been only 
recently CE approved. We wondered how the WA compares to the FA on a routine use. 
Methods: We prospectively tested 321 serum samples (median: 1[1-11]) from 171 patients (sex ratio 
M/F = 60%, mean age 48+/-16 yrs) mainly with hematological conditions (64%; 110/171) using both 
assays from December 21st 2018 to April 23rd 2019. The tests were performed according to the 
manufacturers’ recommendations. 
Results: Twenty-three patients had IFI (pneumocystosis n = 12; invasive aspergillosis n = 4; 
candidemia n = 3; invasive fusariosis n = 2; Hepato-splenic candidiasis n = 1; and cryptococcosis n = 
1). Both assays provided similar AUC around 0.9 (Figure 1). 
 
 Sensitivity, specificity, positive and negative predictive values were as follow: FA (positivity 
threshold ≥80 pg/ml): 91%, 89%, 55%, 98%; WA (positivity threshold at 11 pg/ml): 48%, 97%, 67%, 
92%; WA (positivity threshold at 4 pg/ml): 83%, 94%, 68%, 97%. When removing the FA negative (<80 
J. Fungi 2019, 5, 95 184 of 464 
 
pg/ml) and FA overflow values (> 523 pg/ml), the analytical comparison showed a good correlation 
(R2 = 0.81), the FA values being 28 higher in mean than the WA values (Figure 2). Among 73 samples 
from patients with bacterial sepsis, 21% (15/73) were FA positive, 11% (8/73) were WA positive 
(positivity threshold at 4 pg/ml), whose 7 positive with both methods. These possible false positive 
results should be taken with caution knowing that extensive work-up for diagnosing fungal infection 
was not homogenous between the patients due to the study design and that bacterial and fungal 
diseases are often concomitant.  
 
Conclusion: The WA performed similarly compared to the Fungitell assay when a lower cutoff (4 
instead of 11 pg/ml) is used for the diagnosis of IFI, with a better specificity. The WA is a single 
sample testing which is clinically relevant when prompt therapeutic decision is on stake. 
 
P132 
The development of a real-time PCR assay for the detection of Mucormycosis infections: 
Fungiplex Mucorales 
J. Green, K. Dempsey 
Bruker Microbiology, Glasgow, United Kingdom 
Objectives: Mucorales have been increasingly reported as causes of invasive fungal infections in 
immunocompromised subjects, particularly in patients with haematological malignancies, 
uncontrolled diabetes mellitus or those undergoing dialysis. Mucorales are now also being reported 
in Aspergillus-positive patients who are not responding to first line treatments. Histology and culture 
are still the most important diagnostic approaches for mucormycosis because of the lack of molecular 
diagnostic methods available, and β-d-Glucan detection is not useful due to the extremely low 
content of the biomarker in the Mucorales order. Timely diagnosis of invasive mucormycosis is 
essential due to the rapid progression of the disease, and because signs and symptoms of the infection 
are consistent with other invasive fungal infections. PCR would improve detection of Mucorales and 
complement the current Bruker offering within the area of invasive fungal disease. 
Methods: The Bruker real-time PCR assays are designed in an easy to use format with minimum 
hands on time and results generated in around 1 hour after extraction. Universal primer and probe 
sequences have been designed to target the internal transcribed spacer (ITS) region of the rRNA gene 
for the genera detailed in Table 1. The probes associated with each pathogen have been labelled with 
different fluorescent dyes enabling some differentiation within the multiplex reaction. A specific 
control material has been developed to give the users an option of running it as an extraction control 
J. Fungi 2019, 5, 95 185 of 464 
 
or a PCR inhibition control. 
 
Results: The coverage specified in Table 1 has been confirmed using a range of simulated samples 
prepared from plasmid and genomic DNA. The limit of detection for species representing the highest 
prevalence of IFD for each genus has been assessed over six thermocycler platforms to ensure 
accuracy across a variety of systems. 
Conclusion: Bruker have developed a Mucorales assay which identifies a wide range of clinically 
relevant genera. The assay is being further developed to produce a kit to provide rapid detection of 
the main causative agents in invasive mucormycosis. 
 
P133 
The development of a real-time PCR assay for the diagnosis of Pneumocystis pneumonia: 
Fungiplex Pneumocystis 
J. Green, T. Donnelly 
Bruker Microbiology, Glasgow, United Kingdom 
Objectives: Pneumocystis jirovecii is the causative organism in Pneumocystis pneumonia (PCP); a life-
threatening pneumonia in immunocompromised patients. Due to a lack of methods to propagate P. 
jirovecii in vitro, the most common current practice in diagnosis of PCP is the microscopic 
identification of P. jirovecii through staining of bronchoalveolar lavage (BAL) samples. This method 
lacks sensitivity to detect low fungal burdens, therefore PCR methods of detection would improve 
diagnosis of PCP and complement the current Bruker offering within the area of invasive fungal 
disease. Two different Pneumocystis assays have been designed for initial evaluation against various 
sample types, with the intention of selecting the best performing assay for further development. 
Methods: Two Pneumocystis real-time PCR assays were initially developed, with specific primer and 
probe sequences designed to target different genes of Pneumocystis jirovecii. Assay 1 targeted the 
internal transcribed spacer 2 (ITS) sequence between the 5.8S and 28S rRNA genes, with Cy5 as the 
fluorophore. Assay 2 targeted the mitochondrial large subunit (mtLSU) rRNA gene and used Yakima 
Yellow as fluorophore. During initial feasibility studies a range of plasmid concentrations were 
amplified in the presence of an amplification and extraction control using the standardised Fungiplex 
assay real-time PCR conditions. The real-time PCR assays were also tested against QCMD’s P. jirovecii 
pneumonia EQA panels. 
Results: When assessed against a range of known plasmid concentrations, both assays were found to 
perform equivalently, with a limit of detection of 20 ipc and a dynamic range of 20 – 2x106 ipc as 
displayed in Figure 1. When tested against the QCMD 2017 PCP panel, the correct result was obtained 
in duplicate testing of all extracts using Assay 2, whereas several replicates were undetected using 
Assay 1. The internal control was detected in all samples, showing that there was no inhibition. Assay 
2 was then assessed against the QCMD 2018 PCP panel; again, the correct result was obtained in 
duplicate testing of all extracts using this assay.  
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Conclusion: The assay designed to target the mtLSU gene, is therefore most suitable and will be 
developed further. The better performance of this assay is likely due to the presence of multiple 
copies of the mtLSU gene per organism, compared with just a single copy of ITS2. 
 
P134 
Upgrading the level of diagnosis towards a more targeted treatment. A six year period of 
laboratory monitoring in a Paediatric Haematoloy-Oncology Unit. 
E. Zarkada1, A. Tragiannidis2, T. Papageorgiou2, E. Hatzipantelis2, K. Samaras1, A.-M. 
Markantonatou1, E. Zachrou1, T.-A. Vyzantiadis1 
1First Department Of Microbiology, Medical School, Aristotle University of Thessaloniki, 
Thessaloniki, Greece, 2Haematology-oncology Unit, Second Department Of Paediatrics, Medical 
School, Aristotle University of Thessaloniki, Thessaloniki, Greece 
Objectives: Invasive fungal infections have been proved an important cause of negative prognosis 
in critically ill patients and notably the immunocompromised, while the paediatric haematolgy-
oncology patients form a high risk group among them. Although several laboratory methodologies 
for the diagnosis of fungal infections are not completely validated in these patients, the criteria 
provided by the EORTC/MSG, alongside to the recommendations by ESCMID and ECIL, can be 
followed in order to upgrade the level of diagnosis. The main aim of this study was to show that the 
implementation of laboratory testing in this group of patients, served as a useful tool towards a more 
targeted antifungal approach by managing to upgrade the diagnosis from possible to probable or 
maintain the clinical suspicion in just a state of readiness. 
Methods: Data was gathered retrospectively, over a period of six years, from the records of the forty-
three patients with haematological malignancies that were hospitalised in the Paediatric-Oncology 
Unit and had at least one mycology result during their follow-up. All mycology studies were 
performed in the First Department of Microbiology and included specific cultures, testing for 
galactomannan, mannan and antibodies against Candida, as well as PCR for Aspergillus or Candida. 
Also, sensitivity testing or TMD for antifungal drugs, when necessary. 
Results: Among the above 43 haematology patients the 22 were initially considered to have a possible 
diagnosis according to the EORTC/MSG criteria due to the presence of at least one host factor and a 
clinical criterion (mainly positive CT imaging). From the 22 patients, nine proved to have a probable 
infection by Aspergillus with positive galactomannan and (in one case) / or (in one case) a positive 
PCR for Aspergillus. One patient had a proven diagnosis, based on the isolation of Rhizopus arrhizus 
from several cultures of face biopsies and one was considered with a “probable” diagnosis due to the 
presence of positive high titers of mannan, positive Candida PCR in blood and kidney ultrasound 
imaging of a possible mycotic mass. There were also three “probable” patients with sequential 
positive mannan testing (with decreasing to negative titers after treatment) that although not 
included in the criteria, they could not be considered as just possible. Consequently, the diagnosis 
was considered upgraded, after the mycology findings, in almost 64% (14/22) of patients with 
possible diagnosis. Among the 22 patients with possible diagnosis, the rest eight, as well as all other 
21 patients (from the total of 43), remained with a possible or completely negative diagnosis 
(respectively) for fungal infection proving the utility of negative and often excluding results. 
Conclusion: The results of this study could argue in favor of a meticulous and well organized 
protocol of laboratory monitoring in this group of patients. Taking in consideration that the here-
mentioned monitoring, due to several reasons, is not performed with the proposed frequency and 
combination, the laboratory results are already a useful adjunct towards the documentation or even 
the exclusion of a fungal infection, helping the clinical decision and guiding the targeted treatment. 
 
P135 
Revision of special microscopic techniques for visualization of aspergilli structural elements 
N. Vasilyeva1, I. Riabinin1, Y. Mihaylova2, Y. Borzova1, L. Alieva1 
1Kaschkin Research Institute Of Medical Mycology. Department Of Medical Microbiology, North-
Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 
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2Laboratory Of Biosystematics And Cytology, Komarov Research Institute of Botany, Saint-
Petersburg, Russian Federation 
Objectives: Objective of the study is to select the optimal type of special light optics for obtaining 
microphotographs of Aspergillus spp. 
Methods: Aspergillus clinical strains belonging to 14 species from the Russian Collection of 
Pathogenic Fungi (Saint-Petersburg, Russia) were used: A. fumigatus, A. flavus, A. tamarii, A. terreus, 
A. niger, A. nidulans, A. ustus, A. calidoustus, A. sydowii, A. versicolor, A ochraceus, A. candidus, A. 
amstelodami, Neosartorya hiratsukae. Original strains were previously identified by the target DNA-
sequencing of ITS and β-tubulin loci according to the CLSI MM18 protocol (2nd edition). Subcultures 
were obtained on Czapek yeast extract agar (28°C, 10 days). Micropreparations were studied by three 
microscopic methods: (1) phase contrast (PCM), (2) «dark field» (DFM), (3) water-immersion light 
microscopy with oblique illumination (WILMOI) using an «aplanatic» condenser (Leningrad 
Optical-Mechanical Association, Russia). Presto T55 (Rekam, Canada) and PowerShot A2000IS 
(Canon, USA) cameras were used for taking photo. Digital image processing was performed in 
XnView 2.35 and GIMP 2.8.6 software. 
Results: Series of microphoto for three described techniques were received. As it turned out, the 
phase-contrast microscopy sharply emphasizes the contours of the aspergilli thallic elements and 
their conidia, but the most successful microscopic pictures are obtained only in areas of location of 
the structural elements in single layer. With dark-field microscopy in some species (A. fumigatus, A. 
nidulans, Aspergillus spp. of Versicolores and Usti sections) structural details of the conidial heads are 
not clearly visible at high magnification. In dark-field microscopy, in comparison with elements of 
mycelium, vegetative spores and ascospores are better visualized. Dark-field and phase-contrast 
microscopy to varying degrees distort the natural color of the microscopic elements of the Aspergillus 
spp. cultures. In contrast to the techniques mentioned above, the use of a condenser with a shiftable 
iris diaphragm and a water-immersion diaphragmatic lens made it possible to take microphoto while 
preserving the natural pigmentation of aspergilli, sufficient contrast and creating a «relief» of a 
microscopic picture. In addition, by changing the setting of the aplanatic condenser, it is easy to 
transform the microscope in dark-field microscopy mode. Examples of taken images are shown in 
the figure.  
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Figure. Aspergillus flavus micrographs made by using three special microscopic techniques 
(abbreviations are placed in text). 
Conclusion: Water-immersion microscopy with oblique illumination allows to obtain the most 
natural microphoto of aspergillosis causative agents with the effect of «soft» contrasting. Moreover, 
the WILMOI mode is much faster adjusted by a microscopist than the DFM and PCM modes. We 
believe high-quality reproduction of the WILMOI technique is fundamentally available on 
microscopes of various manufacturers. With the help of phase-contrast and dark-field microscopy, it 
is possible to make quite spectacular images, but for complex representation of the strains they must 
be supplemented with the results of traditional light microscopy or WILMOI technique. 
 
P136 
Evaluation of 99mTc-Amphotericin B for nuclear imaging of mould infections in a transwell in 
vitro system 
L. Page1, S. Wurster2, F. Schadt3, H. Einsele4, A.J. Ullmann1, S. Samnick3 
1Internal Medicine Ii, Division Of Infectious Diseases, University Hospital of Wuerzburg, Wuerzburg, 
Germany, 2Ut Md Anderson Cancer Center, 1515 Holcombe, Houston, United States of America, 
3Nuclear Medicine, University Hospital of Wuerzburg, Wuerzburg, Germany, 4Internal Medicine Ii, 
University Hospital of Wuerzburg, Wuerzburg, Germany 
Objectives: Several studies have evaluated molecular imaging using positron emission tomography 
(PET) and single photon emission computed tomography (SPECT) to diagnose invasive mycoses. The 
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most promising tracers described in the literature include 68Ga-labelled Aspergillus-derived 
siderophores [1] or A. fumigatus-specific antibodies labelled with 64Cu [2]. However, these PET-tracers 
are cost-intensive and onsite generation may not be feasible at regional medical centers. Therefore, 
we investigated the potential of Amphotericin B (AMB) labelled by the gamma emitter technetium-
99m (99mTc) to visualize pathogenic moulds. 
Methods: Sodium pertechnetate (derived from a 99Mo/99mTc generator, 1000 MBq in 0.35 mL saline) 
was added to a suspension of 50 µg AMB in 100 µL HBSS, followed by 20 µL of a stannous chloride 
solution (10 mg SnCl2 in 1 mL 0.1 N HCl). After 20 min incubation at room temperature, the 99mTc-
AMB solution was neutralized by addition of 3 ml PBS and sterile filtered. To prepare the transwell 
assay, 1x105 human pulmonary artery endothelial cells (HPAEC) were seeded on the lower side of a 
transwell insert (24-well format, 3 µ m pore size) according to previously published protocols [3-4]. 
The HPAEC layer was infected with 2.5x101-2.5x106A. fumigatus conidia or a bacterial control 
(Staphylococcus aureus). Additional inserts were infected with 2.5x105 spores of different Mucorales 
species. After an incubation period of 15 h to obtain early mycelial biofilms, 99mTc-AMB was added 
to the medium at 50 ng/mL, a concentration that is significantly below commonly achieved 
therapeutic serum levels [5]. Transwell inserts were incubated for 120 min in 600 µL of the tracer 
solution (initial activity: 30 kBq per well) and were subsequently washed five times with HBSS. 
Thereafter, the activity was measured using a gamma counter and normalized to the activity of 600 
µL tracer-supplemented medium to calculate percent uptakes. Independently prepared inserts were 
imaged by autoradiography. 
Results: Radiochemical yield and purity of 99mTc-AMB, as determined by thin layer chromatography, 
reached >98 % and >99 %, respectively. Minimal unspecific tracer uptake was found in uninfected 
(0.03-0.14 %) or S. aureus infected inserts (0.05-0.16 %). An inoculum-dependent increase in tracer 
uptake was seen in A. fumigatus infected inserts, with a limit of detection at 2.5x104 fungal cells (Panel 
A). Low inter-assay variability was found (mean coefficient of variation = 0.32, n = 3). Quantitative 
results were validated by autoradiography imaging, confirming inoculum-dependent tracer 
enrichment in A. fumigatus-infected HPAEC monolayers (Panel B). Finally, we tested the applicability 
of 99mTc-AMB to detect Mucorales. Mean 4.4 and 6.2-fold 99mTc-AMB enrichment compared with an 
uninfected control was found in inserts infected with 2.5x105 spores of Rhizopus arrhizus or 
Cunninghamella bertholletiae, respectively. 
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Conclusion: Our in vitro results suggest promising potential of 99mTc-AMB as an easily producible, 
cost-efficient alternative for nuclear imaging of pathogenic moulds by SPECT. These data could 
encourage further in vivo evaluation of modified antifungal drugs as nuclear medical tracers. [1] 
Petrik et al., 2014, Mol Imaging Biol; [2] Rolle et al., 2016, PNAS; [3] Hope et al., 2007, J Infect Dis; [4] 
Belic et al., 2019, Front Microbiol; [5] Hamill, 2013, Drugs. 
 
P137 
Detection of circulating DNA in serum by PCR for the diagnosis of invasive mucormycosis 
J. Savio, J. Mathew 
Microbiology, St. John's Medical College, Bangalore, India 
Objectives: Mucormycosis is an invasive fungal infection with increasing incidence in developing 
countries like India. Because of its rapid and fatal progression, early diagnosis is essential. 
Conventional methods like microbiological and histopathological investigations have limitations. In 
the absence of specific biomarkers for diagnosis, detection of circulating Mucorales DNA in serum by 
PCR proves a better alternative to conventional methods. The objectives of this study were to 
compare detection of circulating Mucorales DNA in serum by PCR with the conventional 
microbiological and histopathological investigations. 
Methods: The Institutional Ethics Committee approved this study. 36 patients with a clinical 
diagnosis of mucormycosis whose samples were received in the microbiology and or histopathology 
laboratories were included. Three patients with laboratory finding not suggestive of mucromycosis 
were excluded. Blood samples from all 33 patients were collected. Serum was separated and stored 
until further analysis. Microbiological investigations included microscopy and culture. Isolates were 
identified by the conventional techniques. Histopathological examination by microscopy was carried 
out using H and E, PAS and GMS stains. DNA was extracted from serum by the salting out and 
TRIZOL methods. Conventional Pan-Mucorales PCR was performed on the extracted DNA. 
Results: Of the 33 patients, 20 were males and 13 were females. Mean age was 52 years. 29 of the 33 
patients had diabetes mellitus and 3 were diagnosed following admission. Clinical presentation 
included rhino orbito cerebral in 25, cutaneous in 4, pulmonary in 3 and renal in one. All 32 samples 
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received for microbiological investigations were positive by microscopy and 22 (68.8%) were culture 
positive. Isolates included Rhizopus species 17, Apophysomyces 2, Lichtheimia 1 and one is yet to be 
identified. 24 of the 25 samples on histopathological examination was suggestive of mucormycosis. 
19 of the 33 serum samples were positive for circulating DNA. PCR was positive in 80% of the culture 
negative patients. PCR was positive in 42.1% of samples with no angioinvasion. PCR was positive in 
50% of ROC and cutaneous manifestation and all 3 patients with pulmonary mucormycosis. 61.9% of 
PCR positive patients had an unfavorable outcome. 
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Conclusion: Most patients were above 40 years of age and from urban and rural areas DM was the 
most common underlying risk factor. ROC was the most common presentation. Rhizopus species was 
the most common isolate, Apophysomyces and Saksenaea were isolated from cutaneous lesions. 57.6% 
of the samples were positive for circulating Mucorales DNA PCR was positive in 80% of culture 
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negative samples PCR was positive in 42.1% of samples with no angioinvasion Detection of 
circulating Mucorales DNA could serve as an indicator of angioinvasion and help in early diagnosis 
36.4% of the patients recovered Other factors that could influence the PCR results include: use of 
different volumes of serum for DNA extraction and commercial extraction kits A larger sample size 
and serial sampling during the course of illness is required to critically evaluate the utility of this test 
 
P138 
Rapid Diagnosis of Invasive Aspergillosis in Bronchoalveolar Lavage: Performance of the 
Aspergillus Galactomannan Lateral Flow Assay and the Aspergillus-specific Lateral Flow Test in 
a Mixed Patient cohort 
J. Jenks, S. Reed, S. Mehta, N. Law, S. Aslam, R. Taplitz, M. Hoenigl 
Medicine, University of California San Diego, San Diego, United States of America 
Objectives: Early diagnosis and treatment of invasive pulmonary aspergillosis (IPA) remains the 
most important factor to reduce mortality and improve outcome. Diagnosis remains a challenge, 
however, due to unspecific clinical presentation and radiological findings. Only very recently rapid 
tests for IPA have been developed. The objective of this study was to evaluate the performance of 
two new CE-marked tests, the Aspergillus Galactomannan Lateral Flow Assay (LFA; IMMY, 
Norman, Oklahoma, USA) and the Aspergillus-specific Lateral Flow Device Test (LFD; OLM, 
Newcastle, UK) for IPA in a mixed cohort of patients with and without hematological malignancies. 
Methods: The LFA and LFD were retrospectively performed according to the manufacturer’s 
instructions in 106 previously frozen bronchoalveolar lavage fluid samples from 106 patients at risk 
for IPA (23% with underlying hematological malignancies). Samples were collected between 
September 2016 and September 2018 at the University of California San Diego, United States. 
Performance of the LFA and the LFD were compared to Galactomannan, and BAL culture. IPA was 
classified according to revised EORTC/MSG criteria. 
Results: Overall, 22 patients met criteria of probable or proven IPA, 9 criteria of possible IPA, while 
75 patients did not fulfill EORTC/MSG criteria of IPA. Sensitivity of the Apergilllus Galactomanann 
LFA for probable/proven IPA was 77% (17/22), and thereby slightly higher than sensitivity for the 
Aspergillus-specific LFD (59%; 13/22). Sensitivity was similar to BAL GM (77% with a cutoff of 1.0 
ODI), but higher compared to BAL culture (23%). The LFA resulted negative in 7/9 cases with possible 
IPA and 47/73 cases without IPA (overall specificity 66%, 54/82). The less than perfect specificity was 
driven particularly by non-neutropenic patients (specificity 62%, 43/69), while specificity was 85% 
among patients with underlying hematological malignancies. Specificity was slightly higher for the 
LFD (70% specificity; 67% among non-neutropenic patients). Lower specificity among non-
neutropenic patients was also observed for the BAL GM (overall specificity 77%, 72% among non-
neutropenic patients), and BAL culture (overall 90%, 88% among non-neutropenic patients). 
Conclusion: Our study indicates that both the LFA and LFD may be useful for rapid diagnosis of IPA 
in BALF when IPA is clinically suspected. The lower specificity in non-neutropenic patients without 
underlying hematological malignancies may be explained by limited applicability of the 
EORTC/MSG criteria in non-neutropenic patients. Better consensus criteria for classifying IPA in 
those patients are needed. 
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Use of the basophil surface marker CD203c in the diagnosis of fungal sensitization in patients 
with cystic fibrosis 
Y. Kozlova1, E. Frolova2, A. Uchevatkina2, L. Filippova2, Y. Borzova2, V. Makhmutova3, T. 
Stepanenko3, O. Aak2, T. Bogomolova2, V. Spiridonova2, N. Vasilyeva4, N. Klimko5 
1Department Of Clinical Mycology, Allergology And Immunology, 1.North-Western State Medical 
University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2Kashkin Research 
Institute of Medical Mycology, Saint-Petersburg, Russian Federation, 3Multidisciplinary City 
Hospital №2, St. Petersburg, Russia, Saint-Petersburg, Russian Federation, 4Kaschkin Research 
Institute Of Medical Mycology. Department Of Medical Microbiology, North-Western State Medical 
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University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 5Department Of 
Clinical Mycology, Allergology And Immunology, North-Western State Medical University n.a. I.I. 
Mechnikov, Saint-Petersburg, Russian Federation 
Objectives: Allergic bronchopulmonary aspergillosis (ABPA) is the most common form of 
aspergillosis in patients with cystic fibrosis (CF). ABPA affects from 2% to 15% of patients with CF 
and significantly worsens the course of the underlying disease. Diagnosis of ABPA with CF is 
complicated because many diagnostic criteria intersect with typical manifestations of the underlying 
disease. Recent studies show that the sensitization to A.fumigatus associated with a significant 
reduction in lung function and an increased incidence of pulmonary exacerbations in CF patients. 
Thus, early detection of fungal sensitization very important for the diagnosis of ABPA, and 
appointment of adequate therapy which prevents the progression of lung disease. Now there is a 
search for new diagnostic tests that will identify fungal sensitization in these patients.To study 
possibility of basophil activation test use for identification of fungal sensitization in patients with 
cystic fibrosis. 
Methods: The study included 190 patients with CF aged 1 to 40 years. All patients underwent 
allergological (skin tests with fungal allergens, determination of serum levels of total IgE 
(“Polygnostus”, Russia) and specific IgE (sIgE) for fungal allergens(“AlcorBio”, Russia)) and 
mycological (microscopy and culture of respiratory substrates) examination. Computed tomography 
of the chest was performed according to the indications. Diagnostic criteria of ABPA 2003 [Stevens et 
al] were used. Study of the activation of basophils by flow cytometry was performed using 
Allergenicity kit (“Beckman Coulter”, USA). Basophils were identified by CD3-CRTH2+ marker, 
basophil activation – by elevated expression of CD203c. For basophil stimulation were used allergens 
A.fumigatus (“AlcorBio”, Russia). The basophil activation test with the A. fumigatus allergen was 
conducted in 12 CF patients with ABPA and 25 CF patients without ABPA in addition to the standard 
allergological examination. The obtained data was processed using the STATISTICA 10 software 
system. 
Results: In patients with cystic fibrosis the frequency of sensitization to A. fumigatus was 27%, the 
incidence of allergic bronchopulmonary aspergillosis - 5.7%. The number of eosinophils, total IgE 
and specific IgE levels in CF patients with ABPA were significantly higher than in CF patients without 
ABPA. In blood of were identified 77.1 (46.3-87.8) % basophils activated by A.fumigatus allergen, the 
stimulation index was 19.2 (11.3-30.6). In the comparison group stimulation index did not exceed the 
value of 2.5 (p = 0.000). Direct positive correlation between the level of sIgE to A. fumigatus and the 
number of basophils activated by A. fumigatus allergens (r = 0,67; р<0,05) was established. In CF 
patients with ABPA the FVC and body mass index were significantly lower comparing with patients 
without fungal sensitization. 
Conclusion: The basophil activation test applying, along with traditional methods, will allow a more 
differentiated approach to assessing the development of ABPA in CF patients. Timely identification 
of the associated with A. fumigatus clinical status of CF patients will facilitate early and effective 
assignment of specific therapy. 
 
P140 
Comparison of In-house Real-time Assay and MucorGenius Assay performance for testing of 
Clinical Samples from Immunocompromised Patients 
M. Lengerova1, P. Volfova1, J. Langer1, D. Pantuckova1, J. Pospisilova1, M. Bezdicek1, I. Kocmanova2, 
J. Mayer1, Z. Racil1 
1Department Of Internal Medicine - Hematology And Oncology, University Hospital Brno, Brno, 
Czech Republic, 2Department Of Clinical Microbiology, University Hospital Brno, Brno, Czech 
Republic 
Objectives: Diagnostics of infections caused by mucormycetes is still quite complicated because no 
serological tests (unlike in aspergillosis) are available. Therefore, PCR methods are currently the 
methods of choice. The aim of this study was to compare MucorGenius assay results (Pathonostics) 
on samples that previously tested positively using our in-house PCRs. 
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Methods: In our laboratory, we use nested real-time PCR assay followed by high-resolution melting 
analysis (RT-HRM) for PCR screening of clinical samples from patients at risk of invasive 
mucormycosis. This assay enables not only detection but also identification of detected species. If the 
result is positive, we confirm the result and determine the fungal load with species-specific real-time 
quantitative PCR (RQ-PCR). In this study, we tested 29 selected clinical samples (10 tissues, 15 
bronchoalveolar lavage (BAL)samples, 3 cerebrospinal fluid samples and 1 endosecret), 25 that had 
been tested as positive using our screening assay and 4 mucormycetes negative samples. The results 
were compared to tests with the MucorGenius assay. 
Results: Out of 25 RT-HRM positive samples, 21 were positive using species-specific RQ-PCR. A 
significant fungal load (Ct £ 35) was detected in 10 samples. Using MucorGenius assay, 17 out of 25 
samples (68%) were positive (Ct 18.1 – 37.3). RT-HRM detected Rhizopus sp. (17 samples), Mucor sp. 
(3 samples), Lichtheimia corymbifera (2 samples), Lichtheimia ramosa (2 samples) and Rhizomucor sp. (1 
sample). 12 out of 17 samples with Rhizopus sp. detected revealed low fungal load or were negative. 
To analyze this discrepancy, sequencing was performed and in 10 samples and R. stolonifer was 
identified (which is not targeted by in-house RQ-PCR). The MucorGenius assay was positive in 7/10 
R. stolonifer positive samples (Ct 31.0-37.3). 
Conclusion: Using commercial assays for PCR diagnostics is currently preferred because of 
standardization; therefore we compared our in-house assay results with a commercial kit for 
mucormycetes detection. In this study, we also analyzed samples with discrepant results and 
identified R. stolonifer as a frequent finding when testing BAL samples. As this species is rarely 
described as a cause of infection, its detection most probably represents colonization or 
contamination. Based on these results, we added R. stolonifer specific RQ-PCR to our diagnostic 
algorithm (if RT-HRM detects Rhizopus sp. than R. microsporus, R. oryzae and R. stolonifer RQ-PCRs 
are used to verify the results). Due to our experience, the MucorGenius kit is easy to use, as it is a one 
tube real-time PCR assay and has very good sensitivity. The main disadvantage is the inability to 
identify mucormycetes species. Although this information is not critical to initiating treatment, it is 
essential for epidemiological reasons and might help to distinguish colonization/contamination from 
a truly ongoing infection. This study was supported by the Ministry of Health, Czech Republic - 
conceptual development of research organization (FNBr, 65269705) and TE02000058. 
 
P141 
Pythium insidiosum - sporulation with leaves of grass: Two case reports 
J. Mathew, J. Savio, J. Mathew, M.S. Reddy 
Microbiology, St. John's Medical College, Bangalore, India 
Case Report: Pythium insidiosum is a filamentous, aquatic parasite which was till recently considered 
to be a fungus. It is known to cause sight-threatening keratitis. The filaments of Pythium resemble 
pauci-septate hyphae of Mucorales. Case history: Both patients presented with redness, irritation and 
reduced vision of right eye since one month. There was no history of trauma or any co-morbid 
conditions. Patient 1 (27 years old gentleman): Ocular examination revealed corneal ulcer with 
feathery margins, stromal infiltrates and endothelial plaque. Hypopyon and corneal congestion were 
noted. Fungal keratitis was the clinical diagnosis. KOH microscopy of corneal scraping revealed 
broad pauci-septate fungal hyphae. The patient was started on oral fluconazole and topical 
voriconazole and amphotericin-B along with antibiotics. With deterioration in the clinical course, 
therapeutic penetrating keratoplasty was performed and the patient was discharged on topical 
Natamycin. Progressive loss of vision in the eye was managed with iris repositioning and tightening 
of corneal suturing. The patient developed a white corneal opacity and was later lost to follow-up. 
Patient 2 (26 years old lady): Ocular examination revealed a corneal epithelial defect, satellite lesions, 
corneal scarring with stromal infiltration and no hypopyon. The impression was healing fungal 
ulcer/viral keratitis. Initially, she was started on topical acyclovir. On her follow-up OPD visit she 
still complained of pain in the right eye. KOH microscopy of corneal scraping revealed broad, pauci-
septate fungal hyphae. The patient was started on oral ketoconazole and topical voriconazole. Topical 
linezolid, doxycycline and azithromycin were also added. On follow-up visit, the patient was 
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asymptomatic and ocular examination revealed healed lesions. No surgical management was 
undertaken. Both samples of corneal scraping on fungal culture yielded a non-sporulating mould. 
Colonies were flat, feathery, glabrous and light-brown coloured. Attempts were made to induce 
sporulation using the conventional techniques such as water agar, water culture and using non-
nutrient media such as corn meal agar. With colony morphology resembling Pythium, literature 
search was made for specific sporulation techniques. The induction medium required chemicals such 
as K2H2PO4, MgCl2. Due to the non-availability of these in our laboratory, we set out to use the grass 
on our campus (the common Bermuda grass, Cynodon dactylon) with yeast extract and sterile distilled 
water with the hope to induce sporulation. To our surprise, the isolates produced sporangia and 
motile zoospores, which were visualized under light microscope. The isolates were sent to PGIMER, 
Chandigarh for confirmation by gene sequencing and the identification was confirmed as Pythium 
insidiosum. Video link-zoospore: https://drive.google.com/file/d/1cxHGWR-
EwHgx0ucuTQZGy81nwfVagFEj/view Conclusion: Pythium insidiosum keratitis may present as 
chronic corneal ulcers. The simple Grass leaf culture as a technique for induction of sporulation of 
Pythium insidiosum can be performed in resource-limited settings. Experimentation can be attempted 
using leaves from different species of grass. Increased awareness and high index of suspicion on 
direct microscopy (pauci-septate, ribbon-like hyphae) and colony morphology (flat, feathery 
colonies) is integral to prevent misdiagnosis as fungal infection. Studies prove that prognosis of such 
infections is better when treated by a combination of antibiotics and antifungals than antifungals 
alone, which may occur when misdiagnosed as a fungal infection. 
 
P142 
An Evaluation to assess the performance of the Fungiplex Aspergillus and the Fungiplex 
Aspergillus Azole-R IVD Real-Time PCR Kits following the implementation of an extraction 
control 
J. Green 
Bruker Microbiology, Glasgow, United Kingdom 
Objectives: This Performance Evaluation was designed to test contrived samples spiked into serum, 
plasma and BAL material to assess the impact of a new extraction control on the limit of detection of 
the Fungiplex Aspergillus and Fungiplex Aspergillus Azole-R IVD Real-Time PCR Kits and to ensure 
sensitivity was unaffected by this change. The results from this study have been evaluated to 
determine whether the inclusion of an extraction control has an impact on the limit of detection 
defined in previous studies. 
Methods: Simulated samples were prepared and analysed by the clinical evaluators. Samples 
prepared in serum, plasma and BAL were spiked with specific concentrations of Aspergillus fumigatus 
or Aspergillus terreus genomic DNA prior to extraction. Aspergillus fumigatus wild type strains were 
used as well as resistant strains containing DNA mutations TR34 and TR46 in the Cyp51A gene. 
Samples were prepared in replicates of five and negative controls were included for each sample 
type. Prior to extraction 10 µL of the new extraction control formulation was added to each sample. 
Extraction was performed using two commercial extraction platforms; the eMAG®  by bioMérieux 
and the BioRobot®  EZ1™ by Qiagen. The PCR was prepared in duplicate for each sample and run on 
the Qiagen Rotor-Gene Q 5plex HRM platform. 
Results: When tested with the Fungiplex Aspergillus IVD Real-Time PCR Kit, the limit of 
reproducibility for Aspergillus fumigatus and Aspergillus terreus samples was 5 ge (genome 
equivalents). No difference in sensitivity was observed when the results from two different extraction 
platforms were compared, however, on average the resultant Ct (cycle threshold) values were 1.2 
cycles higher when the EZ1™ platform was used. When tested with the Fungiplex Aspergillus Azole-
R IVD Real-Time PCR Kit, the limit of reproducibility for Aspergillus fumigatus samples containing 
mutations TR34 and TR46 was 50 ge. This higher limit of reproducibility was expected as the Cyp51A 
gene is single copy. The limit of reproducibility was consistent between all sample types, where in a 
previous study, without an extraction control, the limit of reproducibility had been reported between 
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50 and 75 ge depending on which sample type was used. The extraction control was detected in every 
sample analysed with no significant differences observed in Ct value reported. 
Conclusion: 100% sensitivity was reported for the Fungiplex Aspergillus Kit when analysing 
Aspergillus samples at 5 ge and for the Fungiplex Aspergillus Azole-R Kit when analysing resistant 
strains at 50 ge. The sensitivity is not dependent on sample type and the new extraction control 
implemented in these products did not affect the performance of either Kit. Data has shown that 
results from this study are equivalent, and in some cases, superior to previous studies performed. 
 
P143 
Evaluation of the clinical usefulness of dermatophyte EQA panels using molecular tests 
G. Gaajetaan, T. Kampermann, D. Van Tegelen, G. Dingemans 
PathoNostics, Maastricht, Netherlands 
Objectives: Determine the relevance of external quality assessment (EQA) panels for detection of 
dermatophytes by real-time PCR. For this purpose, the commercially available DermaGenius®  2.0 
Complete real-time multiplex PCR was used and simultaneously it’s performance was assessed. 
Methods: Samples from the Dermatophytosis EQA pilot study (years 2016-2018) from QCMD 
(Quality Control for Molecular Diagnostics, Glasgow, UK) and the dermatophytes EQAS program 
(years 2017-2018) from INSTAND e.V. (Düsseldorf, Germany) were all tested with the 
DermaGenius®  2.0 Complete real-time multiplex PCR after suitable DNA-extraction. The samples 
from QCMD were processed with a NucliSENS®  easyMag®  DNA extraction system (bioMérieux) 
and the samples from the EQA from INSTAND e.V. were processed with the PathoNostics Extraction 
kit. 
Results: The Dermatophytosis EQA pilot study panel from QCMD is provided once a year and 
contains 8 samples. All 8 samples in each year were correctly identified with the DermaGenius®  2.0 
Complete real-time PCR. The composition of the EQA panel was comparable every year and contains 
1 negative, three samples with different T. rubrum concentrations (Ct 26-35) and three samples with 
different T. interdigitale concentrations (Ct 27-38). Remarkably, each year the panel contained one 
sample which was positive for C. albicans (Ct 34-36), which is not a dermatophyte (and not in the 
scope of the panel) but can cause a nail infection. The dermatophytes EQAS panel from INSTAND 
e.V. is provided twice a year and contains 4 samples. Most samples were correctly identified with the 
DermaGenius®  2.0 PCR, only Nannizzia gypsea was not detected because this dermatopyte target is 
not included in the PCR assay. Other dermatophytes included in the four panels were T. rubrum (4x), 
T. tonsurans (2x), T. interdigitale (1x), M. canis (1x), T. violaceum (1x), T. benhamiae (1x) and M. audouinii 
(1x). Almost all dermatophytes were detected at very low Ct-values (Ct 19-26) representing a high 
DNA load. A negative control was included in each panel and was also identified as negative by the 
PCR. 
Conclusion: Both dermatophyte EQA panels are intended for performance evaluation of molecular 
detection methods. The DermaGenius®  2.0 Complete real-time multiplex PCR showed good 
performance on both EQA panels, but the panels from these organisations have a different scope. The 
EQA panel from QCMD contains variable DNA concentrations of common dermatophytes and 
thereby focuses on sensitivity and clinical prevalence of dermatophyte species. The EQA panel from 
INSTAND e.V. panel contains a very high load of common but also more rare dermatophytes and 
thereby focussing more on specificity rather than sensitivity and prevalence/clinical significance. 
More importantly, the sample type is very difficult to mimic and therefore quality control samples 
do not really reflect the actual situation. Nevertheless, the EQA panel from INSTAND e.V. supplies 
a solid sample (lyophilized) and can therefore be processed in a more realistic way in comparison 
with the liquid samples from the EQA samples from QCMD. Overall, it is important to select a quality 
assessment program which serves your purpose. 
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Diagnosis of fungal peritonitis: optimization by evaluating two culture procedures 
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S. Martínez1, E. Vallina1, I. Costales1, L. Milian2, E. Llamas1, M. Sandoval1, J. Fernández1, M.S. Zapico1, 
T. Peláez1 
1Servicio De Microbiología Y Parasitología, HUCA, Oviedo, Spain, 2Servicio De Microbiología Y 
Parasitología, CAUSA, Salamanca, Spain 
Objectives: Peritonitis is one of the most serious intra-abdominal infections. Among them, the most 
frequent is secondary peritonitis, usually caused by intestinal perforation and with polymicrobial 
etiology. Fungal involvement in peritonitis is especially relevant, as fungal peritonitis is associated to 
a high mortality rate. Regular culture-based diagnosis of fungal peritonitis is difficult, due to bacterial 
growth may mask the presence of yeasts with slower growth. The use of selective culture media for 
these microorganisms means an improvement of the diagnosis. The aim of this study is to evaluate 
the improvement of the microbiological diagnosis of fungal peritonitis, comparing two culture 
procedures. 
Methods: Between 2016 and 2019, a total of 1671 peritoneal fluids were retrospectively studied. Two 
time periods were established to evaluate two culture procedures: Period 1 (January 2016 to May 
2018) and Period 2 (June 2018 to April 2019). During Period 1, if sample volume was enough, 
peritoneal fluids were inoculated in blood-culture bottles (BD BACTEC Plus Aerobic/F culture vials) 
and incubated in an automatic incubator (BACTEC FX Instruments, Becton-Dickinson). Otherwise, 
they were inoculated in growth media agar plates (blood agar, chocolate agar, McConkey agar and 
Brucella agar). During Period 2, all peritoneal fluids were also inoculated at the same time in a fungus 
selective culture medium (Gentamycin + Chloramphenicol Sabouraud Agar, Biomèrieux). 
Results: A total of 1671 peritoneal fluids were evaluated, 1254 during the first period and 417 during 
the second period. Of them 147 (8.8%) were positive for fungal growth. The positivity rates of fungal 
growth during the first and the second period were, respectively: 6.7% vs 15.1%. The new culture 
protocol (Period 2) increased significantly the number of yeast isolates in peritoneal fluids (p = 
0.0001), rising from 7% in the first period to 19.5% in the second (Table1). Comparing data by yeast 
species, a significant rise in incidence of C. albicans (4.5% vs 10.5%) and C. parapsilosis (0.48% vs 3.4%) 
was observed (Table 2). 
 
Conclusion: Our data show that the incorporation of selective culture medium for fungi improves 
significantly the microbiological diagnosis of fungal peritonitis, increasing the positivity rates and 
the recovery of fungal isolates. C. albicans was the most frequent species isolated, followed by C. 
glabrata and C. parapsilosis. The incidence of C. albicans and C. parapsilosis increased significantly 
during the second period of the study. 
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Direct detection of Candida auris and its ERG11-associated azole resistance and FKS1-associated 
echinocandin resistance in clinical skin swabs 
M. Kordalewska, A. Lee, Y. Zhao, D.S. Perlin 
Center For Discovery And Innovation, Hackensack Meridian Health, Nutley, United States of 
America 
Objectives: Candida auris is a multidrug resistant yeast, recognized as a cause of invasive infections 
and health care associated outbreaks around the world. Major obstacles impacting control of C. auris 
spread include common misidentification by diagnostic platforms available in clinical and public 
health laboratories; a poor understanding of resistance to antifungal drugs and disinfectants; and a 
high propensity to contaminate health care environments which results in transmission of clonal C. 
auris isolates. Ultimately, correct detection and identification of the pathogen and its antifungal 
susceptibility, followed by strict adherence to appropriate treatment and infection prevention and 
control strategies is crucial for limiting the spread of C. auris. Here, we have developed and validated 
platforms for direct detection of C. auris and its ERG11-associated azole resistance and FKS1-
associated echinocandin resistance in clinical skin swabs. 
Methods: DNA isolated from 112 de-identified clinical axilla/groin skin swab samples was tested in 
the recently developed C. auris-specific SYBR Green qPCR assay (Kordalewska et al. JCM 2017) with 
the addition of inhibition control. Enrichment culture (Welsh et al. JCM 2017) followed by sequencing 
of rDNA was used as a reference method. 24 samples, determined as C. auris-positive by both qPCR 
and reference method, were further screened in the ERG11-associated azole resistance and FKS-
associated echinocandin resistance assays (Hou et al. AAC 2018). Antifungal susceptibility testing 
with echinocandins (anidulafungin, micafungin) and azoles (fluconazole, voriconazole) according to 
CLSI guidelines and sequencing of ERG11, and FKS1 were used as reference methods. 
Results: In the C. auris-specific SYBR Green qPCR assay 45% of swabs were C. auris-negative (50/112), 
and 55% were C. auris-positive (62/112). However, only 21% (24/112) of swabs were culture-positive. 
The finding that C. auris cells lost their viability in 34% of swabs, but the DNA was still present (giving 
a positive real-time PCR result), was possibly due to the long swabs storage (4-5 months) before 
processing. Detection of C. auris was not affected by the presence of other microorganisms present in 
the sample. Thus, the assay was found to produce results comparable to the enrichment culture 
approach currently implemented at CDC and Antibiotic Resistance Laboratory Network (ARLN) 
laboratories. The resistance detection assays identified all C. auris-positive swabs as FKS1 wild-type, 
and ERG11 wild-type. The molecular diagnostic results from the assays were 100% concordant with 
DNA sequencing results. Moreover, all isolates exhibited low minimal inhibitory concentration 
(MIC) values (MIC ranges - anidulafungin: 0.06-0.125 mg/l; micafungin: 0.06-0.125 mg/l; fluconazole: 
1-2 mg/l; voriconazole: ≤0.03 mg/l) and were categorized as echinocandin- and azole-susceptible. 
Conclusion: Overall, we found the C. auris-specific SYBR Green qPCR assay can be successfully 
applied for rapid and accurate detection of C. auris in patient skin swabs, thereby increasing high-
throughput diagnostic options for this emerging pathogen. Moreover, the ERG11-associated azole 
resistance and FKS1-associated echinocandin resistance detection platform has the potential to 
overcome the deficiencies of existing in vitro susceptibility-based assays to identify azole and/or 
echinocandin resistant C. auris, and thus, it holds promise as a surrogate diagnostic method to direct 
antifungal therapy more effectively.  
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Role of PCR, mannan antigen and 1,3-beta-d-glucan measurements in cerebrospinal fluid for the 
diagnosis and follow-up of Candida meningitis 
E. Kampouri1, V. Scherz2, P. Marquis3, J.-L. Pagani3, G. Greub1,2, F. Lamoth1,2 
1Infectious Diseases Service, University Hospital of Lausanne, Lausanne, Switzerland, 2Microbiology 
Institute, University Hospital of Lausanne, Lausanne, Switzerland, 3Intensive Care Department, 
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Objectives: Infections of the central nervous system due to Candida spp. are rare and usually 
associated with intracranial devices. Diagnosis is challenging because of low sensitivity of cultures 
and lack of specificity of clinical and biological signs of meningitis. Optimal treatment is not well 
established and response to therapy is difficult to assess. We present two cases of Candida albicans 
meningitis occurring in the setting of craniofacial surgery without intracranial device for which 
different fungal markers (1,3-beta-d-glucan, mannan, PCR) in the cerebrospinal fluid (CSF) were used 
for diagnosis and follow-up. 
Methods: PlateliaTM Candida Ag plus (Bio-Rad), FungitellTM (Associates of Cape Cod) and a home-
made quantitative C. albicans-specific PCR (targeting 26S rDNA) were used for detection of mannan 
antigen (Mn-Ag), 1,3-beta-d-glucan (BDG) and fungal DNA, respectively, in serum and cerebrospinal 
fluid (CSF). 
Results: Candida meningitis presented as a complication of neurosurgery, following transsphenoidal 
surgery and skull base reconstruction with CSF leakage respectively. Biological analyses of CSF were 
consistent with bacterial meningitis, but with negative culture and broad-spectrum 16S rDNA PCR 
for bacteria. C. albicans was detected by CSF culture in one case and PCR in CSF in both cases. 
Antifungal therapy consisted in fluconazole and liposomal amphotericin B. PCR fungal loads 
subsequently declined along with clinical and biological improvement. BDG levels in CSF were very 
high at diagnosis while negative in serum and remained elevated during follow-up in both cases. 
Mn-Ag was measured in one case with elevated value in CSF (>500 pg/ml vs 20 pg/ml in serum) at 
diagnosis and significant decline in follow-up. 
  
Conclusion: These two cases illustrate the potential value of PCR, Mn-Ag and BDG measurements 
in CSF for the diagnosis of Candida meningitis. Further analyses are required to define a threshold of 
positivity for BDG and Mn-Ag in CSF or the diagnostic value of CSF/serum indexes. Moreover, PCR 
and Mn-Ag may be useful for monitoring of response to therapy. 
 
P147 
Usefulness of Galactomannan antigen test in Serum or Bronchoalveolar lavage sample in Kidney 
transplant patients 
A. Xess1, I. Xess2, G. Singh2 
1Microbiology, all india institute of medical sciences, new delhi, India, 2Microbiology, All India 
Institute Of Medical Sciences, new delhi, India 
Objectives: Evaluation of Galactomannan in BAL and Serum samples in Kidney Transplant Patients 
Methods: A total of 127 kidney transplant patients (KTP) suspected of invasive pulmonary 
aspergillosis (IPA) were enrolled for the study. Patients were further investigated radiologically and 
microbiologically. Galactomannan was done in serum and BAL samples Receiver Operating Curve 
(ROC) was generated to determine the optimal cut off value for Galactomannan in BAL and serum 
samples. 
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Results: Out of 127 patients 32(25.2%) were females and 95(74.8%) were males. 76/127(59.8%) patients 
presented with fever not responding to antibiotics and 62/127(48.8%) presented with 
cough/respiratory distress. 54/127 (42.5%) presented with both fever and cough. In CT scan, 
24/127(18.9%) patients showed consolidation,10/127(7.9%) showed ground glass appearance, 
5/127(3.9%) showed nodules and 3/127(2.4%) patients had only opacity. Galactomannan antigen was 
tested in 138 serum and 47 BAL samples of 127 patients. Forty-four serum samples and 34 BAL 
samples were positive for galactomannan antigen. Three patients were positive for fungal elements 
on KOH-calcofluor stain and two were only positive for culture. During the course of hospitalization 
12/127(9.4%) received Amphotericin-B, 4/127(3.1%) voriconazole, 3/127(2.4%) caspofungin, 
2/127(1.6%) posaconazole and 1/127(0.8%) itraconazole. Mortality was around 22% (28/128). Receiver 
operating characteristic (ROC) curve was plotted for BAL and Serum galactomannan levels. The 
value for BAL was found to be 1.0 and for serum it was 0.7. 
Conclusion: Corrected BAL and serum galactomannan values for diagnosis of invasive fungal 
aspergillosis in kidney transplant patients were found to be 1.0 and 0.7 respectably, can be useful for 
diagnosis where the sensitivity of direct demonstration and culture is very low. 
 
P148 
Potential impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of 
invasive aspergillosis: a Fungal PCR initiative (FPCRI) systematic review and meta-analysis. 
M. Cruciani1, P. White2, J. Löffler3, C.O. Morton4, R. Barnes5, J.P. Donnelly6, L. Klingspor7, D. 
Buchheidt8, J. Maertens9, W.J. Heinz10, T. R Rogers11, A. Warris12, C. Mengoli13, D. Lockhart12, C. 
Cordonnier14 
1Infectious Diseases, San Bonifacio Hospital, Verona, VERONA, Italy, 2Microbiology, Public Health 
Wales Microbiology, Cardiff, United Kingdom, 3Medizinische Klinik Und Poliklinik Ii, 
Universitätsklinikum Würzburg, Würzburg, Germany, 4western Sidney University, Sidney, 
Australia, 5Medical Microbiology And Infectious Diseases, Cardiff University School of Medicine, 
Cardiff, United Kingdom, 6EAPCRI, Nijmegen, Netherlands, 7Laboratory Medicine, Karolinska 
Insitutet, Stockholm, Sweden, 8Mannheim University Hospital, Heidelberg University,, Mannheim, 
Germany, 9KU Leuven, Leuven, Belgium, 10University hospital, Wuerzburg, Germany, 11Department 
Of Clinical Microbiology, St. James's Hospital, Dublin, Ireland, 12Mrc Centre For Medical Mycology,, 
University of Aberdeen, Aberdeen, United Kingdom, 13University of Padua, Padua, Italy, 14University 
of Paris, Paris, France 
Objectives: To analyse the impact of anti-mould prophylaxis on the diagnostic accuracy of Aspergillus 
PCR for the diagnosis of Invasive Aspergillosis (IA) in immunocompromised patients. 
Methods: Systematic review and meta-analysis of prospective cohort studies evaluating Aspergillus 
PCR testing of blood from high-risk neutropenic cancer patients, haematopoietic stem cell transplant 
(HSCT) and solid organ transplant recipients . QUADAS-2 was used to assess methodological quality 
of included studies. The sensitivity and specificity of Aspergillus PCR was evaluated by meta-
analytical pooling of logit sensitivity and logit specificity. We also calculated the diagnostic Odd 
Ratio (DOR). A subgroup analysis of studies using anti-mould prophylaxis compared to studies not 
using anti-mould prophylaxis (or using placebo or fluconazole) was performed 
Results: Nine studies used anti-mould prophylaxis (itraconazole, voriconazole, amphotericin B or 
caspofungin) in the entire population or in a subset of patients, while 13 studies did not use any anti-
mould prophylaxis. The incidence of IA was significantly lower in the prophylaxis group compared 
to the non prophylaxis group (11.43 vs 16.13; p = 0.0005). The use of anti-mould prophylaxis increased 
sensitivity (from 0.80 to 0.86; p = n.s) and decreased specificity (from 0.78 to 0.64; p = 0.059) and DOR 
(from 17.10 to 11.14; p = n.s.). In sensitivity analysis, removing 3 studies using prophylaxis with 
itraconazole has no significant impact on sensitivity, Sensitivity and specificity of PCR test in studies 
using or not anti-mould prophylaxis. TP, TN = true positive and true negative results of PCR test, 
compared to total cases of IA according to the reference standard (EORTC/MSG criteria) or no-IA. 
specificity and DOR. 
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Conclusion: The cumulative incidence of IA was significantly lower in patients receiving anti-mould 
prophylaxis. The use of prophylaxis decreases the specificity of Aspergillus PCR testing of blood, 
which is of borderline statistical significance. Although an increase in sensitivity and decrease in DOR 
was observed, this did not reach statistical significance between the 2 groups. Anti-mould 
prophylaxis reduces the proportion of proven/probable cases of IA (according to EORTC/MSG 
criteria) which is associated with a lower specificity of the Aspergillus PCR testing of blood. 
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Comparison of fungal cultures and Aspergillus PCR kits results in SOT patients: an evaluation of 
five new commercial kits on respiratory samples. 
N. Argy1, C. Bonnal1, C. Godet2, J.F. Timsit3, B. Lortat-Jacob4, S. Houzé1 
1Laboratoire De Parasitologie Mycologie, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 
PARIS, France, 2Service De Pneumologie B, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 
PARIS, France, 3Service De Réanimation Médicale Et Infectieuse, Hôpital Bichat-Claude Bernard, 46 
rue Henri Huchard, PARIS, France, 4Service De Réanimation Chirurgicale, Hôpital Bichat-Claude 
Bernard, 46 rue Henri Huchard, PARIS, France 
Objectives: The diagnosis of invasive aspergillosis (IA) is difficult in patients without hematological 
malignancies. For diagnosis, direct microscopy, histopathology and culture are strongly 
recommended and, in solid organ transplant patients (SOT), broncho-alveolar lavage (BAL) 
galactomannan measures are recommended as well. Recent recommendations suggest that BAL-PCR 
should be considered in conjunction with other diagnostic tests in lung transplanted patients 
particularly1. Commercially Aspergillus fumigatus and Aspergillus spp PCR kits are now available but 
their evaluation in clinical practice remains to be performed. The aim of our study was to compare 
the results obtained with some of those Aspergillus PCR kits and cultures performed on respiratory 
samples in non-hematological patients. 
Methods: Five kits (Ademtech MycoGENIE®  Aspergillus fumigatus and MycoGENIE®  Aspergillus 
species, AsperGenius®  Species PathoNostics (A fumigatus, A terreus, Aspergillus spp), Fungiplex®  IVD 
PCR (Aspergillus spp, A terreus) Bruker and Aspergillus ELITe MGB®  ElitechGroup (Aspergillus spp.)) 
were evaluated on respiratory samples which were routinely analyzed for patients (including SOT) 
in our hospital. The PCR results were considered as not acceptable if the matching between fungal 
cultures and PCR results represents less than 70% of the samples tested (in bold in results). 
Results: Forty respiratory samples (BAL, bronchial aspirates) from 36 patients were included. For 30 
samples, 8 A fumigatus, 14 Aspergillus spp (4 A flavus, 4 A niger, 2 A hiratsukae, 1 A terreus, 1 A nidulans, 
1 A calidoustus and 1 Aspergillus spp.) and 8 Penicillium spp. were isolated. Twelve were negative. For 
MycoGENIE®  A fumigatus, MycoGENIE®  Aspergillus species, AsperGenius®  A fumigatus, AsperGenius®  
Aspergillus spp, Fungiplex®  and ELITe MGB®  respectively, the results were: - PCR positive 
results/number of samples tested and A fumigatus positive cultures: 7/8, 7/8, 5/8, 6/8, 5/7, 3/8, - PCR 
positive results/number of samples tested and Aspergillus spp positive cultures: 0/12, 6/12, 1/10, 6/10, 
6/12, 2/12, - PCR negative results/number of samples tested and Penicillium spp. positive cultures: 6/7, 
6/8, 8/8, 3/8, 4/7, 7/7 - PCR negative results/number of samples tested and negative cultures: 7/8, 10/12, 
7/9, 5/9, 8/12, 11/12. MycoGENIE®  Aspergillus fumigatus shows a high concordance for A fumigatus 
positive cultures without false positive results for Aspergillus spp or Penicillium spp. AsperGenius®  A 
fumigatus does not give satisfactory results for positive cultures. Neither of the Aspergillus spp. PCR 
kits have a good correlation with the culture results. 
Conclusion: MycoGENIE®  Aspergillus fumigatus seems to be suitable for the diagnosis of AI due to 
A fumigatus and must be prospectively studied in non-hematological patients. For Aspergillus spp. 
PCR kits, all except ELITe MGB®  gave unsatisfactory results for negative results, mainly because of 
the cross reactivity with other hyalohyphomycetes. This is a real problem for lung transplanted 
patients who are often colonized with filamentous fungi and may have positive PCR results without 
AI. On the other hand, it is difficult to conclude about their correlation with positive cultures because 
it may reflect colonization without infection. The cohort was too small for a clinical evaluation 
therefore prospective evaluation of these PCRs in patients without hematological malignancies are 
needed. Ullmann AJ et al. Clin Microbiol Infect. 2018 
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Objectives: Sputum culture is an insensitive method for the diagnosis of pulmonary aspergillosis. 
Growth of the organism allows identification of the causative species and susceptibility testing, both 
of which can inform treatment choices. The current practice is to culture an aliquot of diluted sputum. 
We assessed the value of culturing large volumes of unprocessed sputum, a method that we have 
termed high-volume culture (HVC). 
Methods: Specimens were processed by conventional culture (using an aliquot of homogenized, 
diluted sputum on Sabouraud agar at 37°C and 45°C for up to 5 days) and HVC (using undiluted 
sputum on Sabouraud agar at 30°C for up to 14 days). A separate specimen was tested by quantitative 
real-time PCR (qPCR). Aspergillus MycAssay (Myconostica) was used from January 2015 until 
February 2016. Aspergillus FUMI (Progenie) was used from February until October 2016. Aspergillus 
Elite MGB (ELITechGroup) was used from October 2016 through February 2017. Antifungal 
susceptibility testing was performed by the EUCAST standard. 
Results: We obtained 290 sputum specimens from 231 patients with the following conditions: 
Chronic pulmonary aspergillosis (67.1%), allergic bronchopulmonary aspergillosis/severe asthma 
with fungal sensitization (25.1%) and Aspergillus bronchitis (7.8%). The sensitivity of conventional 
culture was 16.2% (95% CI: 12.4-20.9%) and that of HVC was 52.4% (95% CI: 46.7-58.1%) (p<0.001). 
qPCR had an overall sensitivity of 49.0% (95% CI: 41.2%-56.9%), comparable to that of HVC (p = 0.46). 
Rates of growth by HVC in correlation with transformed Ct values (TCt) for MycAssay and FUMI 
are shown in Fig. 1. There is a correlation between higher TCt values and the percentage of growth 
by HVC. By combining HVC and qPCR, the sensitivity increased to 66.0% (Fig. 2. Solid bars patients 
not receiving antifungal treatment. Dotted bars represent specimens of patients receiving treatment). 
A. fumigatus was the most commonly isolated species (82.9%) followed by A. niger (9.2%), A. 
montevidensis (3.3%) and A. flavus (2.6%). Among A. fumigatus isolates, pan-azole resistance was 
detected in 17.2%. At the time of sputum collection, 52.1% of patients were receiving antifungal 
treatment. Among patients with CPA, the sensitivity of HVC was higher compared to conventional 
culture for those treated with itraconazole (48.0% vs 12.0%, p<0.001) as well as those not receiving 
antifungal drug treatment (60.5% vs 26.7%, p<0.001). This trend is replicated in patients treated with 
other antifungals for all three conditions. HVC allowed for detection of azole-resistant isolates that 
would have been missed by conventional culture.  
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Conclusion: The recovery rate of Aspergillus spp. is significantly higher for HVC compared to 
conventional culture. HVC can be performed in any microbiology laboratory without the need for 
additional equipment or technical skills. The sensitivity of HVC is comparable to that of qPCR, 
although susceptibility testing is not possible by the latter technique. Combination of the two 
methods can lead to further increase in the recovery of Aspergillus from sputum specimens. Use of 
HVC of expectorated sputum for the detection of fungi can have a significant impact in the diagnosis 
and management of patients with pulmonary mycoses. 
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Objectives: Invasive fungal infections (IFI) remain a major complication in patients with 
haematological malignancies (HM) and post allogeneic haematopoietic stem cell transplantation 
(HSCT). In these patients, invasive aspergillosis (IA) is the most common cause of mortality due to 
infection. Early detection of fungal infections has the potential to facilitate a more effective 
management of invasive disease. Bronchoalveolar lavage samples (BAL) directly obtained from the 
focus of infection are often used as diagnostic tool. In this study, BAL samples were tested using 
different real-time PCR assays and correlated to EORTC/MSG classification for IFI (DePauw 2008). 
Methods: In a multi-centre approach, nine hospitals collected BAL samples from HM/HSCT patients 
comprising a CT scan suspicious for IFI. DNA was isolated from supernatant and BAL pellet and 
analysed for the presence of fungal DNA. Analysis was performed in Wuerzburg only by using 3 
specific real-time PCR assays and one panfungal assay (Khot 2009, 28S 10f-12r). All samples were 
analysed for the presence of Aspergillus and Mucorales, additionally some for Fusarium and fungal 
DNA. 
Results: In total, 294 samples were collected. 69/294 showed Aspergillus DNA, 20/294 Mucorales, 
2/141 Fusarium and 62/69 panfungal DNA (Tab. 1). Sequencing of panfungal amplicons revealed 
mostly DNA of yeasts (mainly Malassezia sp. and Candida sp.) which were classified as non-
invasive/contaminations. Only in 7 cases (7.9%; 6 Aspergilli, 1 Mucorales) the result of the specific 
assay could be confirmed. Therefore no further PCR analysis using the panfungal assay was 
performed. In correlation to EORTC/MSG criteria (6 proven, 85 probable, 130 possible IFD and 26 
undetermined cases; 47 without data) Aspergillus DNA was detected in 42 probable/proven cases, 
Mucorales in 11, Fusarium in 1 and panfungal DNA in 24 (only 7 if excluding contaminations) (Table 
2). DNA of Aspergillus and Mucorales was detected in just one or none control samples 
(undetermined cases), 10/69 samples (14.5%) showing DNA of Aspergillus were also positive for 
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Mucorales (n = 9) or Fusarium (n = 1). Changing the perspective revealed that almost half of the 
Mucorales positive samples were double-infected with Aspergillus (9/20; 45%). 
  
 
Conclusion: qPCR was able to detect DNA of specific fungi in BAL samples. Specific assays for 
Aspergillus, Mucorales and Fusarium proved to be helpful to detect fungal pathogen DNA, whereas 
the panfungal approach mainly detected non-invasive contaminations. The number of double-
infections seems to be higher than expected (14.5% to 45%). 
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Objectives: Invasive pulmonary aspergillosis (IPA) is a leading cause of morbidity and mortality in 
immunocompromised patients. This is due in part to the absence of optimal diagnostic modalities, 
which hamper early specific disease detection. Systemic detection of serum biomarkers is a standard 
noninvasive practice used to early diagnose and treat IPA in high risk population. During the last 
years, doubts have been raised regarding the use of galactomannan (GM) in onco-hematological 
population mainly due to the large number of patients with false positive test as well as the low 
efficacy in patients under antifungal profylaxis. In a previous study, we demonstrated the high 
diagnostic accuracy of bis(methyl)gliotoxin (bmGT) compared to GM for IPA diagnosis in adult 
oncohematological patients. However, the performance of bmGT as a diagnosis biomarker in 
pediatric patients is unknown. The objective of this study is to compare the ability of bmGT and GMN 
detection for IPA diagnosis in oncopediatric patients and to analyse the efficacy of bmGT to serve as 
guide for voriconazol treatment. 
Methods: The presence of bmGT and voriconazole levels in sequential series of serum from 7 
oncopediatric patients at risk of IA (prospective samples) is simultaneously quantified by High 
Performance Thin Layer Chromatography (HPTLC) as well as LC/MS/MS. 
Results: We have established a fast and sensitive technique for simultaneous separation, detection 
and quantification of bmGT and voriconazole in serum and BAL of pediatric patients. bmGT and GM 
were negative in all possible IA cases (5 patients). Two patients, presenting prolonged neutropenia 
after chemotherapy treatment, fever, hypoxemia and pulmonary infiltration compatible with 
Aspergillosis in high resolution CT, were categorised as probable IA. GM and bmGT was monitored 
in serum and bronchoalveolar lavage. In one patient, GM and bmGT were detected in serum and 
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with the voriconazole treatment GM was negativized and the bmGT levels decreased. bmGT was 
positive earlier than GM allowing early initiation of treatment. In the second patient, GM was 
negative and bmGT positive in both serum and BAL, so treatment with voriconazole was started. 
Treatment decreased bmGT values coinciding with the patient clinical improvement. 
Conclusion: BmGT has allowed us the early diagnosis and successful treatment of pediatric IA, being 
a promising tool for early detection of IA in neutropenic pediatric patients. 
 
P153 
Identification for major Aspergillus species in paraffin-embedded tissue: newly developed 
multiplex real-time PCR method using hydrolysis probes 
J.-K. Choi1,2, S.-Y. Cho1,2,3, C. Park2, D.-G. Lee1,2,3 
1Division Of Infectious Diseases, Department Of Internal Medicine, College of Medicine, The Catholic 
University of Korea, Seoul, Korea, Republic of, 2Vaccine Bio Research Institute, Seoul, Korea, Republic 
of, 3Catholic Hematology Hospital, Seoul, Korea, Republic of 
Objectives: Species identification is crucial for determining appropriate antifungal agents in 
treatment of fungal infections. However, current culture-based methods are insensitive due to low 
positive rate and slow process. Microscopic examination of tissue specimens has limitations in 
distinguishing fungal organisms. Detection of fungal DNA by polymerase chain reaction (PCR) 
method in tissue samples is expected to be useful for the diagnosis of fungal infections. Herein, we 
describe the performance and clinical impact of a multiplex fungal PCR assay of formalin-fixed 
paraffin-embedded (FFPE) sample for the diagnosis of Aspergillus infections. 
Methods: FFPE samples previously collected from patients diagnosed as fungal infections by 
histopathologic finding between June 2009 and June 2012 were used for PCR analysis, and 
retrospective chart review was also performed for correlation with clinical diagnosis. Real-time PCR 
primers and multiplex hydrolysis probes were newly designed for four major Aspergillus species (A. 
fumigatus, A. niger, A. terreus, and A. flavus) based on molecular analysis data of β-tubulin gene (benA) 
in Aspergillus isolates. The method of real-time PCR was qualified and quantified using the reference 
genomic DNA (gDNA) of Aspergillus species. DNA was extracted from FFPE sample using TaKaRa 
DEXPAT kit (TaKaRa Biomedicals, Shiga, Japan). The amplified benA amplicon was analyzed by 
comparing with the standard curve of the reference gDNA. Multiplex PCR was performed on 72 
FFPE samples. The sample quality was validated by human globulin detection, and 61 qualified 
samples were analyzed.  
 
Results: Twenty-seven of 35 cases clinically suspected as aspergillosis presented positive results in 
this real-time PCR method (sensitivity: 77.1%). The positive rate was higher than that of the fungal 
culture (12/35, 34.3%) or galactomannan test (20/33, 60.6%). Among the 23 cases with culture-negative 
proven/probable invasive aspergillosis, 17 cases were confirmed as positive by real-time PCR. 
Aspergillus gene was identified in 5 of 9 IFI cases that causative fungal organisms were not confirmed 
in clinical and pathological examination. In cases with non-Aspergillus infection, Aspergillus gene was 
detected in 2 of 13 cases. By real-time PCR for FFPE specimen, additional informations, not only 
detection of benA gene, but also species-level identification, were obtained in 51.7% (32 of 61) cases 
included in this study. 
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Conclusion: This study revealed that this newly developed real-time PCR method for FFPE tissue 
could improve diagnostic accuracy of aspergillosis. Further study is needed to understand mixed 
mold infections or false positive cases with additional assays including PCR for non-aspergillus mold. 
 
P154 
New approaches to the verification of bacterial and candidal bloodstream infection. 
O. Kutsevalova1, A. Antonets2, O. Kit3, N. Panova1, I. Lysenko4, V. Dmitrieva3, E. Pak3, O. Kozyuk3, E. 
Marykov3, G. Klyasova5 
1Laboratory Of Clinical Microbiology, Rostov Research Institute of Oncology, Rostov-on-Don, 
Russian Federation, 2Laboratory Of Molecular Oncology, Rostov Research Institute of Oncology, 
J. Fungi 2019, 5, 95 209 of 464 
 
Rostov-on-Don, Russian Federation, 3Rostov Research Institute of Oncology, Rostov-on-Don, Russian 
Federation, 4Oncohematology Department, Rostov Research Institute of Oncology, Rostov-on-Don, 
Russian Federation, 5National Research Center for Hematology, Moscow, Russian Federation 
Objectives: To evaluate the prognostic significance of procalcitonin and mannan antigen of Candida 
spp (MA) for early and accessible verification of the causative agent of bloodstream infection (BSI). 
Methods: We examined 349 patients with suspected BSI from 16 intensive care, oncology and 
oncohematology units of 9 hospitals in the Southern Federal District of Russia. The diagnostic 
algorithm included sterility blood testing and a study of biochemical markers with 
immunoenzymatic assays. Sterility blood testing was performed using `BacT/ALERT3D analyzer. 
Identification of strains and detection of their antimicrobial drugs sensitivity was made with Vitek-2 
automatic analyzer (BioMerieux, France). Simultaneously we measured the levels of procalcitonin 
and MA with the use of Procalcitonin kit ELISA-BEST (Russia) and Platelia™ Candida Ag Plus kit 
(France) correspondingly. Only high values of procalcitonin (10 and above ng/ml) were considered 
as expedient in the diagnosis of bacterial sepsis. The measurement of MA made it possible to judge 
about the involvement of Candida spp. in the infectious process. The result of MA testing was regarded 
as positive with the concentration ≥125 pg/ml. 
Results: Positive blood cultures were obtained in 84 (24.1%) patients. Bacteria accounted for 77.4% 
(65 strains), Candida spp. - 22.6% (19 isolates). In 3 cases (3.6%) bacterial-candidal associations were 
detected which worsened the condition of the patients. In a parallel study of biochemical markers, an 
increased level of one of them was in 205 (58.7%) patients. High values of procalcitonin accounted 
for 68 (33.2%) that was in favor of a severe bacterial infection. Positive results for MA were in 118 
(57.6%) patients. Positive results of MA testing in the presence of clinical symptoms and risk factors 
for the development of invasive candidiasis suggested a candidal BSI. In 19 (9.2%) patients two 
biochemical markers were elevated indicating a possible mixed infection (picture 1,2). For 144 (41.3%) 
patients with initial negative blood culture testing and normal biomarker levels additional studies 
were needed to exclude or confirm BSI. As a result, in 26 patients a negative results were regarded as 
a cancer relapse. 118 patients needed dynamic blood testing. 70 patients received a positive results. 
14 of them had high procalcitonin and 56 had a positive MA. 18 patients also had a positive blood 
culture (4 patients had bacteria isolated, 14 - candida). 52 patients were observed with only positive 
biomarkers (10 with procalcitonin, 42 with MA). The rest 48 patients were with fever of unknown 
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origin.
 
Conclusion: A comprehensive approach to the diagnosis of BSI has increased the percentage of 
pathogen verification to 58.7%. It should be taken into consideration that both blood culture and 
biomarkers testing of bacterial infection revealed almost the same diagnostic significance. However, 
MA testing improved dramatically the early diagnosis of a candidal BSI despite negative blood 
culture testing which is probably due to the prolonged cultivation of Candida spp. in the blood. The 
inclusion of biochemical markers testing in the diagnostic algorithm for suspected BSI allowed to 
identify the causative infectious agent as early as possible and to start adequate antibacterial or 
antifungal therapy. 
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Objectives: Pneumocystis pneumonia (PCP) is a frequent opportunistic infection in HIV-positive and 
immunocompromised individuals. Healthy individuals have been shown to harbor the organism 
without clinical signs of infection and may play a role in the transmission of PCP. PCR based assays 
for detection of P. jirovecii are reported to be more sensitive compared to conventional 
immunofluorescence assays (IFA). We report experience of a tertiary care hospital laboratory in 
Pakistan which recently shifted from IFA based to PCR based diagnosis for PCP pneumonia. 
Methods: The study was conducted at the clinical laboratory of Aga Khan University Hospital, 
Karachi Pakistan. In the first phase (January-May 2018), a real time PCR assay was validated against 
twenty archived PCP positive or negative bronchoalveolar lavage (BAL) specimens. Once validation 
was completed satisfactorily, PCR based assay was introduced and offered to clinicians in June 2018. 
All BAL specimens submitted for detection for PCP from June 2018-May 2019 after the introduction 
of test were included and evaluated. Clinical data collected as routine part of reporting was assessed. 
Positivity rate for Pneumocystis detection was evaluated for PCR during this period. Additionally PCP 
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data using IFA was retrieved for the year 2016-2017 to compare the positivity rate of IFA with PCR 
over these two time periods. 
Results: Initially twenty samples from patients clinically suspected of PCP were compared using both 
IAF and PCR. PCR confirmed five (25%) positive cases compared to IAF which confirmed 3(12%). 
After introduction of PCR in the laboratory, a total of 145 suspected patient BAL samples were tested 
for P. jirovecii of which 25 (17%) were PCR positive. Majority of the PCR confirmed patients were 
male (72%). Clinical data available on 18/25 (72%) positive patients revealed 4 (16%) patients positive 
for human immunodeficiency virus; 3 (12%) with underlying autoimmune disease; 6 (20%) with 
malignancy, 2 (4%) on corticosteroid therapy and 1 patient on immunosuppressive therapy post renal 
transplant. PCP detection increased from 4.5% during 2016-2017 using IFA based assay to 17% using 
PCR based assay during June 2018-May 2019. 
Conclusion: A high positivity rate of 17% was seen in clinically suspected PCP patients using PCR 
based diagnosis in this study. PCP cases were reported in both HIV positive and negative patients. 
There was an improvement in case detection using PCR compared to IFA. However, high cost of PCR 
compared to IFA limits wider availability of PCR based PCP diagnosis in resource limited settings. 
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Objectives: The current gold standard of identifying eumycetoma causative agents is to culture the 
isolate and assess the morphological characteristics. This method of identification is time consuming 
and can often lead to misidentifications. Precise and early detection of the causative agent is crucial 
for clinical management. Currently precise species identification can only be achieved by sequencing 
the internally transcribed spacer (ITS) regions or by using species-specific PCRs. Only for M. 
mycetomatis a species specific PCR was developed, but recently it was demonstrated that this PCR 
did cross-react with other Madurella species. We therefore looked into the sequenced M. mycetomatis 
genome in search for unique and specific protein coding sequences which could be transformed into 
a species specific diagnostic PCR. 
Methods: We used a comparative genome approach to identify unique sequences for M. mycetomatis 
based on its predicted protein coding sequences. The homology of these sequences were identified 
using blastclust, localization of the proteins was identified using WolfPSORT and SignalP was used 
to predict the secretion signals in these predicted proteins sequences. Based on these sequences, PCR 
primers were developed and validated in a collection of 61 M. mycetomatis, 4 Madurella tropicana, 3 
Madurella pseudomycetomatis, 3 Madurella fahalii, 2 Falciformispora senegalensis, 3 Trematosphaeria 
subthermophilia, 3 Thielavia terrestris, 3 Trematosphaeria grisea, 2 Chaetomium globosum, 1 Aspergillus 
fumigatus and 1 Aspergillus terrus isolates using conventional PCR. 
Results: By using a comparative genomic approach, we were able to identify at least 32 M. 
mycetomatis unique protein sequences. For the top 16 most promising candidate sequences, PCR 
primers were developed. Of these primer pairs, only 12 were able to detect all M. mycetomatis isolates 
tested. Of these 12, only 1 did not react with any other fungal species tested. 
Conclusion: Based on this comparative genomics approach, we identified a novel M. mycetomatis 
specific PCR primer pair to detect M. mycetomatis. 
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Objectives: Intra-abdominal candidiasis (IAC) is a frequent and life-threatening infection in critically 
ill patients following complicated abdominal surgery. Diagnosis of IAC is difficult because of the lack 
of sensitivity of blood cultures and the limited specificity of indirect markers, such as the beta-D-
glucan (BDG) test. The T2Candida Panel (T2C, T2Biosystems) is a magnetic resonance-based 
molecular diagnostic test that identifies the five most common pathogenic Candida spp, (C. albicans 
and C. tropicalis [CA/CT], C. glabrata and C. krusei [CG/CK], and C. parapsilosis) directly in whole blood 
specimens within 7 hours. T2C demonstrated excellent performance for the diagnosis of candidemia, 
but data for non-candidemic invasive candidiasis are lacking. We tested T2C’s efficiency in detecting 
IAC. 
Methods: We used the T2C panel to test frozen whole blood samples from critically-ill patients 
previously enrolled in a prospective cohort study of the Fungal Infection Network of Switzerland 
(FUNGINOS), who were at high risk for IAC due to at least one of the following conditions: i) 
recurrent gastro-intestinal tract perforation, ii) abdominal surgery and Candida colonization, iii) 
necrotizing pancreatitis or iv) burns (>25% body surface area). IAC was defined as growth of Candida 
spp. in a per-operative culture sample from an intra-abdominal abscess or peritoneal fluid. The 
samples were collected within 72h of IAC diagnosis or between days 7-10 from study inclusion for 
patients without IAC. Results of concomitant serum BDG (Fungitell) determined previously were 
included in the analysis. 
Results: Whole blood samples from 46 patients were available for testing. Most patients had Candida 
colonization of ≥1 non-sterile site (98%) and Candida score ≥3 (89%). Eighteen (33%) of them had IAC: 
13 were due to CA, 2 to CT, 1 to mixed CA/CG and 2 to Candida spp. not included in the T2C Panel 
(C. kefyr and C. lusitaniae). Antifungal therapy was ongoing at time of IAC diagnosis and blood 
sampling in 2 (11%) cases. Table 1 shows the comparative diagnostic performance of blood cultures, 
T2C and BDG. Blood cultures were positive in 2/18 (11%) IAC cases. T2C was positive in 6/18 (33%) 
IAC cases (including the 2 candidemic patients) with Candida spp. matching those isolated in cultures. 
Analysis limited to IAC cases due to Candida spp. of the T2C panel yielded a sensitivity of 37.5%. A 
positive T2C result was found in 2 of the 28 patients who did not fulfill IAC criteria (specificity 93%). 
While discordant results for T2C and BDG were observed in 21 (46%) cases, concordant positive 
results were associated with IAC in 100% of cases and concordant negative results with absence of 
IAC in 90% of cases. 
 
Conclusion: T2C has higher sensitivity than blood cultures and higher specificity than BDG for IAC 
diagnosis. T2C and BDG are anticipated to be most useful in guiding management of patients at risk 
for IAC, in particular when they provide concordant results to confirm or exclude IAC in cases for 
which intra-abdominal cultures are not feasible or delayed. 
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Objectives: Fungemia is associated with high rate of morbidity increasing length of hospital stay and 
mortality. Delay of effective antifungal treatment is associated with unfavorable outcome and rapid 
species identification contributes to adapt antifungal therapy. ePlex®  Blood Culture Identification 
fungal pathogen panel (ePlex®  BCID-FP) developed by GenMark®  Diagnostics, Inc. (Carlsbad, CA, 
USA) is a fully automated easy-to-use cartridge designed to detect 15 fungal pathogens from positive 
blood culture (BC) including the emerging pathogen Candida auris. The objective of this study was to 
evaluate prospectively the performance of ePlex®  BCID-FP test using clinical BC samples. 
Methods: The evaluation was performed prospectively on consecutive fungal BC over 2 years-period 
(from April 2017 to Mars 2019) in Henri Mondor University Hospital in France. BCs taken from 
patients were incubated in BacT/ALERT®  3D automated system (Biomérieux® ). Once detected 
positive for fungi, the BC underwent classical subcultures. Then, species identification was 
performed on MALDI-TOF MS Andromas®  system (identification within 24h). In parallel to this 
conventional procedure, ePlex®  BCID-FP was tested (hands-on-time < 5 min and time-to-result: 1.5h). 
Results: A total of 58 BC, corresponding to 52 patients, were tested on ePlex®  using the BCID-FP. 
Invalid results due to technical issues were obtained in 10/58 tests (17.2%). Among the 48 valid tests, 
results were fully concordant with classical identification process in 45/48 BC isolated species (94%) 
including one fungemia caused by two species with C. tropicalis and C. lusitaniae. Identifications were 
available the day of BC positivity in less than two hours. This technique saved at least 24 hours 
compared to conventional methods. The non-concordant results consisted on one C. parapsilosis 
missed by ePlex and two species absent from the BCID-FP panel (1 C. metapsilosis and 1 Saccharomyces 
cerevisiae). Species distribution on valid tests was: 19 C. albicans (41%), 12 C. parapsilosis (26%), 8 C. 
glabrata (18%) and 7 others (C. krusei (n = 3), C. tropicalis (n = 2), C. dublininiensis (n = 1) and C. lusitaniae 
(n = 1) (15%). Thus, fluconazole could be introduced in first intention in 76% of cases, saving the use 
of caspofungin. 
Conclusion: To our knowledge, this is the first large prospective evaluation of the ePlex®  BCID-FP 
on more than 50 fungal BC. ePlex®  BCID-FP accurately identified 78% of the fungal species from 
positive BC. Focusing on targets which are currently present in the panel, 100% of correct 
identification was achieved. A prospective clinical study evaluating the time-to-result benefit on 
antifungal stewardship and on length of hospital stay is needed. 
 
P159 
Integrating miRNA and mRNA expression profiles for improving diagnosis of invasive 
aspergillosis 
T. Zoran1,2, B. Seelbinder1, P. Sieber1, S. Schaeuble1, J. Loeffler2 
1Pidomics, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knoell 
Institute, Jena, Germany, 2Department Of Internal Medicine Ii, WÜ 4i, University Hospital 
Wuerzburg, Wuerzburg, Germany 
Objectives: Invasive aspergillosis (IA) is a life-threatening disease affecting immunocompromised 
patients. Due to unspecific symptoms of this disease and limitation of current methods based on 
fungal biomarkers, diagnosis of IA remains challenging. MicroRNAs (miRNAs) are small non-coding 
RNAs involved in the post-transcriptional regulation of several biological processes including 
various disease pathways and immune response to numerous pathogens. Due to their involvement 
in gene regulation, their stability and ubiquitous presence in biofluids they are considered as good 
biomarkers for different diseases. The aim of our in vitro study was to investigate miRNA profiles in 
immune cells following fungal and bacterial exposure and identify potential miRNAs and their target 
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genes that may be useful as diagnostic and prognostic human biomarkers for improving IA 
diagnosis. 
Methods: We used next generation sequencing (NGS) to investigate miRNA profiles in monocyte-
derived dendritic cells (moDCs) generated from healthy volunteers. Immune cells were stimulated 
for 12 hours with inactivated Aspergillus fumigatus germ tubes and a clinical isolate of Escherichia coli. 
Next, we evaluated transcriptome by RNA-sequencing of moDCs infected with E. coli and A. 
fumigatus and investigated in silico interaction between differentially expressed miRNAs (DEMs) and 
their targets. After correlation analysis and prediction of interactions with mRNA, selected miRNA 
and their immunological relevant target genes were further experimentally investigated. 
Results: Our data showed 32 significantly DEMs in moDCs stimulated with fungal and bacterial 
pathogens in comparison to normal expression in unstimulated moDCs. 28 miRNAs were 
differentially regulated after infection with A. fumigatus and 8 miRNAs after infection with E. coli. We 
identified 24 miRNAs significantly differentially regulated in moDCs after fungal but not bacterial 
infection. Among all significantly DEMs in stimulated moDCs, the following four miRNAs were 
observed to be differentially expressed after infection with A. fumigatus and E. coli: hsa-miR-9-5p, hsa-
miR-155-5p, hsa-miR-155-3p and hsa-miR-1303. Based on two DEMs specific to A. fumigatus exposure 
and one DEM identified in moDCs infected with A. fumigatus as well as E. coli, we further investigated 
potential targets that had been predicted by investigating transcriptome data. Integration of hsa-miR-
9-5p and gene expression showed 45 common differentially expressed (DE) target genes in both types 
of infection. Furthermore, our data showed 26 unique DE target genes in moDCs after exposure to A. 
fumigatus and 13 in moDCs infected with E. coli (n = 13). We validated the expression of three selected 
DEMs and their selected immunological relevant target genes in additional donors with Real-Time 
PCR, where we confirmed our observations from NGS data. 
Conclusion: Our data showed distinctive miRNA profiles between uninfected moDCs as well as 
moDCs after exposure to A. fumigatus and E. coli, suggesting miRNAs profiles can be used to detect 
and distinguish bacterial from fungal infection. Furthermore, characteristic miRNA and mRNA 
expression profiles may be used as a diagnostic and prognostic biomarker of IA. Further experimental 
validation is necessary to confirm predicted miRNA-mRNA interactions and investigate the potential 
use of miRNA and mRNA expression profiles for IA diagnosis. 
 
P160 
The Fungal PCR Initiative’s evaluation of in-house and commercial Pneumocystis jirovecii qPCR 
assays: towards a standard for a diagnostics assay 
M. Gits-Muselli1,2, P. White3, C. Mengoli4, S. Chen5, B. Crowley6, G. Dingemans7, E. Frealle8, R. 
Gorton9, M. Guiver10, F. Hagen11, C. Halliday12, G. Johnson13, K. Lagrou14, M. Lengerova15, W. 
Melchers16, L. Novak-Frazer17, R. Rautemaa-Richardson18,19, E. Scherer20, J. Steinmann21,22, M. 
Cruciani23, R. Barnes24, J.P. Donnelly25, J. Loeffler26, S. Bretagne27, A. Alanio27 
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Lariboisière Saint-Louis Fernand Widal Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 
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4Molecular Medicine, University of Padova, Padova, Italy, 5Medicine, The University of Sydney, 
Camperdown, New South Wales, Australia, 6Department Of Virology, St James's Hospital, Dublin, 
Ireland, Dublin, Ireland, 7PathoNostics, Maastricht, Netherlands, 8Parasitology-mycology, CHU Lille, 
Lille, France, 9Infection Sciences, Health Services Laboratories, London, United Kingdom, 10Public 
Health Laboratory, National Infection Service Public Health England, Manchester University NHS 
Foundation Trust, Manchester, UK, Manchester, United Kingdom, 11Medical Mycology, Westerdijk 
Fungal Biodiversity Institute, Utrecht, Netherlands, 12Clinical Mycology Reference Laboratory, 
Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology 
and Medical Research, New South Wales Health Pathology, Westmead Hospital, and the University 
of Sydney, Australia, Sydney, Australia, 13Scientific Development, OLM diagnostics, Newcastle, 
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And Immunology, Excellence Center For Medical Mycology (ecmm), KU Leuven, Leuven, Belgium, 
J. Fungi 2019, 5, 95 215 of 464 
 
15Department Of Internal Medicine - Hematology And Oncology, University Hospital Brno, Brno, 
Czech Republic, 16Medical Microbiology, RadboudUMC, Nijmegen, Netherlands, 17Mycology 
Reference Centre, Excellence Center For Medical Mycology (ecmm), Wythenshawe Hospital, 
Manchester University NHS Foundation Trust, Manchester, United Kingdom, 18Division Of 
Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, United 
Kingdom, 19Manchester Academic Health Science Centre, Manchester, United Kingdom, 
20Parasitology - Mycology - Umr6249 Cnrs Chrono-environnement, University Hospital Besançon, 
Besançon, France, 21Institute Of Clinical Hygiene, Medical Microbiology And Clinical Infectiology, 
Klinikum Nuernberg, Nuremberg, Germany, 22Institute Of Medical Microbiology, University 
Hospital Essen, Essen, Germany, 23Infectious Diseases, San Bonifacio Hospital, Verona, VERONA, 
Italy, 24Medical Microbiology And Infectious Diseases, Cardiff University School of Medicine, 
Cardiff, United Kingdom, 25EAPCRI, Nijmegen, Netherlands, 26Department Of Internal Medicine Ii, 
WÜ 4i, University Hospital Wuerzburg, Wuerzburg, Germany, 27Paris-diderot, Sorbonne Paris Cité 
University, Institut Pasteur, Molecular Mycology Unit, Cnrs Cmr2000, Parasitology-Mycology 
Laboratory, Lariboisière Saint-Louis Fernand Widal Hospitals, Assistance Publique-Hôpitaux de 
Paris, Paris, France 
Objectives: Quantitative real-time PCR (qPCR) is increasingly used to detect Pneumocystis jirovecii 
for the diagnosis of pneumocystis pneumonia (PCP). PCP is more severe and mortality rates are 
significantly higher in non-HIV patients than in HIV-infected/AIDS people, despite a lower fungal 
load during infection. Currently, definite thresholds for Pneumocystis pneumonia (PCP) in non-HIV 
patients have not been established to be consensual and universally used in different diagnostic 
laboratories. Therefore, diagnosis of PCP remains a challenge because of the importance of 
quantification of the low fungal loads. An evaluation of the performance of different qPCR assays is 
needed to assist laboratory standardization of quantification. 
Methods: Through the Fungal PCR Initiative, a working group of the International Society for 
Human and Animal Mycology, one inter- and one intra-laboratory comparison of qPCR assays was 
performed. For the interlaboratory study, sixteen reference laboratories in eight countries running 19 
assays analysed a panel consisting of two negative and three positive specimens from a pool of three 
different P. jirovecii positive bronchoalveolar lavage (BAL) fluids at three different dilutions (pure 1:1, 
1:100 and 1:1000). Participants were asked to test the panel specimens as part of their routine 
molecular biology workflow. The results were collected using a dedicated Google form that included 
requests for the qualitative result (positive/negative), the quantification cycle (Cq) values for each 
replicate related to each specimen and specific information regarding the methods and workflows 
applied. The intra-laboratory study compared 10 different assays with the same person and qPCR 
thermocycler, by testing 10 previously confirmed P. jirovecii qPCR-negative and 9 previously 
confirmed P. jirovecii qPCR-positive BALs. Those 10 assays consisted of 5 in-house assays and 5 
commercial kits and included 3 RT-qPCR (1 commercial and 2 in-house) and 7 qPCR assays (4 
commercial and 3 in-house) 
Results: from 20 qPCR assays (16 qPCR amplifying DNA only and 4 RT-qPCR assays amplifying 
Whole nucleic acids (WNA, i.e DNA+RNA) were obtained from 16 laboratories across eight countries 
(including seven European countries and one Australian). The different targets evaluated were 
mtSSU (n = 2), mtLSU (n = 16), MSG (n = 1) and beta-tubulin (Tub, n = 1). The inter-laboratory 
analytical sensitivity was 100% at 1:1 genomic load, 95% at 1:100, and 82.5% at 1:1000. Analytical 
specificity was 100% for all assays but yielded a false-positive test (95% specificity). For both 
evaluations and for all genomic loads, testing whole nucleic acid (RNA plus DNA) using reverse-
transcriptase RT-qPCR was superior to qPCR (p≤0.001) testing DNA only. (Figure 1 and Figure 2). 
The target gene mitochondrial small sub-unit (mtSSU) was significantly more sensitive than the 
mitochondrial large subunit, the major surface glycoprotein, or the beta-tubulin (Figure 1 and Figure 
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Conclusion: Thus, RT-qPCR targeting the mtSSU gene had the best sensitivity and could serve as a 
basis for standardizing the P. jirovecii load, which is essential if qPCR is to be incorporated into clinical 
care pathways. 
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Identification of Cyp51A-mediated triazole resistance in Aspergillus fumigatus using 
pyrosequencing: an audit of UK National Aspergillosis Centre cases 
L. Brown1, R. Rautemaa-Richardson1,2,3, L. Novak-Frazer1,3, S. Hill1,3, D. Hassan3, M.D. Richardson1,3 
1Division Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, 
United Kingdom, 2National Aspergillosis Centre, Manchester University NHS Foundation Trust, 
Manchester, United Kingdom, 3Mycology Reference Centre, Excellence Center For Medical Mycology 
(ecmm), Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom 
Objectives: Globally, triazole resistance rates are rising. Azole-naïve patients acquiring an azole-
resistant isolate from the environment, or because of long courses of azole treatment is a growing 
concern. TR34/L98H within the cyp51A gene of A. fumigatus leads to pan-triazole resistance and is the 
most common mutation found in environmental isolates. Other mutations in this gene have also been 
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associated with various patterns of azole resistance. Failure of microbiological testing to detect 
resistance delays the initiation of appropriate antifungal therapy and negatively impacts the clinical 
outcomes of patients with aspergillosis. Therefore, empiric combination therapies are increasingly 
used which has significant stewardship implications. We compared the performance of high-volume 
culture (HVC) and Aspergillus fumigatus PCR combined with pyrosequencing (AfPCR-Pyro) for the 
detection of triazole resistance in aspergillosis patients. 
Methods: We performed a retrospective audit over a 27-month period (between January 2017 and 
March 2019) at the Mycology Reference Centre Manchester (MRCM) and the UK National 
Aspergillosis Centre (NAC), UK. Respiratory samples collected from patients with chronic 
pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA) and analysed by 
both HVC and AfPCR-Pyro were included in the study. Hospital and laboratory databases were 
searched for patient history, laboratory findings and if the pyrosequencing result triggered a change 
in antifungal treatment. 
Results: Three hundred and forty-nine samples from 162 patients were analysed for susceptibility 
using AfPCR-Pyro. Of these 28% (96/349) were positive for A. fumigatus by HVC while 68% (236/349) 
were reported with no growth after 14 days. The remaining 3% (9/349) of samples were positive for 
other Aspergillus spp, but excluded from further analysis as pyrosequencing is limited to A. fumigatus. 
Resistance was found by pyrosequencing in 29% (99/340) of samples compared to 15% (52/340) by 
HVC. Resistance was found by both culture and pyrosequencing in 9% (30/340) of cases, with 
agreement in susceptibility profiles between the two methods in 66% (63/96) of cases. Resistance was 
identified by pyrosequencing in 23% (54/236) of culture negative samples. If pyrosequencing had not 
been used in these patients, 46 resistant cases would have been missed. Pyrosequencing identified 
the environmental TR34/L98H mutation in 20% (69/340) of samples. Importantly, resistance was 
recognised by pyrosequencing before HVC results in 17% (57/340) of cases. A change in antifungal 
therapy was initiated in 19% of cases (58/299) due to pyrosequencing results. 
Conclusion: Compared to HVC, AfPCR-Pyro has a higher sensitivity for detecting triazole resistance. 
The technology allows for prompt recognition of resistant organisms and the selection of appropriate 
antifungal treatment. Increased availability of pyrosequencing would likely lead to improved patient 
outcomes and better antifungal stewardship. 
 
P162 
Evaluation of two mass spectrometry platforms, the Bruker MALDI Biotyper and the MSI online 
application, for the identification of clinically important moulds 
 
L. Kristensen1, J.B. Gertsen1, T.M. Petersen1, K. Handberg1, A.C. Normand2, M. Hendrickx3, N. 
Nørskov-Lauritsen1 
1Department Of Clinical Microbiology, Aarhus University Hospital, Aarhus N, Denmark, 2Ap-hp, 
Groupe Hospitalier Pitié-salpêtrière, Service de Parasitologie Mycologie, Paris, France, 3Service Of 
Mycology And Aerobiology, Bccm/ihem Fungal Collection, Sciensano, Brussels, Belgium 
Objectives: The matrix-assisted laser desorption ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) method has emerged as a rapid identification method of filamentous fungi. The 
aim of this study was to evaluate the performance of the Bruker MALDI Biotyper and the recently 
introduced MSI (mass spectrometry identification) platform to identify a collection of moulds, 
followed by an evaluation in the clinical setting. 
Methods: Thirty-four well-characterised mould isolates (18 species from 10 genera) were selected 
from our collection of fungal strains. For the subsequent evaluation, 75 clinical isolates were 
prospectively collected. Aspergillus fumigatus and Aspergillus flavus with typical morphology were 
excluded. The isolates were cultured 2-3 days on Sabouraud glucose agar (Oxoid). Prior to MS 
analysis, a simple ethanol-formic acid-acetonitrile inactivation/extraction procedure was used. 
Acquisition of mass spectra was performed with the Bruker MALDI Biotyper, software v. 3.1. Data 
analysis was performed using the general Bruker library (MBT 7311 MSP) combined with the Bruker 
Fungi Library 1.0, and with the MSI online library after uploading of spectra. In the initial assessment, 
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identification thresholds of 2.0 and 1.7 for species and genus, respectively, were used. The data were 
compared to a species identification threshold of 1.7. Based on these results the 1.7 threshold for 
species identification was applied in the subsequent evaluation. 
For MSI online identification, a species identification threshold of 20 was used. Identification by 
sequencing of internal transcribed spacer (ITS2) was used as gold standard. 
Results: Initial evaluation 
ITS sequence identified 25 isolates to the species level and nine isolates to the species complex level 
(insufficient separation of closely related species). 
Bruker (species threshold 2.0): 22 of 34 isolates (65%) were correctly identified to the species or species 
complex level, six isolates (18%) were correctly identified to the genus level, six isolates (18%) were 
not identified. 
Bruker (species threshold 1.7): 28 of 34 isolates (82%) were correctly identified to the species or species 
complex level while six isolates (18%) were not identified. 
MSI: 31 of 34 isolates (91%) were correctly identified to the species or species complex level. One 
Fusarium oxysporum was misidentified as Fusarium acutatum, two isolates (6%) were not identified. 
Clinical evaluation 
The clinical isolates comprised 19 species from 11 genera. 
ITS sequence identified 55 isolates to the species level and 20 isolates to the species complex level. 
Bruker: 60 of 75 isolates (80%) were correctly identified to the species or species complex level. Fifteen 
isolates (20%) were not identified. 
MSI: 70/75 isolates (93%) were correctly identified to the species or species complex level. Five isolates 
(7%) were not identified. 
Conclusion: Both the Bruker library (species identification threshold 1.7) and the MSI platform were 
accurate and reliable in the initial evaluation. The results were confirmed in the clinical setting, 
however, compared to Bruker the MSI library obtained the highest degree of identification to the 
species or species complex level (93%) with a considerably lower number of unidentified isolates. 
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Rapid identification of a rare fungi: A skillful mycologist against the state of the art methods 
C. Gronfors Seeth, K. Gieng Axelov, M. Ullberg, V. Ö zenci 
Clinical Microbiology, Karolinska University Hospital, karolinska Institutet, Stockholm, Sweden 
Case Report: Modern diagnostics methods in clinical mycology have become widely available. 
However, it is important to acknowledge that these methods cannot replace the conventional 
methods requiring theoretical knowledge and hands on experience. The patient was 52 y old, female 
with a history of cystic fibrosis. Previous sputum samples showed growth of Staphylococcus aureus 
and Pseudomonas aeruginosa. On 16 April 2019 the patient contacted cystic fibrosis clinic and 
presented decreased lung capacity. The Forced expiratory volume in one second (FEV1) was 53% 
expected value. Sputum sample was taken for both bacterial and fungal culture. Bacterial cultures 
showed growth of Pseudomonas aeruginosa on 17 April 2019. Growth of mold was observed after 6 
days on Sabouraud agar at 30 C. Microscopy from agar plates showed hyphi without septa. In 
combination with the presence of abundant and relatively rapid growth the preliminary laboratory 
diagnosis was reported as Zygomycetes spp. on 23 April 2019. One day later new microscopy from 
the plates showed the presence of spherical-, multi-spored- sporangia without columellae. The 
laboratory technician who had never seen a similar morphology reported the isolate preliminary as 
Mortierella spp. The report was solely based on her theoretical knowledge in combination with clinical 
experience. The isolate could not be diagnosed by repetitive MALDI-TOF MS tests and was sent to 
internal transcribed spacer (ITS) sequencing. The results from the ITS sequencing showed that the 
isolate was Umbelopsis isabellina (99%) on 2 May 2019. The literature search showed that Umbelopsis 
isabellina is used as synonym for Mortierella spp. Mortierella spp. is a mold belonging to the order 
Mortierellales according to the most recent taxonomy and is considered a pathogen solely of animals. 
To our knowledge, there has been only one other case report describing an invasive disease in an 
immunocompromised patient with Mortierella wolfii, isolated from the liver biopsy and blood 
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culture (Layios et al., 2014). In that case the isolate was identified by ITS sequencing. Therefore the 
present case is the first describing the preliminary identification of Mortierella spp. with a 
conventional method. It is important to note that the conventional method could identify Mortierella 
spp. seven days earlier than ITS sequencing. It is still not clear if the present case with Mortierella spp. 
is colonization or an infection. The patient is currently being followed up clinically and further lower 
respiratory samples will be taken up. In the laboratory it feels comfortable to have access to both 
conventional and modem diagnostic methods. The present study describes the importance of hands 
on experience in diagnosis of rare fungal patogens. 
 
P164 
An inter-laboratory multi-centre evaluation of the performance of Mucorales PCR assays when 
testing serum specimens: A study by the ISHAM Fungal PCR Initiative and the ModiMucor study 
group - FPCRI Mucor Laboratory Working group (A. Alanio, M. Cogliati, S. Fuchs, F. Hagen, C. 
Halliday, R. Hare, C. Klaassen, M. Lackner M. Lengerova, W. Posch, B. Sendid, J. Springer, B. 
Willinger) - ModiMucor study group (F. Botterel, M. E. Bougnoux, S. Bretagne, C. Damiani, F. 
Dalle, J. Denis, M. Gitts-Muselli, X. Iriart, F. Morio, P. Poirier, E. Scherer) 
S. Rocchi1, C. Mengoli2, P. White3, R. Barnes4, J.P. Donnelly5, J. Loeffler6, L. Millon1 
1Parasitology - Mycology - Umr6249 Cnrs Chrono-environnement, University Hospital Besançon, 
Besançon, France, 2Molecular Medicine, University of Padova, Padova, Italy, 3Microbiology, Public 
Health Wales Microbiology, Cardiff, United Kingdom, 4Medical Microbiology And Infectious 
Diseases, Cardiff University School of Medicine, Cardiff, United Kingdom, 5Division Of Infectious 
Diseases, San Antonio Center for Medical Mycology, San Antonio, United States of America, 
6Department Of Internal Medicine Ii, WÜ 4i, University Hospital Wuerzburg, Wuerzburg, Germany 
Objectives: Real-time qPCR detection of Mucorales DNA in serum, plasma and BAL fluid has been 
shown to be sensitive and early tool for diagnosing mucormycosis. Several qPCR assays have been 
developed, but little comparison and no standardization is available. In 2016, the Mucorales 
Laboratory Working Group of the ISHAM Fungal PCR Initiative (FPCRI) organised inter-laboratory 
evaluations of Mucorales PCR assays currently in use, with the objectives of: 1) determining the 
uniformity of qualitative detection (positive/negative) and 2) assessing qPCR performance. 
Participants were members of the FPCRI, laboratories involved in the ModiMucor* study and three 
other French laboratories which have already implemented this tool to diagnose mucormycosis. 
Methods: For the 1st panel (A), four sera (2ml/sample) were inoculated with genomic DNA (between 
27 to 116 pg of DNA/mL of serum) from four different mucorales species (Rhizomucor pusillus, 
Lichtheimia corymbifera, Cunninghamella bertholetiae, Rhizopus oryzae). For the 2nd panel (B), six sera (2 
ml/sample) were inoculated with three concentrations of R. pusillus and L. corymbifera equivalent to 
one, 10 and 100 genomes/mL of serum. For each panel, a negative control serum was also sent. 
Twenty laboratories analysed the panel A (10 FPCRI, two Modimucor/FPCRI, seven Modimucor, 
three others French laboratories) and 22 laboratories analysed the panel B (two more FPCRI 
laboratories). All participants were requested to use their own DNA extraction methodology. The 12 
French participants used the same qPCR technique (combination of three qPCR assays targeting the 
four most frequent genera: Lichtheimia, Mucor, Rhizopus, Rhizomucor) (1). For panel B, only 
quantitative PCR results were analysed (two techniques that used conventional PCR were excluded). 
Twenty-two laboratories returned multiple datasets, leading to 26 different datasets for analysis: - 16 
datasets using a single technique (1) - 10 datasets using other techniques (Four Pathonostics 
MucorGenius® , Six "in-house" assays, (2-5), three of which were not previously described). 
Results: For panel A, all datasets were negative when testing the negative control serum. Conversely, 
85-90% of the sera inoculated with “common” Mucorales (R. pusillus, R. oryzae, L. corymbifera) were 
positive. Detection of sera containing C. bertholetiae DNA was lower (12%). For panel B, the 
probability of qPCR positivity increased predictably with DNA quantity, generating a mean PCR 
efficiency of 0.85. Detection of Lichtheimia DNA was optimal, irrespective of the technique. Regarding 
the qPCR systems, Millon et al. and MucorGenius®  techniques generated greater positivity rates, 
with earlier Cq values. 
J. Fungi 2019, 5, 95 220 of 464 
 
Conclusion: Despite the diversity of techniques, Mucorales DNA detection in sera was very 
reproducible with little inter-laboratory variability providing support for including Mucorales PCR 
in the EORTC/MSG definitions of invasive fungal disease and for its use in the clinical diagnosis of 
mucormycosis ModiMucor* : French prospective multicenter study for evaluation of Mucorales PCR (PHRC 
(Projet Hospitalier de Recherche Clinique) national-Modimucor 2014-A00580-47.) References 1- Millon et 
al. CID 2013 2- Springer et al. J. Med. Microbiol. 2016 3- Lengerova et al. J Clin Microbiol 2014 4- 
Machouart et al. J Clin Microbiol 2006 5- Hrncirova K., J Clin Microbiol 2010 
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Comparison of a point-of-care (PreventID®) with the DermaGenius® Nail real-time PCR kit for 
the detection of dermatophytes species in nail samples 
G. Gaajetaan, T. Kampermann, D. Van Tegelen, G. Dingemans 
PathoNostics, Maastricht, Netherlands 
Objectives: Compare the performance of a point-of-care test for the detection of dermatophyte fungi 
(PreventID® ) with the DermaGenius®  2.0 Nail real-time multiplex PCR assay on a set of clinical nails. 
Both methods are compared to microscopy as the gold standard method. 
Methods: Left over nail samples were split into different parts. The culture and microscopy of all nail 
samples was performed by an external clinical microbiology laboratory. One part of the nail sample 
was used for DNA-extraction with the PathoNostics Extraction kit and identification of the pathogen 
was enabled by using the DermaGenius®  2.0 Nail real-time multiplex PCR. Finally, an 
immunochromatographic poin-of-care test (PreventID®  Dermatophyte) was applied to determine 
the presence of dermatophyte-derived antigens in the nails. 
Results: Microscopy of the nails was considered as the gold standard. The DermaGenius®  2.0 Nail 
real-time multiplex PCR was able to detect all positive samples, resulting in a sensitivity of 100%. 
Specificity was however lower (83%) due to detection of dermatophyte DNA in microscopy-negative 
samples. Interestingly, these samples were culture-positive. Culture resulted both in a reduced 
specificity (67%) and sensitivity (57%). Both the sensitivity (79%) and specificity (83%) for the 
PreventID®  Dermatophyte test were promising. Although the PCR assay is sensitive, the clinical 
relevance is still a matter of debate. High Ct-values indicate limited amounts of DNA and do not 
always represent a clear infection. Interestingly, the Ct-values for samples which were negative with 
the PreventID®  test were between 26-33 with the DermaGenius®  real-time PCR. In addition, 
readability of the test strips was limited in some samples while Ct-values of 22-28 with the 
DermaGenius®  PCR was obtained, indicating a high fungal load. These samples were also positive 
with microscopy. 
Conclusion: Microscopy and the DermaGenius®  2.0 Nail real-time PCR showed a good correlation 
and are useful for rapid identification of dermatophyte infection. For specific pathogen identification, 
the DermaGenius®  PCR can be used. Culture can result in false negatives and in combination with a 
long turnaround time, it has limited value in routine diagnostics. The use of an 
immunochromatographic point-of-care test is uncommon in dermatophyte diagnostics but was 
included in this study to determine its suitability. Although the PreventID®  Dermatophyte test 
results in a sensitivity of 79%, some dermatophyte infections with low Ct-values were missed. The 
difference in sensitivity could be explained by the fact that the PreventID®  test is using a protein 
target while the DermaGenius®  PCR detects DNA, which is normally not influenced by treatment. 
But more important is that the interpretation of the PreventID®  test is based on visual inspection 
which makes the test less reliable. The PreventID®  should be compared in a larger sample set to 
determine suitability for routine dermatophyte diagnostics. Currently, microscopy and the 
DermaGenius®  2.0 Nail real-time PCR seem to be the most reliable and suitable methods for 
diagnosis of dermatophyte infections in nails. 
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Polymerase chain reaction on respiratory tract specimens of immunocompromised patients to 
diagnose Pneumocystosis - A systematic review 
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L. Brown1, R. Rautemaa-Richardson1,2, E. Rowbotham1, S. Chen3, B. Jones4,5 
1Division Of Infection, Immunity And Respiratory Medicine, University of Manchester, Manchester, 
United Kingdom, 2Mycology Reference Centre, Excellence Center For Medical Mycology (ecmm), 
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom, 3Medicine, The University of Sydney, Camperdown, New South Wales, Australia, 4NHS 
Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom, 5Institute Of Infection 
Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom 
Objectives: Pneumocystis jirovecii pneumonia (PCP) is a severe, life-threatening infection affecting 
immunocompromised patients. The highest rates are seen in those with HIV infection, but other 
groups are increasingly affected such as solid organ recipients and those receiving long-term 
corticosteroid therapy. Polymerase Chain Reaction (PCR) is highly sensitive for the detection of P. 
jirovecii when compared to microscopy, but may not differentiate between infection and colonisation. 
The Fungal PCR Initiative group (FPCRI) working group of the international Society for Human and 
Animal Mycology (ISHAM) aims to develop international standards for P. jirovecii PCR. A systematic 
review to determine the diagnostic accuracy of PCR testing in respiratory tract specimens for PCP 
was undertaken. 
Methods: Following protocol registration with PROSPERO, a systematic review of the literature was 
performed using PubMed, Scopus, Embase and Cochrane without applying any language or date 
limits. Studies where PCR techniques were used on respiratory specimens for the diagnosis of PCP 
in humans were included if they (i) compared the PCR test results with the diagnosis made using 
standard laboratory methods and clinical presentation; (ii) sufficient information was provided to 
assess the strength of diagnosis; (iii) results were reported as false- positive, true-positive, false-
negative and true-negative; and (iv) evaluation of the test(s) was performed in prospective cohorts of 
patient populations, defined as groups of individuals at high risk for PCP. Where relevant, the 
diagnostic performance of PCR techniques to the beta-d-glucan (BDG) assay, was compared. 
Breakpoint analyses for differentiating colonisation from infection will also be investigated. 
Results: A total of 2843 unique records were identified. Abstracts of these records were sent out to 
six pairs of reviewers to be assessed against the inclusion and exclusion criteria. The reviewers were 
in agreement on 2371 abstracts; 472 abstracts with reviewer discrepancies were sent out for a third 
review. After screening, 2509 records were excluded and 334 full-text articles are now being assessed 
for eligibility by pairs of reviewers. Papers meeting the inclusion criteria after reading in full will be 
included in the meta-analysis to be carried out by the group. Risk of bias will be assessed using the 
QUADAS-2 tool. 
Conclusion: This systematic review will provide essential information about the diagnostic accuracy 
of PCR tests in respiratory tract specimens for PCP required for the development of a standardised 
method for Pneumocystis PCR which will be later validated in clinical trials. 
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Evaluation of the LDBio Aspergillus ICT lateral flow assay as a point-of-care test for serological 
antibody detection in allergic bronchopulmonary aspergillosis 
E. Hunter1, M.D. Richardson1,2, D. Denning1,3 
1Division Of Infection, Immunity, And Respiratory Medicine, University of Manchester, Manchester, 
United Kingdom, 2Mycology Reference Centre, Excellence Center For Medical Mycology (ecmm), 
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom, 3National Aspergillosis Centre, Manchester University NHS Foundation Trust, 
Manchester, United Kingdom 
Objectives: Allergic bronchopulmonary aspergillosis (ABPA) is an immunological pulmonary 
disorder complicating asthma, as a result of hypersensitization to Aspergillus species (predominantly 
A. fumigatus). It is estimated to affect 2.5% of adults with asthma, which accounts for approximately 
4.8 million patients worldwide. Early recognition and diagnosis of ABPA is critical to improve patient 
symptoms and prevent or delay progression of bronchiectasis and development of chronic 
pulmonary aspergillosis (CPA). It is especially important to make the distinction between asthma 
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and Aspergillus sensitization. LDBio Diagnostics has recently commercialized a lateral flow assay 
(Aspergillus ICT) that detects Aspergillus antibodies less than 30 minutes, requiring minimal 
laboratory equipment. Herein, we evaluate this assay for specific diagnosis of ABPA as compared to 
asthma controls. 
Methods: A retrospective, ongoing study was performed using 94 patient sera collected at the 
National Aspergillosis Centre (NAC, Manchester). Patient sera were selected based on a clinical 
diagnosis of ABPA and classified as ‘proven’ (n = 70) or ‘probable’ (n = 24). Control sera (n = 93) were 
obtained from the Manchester Allergy, Respiratory and Thoracic Surgery (ManARTS) biobank. 
LDBio Aspergillus ICT was performed as per manufacturer’s instruction. Results were read at 
intervals, and determined after 20 to 30 minutes as recommended (any line at the “T” marker 
considered positive), both manually and using the Qiagen ESEQuant LR3 lateral flow reader. 
Serological Aspergillus-specific IgG and IgE, and total IgE titres were measured by ImmunoCAP. 
Results: We found the LDBIO Aspergillus ICT to have a sensitivity of 88.6% across for 70 proven 
ABPA cases, and 89.4% for all cases (‘proven’ and ‘probable’) combined. Specificity was 91.4% for 93 
control sera (Table 1). A comparison of ICT result with Aspergillus-specific IgG and IgE titres showed 
no evident immunoglobulin isotype bias (Figure 1). Using digital measurements obtained using the 
Qiagen LR3, we found no correlation between ImmunoCAP Aspergillus-specific IgE level and 
Aspergillus ICT test line intensity. Finally, assessment of 3 assay lots using 30 samples showed perfect 
agreement between lots when tests were read visually. 
 
 
Conclusion: The LDBio Aspergillus ICT lateral flow assay exhibits good sensitivity for serological 
screening for ABPA. The assay is easy to perform and interpret, using minimal equipment and 
resources. As such, it provides a valuable point-of-care screening resource to rapidly distinguish 
between asthma and Aspergillus sensitization. 
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Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect 
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United Kingdom, 2National Aspergillosis Centre, Manchester University NHS Foundation Trust, 
Manchester, United Kingdom, 3Mycology Reference Centre, Excellence Center For Medical Mycology 
(ecmm), Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom 
Objectives: Prevalence of chronic pulmonary aspergillosis (CPA) is estimated at approximately 3 
million cases worldwide, and serological detection of Aspergillus-specific antibody is a critical 
component in the CPA diagnostic pathway. Some patients with CPA, however, have subtle immune 
deficits, including low CD4 or CD19 (B cell) counts, mannose binding lectin deficiency and/or low 
gamma IFN or IL12 production. It is possible these deficits contribute to poor Aspergillus antibody 
production to one or more ordinarily immunodominant antigens, and may lead to false negative 
results by diagnostic assays used to detect Aspergillus-specific antibodies. Herein, we examine the 
potential effect of patient immunodeficiencies on the accuracy and performance of CPA serological 
diagnostics. 
Methods: We analyzed patient data, as available, from 167 cases of clinically confirmed CPA that 
were previously evaluated by ImmunoCAP Aspergillus-specific IgG EIA and LDBio Aspergillus ICT 
lateral flow assay, to determine the presence of deficiencies in the following: mannose binding lectin 
(MBL), IgG, IgA, IgM, IL12 production, IL17 production, and/or cell markers (CD4, CD19, CD56). We 
compared patient data with test results (ImmunoCAP, ICT) as well as for ImmunoCAP ‘seronegative’ 
patients -- defined as cases for which ImmunoCAP Aspergillus IgG was consistently and repeatedly 
positive for up to 3 years of patient history. Seronegative cases accounted for 12.6% of all cases 
evaluated (n = 21). ‘Seropositive’ was defined as all other CPA cases (n = 146). 
Results: We found the rate of false negatives by ImmunoCAP Aspergillus IgG EIA to be more 
prevalent in patients with low levels of IgG, IgA, or IgM. The performance LDBio Aspergillus ICT 
appears to relatively unaffected by these (Figure 1). Similar findings were observed for IFN gamma 
production. Additionally, though not significant, we observed a trend in lower levels of CD4, CD19, 
or CD56 cell markers amongst seronegative CPA patients as compared to seropositive CPA patients, 
according to ImmunoCAP results (Figure 2). 
 
 
J. Fungi 2019, 5, 95 224 of 464 
 
 
Conclusion: In select cases of CPA, ImmunoCAP EIA yields a false negative result, making 
serological diagnosis difficult and requiring increased diagnostic sensitivity. Our previous findings 
demonstrated that LDBio Aspergillus ICT show greatly improved sensitivity and ability to detect 
Aspergillus-specific antibody in patient sera, especially for ImmunoCAP IgG-negative (‘seronegative’) 
cases. Our analysis of patient immunodeficiencies reveals that ImmunoCAP false negatives are more 
prevalent in patients with certain immunodeficiencies, and that diagnostic performance of 
ImmunoCAP Aspergillus-specific IgG EIA may be more adversely affected by these patient 
conditions, as compared to LDBio Aspergillus ICT. 
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The diagnostic value of a molecular assay for Fusarium infections recently introduced in the 
Danish national reference laboratory 
R. Hare1, N. Abou-Chakra1, R. Datcu1, M.C. Arendrup1,2,3 
1Unit Of Mycology, Statens Serum Institut, Copenhagen, Denmark, 2University Of Copenhagen, 
Dept. of Clinical Medicine, Copenhagen, Denmark, 3Department Og Clinical Microbiology, 
Rigshospitalet, Copenhagen, Denmark 
Objectives: Fusarium keratitis and other infections remain difficult to diagnose even in the modern 
mycology laboratory. Molecular methods have enabled genus and species specific detection 
independent of culture and have improved diagnostic speed, sensitivity and accuracy of fungal 
infections. A specific diagnostic assay for Fusarium infections has been introduced in the Danish 
mycology reference laboratory and this study sought to evaluate the clinical performance. 
Methods: Clinical samples from patients suspected for fusariosis were subjected to Fusarium PCR 
(detecting Fusarium solani, Fusarium dimerum and Fusarium oxysporum) during the period October-
2017 to April-2019. The real-time multiplex Fusarium PCR assay using Taqman probes was slightly 
modified from that described by Salehi et al. 2016 (Pubmed ID 27605714). Patient samples were DNA 
extracted using the Qiacube (Qiagen, Denmark) standard protocol for blood and tissue samples, with 
up to 200 µL input volume and elution in 100 µL. Bronchoalveolar lavage samples were processed 
on the NucliSENS easyMAG (Biomérieux, Denmark) DNA extraction platform with up to 1 mL input 
volume and elution in 60 µL. Specimens were subjected to PCR in combination with culture and 
Blankophor microscopy, except for one patient (PCR only) due to insufficient amount of material. 
PCR was performed on the Applied Biosystems 7500 or the Quantstudio 5 thermocyclers (Thermo 
Fisher Scientific, Denmark). Positive and negative template controls were applied but not PCR 
inhibition or DNA extraction controls. PCR results were compared for each patient to our other 
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laboratory results and to results from the Danish Microbiological Database (MiBa), which captures 
clinical microbiological results from every laboratory in the entire country. 
Results: In total, 71 samples from 34 patients, among which 50 samples were from 29 patients with 
suspected keratitis, were included. Five patients (14.7%) accounted for 19/33 (57.6%) samples positive 
for Fusarium spp. DNA (Table). Four PCR positive patients provided 12/32 (37.5%) samples 
microscopy positive (septate hyphae) and 10/32 (31.3%) culture positive with Fusarium species 
(Table). The fifth PCR positive patient, was culture negative, but clinically diagnosed with a fungal 
keratitis and responded to targeted antifungal treatment. The remaining 29 patients provided 38 PCR 
negative samples. The majority of those patients (18/29) had culture positive samples for other 
potential culprits (clarification pending) and none were culture and microscopy positive for Fusarium.  
 
Conclusion: The diagnostic platform for Fusarium infections has proven accurate to the species level 
and was applied successfully in three incidents of Fusarium keratitis, one invasive fusariosis and one 
cutaneous infection. These data indicate a superior sensitivity of PCR compared to microscopy and 
culture. Of note, no clinically false positive findings were identified. Still, the specificity needs to be 
confirmed including a larger sample set. PCR performance may be further improved upon ongoing 
optimisation of the extraction procedures and quality control as well as introduction of a PCR 
inhibition control. In conclusion, the Fusarium PCR assay appears to be a significant improvement of 
the overall diagnostic algorithm at this reference laboratory both in speed and accuracy and thus 
important for those suffering from this uncommon but sight or potentially life-threatening disease. 
 
P170 
Mucorales PCR: a diagnostic improvement at the Danish national reference laboratory 
R. Hare1, N. Abou-Chakra1, R. Datcu1, M.C. Arendrup1,2,3 
1Unit Of Mycology, Statens Serum Institut, Copenhagen, Denmark, 2University Of Copenhagen, 
Dept. of Clinical Medicine, Copenhagen, Denmark, 3Department Og Clinical Microbiology, 
Rigshospitalet, Copenhagen, Denmark 
Objectives: Invasive Mucorales infections are associated with a poor prognosis for affected patients 
due to challenging therapeutic management strategies and often inadequate diagnostic tools. 
Molecular methods are increasingly complementing conventional culturing and microscopy to 
improve the overall diagnostic performance for invasive Mucorales infections. In the Danish 
mycology reference laboratory, a molecular assay detecting Mucorales DNA has been introduced 
which in a recent EQA panel managed by the Mucorales subgroup of the Fungal PCR Initiative scored 
100% (7/7 correct). This study sought to evaluate the clinical performance. 
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Methods: Clinical samples from patients suspected for invasive Mucorales infections were subjected 
to two Mucorales PCR tests (1: Rhizopus microsporus, Rhizopus arrhizus and Mucor spp. and 2: 
Lichtheimia spp. and Rhizomucor spp.) during the study period October-2017 to April-2019. Both real-
time multiplex Mucorales PCRs (Taqman probes) were slightly modified from those described by 
Salehi et al. 2016. Patient samples were DNA extracted using the Qiacube (Qiagen, Denmark) 
standard protocol for blood and tissue samples, with up to 200 µL input volume and elution in 100 
µL. Formalin fixed paraffin-embedded tissue samples were processed using Neo-clear (Sigma-
Aldrich, Denmark) followed by the Tissue protocol as described above. BALs were processed on the 
NucliSENS easyMAG (Biomérieux, Denmark) DNA extraction platform with up to 1 mL input 
volume and elution in 60 µL. PCR was performed on the Applied Biosystems 7500 and since mid-
2018 the Quantstudio 5 thermocyclers (Thermo Fisher Scientific, Denmark). Positive and negative 
template controls were applied but not PCR inhibition or DNA extraction controls. PCR results were 
compared to culture and Blankophor microscopy whenever possible and to results from the Danish 
Microbiological Database (MiBa), which captures clinical microbiological results from every 
laboratory in the entire country. 
Results: In total, 116 samples from 18 patients were included. Four patients diagnosed with invasive 
mucormycosis contributed with 91 samples of which 38 were Mucorales PCR-positive (41.8%, range 
25-100% per patient) (Table). Among those four patients, microscopy revealed pauci-septate hyphae 
in 31/85 (36.5%) and Mucorales species was cultured from 10/81 (12.3%) samples (Table). All patients 
received targeted treatment and surgical interventions guided by PCR results and all survived. The 
remaining 14 patients had 25 PCR negative samples, of which 20/21 and 19/19 were also negative by 
microscopy and culture, respectively. One patient, was microscopy positive with pauci-septate 
hyphae and by pan-fungal ITS DNA sequencing, Cunninghamella spp. DNA was detected, which is 
not included in the current Mucorales tests. 
 
Conclusion: Both diagnostic tests for Mucorales proved accurate to the genus or species level and 
with a sensitivity comparable to that for microscopy but significantly superior to that for culture 
(p<0.001). No clinically false positive findings were reported suggesting a high specificity. Yet, further 
evaluation including a larger sample set is warranted. PCR performance may be further improved 
upon ongoing optimisation of extraction procedures and PCR parameters as well as introduction of 
a PCR inhibition control. In conclusion, the Mucorales PCR assay appears to improve the diagnostic 
armamentarium and may play a pivotal role in managing patients suffering from Mucorales 
infections. 
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An evaluation of the analytical specificity of PCR assays for the detection of Candida species – A 
study by the ISHAM working group, the Fungal PCR initiative 
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Diseases, Cardiff University School of Medicine, Cardiff, United Kingdom, 5Division Of Infectious 
Diseases, San Antonio Center for Medical Mycology, San Antonio, United States of America, 
6Infectious Diseases, San Bonifacio Hospital, Verona, VERONA, Italy, 7Unit Of Mycology, Statens 
Serum Institut, Copenhagen, Denmark, 8Public Health England UK National Mycology Reference 
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University NHS Foundation Trust, Manchester, United Kingdom, 10Laboratorio di Micologia Medica, 
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Austria, 13Division Of Hygiene And Medical Microbiology, Medical University of Innsbruck, 
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15Medical Microbiology, RadboudUMC, Nijmegen, Netherlands, 16Department Of Microbiology, 
Palacký University, Faculty of Medicine and Dentistry and University Hospital Olomouc, Olomouc, 
Czech Republic, 17Faculty Of Medicine, Department Of Human Genetics, University of Debrecen, 
Debrecen, Hungary, 18Laboratory Of Mycology And Parasitology, University Hospital of Lille, Lille 
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Objectives: The use of PCR to detect Candida in clinical samples has been described for two decades, 
yet standardization is limited, hampering its widespread application. Following the successful efforts 
of the Fungal PCR initiative (FPCRI) in standardizing Aspergillus PCR the FPCRI has expanded it 
efforts to standardising the molecular detection of other fungi, including Candida. This research 
describes the efforts of the FPCRI Candida Laboratory Working Party to determining the analytical 
specificity (detection range and cross-reactivity) of Candida PCR assays currently used in clinical 
mycology centres. 
Methods: A panel of 12 samples containing genomic DNA extracted from nine yeast species (Candida 
albicans (2 concentrations), Candida glabrata (Nakaseomyces glabrata) (2 concentrations), Candida krusei 
(Pichia krusei), Candida parapsilosis, Candida tropicalis, Candida auris, Clavispora lusitaniae, Meyerozyma 
guilliermondii and Dipodascus geotrichum) and commercially bought human genomic DNA was 
distributed to 11 centres. The recipients were requested to perform Candida PCR following local 
protocols. Qualitative results (positive/negative), together with associated CT values (for real-time 
PCR) were reported for each sample, along with the assay’s technical details.. True positivity rates 
(detection of the correct species) and false positivity rates (detection of species not included in the 
panel, or misidentification as another species in the panel) were calculated for the overall panel and 
for individual samples. Regression analysis has been performed to identify any technical variables 
associated with improved analytical specificity. 
Results: Across 11 datasets ten different PCR protocols were utilized. At the high DNA concentration 
detection of the five main causes of invasive candidiasis (C. albicans, C. glabrata, C. krusei, C. 
parapsilosis, C. tropicalis) was 92.7%, ranging from 100% for C. parapsilosis to 90.9% for the other 
species. Detection of less common yeast pathogens (C. lusitaniae, M. guilliermondii) was 36.3%. At the 
lower DNA concentration the detection of C. albicans and C. glabrata was 72.7% and 54.5%, 
respectively. For C. auris, 63.6% of datasets were negative, but 36.4% generated an incorrect 
identification. Similarly for Dipodascus geotrichum, 45.5% were correctly negative but 45.5% provided 
an incorrect identification; only one assay identified Dipodascus geotrichum correctly. One assay 
generated a false positive result when testing human DNA. Nine centers used real-time PCR. 
Analysis of CT values for the five main Candida species indicated variance in the sensitivity of the 
assays with a mean Sd of 5.7 (range 4.3 – 6.9) with higher variance in CT values observed for C. 
parapsilosis, C. tropicalis or lower concentrations of C. albicans and C. glabrata, shown in Figure 1 and 
Table 1. 
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Conclusion: The detection of the main Candida pathogens that account for >95% of invasive disease 
is excellent, albeit at lower concentrations detection may be reduced. The detection of less common 
species is poor. In particular, only one of the 11 assays evaluated was designed to detect and identify 
C. auris but failed to do so which, given the susceptibility profile and infection control concerns 
associated with C. auris, highlights the design limitations of current Candida PCR assays. Preliminary 
analysis of CT values for the main Candida pathogens indicates differing sensitivity levels across real-
time Candida assays. 
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An evaluation of human β-globin gene detection to assess the quality of broncho-alveolar lavage 
and sputum specimens submitted for the diagnosis of Pneumocystis Pneumonia (PcP). 
R. Gorton1, E. Wey2, M. Hussein1, K. Patabendige1, G. Johnson3 
1Infection Sciences, Health Services Laboratories, London, United Kingdom, 2Microbiology, Royal 
Free Hospital Foundation Trust, London, United Kingdom, 3Scientific Development, OLM 
diagnostics, Newcastle, United Kingdom 
Objectives: The use of PCR to diagnose Pneumocystis Pneumonia (PcP) from clinical samples is 
recommended in recent guidelines for the diagnosis of PcP. One component of the diagnostic 
pathway, specifically sampling of broncho-alveolar lavage and sputum, is poorly controlled and 
often the laboratory receives specimen that is not standardised in volume or portion. This research 
aims to evaluate the use of a human β-globin gene (HgG) PCR from respiratory samples as a method 
for quality control of specimens, with the hypothesis that adequate levels of HgG present in a 
specimen is an indicator of a good quality sample, 
Methods: DNA was extracted from 47 BAL and 18 sputua using the Diasorin Arrow with DNA 
extraction cartridges. 500μL of BAL concentrate was centrifuged at 8000g for 10 minutes. The 
supernatant discarded; 50μL of glass beads were added and ribolysed for 45 seconds. The lysate was 
suspended in 240 μL Diasorin buffer 2 and 10μl proteinase K and incubated at 56°C for 10 minutes. 
J. Fungi 2019, 5, 95 229 of 464 
 
Extraction was performed as per manufacturer’s instructions on the Arrow platform. PCR was 
performed using the OLM PneumID assay with 6µL template in a total reaction volume of 20µL, 
following manufacturer’s instructions. PCR was performed on the RotorGeneQ platform. Outliers 
were determined using the 1.5 x IQR rule. 
Results: HgG CT characteristics are presented in Table 1 and Figure 1a) and b).
 
The mean HgG CT value from BAL was 19.49 (IQR 21.73, 23.49) and the lower threshold was 
determined to be 26.13. 10.6% (5/47) of the BAL samples had HgG amplification below the threshold. 
One sample was negative for P. jirovecii, two samples were sub-clinical (internal threshold 1E+5) 
positive for P. jirovecii measuring 2.3E+1 and 8.5 E+4 copies per mL. The remaining two samples were 
positive for P. jirovecii measuring 2.1 E+7 and 8.3 E+9 copies per mL. The mean HgG CT value from 
sputum was 18.04 (IQR 19.16, 20.26) and the lower threshold was determined to be 21.91. 16.7% (3/18) 
of the sputum samples had HgG amplification below the threshold. One sample was negative and 
two samples were positive for P. jirovecii at 9 E+5 and 1.9 E+6 copies per mL. From the total dataset 
of 65 specimens 47.7% (31/65) were positive for P. jirovecii. No significant difference (p = 0.38) was 
observed between the measured copies per mL using the OLM PneumID assay and the FTD 
Pneumocystis assay indicating that inclusion of the HgG PCR did not competitively inhibit the 
detection of P. jirovecii. 
Conclusion: This study has demonstrated HgG detection enables the laboratory to quality control 
respiratory specimens by determining if the specimen contains sufficient host material, which can be 
used as an indicator of good quality specimen. In this study almost 90% of samples had measured 
HgG above the established threshold, therefore negative and positive P. jirovecii PCR results could 
be reported with confidence. Where the HgG is below the acceptable threshold, negative or low 
positive samples should be interpreted with caution, as results may be derived from poor quality 
samples, seen for >10% of samples in this study. 
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Objectives: Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry 
(MALDI-TOF MS) has been widely used in clinical laboratories for routine identification of bacteria 
and yeast. However, there remain difficulties when applied to filamentous fungi. The standard liquid 
cultivation method recommended for identification is labour intensive and time-consuming. The aim 
of this study was to develop a quicker and less laborious method for cultivating filamentous fungi 
which leads to a reliable identification using Bruker MALDI-TOF MS. 
Methods: Reference strains of Aspergillus section Fumigati (n = 55) and section Flavi (n = 104), which 
were previously identified by molecular methods, were cultivated on top of and in between 
polycarbonate filters placed on Sabouraud’s dextrose agar (SDA) plate, and by the Bruker standard 
liquid cultivation method. After 24 hours of incubation at 35°C, mycelia were harvested for 
ethanol/formic acid protein extraction. Main Spectra Profiles (MSPs) were created and databases 
were constructed for each cultivation method. These databases were validated by identification of 50 
reference strains and 100 clinical strains of Aspergillus and Penicillium species which were previously 
characterized by DNA sequencing. 
Results: Growth: On top of a polycarbonate filter: The strains grew as a monolayer of mycelia with 
some spores in the middle. In between two polycarbonate filters: The strains grew as a mycelial 
monolayer without spores. Bruker method: Mycelial growth without sporulation MSP creation: 
55/55 MSPs of Aspergillus section Fumigati strains were created by cultivation in between 2 
polycarbonate filters, 52/55 by cultivation on top of a polycarbonate filter and 47/55 by Bruker 
standard method. Out of 104 Aspergillus section Flavi strains, 94, 92 and 76 MSPs were created by 
cultivation on top of and in between polycarbonate filters, and Bruker standard method, respectively. 
Validation: Identification of 50 reference strains of Aspergillus and Penicillium species against in-
house databases resulted in 95%, 90% and 62% correct identifications for the strains cultivated on top 
of a polycarbonate filter, in between 2 polycarbonate filters and by Bruker method, respectively. 
Identification against Bruker database (BDAL) resulted in 79%, 64% and 61% correct identifications 
by 1 polycarbonate filter, 2 polycarbonate filters, and Bruker method, respectively. Identification 
against in-house databases and Bruker database together yielded 87%, 82% and 61% correct 
identifications by 1 polycarbonate filter, 2 polycarbonate filters, and Bruker method, respectively 
(Figure 1).  
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Identification of clinical strains: Out of 100 clinical Aspergillus and Penicillium strains cultivated on 
top of a polycarbonate filter, 81% were correctly identified against in-house databases of strains 
grown on top of a polycarbonate filter, 78% with 2 polycarbonate filters and 59% by Bruker 
commercial database (BDAL) (Figure 2).  
 
Savings: For 50 strains, the cultivation method using polycarbonate filter was 270 minutes quicker 
and 81 Euros cheaper than Bruker standard method. 
Conclusion: Cultivation of filamentous fungi on top of a polycarbonate filter showed significantly 
improved results compared to the Bruker standard liquid cultivation method in terms of correct 
identification, MSP creation, time consumption, cost, and labour intensity. This can reliably be 
applied for identification of clinically significant filamentous fungi. 
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Objectives: Mucormycosis is a life-threatening fungal infection whose diagnosis remains challenging 
due to a lack of reliable diagnostic tests. Clinical and radiological signs are often unspecific. The 
contribution of histopathological and cultural procedures for early diagnosis is limited. In this 
context, Mucorales in-house real-time PCRs have been previously shown to be of high interest for a 
reliable and early diagnosis both in serum and respiratory specimens. A multiplex real-time PCR 
assay (MucorGenius® , Pathonostics, the Netherlands) has been newly marketed to detect the main 
genera involved in human mucormycosis. The aim of this study was i) to assess the diagnostic 
performances of MucorGenius®  assay in pulmonary samples compared to in-house Mucorales PCRs, 
and ii) to evaluate the occurence of Mucorales detection among invasive aspergillosis (IA) patients. 
Methods: We retrospectively included 320 pulmonary samples between January 2012 and May 2019: 
bronchoalveolar lavage fluids (n = 293), tracheal aspirations (n = 13), sputum samples (n = 5), pleural 
fluids (n = 3), and lung biopsies (n = 6) collected from 320 patients with respiratory symptoms at 
Rennes, Toulouse and Paris-Necker teaching Hospitals (France). Among the 320 patients, 30 patients 
were classified as a proven mucormycosis based on a positive direct examination and/or a positive 
culture in the respiratory sample and/or a positive serum mucorales PCR. Fifty-eight patients were 
proven/probable IA cases according to EORTC-MSG criteria. The 232 remaining patients were 
considered as having no IA and no mucormycosis (negative group). In-house real-time PCRs 
consisted in 3 assays targeting respectively Mucor-Rhizopus spp, Lichteimia spp, and Rhizomucor spp. 
MucorGenius®  targeted the same genera, including Cunninghamella spp. Amplification was 
performed according to manufacturer’s instructions using a LC480 (Roche) device. 
Results: The global concordance of both tests was high, of 97.8% (kappa coefficient = 0.877). 
Discordant results were mainly related to a higher sensitivity of in-house PCRs compared to 
MucorGenius®  assay (100% (30/30) versus 90.0% (27/30). The 3 cases missed by MucorGenius®  PCR 
were related to low fungal burden (mean Cq of in-house PCRs of 39.5±1.4) and were positive for 
Mucor-rhizopus (n = 2) and Rhizomucor (n = 1) with in-house PCRs. The specificity of both tests was 
similar (98.6% (286/290) versus 99.3% (288/290). No Mucorales DNA was detected in IA patients using 
in-house PCRs whereas one was found positive with MucorGenius®  assay, without other biological 
evidence for mucormycosis. Of the 4 positive-PCR samples in the negative group, one was probably 
a true positive result, from a real mucormycosis episod missed at the time of diagnosis (hematological 
malignancy, imaging compatible with IA during aplasia, early death under voriconazole treatment). 
The 3 other could be associated with fungal colonization. 
Conclusion: The commercial MucorGenius®  assay provides the possibility to detect in one well the 
main mucorales responsible for human mucormycosis, and then could reduce the diagnostic delay 
and improve the outcome. MucorGenius®  assay is an easy to use marketed kit including internal 
quality control, that shows good diagnostic performances with 97.8% of concordance compared to 
in-house PCRs, missing 3 low fungal burden cases. 
 
P176 
Development and Validation of an In-House Candida auris database in MALDI TOF MS to 
improve the yeast identification. 
A. Ceballos-Garzon1,2, C.M. Parra Giraldo2, D. Amado2, N. Velez2, C. Rodríguez3 
1Department Of Parasitology And Medical Mycology Of The University Of Nantes., Universite de 
Nantes, Nantes, France, 2Microbiology, Pontificia Universidad Javeriana, Bogotá, Colombia, 3Bruker 
Mexicana, Ciudad de México, Mexico 
Objectives: to construct an In-house Colombian database to improve Candida auris identification by 
MALDI-TOF MS. 
Methods: 30 clinical isolates of C. auris were used to construct an in-house data base. For each 
isolation, protein extraction was performed using the formic acid/ethanol method according to the 
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Bruker Daltonics protocol. Minimum 20 mass spectra of each one was obtained. The library was 
named “Candida auris Colombia”. For its validation 300 Colombian isolates of C. auris were used, 
comparing the results between the BDAL (Bruker) and Candida auris Colombia (in house) libraries. 
Finally, Cohen's kappa index was used to compare the results of the classification with both libraries. 
Results: From 30 clinical isolates, 770 mass spectra were obtained for the construction of the database. 
The validation was carried out with 300 isolates to compare the identification of results in the BDAL 
and Candida auris Colombia libraries (Figure 1). Our library allowed us to obtain an identification 
result for 100% of the evaluated isolates and improve significantly the scores obtained, which shows 
a better performance compared to the library present in the Bruker spectrometer. 
 
Figure 1 BDAL and Candida auris Colombia libraries identification results. A Total results and B 
Matrix of concordance identification from BDAL and Colombia databases. The MALDI-TOF MS 
results according to the manufacturer’s technical specifications as follows: Correct genus and species 
identification (>2,300), correct genus and probably species identification (≥2.0), correct genus 
identification and (1.7–2.0) no reliable identification (<1.7). 
Conclusion: The current bruker database has only 3 C. auris isolates from Korea and Japan, what it 
entails with identifications problems and low punctuation. Our database had a remarkable 
improvement in the identification of the 300 isolates, evidencing that the strengthening of the 
database is a great opportunity to improve the punctuation and C. auris identification. 
 
P177 
Aspergillus-specific IgG assay optimum cut-off for the diagnosis of chronic pulmonary 
aspergillosis 
B. Wilopo1, E. Hunter1, I. Page1, C. Moore1,2, M.D. Richardson1,2, D. Denning1,3 
1Division Of Infection, Immunity And Respiratory Medicine, The University of Manchester, 
Manchester, United Kingdom, 2Mycology Reference Centre, Excellence Center For Medical Mycology 
(ecmm), Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom, 3National Aspergillosis Centre, Manchester University NHS Foundation Trust, 
Manchester, United Kingdom 
Objectives: Chronic pulmonary aspergillosis (CPA) is a fungal disease characterised by cough, 
haemoptysis and weight loss present for at least for three months in non-immunocompromised 
people. It is caused by Aspergillus spp. especially Aspergillus fumigatus that can reach the respiratory 
tract by airborne transmission. The diagnosis of CPA can be made by a variety of clinical symptoms, 
radiological and laboratory evidence of Aspergillus. Most patients with CPA have positive Aspergillus 
precipitating antibodies or an abnormally high level of Aspergillus-specific IgG (Aspf IgG). The 
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Bordier Aspergillus fumigatus ELISA kit is one assay that can detect Aspf IgG and the result is deemed 
positive when the optical density (OD) index is higher than 1.0. We have re-evaluated this cut-off in 
patients with CPA in the UK. 
Methods: Aspf IgG levels in sera from 114 CPA patients and 150 British healthy controls were 
measured by the Bordier Aspergillus fumigatus ELISA kit. The results obtained were organised in MS 
Excel spreadsheets and analysed were performed using SPSS. Sensitivity and specificity at a number 
of points on the receiver operating characteristics (ROC) curve were described. The optimum 
diagnostic cut-off for the Bordier assay was calculated using Youden’s J statistic (sensitivity + 
specificity - 1). 
Results: Based on statistical analyses, we determined that the ROC area under the curve (AUC) of 
the Bordier Aspergillus fumigatus ELISA kit was 0.928. This assay has 77.2% sensitivity and 99.3% 
specificity using the manufacturer’s cut-off (1.0). The sensitivity and specificity of this assay at 
various points on the ROC curve improves to 83.3% sensitivity and 97.3% specificity if the OD index 
cut-off is lowered to 0.9. At this cut-off, the diagnostic odds ratio and diagnostic accuracy are 145 and 
90.9%.  
 
Conclusion: We have performed a ROC AUC analysis comparing Aspf IgG levels in a large group of 
patients with CPA compared to healthy British controls. Diagnostic performance improves if the OD 
index cut-off falls from 1.0 to 0.9. 
 
P178 
Influence of Intravenous Human Immunoglobulins on the Accuracy of Aspergillus 
Galactomannan Antigen Assays 
W.-D. Liu1, M.-C. Shih2,3, Y.-W. Wang4, S.-C. Lin4, Y.-F. Lee5, S.-W. Lin4,6, W.-C. Chou5,7, U.-I. Wu1,8, Y.-
C. Chen1,9 
1Department Of Internal Medicine, Division Of Infectious Disease, National Taiwan University 
Hospital, Taipei City, Taiwan, 2Institute of Epidemiology and Preventive Medicine, College of Public 
Health, National Taiwan University, Taipei City, Taiwan, 3Department Of Medical Education, 
National Taiwan University Hospital, Taipei City, Taiwan, 4Department Of Pharmacy, National 
Taiwan University Hospital, Taipei City, Taiwan, 5Department Of Laboratory Medicine, National 
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Taiwan University Hospital, Taipei city, Taiwan, 6Graduate Institute Of Clinical Pharmacy, National 
Taiwan University, Taipei City, Taiwan, 7Department Of Internal Medicine, Division Of Hematology, 
National Taiwan University Hospital, Taipei City, Taiwan, 8Department Of Internal Medicine, 
National Taiwan University Cancer Center, Taipei City, Taiwan, 9Center Of Infection Control, 
National Taiwan University Hospital, Taipei City, Taiwan 
Objectives: Galactomannan (GM) enzyme immunoassay (EIA), a diagnostic tool that detects the cell 
wall component secreted by Aspergillus species, provide a non-invasive method for early diagnosis 
of invasive aspergillosis (IA). However, its performance in diagnosing IA can be limited by potential 
false positivity caused by cross-reaction with other fungal species, food consumption and 
administration of certain antibiotics and blood products. False positive results were also 
demonstrated in a few patients having received intravenous immunoglobulins (IVIG). Some cases 
were attributed to cross-reactivity between the GM kits and saccharose contained in some IVIG 
products. Recently, we observed a growing number of patients prescribed with maltose-stabilized 
IVIG had false positive GM results despite absence of factors reported in the literature. We thus 
sought to determine if the false positivity was due to the processing procedures and presence of other 
unrecognized cross-reactive antigens contained in IVIG. 
Methods: Two new, unopened bottles of human IVIG (TBSF, CSL Behring, Australia) was randomly 
obtained from our hospital pharmacy. Each vial contained 3g (6%) human IVIG and 14.6 mmol 
maltose in 50ml solution. From each bottle, solution were aspirated for dilution using 0.9% saline to 
the concentration of 1% and 0.1%, respectively in order to simulate the peak (15.8 g/L) and trough 
(7.4 g/L) of serum IVIG level in an adult having received IVIG infusion at a concentration of 0.2-0.6 
g/Kg. A total of three different concentrations (6%, 1% and 0.1%) of IVIG together with negative 
controls (0.9% saline) were prepared in duplicates for GM detection using the Platelia Aspergillus EIA 
Kits (Bio-Rad) according to the manufacturer’s instructions. In order to explore if heat treatment and 
addition of EDTA required in standard sample processing procedures were associated with false 
positivity, samples were prepared with and without the investigated pretreatment, respectively for 
comparisons. A GM test result was considered positive if the optical density index (ODI) reached 0.5 
or above. In addition, conventional bacteria and fungus cultures, pan-fungal polymerase chain 
reaction (PCR) were performed using undiluted samples from the bottles of IVIG to assess the 
presence of contaminants. All procedures were performed under strict sterile conditions. 
Results: Using standard procedures with heat pretreatment and addition of EDTA, all IVIG samples 
tested positive for GM regardless of the concentrations used for the experiments (Figure 1), while all 
0.9% saline controls yielded negative results. Pre-treatment of samples with boiling water-bath 
resulted in considerable elevation of GM ODI in both presence and absence of EDTA compared to 
samples without heat treatment. No fungus or other microorganisms were isolated from our IVIG 
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samples using PCR or conventional culture methods.
  
Fig 1. GM ODI of IVIG samples prepared with different concentrations and pretreatment 
methods. 
Conclusion: IVIG treatment can cause false GM positivity owing to the reaction between the contents 
in the IVIG products and standard pretreatment procedures of the assays. Interpretation for a positive 
GM assay result should be cautious in patients having received human IVIG infusion. 
 
P179 
Evaluation of the relevance of use of the BD BACTECTM mycosis IC/F, BD BACTECTM Plus 
Aerobic/F, BD BACTECTM Lytic/10 anaerobic/F et BD BACTECTM Peds Plus/F culture bottles 
system for fongemia detection: A 4-year retrospective study at the University Hospital of Dijon, 
France. 
A. Magallon1, L. Basmaciyan1, S. Valot1, C. Goulard De Curraize2, M. Sautour3, J. Bador2, F. Dalle4 
1Mycology, University Hospital of Dijon, Dijon, France, 2Bacteriology, University Hospital of Dijon, 
Dijon, France, 3Laboratoire Parasitology Mycology, CHU Dijon, Dijon, France, 4Parasitology-
mycology, University Hospital Dijon, Dijon, France 
Objectives: Fongemia are severe invasive fungal diseases that combine rapid evolution with high 
mortality. The early diagnosis of these pathologies is therefore fundamental in the care of patients 
and is a vital emergency. Currently, only the BD BACTECTM Automated Blood Culture System 
(Becton Dickinson, Franklin Lakes, New Jersey, USA) has a bottle specifically dedicated to the 
detection of fungal agents, the BD BACTECTM Mycosis IC/F bottle. The objective of this study was to 
(i) evaluate the fongemia detection performance of the BD BACTECTM Mycosis IC/F culture bottles in 
comparison to the so-called "bacteriological" culture bottles (i.e. BD BACTECTM Plus Aerobic/F 
bottles, BD BACTECTM Lytic/10Anaerobic/F bottles, and BD BACTECTM Peds Plus/F) in different 
clinical situations and so (ii) the relevance of their use. 
Methods: This retrospective study was conducted over a period of 4 years (i.e. from January 2013 to 
December 2016) at the University Hospital of Dijon. 331 pairs of blood cultures (i.e. each pair 
combining a BD BACTECTM Mycosis IC/F culture bottle with at least one of the bacteriological culture 
bottle). Univariate analysis by the MacNemar chi² test was carried out globally as well as in the 
subgroups corresponding to the various clinical situations encountered. 
Results: Of the 331 pairs of positive for fungi blood cultures included in the study, the BD BACTECTM 
Mycosis IC/F culture bottles showed a diagnostic advantage over bacteriological culture bottles in 
57.4% of cases (p <0.01). In addition, for 96 pairs of blood cultures, only the BD BACTECTM Mycosis 
IC/F culture bottles was positive for fungi versus 66 pairs in which only the bacteriological culture 
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bottles was positive for fungi. On the other hand, a fungus / bacterium co-infection was observed in 
46 of the 331 pairs of blood cultures included in the study. In this "co-infection" subgroup, the overall 
"diagnostic advantage" variable was significantly in favor of the BD BACTECTM Mycosis IC/F culture 
bottles (n = 30, p<0.05). Multivariate analysis revealed an association between diagnostic performance 
and (i) the existence of yeast-bacteria co-infections, (ii) the mode of sampling, (iii) the type of fungus 
and (iv) diagnostic indication or follow-up of the patient, showing the relevance of the use of the BD 
BACTECTM Mycosis IC/F culture bottles in addition to those of bacteriology. 
Conclusion: This study showed the necessity of the of the BD BACTECTM Mycosis IC/F culture bottles 
in the diagnosis of candidemias, in particular in case of bacterial co-infections. 
 
P180 
Gliotoxin (GT) and bis-methyl-Gliotoxin (bmGT) characterization during Aspergilllus fumigatus 
infection. 
A. Gomez Lopez, C. Rueda Hernández, R. Pando Pozo 
Reference Laboratory On Mycology, CNM-ISCIII, MAJADAHONDA-MADRID, Spain 
Objectives: To develop a new method based on liquid-liquid extraction and chromatographic 
separation to specifically and simultaneously characterize both mycotoxins. We also describe the 
primary bmGT and GT’s role as defence molecule during Aspergillus progression in two cell lines 
infection model of IA that mimic human disease by measurement of GT and bmGT amount and their 
cytotoxic effect. 
Methods: An UHPLC/PDA method was first developed and validated to specifically characterize 
both compounds. Chromatographic separation was achieved using an ACQUITY UPLC-H Class 
apparatus. The analytical conditions were selected after testing different parameters such as 
extraction procedures, column type, mobile phase composition, etc. We applied the developed 
method to define temporal kinetics of GT and bmGT production by using a fungal infection in two 
different cell line models, A549 (ATCC CCL-185, alveolar basal epithelial cell of human 
adenocarcinoma), and RAW 264.7 (ATCC TIB-71, murine macrophages) and an Asperillus fumigatus 
clinical isolate, GT producer. After the establishment of a specific infection model (ratio1:1, inoculum 
size 5x10t5 spores), we harvested each supernatant from cell line cultures at fixed time points, for 
assessment of GT/bmGT production. Galactomannan (GM) antigen was also quantified in order to 
establish the fungal burden at each time. In addition, a microscopic evaluation was performed to 
prove spores progression in each cell line. Specific stains (Sytox, calcofluor) were used to better define 
the characteristics of infection 
Results: The best overall selectivity and peak shape were achieved by using a silica column 
(ACQUITY UPLC® HSS, C18, 2,1 x 75 mm 1,8μm particle size) combined with a mobile phase 
consisting of a gradient of water and acetonitrile and a flow rate of 0.1 mL/min. The developed 
method was applied to analyze the extracted supernatant (using chloroform) obtained from each 
condition. In the laboratory condition established, GT was firstly detected after 30 h of incubation. 
The kinetic profile showed a maximum production after 48 h and then a continuous decrease. 
Enrichment of GT in infected cell lines did not correlate with GM. Additionally, the level of bmGT, 
the inactive derivate of GT, was detected later. Contrary to GT, the levels of bmGT showed a 
continuous increase after 48 h of incubation. No great differences were found in GM, GT and bmGT 
amounts by cell lines studied. In both models, GT showed a concentration-dependent cytotoxic effect. 
Of note, bmGT did not show any toxic effect and appear to be more stable than GT. 
Conclusion: 1) GT and bmGT may be excreted to extracellular media during the course of Aspergillus 
fumigatus infection, although these components showed different kinetics during the Aspergillus 
fumigatus growth. 2) The chromatographic method described was successfully applied to characterize 
these secondary metabolites, having potential as a diagnostic technique for aspergillosis. 
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In vitro comparison between two commercial kits for the detection of Aspergillus galactomannan. 
Preliminary results. 
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D.-A. Giannakopoulou, E. Zachrou, E. Zarkada, T.-A. Vyzantiadis 
First Department Of Microbiology, Medical School, Aristotle University of Thessaloniki, 
Thessaloniki, Greece 
Objectives: Galactomannan is an important component of fungal cell wall, mainly measured for the 
early diagnosis and monitoring of invasive Aspergillosis. Several commercial kits have been released 
and the aim of this study was to compare the recently available kit of Dynamiker Aspergillus 
Galactomannan Assay (Dynamiker Biotechnology Co, Ltd, China) to the internationally used and 
broadly evaluated PlateliaTM Aspergillus Ag (Bio-Rad, France). 
Methods: Both kits are immunoenzymatic assays, based on the same principle with slight technical 
differences. An advantage of the Dynamiker method is the use of breakable strips, while both 
produce results after the calculation of an index value. The interpretation of positivity is based on the 
cut-off index of 0.5 for serum and 1.0 for BAL, defined after years of use and evaluation of results 
produced by the Bio-Rad kit. Forty four (39 serums, 4 BALs, 1 pleural fluid) specimens were tested 
by both methods (18 positive by the Bio-Rad kit). The positive and negative controls of the Bio-Rad 
kit were also tested by the Dynamiker one. Further on, in order to test the precision of the Dynamiker 
kit, twelve specimens were tested for their inter-day variation between two or three sequential 
measurements and their intra-day variation concerning double measurements. Alongside, two 
positive specimens (one serum and one BAL) were further diluted in three sequential two-fold sub 
dilutions (1:2, 1:4 and 1:8) in order to test the detection ability of the kit. 
Results: The values (mean±SEM) were 1.12±0.24 by Bio-Rad and 0.68±0.12 by Dynamiker. Although, 
the strict numeric values were quite different, they didn’t differ statistically (p = 0.35) and they were 
positively correlated (r = 0.65, p = 0.000001). The precision of the Dynamiker kit was good with an 
intra-run CV (coefficient of variation) of 13.01% and an inter-run CV of 13.25%. However, while all 
negative (26 specimens) by Bio-Rad were found again negative by Dynamiker, this was not the case 
with the positive specimens, where there was a disagreement in six out of eighteen (33.3%, positive 
by Bio-Rad and negative by Dynamiker) and the strict numeric values differed statistically (p = 0.016). 
Both Bio-Rad positive and negative controls were found at the same level with the Dynamiker and 
all dilutions of the tested two positive samples provided positive results. 
Conclusion: If the long used Bio-Rad kit is going to be considered the reference kit for the comparison 
of other recently available commercial kits, then it is probable that the here-tested Dynamiker kit is 
quite efficient and could probably offer a reliable alternative. However, these preliminary results 
show that there is a possible issue of sensitivity by not being able to detect a percentage of positive 
samples, while the kit is highly specific. Further in vitro studies with larger number of samples in 
combination to clinical information and outcome would provide a more documented and evaluated 
use of the kit. 
 
P182 
External Validation of a bedside prediction rule for candidemic patients 
K. Alobaid1, A. Chadha2, A. Alansari3 
1Mycology Reference Lab, Mubarak Alkabeer hospital, Jabryia, Kuwait, 2Microbiology Unit, Mubarak 
Alkabeer hospital, Jabryia, Kuwait, 3Medical Department, Mubarak Alkabeer hospital, Jabryia, 
Kuwait 
Objectives: The aim of this study is to examine Ostrosky-Zeichner’s rule (CPR) on predicting cases 
of candidemia among hospitalized patients in ICU and non ICU settings. 
Methods: This is a prospective study on cases of candidemia from March 2017 till May 2018 in a 
secondary hospital. All candiemic cases were analyzed and tested by applying Ostrosky-Zeichner’s 
rule (CPR). Another group of patients who developed bacteremia were also tested as a control. The 
inclusion criteria for cases and controls are (1) positive blood culture in a patient with signs of 
infection, (2) hospital acquired infections. CPR was modified to include ICU and non ICU patients. 
The rule included presence of central line or broad spectrum antibiotic plus two of the following: 
steroids, immune suppressive agents, pancreatitis, major surgery, TPN, and major surgery. 
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Results: In the period from March 2017 till May 2018, 50 cases of candidemia were found. Two cases 
were excluded, as they represented contamination. Control group involved 60 patients. Majority of 
cases were hospitalized in medical wards (27), seven patients were surgical, 12 patients were 
hospitalized in ICU, and two patients were pediatric cases. The sensitivity, specificity, PPV, and 
NPV of modified Ostrosky-Zeichner’s rule were 40.4%, 98.3%, 67%, and 95% respectively. Area 
under the curve (AUC ROC) is 0.69 and 95 % CI is (0.62-0.76). Although 29 cases (59.6%) were not 
predicted by the rule, 6 patients (21%) had femoral catheters. 
Conclusion: Clinical prediction rules are helpful adjunctive tool to rationalize the use of antifungals. 
Modified Ostrosky-Zeichner’s rule, in particular, appears to have good specificity for candidemic 
patients. The results also suggest that around 40% of patients can be treated empirically before culture 
results and this may improve survival. The possibility of femoral catheters as a risk factor for 
candidemia needs further evaluation. As shown in other studies, the high negative predictor value 
helps avoiding or stopping unnecessary use of antifungals. 
 
P183 
Real Time PCR and galactomannan test for detection of Aspergillus spp. in bronchoalveolar 
lavage fluid of patients with aspergillosis 
S. Ignatyeva1, V. Spiridonova1, T. Bogomolova2, O. Shadrivova3, Y. Borzova1, E. Desyatik2, N. 
Vasilyeva2, N. Klimko4 
1Kaschkin Research Institute Of Medical Mycology, North-Western State Medical University named 
after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2Kaschkin Research Institute Of Medical 
Mycology. Department Of Medical Microbiology, North-Western State Medical University named 
after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 3Department Of Clinical Mycology, 
Allergy And Immunology, North-Western State Medical University named after I.I. Mechnikov, 
Saint-Petersburg, Russian Federation, 4Department Of Clinical Mycology, Allergology And 
Immunology, North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, 
Russian Federation 
Objectives: The success of treatment of fungal infection depends on early etiological diagnostics. The 
aim of the study was to test a real time PCR with High Resolution Melt analysis (mHRM-RT-PCR) 
and galactomannan (GM) for detection of Aspergillus spp. in bronchoalveolar lavage fluid (BAL) of 
patients with aspergillosis. 
Methods: We tested 33 BAL from 33 patients with aspergillosis in Saint-Petersburg between 2015 and 
2018 yy. As controls, 50 BAL were collected from patients without mycoses. BAL was examined by 
direct microscopy with calcofluor white and culture. Fungal DNA was extracted from clinical 
samples by a chloroform-isoamyl extraction method. DNA amplification was performed using 
aspergillus - specific primers and EvaGreen based mHRM-RT-PCR on Rotor-Gene 6000 cycler. 
Detection of GM was performed using “Platelia Aspergillus Ag” (Bio-Rad). The test was considered 
as positive with a cut-off of ≥0,5. We calculated the sensitivity and specificity for the PCR assay and 
GM with the level of statistical significance <0,05. 
Results: Direct microscopic examination of BAL from patients with aspergillosis was positive in 42% 
cases, Aspergillus spp. were isolated in 91% cases. Cultures of 33 BAL samples revealed various 
Aspergillus spp.: A. fumigatus (63%), A. niger (19%), A. flavus (6%), A.versicolor (3%). From 3 patients 
(9%) two different species were isolated: A.fumigatus + A.niger (6%) and A.fumigatus + A.flavus (3%). 
GM test was positive in 23 BAL samples from patients with confirmed aspergillosis. Sensitivity of 
PCR assay in BAL was higher, than sensitivity of GM test (84% vs. 70%, p = 0,013). At the same time, 
specificity of GM test was higher than of PCR assay in patients without aspergillosis (87% vs. 71%, p 
= 0,018). The positive results of PCR assay in patients with aspergillosis correlated with positive 
results of microscopy and cultural investigations from BAL in 75% and 78%, positive GM test - in 
55% and 95%, respectively. Complex investigation of biological materials by immunological and 
molecular methods increased the diagnostic effectiveness to 91 - 92%. 
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Conclusion: This study indicated that the mHRM-RT-PCR may be a very useful tool for detection of 
Aspergillus spp. in bronchoalveolar lavage fluid of patients with aspergillosis. Real Time PCR assay 
together with GM test increase the diagnostic effectiveness of biological materials investigations. 
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Detection and identification of mucormycosis etiologic agents in biological samples of 
oncohematological patients using multiplex real time PCR 
S. Ignatyeva1, V. Spiridonova1, T. Bogomolova2, Y. Avdeenko1, O. Shadrivova3, I. Zyuzgin4, Y. 
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Objectives: Mucormycosis is an opportunistic infection characterized by rapid progression, high 
morbidity and mortality.The success of treatment of fungal infection depends on early etiological 
diagnostics. The aim of the study was to test a multiplex real time PCR with High Resolution Melt 
analysis (mHRM-RT-PCR) on clinical samples for simultaneous detection and identification of 
Mucormycetes in biological samples. 
Methods: We tested 12 clinical samples from 10 oncohematological patients with mucormycosis in 
Saint-Petersburg between 2014 and 2018 yy. As controls, 21 tissue samples and 20 BAL were collected 
from patients without mycoses. Fungal DNA was extracted from clinical samples by a chloroform-
isoamyl extraction method. DNA amplification was performed using mucormycetes - specific 
primers and EvaGreen based mHRM-RT-PCR on Rotor-Gene 6000 cycler. 
Results: The mHRM-RT-PCR allows to identify In clinical samples from patients with aspergillosis 
and mucormycosis the representatives of Aspergillus to the genus and Mucormycetes to the species 
level: Rhizopus arrhizus, Mucor racemosus, Rhizomucor pusillus, Lichtheimia corymbifera. We tested 3 
native tissue, 7 formalin-fixed paraffin-embedded tissue samples and 2 BAL of patients with 
mucormycosis. In 1 of 3 native tissue and 2 BAL with positive direct microscopic examinations 
Lichtheimia corymbifera was isolated. In 7 formalin-fixed paraffin-embedded tissue non-septate 
mycelium of mucormycetes was detected. mHRM-RT-PCR was positive in native, formalin-fixed 
paraffin-embedded tissue samples and BAL of all patients with mucormycosis. PCR assay allowed 
to identify the representatives of Mucormycetes: Lichtheimia corymbifera in 10 and Rhizomucor pusillus 
in 2 from 12 samples. In biological specimens of 2 patients the PCR assay detected a mixed infection 
by Aspergillus and Mucormycetes spp. The results of mHRM-RT-PCR in patients with mucormycosis 
correlated with traditional methods. In 21 controls tissue samples and 20 BAL PCR test was negative. 
Conclusion: The multiplex RT-PCR has high sensitivity and specificity in patients with 
mucormycosis. This study indicated that the mHRM-RT-PCR may be a very useful tool for detection 
of etiologic agents of mycoses, particularly in the case of a mixed infection caused by Aspergillus and 
Mucormycetes spp. 
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Clinical application of free circulating microRNAs in patients with hematologic malignancies as 
promising biomarkers in monitoring invasive aspergillosis 
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E. Tolnai, K. Okechukwu Nwozor, G. Fidler, R. Szasz, L. Rejto, S. Biro, M. Paholcsek 
Faculty Of Medicine, Department Of Human Genetics, University of Debrecen, Debrecen, Hungary 
Objectives: MicroRNAs (miRNAs) are small 19- to 23- nucleotide long, noncoding single stranded 
RNA molecules. They play an important role in regulating various biological processes through 
complementary base pairing with 3’- untranslated regions (3’ UTR) of the corresponding target 
mRNAs. MiRNAs are key regulators of various physiological and pathophysiological processes like 
cell proliferation, differentiation, apoptosis, inflammation and cancer. Altered expression levels of 
miRNAs have been associated with many diseases. Increasing number of evidences demonstrate that 
specific miRNAs can be a great promise as novel biomarkers for clinical diagnosis of many types of 
diseases due to their stability in various body fluids. However, little is known about the potential use 
of circulating miRNAs as biomarkers in fungal infections. Invasive aspergillosis (IA) is a life-
threatening infection caused by Aspergillus especially in immunocompromised patients. With this 
pilot study our aim was to verify the different expression profiles of 21 pre-selected target miRNAs 
in hematologic malignant patients with (proven, probable IA) and without (possible IA and healthy 
controls) IA. We assessed the association of IA disease characteristics with the abundance of the free 
circulating microRNAs in the liquid biopsy samples of these patients to identify potential diagnostic 
markers for further studies. 
Methods: We obtained whole blood (WB) samples from 40 patients at the onset of fevered 
neutropenia (FN) and from 5 healthy volunteers. Total RNA was isolated from the WB samples using 
the MagMaxTM mirVanaTM Total RNA Isolation Kit (Thermo Fisher Scientific). MiRNAs were reverse 
transcribed to cDNA with TaqMan®  Advanced miRNA cDNA Synthesis Kit (Thermo Fisher 
Scientific). TaqMan®  quantitative real-time PCR (miRNA assay) was used for detecting miRNA 
expression profiles. Relative miRNA expressions were calculated with the ΔΔCt method. 
Results: We found that 7 out of the 21 miRNAs were strongly associated with IA by being 
significantly (p<0.05; p<0,01) upregulated in our patient group compared to the control group. 
Increase in miRNA expressions were also observed in the case of further 7 miRNAs which expression 
differences did not prove to be statistically significant. 
Conclusion: Based on the result of this pilot study, we detected significant expression differences in 
the case of seven miRNAs. We think that these may be promising and effective biomarker targets to 
support the diagnosis of IA. We also believe that the diagnostic strategy relying on the combination 
of multiple circulating miRNAs promises better positive predictive values in monitoring of IA. 
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Indication of opportunistic micromycetes in mycobiota of municipal solid waste compost by 
metagenomic approach 
G. Kozlov1, N. Vasilyeva2, I. Riabinin2 
1Department Of Technology For Microbiological Synthesis, Saint-Petersburg State Institute of 
Technology, Saint-Petersburg, Russian Federation, 2Kaschkin Research Institute Of Medical 
Mycology. Department Of Medical Microbiology, North-Western State Medical University named 
after I.I. Mechnikov, Saint-Petersburg, Russian Federation 
Objectives: Objective of the study is to perform the genotaxonomic analysis of mycobiota of thermal-
treated compost from municipal solid waste (CMSW) to identify the microfungi of medical interest. 
Methods: The metagenomic study of samples using an internal transсribed spacer (ITS2) as a 
tacosomic marker was performed on the Illumina MiSeq instrument (Illumina, USA) according to the 
Manufacturer's protocol. DNA-extraction, post-PCR purification of apmplicons and DNA 
concentration measurement were made by utilization PowerSoil DNA Isolation (Qiagen, Germany), 
AMpure XP magnetic beads (Beckman Coulter, USA) commercial kits and Qubit 4 Fluorometer 
(ThermoFisher Scientific, USA) respectively. Bioinformatic data processing was performed using 
QIIME 1.9.1 software, Silva and Unite databases. Classification algorithm of open-reference 
operational taxonomic units was utilized. 
Results: Among a variety of microfungi from CMSW-mycobiota representatives of 20 taxa to varying 
degrees associated with pathologies and the indigenous human microbiota were revealed. They can 
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be divided into three groups. Group A consist of micromycetes, which do not colonize the human 
body normaly (or occasional contaminants of the body's open loci) but can cause opportunistic 
mycoses: Aspergillus niger, Cryptococcus uniguttulatus, Rhodotorula glutinis. Group B including 
micromycetes, sometimes occuring in biomaterials of human body, as well as colonizing 
environmental objects: Candida zeylanoides#, C. inconspicua*, C. membranifaciens#, Pichia norvegensis*, 
Meyerozyma guilliermondii#, Kluyveromyces marxianus, Lodderomyces elongisporus, Issathenkia orientalis*, 
Trichosporon asahii and Cutaneotrichosporon cutaneum. Group C: micromycetes that live mainly in the 
human body (sometimes in animals) and are not common inhabitants of abiotic objects: C. albicans, 
C. parapsilosis#, C. metapsilosis, C. glabrata*, C. tropicalis#, Malassezia sp. 
Conclusion: CMSW is expected to be a habitat for microorganisms that are interesting in two aspects: 
(1) cause of their capability of carrying out uniqe metabolic pathways associated with the 
biodegradation of plant polymers, synthetic plastics and metallic materials and, on the other hand, 
(2) cause of representation by them the «microbiome imprint» of human population of a settlement 
area. Some of the detected yeast organisms are known to be resistant to antimycotics: the lists of 
groups B and C contain species with intrinsic resistance to fluconazole (*) as well as containing strains 
with secondary resistance mechanisms (#). The most unusual representative among the identified 
microbiota was Malassezia sp. Despite the deep adaptation of malasseziae to the humans and animals 
skin and numerous unsuccessful attempts to find their free-living related yeast, the application of 
molecular genetics technologies in the 21st century made it possible to identify the genetic material 
of these fungy in the most unexpected habitats (deep-sea sediments, invertebrates, some freshwater 
fishes, soil of arctic zones etc.). Ways to supply the high nutritional needs of malasseziae in the 
environment are not yet clear, theoretically, Malassezia spp. in CMSW can borrow the polyunsaturated 
fatty acids necessary for them directly from the remnants of dietary fats, or through symbiotic 
interaction with other members of the microbial community. Cunducted research made it possible to 
consider the CMSW-mycobiota as a potential niche associated with the circulation of opportunistic 
micromycetes in the anthropogenic ecosystem of the city. 
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Hunt for Cryptococcus : two years survey of the wild avian fauna of Southern France 
P. Drakulovski1, T. Gouveia1, J. Pierru2, D. Krasteva1, C. Pottier1, E. Arianiello2, V. Bellet1, F. Roger1, S. 
Bertout1 
1Laboratoire De Parasitologie Et Mycologie Médicale, University of Montpellier, Montpellier, France, 
2Centre De Sauvegarde De La Faune Sauvage, LPO, Villeveyrac, France 
Objectives: Cryptococcus sp. are environmental yeast whose natural biotope is still poorly understood. 
Indeed, C. neoformans has been isolated mostly from pigeon faeces but also from vegetable surfaces 
and several trees. C. gattii has been mostly isolated from decaying wood of various tree species, like 
Eucalyptus, Pinus, Olea, and Ceratonia trees but also from animals. C. laurentii, C. albidus have been 
isolated from soil, water but also from animal faeces. A few other species like C. terrestris or C. aerius 
are considered environmental only. In order to clarify the biotope of these yeasts, we are conducting 
a two year survey of the wild avian fauna in Southern France. 
Methods: Six hundred and four birds from 70 genera and 86 species, randomly selected from the 
animals arriving for care at the Center for Protection of the Wild Fauna of Herault were sampled. 
Sampling was performed during care protocols either by direct cloacal swab or, when impossible, by 
swabbing of faecal drops present in cages. The samples were treated as per the standardized protocol 
used by the ISHAM Cryptococcal Working Group i.e transferred onto Niger Agar seed medium and 
grown at 28°C and 37°C during 7 days minimum. Each suspected Cryptococcus colony was checked 
for the presence of a capsule by India ink staining, for its urease activity and identified by API ID32C 
and ITS sequencing. 
Results: Identification allowed to find 39 C. albidus, 30 C. magnus, 13 C. laurentii, 2 Cutaneotrichosporon 
curvatus, 2 C. oeirensis, 2 C. diffluens, 2 C. carnescens, 2 Filobasidiella elegans, 1 C. wiriengae, 1 C. terrestris 
and 1 C. aerius coming from 33 different bird species. No C. neoformans nor C. gatti were found so far. 
Global cryptococcal prevalence was of 15.7%. 
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Conclusion: Several Cryptococcus were found from bird wherein they were not described until now. 
As such, this study brings new data on the avian species potentially carrying various Cryptococcus sp 
yeast. 
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Microbial monitoring and environmental influence before and after hospital architectural design 
F. Bonadio1, M. Caetano2, J.P. Siqueira3, M. Almeida1 
1Infectious Disease, Medical School, sao jose do rio preto, Brazil, 2UNESP, São José do Rio Preto, 
Brazil, 3Infeciosas Disease, FAMERP, São José do Rio Preto, Brazil 
Objectives: To assess the microbial contamination and the environmental impact of reform in a 
hemodynamic service hospital ward, in a Hospital of the Interior of the State of São Paulo, Brazil. 
Methods: Environmental samples were collected from 10 surfaces (floor, walls, sinks, and counters), 
in two different moment, in rooms of medical procedures. RODAC®  plates were imprinted in the 
different surfaces. Considering fungi and bacteria, plates were incubated at 35°C for up to hours to 
allow all organisms to grow. Colonies were isolates in agar BHI (DIFCO® ) with identification of 
bacterial species conducted by automated system VITEK® , and fungi by slide culture in Potato Agar 
(DIFCO® ) and biochemical characteristic. After first sampling, the rooms of the Hemodynamics 
Service in the hospital ward was reformed, using all principles and materials commercially available 
to control microorganisms. Innovative material and procedures of civil construction were adopted, 
including paint, mortar, and coating following normative criteria according to Brazilian legislation. 
Then, 10 new surface samples were obtained from the same points of the previous collection, at the 
same incubation, isolation, and identification criteria. 
Results: In the first sampling, it was detected contaminated surfaces with high microbial load: 100% 
for bacteria, and 80% for fungi, ranging from 1 to 400 CFU, according to the collection point. 
Considering the microbial diversity, there was prevalence for Gram positive bacteria from 
Staphylococcus spp, and filamentous fungi, especially Aspergillus spp., Acremoniumspp., and 
Scopulariopsisspp. After the reform, microbiological analysis showed a significant reduction of 
microbial counts, as well as reduction in the diversity of bacterial and fungal species. It was noted 
that 80% of the cultures were negative. No fungi were observed and the bacterial isolates are still 
being identified. 
Conclusion: The hospital environment should be constantly monitored for its competence in non-
proliferation of infectious agents. The presence of bacteria and fungi on surfaces may constitute a risk 
factor for dissemination and occurrence of infectious diseases, with great impact on Public Health. 
Old constructions may favor the dissemination of these organisms. This study confirmed the high 
microbial contamination in the hospital environment before reform and showed that a well-designed 
architectural design, with appropriate material and adoption of normative procedures, can minimize 
the risks of contamination and dissemination of potentially pathogenic microorganisms. 
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Study of fungal environmental contamination in nests of the penguin enclosure of a large French 
animal zoo park. 
N. Cartier1, R. Le Sénéchal1, M. Becerra1, E. Bailly1, E. Cateau1, J. Chandenier2,3, B. Mulot4, A. Leclerc4, 
G. Desoubeaux2,3 
1Parasitology - Mycology - Tropical Medicine, Hôpital Bretonneau, Tours, France, 2Parasitology - 
Mycology - Tropical Medicine, Hôpital Bretonneau, TOURS, France, 3Cepr Inserm U1100, Université 
de Tours, Tours, France, 4Clinique Vétérinaire, ZooParc de Beauval & Beauval Nature, Beauval, 
France 
Objectives: Aspergillus fumigatus is an environmental mold with opportunistic pathogenicity. It is 
responsible for aspergillosis, a disease particularly common in penguins that are kept in a confined 
or insufficiently ventilated environment. At ZooParc de Beauval (Saint-Aignan, France), the 
incidence of aspergillosis was estimated by autopsy at 4% in Humboldt penguins (Spheniscus 
humboldti) during the period [April 2018 - April 2019]. Antifungal treatment is based on the 
J. Fungi 2019, 5, 95 244 of 464 
 
administration of azole drugs. This study assessed the environmental contamination in the penguin 
enclosure and searched for azole resistances in A. fumigatus isolates. 
Methods: Two sets of environmental samples were carried out in the spring and fall 2018, by 
swabbing the artificial nests of the penguin enclosure in ZooParc de Beauval. The collected specimens 
were inoculated onto malt extract agar at 35°C. In case of fungal growth, a count of the colony 
number, as well as a phenotypic and molecular identification were achieved. Each DNA of all the A. 
fumigatus isolates was systematically sequenced to look for azole resistance mutations in CYP51 gene. 
Results: Overall in spring and fall sampling, 0.8 and 2.6 mean fungal CFU per sample of penguin nest 
were counted, i.e. 83% and 100% nests were contaminated with at least one fungal species, 
respectively. Moreover, Aspergillus fumigati section was isolated in 67% and 75% of them. Thus, the 
concordance rate was 67% between the two sets of samling. Through to DNA sequencing, all but one 
isolate (Aspergillus nishimurae) were eventually identified as A. fumigatus stricto sensu. To date, only 
one resistance mutation for azole drugs was detected once in the CYP51 gene (G138A). 
Conclusion: Despite the geographical location of ZooParc de Beauval in a rural environment, 
intensive adjacent agricultural practices do not exhibit any impact on the selection of resistant strains. 
However, the very high contamination rates herein encourage great caution and regular checks of 
the fungal populations. 
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Specific Identification and Antifungal Susceptibility Pattern of Fungal Species Isolated from 
Patients with Onychomycosis 
I. Haghani1, M. Shams-Ghahfarokhi2, T. Shokohi3, M.T. Hedayati3, A. Dalimi Asl4, M. Fathi4 
1Medical Mycology, Mazandaran university of Medical sciences, Sari, Iran, 2Department Of 
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Tarbiat Modares University, Tehran, Iran 
Objectives: Onychomycosis is a common nail problem, accounting for up to 50% of all nail diseases. 
The aim of the present study was to determine the species distribution based on the restriction 
fragment length polymorphism and susceptibility patterns of the causative agents of onychomycosis. 
Methods: This cross-sectional study was conducted on nail samples collected from 257 patients 
suspected of onychomycosis within a year. Fungal isolates was identified by polymerase chain 
reaction-restriction fragment length polymorphisms (PCR-RFLP) with the enzymes Msp I, Mva I, Alw 
I and sequencing. 
Results: According to the results, Out of the 257 patients participating in the study, onychomycosis 
was diagnosed in 180 (70.03 %.) cases, among which 51.1% were caused by non-dermatophyte molds 
(NDMs), 34.4% by yeasts, and 10.6% by dermatophytes. Numerous cryptic species recovered from 
onychomycosis for the first time. In the majority of cases, novel triazoles and imidazoles (i.e., 
efinaconazole, luliconazole, and lanoconazole) showed potent activity in comparison to other 
antifungal agents. The minimum inhibitory concentration (MIC) of luliconazole and lanoconazole 
ranged within 0.001 to >1μg/ml and their geometric mean MICs were 0.0154 and 0.0309 μg/ml against 
all isolates, respectively. 
Conclusion: It seems that obtained data will be useful to improve the knowledge of researchers, 
clinicians, and dermatologists about onychomycosis distribution, species diversity and adoption of 
appropriate treatment. 
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Objectives: Candida auris is a growing global threat; a pathogen associated with high mortality (up 
to 60%), multi-drug resistance, the ability to spread from person-to-person and surface-to-person, 
presenting high risk for outbreaks in healthcare facilities. Ibrexafungerp is a novel IV/oral glucan 
synthase inhibitor (triterpenoid) antifungal with activity against Candida, Aspergillus and 
Pneumocystis spp, in Phase 3 development. Given the potent activity of ibrexafungerp against Candida 
spp., Scynexis has embarked on a development program to understand the activity and effectiveness 
against Candida auris. We will present the current preclinical and clinical data sets of ibrexafungerp 
against Candida auris. 
Methods: In vitro studies tested ibrexafungerp against >100 clinical isolates of C. auris. Other in vitro 
studies evaluated the effects of ibrexafungerp against C. auris biofilms. In vivo activity against C.auris 
was evaluated using a disseminated murine model and a cutaneous infection guinea pig model. In 
humans, an ongoing open-label trial of ibrexafungerp for treatment of patients with infections caused 
by C. auris (the CARES study) has been initiated in the USA and India. 
Results: In vitro and in vivo studies demonstrated that ibrexafungerp is active against C. auris, 
including MDR strains. The MIC mode for ibrexafungerp was 1ug/ml and the MIC50 and MIC90 were 
0.5 and 1 ug/ml, respectively. Many echinocandin resistant C. auris isolates have shown susceptibility 
to ibrexafungerp. Further, ibrexafungerp has been shown to reduce biofilm thickness. In animal 
models of C. auris infection, treatment with ibrexafungerp resulted in improved survival and reduced 
fungal burden in both the murine model of disseminated infection and the guinea pig model of 
cutaneous infection as compared to untreated controls. In humans, two patients with difficult to treat 
C. auris candidemias were enrolled in the CARES study and responded positively to oral 
ibrexafungerp with eradication of the infection. 
Conclusion: This data demonstrate that ibrexafungerp possess potent in vitro and in vivo activity as 
well as promising clinical activity. Therefore, continued clinical evaluation of ibrexafungerp as an 
option to treat C. auris infections is warranted. 
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Microsporum ferrugineum in Germany – an anthropophilic dermatophyte on the rise 
S. Uhrlass1, C. Sitaru2, C. Scholz2, M. Gebhardt3, A. Baunacke4, C. Friedrichs5, I. Ranke-Greve6, U. 
Cleffmann6, D. Koch1, H. Muetze1, C. Krueger1, N. Rahmig7, U.-C. Hipler7, P. Nenoff1 
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Moelbis, Germany, 2Klinik Für Dermatologie Und Venerologie- Mykologisches Labor, 
Universitätsklinikum, Freiburg, Germany, 3Hautarztpraxis, Zwickau, Germany, 4Hautarztpraxis, 
Radeberg, Germany, 5Medizinisches Labor Ostsachsen, Görlitz, Germany, 6Dr. Stephan Bartels, 
Hautarztpraxis, Göttingen, Germany, 7Klinik Für Hautkrankheiten, Universitätsklinikum, Jena, 
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Objectives: In Germany, the anthropophilic dermatophyte Microsporum (M.) ferrugineum was nearly 
never isolated during the last 50 years. Currently, starting with the year 2016, single strains were 
detected, and small outbreaks of infections due to this difficult to differentiate fungus have been 
observed in Germany. From July 2016 until April 2019, altogether 19 M. ferrugineum strains were 
isolated. The dermatophytes originated from patients all over Germany. 
Methods: Cultural investigation revealed slowly growing colonies with white thallus and peripheral 
yellow brownish submerged hyphae bundles. The reverse side of the furrowed colonies showed 
cream coloured to yellow staining. Microscopically, large spherical and oval double-walled 
intercalary localized chlamydospores, typical `bamboo` hyphae, and acute-angled branched hyphae 
developed. Fungal culture material from all isolates was identified by PCR and genomic Sanger 
sequencing of the internal transcribed spacer (ITS) region and/or the translation elongation factor 
(TEF)-1α gene. Reference strain for comparative identification was M. ferrugineum CBS 497.48 
(Centraalbureau voor Schimmelcultures CBS, Utrecht, The Netherlands, 
www.westerdijkinstitute.nl). Patients were children and adolescents under 18 years, mainly males. 
Suggested source of infection was martial sports, e.g. wrestling, judo, and boxing. Surprisingly, a 
significant part of affected patients counted to Russian Germans. A migrant 3 years old boy from 
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Afghanistan suffering from tinea capitis was also among the patients. Another strain was isolated 
from a 10 years old wrestler with suspicion of tinea corporis. There was no background of migration 
or contact to foreigners, the boy did not stay abroad. The mycological challenge is the cultural 
identification of M. ferrugineum. Confusion with the morphological similar species M. canis, but also 
M. audouinii, and Trichophyton verrucosum is possible. 
Results: The comparison of the found ITS-2 sequence with known sequences deposited at the 
database of the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, U.S., 
confirmed the species identification M. ferrugineum. The phylogenetic analysis of the dermatophytes 
– the dendrogram of fungal strains – demonstrated the genetic differences between M. ferrugineum 
strains and M. audouinii or M. canis. The three species could clear distinguished from each other. In 
particular, sequencing of the TEF-1α gene allowed discrimination between M. ferrugineum and M. 
audouinii or M. canis better than sequencing the ITS-2-region. Meanwhile, the M. ferrugineum strain 
208361/2016 is deposited at the „Deutsche Sammlung von Mikroorganismen und Zellkulturen” 
(DSMZ, German Collection of Micro organisms and Cell cultures) in Braunschweig, Germany (DSM 
no. 103785). The DNA sequences of the M. ferrugineum strains are currently deposited as MF173061- 
ITS - and as MF173060 - TEF-1α gene - at the NCBI database. 
Conclusion: In Germany, in the last decades, M. ferrugineum was not isolated and described so far. 
Currently, with this forgotten dermatophyte must be expected in particular in migrants and asylum 
seekers. The species identification of M. ferrugineum represents a challenge for the dermatologist. If 
there are morphological and microscopic features suspicious for such a rare Microsporum-species, 
molecular identification of the causative pathogen should be performed. For oral therapy of tinea 
capitis due to M. ferrugineum griseofulvin should be given, alternatively itraconazole or fluconazole. 
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Arthroderma chiloniense - a new geophilic dermatophyte – isolated from human and hedgehog 
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Objectives: Due tot he new taxonomy of the dermatophytes, geophilic fungal species are 
summarized within the genus Arthroderma (A.). Until now known Arthroderma species are e.g. A. 
insingulare, A. gertleri, A. uncinatum, A. thuringiensis, besides, there are the three relatively new species 
A. amazonicum, A. crocatum, and A. vespertilii. Altogether four strains of an until now not known 
geophilic fungus - suggested as mould or dermatophyte - were isolated between 2011 and 2017 from 
different patient ś materials. Underlying dermatoses were a hand eczema or suspected tinea manus, 
nail changes (nail plate pigmentation) to exclude an onychomycosis, and skin scrapings vom the 
lower leg and body trunk to exclude a tinea corporis. An additional strain of A. chiloniense was found 
in clinical material originationg from the skin and stings of a hedgehog with alopecia diffusa and 
scaly skin. 
Methods: Conventional and molecular mycological diagnostic was performed. Kind of growth of the 
fungal colonies on common fungal media was assessed. Fungal culture material from all five isolates 
was identified by PCR and genomic Sanger sequencing of the internal transcribed spacer (ITS: 18S 
rRNA, ITS1, 5.8S rRNA, ITS2, and 28S rRNA) region, the translation elongation factor (TEF)-1α gene, 
and β-tubulin. Human strains 216228/16- DSM106573, 211495/17- DSM106575, 211496/17- 
DSM106574 and 215488/17- DSM108904 are deposited at the „Deutsche Sammlung von 
Mikroorganismen und Zellkulturen” (DSMZ, German Collection of Micro organisms and Cell 
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cultures) in Braunschweig, Germany. The from hedgehog isolated strain with laboratory number 
250173/2018 has already been submitted to the DSMZ, too. 
Results: The white, flat, fast growing colonies presented with yellow reverse sides. Microconidia are 
small, elongated, sessile lateral directly at the hyphae or the conidiophores, also in dense aggregates. 
Later arthroconidia and multiple chlamydospores have developed, however, no macroconidia. Urea 
splitting of all isolates was positive. By sequencing of the gene regions ITS-1 and ITS-2, TEF-1α and 
β-tubulin showed, that the new species showed the highest genetic similarity to the species A. 
crocatum and A. amazonicum. Ultimately, the sequences of the here isolated unknown fungi could be 
assigned to the new described geophilic dermatophyte Arthroderma chiloniense sp. nov. 
Conclusion: A. chiloniense presents a new geophilic dermatophyte, first described in Kiel, Germany, 
in 2018, and published 2019. This species is obviously widely prevalent in Germany. Isolated from 
human beings under the suspicion of a dermatophytosis of the skin or nails, seems to indicate that A. 
chiloniense possesses pathogeic potential. Here, A. chiloniense, for the first time was isolated from an 
animal, an European hedgehog. 
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Case Report:  
Objectives: Candida auris is an emerging fungal species resistant to several antifungal agents. There 
is an increasing worldwide awareness of C. auris. We therefore aim to report the first case of C. auris 
infection in Thailand.  
Methods: We present the first case of C. auris fungemia in an elderly woman from Thailand.  
Results: A 81-year-old woman was admitted in a private hospital in January 2018 due to status 
epilepticus which required ICU support with prolonged mechanical ventilation. In addition, she had 
chronic kidney disease requiring hemodialysis through her right subclavian central venous catheter. 
During 4 months in the hospital, she experienced catheter-related bacterial blood stream infection, 
nosocomial pneumonia, urinary tract infection and tracheobronchitis which was treated with several 
regimens of broad-spectrum antibiotics. On day 110 of hospitalization, she had hypotension with 
low-grade fever during hemodialysis. Blood cultures from her central venous catheter grew Candida 
spp. While peripheral line cultures remained negative. The central catheter was removed and she 
was treated with micafungin. The Candida isolate was subsequently identified as Candida auris by 
MALDI-TOF and sequencing. Swab cultures from the central catheter exit site also grew C. auris. She 
denied any travel outside of Thailand prior to admission. Despite intravascular catheter removal, she 
had again candidemia from C. auris three weeks later and micafungin was re-introduced. However, 
the patient died 6 days after restart of treatment. After diagnosis, strict contact precautions were 
installed with no further intra-hospital transmission. CLSI microbroth dilution antifungal 
susceptibility testing of all isolates showed resistance to fluconazole (32 mg/L) and voriconazole (0.25 
mg/L), higher MICs of amphotericin B (1 mg/L) and low MICs to echinocandins (0.063 mg/L). 
Isavuconazole had low MICs of < 0.016 mg/L. By using AFLP and MLVA genotyping the isolates had 
the same genotype and were shown to belong to the south-Asian C. auris clade.  
Conclusion: We report the first case of C. auris (south-Asian clade I) fungemia from Thailand. The 
index case for this C. auris introduction into Thailand remained unclear and no secondary cases were 
discovered. Active surveillance for this emerging antifungal-resistant Candida species should be 
brought into attention to prevent healthcare-associated outbreaks. 
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Disseminated phaeohyphomycotic lymphadenitis with Cladophialophora carrionii 
J. Farooqi1, S. Moin1, S.F. Mahmood2, R. Idress1, F. Naqvi1, A. Zafar1 
1Pathology And Laboratory Medicine, Aga Khan University, Karachi-KHI, Pakistan, 2Medicine, Aga 
Khan University, Karachi, Pakistan 
Case Report:  
Objective: This study describes a case of disseminated phaeohyphomycotic lymphadenitis in a 
young woman with delayed diagnosis and good clinical response after appropriate treatment.  
Methods: A 32 year old lady presented with erythematous to violaceous papules, with oozing 
discharge bilaterally in her inguinal region, for a few months. The history revealed that she had a 
past history of tuberculous meningitis, treated with first line antituberculous therapy for eighteen 
months, and two years back she developed pigmented discharging lymph nodes bilaterally in her 
axillae. The histopathology of the biopsy showed chronic granulomatous inflammation with multiple 
branching septate fungal hyphae. She received amphotericin B for 21 days but without improvement. 
Now, sample from these inguinal lesions was sent for histopathology and culture.  
Results: Histopathology of the biopsy material showed dense inflammation and well-formed 
granuloma comprising of epithelioid cells and multinucleate giant cells. Multiple branching septate 
fungal hyphae noted in the inflammatory debri and in and around granuloma. PAS stain highlighted 
septate fungal hyphae. Gram stain revealed moderate septate hyphae with numerous pus cells. 
Culture on Sabouraud dextrose agar yielded velvety olive-black colony in the fourth week. 
Microscopic slide examination of culture material was suggestive of Cladophialophora carrionii. The 
patient was started on voriconazole and was continued this for 6 months and the patient improved. 
On discontinuing voriconazole after six months, there was a relapse in the disease. Voriconazole was 
restarted and the patient improved.  
Conclusion: Incomplete investigation of infectious lesions may delay diagnosis. Both 
histopathological and microbiological assessments are equally important for making a conclusive 
diagnosis. Antifungal therapy may delay growth of fungi that normally grow within a week, hence 
a longer incubation time may be warranted for fungal smear positive samples. In 
phaeohyphomycosis, the infection is usually introduced by traumatic inoculation or inhalation of the 
etiologic agent; and clinical presentations are greatly influenced by the immune status of the host. In 
our case there was no known immune deficiency and no trauma that the patient could recall. 
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Genomic sequencing of Candida auris cases in Canada, 2012 - Feb 2019 
A. Bharat1, D. Alexander2, T.C. Dingle3, P.J. Dufresne4, L.M. Hoang5, J.V. Kus6, I.S. Schwartz7, L. Gade8, 
A.P. Litvintseva8, A. Mcgeer9, M.R. Mulvey1 
1Antimicrobial Resistance And Nosocomial Infections, National Microbiology Laboratory Canada, 
Winnipeg, Canada, 2Cadham Provincial Laboratory, Winnipeg, Canada, 3Alberta Public 
Laboratories, Edmonton, Canada, 4Laboratoire de santé publique du Québec, Sainte-Anne-de-
Bellevue, Canada, 5BC Centres for Disease Control, Vancouver, Canada, 6Public Health Ontario, 
Toronto, Canada, 7University of Alberta, Edmonton, Canada, 8Mycotic Diseases Branch, US Centers 
for Disease Control and Prevention, Atlanta, United States of America, 9Mount Sinai Hospital, 
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Objectives: Candida auris is an emerging yeast that is associated with high rates of antifungal 
resistance and healthcare-associated outbreaks that can be difficult to control. Our objective was to 
carry out genomic characterization of all known C. auris cases in Canada to monitor the emergence 
of this species. 
Methods: Nineteen isolates of C. auris identified from 2012 - Feb 2019 were submitted to the Canadian 
Mycology Reference Centre which is in development at Canada's National Microbiology Laboratory 
(NML). Isolates from all 19 cases were subjected to whole genome sequencing (WGS) on the Illumina 
Nextseq platform. Phylogenetic analysis based on nucleotide differences in the core genome was 
carried out with the SNVPhyl v1.1 pipeline and assemblies were performed with SPAdes v1.6. 
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Results: The isolates were obtained from axilla/groin (n = 7), blood (n = 4), ear (n = 3), and other sites 
(n = 5). All Canadian isolates of C. auris fell within the four known genomic lineages (clades), which 
were initially named after the continents where they were identified and then renamed Clades I - IV. 
Canadian cases were linked to the Clade I (South Asian clade, n = 10), Clade IV (South American 
clade, n = 4), Clade III (African clade, n = 3), and Clade II (East Asian clade, n = 1). The four 
geographical clades were highly divergent with approximately 15,000 - 60,000 single nucleotide 
variants (SNV) between clades. Canadian isolates within a clade were often clonal, for example, 
isolates from Clade IV (South American clade) differed by only 14-26 SNVs. Canadian isolates from 
Clade I (South Asian clade) differed by an average of 79 SNVs, however, epidemiologically-linked 
isolates within this clade differed by only 1-19 SNVs. We identified mutations associated with 
fluconazole resistance (ERG11 Y143R) and voriconazole resistance (ERG11 Y132F) but not 
echinocandin resistance (FKS1 hotspot mutations). 
Conclusion: The number of known cases of C. auris in Canada remains low and all cases were 
susceptible to echinocandins. Whole genome sequencing confirmed the global origins of Canadian 
cases. Isolates tended to be clonal within each clade but high resolution WGS may be helpful in 
discriminating between patient transmission and separate introductions into a healthcare facility. 
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Misidentification of Candida duobushaemulonii associated to superficial infection and reduced 
susceptibility to azoles 
I. Jurado1, E. Varela-Echegaray1, C. Marcos-Arias1, P. De Groot2, G. Quindós1, E. Eraso1 
1Inmunology, Microbiology, Parasitology, University of the Basque Country (UVP/EHU), Bilbao, 
Spain, 2Regional Center For Biomedical Research, Castilla-la Mancha Science & Technology Park, 
University of Castilla-La Mancha, Albacete, Spain 
Objectives: Candidiasis by Candida haemulonii complex (Candida haemulonii and Candida 
duobushaemulonii) and closely related species, such as Candida auris and Candida pseudohaemulonii that 
show reduced susceptibility to antifungal drugs are increasing. Conventional phenotypic diagnostic 
methods are unable to identify these species. Therefore, their prevalence may have been 
underestimated. The aim was to use novel molecular techniques to identify isolates from a stock 
culture collection with dubious identities, which could belong to emerging and multi-resistant 
species related to C. haemulonii. 
Methods: The study included 150 clinical isolates from the yeast stock collection of the Medical 
Mycology Laboratory at the University of the Basque Country (UPV/EHU) collected between 1993 
and 2017 that could be inaccurately identified by API® ID 32C (bioMérieux, France). Three clinical 
confirmed isolates (two C. auris and one C. duobushaemulonii) and one C. pseudohaemulonii reference 
strain (CBS 10004) were included as positive controls. All isolates were analysed by two different 
PCR techniques: a C. auris-specific PCR1 and a C. haemulonii complex-tetraplex PCR2. Species 
identities were confirmed by sequencing the ITS1-5.8S-ITS2 region. Finally, in vitro susceptibility to 
nine antifungal agents (anidulafungin, micafungin, caspofungin, posaconazole, voriconazole, 
itraconazole, fluconazole, amphotericin B and 5-fluorocytosine) was tested using SensititreTM 
YeastOneYO10 (Thermo Scientific, USA). 
Results: C. auris-specific PCR accurately identified both confirmed isolates of C. auris and no bands 
were detected for the other isolates. Eight isolates previously identified as C. haemulonii were 
confirmed by tetraplex PCR. Neither C. auris nor C. pseudohaemulonii were detected in the collection. 
One isolate from a toenail previously identified in 1996 by API® ID 32C panel as Candida intermedia 
produced a 115 bp sized band in the tetraplex PCR, corresponding to C. duobushaemulonii. All 
identifications were confirmed by ITS sequencing. The C. duobushaemulonii isolate was re-analysed 
by the current API® ID 32C panel, which identified it as Candida sake. The C. duobushaemulonii isolate 
was susceptible dose-dependent to itraconazole (MIC 0.5 µg/mL) and fluconazole (MIC 32 µg/mL). 
All C. haemulonii were susceptible dose-dependent to itraconazole (MIC 0.5 µg/mL) and fluconazole 
(MIC 16 µg/mL) except two, who were resistant (MIC 1 and 64 µg/mL, respectively), and their 
susceptibility to amphotericin B was reduced (MIC 2->8 µg/mL). The C. pseudohaemulonii reference 
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strain CBS 10004 was susceptible to all antifungal drugs. Both C. auris isolates showed resistance to 
fluconazole (MIC >256 µg/mL), dose-dependent susceptibility to itraconazole (MIC 0.25 µg/mL), and 
one of them was also susceptible dose-dependent to voriconazole (MIC 2 µg/mL). 
Conclusion: Candida haemulonii complex and closely related species may have been associated to 
superficial infections prior to its emergence related to invasive infections, as indicated by the 
identification of a C. duobushaemulonii isolate from before 2012, when current classification of the 
complex was established. This complex shows reduced susceptibility to azoles and amphotericin B. 
Funding: GIC15/78 IT-990-16 (Gobierno Vasco) and SAF2017-86188-P (MINECO, Spain). 1. Ruiz-
Gaitán et al. Molecular identification of Candida auris by PCR amplification of species-specific GPI protein-
encoding genes. Int J Med Microbiol. 2018;308:812-818. 2. Arastehfar et al. Low-cost tetraplex PCR for the 
global spreading multi-drug resistant fungus, Candida auris and its phylogenetic relatives. Front Microbiol. 
2018;29;9:1119. 
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Acute fungal obstructive pyelonephritis, echinocandin is a possible treatment? A case report 
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1Biotechnologies And Life Sciences Department, Center for Clinical Ethics, University of Insubria, 
Varese, Italy, 2Busto Arsizio Hospital, Asst-valleolona, Infectious Diseases Unit, Busto Arsizio (VA), 
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Case Report:  
Objectives/Introduction: Urinary tract candidiasis is the most frequent nosocomial fungal infection 
worldwide; ascending acute pyelonephritis (AP) due to Candida species are uncommon 
complications. Nowadays we observe a change in the distribution of Candida species, with an 
increasing number of non-albicans Candidaisolations. In this setting Fluconazole is the treatment of 
choice; the role of echinocandin is unknow, because of the limited repository of antifungals that 
achieve adequate urinary concentrations.  
Methods: We report a Candida tropicalis complicated urinary tract infection (cUTI) in a patient with 
diabetes mellitus who successfully treated by high dosage of Caspofungin and oral fluconazole 
(FLC). The infection was triggered by the placement of a ureteral double J stent and bladder catheter, 
arranged for kidney stones.  
Results: A 67-year-old Italian woman affected by diabetes mellitus, metabolic syndrome and recent 
breast cancer, was transferred in the autumn of 2018 from an outside institution after double J stent 
positioning for left ureteral stone complicated by grade III hydronephrosis. At the admission fever 
and increase inflammatory values were present, so blood and urine cultures were performed. Empiric 
antibiotic therapy with carbapenems was started, without clinic improvement in 5-6 days, so we 
interrupted this therapy. We isolated only pan-sensitive Candida tropicalis in urine sample but with 
few colonies, so we considered as colonization. She therefore underwent to CT-scan with urological 
and thoracic studies: we found left AP complicated by micro abscesses and pulmonary thrombo-
embolism. We decided to introduce high dosage of FLC and to remove ureteral catheter double J and 
bladder catheter; we isolated from them another time the same type of Candida tropicalis. Considering 
a diffuse disease, trans-thoracic echocardiography and fundus oculi exam were performed, excluding 
fungal manifestations. After few days she remained febrile and blood inflammation biomarkers not 
decreased very well, so we decided to switch therapy with an alternative one, suspending FLC, we 
started Caspofungin at the dosage of 70 mg/die. Immediately after initiation of treatment we 
observed a rapid improvement with disappearance of the fever. After two weeks, abdomen CT-scan 
showed an inflammation reduction and she was discharged home with maintenance high dosage 
FLC (800 mg/die), concluding antifungal therapy after 3 overall months. Finally, after therapy, CT-
scan and urine culture were prescribed with no evidence of recurrence. The patient is currently alive, 
without urinary problems.  
Conclusion: Candida tropicalis is a rare cause of AP. Echinocandins have been traditionally avoided 
in the treatment of cUTI because of their poor urinary concentrations; their use with high dosage, 
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owes an achieved high renal tissue concentration. This case shows that in fungal cUTI we can use 
high dosage echinocandin if fluconazole is no possible for any reasons. We want also to stress that is 
necessary a prolonged therapy in fungal AP. 
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The first two cases of Candida auris in The Netherlands 
E. Vogelzang1, A. Weersink2, J. Meis3, K. Van Dijk1 
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Objectives: Candida auris is a rapidly emerging, multidrug resistant pathogenic yeast. In recent years 
an increasing number of Candida auris invasive infections and colonized patients have been reported 
from several continents, including the USA, Africa, Europe and Asia. Here, we describe the first two 
cases of Candida auris in The Netherlands. 
Methods: Case 1 was a middle aged patient repatriated from an Indian hospital to a Dutch intensive 
care unit (ICU). He had been hospitalized for five weeks in an Indian hospital for treatment of sepsis 
with multiple organ failure due to pneumonia. He was mechanically ventilated and repatriated with 
a tracheostomy tube and continuous renal replacement therapy for which he had a central venous 
catheter. Routine admission screening cultures for MRSA and multidrug-resistant gram-negative 
bacteria showed yeast growth from Continuous renal replacement therapya removed central venous 
catheter which the Bruker MALDI-TOF MS identified as Candida auris. Case 2 was a middle aged 
patient, referred by the Amsterdam airport medical services to the hospital due to shortness of breath 
and inability to stand without assistance. He was in Amsterdam airport for a layover flying from 
India to the USA. Due to renal insufficiency, he had received hemodialysis in an Indian healthcare 
facility up to two days before presentation in our hospital. Due to subfebrile temperature a urine 
sample was cultured which grew 10^4-5 CFU yeasts. The Bruker MALDI-TOF MS identified the yeast 
as Candida auris. 
Results: In both cases contact precautions were instituted since patients had been previously 
admitted to an Indian healthcare facility. Routine screening cultures were taken from nose, throat 
and perineum to identify potential multidrug-resistant gram-negative bacteria and MRSA. At present 
no routine screening for Candida auris is performed in the Netherlands. Screening failed to detect 
Candida auris, but groins and axilla screens were not included. Molecular typing with AFLP and 
MLVA showed that both isolates had closely similar genotypes and both belonged to the South Asian 
Candida auris Clade I. Broth microdilution showed that both Candida auris isolates had high 
fluconazole (>64 mg/L) and voriconazole (4 mg/L) MICs. Amphotericin B (0.5-1 mg/L), anidulafungin 
(<0.016-0.063 mg/L) and micafungin (0.063 mg/L) had low MICs. In both cases antifungal therapy was 
not indicated since there were no signs of an infection. Due to installment of contact precautions no 
transmission of Candida auris was observed. 
Conclusion: We report the first two cases of Candida auris in The Netherlands in patients who were 
recently admitted to an Indian healthcare facility. The patients were immediately placed in contact 
isolation after admission and no transmission of Candida auris occurred. Concern is raised regarding 
surveillance for multidrug-resistant organisms, since routine screening of patients from foreign 
hospitals is still focused on multidrug-resistant gram-negative bacteria and MRSA and not yet on 
(multi)drug resistant yeast, such as Candida auris. 
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Objectives: Healthcare-associated infections are caused by different microorganisms, including 
bacteria, viruses and fungi. In the recent years, Candida auris has emerged as a multidrug-resistant 
fungal pathogen difficult to eradicate from hospital environment. It has been isolated from medical 
equipment, and from different objects that hardly ever are disinfected and can act as fomites (bed 
hand-controllers or mobile phones). In some cases, routine chemical and physical decontamination 
approaches are used but not all the above-mentioned objects can be treated with them due to possible 
deterioration. Ultraviolet C radiation could represent an alternative, which does not cause aesthetic 
or functional alterations in inanimate objects. Therefore, the objective of this study was to evaluate 
the disinfection capacity of a portable ultraviolet C (UV Sanitizer Corvent® ) equipment. 
Methods: The disinfectant effect of the UV sanitizer equipment was evaluated using different 
exposure times (30 s, 1 min, 2 min, 3 min and 5 min), against five Candida isolates: three clinical strains 
of C. auris, and two reference strains, Candida albicans SC5314 and Candida parapsilosis ATCC 22019. 
These microorganisms were inoculated onto slides, starting from a suspension of 1.5-5.0 x 109 ufc/mL, 
that was mixed with an interference solution to analyze the disinfecting effect in both clean and dirty 
conditions (presence of organic matter). Slides were exposed to ultraviolet C radiation inside the 
equipment. The results were compared with those obtained after the disinfection of the slides by 
immersion in 70% ethanol following the protocol described in EN 14562:2006 standard. 
Results: Disinfection, considered as a logarithmic reduction equal to or greater than 5 from the initial 
inoculum, was achieved at a minimum exposition time of 3 min, in both clean and dirty conditions. 
The presence of organic matter interfered in the disinfection process to some extent, since the final 
values were slightly higher after the treatment of the samples in dirty conditions. The effectivity of 3 
min immersion in 70% ethanol was very high against all microorganisms, obtaining a total reduction 
in all cases. 
Conclusion: The ultraviolet C radiation applied for 3 minutes using the portable ultraviolet C UV 
Sanitizer Corvent®  equipment was effective in the disinfection of slides inoculated with C. auris, C. 
albicans and C. parapsilosis. This equipment is a promising alternative for implementing disinfection 
protocols in hospitals and laboratories with inanimate objects of common use (mobile phones, TV or 
bed controllers) reducing risk of infection transmission. 
 
P211 
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GmbH, Bremen, Germany, 8Div Hygiene & Med. Microbiology, Med. Univ. Innsbruck, Innsbruck, 
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Objectives: The recent emergence of azole resistant C. parapsilosis isolates carrying Y132F mutation 
in ERG11 is a matter of concern in India, Kuwait, South Korea, and USA. Given the horizontal transfer 
of C. parapsilosis and the propensity of Y132F mutants to colonize the hospital environments, their 
prompt identification followed by application of appropriate infection control strategies are of 
importance. 
Methods: During 10 years (2009-2019), 228 non-duplicate isolates of C. parapsilosis were recovered 
from the blood samples of patients admitted to Ege University Hospital, Izmir, Turkey. All isolates 
were primarily identified by API 20C AUX and re-identified via MALDI-TOF MS. Regardless of 
fluconazole MIC values, ERG11 sequencing was performed for all 228 isolates. In the next step, MRR1, 
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TAC1, and UPC2 sequencing was performed for 90 isolates containing all resistant isolates with or 
without ERG11 Y132F mutation and randomly selected susceptible dose-dependent and susceptible 
isolates. 
Results: Surprisingly, Y132F was the most predominant mutation in ERG11 (n = 46, 20.2%), followed 
by K143R (n = 21, 9.2%), and G458S (n = 6, 2.6%), all implicated in fluconazole resistance. Moreover, 
Q250K and G307A were two newly suggestive mutations exclusively occurred in fluconazole 
resistant isolates. Among isolates harboring ERG11 Y132F, 43.5%, 17.3%, and 10.8% of isolates carried 
nonsynonymous mutations in UPC2, TAC1, and MRR1, which is inconsistent to what was previously 
reported from a South Korean study. The first isolate carrying Y132F mutation emerged in 2012 and 
isolates carrying this mutation persistently recovered from the blood samples onwards (2012-2019). 
Strikingly, the number of isolates harboring ERG11 Y132F, doubled and increased 5 fold between 
2009-2015 and 2009-2019, respectively (Figure 1). Future studies are ongoing to determine the 
corresponding genotype of each isolate using microsatellite typing and the antifungal susceptibility 
data for voriconazole, micafungin, and anidulafungin remain to be completed. 
Conclusion: We observed a significant and persistent isolation of emerging ERG11 Y132F 
fluconazole-resistant C. parapsilosis isolates, which is a worrisome complication in our hospital 
requiring implementation of typing and sequencing of target genes followed by establishing 
appropriate infection control strategies to confine further spread of such isolates. The widespread use 
of azoles in clinical settings, especially developing countries, highlights the importance of worldwide 
surveillance studies to evaluate the prevalence and spread of ERG11 Y132F isolates. Figure 1. 
Accumulation of ERG11 Y132F mutation in C. parapsilosis isolates over 10 years of study from the 
blood samples of patients admitted to Ege University Hospital, Izmir, Turkey. 
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Objectives: Candida auris involvement in candidemia and other deep-seated invasive infections is 
associated with very high mortality. The inability of several available commercial identification 
systems to quickly diagnose C. auris remains a challenge to early therapy. The data is limited 
especially in patients with hepatobiliary diseases, in whom the risk factors and mangement differs 
due to the risk of antifungal toxicity. We aimed to study the epidemiology, risk factors and 
therapeutic management of invasive infections caused by C. auris in patients with hepatobiliary diseases. 
Methods: Single-center, prospective study of patients with suspected invasive fungal infections 
between January2017-December 2018. the patients with hepatobiliary diseases were included inthe 
study based on vlinical diagnosis and radiological features. Demographics, comorbidities, and 
laboratory variables were recorded. The samples recieved in the microbiology laboratory as a part of 
clinical diagnostic protocols were processed accordingly. The positive yeast cultures were subjected 
to identification by Vitek 2(Biomerieux, India) with updated software using YST cards, and 
antifungal sensitivity confirmed by Broth microdilution in accordance with CLSI guidelines. The final 
outcome considered were mortality within one month after diagnosis or discharge of the patient with 
stable parameters. 
Results: Total of 109 isolates of C. auris from 55 patients, blood 14(12.8%), abdominal fluids 14(12.8%), 
urine 58(53.21%), respiratory 4(3.6%), liver abscess 2 (1.83%), pancreatic abscess 1(0.9%) and wound 
infections 3 (2.75%). Underlying disease was chronic liver disease 37 (68%), 10 (20%) post liver 
transplant patients, acute on chronic liver failure 4 (7%), acute liver failure 2 (3%), acute pancreatitis 
1 (1.8%) and pancreatic neuroendocrine tumor 1 (1.8%). 14 (25%) patients were discharged, mortality 
was 41( 74.04%). Risk factors were MELD 40 (p0.04), Child C (p 0.05) and CTP score above 12. Prior 
use of steroids (p 0.02), neutropenia (p 0.03), prolonged hospital stay (0.029), use of broad spectrum 
antibiotics more than 7 days (p 0.05) were the risk factors significantly associated with development 
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of Candida auris infections and higher mortality. Co-morbidities, acute renal failure, diabetes, hepatitis 
infection were not significantly associated with mortality. The antifungal resistance: fluconazole 
68.42%, voriconazole 14.03%, flucytosine 59.64%, amphotericin B 28 % with no resistance to 
caspofungin and micafungin. 
Conclusion: C.auris infections are associated with misidentification, intrahospital transmission, poor 
treatment outcomes and higher mortalities. Prompt detection, earlier initiation of therapy and 
effective surveillance can curtail C. auris in hospitals. Our study depicts the spectrum of invasive 
infections caused by C. auris, its prevalence, risk factors and therapeutic options. The presence of risk 
factors like steroid use, neutropenia, broad spectrum antibiotic use and hospital stay of more than 7 
days should prompt towards escalating diagnostic measures for rapid identification of C.auris for 
early initiation of therapy. Active screening of patients with risk factors can also reduce mortality. 
The study results also help to guide empiric therapy with echinocandins as azoles and amphotericin 
B show high resistance in these isolates. This study will guide prophylactic and therapeutic options 
in hepatobiliary disease patients with underlying risk factors to reduce mortality. 
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Objectives: Scedosporium are usually soil saprophytes. Among the ten species recognized within the 
genus, three have been regularly reported as causing human infections, particularly in patients with 
cystic fibrosis (CF): Scedosporium apiospermum, Scedosporium aurantiacum and Scedosporium boydii. 
Because of their low sensitivity to almost all available antifungal drugs, a better understanding of the 
pathogenic mechanisms of these fungi is required in order to identify new therapeutic targets. 
Likewise, identification of the origin of the contamination of patients may be helpful to propose 
prophylactic measures. In this aim, environmental studies were conducted on the ecology of these 
opportunistic molds. Scedosporium species are abundant in human-made environments, in relation 
with specific traits of the fungi: ability to survive at low oxygen pressure and to degrade 
hydrocarbons. Recent studies have demonstrated the correlation between the lignocellulolytic 
properties of filamentous fungi and their ability to degrade environmental organic pollutants such 
as aromatic hydrocarbons. Among the lignocellulosic compounds, the particular properties of lignin 
make it an interesting study molecule. In this context, we attempted to elucidate the mechanisms 
developed by Scedosporium species to degrade this polyphenolic molecule, with a special emphasis 
on the opening of aromatic rings. 
Methods: Culture in specific media and biochemical analyses were performed to characterize 
Scedosporium properties. Orthologue enzymes from the literature were used to screen Scedosporium 
genomic data by tBLASTn (Basic Local Alignment Search Tool) searches and real-time PCR 
experiments were then conducted to analyze the relative expression of these candidate genes. 
Results: The lignolytic properties of Scedosporium species were first confirmed by cultivation of the 
fungi on agar media containing the different components of lignocellulose as carbon source. 
According to literature, the early steps in the lignin degradation pathway involve peroxidases and 
oxidases. Biochemical analyses allowed us to detect these enzyme activities in the culture supernatant 
of these fungi grown in lignin-containing media. Fifteen ortologue genes were identified by tBLASTn 
searches, four encoding members of the peroxidase family and the others encoding oxidase. However 
real-time PCR experiments revealed that only four of these genes encoding peroxidases (2) and 
oxidases (2) were over-expressed in the presence of lignin. Based on an exhaustive bibliography, at 
least three different pathways, i.e the β-ketoadipate, the oxoadipate and the gentisate pathways, were 
identified as potential routes for the degradation of molecules resulting from the early oxidation steps 
and the opening of the aromatic rings. In all Scedosporium species, enzymes involved in the gentisate 
pathway are encoded by genes organized into a six membered gene cluster as revealed by 
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bioinformatic analyses, and real-time PCR experiments demonstrated the over-expression of all these 
genes in culture media containing dihydroxybenzoate. 
Conclusion: Results obtained in this study confirm that Scedosporium species exhibit the enzymatic 
arsenal to degrade natural complex molecules and are capable to open aromatic rings. This may 
explain their presence in polluted environments, but one may also consider these enzymes as 
virulence factors since it has been suggested a link between the ability to use aromatic compounds 
and the propensity of these fungi to cause cerebral infections in receptive hosts. 
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Fusarium keratitis with poor prognosis: a report of four cases. 
H. Chouaieb1, A. Yaacoub1, W. Mili2, S. Ismail1, M. Ghorbel2, A. Fathallah1 
1Parasitology Mycologie Laboratory, Farhat Hached university hospital, Sousse, Tunisia, 
2Ophthalmology Department, Farhat Hached University Hospital, Sousse, Tunisia 
Case Report:  
Introduction and objective Keratitis caused by Fusarium species, a sight-threatening disease, is 
difficult to treat because Fusarium spp are highly resistant to most antifungals. Our objective was to 
describe four cases of Fusarium keratitis with poor prognosis.  
Methods Direct microscopic examination of corneal scrapings and culture on Sabouraud-
chloramphenicol medium were performed. The identification of fungi was based on macroscopic and 
microscopic characteristics of culture.  
Results All patients were male and the median age was 53, 5 years (range: 38-70). The predisposing 
factors were corneal trauma by a vegetative matter in three cases (75%), past history of herpetic 
keratitis in one case (25%) and steroid use in one case (25%). Direct microscopic examination was 
positive in 75% of cases and culture was positive in all cases. Culture grew Fusarium solani (50%) and 
Fusarium solani/Fusarium chlamydosporium (50%). It is important to mention that the two patients with 
Fusarium solani/Fusarium chlamydosporium keratitis were hospitalized in the same room; the first one 
was referred to ophthalmology department for Fusarium keratitis, when the second one developed 
the infection during his hospitalization. On the other hand, the antifungal susceptibility of the two 
strains were identical, so, it is quiet likely that the second patient was contaminated by the first one. 
Three patients underwent surgery and received antifungal therapy. One patient was treated by 
topical Amphotericin B associated to oral Itraconazole, the second received topical Amphotericin B, 
topical Betadine and oral Voriconazole and the third patient was treated by diluted Betadine, topical 
and oral Voriconazole. The fourth patient was lost to follow-up; he was discharged against medical 
advice. In most cases, the outcome was adverse.  
Conclusion Keratomycosis is a severe disease that can lead to severe visual loss and even loss of the 
eye. Prompt diagnosis and early treatment are needed to avoid complications. 
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Candida blankii as an emerging pathogen of cystic fibrosis patients 
Y. Borzova1, O. Voronina2, N. Ryzhova2, M. Kunda2, E. Aksenova2, O. Simonova3, D. Davletgareeva4, 
I. Suslova4, T. Bogomolova1, O. Skorbunova4, N. Klimko5, N. Vasilyeva4 
1Department of Medical Microbiology, North-Western State Medical University named after. I.I. 
Mechnikov, Sant-Petersburg, Russian Federation, 2N.F. Gamaleya National Research Center of 
Epidemiology and Microbiology, Ministry of Health of Russia,, Moscow, Russian Federation, 
3National Medical Research Center for Children's Health, Ministry of Health, Moscow, Russian 
Federation, 4Kashkin Research Institute of Medical Mycology, North-Western State Medical 
University named after. I.I. Mechnikov,, Sant-Petersburg, Russian Federation, 5Department of 
Clinical Mycology, Allergy and Immunology, North-Western State Medical University named after. 
I.I. Mechnikov, Sant-Petersburg, Russian Federation 
Objectives: Candida blankii is emerging pathogen for children, and can be important for patients with 
cystic fibrosis (CF). Publications about C. blankii in CF patients are limited. 
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Methods: Tracheal aspirate and sputum of 255 CF children 0-18 years old were analyzed by DNA 
extraction, amplification of ITS1-5.8SrDNA-ITS2 fragments of Fungi genomes, Sanger sequencing 
and identification of sequences using BLAST NCBI. Massively parallel sequencing of amplicons 
based on the MiSeq Illumina platform was used for some samples. Bioproject PRJNA545010 was 
published in GenBank. 
Results: C. blankii was revealed in the samples of two patients (P). P1 was 12 years old when C. blankii 
was detected in microbiome containing Pseudomonas aeruginosa, Mycobacteroides abscessus, but 
dominating bacteria were Streptococcus spp. The month later C. blankii was replaced by C. sake. In 
response to the therapy microbiome cleared of M. abscessus, but saved P. aeruginosa. The year later 
fungi and P. aeruginosa were not revealed in the low airway sample of P1. P2 has C. albicans and P. 
aeruginosa in the low airway sample at 7 years. Dominating bacteria were Streptococcus spp. At 8 years, 
when P2’s conditions worsened, C. blankii, P. aeruginosa and Capnocytophaga spp. as main bacteria 
were revealed. Active therapy eliminated P. aeruginosa, but did not influence on C. blankii. The year 
later C. blankii accompanied Staphylococcus aureus and P. aeruginosa in P2 microbiome. 
Conclusion: Repeated isolation of C. blankii from low airway samples of CF patient suggests the 
possibility of respiratory tract colonization by C. blankii. 
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The mortality attributable in Candidemia to C. auris is higher than other Candida species: Myth 
or or reality? 
C. Alvarez Moreno1, S.E. Morales-López2, G.J. Rodriguez3, J.Y. Rodriguez3, E. Robert4, C. Picot5, C.M. 
Parra-Giraldo6, P. Le Pape7 
1Universidad Nacional De Colombia, Bogotá, Clínica Universitaria Colombia, Colsanitas, Colombia, 
bogota, Colombia, 2Universidad Popular del Cesar, Valledupar, Colombia, valledupar, Colombia, 
3Cesar, Cimce, Cl. c #d - , Valledupar, Cesar, Colombia, 4Ea1155 Iicimed, Nantes University Hospital, 
NANTES, France, 5Pontificia Département de Parasitologie-Mycologie, Université de Nantes, Nantes 
Atlantique Universités, EA1155-IICiMed, Faculté de Pharmacie, Nantes, France, Dantes, France, 
6Unidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas Departamento de 
Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C, Colombia, 
Bogota, Colombia, 7Ea1155 Parasitology And Mycology Department, Nantes University, Nantes, 
France 
Objectives: Candida auris has emerged as a major threat in the healthcare setting, having caused 
invasive infections outbreaks around the world. Besides, it has been proved difficult to treat due to 
its multidrug-resistant nature and mortality rates have varied significantly among 30-60% in 
candidemia(1-2). However, the overall attributable mortality rate related to candidemia is unclear, 
nor is there any difference with other candida species (Candida non-auris). We investigated 
epidemiological, clinical and laboratory features of patients with candidemia to evaluate the 
mortality by C. auris or C. non-auris. 
Methods: A case-control study was conducted between 2013 and 2017 in 12 hospitals of Valledupar, 
Colombia comparing 22 cases of C. auriscandidemia with 52 of C. non-auris. All isolates of candidemia 
were recovered to confirm identification by automated matrix-assisted laser desorption/ionization 
time of flight (MALDI-TOF MS) (Bruker Daltonik, Bremen, Germany) and susceptibility to widely 
used antifungals was determined with Sensititre Yeast One®  AST plates (Thermo Fisher Scientific). 
Appropriate antifungal therapy was defined according to the antimicrobial susceptibility tests, for 
the case of C. non-auris the CLSI M27-A3 breakpoints were used, in the case of AmB, resistant isolates 
were defined as isolates with MIC> 1 μg / mL. For C. auris, breakpoints recommended by the CDC 
were used. The risk factors, clinical and microbiological characteristics and outcomes of patients with 
C. auris and C. non-auris candidemia (CAC) were compared. Odds ratio and corresponding 95% 
confidence intervals were calculated using EPI Info 7™. 
Results: Seventy four patients of candidemia were enrolled. Total number of 22 cases (29.7%) and 52 
controls (C. albicans, 21.6%; C. parasilopsis, 21.6%; C. tropicalis, 21.6%; C. glabrata, 1.4% ) were included 
and analyzed in this study. The comparison of the main clinical and epidemiological variables is 
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summarized in Table 1. Previous fluconazole exposure was significantly higher in C. auris 
candidemia patients (OR 3.3: 1.15-9,5). In vitro antifungal susceptibility of Candida species isolates is 
presented in Table 2. Most C. auris isolates were resistant to fluconazole (86.3%) and amphotericin B 
(59%) while C. non-auris isolates were in general susceptible (fluconazole resistant, 1.9%; 
Amphotericine B resistant, 3.8%). No isolates resistant to echinocandins were detected. The average 
time to start antifungal therapy was 3.6 days. Sixty three (85.1%) patients received adequate 
antifungal therapy, without significant differences between the two groups (C. auris Vs C. non-auris; 
86.4%vs 84.6%, respectively). The crude mortality at 30 and 90 days of candidemia was up to 37.8% 
and 40.5%, respectively. However, there was no difference in mortality both at 30 and 90 days, 
between the group with candidemia by C. auris and by C. non-auris, 31.8% vs 42.3% (OR 0.6; 95% IC 
0.24-1.97) and 36.4% and 42.3% 0,77 (0,27-2,1). 
Conclusion: Mortality due to candidemia is similar between C. auris and C. non-auris in this study. 
Appropriate antifungal therapy in both groups could contribute to finding no differences in 
outcomes. A high resistance to Anfo B was evidenced as previously described in Colombia(3). 
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1Kashkin Research Institute Of Medical Mycology, North-Western State Medical University named 
after I.I.Mechnikov, St. Petersburg, Russian Federation, 2Pavlov First Saint Petersburg State Medical 
University, Saint Petersburg, Russian Federation, 3Kaschkin Research Institute Of Medical Mycology, 
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian 
Federation, 4City Hospital No. 40, Saint Petersburg, Russian Federation, 5Kashkin Research Institute 
Of Medical Mycology, North-Western State Medical University named after I.I. Mechnikov, Saint 
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Objectives: The yeast Candida auris is an emergent nosocomial pathogen. In October, 2017, the first 
case of candidaemia due to C. auris in Russia has been diagnosed. A large series of isolates was 
published from Moscow. However, the source of the pathogen and its spreading to other Russian 
cities remained obscure. Our objective was to provide genetic characteristic and describe antifungal 
drug susceptibility profiles of C. auris clinical isolates from Russia. 
Methods: For the study, a total of six C. auris strains were available. Four originated from Moscow 
and two originated from St. Petersburg. We identified isolates by ribosomal ITS region sequencing. 
Whole genome sequence of one isolate was obtained by Illumina MiSeq technology. Antifungal 
susceptibility testing was performed using colorimetric Sensititre YeastOne YO10 broth dilution 
panels. 
Results: For the first Russian C. auris isolate from Moscow, we obtained whole genome sequence. It 
clustered within Indian/Pakistani clade with isolates from Indian subcontinent. The earliest C. auris 
isolate from outside Moscow was obtained in St. Petersburg in March, 2019. All six studied isolates, 
including two strains from St. Petersburg, harbored exactly the same ITS region genotype 
(MK829041). Also, antifungal drug susceptibility profiles were highly similar. All isolates were 
resistant to fluconazole, but susceptible to echinocandins and amphotericin B. 
Conclusion: Currenty, C. auris is being detected in two Russian cities. The spreading clone has 
Indian/Pakistani origin, probably independent from known outbreaks outside Indian subcontinent. 
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Candida auris in China 
G. Liang 
Department Of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Science, 
Nanjing, China 
Objectives: Since 2009, Candida auris has been spreading globally, which is a serious threat to human 
health and has attracted the international attention. We analyzed the epidemiological trend and 
pathogenic characteristics of Candida auris in China and try to discover the problem behind and put 
forward the reasonable strategies to provide useful information for prevention and treatment of the 
diseases. 
Methods: We reviewed all Candida auris cases reported from China by searching Pubmed, EMbase, 
Wanfang and CNKI; also deeply speculated the hidden clinical problems in China. 
Results: First, there are more than 19 cases has been recorded in China. Second, immunosuppressor 
and Long-term use of broad-spectrum antibiotics may be the high risk. Thirdly, fifteen cases was 
reidentified as Candida auris by PCR and sequencing the ITS and D1/D2 regions which was 
misidentified as C. haemulonii by Vitek. Fourth, both Azole-resistant and non-Azole-resistant 
Candida auris was found.Fiveth, the infection by Candida auris can not be effective diagnosed and 
identified timely 3 years ago in the most third-grade class-A hospital in China, but now it is being 
improved because of popularized MALDI-TOF equipment. 
Conclusion: The situation of Candida auris infection may be much severer than expected because of 
the misidentification especially in high-risk groups and more attention has been paid and better 
medical conditions has been strengthened for the Challenges ahead. 
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Candida auris Candidemia in a Tertiary Care Centre in North India: Rapid Identification from 
Direct Blood Culture Positive Samples by MALDI-TOF MS and Analysis of Risk Factors 
R.S.K. Marak1, S. Yadav2, A.K. Dixit2 
1Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 
2Microbiology, sanjay Gandhi Postgraduate Institute of Medical Sceinces, Lucknow, India 
Objectives: To identify the Candida auris from direct positive blood cultures by MALDI-TOF MS and 
analyse the risk factors associated with this multidrug resistant yeast- Candida auris 
Methods: A prospective study was conducted from February 2017 to January 2018 by taking 8 ml of 
positive blood cultures. After multiple washings and treating with triton X, it was directly subjected 
to the MALDI-TOF MS assay. The clinical data of candidemia cases due to C. auris were determined 
for significant associated risk factors with C. auris infection. 
Results: Of the 122 candidemia cases reported during the study, 23 (18.85%) were due to C. auris; 
being the 3rd most common species after C. tropicalis and C. parapsilosis. The age ranged from 4-day 
old neonate to 80 years old and there was female preponderance (n = 13). MALDI-TOF MS was able 
to rapidly identify all Candida auris species on the same day when the blood culture was flagged 
positive thereby shortening the time for species identification by MALDI-TOF MS from culture. The 
underlying risk factors significantly associated with C. auris candidemia were diabetes mellitus, 
underlying respiratory illness, gastrointestinal surgery, prior antifungal exposure. Mortality was 
seen in 60.8%. All isolates were resistant to fluconazole (MIC ≥ 64μ/ml). 
Conclusion: Candida auris is a recently described agent of fungemia that poses a serious global health 
threat. C. auris infection has been observed across India and notable for its antifungal resistance; often 
multidrug-resistant. C. auris is difficult to identify; polymerase chain reaction, DNA sequencing and 
MALDI-TOF MS can correctly identify it. C. auris known to cause outbreaks in healthcare settings 
and therefore, it is important to quickly identify C. auris in a hospitalized patient and the healthcare 
facilities can take special precautions to prevent its spread. 
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Epidemiology of Cryptococcal antigenemia among HIV infected patients in southwestern, Nigeria 
2018 
O.B. Odegbemi1, H.O. Dada-Adegbola2, I. Adeoye1, S.A. Fayemiwo3 
1Epidemiology And Medical Statistics, University of Ibadan, Ibadan, Nigeria, 2Medical Microbiology 
And Parasitology, University of Ibadan, Ibadan, Nigeria, 3Medical Mycology Unit, Division Of 
Infection, Immunity And Respiratory Medicine, School Of Biological Sciences, University of 
Manchester, Manchester, United Kingdom 
Objectives: Cryptococcal antigenemia occurs in Nigeria, but the magnitude of this disease remains 
unclear. This study was carried out i. To determine the prevalence of Cryptococcal antigen (CrAg) 
among HIV-seropositive subjects ii. To determine the prevalence of CrAg among HIV-seronegative 
subjects and iii. To assess the relationship between CD4 count and CrAg in HIV-seropositive subjects 
attending Adeoyo Maternity Teaching Hospital, Yemetu, Ibadan 
Methods: It was hospital based case-control study using simple random sampling. Semi-structured 
interviewer administered questionnaire was used to collect data from subjects and retrospective 
review of CD4 count records in HIV infected subjects. Five millilitres venous blood was collected 
from each participant. Serum CrAg testing was done using CrAg Lateral Flow Assay. Data was 
analyzed using descriptive statistics and bivariate analysis at 5% confidence level. 
Results: One hundred and fourteen HIV-seropositive individuals (cases) and 228 HIV-seropositive 
individuals (controls) were recruited. Mean age of cases was 41.2 ± 10.0 years and 85 (74.6%) were 
females while mean age of controls was 38.9 ± 13.7 years 156 (68.4%) were females. The prevalence of 
CrAg among cases was 11.4% and 7.0% among controls. Cases were about two times more likely to 
test positive for CrAg. However, the association was not statistically significant (OR: 1.71, 95%CI: 
0.79 - 3.68). Individuals with CD4 counts of ≤100 cells/μl were 20 times more likely to have positive 
serum cryptococcal antigen than individuals with CD4 counts >100 cells/µ l (OR: 20.3, 95%CI: 5.23-
78.9). 
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Conclusion: This study demonstrated significant prevalence of Cryptococcal antigenemia among the 
study population; however, prevalence was higher among cases. Screening for CrAg should therefore 
be part of routine tests amongst all confirmed HIV-seropositive subjects, since asymptomatic 
cryptococcal antigenemia predicts impending cryptococcal infection with probable mortality. 
 
P221 
High prevalence of Fusarium proliferatum isolates from onychomycosis and antifungal 
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Objectives: Onychomycosis refers to any fungal infection of the nail and is usually caused by 
dermatophytes; however, non-dermatophyte molds (NDM) and yeasts are increasingly recognized 
as the pathogens accounting for nail disease. Regarding this, the present study was conducted to 
describe the molecular epidemiology of Fusarium onychomycosis in the North of Iran. 
Methods: To this end, 257 nail samples collected from the Iranian patients clinically suspected of 
onychomycosis were subjected to direct microscopy, calcofluor white staining, and fungal culture. 
The characteristics of Fusarium isolates were further identified at a species level by determining multi-
locus sequences for internal transcribed spacer and translation elongation factor 1 alpha 
Results: According to the results, Fusarium species were isolated from 27 patients with 
onychomycosis. Based on previous partial genes analysis, the recognized species in our study were 
among the members of F. fujikuroi species complex (n = 14), F. solani species complex (n = 12), and 
Fusarium incarnatum-equiseti species complex (n = 1). In the present study, F. proliferatum was the 
dominant Fusarium species isolated from the samples. With regard to the increased prevalence of 
Fusarium onychomycosis and the intrinsic resistance of these agents to a broad range of antifungals, 
it is necessary to correctly identify Fusarium species. Our results were indicative of a change in the 
epidemiology of Fusarium species isolated from onychomycosis. The minimum inhibitory 
concentration (MIC) of luliconazole and lanoconazole ranged within 0.001 to - 1 μg/mL and their 
geometric mean MICs were 0.0103 and 0.0343 μg/mL against Fusarium species, respectively. 
Conclusion: The increased prevalence of Fusarium onychomycosis and the intrinsic resistance of 
these infectious agents to a broad range of antifungals have highlighted the importance of the 
accurate identification of Fusarium species. According to the results of the present study, it seems that 
the epidemiology of Fusarium species isolated from onychomycosis has been changed. In addition 
we conclude that luliconazole and lanoconazole demonstrate potent activity against Fusarium species 
isolated from onychomycosis. These compounds are accordingly promising for the treatment of 
superficial fusariosis such as onychomycosis. 
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Fungal disease burden: an underestimated health challenge in Cote d’Ivoire 
D. Koffi1, B. Ira1, A.O. Toure1, R. Jambou1, D. Denning2 
1Parasitology And Mycology, ABIDJAN, Côte d'Ivoire, 2University of Manchester, Manchester, 
United Kingdom 
Objectives: Due to limited access to more powerful diagnostic tools, there are few data on the burden 
of fungal infections in Cote d’Ivoire, despite a high HIV and TB burden and many cutaneous diseases. 
Here we estimate the burden of serious fungal infections in this sub-Saharan country. 
Methods: National demographics were used to perform a PubMed search and retrieve all published 
articles on fungal infections in Cote d’ivoire and countries bordering West Africa. When no data 
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existed, risk populations were used to estimate frequencies of fungal infections, using previously 
described methodology by LIFE (www.LIFE-Worldwide.org). 
Results: The population of Cote d’ivoire is around 24 millions; 37% are children, and 9% are >65 
years. Tinea capitis in children is common, measured at 13,9% in the last epidemiological study 
(2013). Considering the prevalence of HIV infection (2.7% of the population, a total of ~500,000) and 
a hospital incidence of 6% of cryptococcosis, it is estimated that 3726 patients per year develop 
cryptococcosis. For pneumocystosis, it is suggested that 6023 new cases occur each year with the 
pevalence of 14,1% in paediatric HIV infection. An estimated 1567 new cases of chronic pulmonary 
aspergillosis occur after pulmonary tuberculosis (a 5 year prevalence of 4938 cases (20.3/100,000). 
Allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitisation (SAFS) 
were estimated in 104/100,000 and 151/100,000 respectively, in 1,100,000 adult asthmatics. 
Vulvovaginal candidiasis (VVC) is common and recurrent VVC affects ~6% of women in their fertile 
years - 407,000 women. An unknown number develop candidaemia and invasive aspergillosis. There 
are no incidence data on fungal keratitis, histoplasmosis and chromoblastomycosis, although some 
cases of mycetoma and histoplasmosis have been reported. 
Conclusion: The present study indicates that around to 6.8% (1.6 million) of the population is affected 
by a serious fungal infection, predominently tinea capitis in children and rVVC in women. These data 
should be used to inform epidemiological studies, diagnostic needs and therapeutic strategies in Cote 
d’Ivoire. 
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Frequency and molecular epidemiology of Aspergillus isolated from patients with suspicion of 
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Objectives: The aim of this study was to determine the frequency of Aspergillus detected in 
respiratory samples from a cohort of patients with suspicion of fungal infection of the respiratory 
tract as well as to determine the susceptibility to azoles of the isolates from the Fumigati section. 
Methods: A retrospective study was performed involving samples obtained from 16 hospitals 
covering different districts of continental Portugal and Azores islands. One hundred and eighty-
seven respiratory samples (101 bronchoalveolar lavage fluids, 52 bronchial lavages, 27 bronchial 
secretions, 6 expectorations and 1 bronchial aspirate) were collected between November 2011 and 
December 2017 from a cohort of 146 patients with suspicion of respiratory fungal infection (ages 
ranging from 20 to 87 years old). Demographic and clinical data were recorded. Detection of 
Aspergillus was done by culture, immunoenzimatic assay and/or molecular techniques. Aspergillus 
molecular identification to species level was performed by sequencing of the calmodulin and β-
tubulin genes. To detect possible resistance to azoles, isolates belonging to section Fumigati were 
inoculated into Sabouraud dextrose agar media supplemented with 1 µg/ml or 4 µg/ml of 
voriconazole, 4 µg/ml of itraconazole and 0.5 µg/ml of posaconazole and their growth was observed 
and recorded after 7 days of incubation at 27ºC. Doubtful results were confirmed when possible by 
E-test and by real-time multiplex PCR for the detection of mutations in the Cyp51A gene. 
Results: Fifty-seven (39.0%) of the studied patients were positive for Aspergillus. From the cases with 
a positive culture (n = 58) the species were identified by sequencing and belonged to six different 
sections. The most frequently isolated was the section Nigri (42.1%) followed by the Fumigati (33.3%) 
and Flavi sections (8.6%). Regarding the species, the most frequent was A. niger sensu stricto (33.9%) 
followed by A. fumigatus sensu stricto (32.1%). Nine cryptic species were also identified which 
frequency was 21.4%. In order to study the frequency of azole resistance in Fumigati isolates collected 
from the samples of this cohort as well from other biological products, 52 isolates - Aspergillus 
fumigatus sensu stricto (n = 45), A. lentulus (n = 4), A. udagawae (n = 2) and A. pseudofelis (n = 1) – were 
tested. The tested A. fumigatus sensu stricto isolates did not show resistance to azoles. An A. udagawae 
J. Fungi 2019, 5, 95 263 of 464 
 
strain revealed low susceptibility to voriconazole (MIC was not determined due to loss of strain 
viability). An A. pseudofelis strain also showed decreased susceptibility to voriconazole (MIC = 1 
μg/ml) as well as to and itraconazole (MIC = 2 μg/ml). 
Conclusion: In this study, the genus Aspergillus was frequently isolated in the respiratory samples 
tested and a high number of cryptic species was detected. Although resistance to azoles was not a 
problem identified in the tested isolates, determination of the in vitro susceptibility profile and 
molecular identification of the Aspergillus species is essential to improve the diagnosis and 
management of aspergillosis since several cryptic species have intrinsic resistance to antifungal 
drugs. 
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Epidemiological analysis of a large Tinea epidemic in schools of a city in the northern suburbs of 
Paris, France 
S. Brun, Y. Vingataramin, M. Akhoundi, M. Lintanf, C. Bruel, A. Izri 
Parasitology-mycology, Avicenne Hospital, Bobigny, France 
Objectives: The main goals of this investigation were i) to identify the causative agents of a large 
Tinea epidemic in several schools of a city in the northern suburbs of Paris, France, and ii) to 
determine the epidemiological factors which played an important role in dissemination of this 
dermatophyte infection. 
Methods: Following a report to the Parasitology-Mycology Department of Avicenne hospital 
(Bobigny, France) regarding a possible Tinea epidemic in two schools of Clichy-sous-Bois city 
(northern-suburbs of Paris), all the children of these schools were screened for dermatophytosis by 
clinical and mycological examinations. Some children from other schools of this city and members of 
their families came to the same laboratory for dermatophytosis screening. Suspected lesions of hair 
or skin were sampled by scraping and swabbing for mycological diagnosis and demographic data 
were recorded in parallel. A dermatophytosis case was determined by positive direct microscopic 
examination (presence of fungal filaments or spores in hair or scales) and/or positive dermatophyte 
culture. A map of the cases repartition was realised. Next, in order to evaluate the intra- and 
interspecific genotypic relationships among T. tonsurans isolates, they were subjected to sequencing 
of two fragments of the alkalin protease 1 (ALP1) gene. The obtained sequences were aligned using 
the Basic Local Alignment Search Tool (BLAST) and compared to the sequences deposited in 
GenBank. 
Results: During 15 months, 122 individuals (coming from 12 schools of the city and members of their 
families) were sampled and 139 samples were analysed for mycological direct microscopic 
examinations and mycological cultures. Ninety-three (70%) samples (79 scalp and 14 skin samples) 
were positive for dermatophyte culture or direct examination in 82 (67%) individuals. Trichophyton 
tonsurans was isolated in 60 samples (87%), followed by Microsporum audouinii (4 isolates), 
Trichophyton rubrum (4) , Trichophyton soudanense (1) and Microsporum canis (1). The infected 
individuals had an age ranging from 3 months to 53 years with an average of 8 years old. All of these 
infected individuals were living in houses that, together with their schools, are located in an area of 
less than 1 km2. Most of them were originated or had parents coming from sub-Saharan Africa, 
followed by Haiti and North Africa. According to the sequence analysis of ALP1 gene, the T. tonsurans 
isolates all shared the same nucleotide sequences, but were different from the only sequence available 
in GenBank coming from USA. 
Conclusion: This study presents likely the largest Tinea epidemic recorded not only in France but 
also in Europe, with a large majority of infections caused by T. tonsurans. The genotypic analysis of 
the T. tonsurans isolates revealed the circulation of a unique strain in this city of the northern suburbs 
of Paris, distinct from the strain described in USA. The high population density together with the 
high poverty rate of this city are of the major factors, beside the high transmission rate of T. tonsurans, 
that have facilitated the transmission of the dermatophytes between the individuals in a same family 
and a same district, as well as in schools. 
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Presence of Malassezia furfur in the cutaneous microbiome of preterm infants in a Neonatal 
Intensive Care Unit 
R.T.F. Moreira1, D.P. Silva1, F.C.A. Maranhão2, I.F. Moreira3, F.I.R. Farias3, J. Alvarez4, S.D.A. 
Coutinho4 
1Nursery School, Federal University of Alagoas, Maceió, Brazil, 2Biological Sciences Institute, Federal 
University of Alagoas, Maceió, Brazil, 3Medicine Faculty, Federal University of Alagoas, Maceió, 
Brazil, 4Post-graduation Program In Environmental And Experimental Pathology, Paulista 
University, São Paulo, Brazil 
Objectives: In humans, the colonization of the skin by yeasts belonging to the genus Malassezia starts 
from the birth. They usually live in commensalism but may become pathogenic depending on 
predisposing factors and may cause superficial mycoses. Although in a lower percentage, M. 
pachydermatis and M. furfur are responsible for serious invasive infections in man. In outbreaks of 
fungemia reported in neonatal intensive care units (NICU), the neonates showed prematurity, low 
birth weight, multiple comorbidities and parenteral nutrition with lipid supplementation. The aim of 
this study was to investigate the occurrence of Malassezia spp. in the cutaneous microbiome of low 
and extremely low birth weight neonates hospitalized in a neonatal intensive care unit. 
Methods: Forty newborns, gestational age between 21 and 34 weeks, weight between 405 and 1,430 
grams, hospitalized in a NICU of a public hospital in the city of Maceió, Brazil, were evaluated. Using 
sterile swabs, samples from the oral and nasal cavities, axilla, inguinal and anal areas of the neonates 
were collected at the time of admission to the unit, which did not exceed 12 hours postpartum. The 
samples from the same areas were collected after 48 h, 96 h, and then twice a week until the discharge 
resulting from clinical improvement or death, making a total of 192 clinical samples. The samples 
were seeded on Dixon’s medium and microbial colonies were phenotypically characterized using 
standard biochemical tests. After extraction of DNA, the strains were submitted for 26S rDNA gene 
PCR amplification. Subsequently, the RFLP analysis using the restriction enzymes BtsCI and HhaI 
was performed on PCR products. The standard strain Malassezia furfur CBS-1878 was used as a 
positive control. 
Results: Eight preterm infants (20% - 8/40), weighing between 585 and 1,344 g, presented the 
colonization by Malassezia sp from 48 h of life. Some newborns showed colonization from the 1st to 
the 6th week, before they left the NICU. There was a higher frequency of Malassezia in the axillae and 
anal region, followed by the nasal cavity and inguinal area. The difficulty in culture maintenance was 
observed and some strains failed to survive after the first isolation, making a total of 12 characterized 
strains. The biochemical phenotypic behavior of the 12 strains was similar and consistent with M. 
furfur. These strains submitted to PCR showed bands between 500 and 600 bp and presented the same 
pattern of bands in the RFLP analysis indicating M. furfur. 
Conclusion: This study demonstrated the colonization by M. furfur in different sites of the cutaneous 
microbiome of preterm infants in NICU. Since the infections caused by these yeasts are less frequent, 
these agents are mostly neglected. However, our findings reveal the need for monitoring low and 
extremely low birth weight neonates, as this yeast may be pathogenic, as described in malasseziosis 
outbreaks in NICUs. It is worth to note that adequate isolation and cultivation techniques should be 
employed since most species of the genus Malassezia are lipid-dependent and do not grow in the 
media usually employed for fungal isolation. 
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Cryptococcosis in HIV-infected patients in Madagascar: high prevalence and mortality 
R.A. Rakotoarivelo1, M. Raberahona2, T. Rasamoelina3, A. Rabezanahary4, F.A. Rakotomalala3, T. 
Razafinambinintsoa2, T. Bénet5, P. Vanhems6, M.J.D.D. Randria2, L. Romanò7, M. Cogliati8, M. Cornet9, 
M.R. Andrianarivelo3 
1Service des Maladies Infectieuses, Hôpital Universitaire Tambohobe, Faculté de Médecine, 
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Universitaire Joseph Raseta Befelatanana, Antananarivo, Madagascar, 3Centre d’Infectiologie Charles 
Mérieux, Université Ankatso, Antananarivo, Madagascar, 4Service de Pneumologie, Hôpital Régional 
de Reference, Toamasina, Madagascar, 5Service d’Hygiène, Epidémiologie et Prévention, Hospices 
Civils de Lyon, Lyon, France, 6Laboratoire des Pathogènes Emergents, Fondation Mérieux, Centre 
International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS de Lyon, UCBL1, 
Lyon, France, 7Laboratorio di Micologia Medica, Dipartimento di Scienze Biomediche per la Salute, 
Universita degli Studi di Milano, Milano, Italy, Milano, Italy, 8Laboratorio di Micologia Medica, 
Dipartimento di Scienze Biomediche per la Salute, Universita degli Studi di Milano, Milano, Italy, 
9Université Grenoble Alpes, CNRS, CHU Grenoble Alpes, Grenoble INP, TIMC-IMAG, Grenoble, 
France, Grenoble, France 
Objectives: In Madagascar, the epidemiology of cryptococcosis is poorly documented. The main 
objective was to estimate its prevalence in HIV-infected patients and to describe the fungal isolates 
and the patient outcome 
Methods: An observational study was conducted in the hospitals of Antananarivo (central highlands) 
and Toamasina (eastern coast). Consecutive HIV-infected adults with CD4≤ 200/μl were enrolled 
between November 2014 and December 2016. The serum crytococcocal antigen (CrAg) was screened 
using a lateral flow immunoassay (IMMYCrAg ® ). In case of positive result and clinically suspected 
cryptococcal meningoencephalitis (CM), a lumbar puncture was performed to evaluate the presence 
of CrAg in the cerebrospinal fluid (CSF), as well as India ink staining and culture. The isolates were 
identified using MALDI-ToF and genotyped. Antifungal susceptibility was evaluated using the E-
test. A high-dose oral fluconazole (at least 1200/day) was given for 10-12 weeks followed by 200 
mg/day. Adjusted prevalence ratios (aPR) based on multivariate robust variance Poisson regression, 
and 90-days survival based on Kaplan-Meier method were used 
Results: Overall, 129 patients were included, median age was 37 years. At baseline, the median CD4 
count was 83 cells/µl, 62.8% had a CD4 count <100 cells/µ l and 38.1% were on ART. Overall, 17 
patients had a serum CrAg-positive (CrAg+) and 112 CrAg-negative (CrAg-). CrAg+ patients were 
more likely than CrAg- patients to present low CD4 cells count 38 Vs 86; p = 0.018). Among the 17 
CrAg+ in serum, 14 had a CSF CrAg+ of which 13 yielded Cryptococcus spp. in culture. After 
multivariate regression, adjusted on CD4 count, previous ART initiation (aPR = 0.4, 95% CI: 0.2-0.9) 
and presence of neck pain (aPR = 15.7, 95% CI: 3.4-72.1) were associated with CM. The prevalence of 
cryptococcal infection was 13.2% (95%CI 7.9–20.3) and that of CM was 10.9% (95%CI 6.1-17.5). The 
prevalence of cryptococcal infection in Toamasina (20%) was not different from the one in 
Antananarivo (11.1%) (p = 0.21). The mortality rates were 70.6% and 71.4% for cryptococcal infection 
and CM, respectively. Survival was significantly higher for CrAg- patients as compared with CrAg+ 
(p = 0.049, Log-rank test). All 17 clinical isolates obtained from CSF (13 at baseline and 4 during 
follow-up) were identified as Cn var. grubii. The 13 initial isolates were genotyped and belonged to 
the VNI type (3 isolates), the rarer but also globally distributed VNII type (4 isolates) and a hybrid 
intra-varietal type VNI/VNII (6 isolates). All three molecular types were found in Antananarivo 
whereas only VNI/VNII was found in Toamasina. Among the 13 Cn var. grubii strains, 2 acquired 
fluconazole resistance after 4 and 5 months of exposure, respectively. 
Conclusion: Prevalence of cryptococcal infections and CM in HIV-infected patients in Madagascar 
were 13.2% and 10.9% respectively. The point-of-care LFA CrAg test confirmed to be reliable and cost 
effective for the diagnosis. Challenges to facilitate access to more effective molecules to treat patients 
with CM include reducing administrative formalities linked to drug importation and increasing 
priorities to implement national control programs. 
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The Burden of Serious Fungal Infections in Tajikistan 
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Objectives: The aim of this work is to estimate the burden of serious fungal infections in Tajikistan. 
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Methods: Initially, we identified all published data on serious fungal infections in the country. We 
have used the model proposed by LIFE (Leading International Fungal Education) to estimate the 
burden of infections where no local data exist. 
Results: Tajikistan is the low-income (GDP Per Capita is 800 USD) country in Middle Asia with a 
population of 8.9 million people. 5% of the population lives on less than 1.9 USD a day and 54% live 
on less than 5.5 USD a day. There are 2,813,903 adult (15-50 yrs.) women in Tajikistan who comprise 
32% of the population. It was estimated that 168,834 Tajik women develop recurrent vulvovaginal 
candidiasis ( = > 4 episodes/year). The number of HIV positive patients is 15,000; 10,067 (67%) of them 
do not receive antiretroviral therapy. We estimate 1,253 patients with oesophageal candidiasis and 
4,530 patients with oral candidiasis annually, 27 cases of cryptococcal meningitis and PCP is 
approximated at 216 cases annually. According to our estimations there are 1,040 cases of chronic 
pulmonary aspergillosis (CPA) as a sequel of TB. Due to the fact, that CPA may occur as a 
consequence of multiple other pulmonary conditions, the total prevalence of 4,161 cases was 
estimated. We have estimated 6,008 cased of ABPA and 7,930 cases of SAFS; 196 annual deaths from 
asthma provides us with an estimation of 137 fungal asthma deaths annually. We have estimated 445 
cases of candidemia a year applying a low European rate. There are approximately 205 cases of 
invasive aspergillosis in immunocompromised patients annually and 1,388 cases in patients with 
COPD which gives us a total of 1,593 cases of invasive aspergillosis annually.  
 
Conclusion: According to our estimations, there are 196,778 (2.21% of the population) people 
suffering from serious fungal infections in Tajikistan. Hence, improving diagnostics is the first step 
of understanding a scale of the fungal burden and the foundation of addressing the problem of 
serious fungal infections. 
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Cases of Mycetoma reported from a Histopathology laboratory of Pakistan: Two years’ Experience 
M. Zeeshan1, S. Fatima1, M.O. Arif2, J. Farooqi1,3, A. Arsalan1, K. Jabeen1,2,4, A. Zafar3 
1Pathology And Laboratory Medicine, Aga Khan University, Karachi, Pakistan, 2Dow University of 
Health Science, Karachi, Pakistan, 3Pathology And Laboratory Medicine, Aga Khan University, 
Karachi-KHI, Pakistan, 4Pathology And Laboratory Medicine, Aga Khan University, Karachi, 
Pakistan, Pakistan 
Objectives: Mycetoma is a chronic granulomatous infection that is found worldwide and is endemic 
in tropical and subtropical regions. Occurrence of mycetoma varies in different regions as per 
environmental temperature and rainfall in that particular area. The exact prevalence of this disease 
is largely unknown, though estimates are available for various countries. (van de Sande. 2013). 
Pakistan is a tropical country with diverse climatic conditions. Our green and lush north-eastern 
border consists of agricultural land is shared with Indian Punjab . South eastern part is close to Indian 
desert of Rajasthan, and the western border with Iran and Afghanistan is arid. There are multiple 
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reports published from various regions of India as well as Iran. There is dearth of information 
regarding the frequency of mycetoma, both eumycetoma and actinomycetoma, from Pakistan. The 
objective of this study was to find out the number of cases reported during year 2017 and 2018 from 
histopathology department of Aga Khan University Hospital laboratory, a tertiary care hospital 
laboratory also providing diagnostic services to outside patients 
Methods: Retrospective data of subcutaneous surgical tissue biopsies with positive findings of 
mycetoma were retrieved from hospital laboratory database from the years 2017-2018. Site of lesion, 
age, gender, type of mycetoma and geographical location of patients were analyzed The data was 
entered and descriptive epidemiologic assessment was carried out using MS excel 2013 
Results: Total 30 cases of mycetoma reported in these two years. Eumycetoma was reported in the 
majority of the cases 25/30 (83%) while actinomycetoma in 4/30 (13%). In one case, both entities of 
mycetoma were detected in a single lesion (3%). Our cohort was all adults with age range of 25-60 
years. Eumycetoma cases were mostly observed in male 18/25 (72%) whereas Actinomycetoma cases 
were mostly seen in females 3/4 (75%). In eumycetoma anatomical site involvement were 
predominantly lower extremities 22/25 (88%) followed by hand in rest of the other cases. All the 
reported cases of actinomycetoma had foot involvement only. In majority of cases tissue specimen 
culture was not performed 23/30 (77%). Out of 7 specimens only 2 were culture positive for fungal 
etiological agents (29%) 
Conclusion: In view of our data, we can definitely describe the presence of mycetoma in Pakistan. 
However, there is a desperate need of national registry to report cases and creating strong liaison 
between dermatologists, radiologist, surgeons and clinical microbiology laboratory and 
Histopathologist, so that burden of the disease may be estimated. Only then can we stress upon our 
national health authorities to prioritize this neglected disease by improving patients’ access to 
specialized facilities for better management. 
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Radiological and microbiological profile of patients with allergic bronchopulmonary aspergillosis 
presented in outpatient pulmonary clinics of Karachi-Pakistan 
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Objectives: There is limited data available on microbiology and radiographic features in patients 
with allergic bronchopulmonary aspergillosis (ABPA) from Pakistan. The aim of the study is to 
determine the radiological and microbiological profile of patients visited outpatient pulmonary clinic 
of a tertiary care hospital of Karachi Pakistan 
Methods: A retrospective study was conducted at pulmonary outpatient clinics, Aga Khan 
University Hospital, Karachi, Pakistan from January 2017 to December 2018. Patient with ABPA was 
enrolled using ISHAM criteria, data was collected on microbiology and radiology features. 
Results: A total 7759 asthmatic patients presented at outpatient pulmonology clinics, 245 were 
labelled as ABPA, 167 patients fulfilled the inclusion criteria and 91(54.5%) were female (mean age 
41.9 ± 13.0 years). High resolution CT scan (HRCT) chest was done in 126, out of these 104(82.5%) 
patients had bronchiectasis. Central bronchiectasis was noted in 98(94.2%), Mucus plugging in 
71(56.3%) and hyperinflation seen in 30(23.4%) patients. Microbiological testing was available in 
103(61.7%). The commonest bacterial pathogen isolated was Pseudomonas aeruginosa 32(31.1%) 
followed by Hemophilus influenzae 16(15.5%) and Morexella catarrahlis 7(9.7%). While among fungal 
cultures commonest isolated fungas was Aspergillus fumigatus 17(23.6%) followed by Aspergillus flavus 
16(22.2%) and Aspergillus Niger 11(15.3%). Co infection (bacterial and fungi) isolated in 18(17.45%) 
patients. 
Conclusion: Extensive bronchiectasis was noted in our cohort of patients with ABPA that leads to 
frequent bacterial exacerbation. Pseudomonas aeruginosa was found to be common among bacterial 
pathogens. Early diagnosis can prevent lung damage. 
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Epidemiology and outcomes of patients with invasive mould infections: a retrospective 
observational study at Karolinska University Hospital, 2010 - 2014 
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1Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden, 2Laboratory Medicine, 
Karolinska Insitutet, Stockholm, Sweden, 3Pathology And Cytology, Karolinska University Hospital, 
Stockholm, Sweden 
Objectives: To investigate the epidemiology and outcomes of invasive mould infections (IMI) during 
2010-2014, compared to 2005-2009 (1). 
Methods: Patients with proven or probable IMI were included. Data regarding patient baseline 
characteristics, underlying diseases, types of transplant, infecting mould species, sites of infection, 
antifungal therapies, etc were extracted from patient journals. Outcome was 90-days and 1-year 
survival post diagnosis. 
Results: A total of 127 (vs 100) patients were included, an increase by 27% compared to the previous 
period. The rise in incidence occurred mainly during 2010-2011 (Fig 1). The majority, 54% (vs 66%) 
were in the age group 18-65 and 30% (vs 24%) were over 65 years old. Males predominated with 57% 
(vs 60%). Most isolates were Aspergillus spp, n = 59 (vs 75) followed by Mucorales spp, n = 14 (vs 9) 
and Fusarium spp, n = 8 (vs 3). In n = 7 cases (vs 10), more than one mould was isolated. An additional 
n = 45 had a positive galactomannan antigen test. Lungs were the most often affected organ, 92% (vs 
88%) and haematological malignancies (HM) were the most common underlying diseases, 71% (vs 
70%). In total, 431 (vs 354) allogeneic Haematopoietic Stem Cell Transplants (HSCT) were performed 
during the study period, of which 6.5% (vs 7.6%) developed IMIs. Following diagnosis, 75% (vs 87%) 
received antifungal therapy, usually voriconazole, 53% and liposomal amphotericin B, 38%. 
Breakthrough infections occurred in 33% of the cases in spite of prophylaxis, mainly posaconazole, 
59% and caspofungin, 24%. The 90-days overall survival remained basically unchanged, 48% (vs 
49%), but with significant yearly variations (Fig 2). The allogeneic HSCT and HM cohorts had highest 
overall survival rates, 68% respectively 55% (vs 37% respectively 43%). The 1-year overall survival 
declined to 35% (vs 46%) with lowest rate 13% in 2012. 
  
Conclusion: There were no significant changes in patient characteristics, mould epidemiology or 
underlying diseases. Survival rates improved for the HM and allogeneic HSCT cohorts. The yearly 
variations in mortality rates coincide with construction work around the hospital, notably with 
periods of intense blasting. During these periods there was also an increase in the incidence of IMIs. 
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Objectives: Given the differences between local epidemiologies, we have to know our fungal 
epidemiology, in order to adapt our antifungal strategies. The purpose of this study is: 1. to identify 
the epidemiology and antifungal susceptibilities of candidemia over 5 years; 2. to evaluate the anti-
fungal treatment and to see the survival in the third month (M3) of the patients after the diagnosis of 
fungemia. 
Methods: This study was retrospective, conducted from January 2014 to December 2018. All patients 
who had at least one positive fungal blood culture were included. A single blood culture per patient 
was taken into account with a study of the MICs (Molecules tested: amphotericin B, caspofungin, 
voriconazole and fluconazole). 
Results: In total, 306 Candida blood culture isolates were obtained from 280 patients (39 in 2014, 62 in 
2015, 72 in 2016, 60 in 2017 and 47 in 2018). The three most common Candida spp isolated from blood 
cultures were Candida albicans (44%), Candida glabrata (22%) and Candida; parapsilosis (13%). Any 
resistance to the four tested antifungals is observed for C. albicans and C.parapsilosis. However, 
resistance was observed for C. glabrata in 10 % for amphotericin B, 28% for voriconazole, and 15% for 
fluconazole. In 2 % and 75%, there is respectively a resistance and an intermediate susceptibility to 
caspofungin. For the time being, the antifungal treatment was recovered for 170 patients. Among 
them, 67%, 26% and 5% received respectively caspofungin, fluconazole and ambisome. 2% have not 
received antifungal treatment, because they were at the end of their life. Evolution at M3 was reported 
and the mortality rate was 32%. Candidemia has probably a role in 51% of them. 
Conclusion: We report an overall increase in candidemia but a constant distribution of C albicans, C 
paraspsilosis and C glabrata. The lack of antifungal resistance for C. albicans and C. parapsilosis for 
candidemia suggests a possibility of treatment with fluconazole as a first-line in our hospital, without 
waiting for the results of the antifungal susceptibilities. We have also to analyse the possible 
nosocomial etiology, and the link between antifungal resistance, and the cause of death of those 
patients. 
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Objectives: Malassezia species are yeasts that are inhabitants of the cutaneous microbiome of animals 
and men; however, they can eventually cause infections. In dogs, M. pachydermatis, a zoophilic and 
non-lipid-dependent species, particularly causes otitis and dermatitis. Although malasseziosis is not 
considered zoonotic, it was suggested the disease may be transmitted to neonates by the professionals 
of intensive care units (ICU) who have dogs. No data on the exchange of Malassezia species between 
animals and men who have close contact are available. The aim of this study was to isolate and 
identify M. pachydermatis from the cutaneous microbiome of dog owners and compare with that of 
people who do not have contact with animals. 
Methods: A total of 15 dogs with otitis and/or dermatitis caused by M. pachydermatis and their owners 
were selected. We collected three clinical samples of each owner (total 45 samples) from the upper 
trunk, scalp, and behind the ears. At the same time, three clinical samples were collected from 24 
people (total 72 samples) of the same regions, who did not have any contact with animals. The 
samples were seeded on Dixon’s medium and the isolates obtained were inoculated on Sabouraud 
dextrose agar. Cultures that grew only on the Dixon's medium were considered lipid-dependent 
Malassezia species and those on Sabouraud dextrose agar were considered as M. pachydermatis. For 
genus confirmation, DNA was extracted and 26S rDNA was amplified using the polymerase chain 
reaction. The standard strain M. pachydermatis CBS-1879 was used as a positive control. 
Results: The presence of Malassezia spp. in the people living with dogs (80.0% - 12/15) and those who 
not living with animals (83.3% - 20/24) was similar (Table 1). Malassezia spp. were isolated from 37.8% 
(17/45) and 58.3% (42/72) of clinical samples from those cohabiting with dogs and those who were 
not, respectively (Table 1). Malassezia pachydermatis was the most common species in the cutaneous 
microbiome of the owners found in 52.9% (9/17) of the isolates, whereas lipid-dependent Malassezia 
spp. were isolated from 47.1% (8/17) (Table 1). Malassezia pachydermatis was isolated from the three 
sites sampled, scalp, upper trunk, and behind the ears. Only lipid-dependent Malassezia (100.0% of 
the isolates) was found in people who did not cohabit with dogs, M. pachydermatis was not isolated 
from these people (Table 1). "Dog cohabitation" has a statistically significant effect on the presence of 
M. pachydermatis in the cutaneous microbiome of the owners (p < 0.05).  
 
Conclusion: Malassezia pachydermatis was associated with the nosocomial outbreaks of fungemia in 
neonates hospitalized in ICUs, with the possibility of transmission occurring by health professionals 
who were having dogs and carried the yeast to the ICU. However, limited literature exists on the 
association of close cohabitation with dogs or other pets with the human microbiome. Our results 
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show that there is a change in the Malassezia spp. in the cutaneous microbiome of people cohabiting 
with dogs, thus significantly increasing the presence of a zoophilic strain of M. pachydermatis. 
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Objectives: Taking into consideration the challenges related to epidemiology, treatment and 
outcome of mucormycosis, a Working Group (WG) on Zygomycosis was initially formed in ECMM, 
in 2004. It aimed to create a registry by collecting mucormycosis cases from European countries. From 
2008 onwards the WG expanded under also the auspices of the ISHAM and it now includes 
participants from all over the world. The aims of this project are: 1) to conduct a prospective 
international registration of patients with mucormycosis using a well-established global network, 2) 
to collect and molecularly identify mucormycetes and tissue specimens from the patients enrolled in 
order to establish an international archive that will be used in future studies and 3) to provide 
information about this rare but devastating disease and enhance the collaboration of physicians and 
researchers all over the world. 
Methods: Definitive and probable mucormycosis cases from each participating country were initially 
prospectively recorded in standardized case report forms (CRFs) and sent to the study coordinator. 
Since the creation of the registry platform (www.zygomyco.net) participants can submit cases 
directly. Isolated mucormycetes are identified at the participating institutions and molecular 
identification, if not available, is performed at an appointed laboratory (National Centre for 
Mycology, Madrid, Spain). In absence of culture data, paraffin-embedded tissues are sent to an 
appointed laboratory for PCR. Appropriate statistical methods are used for univariate and 
multivariate analysis. 
Results: The WG on zygomycosis has organized 3 international fora on zygomycosis, co-organized 
international workshops, and meetings are regularly held. As an ongoing study, results are being 
presented at conferences and related papers are published. During 2005-2007, 230 cases were 
submitted and analyzed. The first analysis (A. Skiada et al., Clin Microbiol Infect 2011;17:1859–1867) 
has shown a wide variation regarding underlying diseases, clinical presentations, fungal species and 
treatment modalities in different countries. These observations have increased our understanding of 
the risk for transmission and diversity of this disease, which may lead to increased suspicion, earlier 
diagnosis and appropriate management. The analysis has also contributed to issuing guidelines on 
the diagnosis and treatment of mucormycosis. More than 300 further cases have been added during 
2008-2018, from more than 15 countries, Brazil, India, Iran, Lebanon and the USA included. 
Conclusion: The existence of the ECMM/ISHAM Working Group on Zygomycosis and its official 
website and registration platform, provide the means for a network of investigators, including many 
experts, to interact, exchange information and hopefully improve the outcome of mucormycosis. 
Focus on more detailed information on the development of the disease according to various 
underlying conditions and mucoralean species involved is a future perspective, as a tool for the 
construction of predictive risk models for patients at risk. This project can also be a powerful tool for 
the assessment of novel diagnostic procedures, therapeutic modalities and efficacy of new 
antifungals. 
 
P236 
First report on the isolation of five new geophilic Arthroderma species in hedgehogs 
S. Uhrlass1, D. Rimek2, V. Hubka3, W. Schroedl4, M. Reuschel5, H. Muetze1, D. Koch1, C. Krueger1, Y. 
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1Partnership Dr. C. Krueger & Prof. P. Nenoff, Laboratory of medical microbiology, Roetha OT 
Moelbis, Germany, 2Gesundheitsschutz, Thueringer Landesamt für Verbraucherschutz, Bad 
Langensalza, Germany, 3Laboratory Of Fungal Genetics And Metabolism, Institute of Microbiology 
ASCR, Prague, Czech Republic, 4Ag Mykologie, Institut für Bakteriologie und Mykologie, Leipzig, 
Germany, 5Klinik Für Heimtiere, Reptilien, Zier- Und Wildvögel, Stiftung Tierärztliche Hochschule, 
Hannover, Germany, 6Institut Für Mikrobiologie Und Hygiene, Universitätsmedizin – Charité, 
Berlin, Germany 
Objectives: During the last years an increase of rare and new dermatophytes in human beings, but 
also in animals has been observed in routine diagnostics of mycological laboratories, not at least due 
to the significantly improved molecular identification methods. The conventional diagnostics 
includes native preparation plus fungal culture. Today, molecular methods, e. g. polymerase chain 
reaction (PCR), in particular an in-house- PCR-ELISA, are completing mycological diagnostics. 
Methods: Recently, between April and September 2018, a survey of the health of hedgehogs was 
performed in the city of Hanover, Germany. Altogether 50 European hedgehogs were included in 
this study. Skin and sting samples from the animals were collected, and mycological investigation 
was done as described before. A minor part of hedgehogs showed clinical signs of a dermatomycosis, 
most animals were, however, asymptomatic. For confirmation of cultural dermatophyte isolates, 
sequencing of the Internal Transcribed Spacer (ITS) region of the rDNA, and the Translation 
Elongation Factor (TEF)-1α gene was performed. 
Results: The following dermatophytes were isolated from the hedgehogs: Trichophyton erinacei (8), 
Arthroderma (A.) crocatum (4), A. quadrifidum (2), A. insingulare (1), A. chiloniense (1) and A. tuberculatum 
(1). Based on their macro architecture, their microscopic features, and their genetic characteristics, all 
from hedgehogs isolated strains were compared with each one or two clinical isolates of the 
respective Arthroderma species. These reference strains were isolated from human skin samples, e.g. 
scrapings, nail samples, and hair roots, achieved between 2016 to 2018. Clinical diagnoses were tinea 
manuum, tinea corporis, tinea capitis, and tinea unguium. 
Conclusion: Meanwhile, both the here described new animal isolates from hedgehogs, but also the 
human strains of different Arthroderma species are deposited at the deposited at the „Deutsche 
Sammlung von Mikroorganismen und Zellkulturen” (DSMZ, German Collection of Microorganisms 
and Cell cultures), Brunswick, Germany. The DNA sequences (ITS and TEF-1α) of all strains are 
available now at the gene bank of the National Center for Biotechnology Information (NCBI) in 
Bethesda, Maryland, USA. 
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Epidemiology, Clinical characteristics, and Outcome of adult Candidemia in a Chinese tertiary 
hospital: from 2008 to 2015 
L. Zhang1, Z. Liu1, T. Li1, M. Xiao2, Y. Wang2, Y. Xu2 
1Department Of Infectious Disease, Peking Union Medical College Hospital, Beijing, China, 
2Department Of Clinical Laboratory, Peking Union Medical College Hospital,, Beijing, China 
Objectives: The aim of this study was to assess the epidemiology, clinical characteristics，risk factors 
and outcome of candidemia patients in a tertiary hospital. 
Methods: A retrospective observational study of all cases of candidemia which occurred during 
hospitalization was carried out in a tertiary hospital including 6 intensive care units (ICUs), 22 
medical and 24 surgical wards in Beijing, China(2008-2015). Demographic and clinical data were 
collected from the database of the patient’s medical records. Chi Square test (or Fisher’s Exact Test 
when expected frequencies were less than 5) and multivariate logistic regression models were used 
to identify the risk factors associated with the higher mortality during hospitalization. 
Results: A total of 192 episodes of candidemia were identified in 181 patients(male 102,female 79, 
mean age 58.96±17.86). All cause mortality during hospitalization was 64/181 (35.4%) , and 
attributable mortality was 50/181 (27.6%). Multivariate analysis showed that age≥65 years, ICU 
hospitalization and polymicrobial bloodstream infections were independently associated with a 
higher risk of crude mortality. Candida albicans was the predominant specie 100/192(52.1%) followed 
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by C.glabrata 31/192(16.1%), C.parapsilosis 28/192(14.6%) and C.tropicalis 26/192(13.5%). Species 
distribution differed significantly according to different wards and sources. Candida albicans was 
predominant in obstetrics gynecological ward 9/12(75%), emergency ward 16/23(69.5%) and ICU 
38/70(54.3%). Non-albcan candida spp. were predominant in surgical wards 23/37(62.2%) and internal 
medical wards 27/50(54%). Intra-abdominal infection34/192 (17.7%) was the most frequent infective 
source of candidemia, followed by pulmonary infection 34/192(16.1%) and CVC-related candidemia 
27/192(14.1%), however, the source of infection was not identified in 71/192(40.0%) episodes. 
Meanwhile, we also found higher percentages of C.albicans in candidemia secondary to abdominal 
infection 22/34(64.7%) and multifocal infections 7/11(63.6%), but higher percentages of non-albicans 
in skin and soft tissue infection 4/6(66.7%) and CVC-related candidemia 17/27(63.0%) (Figure 
2).Fluconazole resistance accounted for 1.0%, 3.6%,3.8% and 6.5% of isolates of C.albicans 
(1/100),C.parapsilosis (1/28), C.tropcalis (1/26) and C.glabrata (2/31) , respectively. 
 
  
Previous antibiotic exposure (<30 days)154/181(85.1%), reservation of central venous catheter 
150/181(82.3%), previous hospitalization history 140/181(77.3%)and retention of Foley catheter 
122/181(67.4%) were the most frequent risk factors. 
Conclusion: Our study showed that candiemia was associated with poor outcome and higher 
mortality. Identification of risk factors associated with candidemia diagnostic and prognositic may 
lead to better management in terms of preventive and therapeutic measures. Given the difference of 
candida species distribution in different wards and different infecive sources, improving the 
awareness of epidemiology are in urgent need in candidemia treament . 
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Epidemiology and Outcome of Culture-Proven Coccidioides immitis Infections in San Diego, 
California, United States 
J. Jenks, S. Reed, M. Hoenigl 
Medicine, University of California San Diego, San Diego, United States of America 
Objectives: Coccidioides are dimorphic fungi endemic to the Southwestern United States (Coccidioides 
immitis) and parts of Central and South America (Coccidioides posadasii). Infection from these fungi, 
coccidioidomycosis, can cause a range of disease from self-limited acute pneumonia to severe, 
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disseminated disease. The objective of this study was to describe clinical manifestations, treatment 
and outcome of patients with culture-proven Coccidioides immitis infections in San Diego, California, 
United States, an area endemic to Coccidioides immitis. 
Methods: We performed a retrospective chart review of medical records of all patients with culture-
proven Coccidioides immitis infection at UCSD between 5/01/2017 - 12/31/2018 (1 1/2 year period). The 
study was approved by the UCSD Human Research Protection Program. 
Results: A total of 11 cases with detection of Coccidioides immitis in culture were identified (Table). Of 
11 cases, 10 were evaluable, and of those 1 had chronic coccidioidomycosis and 9 had proven acute 
infection. Of those with acute infection, 56% (5/9) had traditional risk factors for coccidioidomycosis 
infection including African American race, immunosuppressive state, lung transplant status, 
HIV/AIDS, and type II diabetes mellitus, while the remaining 4/9 lacked traditional risk factors. Five 
of 9 (56%) had primary coccidiodomycosis of the lungs and 4/9 (44%) disseminated disease. Of those 
who received antifungal therapy, 3/7 (43%) received combination therapy and 4/7 (57%) 
monotherapy with fluconazole. At 180 days, 5/9 (56%) were alive, 3/9 (33%) deceased, and 1/9 (11%) 
lost to follow-up. Of those who were not alive at 180 days, 1/3 (33%) had disseminated disease and 
2/3 (67%) primary coccidioidomycosis, both who were on immunosuppressive therapy. 
Conclusion: Culture-proved Coccidioides immitis infection occurred in a variety of hosts, with 44% 
lacking typical risk factors for infection. Disseminated coccidioidomycosis infection occurred in 44%; 
of these, 50% lacked traditional risk factors and 75% were alive at 180 days. 
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Positive fungal culture in tissue specimens from burns patients: Data from a tertiary care hospital 
laboratory in Pakistan 
K. Jabeen1, S. Umar2, N. Shaheen2, M. Khan3, J. Farooqi2 
1Pathology And Laboratory Medicine, Aga Khan University, Karachi, Pakistan, Pakistan, 2Pathology 
And Laboratory Medicine, Aga Khan University, Karachi, Pakistan, 3Medical College, Aga Khan 
University, Karachi, Pakistan 
Objectives: Due to defective skin barrier burns patients are at great risk of development of fungal 
wound infections. Fungi are frequently cultured from tissue specimens from these patients either 
singly or in combination with bacteria. Spectrum of fungal wound infection in burns patients from 
Pakistan has not been reported previously. We evaluated positive cultures from burn wounds 
samples received at a tertiary care hospital laboratory in Karachi, Pakistan. Positivity rate of fungal 
isolation within these cases and spectrum of yeast and filamentous mold was reported. 
Methods: We reviewed laboratory data of tissue and wound samples received for bacteriological 
assessment from burn patients at the Aga Khan University Hospital laboratory, Karachi, Pakistan 
from September 2017-March 2018. Specimens were inoculated on chocolate agar and sheep blood 
agar with colistin and nalidixic acid incubated in 5% CO2, a triplate with MacConkey agar, Mannitol 
salt agar and Sabouraud’s dextrose agar incubated in ambient environment, and sheep blood agar 
incubated in anaerobic environment. All cases were incubated at 37oC and pus and tissue samples 
were also enriched by inoculating in cooked meat broth. Clinical and demographic information 
recorded on the worksheet at the time of clinical reporting was collected for the study. Frequencies 
were computed to describe the data. 
Results: A total of seventy positive tissue cultures from burn patients were identified over the study 
period. These specimens were received for 36 male patients and 34 female patients with age ranging 
from eight months to eighty five years (average: 15.5 year). Of these, 26 (37%) had growth of either 
filamentous mold (17 cases) or Candida species (11 cases). Two cases had growth of both mold and 
yeast. Aspergillus flavus was the most common mold (9 cases) followed by Fusarium species (3 cases) 
and Lichtheimia corymbifera (2 cases). Candida tropicalis was the most common yeast (5 cases) followed 
by Candida parapsilosis (3 cases). There was a concomitant bacterial growth in 19 cases predominantly 
of Staphylococcus aureus (13 cases), Pseudomonas aeruginosa (8 cases) and other Gram negative rods (6 
cases). 
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Conclusion: High rate of fungal isolation from burn wound infection was seen in this study despite 
less optimal culture techniques. The findings in our study are consistent with the global increase in 
incidence of fungal infections in burn wounds. High index of suspicion of fungal infections by 
clinicians and revision of culture protocols in burn patients may be warranted for optimal 
management of these patients. 
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Fungal isolation from wound samples submitted for culture at a tertiary care hospital laboratory 
in Karachi, Pakistan 
J. Farooqi1, A. Ladak2, N. Shaheen3, K. Jabeen4 
1Pathology And Laboratory Medicine, Aga Khan University, Karachi-KHI, Pakistan, 2Medical 
College, Aga Khan University, Karachi, Pakistan, 3Pathology And Laboratory Medicine, Aga Khan 
University, Karachi, Pakistan, 4Pathology And Laboratory Medicine, Aga Khan University, Karachi, 
Pakistan, Pakistan 
Objectives: Skin and Soft tissue infections rank the fourth most common infections worldwide. These 
often emerge from chronic wounds, traumatic implantation and surgical wounds. Bacteria are the 
most common isolated organisms from such wounds. However, recently, many centers across the 
world have started to report an increase in fungal isolates, possibly due to excessive use of antibiotics 
and expansion in host risk factors. This study aims to present the frequency of reported fungal isolates 
in patients with skin and soft tissue infections and relate the incidence of these infections with 
concomitant risk factors. 
Methods: We reviewed laboratory slips of all tissue and pus samples received for bacteriological 
assessment at the Aga Khan University, Hospital clinical laboratory from mid-September till to mid-
October 2018. All samples were inoculated on Chocolate Agar and Sheep Blood Agar with colistin 
and nalidixic acid incubated in 5% CO2, a triplate with MacConkey Agar, Mannitol Salt Agar and 
Sabouraud’s Dextrose Agar incubated in ambient environment, and Sheep Blood Agar incubated in 
anaerobic environment. All cases were incubated at 37oC and also enriched by inoculating in Cooked 
Meat Broth. Clinical information recorded on the worksheet at the time of clinical reporting was 
collected for the study. Any missing information was filled in from the in-house hospital information 
management software if available. Variables such as patient age, location, gender, relevant medical 
history, type and site of wound, microbial isolates and drug resistance were collected. Frequencies 
were computed to describe the data. 
Results: We reviewed a total of 140 patients’ information over the study period. Our study 
population consisted of 48.6% (n = 68) females and 51.4% (n = 72) males with the median age of 30.5 
years. Of the 140 samples submitted, 76.4% (n = 107) were culture positive; pathogens were isolated 
from 81.3% of these (n = 87), and 9.3% yielded fungi. The categories of lesions included accidental 
wounds [8.6% (n = 12)], burn and blast injuries [2.9% (n = 4)], diabetic wounds [7.9% (n = 11)], 
nosocomial infections [15% (n = 21)], skin and soft tissue infections [57% (n = 80)] and unknown [8.6% 
(n = 12)]. The fungal isolates were spread across all categories of lesions. Skin and soft tissue infections 
had the highest number of fungal isolates (n = 4) while diabetic wounds had none. Yeasts (Candida 
species) were most commonly isolated (n = 4), followed by Fusarium species (n = 3), Aspergillus species 
(n = 2), Bipolaris species (n = 2) and Curvularia species (n = 1). 
Conclusion: Our center has reported a high number of fungal isolates over the short study period. 
Our study raises the question of identifying underlying causes that has led to this high number of 
fungal isolates reported in just one month from samples sent only for bacterial culture. Moreover, 
centers across the region should be educated about the rising fungal load in the population especially 
wound samples. Setting an additional fungal isolation medium may be life saving for patients with 
severe necrotizing fungal wound infections. 
 
P241 
Subcutaneous Mucormycosis – Beyond Rhizopus and Mucor species 
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C. Sebastian1, R. V1, J. Mathew2, J. Savio2 
1Microbiology, St.John's Medical College, Bangalore, India, 2Microbiology, St. John's Medical College, 
Bangalore, India 
Case Report: Introduction The Mucorales, Apohysomyces and Saksenaea species are unusual human 
pathogens that are reported with increasing frequency as a cause of subcutaneous infection in 
previously healthy patients following trauma or invasive procedures.Identification of these species 
in a routine laboratory is challenging due to their difficulty in sporulation. Special techniques for 
inducing sporulation must be employed for their identification. Objective To report 4 cases of 
subcutaneous mucormycosis due to the mucorales - Apohysomyces and Saksenaea species Case 1 25 
years old farmer presented with necrotising fasciitis of the entire back following religious self-
flagellation. Microscopic examination of the tissue revealed aseptate hyphae. Culture yielded a 
mucorale that was identified as Apophysomyces variabilis. Patient condition improved with wound 
debridement and liposomal Amphotericin B. He was discharged on Posaconazole. Case 2 A 30 year 
old male patient, diabetic since 6 months presented with submandibular swelling of 10 days duration 
following an injury to the neck. Pus sample revealed aseptate hyphae. Culture isolate was identified 
as Apophysomyces species on culture. Case 3 55 years old patient presented with persistent fever and 
necrotising fasciitis of the right leg. It all started following a bite by a pig 15 days back. He was not a 
known case of diabetes mellitus but was diagnosed on admission. The tissue sample yielded 
Apophysomyces elegans on culture. Case 4 25 years old retro positive patient presented with a gluteal 
abscess following an intramuscular injection. The fungal culture of the tissue sample yielded 
Saksenaea vasiformis. Conclusion Mucormycosis is an angio-invasive infection which is rapidly 
progressive and associated with a high morbidity and mortality. Rhizopus species is the most common 
mucoralean worldwide causing mainly rhino-orbito-cerebral mucormycosis. Genera other than 
Rhizopus like Apophysomyces and Saksenaeae are associated with cutaneous and subcutaneous 
manifestations. More and more cases are presently being diagnosed in developing countries like 
India where the at-risk population of diabetic patients and other immunocompromised states are 
continually on the rise. 39 cases of mucormycosis were reported from our laboratory in the last 2 and 
a half years, from January 2017 to May 2019. 34 were rhino-orbito-cerebral mucormycosis caused by 
Rhizopus species. Of the 5 cases of subcutaneous mucormycosis, 3 were caused by Apophysomyces 
species and one each by Saksenaea vasiformis and Rhizopus arrhizus respectively. All three 
Apophysomyces species were identified as Apophysomyces elegans in our laboratory. However 
sequencing at PGIMER Chandigarh has confirmed one of them as A.variabilis. Two of the four cases 
were diabetic patients and one was retro positive. All the four patients gave a history of trauma. In a 
country like India, mucormycosis should be considered in patients presenting with non healing 
wound especially following a trauma, even in young adults as they may be silent diabetics. 
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Changing trends in genus and species distributions of clinical fungal strains: An evaluation of 
ten-year data from a tertiary care center in Turkey 
D. Gulmez, A.K. Sığ, N. Akar, S. Duyan, S. Arikan-Akdagli 
Medical Microbiology, Mycology Laboratory, Hacettepe University Medical School, ANKARA, 
Turkey 
Objectives: Opportunistic fungal infections may develop due to a wide variety of fungal species. 
Changes in species distribution profiles are reported from many centers and occasionally reflect an 
increase in rates of antifungal drug-resistant or -less susceptible species. The aim of this retrospective 
evaluation is to determine the fungal species and their relative isolation rates in the last ten years in 
our center with a specific focus on bloodstream yeast isolates and mould growth from lower 
respiratory tract specimens. 
Methods: Fungal strains isolated from clinical samples from 2009 to 2018 were included. Isolation 
and identification were done by standard mycological methods. Fungal growth in all sample types 
was evaluated and repetetive growths from the same type of specimens were excluded. Isolated 
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fungal species were analysed in course of time and with respect to the specimen types. Distribution 
of species in five-year periods (2009-2013 vs. 2014-2018) was compared by z test. 
Results: A total of 23046 specimens sent to the laboratory during the study period revealed fungal 
growth. Excluding the episodes of repetetive growth, 17239 fungal strains were isolated from 15465 
clinical samples. Total number of specimens and isolates markedly increased in time, from 757 and 
819 in 2009 to 2511 and 2875 in 2018, respectively. Urinary tract (n = 7164, 46%) and lower respiratory 
tract (n = 4523, 29%) were the most common fungal isolation sites followed by blood (specimens from 
peripheral vein and catheter, n = 1076, 7%). For all specimen types, most common species were 
Candida albicans (58%) and Candida glabrata species complex (SC) (12%). Among moulds, Aspergillus 
fumigatus SC (51%) was the most common. Per the yeast species isolated from blood cultures (Figure 
1), isolation rate of C.albicans decreased from 48% to 44% (p = 0.186) and that of C.glabrata SC increased 
from 10% to 15% (p = 0.014) in 2014-2018 as compared to 2009-2013. No significant change was 
observed in species distribution of isolates from sterile specimens other than blood. Distribution of 
mould genera from lower respiratory tract specimens is shown in Figure 2. Although A.fumigatus SC 
was always the most common, its rate of isolation decreased from 63% in 2009-2013 to 46% in 2014-
2018 (p<0.001). In the same time intervals, isolation of Aspergillus species other than A.fumigatus SC 
increased from 26% to 34% (p = 0.145) and moulds other than Aspergillus (Penicillium spp., Order 
Mucorales, Scedosporium spp., Alternaria spp., Paecilomyces spp., dematiaceous fungi and unidentified 
moulds) increased from 11% to 20% (p = 0.185). 
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Conclusion: In our center, while the most commonly isolated yeast and mould species display a usual 
profile, species distribution is diverse. Evaluation of bloodstream yeast isolates revealed a decrease 
of C.albicans and an increase in C.glabrata SC, which appears as a recent change. Significance of 
increase in rate of C.glabrata SC remains noteworthy also with respect to potential resistance or 
decreased susceptibility to antifungal agents. Isolation of less common mould genera from lower 
respiratory tract samples remains remarkable. 
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A mucormycosis case during the catastrophic flood in Mandra, Attica, Greece, November 2017 
S. Sympardi1, M. Drogari-Apiranthitou2, I. Zervakakis3, M. Kalofonou3, N. Minogiannis3, H. 
Papakonstantinou4, G. Liapi4, A. Arvaniti1, A. Karaiskou1, P. Giannopoulou5, E. Trikka-Grafakos5 
1Infection Control Team, Thriasio General Hospital of Elefsis, Elefsis, Athens, Greece, 2Infectious 
Diseases Research Laboratory, 4th Department Of Internal Medicine, General University Hospital 
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“Attikon”, School of Medicine, University of Athens, Athens, Greece, 3Department Of Plastic Surgery, 
Thriasio General Hospital of Elefsis, Elefsis, Athens, Greece, 4Department Of Pathology, Thriasio 
General Hospital of Elefsis, Elefsis, Athens, Greece, 5Laboratory Of Microbiology, Thriasio General 
Hospital of Elefsis, Elefsis, Athens, Greece 
Case Report:  
Objectives: Cutaneous mucormycosis after major trauma may cause devastating morbidity and 
death if not treated promptly and appropriately. The presentation of this case report aims to sensitize 
health care professionals for the potential occurrence of cutaneous mucormycosis after natural 
disasters.  
Methods: Case report: A previous healthy 75-year-old woman was trapped in her flooded home 
during the flood in Mandra, Attica, Greece, which occurred on 15/11/2017. She remained four hours 
under water until rescued. She was transferred to the Emergency department (ED) of a General 
Hospital with dyspnoea and type-I acute respiratory failure (ARF) due to near-drowning. The patient 
had also multiple blunt injuries with skin rupture in both lower extremities. At the ED she received 
treatment for ARF consisting of oxygenation, tracheal aspiration, bronchodilators and antibiotics. Her 
wounds were surgically cleaned and sutured and tetanus immune globulin was administered. The 
Glasgow Coma Scale score (GCS) was evaluated at 13/15 and the patient was admitted to the 
Pneumology department for further treatment. At day 2 post-admission clinical improvement was 
documented, but on day 3 her consciousness level deteriorated (qSOFA score >2) with onset of fever 
and low blood pressure. The antibiotic scheme was changed. Upon re-evaluation of the leg wounds, 
development of necrotic eschars at the wound margins was observed. On day 4 the patient was put 
on mechanical ventilation (GCS<8/15), underwent extensive tissue debridement and liposomal 
amphotericin B 10mg /kg /24h was added to the antibiotic scheme on suspicion of mucormycosis. 
Excised tissue was sent to the Pathology and Clinical Microbiology departments for histological 
examination and culture.  
Results: The patient was transferred to a high dependency unit (HDU), however, on day 5 she 
suffered severe cardiovascular collapse while the infection on both legs had progressed over a large 
area. The patient’s family denied consent for bilateral hip disarticulation. The patient died on day 6 
after hospital admission. Histology revealed fungal hyphae typical for Mucorales.  
Conclusions: Mucormycosis should be always suspected in victims of natural disasters. Infection can 
progress rapidly, requiring early therapy with antifungals, frequent inspection of the wounds and 
repeated surgical debridement. Early primary wound closure should be avoided. 
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The burden of serious fungal diseases in Sudan 
M.T. Albirair1, A.H. Fahal2, D. Denning3,4 
1Blue Nile National Institute for Communicable Diseases (BNNICD), Wad Madani, Sudan, 
2Mycetoma Research Center, University of Khartoum, Khartoum, Sudan, 3University of Manchester, 
Manchester, United Kingdom, 4National Aspergillosis Centre, Manchester University NHS 
Foundation Trust, Manchester, United Kingdom 
Objectives: Sudan is a large north-African country with a population of about 40 million. Apart from 
mycetoma which is a substantial problem, the burden of fungal infections in Sudan is not well 
documented. Serious fungal infections are increasing with more immunocompromised patients, 
longer lives and a high frequency of respiratory diseases. The aim of this study was to estimate the 
burden of serious fungal infections in Sudan. 
Methods: Epidemiological data reporting fungal infection rates in Sudan and nearby countries 
together with population estimates for general and specific at-risk patient groups were acquired. We 
used previously described deterministic modelling to estimate national incidence or prevalence. 
Results: HIV rates are low in Sudan and we estimated 231, 1,378 and 3,568 cases with cryptococcal 
meningites, Pneumocystis pneumonia and oesophageal candidiasis, respectively. Asthma affects an 
estimated 480,000 adults, and 11,400 and 15,048 people were estimated to have allergic 
bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitisation (SAFS) 
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respectively, probably with some overlap between them. We estimated 1,085 cases of all forms 
chronic pulmonary aspergillosis (CPA) with 50% assumed to occur post tuberculosis or are mis-
diagnosed as TB. We estimated 354 cases of invasive aspergillosis complicating leukaemia, HIV and 
lung cancer. There are no COPD prevalence data. In the absence of local data, we have estimated 
candidaemia at 5/100,000 or 2,000 cases. We estimated ~530,000 women to be affected by recurrent 
vulvovaginal candidiasis (RVVC). As many as 3.6 million school-age children suffer from tinea 
capitis, based on a 21% rate. Mycetoma is a particular problem in Sudan and a minimum of 
1.81/100,000 inhabitants or about 700 estimated cases are found there, predominantly eumycetoma. 
No reliable data exist on fungal keratitis, histoplasmosis or mucormycosis. 
Conclusion: Our study revealed about 4.1 million (10.5%) of the Sudanese population suffer from 
serious fungal infections yearly with about 15,633 affected by life-threatening invasive fungal 
infections. Improvements in fungal disease diagnosis and management is required in Sudan. 
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Global epidemiology of mucormycosis: Preliminary analysis of the cases submitted to the 
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Flörl7, S. Kanj8, K. Lagrou9, V. Arsic-Arsenijevic10, S. Zimmerli11, G. Petrikkos12 
11st Dpt. Of Medicine, Laiko Hospital, Athens University, Athens, Greece, 2Department Of 
Microbiology, Government Medical College Hospital, Chandigarh, India, 3Department Of Clinical 
Mycology, Allergology And Immunology, North-Western State Medical University n.a. I.I. 
Mechnikov, Saint-Petersburg, Russian Federation, 4Department Of Microbiology, Palacký 
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Republic, 5Faculty Of Engineering, Sabzevar University of New Technology, Sabzevar, Iran, 
6Infectious Diseases Research Laboratory, 4th Department Of Internal Medicine, General University 
Hospital “Attikon”, School of Medicine, University of Athens, Athens, Greece, 7Div Hygiene & Med. 
Microbiology, Med. Univ. Innsbruck, Innsbruck, Austria, 8Division Of Infectious Diseases, American 
University of Beirut Medical Center, Beirut, Lebanon, 9Laboratory Of Clinical Bacteriology And 
Mycology, Department Of Microbiology And Immunology, Excellence Center For Medical Mycology 
(ecmm), KU Leuven, Leuven, Belgium, 10Medical Mycology Reference Laboratory, Faculty of 
Medicine University of Belgrade, Belgrade, Serbia, 11Department Of Infectious Diseases, Inselspital, 
Bern University Hospital, University Of Bern,, University Hospital of Bern, Bern, Switzerland, 
12Infectious Diseases, School of Medicine, European University of Cyprus, Nikosia, Cyprus 
Objectives: Mucormycosis is an invasive fungal infection with high morbidity and mortality. Due to 
its rarity, registries are an important tool, used to collect information about risk factors, diagnosis and 
treatment of this potentially lethal infection. The aim of this study was to perform a preliminary 
analysis of the cases submitted to zygomyco.net, the ECMM/ISHAM Working Group on 
Zygomycosis global registry, during a 10-year period (2008-2018). 
Methods: In order to submit a case, a participant must register to the site (www.zygomyco.net), 
giving his name, country of origin and e-mail address.Participants in the study can submit cases on-
line in electronical CRFs. Alternatively, they can download a paper form and send it to the 
coordinators. The required data include demographics, underlying conditions, mode of transmission, 
clinical presentation, diagnosis, treatment and outcome. In order to be included in the study the case 
must pertain to a probable or proven case of mucormycosis. A data review committee reviewed all 
submitted cases. 
Results: During the study period 365 cases were submitted from 16 countries (Austria, Belgium, 
Brasil, Czech Republic, Greece, India, Iran, Italy, Lebanon, Netherlands, Romania, Russia, Serbia, 
Switzerland, United Kingdom and USA). The largest proportion of cases (34%) were submitted from 
India. The analysis was done in the 330 cases which were complete. Sixty-two % of the patients were 
male. The mean age was 45y (range 1 month to 81 years). Underlying conditions were diabetes 
mellitus (37%), hematological malignancies (30%), other malignancies (7%), bone marrow 
transplantation (9%), solid organ transplantation (6%) and trauma (9%). Neutropenia was present in 
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25%. The main sites of infection were lungs (35%), sinus/orbital/cerebral region (34%), soft tissue 
(16%), disseminated (12%) and gastrointestinal (3%). Diagnosis was made only by histopathology in 
11%, only by direct examination in 3%, only by culture in 7%, and with combined methods in the 
rest. Cultures were positive in 74.5% of cases (Rhizopus spp. 56%, Lichtheimia spp. 15%, Mucor spp. 
8%, Apophysomyces spp. 6%, Rhizomucor spp. 4%, Saksenaea spp. 2%, Syncephalastrum spp. 2%, 
Cunninghamella spp. 1% and unspecified Mucorales 6%. Treatment was performed only by surgery 
in 3%, only by antifungals in 37% and by combined approach in 44%. In the remaining 16% of 
patients, either the diagnosis was made post-mortem or the patients declined treatment and left the 
hospital against medical advice. Crude mortality was 41%. 
Conclusion: This is a preliminary analysis of the cases submitted to zygomyco.net in the period 2008 
to 2018. A wide range of clinical presentations, underlying diseases and isolated species was 
observed. Diagnosis is still difficult in many parts of the world and mortality remains high. Further 
analysis of the data is going to highlight the differences occurring in various countries and the risk 
factors associated with mortality. 
 
P246 
Isolation and phenotypic characterization of Sporothrix brasiliensis from cats with suspected 
sporotrichosis 
T. Maschio-Lima1, M. Marques2, B. De Almeida1, T. Lemes1, L. Bianco1, M. Caetano1, N. Brizzotti2, C. 
Silva2, J. Fernandes2, E. Castilho2, J.P. Siqueira2, M. Almeida2 
1UNESP, São José do Rio Preto, Brazil, 2FAMERP, São José do Rio Preto, Brazil 
Objectives: To confirm cases of suspected sporotrichosis in felines in the municipality of São José do 
Rio Preto, Brazil, by isolating and identifying the Sporothrix spp. in clinical samples of symptomatic 
animals; and to evaluate the clinical and epidemiological factors associated with the disease. 
Methods: In a 15 months period (August 2017 to November 2018), 114 samples of secretion and/or 
biopsy of lesions from symptomatic cats were collected at the Center for Zoonoses Control and 
analyzed using traditional mycological techniques. Phenotypic features of the isolates were used to 
differentiate the species of the Sporothrix schenckii complex (S. schenckii var. schenckii, S. brasiliensis, S. 
globosa, S. mexicana, S. luriei, S. albicans). These features include presence or not of sessile pigmented 
conidia, colony growth rates at 30ºC and 37 ºC, and assimilation of sucrose and/or raffinose. 
Epidemiological aspects of the cats, which all had clinical suspicion of the disease, were analyzed 
based on the information presented in research sheets filled in at the time of collection by 
veterinarians. 
Results: Regarding the origin of the animals, 65.79% (75) of the cats were erring, 23.68% (27) semi-
domiciled, and 10.53% (12) fully domiciled. Most of the animals (99, 86.84%) were adults; 91 (79.82%) 
were males, and 23 (20.17%) were castrated. Multiple skin lesions were present in 82 (71.92%) 
animals, 67% (55) of them exclusively ulcerated. Indication of euthanasia was given to 66 (57.89%) 
cats. In relation to the mycological analyses, 83 (72.80%) samples were positive for fungus, exhibiting 
characteristics of the genus Sporothrix, i.e. creamy wrinkled colonies that become blackened due to 
the production of melanin, and septate hyphae with conidiophores giving rise to conidia in the shape 
of a daisy flower. The analyses revealed that the 83 isolates showed morphophysiological profiles 
characteristic of S. brasiliensis. 
Conclusion: Considering the short period of analysis, and that the samples were provided from a 
single center, it is evident the high occurrence of feline sporotrichosis in the municipality of São José 
do Rio Preto, Brazil, caused by S. brasiliensis. The high percentage of positivity in adult, uncastrated 
and erring male felines highlights the need to create control measures in this city. 
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CauSTR – A rapid multiplex microsatellite typing tool for the multi-drug resistant yeast Candida 
auris 
E. Then1, A. De Jong1, A. Ruiz-Gaitan2,3, A. Al-Hatmi1,4, R. Ben-Ami5,6, O. Kurzai7,8, B. Gerrits Van Den 
Ende1, F. Hagen1,9,10 
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1Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, Netherlands, 2Severe Infection 
Research Group, Medical Research Institute La Fe, Valencia, Spain, 3Department Of Clinical 
Microbiology, La Fe University and Polytechnic Hospital, Valencia, Spain, 4Ministry Of Health, 
Directory General of Health Services, Ibri, Oman, 5Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel, 
6Sackler Faculty Of Medicine, Tel Aviv University, Tel Aviv, Israel, 7National Reference Center For 
Invasive Mycoses, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoell 
Institute, Jena, Germany, 8Institute For Hygiene And Microbiology, Julius Maximilian University of 
Wuerzburg, Wuerzburg, Germany, 9Medical Microbiology, University Medical Center Utrecht, 
Utrecht, Netherlands, 10Department Of Dermatology, Jining No. 1 People's Hospital, Jining, China 
Objectives: Since the first description of Candida auris as a novel yeast pathogen it has quickly 
conquered hospital environments causing colonization of patients that ultimately can lead to 
bloodstream infections. During the past decade C. auris has been reported from 25 countries and a 
development of multi-drug resistance has been observed. Molecular epidemiological typing studies 
using whole genome sequencing, amplified fragment length polymorphism fingerprinting and 
multi-locus sequencing typing all identified four lineages linked to geographic regions. The aim was 
to develop a rapid and cost-effective molecular typing tool that relies on genetic diverse microsatellite 
loci. 
Methods: The genome of C. auris strain B8441 (GenBank GCA_002759435.2) was used to search for 
repetitive loci using Tandem Repeat Finder (https://tandem.bu.edu/trf/trf.html). This resulted in 34 
candidate loci that were tested by conventional PCRs using the CDC C. auris reference set. Nine 
microsatellite loci remained and were subsequently tested on a larger set of 92 C. auris isolates (India 
n = 28, Oman n = 24, Spain n = 13, Israel n = 11, Germany n = 6, Korea and Saudi Arabia n = 2 each, 
and n = 1 for Austria, Belgium, Japan, Kuwait, Switzerland and the Netherlands). Three multiplex 
PCRs were developed using fluorescently labeled primers to detect and differentiate the loci when 
analyzed on an ABI3730xL Genetic Analyzer. 
Results: The genome size of C. auris strain B8441 is 12.366 Mbp and contains 2,374 microsatellites 
ranging from 1 bp repeat units up to a 461 bp repeat unit. Based on other fungal genomes it was 
expected that the smaller microsatellite units of 1–10 bp represent the majority of the microsatellites. 
But surprisingly, as can be observed in Figure 1, those with a repeat unit of 12, 15 and 18bp are more 
common than those containing 2–10bp repeat units. The final panel consisted of six tri-nucleotide, 
one with tetra-nucleotide, one nona-nucleotide and one undeca-nucleotide loci. The Simpson’s 
diversity index D ranged from 0.5387–0.8120 for individual loci, when all nine loci were considered. 
Fifty-two genotypes were observed with a Simpson’s D of 0.9656. The isolates from the endemic 
regions (India, Oman) were found to be clonal, while those from nosocomial outbreaks (Israel, Spain) 
could be linked to two different endemic regions. Single reported cases from Europe could be mostly 
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linked to the South East C. auris population. 
 
Figure 1. A selection of microsatellite types that occur at least ten times in the C. auris genome are 
shown. The number in each box stands for the size of the repeat unit and the size of the box represents 
the relative abundance of these specific repeat units. 
Conclusion: Microsatellite loci are abundantly present in the C. auris genome but surprisingly the 
most variable repeat units (2–10bp) are sparsely distributed. The developed nine-loci microsatellite 
typing panel ‘CauSTR’ in this study is able to rapidly differentiate the four recognized lineages 
previously identified by other molecular methods and to observe subtle differences within C. auris. 
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Molecular characterization and epidemiology of Histoplasma isolates from Uruguay 
M. Carbia1, B. Gerrits Van Den Ende2, N. Fernández3, M. Setropawiro2, F. Hagen2,4,5 
1Parasitology And Mycology, Instituto de Higiene, Montevideo, Uruguay, 2Medical Mycology, 
Westerdijk Fungal Biodiversity Institute, Utrecht, Netherlands, 3Sección Micología De La División 
Infectología, Hospital de Clínicas “José de San Martín”, Buenos Aires, Argentina, 4Medical 
Microbiology, University Medical Center Utrecht, Utrecht, Netherlands, 5Department Of 
Dermatology, Jining No. 1 People's Hospital, Jining, China 
Objectives: Histoplasmosis is an invasive fungal infection, often encountered in HIV-positive 
subjects, caused by members of the genus Histoplasma. Historically three varieties were recognized 
within the single known pathogenic Histoplasma species, namely H. capsulatum variety capsulatum, 
variety duboisii (African histoplasmosis) and variety farciminosum (Equine histoplasmosis). However, 
a recent taxonomic revision based on whole genome sequencing, phenotypic and clinical data 
differentiated H. capsulatum var. capsulatum into four species: H. capsulatum sensu stricto, H. 
mississippiense, H. ohiense and H. suramericana. This study was initiated to retrospectively investigate 
the epidemiology of Histoplasma in Uruguay. 
Methods: Forty-two clinical Histoplasma isolates obtained from 42 cases, collected during 1963-2019 
and preserved at the Instituto de Higiene, Montevideo, Uruguay, were included. A set of 25 isolates 
that includes the four newly recognized Histoplasma species was used as reference. Fourteen patients 
(33.3%) were found to be HIV-positive, 12 (28.6%) had other underlying diseases/predisposing 
factors, 1 (2.4%) was immunocompetent and for the remaining 15 cases (35.7%) no clinical data was 
available. Histoplasma DNA was extracted using the CTAB-protocol and subsequently subjected to 
multi-locus sequence typing (partly sequencing of ITS, ARF, OLE, H-anti, M-anti and 60S) and 
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amplified fragment length polymorphism fingerprinting. The mating-type MAT1-1 and MAT1-2 was 
determined by conventional PCR. 
Results: There was a nearly equal distribution of mating-type MAT1-1 and MAT1-2 isolates, 
randomly distributed over time and among Uruguayan patients. By AFLP fingerprinting and multi-
locus sequence typing it was observed that all Uruguayan isolates clustered together. However, 
based on the former molecular typing tool it appears that all these isolates were clonal while with the 
sequence-based approach more subtle clustering was observed. With both molecular tools the 
Uruguyuan Histoplasma isolates clustered closely together with the reference strain of H. suramericana. 
Conclusion: Using AFLP fingerprinting and multi-locus sequencing typing a set of 42 Histoplasma 
isolates from Uruguay was found to belong to the newly described species H. suramericana. There 
was no link observed between the clinical background versus the molecular characteristics of the 
studied isolates. 
 
P249 
The Burden of Serious Fungal Infections in Azerbaijan 
A. Osmanov1, D. Denning1,2, R. Huseynov3 
1Global Action Fund for Fungal Infections, Geneva, Switzerland, 2Manchester Academic Health 
Science Centre, Manchester, United Kingdom, 3Azerbaijan Medical University, Baku, Azerbaijan 
Objectives: We aim to calculate the burden of serious fungal infections in Azerbaijan. 
Methods: We have performed search on published papers of serious fungal infections. Where no 
published data existed, we used population at-risk to identify burden of serious fungal infections. 
Our estimations were based on the model developed by LIFE (Leading International Fungal 
Education). 
Results: Azerbaijan is in the South Caucasus region with the population of 9.8 M people and GDP 
per capita of 5,805 USD. There are 4,051,310 adult women (15-55 yrs) in Azerbaijan, so it was 
estimated that 176,961 women suffer from recurrent vulvovaginal candidiasis (rVVC) which is 
defined as = > 4 episodes/year. There are 8,000 PLHIV which is most likely an underestimate; 54% of 
them do not receive antiretroviral therapy. Hence, we estimate 2,673 and 1,291 patients with oral and 
oesophageal candidiasis respectively. There are probably 16 cases of cryptococcal meningitis and 64 
cases of Pneumocystis pneumonia annually which is likely to be an underestimate. We have estimated 
902 cases of chronic pulmonary aspergillosis (CPA) as a sequel of TB and 2,707 cases of CPA 
complicating other conditions such as pneumothorax, emphysema, and sarcoidosis; which results in 
the total of 3,609 cases of CPA. Based on asthma prevalence there are approximately 4,188 patients 
with allergic bronchopulmonary aspergillosis (ABPA) and 5,528 with severe asthma with fungal 
sensitisation (SAFS). We used a low European rate to estimate invasive candidiasis cases and there 
are approximately 493 and 74 with candidemia and invasive candidiasis respectively. We have 
estimated approximately 111 patients with invasive aspergillosis and 20 patients with mucormycosis. 
 
Conclusion: We have estimated 195,026 (2% of the population) people in Azerbaijan with serious 
fungal infections. Providing diagnostics tools for fungal infection will lead to better understanding 
of this problem and will allow to highlight this problem at the national level. 
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Disability and disease after indoor macrocyclic Trichothecenes mycotoxin and microfungal 
exposure: exposure variable analysis indicates unexpected significant relationship between 
immunosuppression and MTHFR detoxification defects. 
I.H. Grant1, J. Geller2, H. Sabath3 
1Community Medicine, New York Medical College, Tarrytown, United States of America, 
2Information Revelations, Montclair NJ, United States of America, 3International Environmental 
Diagnostics Inc, Irvington NYw, United States of America 
Objectives: Macrocyclic trichothecene mycotoxins are extremely toxic nanoparticulate exotoxins 
dangerous for all mammals, binding to surface dust where mold grow, aerosolized and inhaled if 
disturbed. They damage intracellular protein/DNA/RNA production and mitochondrial function 
causing premature cell death (apoptosis) on contact . A exotoxins, they remain toxic despite 
disinfection. They cause damage to mammalian skin, mucosa, phagocytes, neurons, and organs via 
systemic circulation after inhalation. Produced by Stachybotrys and Trichodermain water-damaged 
indoor environments, they are more potently toxic than T2-toxin and doxynivalenol (DON, 
vomitoxin) mainly produced by Fusarium on agricultural grains. Objectives: Determine: - Severe 
illness frequency due to indoor mold/mycotoxin exposure. - Specific exposure risks - The impact of 
genetically-impaired intracellular MTHFR detoxification capacity. - Conditions that predispose to 
opportunistic fungal infection with such exposures (e.g. mucosal injury, immunosuppression, 
malnutrition) 
Methods: Prospectively monitored 51(21M,30F) adults and children exposed to 30 Trichothecenes-
contaminated indoor-environments with comprehensive environmental-mycological and medical 
investigations, fungal IGGs, urine mycotoxins(MCTs: Aflatoxin, Gliotoxin, Ochratoxin A, 
Trichothecenes), immune parameters(neutrophils, lymphocyte subsets, monocytes, 
IGG,IGA,IGM,IGE,subclasses), immunosuppressants, nutritional deficiencies (protein, Vitamin 
D,zinc), genetic Methylenetetrahydrofolate reductase (MTHFR) single-nucleotide-polymorphisms 
C677T&A1298C. Disease Severity Outcomes(DS), Environmental Mold-Contamination 
Severity(EMCS), Hazardous Exposure Activities(HEA), Exposure Duration (ED), 
MCT/Trichothecenes exposure(MTC/TE), and clinical findings were stratified and analyzed. 
Biostatistical analysis(Pearson Correlation Coefficients) correlated DS with EMCS, HEA, ED, 
MCT/TE, mucosal Injury(MI), Neurological disease, Cell-mediated Immunodeficiencies(CMIs), 
combined cellular-immunoglobulin immunodeficiencies, mucosal injury (MI), mold-specific IGG 
response(M-IGG), MCT excretion and MTHFR defects. 
Results:  
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CORRELATIONS: Disease Severity based on formal disability classification/physical injury strongly 
correlated with Hazardous Activities (p = 0.000043), Neurological disease(p = .000263), 
Immunoglobulin deficiencies(p = .000923),Combined Cellular-Immoglobulin Deficiencies (p = 
0.00502), Environmental Mold Contamination(p = 0.007531) and Mucosal Injury-the main expected 
injury from Trichothecenes inhalation (p = 0.018034). Mucosal injury strongly correlated with 
Neurological damage(p = .026842) and combined cellular-immune defects(p = 0.026842). Combined 
Cellular-Immunoglobulin Deficiencies strongly correlated Hazardous Activities (p = .009464). 
Development of mold-specific IGGs correlated with environmental mold-contamination(p = 0.26842) 
and Urine Trichothecenes(p<.00001). Females were more often adversely affected. Environmental 
Exposure Hazardous Activities (especially unprotected mold-disturbance, uncontained 
construction/repairs, basement-living, HVAC-contamination and sewage-overflow) correlated with 
enviromental Trichotehcenes level(p = 046588), Combined Cellular Deficiencies(p = .038993) and 
immunoglobulin deficiencies(p = .005952). Environmental Mold Contamination correlated with 
Disease Severity(p = 007531), Hazardous Activities(p = 0.002153), Environmental Trichothecenes 
level(p = .00502), multiple environmental mycotoxins (p = .02207), Combined Cellular-
Immunoglobulin Deficiencies(p = .04658),immunoglobulin deficiencies(p = .032448) and elevated 
mold IGGs(p = .026842). Environmental mycotoxin contamination correlated with urine mycotoxin 
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excretion(p = .046588). Environmental Trichothecenes contamination significantly correlated with 
Environmental Mold Contamination(p = .00502), Hazardous Activity (p = .046588) and Exposure 
Duration(p = .046588) Urine Macrocyclic Mycotoxin Score strongly correlated with the 
Environmental Mycotoxin Score (p = .046588). 
Conclusion: Indoor exposure to macrocyclic Trichothecenes appears extremely hazardous. The high 
frequency of bleeding (90%), mucosal injury (82%), neurological damage (75%), pain (64%), chronic 
fatigue (63%), burning (57%), with expected respiratory/Gi /Dermatologic symptomatology is 
consistent with known Trichothecenes effects in animal models and military data. The high 
(94%)MTHFR methylation-defect incidence is striking compared to estimated USA 50-60% 
prevalence. MTHFR is a key intracellular detoxifying-enzyme protecting ribosomes/mitochondria 
RNA/DNA damage from Trichothecene injury via glutathione metabolism. Further investigation is 
needed to determine if Trichothecenes trigger genetic damage or autoimmunity. Urine macrocyclic 
Trichothecenes detection appears a useful marker for environmental macrocyclic Trichothecenes 
exposure. Public health education and epidemiological research are urgently needed to investigate 
correlation between environmental mold/mycotoxin exposure, multisystem illness, 
immunodeficiencies and female susceptibility. 
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Survivors of candidemia without antifungal treatment 
L. Hesstvedt1, P. Gaustad2, C. Torp Andersen2, F. Muller2, I. Nordoy1 
1Dept. Of Infectious Diseases, Oslo University Hospital, Oslo, Norway, 2Dept. Of Microbiology, Oslo 
University Hospital, Oslo, Norway 
Objectives: Candidemia is associated with high mortality, which increases without antifungal 
treatment. The aim of this nationwide, retrospective study was to examine factors associated with 30-
day survival in a subpopulation of candidemia patients who did not receive antifungal treatment. 
Methods: We collected data by reviewing medical records from patients who were diagnosed with 
candidemia between January 1st 2008 and December 31st 2012. Age (at or below and above 65 years), 
sex, Candida species (C. albians vs. C. glabrata), predisposing illnesses (malignancy; gastrointestinal 
cancer, hematological malignancy or all other malignancy, organ transplantation, chronic obstructive 
pulmonary disease, diabetes mellitus, inflammatory bowel disease, intravenous drug users – IVDU) 
and health-care related risk factors (central venous catheter - CVC, urine catheter, mechanical 
ventilation, dialysis, abdominal surgery, neutropenia – neutrophils <0.5 x109/L > 5 days, use of 
antibiotics, corticosteroids, chemotherapy, proton pump inhibitor –PPI or total parenteral nutrition-
TPN) were recorded. 
Results: In 144 candidemia patients (60.4% men, age 63.9 ± 16.2 years) not receiving any antifungal 
treatment, the overall 30-day survival rate was 36.8%. No significant difference was found between 
genders of untreated survivors (n = 53, 54.7% men, age 63.6±20.4) and untreated non-survivors (n = 
91, 63.7% men, age 74.2±11.7) Overall significantly more of the patients < 65 years than ≥ 65 years 
survived without treatment (55.8% vs. 26.5%, p = 0.015). Of predisposing illnesses malignancies 
excluding hematological and gastro-intestinal cancers was significantly less common in untreated 
survivors compared to non-survivors (23.5% vs. 76.5%, p = 0.02). Of healthcare related risk factors the 
untreated survivors significantly less often were mechanically ventilated (34.5% vs. 65.5%, p = 0.049), 
less often had urine catheters (27.0% vs. 73.0%, p<0.001), received TPN (23.9% vs. 76.1%, p = 0.04) or 
PPI (28.4% vs. 71.6%, p = 0.03) compared to untreated non-survivors. Central venous catheters were 
more often removed in untreated survivors than in non-survivors (29.2% vs. 10.9%, p = 0.04). 
Untreated intravenous drug users (IVDU) (n = 9) all survived candidemia. No significant difference 
was seen between untreated survivors and non-survivors related to C. albicans or C. glabrata 
candidemia. 
Conclusion: Patients surviving untreated candidemia were significantly younger, had less 
underlying malignancy and fewer risk factors for candidemia, in addition more often having their 
CVC removed than the patients who died without treatment. The prognosis in untreated candidemia 
is influenced by comorbidity and its subsequent treatment. 
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Mucormycosis – A clinicoepidemiological review of cases over 10 year 
M. O'Sullivan 
Clinical Microbiology, Chrisitan Medical College, Vellore, Tamil Nadu, India 
Objectives: Objectives: To study the epidemiology and outcomes of various agents causing 
mucormycosis in different clinical settings in a tertiary care hospital from South India. 
Methods: Patients and methods: We reviewed details of 184 consecutive patients with culture-
proven mucormycosis with consistent clinical syndrome and supporting features from September 
2005 to September 2015. 
Results: Results: The mean age of patients was 50.42 years; 70.97% were male. Unlike developed 
countries, Rhizopus microsporus (29/184; 15.7%) and Apophysomyces elegans (20/184; 10.8%) also 
evolved as important pathogens in addition to Rhizopus arrhizus in our setting. Paranasal sinuses 
(136/184; 73.9%) followed by musculoskeletal system (28/184; 15.2%) were the common areas of 
involvement. A. elegans typically produced skin and musculoskeletal disease in immune-competent 
individuals with trauma (12/20; 60%) and caused significantly lower mortality (P = 0.03). R. 
microsporus was more common in patients with haematological conditions (25% vs 15.7%) and was 
less frequently a cause for sinusitis than R. arrhizus (27.58% vs 10.9%). The overall mortality was 
30.97%. Combination therapy with surgery and antifungals offered the best chance for cure. 
Conclusion: Conclusions: Agents causing mucormycosis may have unique clinical and 
epidemiological characteristics. 
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Biliary Tract Candidiasis: an overview of the epidemiology in a general hospital 
I. Costales1, L. Milian2, E. Vallina1, S. Martínez1, A. Templado1, J.A. Boga1, T. Peláez1 
1Servicio De Microbiología Y Parasitología, HUCA, Oviedo, Spain, 2Servicio De Microbiología Y 
Parasitología, CAUSA, Salamanca, Spain 
Objectives: Infections of the biliary tract are a common gastrointestinal disorder. Infections caused 
by Candida spp. and other fungal species have increased their incidence in the last few years. Knowing 
the autochthonous epidemiology is advisable in order to ensure an effective empirical therapy and 
an optimal management of the patients. 
Methods: Biliary tract samples from patients diagnosed with acute cholangitis from January 2017 to 
June 2019 were included in the study. We considered only one one sample per patient and clinical 
episode. All isolates were identified using MALDI-TOF Biotyper®  (Bruker Daltonics) methodology 
and yeast susceptibility testing were performed by SensititreTM YeastOne®  (Thermo Scientific, TREK 
Diagnostic systems, UK). In case of polyfungical infections, all yeast isolates were identified and 
susceptibility test weas performed, but were considered as a single sample. 
Results: From a total of 299 biliary samples analyzed, 80 of them (26.8%), corresponding to 65 
patients, showed positive fungal growth. During the study period, the incidence of yeasts isolated 
from biliary tract increased from 2017 (0.49/1.000 admissions) to 2019 (0.95/1.000 admissions). The 
species most frequently recovered from biliary tract candidiasis episodes were C. albicans (56.25% of 
cases), C. glabrata (16.25%), C. Krusei (6.25%), C. tropicalis (6.25%), C. parapsilosis (6.25%) and other 
yeasts (8.75%). The percentages of isolation of different yeasts isolated in the first and last year of the 
study were respectively as follows: C. albicans (70.6% vs 53%), C. glabrata (11.7% vs 23.6%), C. krusei ( 
5.9% vs 11.8%), C. tropicalis (0% vs 16.7%), C. parapsilosis (0% vs 13.3%) and other yeasts (11.8% vs 
23.5%). A total of 51 cases (78.46%) of biliary tract candidiasis were monofungal infections and 14 
(21.54%) were polyfungal infections. 
Conclusion: In our hospital, the incidence of biliary tract candidiasis increased during the study 
period probably due to an improvement of culture methods, as well as greater clinical suspicion 
requesting a micologycal analysis of bile samples. Globally, C. albicans was the most frequent yeast 
species isolated, followed by C. glabrata. However, a significant increase in potentially fluconazole 
resistant species (C. glabrata and C. krusei) occurs in the last year of the study. 
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Prevalence of severe asthma with fungal sensitization (SAFS) in European population. 
A. Iunovidova1, N. Klimko2, A. Sobolev1 
1Department Of Clinical Mycology, Allergology And Immunology, North-Western State Medical 
University named after I.I, Mechnikov, Saint-Petersburg, Russian Federation, 2Department Of 
Clinical Mycology, Allergology And Immunology, North-Western State Medical University n.a. I.I. 
Mechnikov, Saint-Petersburg, Russian Federation 
Objectives: SAFS can be defined as a continuum of fungal sensitization with asthma at one end 
andallergis bronchopulmonary aspergillosis at the other. The main goal was to determine the 
prevalence of SAFS in the European population due to insufficient data. 
Methods: Incident case and population data were obtained for SAFS fron the Surveillance, 
Epidemiology, and End Results between 2011 and 2018. 
Results: Recent global estimates have found 10,000,000 cases of fungal asthma occur annually. The 
major assumptions made were based on previous studies of SAFS; severe asthma is thout to affect 
about 10% of adults and 33-70% are sensitised to fungi and that 2.77-2.90% of population have 
asthma. Although the prevalence of SAFS is uncertain as this disease has been recently described it 
was conservatively estimated that 30% of patients with severe asthma have or develop SAFS. Patients 
with SAFS probably constitute a significant proportion (~50% estimated) of the nearly 0.5 million 
asthma related deaths worldwide. The burden of SAFS has been estimated to 4,125,428 (+-174,033) 
cases in 43 countries. 
Conclusion: The diagnostic gap between estimated burden and recorded cases numbers provides a 
clear cut target to close, to improve patient outcomes. 
Therecognitionoffungalinfectionsasamajorcontributortomortalityofseveralconditionsemphasizes the 
need for public health efforts in reducing the incidence and mortality of these infectious diseases 
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Epidemiological aspects of superficial mycosis among arabic school children in two localities in 
Sénégal (Thies and Touba) 
A. Badiane, K. Diongue, M.C. Seck, M. Ndiaye, D. Ndiaye 
Parasitology And Mycology, Universite Cheikh Anta Diop de Dakar, Dakar, Senegal 
Objectives: The objective of this study was to determine the prevalence of superficial mycosis in 
koranic schools of Thies and Touba, two cities located in western Senegal. 
Methods: This study were conducted in children from seven (07) koranic schools in two cities of 
Senegal (Thies and Touba). A total of 210 children were recruited. For each child, depending of the 
lesions squama, hairs or nail pieces were collected using sterile material. Fungal pathogens were 
identified using direct examination with 30% Potassium Hydroxide (KOH) and culture on Sabouraud 
addionned with chloramphenicol and actidone (cycloheximide). 
Results: The most prevalent lesion was tinea capitis (90%). The culture was positive for 25.1% of the 
pupils. The species identified were Trichophyton soudanense (85.18%), Microsporum audouinii 
langeronii (9.25%), Trichophyton rubrum (3.70%), and Chrysosporium keratinophilum (1.85%). 
Among infected participants, children aged 3 to 10 years were more contaminated (53.70%), followed 
by the age group of 11 to 15 years (44.44%) and participants over the age of 15 were less infected 
(1.85%). The prevalence of infection was higher among boys (85.18%). 
Conclusion: This study showed a fairly prevalence of superficial mycoses among koranic school 
children. 
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Objectives: Mucoraceous moulds are very common in natural environment. They may rarely be the 
cause of severe or even fatal infections in immunocompromised patients, patients with uncontrolled 
diabetes mellitus or patients bearing deep and dirty wounds. The aim of this study was to record the 
cases of infections by mucoraceous moulds, microbiologically diagnosed in our laboratory and to 
detect the existence of any possible specific feature of these infections. 
Methods: A retrospective recording was performed of all similar cases tested by our laboratory 
during the last twelve years 
Results: Eleven cases of mucoraceous mould infections were recorded (7 male, 4 female). The fungal 
pathogens isolated were: 9 Rhizopus arrhizus, 1 Mucor circinelloides and 1 Saksenaea vasiformis. Seven 
patients were immunocompromised, two were suffering from uncontrolled diabetes mellitus and 
two of them had deep, dirty wounds. Five of the aforementioned cases concerned culture plates sent 
to the laboratory for identification of the fungal isolate. As for the other six specimens, direct 
microscopy of the clinical sample was positive for all of them. In 8 cases, antifungal susceptibility 
testing was performed and the range of MICs was 0.003-16 μg/ml for amphotericin B and 0.75-12 
μg/ml for posaconazole. The outcome was favourable for five patients. In nine out of the eleven cases 
the infection was presented in spring or autumn, seasons that in our country are characterized by 
mild to moderate temperatures and relatively high humidity. 
Conclusion: All patients had at least one risk factor for mucormycosis. A seasonal distribution was 
noticed, something that has been noted by other authors too. Positive direct microscopy in all clinical 
samples demonstrates the great importance of the procedure which provides promptly very 
characteristic images and contributes to the initiation of targeted treatment which may be life saving. 
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Molecular Epidemiology of Histoplasmosis in Germany 
D. Wilmes, H.L. Losert, H. Leibhan, J. Gerkrath, V. Rickerts 
Fg16-mycology, Robert Koch Institute, Berlin, Germany 
Objectives: Histoplasmosis is a systemic fungal infection caused by obligate pathogenic fungi of the 
genus Histoplasma. Autochthonous infections in wild and domesticated animals document the 
presence of Histoplasma in the environment in Germany. The aim of this study is to characterize the 
molecular epidemiology of Histoplasmosis in Germany by multilocus sequence typing (MLST) of 
Histoplasma cultivated from patients diagnosed in Germany and to compare them to strains 
characterized by a modified MLST from infected animals in Germany. 
Methods: Since the year 2000, we participated to the diagnosis of 76 human cases (mean = 4/year) 
and 10 animal cases (7 cats, 3 badgers) of proven and probable infection. Twenty-two Histoplasma 
strains cultivated at our Laboratory, including two CBS reference strains were typed using a 4 gene 
scheme (arf, H-anti, ole and tub) previously described by Kasuga (1). Concatenated sequences were 
aligned with reported sequences of worldwide isolates. Then a modified MLST for formalin fixed 
paraffin (2) embedded samples was performed on pathology blocks from veterinary samples. 
Neighbour joining trees were constructed to demonstrate relationships using the Geneious software 
suite. 
Results: All four genes could be sequenced for 16 of 22 isolates while the amplification of the ole gene 
failed for 6 isolate. The phylogenetic analysis demonstrated clustering of the German patient isolates 
with previously defined clades (African: n = 7; Latin American: n = 7; Bat associated clade1: n = 1; 
Netherlands: n = 1) corresponding to the patients travel history. Of note, 3 patient isolates clustered 
with the Eurasian clade, in which also 7 animal samples (5 cats and 1 badger) clustered, suggesting 
related organisms. Two of the patients had a travel history to Southeast Asia, while for one no travel 
history was reported. 
Conclusion: Our study demonstrates that histoplasmosis in Germany is mostly imported from 
endemic regions including Latin America, Africa and Southeast Asia. However, clustering of human 
isolates and veterinary cases from Germany within the Eurasian clade suggest the presence of 
Histoplasma in the German environment. Further molecular studies on human and veterinary cases 
and environmental sampling are needed to define environmental niches. 
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Burden of fungal infections in Morocco 
B.E. Lmimouni1, S. Azelmat2, C. Hennequin3, D. Denning4 
1School Of Medicine And Pharmacy, University Mohamed The Fifth, Parasitology and Medical 
Mycology Lab, Military Teaching Hospital Mohamed the Fifth, Hay Riad, Rabat, Morocco, 
2Parasitology And Medical Mycology, Military Teaching hospital Mohammed the Fifth, Rabat, 
Morocco, 3Parasitology-mycology, APHP, Hôpital St Antoine, Paris, France, 4University of 
Manchester, Manchester, United Kingdom 
Objectives: We report for the first time in Morocco burden estimates of fungal infections. The aim of 
this study was to estimate the incidence and prevalence of fungal infection in Morocco. 
Methods: We used the national demographic data and performed a PubMed and Scopus search to 
retrieve all published papers on fungal infections from Morocco. We have also modelled the likely 
burden of serious fungal infections using methodology previously published by LIFE. 
Results: We report for the first time the main causes of these diseases in our country. Superficial 
mycoses and dermatophytic infection (onychomycosis, tinea capitis, others …) are very commonly 
diagnosed, We have found 13,294 cases in the published papers. Deep fungal infection are less found 
in the literature. Modlelling shows higher rates for all infections where modelling is possible, 
especially for pulmonary fungal infections. Literature Modelling Infection Rate/100,000 Total burden 
Rate/100,000 Total burden Cryptococcal meningitis 0.32 115 0.7 252 Pneumocystis pneumonia 0.22 78 
1.2 420 Invasive aspergillosis 0.88 315 1.9 674 Mucormycosis 0.01 4 0.2 72 Chronic pulmonary 
aspergillosis post TB 0.74 266 8.6 3085 Allergic bronchopulmonary aspergillosis (ABPA) 0.01 4 51 
18,400 Severe asthma with fungal sensitization (SAFS) 0.28 100 67 24,292 Candidaemia 1.47 528 5 1800 
Oral Candidiasis 0.25 90 22 7800 Mycetoma 0.11 40 Recurrent Candida vaginitis (>4x/year) 0.17 30 
2755 496,000 Histoplasmosis 0.01 4 - - Skin dermatophytic infection 13.97 5031 - - Onychomycosis 
14.08 5069 - - Tinea capitis 8.87 3194 - - Deep dermatophytosis 0.02 10 - - Total burden estimated 14522 
551,400 
Conclusion: A focus on improving the diagnosis and epidemiological data related to fungal infection 
is necessary in Morocco. 
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Fusarium keratitis in the Netherlands (2005 – 2016). 
C. Oliveira Dos Santos1, E. Kolwijck1, C. Eggink2, P.E. Verweij3 
1Medical Microbiology (777), Radboud University Medical Center, Nijmegen, Netherlands, 
2Ophthalmology, Radboud University Medical Center, Nijmegen, Netherlands, 3Medical 
Microbiology, RadboudUMC, Nijmegen, Netherlands 
Objectives: Recognizing the clinical picture of fungal keratitis is difficult. As a consequence, the 
fungal diagnosis might be delayed due to primary therapy with antibacterial agents and topical 
corticosteroids, resulting in spreading of the fungus in the cornea which ultimately may lead to more 
severe infection and monocular blindness. There seems to be a trend of increasing incidence of fungal 
keratitis in the Netherlands, especially caused by Fusarium species. Here, we describe the 
epidemiology and clinical management of fungal keratitis in the Netherlands. 
Methods: The Dutch national reference center for medical mycology has received Fusarium strains 
isolated from 89 Dutch fungal keratitis patients, in the period 2005 up to 2017. The clinical data was 
added in retrospect by the ophthalmologists. All Fusaria were identified up to genus level using 
conventional techniques and/or molecular techniques. Antifungal susceptibility testing was 
performed according to the method described by the EUCAST. The antifungal agents tested were 
amphotericin B, voriconazole and natamycin. Susceptibility to the antisepticum chlorhexidine was 
also tested. 
Results: In this period there was a mean incidence of Fusarium keratitis of 0.5 (range 0 – 1.5) per 
million per year. The male to female ratio was 1:3 (p = 0.014). The use of contact lenses in this cohort 
was high; 92.9% of patients with reported use or non-use of contact lenses. The time between start of 
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symptoms to the diagnosis of fungal keratitis was significantly longer in the group with therapy 
failure opposed to the group with restored vision; respectively 22 days versus 15 days (p = 0.024). 
The need of a corneal transplantation or enucleation of the affected eye occurred in 27 cases (n = 20 
[22.5%] resp. n = 7 [7,9%]). Enucleation occurred in patients with delayed diagnosis of the fungal 
culprit (>14 days after start symptoms). The mean visual acuity was moderately impaired with a 
logMAR of 0.8 (95% CI 0.6 – 1) at the time of isolation of the Fusarium strain. The final visual outcome 
had an average logMAR of 0.2 (95% CI 0.1 – 0.3), the equivalent of mild visual impairment. The 
treatment strategies differed greatly between the cases. Of note, five patients were treated with 
chlorhexidine 0.02% monotherapy after Fusarium was isolated with good results; 4 patients had a 
successful outcome. The most frequently isolated species was F. oxysporum (n = 22, 24.7%) followed 
by F. solani sensu stricto (n = 16, 18%) and F. petroliphilum (n = 8, 9%). The lowest MICs were obtained 
with amphotericin B followed by natamycin, voriconazole, and chlorhexidine.  
 
Conclusion: In our population trauma is not the main route of infection. An important risk factor in 
the Netherlands seems to be the use of contact lenses. When correct diagnosis and antifungal 
treatment is delayed the risk of losing the affected eye is great. The lack of a specific national guideline 
is reflected in the greatly varying treatment strategies. Chlorhexidine seems to be a good addition to 
the therapeutic options. 
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Fungal invasive infections after kidney tranplant: a monocenter study 
M. Zaidan1, Z. Mechref1, M. Frank-Soltysiak2, D.-P. Nguyen2, A. Durrbach1, A. Angoulvant3,4 
1Nephrology, Hôpital Bicêtre, APHP, Le Kremlin Bicêtre, France, 2Dim Hups / Aphp Wind, Hôpital 
Bicêtre, APHP, Le Kremlin Bicêtre, France, 3Génétique Quantitative et Évolution – Le Moulon, INRA 
– Université Paris-Sud – CNRS – AgroParisTech, Gif-sur-Yvette, France, 4Mycology-parasitology, 
Hôpital Bicêtre, APHP, Le Kremlin Bicêtre, France 
Objectives: Invasive fungal infections constitute an important cause of morbidity and mortality in 
solid organ transplantation recipients. Epidemiology of invasive fungal infections (IFI) after kidney 
transplantation in the modern era of immunosuppression is poorly described. We aim to describe the 
IFI epidemiology in our centre. 
Methods: We retrospectively analyzed the epidemiology of IFI in a single-center cohort of kidney 
transplant adult recipients between January 2011 and December 2018. 
Results: There were 1646 kidney transplanted patients hospitalized during the study period; 68 (4%) 
cases of IFI were identified. Sex ratio (M/F) was 1.1 and mean age 63 years (44 – 77). IFI occurred 12 
(1-144) months after transplantation, in patients with immunosuppressive therapy containing 
tacrolimus, mofetil mycophenolate and corticosteroids. 100% of them had renal insufficiency, 68% 
had diabetes and 50% were neutropenic at the time of the IFI diagnosis. A. fumigatus proven or 
probable invasive aspergillosis (IA) was the leading cause (n = 28, 1.7 %) followed by pneumocystosis 
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(n = 20, 1.22%), candidemia (n = 15. 0.92%) and other IFI (n = 6 (0.3%). Urinary source was identified 
in 77% of patients with candidemia. C. albicans (60%) was the leading species followed by C. glabrata 
and C. parapsilosis (20% each). Loss of graft occurred in 20% of them. Mortality was 50%, 40% and 
10% for IA, candidemia and pneumocystosis respectively 
Conclusion: In our centre IFIs, excepted pneumocystosis, were associated with high mortality rates 
in renal transplant patients. IA was the most common and was associated with the higher mortality. 
Candidemia occurred rarely but was associated with high mortality and loss of graft rates. 
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Prevalence and biotypes of vulvovaginal Candidiasis among reproductive-age women in Sarajevo. 
S. Kotoric Keser1, A. Pilav2, S. Bektaš1, D. Hodžić1, A. Obradović Balihodžić1 
1Microbiology, P.I. INSTITUTE FOR PUBLIC. HEALTH OF CANTON. SARAJEVO, Dr. Mustafe 
Pintola 1/III 71 000 Sarajevo, Sarajevo, Bosnia and Herzegovina, 2Social Medicine, P.I. INSTITUTE 
FOR PUBLIC. HEALTH OF CANTON. SARAJEVO, Dr. Mustafe Pintola 1/III 71 000 Sarajevo, 
Sarajevo, Bosnia and Herzegovina 
Objectives: The study aimed to determine the prevalence of VVC among reproductive-age women 
attending the Institute for Public Health of Canton Sarajevo. And to know the fungal profile/biotypes 
of vulvovaginal candidiasis using Candida CHROMagar. 
Methods: This is a 4-month cross-sectional study performed at the Department of Medical 
Microbiology of the Institute for Public Health of Canton Sarajevo. A pair of high vaginal swab and 
endocervical swab samples was collected from each of 213 individual participating subjects. They 
were separately inoculated on Sabouraud's dextrose agar and incubated aerobically at 33°C for 48 
hours and Candida CHROMagar. Infection with Candida species was diagnosed by microscopy of a 
saline wet mount, Gram-stained smear and colony growth on SDA and Candida CHROMagar. 
Results: Of the 213 sampled, 109 were positive for candidiasis giving a prevalence rate of 51.1%. 
Candidiasis was observed mostly among the 20- to 30-year age-group .The ages of the women ranged 
from 16 to 45 years with a mean of 26.8 (standard deviation ± 4.93).Women aged 26–30 years recorded 
the highest prevalence of 37.6% (41/109).Candida albicans was the most prevalent species isolated in 
85.3% of the women followed by Candida crusei 12.8% and Candida parapsilosis 1.83%. 
Conclusion: High prevalence rate of vulvovaginal candidiasis among females in Sarajevo and the 
predominant agent is Candida albicans. In addition, correct identification of Candida species could play 
an important role in management and treatment of VVC. 
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Cryptococcal antigenemia in HIV-uninfected patients with stroke in Nigeria 
S.A. Fayemiwo1, O. Makanjuola1, F. Bongomin2, J. Nwaokenye3, R. Akinyemi4, S. Diala4, M. Faniyan5, 
M. Owolabi4 
1Department Of Medical Microbiology & Parasitology,, College of Medicine, University of Ibadan, 
Ibadan, Nigeria, 2Department Of Medical Microbiology And Immunology, Gulu University, 
Kampala, Uganda, 3Department Of Medical Microbiology & Parasitology,, University College 
Hospital, Ibadan, Nigeria, 4Centre For Genomic And Precision Medicine,, College of Medicine, 
University of Ibadan,, Ibadan, Nigeria, 5Department Of Medicine, University of Ibadan, Ibadan, 
Nigeria 
Objectives: Stroke continues to be a leading cause of morbidity and mortality globally. Infections 
have been associated with stroke occasionally, but are not considered to be a direct cause, and so they 
are not often included in the traditional stroke workup and management. Sub-Saharan Africa also 
has the highest incidence, prevalence, and fatality from stroke in the world. Cryptococcal infections 
occur globally and in a wide variety of individuals, ranging from those who are severely 
immunocompromised to those who are assumed to be immunocompetent. Recurrent strokes 
secondary to cerebral infarction may occur and has been reported in immunocompetent persons 
following reactivation of a latent infection. The study aimed to determine the prevalence of 
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Cryptococcal antigenaemia in stroke patients, to identify risk factors for Cryptococcal antigenaemia 
in stroke patients and to compare Cryptococcal infection among stroke and non-stroke patients. 
Methods: The Stroke Investigative Research and Education Network (SIREN) project, which this 
study was a part of, is a multicentre, multidisciplinary, case-control study carried out in Ghana and 
Nigeria. One of the objectives of this extensive study is to evaluate the risk factors of stroke in blacks 
in Sub-Saharan Africa. Cases were adults (aged ≥18 years) with stroke confirmed by CT or MRI. 
Controls were age-matched and gender-matched stroke-free adults (aged ≥18 years) recruited from 
the communities in catchment areas of cases. A simple random sampling was used to select blood 
samples of 50 stroke patients and 50 controls from the study population. Inclusion criteria were stroke 
patients and controls who were HIV negative confirmed by HIV testing. Serum from study 
participants was tested for the presence of Cryptococcal antigen with the Cryptococcal Antigen 
Lateral Flow Assay (LFA) (Dynamiker Cryptococcal Antigen Lateral Flow Assay (LFA)), a point-of-
care test for the diagnosis of Cryptococcosis. 
Results: Ninety-nine HIV-uninfected patients (50 cases and 49 controls) constituted the study 
population. Majority of the participants were males (n = 69, 70%), with a median age of 57 (range: 33-
86) years. 36 (n = 50, 72%) for cases and 22 (n = 49, 44.9%) were hypertensive while six (n = 50, 12%) 
for cases and 14 (n = 49, 28.6%) were diabetic. Overall, CrAg was positive in 16% (n = 16) of the 
participants. Similar proportions of the cases and controls were CrAg positive (18% vs. 14%, p = 
0.786). 8(n = 9, 89%) for cases and 3 (n = 7, 43%) hypertensive particiapnts were CrAg postive.Death 
rates was the same between CrAg positive and CrAg negative patients (13% Vs 13%, p = 1.000 by 
Fisher’s exact test). Multinomial Logistic Regression DM (odds ratios, 0.77 (95%CI: 0.55-1.08); p = 
0.130). 
Conclusion: Cryptococcal Infectious causes should be considered in the differential and work up of 
stroke in certain patient populations, especially in Sub-Saharan Africa, and appropriate treatments 
should be initiated to minimize adverse stroke-related outcomes. 
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1Service De Parasitologie-mycologie/section De Biologie, UFR Sciences de la Santé, Université Gaston 
Berger, Saint-Louis, Senegal, 2Service De Dermatologie, Faculté de médecine, UCAD, Dakar, Senegal, 
3Service D'orthopédie, Faculté de médecine, UCAD, Dakar, Senegal, 4Service De Parasitologie, 
Faculté de médecine, UCAD, Dakar, Senegal, 5IHU-Méditerranée Infection, Marseille, France 
Objectives: Mycetoma is a neglected tropical disease, characterized by the formation of tumor like-
swellings and grains. This disease transmitted through subcutaneous tissue is caused by a range of 
actinomycetes (actinomycetoma) and fungi (eumycetoma). Treatments for eumycetoma are 
unsatisfactory leading to high amputation rates. Senegal represents one of the country where the 
disease is highly endemic. However, many mycetoma cases are underdiagnosed/misdiagnosed due 
to the lack of informations in health workers and at the community level.The purpose of this study 
is to generate accurate data of the geographical distribution of Mycetoma spp. cases and their 
management in hospital settings in Senegal. 
Methods: In this retrospective study we report epidemiologic, clinical, diagnostic and therapeutic 
data of mycetoma observed in three hospital centers in Senegal in a 10 year-period (2008 to 2018). 
Results: A total of 193 cases were included in the study. One hundred and sixty two patients (83.5%) 
were recruited in two hospitals of the capital Dakar and the other patients (16.5%) were diagnosed in 
Thies region located at 70km from Dakar. Most of the cases (47.2%) were eumycetoma followed by 
36.8% for actinomycetoma cases and 16.1% undetermined form. The mean age was 38.3 years and 
the patients were predominately aged between 15 and 45 years (68.4%). There was a male 
predominance with a sex ratio of 2.94 and most patients were agricultural workers. One hundred 
fifty six patients (80.8%) have used local and oral phytotherapy before attending hospital with 
sometimes an evolution beyond 10 years (19.1%). The main affected localization was lower limbs 
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(90.6%) and most of the patients had lesions over 10cm. Grains were observed in 85% cases including 
white (25.6%) and yellow (4.3%) grains. The diagnosis was difficult in many cases without positive 
results in direct microscopy, culture and histopathology explaining that 16.1% remained 
undetermined. In most of cases, actinomycetoma form were treated with cotrimoxazole plus 
amoxicillin/clavulanic acid plus streptomycin while eumycetoma cases were treated with terbinafin. 
The surgery was done in 100 cases (51.8%) including amputation performed in 45 patients. 
Conclusion: This study has shown the difficulty of the diagnostic of mycetoma in Senegal, the delay 
in management cases and the lack of adequate therapeutic tools. The baseline data provided will 
contribute to the establishment of a surveillance system, in the context of advocating for much more 
attention. 
 
P264 
Clinical and Microbiological Characterization of Candida parapsilosis complex Infection in a 
Tertiare Care Hospital from Cali, Colombia 
A. Ceballos-Garzon1,2, L. Martinez3, C.M. Parra-Giraldo2, A.M. Sanz Montealegre3, D.M. Martinez3, F. 
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Objectives: To determine the association between the resistance of C. parapsilosis complex 
to Fluconazole and adverse clinical outcomes in patients hospitalized in the Valle del Lili 
Foundation. 
Methods: An observational prospective study was conducted. The study included patients 
with C. parapsilosis complex (CPC) isolations attended at Valle del Lili Foundation (FVL) 
from 2016 to 2017. The 55 strains were identified by MALDI-TOF MS. Minimal inhibitory 
concentrations (MIC) were determined by broth microdilution (M27 A3 CLSI). Statistical 
univariate analysis was performed; differences between resistant cases and non-resistant 
cases were assessed through U Mann-Whitney test, Pearson chi-2 test or Fisher exact test 
Results: 55 patients had CPC isolations during the study period: 18 newborns, 13 children, and 24 
adults. Most isolations were from blood cultures (n = 31) (14 of them newborns), 
bronchoalveolar lavage (n = 9), peritoneal fluid (n = 8), and catheter tips (n = 3). The resistance 
was 36%. 52 strains were C. parapsilosis s.s., of them, 20 were FCZ resistant; 3 strains 
were C. orthopsilosis, all of them FCZ sensitive. The MIC50 = 1 µg/ml and MIC90 = 16 
µg/ml. Patients with previous antifungal treatment had a higher risk of FCZ resistance (RR: 
2. 14, 95% IC 1. 07-4. 26). The mortality brute rate was 30%, patients with renal failure 
death risk (RR: 2.8, 95% CI: 1. 4-6. 9), heart disease (RR: 3.14, 95% CI: 1. 4–6. 9), and 
hemodialysis (RR: 2.97, 95% CI: 1.38-6.4). Candidemia was present in 50% of deaths 
among children with parenteral nutrition 
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Figure 1. Minimal inhibitory concentrations (MIC) to C. parapsilosis complex (n = 55). Strains ATCC 
6258 and ATCC 22019 was used as a control.
 
Figure 2. Graphical analysis of mass spectra obteined by MALDI-TOF MS of cytoplasmic protein 
extracs from clinical isolates of C. parapsilosis complex. 
Conclusion: Fluconazole resistance in CPC has increased in the last decade. Newborns receiving 
parenteral nutrition had a higher proportion of CPC fungemia, we also found higher 
mortality rates among this population 
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Characterisation and Antifungal Susceptibility of Cryptococcus species Isolated from Rodents 
N.N. Tirkey, K. Singh 
Animal Mycology Laboratory, Zoology, Mmv, Banaras Hindu University, VARANASI, India 
Objectives: Rodents are recognized as intermediate hosts of zoonotic diseases that represent a serious 
threat to human health. Cryptococcus is an opportunistic fungal pathogen found worldwide and 
causes life-threatening meningoencephalitis especially in immunocompromised host. In this view, 
the present study was conducted to investigate the role of rodents in the epidemiology of 
cryptococcosis caused by Cryptococcus neoformans. 
Methods: Rodents (Rattus rattus, Mus musculus castaneus, Mus musculus domesticus) were trapped 
from the city of Varanasi, India (eastern Uttar Pradesh). After behavioural and clinical examinations, 
they were euthanized. The organs were removed aseptically for histopathology and isolation of 
fungi. For isolation, homogenates were cultured on Sabouraud’s dextrose agar (SDA). The isolates 
were then grown in Staib’s and tobacco agar medium. In addition, all isolates were identified on the 
basis of different biochemical tests such as germ tube test, urease test and canavanine-glycine-
bromothymol blue (CGB) test. Further, molecular characterization was carried out by using PCR and 
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DNA sequence analysis. In vitro antifungal susceptibility profiles of Cryptococcus strains were 
performed by using broth microdilution method recommended by CLSI (2009) M27-A3. 
Results: Out of 20 screened, 2 rodents were positive for Cryptococcus spp. At the necroscopy, there 
were no pathological lesions. Cryptococcus species were isolated from the lungs, kidney, brain and 
blood of the animals. The isolates were subjected to germ tube test and pseudohyphae were not 
observed after 24 hrs of incubation at 37°C in mammalian serum, therefore the test was considered 
as negative. The presence of brown colonies on Staib’s and tobacco agar media confirmed that the 
isolated pathogen is Cryptococcus. Further the isolates of Cryptococcus were tested for urease 
production using Christensen urea citrate agar medium in which all isolates were found to hydrolyse 
urea rapidly and reddish pink colour was obtained confirming it to be Cryptococcus neoformans. All 
isolates were negative for Canavanine glycine bromothymol blue (CGB) as they failed to produce a 
colour change in the medium. Molecular analyses showed that these isolates were C. neoformans. 
Histological sections of lungs stained with haematoxylin and eosin stain revealed the presence of C. 
neoformans like encapsulated cells. In in vitro antifungal testing, isolates were found susceptible to 
amphotericin B. 
Conclusion: All the rodents screened are synanthropic. As they were found positive for C. neoformans, 
they could be a potential threat for human health. Therefore wide epidemiological survey should be 
conducted. 
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Objectives: Otomycosis or Fungal Otitis External is a superficial infection of the outer ear canal. This 
could lead to complications involving the middle ear. The prevalence of otomycosis has been studied 
in several parts of the world. It is seen more frequently as an opportunistic infection in 
Immunocompromised people and those with ear injury. This study was carried out to determine for 
the first time, the prevalence of otomycosis in patients attending the Ear, Nose and Throat (ENT) 
Clinics at Abia State University Teaching Hospital (ABSUTH), Aba, South Eastern Nigeria and to 
isolate and characterize fungal agents responsible for otomycosis. 
Methods: A total of 380 patients presented at the ENT Clinics during the period of study. Out of this 
number, 100 samples were collected from those patients who presented with symptoms of ear 
infection (pruritis, otalgia, otorrhea and hypacusis) by the ENT Consultant Physician. Patients with 
other types of ear disorders other than otitis media and otitis externa and patients under antibiotic 
therapy within the last 2 weeks were excluded from the study. Demographic characteristics of the 
patients were noted. The samples which consisted of swabs and scrapings were examined in 10% 
potassium hydroxide solution and cultured on Sabouraud Dextrose Agar containing 
Chloramphenicol. Fungal growth were identified using slide culture techniques and physiological 
tests which include growth on some cspecialized media, germ tube test, urease test, growth in Corn 
Meal Agar Containing Tween 80, nitrate assimilation, sugar assimilation and sugar fermentation 
tests. 
Results: Out of the 100 samples examined, (68% males and 32% females)were positive for fungal 
structures both in microscopy and culture. Males were significantly more affected than females in the 
ratio of 19: 4 (P<001). Although ear infection was highest within the age group 1-10 years, fungal 
infection was highest within the age group 31- 40 years. Otomycosis was highest amongst outdoor, 
unskilled labourers (8%), followed closely by students (6%) and lowest among civil servants (2%). 
The aetiologic agents isolated were Candida albicans (13%), Candida tropicalis (5%), Aspergillus 
fumigatus (3%) and Aspergillus niger (2%). 
Conclusion: This study has shown for the first time that fungi are implicated in ear infections in 
ABSUTH. The prevalence of otomycosis in the present study is high. Clinical follow up with 
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mycological diagnosis are important since symptoms (pruritis, otalgia, otorrhea and hypacusis) are 
not specific. In fact many cases of otomycosis are clinically misdiagnosed as otitis media leading to 
chronicity.Laboratory diagnosis and management of otomycosis though challenging is very 
important. This is to detect the causative organism and avoid wrong prescription of drugs. 
Recurrences are common in immunocompromised patients than in immunocompetent patients. 
General practitioners, otologists and laboratory personnel should remain alert for otomycosis. 
Diagnosis of ear infections should not be made on clinical diagnosis only, it should be confirmed by 
laboratory diagnosis. Specimens must be collected by an experienced Medical Personnel by aid of 
otoscope. The frequent use of earphones, pricking the ear with hard objects, and traumatic attacks on 
the ear are factors that could predispose to otomycosis. 
 
P267 
Six Year Surveillance Study of Scedosporium and Lomentospora Isolates Collected from Humans 
in the United States (2012 - 2018) 
S. Bauman, C. Gibas, C. Sanders, D. Mccarthy, H. Patterson, N. Wiederhold 
Fungus Testing Laboratory, The University of Texas Health Science Center at San Antonio, San 
Antonio, United States of America 
Objectives: Scedosporium species and Lomentospora prolificans are increasing causes of invasive 
infections in immunocompromised hosts, and many isolates have reduced susceptibility or are 
resistant to available antifungals. This is especially true for isolates of L. prolificans, which are often 
resistant to all clinically available antifungal agents. Although these fungi can be common colonizers 
in patients with cystic fibrosis, invasive infections can occur, as can breakthrough infections in 
persistently neutropenic and or lymphopenic patients, as well as lung transplant recipients. Our 
objective was to evaluate the species distribution and antifungal susceptibility patterns of 
Scedosporium and Lomentospora clinical isolates in the United States over a 6-year period. 
Methods: The electronic database of our reference mycology laboratory (Fungus Testing Laboratory, 
UT Health San Antonio) was queried for Scedosporium/Pseudallescheria/ Lomentospora isolates received 
between September 2012 and October 2018. Fungal species identification was performed when 
requested by observation of phenotypic characteristics combined with DNA sequence analysis of ITS 
rDNA and the calmodulin gene. Antifungal susceptibility testing was performed by broth 
microdilution according to the CLSI M38 standard. 
Results: 1376 isolates were received over this 6-year period. The overall species distribution as well 
as the distribution of species identified by our laboratory are shown in Table 1. Overall, S. 
apiospermum was the most prevalent species, followed by S. boydii and L. prolificans, and these 3 
species accounted for ~89% of the isolates received. Voriconazole had the most potent in vitro activity 
of the azoles and amphotericin B tested against Scedosporium species (Voriconazole geometric mean 
[GM] MIC range 0.79 – 0.83 mg/L Table 2). In contrast, the activity of isavuconazole was markedly 
reduced (GM MIC range 6.25 – 6.68 mg/L). Caspofungin and micafungin also demonstrated in vitro 
activity against Scedosporium species, although the clinical relevance of the minimum effective 
concentration (MEC) is unknown. The in vitro potency of all agents was reduced against L. prolificans. 
However, greater variability was observed when all isolates were included in the analysis versus 
those that our laboratory identified, especially for L. prolificans, which is considered to be pan-
resistant to clinically available agents. This suggests possible misidentification of species, which may 
be due to reliance on phenotypic characteristics. 
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Conclusion: Scedosporium speices and Lomentospora prolificans are not uncommon fungi cultured from 
patients in the United States. The species distribution we observed is similar to those reported in 
previous surveillance studies from other countries. Although voriconazole had the most potent in 
vitro activity, variability was observed among the different species, with reduced activity observed 
for all antifungals against L. prolificans. 
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Molecular typing of isolates of Microsporum canis collected in Brasil 
J. Neves1, J. Alvarez2, A.R. Molinar1, M. Pasquetti1, S.D.A. Coutinho2, A. Peano1 
1Departament Of Veterinary Sciences, Sector Of Parasitology, University of Turin, Grugliasco, Italy, 
2Post-graduation Program In Environmental And Experimental Pathology, Paulista University, São 
Paulo, Brazil 
Objectives: Microsporum canis is the most common dermatophyte in cats and dogs. M. canis is 
diffused worldwide and plays an important zoonotic role. Methods able to characterize a pathogen 
at a strain level are expected to provide useful information to gain insight into the dynamics of disease 
transmission. Among methods proposed for strain typing of dermatophytes, the microsatellite (MS) 
multilocus typing method is considered one of the most powerful tool. MS are tandem-repeating 
DNA sequences comprised of 1-6 bp per repeating unit, that are polymorphic in populations due to 
their propensity for insertion/deletion mutation of multiples of the repeating unit during replication. 
Multiple loci are generally used, so that a multilocus genotype is obtained (multi-locus microsatellite 
typing – MLMT).This study was aimed to investigate the intra-specific variability of strains of M. 
canis isolated from different animal hosts and environment sites in Brasil, using a panel of 8 MS. 
Methods: Fungal strains were collected in different locations in Brasil (mainly in the city of Sao 
Paulo), from cats, dogs and environment sites. Overall, 73 strains of Microsporum canis from 12 
outbreak episodes were included in the genetic analyses. DNA was extracted using a commercially 
available kit (NucleoSpin®  Tissue, Macherey-Nagel, Düren, Germany). PCR primers were designed 
against sequences flanking the MS detected by a BLAST (Basic Local Alignment Search Tool) search 
using the nucleotide sequence information assembled by the Microsporum canis CBS 113480 genome 
project 
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(http://www.broadinstitute.org/annotation/genome/dermatophyte_comparative/MultiHome.html). 
Primer sequences for the 8 MS markers recognized as the most polymorphic were custom synthesized 
(Applied Biosystems UK) with a fluorescent label attached to the 5’ end of each forward primer. 
Microsatellite fragment analysis was performed using an ABI Prism 310 Genetic Analyzer (Applied 
Biosystems, FosterCity, CA) for capillary electrophoresis. The ML-MS genotypes for the Brasilian 
isolates were compared with the genotypes available in the database of the Departament of 
Veterinary Medicine of Turin, which includes more than 300 strains mainly sampled in Europe. 
Results: Out of the analyzed strains, 5 different multilocus genotypes were detected. One genotype 
was more prevalent as it was shared by 11 strains coming from 9 episodes. Thus the genetic diversity 
was quite low, perhaps due to the fact that a restricted geographic area was sampled. A higher degree 
of diversity is instead present in the existing database. 
Conclusion: These data allow enriching the database of MS profiles already available, which regards 
mainly strains isolated in Europe. Such an enrichment represents a key step to make the database a 
more and more powerful reference in the study of the dynamics of transmission of M. canis. Indeed, 
it must be pointed out that studies that report the same strain among all isolates from a suspected 
outbreak, occurring in a geographic region for which no baseline data on the degree of variation in 
the population exists, remain uninterpretable. 
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Genetic diversity of Pneumocystis jirovecii in a tertiary hospital in Spain 
L. Goterris Bonet1, M. Guerrero Murillo1, L. Pasic2, A. Anton Pagarolas1, J. Aguilar Company3, I. Ruiz-
Camps3, M.T. Martin-Gomez1 
1Microbiology, Vall d'Hebron Universitary Hospital, Barcelona, Spain, 2Molecular Mycology 
Research Laboratory,, Centre for Infectious Diseases and Microbiology,The University of Sydney, 
Sydney, Australia, 3Infectious Diseases, Vall d'Hebron Universitary Hospital, Barcelona, Spain 
Objectives: Pneumocystis jirovecii (PJ) is an opportunistic fungus that can be found in the respiratory 
tract of humans as an asymptomatic colonizer or as a cause of severe pneumonia (PJP) in 
immunocompromised patients. Establishing associations between genetic types and clusters of cases, 
clinical manifestation or underlying pathology is not easy as there is no consensus on the better 
typing scheme. The aim of this study is to apply two multi-locus sequence typing (MLST) protocols 
to ascertain their ability to discriminate the genetic diversity of colonized and infected 
immunocompromised patients visited at a tertiary referral hospital in Spain. 
Methods: Patients and samples: From April 2014 to April 2018, consecutive respiratory tract samples 
with a positive result for P. jirovecii by PCR were included. Only 1 sample per patient and respiratory 
episode was studied. Laboratory procedures: Two different MLST protocols were carried out. 
Protocol A (http://mlst.mycologylab.org/pjirovecii) targeted the B-tubulin, dihydropteroate synthase 
(DHPS) and mitochondrial 26S rRNA (mt26S) loci. Protocol B is a newly developed scheme targeting 
the cytochrome B (cyt), mt26s and superoxide dismutase (SOD) loci (Pasic et al. Establishment and 
optimization of a combined MLST scheme for Pneumocystis jirovecii. 21th ISHAM Congress 2018, P-
223). Phylogenetic analyses: The obtained sequences were depurated and collapsed before achieving 
phylogenetic analyses. The resulting trees were constructed computing genetic distances among 
patients for each protocol. Patients were categorized into PJP (green) or PJ colonized (red) groups. 
Results: Samples from 35 pneumonia cases and 51 colonizations were included. Successful 
amplification rate was non-significantly different for protocol A (total 58.1%; 26/35[LG1] PJP and 
24/51 colonizations) and B (total 72.1%; 26/35 PJP and 34/51 colonizations). As shown in figure 1, 
Protocol A allowed the identification of 11sequence-types (ST) whereas protocol B was able to find 
21 different ST. Both protocols agreed in finding no apparent clustering of cases in time or space. 
However, whereas Protocol A grouped 73.1 %[LG2] of pneumonia cases into a group of 7 closely 
related ST and 61% of colonization cases into the other 4 ST, no apparent correlation between illness 
and ST could be seen with protocol B.  
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Conclusion: In the present study, two MLST protocols were carried out to describe PJ genetic 
diversity in our cohort. The two protocols provided complementary information: greater genetic 
diversity was documented with protocol B, whereas protocol A helped us to find sequence-types 
mostly associated with PJP or colonization. This study allowed us to demonstrate the absence of PJ 
outbreaks in our hospital during the study period. 
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Disability and disease after hazardous indoor exposure to airborne Stachybotrys spores: exposure 
variable analysis shows significant correlation with injury to mucosa, phagocytes and neurons. 
I.H. Grant1, J. Geller2, H. Sabath3 
1Community Medicine, New York Medical College, Tarrytown, United States of America, 
2Information Revelations, Montclair NJ, United States of America, 3International Environmental 
Diagnostics Inc, Irvington NYw, United States of America 
Objectives: While Stachybotrys is a mold that flourishes indoors with chronic water intrusion, its 
spores usually require physical disturbance of its colony growth or prolonged wetness to become 
airborne. The macrocyclic Trichothecenes mycotoxins in its spores are extremely toxic 
nanoparticulates dangerous for all mammals, damaging intracellular protein/DNA/RNA production 
and mitochondrial function causing premature cell death on contact: apoptosis. As exotoxins, they 
remain toxic despite disinfection, bind to dust causing damage to mammalian skin, mucosa, 
phagocytes, neurons, and organs via systemic circulation, especially with inhalation. Objectives: To 
determine: - The frequency of severe illness due to indoor airborne Stachybotrys spore exposure. - 
Specific exposure risks (fungi, hazardous exposure activities) - The impact of genetically-impaired 
intracellular MTHFR detoxification capacity. - Conditions that predispose to opportunistic fungal 
infection with such exposures (e.g. mucosal injury, immunosuppression, malnutrition) 
Methods: Prospectively monitored 14 (7M, 7F) adults and children exposed to 5 documented 
Macrocyclic Trichothecenes-contaminated indoor-environments with airborne Stachybotrys spores 
with comprehensive environmental-mycological and medical investigations, fungal IGGs, urine 
mycotoxins (MCTs: Aflatoxin, Gliotoxin, Ochratoxin A, MT), immune parameters (neutrophils, 
lymphocyte subsets, monocytes, IGG, IGA, IGM, IGE, subclasses), immunosuppressants, nutritional 
deficiencies (protein, Vitamin D, zinc), genetic Methylenetetrahydrofolate reductase (MTHFR) 
single-nucleotide-polymorphisms C677T&A1298C. Disease Severity Outcomes (DS), Environmental 
Mold-Contamination Severity (EMCS), Hazardous Exposure Activities (HEA), Exposure Duration 
(ED), MCT/Trichothecenes exposure (MTC/TE), and clinical findings were stratified and analyzed. 
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Biostatistical analysis (Pearson Correlation Coefficients) correlated DS with EMCS, HEA, ED, 
MCT/TE, mucosal Injury (MI), Neurological disease, Cell-mediated Immunodeficiencies (CMIs), 
combined cellular-immunoglobulin immunodeficiencies (CCIs), mucosal injury (MI), mold-specific 
IGG response(M-IGG) and genetic MTHFR deficiencies. 
Results:  
  
CORRELATIONS: Disease Severity based on formal disability classification or physical injury 
strongly correlated with Hazardous Activities (p = 0.01819), Immune deficiencies (p = .046229). 
Environmental Exposure Exposure Hazards (especially unprotected mold disturbance, uncontained 
construction/repairs, basement living, HVAC contamination and sewage overflow) correlated with 
immunodeficiencies (p = .046229). Environmental contamination with multiple mycotoxins 
correlated with multiple mycotoxin urinary excretion (p = .026354). Duration of exposure correlated 
with urinary excretion of multiple mycotoxins (p = .006314) as well as Trichothecenes p = .00875). 
Urine Trichothecenes correlated with immunoglobulin deficiencies (p = .037285). 
Conclusion: The high frequency of immune deficiencies (93%), mucosal injury and pain (79%), 
bleeding, and neurological damage (71%), burning and chronic fatigue (64%) with expected 
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respiratory/Gi /Dermatologic symptomatology in 50% is consistent with known Trichothecenes 
effects in animal models and military data. The high frequency of cell-mediated immune deficiency 
is consistent with invitro and in vivo research on Stachybotrys spores injuring phagocytes, 
supporting injury from inhalation of Stachybotrys spores. The high 94% MTHFR methylation-defect 
incidence is peculiarly striking compared to estimated USA 50-60% prevalence. MTHFR is a key 
intracellular detoxifying enzyme protecting ribosomes/mitochondria RNA/DNA damage from 
Trichothecene injury via glutathione metabolism. Further investigation is needed to determine if 
Trichothecenes trigger genetic damage. Urine macrocyclic Trichothecenes detection appears a useful 
marker for environmental macrocyclic Trichothecenes exposure. Public health education and 
epidemiological research are urgently needed to investigate correlation between environmental 
mold/mycotoxin exposure and immunodeficiencies. 
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Two different involvement of Aspergillus fumigatus in the same case: endophthalmitis and 
lumbar spondylodiscitis 
G. Dogan1, O. Tunger1, F. Kocoglu1, C. Temiz2, P. Temiz3, S. Senol1, C.B. Cetin1 
1Infectious Diseases And Clinical Microbiology, Manisa Celal Bayar University Faculty of Medicine, 
Manisa, Turkey, 2Neurosurgery, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey, 
3Pathology, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey 
Case Report:  
Aspergillus species are mold type fungi that commonly found in nature and especially for 
immunocompromised people can cause opportunistic infections. Aspergillus-induced endogenous 
endophthalmitis is a very rare ophthalmic emergency that can result in visual loss. Bone infections 
caused by Aspergillus species are also rare clinical manifestation especially occurs in 
immunocompromised patients. In this case report, two rare clinical conditions such as endogenous 
endophthalmitis and lumbar spondylodiscitis due to Aspergillus are reviewed. 
A 39-year-old woman with no known underlying disease was admitted to the Ophthalmology 
Departmant with loss of vision in her left eye. Approximately two months ago, there was a history 
of antibiotic use (moxifloxacin) for pneumonia. No additional physical examination findings were 
detected in the patient. Laboratory tests revealed erythrocyte sedimentation rate 59 mm / h, leukocyte 
count 9.81 103 / /L, hematocrit 34.2%, platelet count 552 103 / /L, neutrophil count 7.53 103 / /L, C-
reactive protein 1 mg / dl. Vasculitis was detected in ocular angiography and corticosteroid therapy 
(prednisolone 32 mg) was started by consultation of Rheumatology Department. Lumbar puncture 
was performed after normal result of cranial MRI that performed for differential diagnosis of 
vasculitis, and CSF examination was normal. The patient had undergone vitrectomy because the 
complaint did not regress despite steroid treatment. Direct examination of the vitreous specimen 
revealed gram positive bacteria and fungi, and intravitreal Liposomal AMB treatment with 
intravenous liposomal amphotericin-B (LAMB) and moxifloxacin was initiated. Aspergillus fumigatus 
was grown in vitreous samples. Bronchoscopy was performed and there was no cultural growth in 
BAL samples. Parenteral antimicrobial treatment was completed and was discharged after 14 days. 
The patient who had low back pain and morning stiffness was hospitalized in Rheumatology with 
the preliminary diagnosis of ankylosing spondylitis and received 250 mg intravenous 
methylprednisolone treatment for 3 consecutive days. Due to the absence of sacroileitis in MR 
imaging and monitoring of L4-L5 spondylodiscitis, piperacillin tazobactam and daptomycin were 
started empirically. The patient was than hospitalized in Infectious Diseases. In the pathological 
examination of the lumbar spine, fungal hyphae were seen and LAMB (3 mg / kg) was added to the 
treatment because of the positive galactomannan antigen (GMA). The patient whose complaints had 
regressed and whose GMA was negative was discharged with oral voriconazole after 45 days use of 
LAMB and 7 days use of parenteral voriconazole. The patient underwent oral voriconazole therapy 
for 160 days during outpatient follow-up, and regression was detected in control magnetic resonance 
imaging. CONCLUSION: In immunosuppressive and immunocompetent patients, fungal agents 
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should be considered in case of treatment failure, and hidden foci such as endocardium, eye and 
vertebrae must be investigated because of hematogenous transmission. 
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Epidemiological trend, spectrum, clinical profile and outcome of fungal keratitis from Delhi, India 
M. Capoor1, S. Kocchar2, V. Gupta2 
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2Opthalmology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India 
Objectives: Fungal aetiology of keratitis ulcer is considered to be one of the leading causes of ocular 
morbidity, particularly in developing countries including India. More importantly, Fusarium and 
Aspergillus spp. are reported commonly implicating corneal ulcer and against this background the 
present work was undertaken so as to understand the current epidemiological trend, clinical profile 
and outcome of fungal keratitis. 
Methods: During the study period (2013-2016), the clinical and mycological characteristics of fungal 
keratitis was investigated. Our aim was to discuss the predisposing factors, clinical manifestations, 
and epidemiological characteristics of the causative agents and describe the management strategies 
that have a high probability of successfully treating this disease. The corneal scrapings were 
processed by direct microscopic methods and standard culture techniques. All the samples were 
inoculated onto Sabouraud dextrose agar (SDA), potato dextrose agar (PDA), brain- heart infusion 
based blood agar in the form of a “C” streak. The SDA and PDA plates were incubated at 30°C for 7 
days, and the other plates were incubated at 37°C for 7 days. 
Results: A Total of 143 corneal scrapings from keratitis were processed, 72 (50.3%) revealed growth, 
of which 60 were culture positive for fungi and 12 were culture positive for bacteria. Direct 
microscopy revealed hyphae or budding yeasts or fungal elements in 60 cases. Among fungal 
aetiologies, Aspergillus spp. (51.7%) and Fusarium spp. (16.7%) were predominantly determined. The 
spectrum of mycotic keratitis cases was: Aspergillus flavus (15), A.fumigatus (12), Fusarium solani (5), 
Fusarium oxysporum (3), Curvularia lunata (3), C. tropicalis (3), C. parapsilosis (2), Fusarium dimerum (2), 
Paecilomyces lilanicus (2), Alternaria alternata (2), A.terreus (2), A. tetrazonus (1), A.niger (1), Bipolaris (1), 
Candida krusei (1), Schizophilum commune (1), Scedosporium apiospermum (1), Chryseosporium 
keratinophillum (1), C. tropicalis (1) and Scytalidium dimidiatum (1). Of the 60 mycotic keratitis male 
preponderance was seen in 66.66%. Predisposing factors included trauma with vegetative material 
(98.66%), contact lens use (1.66%), and bird feather hit (1.66%). Pain, redness of eye and dimunition 
of vision was most common clinical complaints. Steroids and inflammatory drugs were most 
common pretreatment medication taken. The corneal examination revealed central corneal ulcer with 
feathery margins, a paracentral superficial ulcer; a central ulcer with an irregular edge, satellite 
infiltrations, and hypopyon etc. Majority of the patients were given natamycin eye drop alone. 
Concomitant systemic antifungals and supportive surgical intervention was done in 4 and three cases 
respectively. Complete loss of vision was seen in one eye was seen in single case. 
Conclusion: Our study suggests that mycotic keratitis caused by Aspergillus spp. especially A. flavus 
may occur more often in a tropical climate, such as in Delhi, India. Aetiological agents other than 
Aspergillus species and Fusarium species have shown an upward trend. A combination of antifungal 
therapy and supportive surgical intervention may successfully resolve the mycotic infection Proper 
understanding of microbiological and clinical characteristics of keratomycosis will enable 
ophthalmologist to avoid unnecessary and indiscriminate use of steroids or antimicrobials.Early 
stage of diagnosis and formulation of an uncompromising management protocol can prevent 
profound visual morbidity. 
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Objectives: Sporotrichosis is a mycosis mostly caused by a group of thermodimorphic fungi 
embedded in a clinical clade (i.e., Sporothrix brasiliensis, S. schenckii, S. globosa, and S. luriei). The 
infection is caused after a traumatic inoculation of Sporothrix propagules into the (sub)cutaneous 
tissue of mammals. Sporothrix species have been reported around the world, mostly in regions with 
humid (sub)tropical and temperate climates. During the last decades, vast zoonoses have been 
ongoing in Brazil with Rio de Janeiro as the epicenter of this cat-transmitted epidemic. In this 
scenario, the development of new molecular markers is mandatory to explore the genetic diversity 
and track Sporothrix expansion during outbreaks. The purpose of this study was to analyze the genetic 
diversity of Sporothrix originating from different geographic regions of Brazil, using AFLP (Amplified 
fragment length polymorphism) markers. 
Methods: Sporothrix spp. genome sequences were retrieved from Genbank 
(https://www.ncbi.nlm.nih.gov/genbank/) and were in silico-digested with EcoRI and MseI using the 
software AFLPinSilico. Only fragments of 50-500 bp were considered. A total of 256 combinations of 
selective pairs of primers (based on 2 selective nucleotides) were employed to generate 2.304 
fingerprints profiles with different fragment numbers and sizes (0 to 56 fragments/per combination). 
Results: In silico analysis highlighted 6 combinations to be tested in a subset of 15 medically relevant 
Sporothrix isolates. In vitro, AFLP presented strict concordance with in silico results considering the 
number and size of the amplicons resolved during capillary electrophoresis. A total of 58 AFLP 
markers were unambiguously scored in the electropherograms using the software BioNumerics v.7.6. 
Dendrograms were constructed (UPGMA, Jaccard Distance) based on a banding match table and 
isolates were correctly clustered according to the taxon name. Intraspecific variation was observed 
for all agents, including S. brasiliensis, a species previously known to be clonal. Based on the data 
above we recommend the use of 3 different AFLP combinations to explore genetic diversity and 
taxonomy in Sporothrix. 
Conclusion: Independent experiments with similar results showed that the AFLP is highly 
reproducible, making this technique interesting to evaluate the genetic diversity and the spreading 
of Sporothrix. The present content in this study will enable the development of strategies to control 
the disease and will contribute to further studies about diversity in Sporothrix. 
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Kingdom, 3Westerdijk Fungal Biodiversity Institute, Utrecht, Netherlands, 4Department Of Infectious 
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Objectives: Histoplasmosis is a serious infectious disease in humans caused by Histoplasma spp. 
(Onygenales), whose natural reservoirs are thought to be soil enriched with bird and bat guano. The 
true global burden of histoplasmosis is underestimated and frequently the pulmonary manifestations 
are misdiagnosed as tuberculosis. Molecular data on the epidemiology of Histoplasma are still scarce, 
even though there is increasing recognition of histoplasmosis in recent years in areas distant from the 
traditional endemic regions in the Americas. 
Methods: We used multi-locus sequence data from protein-coding loci (ADP-ribosylation factor, H 
antigen precursor, and delta-9 fatty acid desaturase), DNA barcoding (ITS1/2+5.8s), AFLP markers 
and mating type analysis to determine the genetic diversity, population structure and recognize the 
existence of different phylogenetic species among 436 isolates of Histoplasma obtained globally. 
Results: Our study describes new phylogenetic species and the molecular characteristics of 
Histoplasma lineages causing outbreaks with a high number of severe outcomes in Northeast Brazil 
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between 2011 and 2015. Genetic diversity levels provide evidence for recombination, common 
ancestry and clustering of Brazilian isolates at different geographic scales with the emergence of LAm 
C, a new genotype assigned to a separate population cluster in Northeast Brazil that exhibited low 
diversity indicative of isolation. The global survey revealed that the high genetic variability among 
Brazilian isolates along with the presence of divergent cryptic species and/or genotypes may support 
the hypothesis of Brazil being the center of dispersion of Histoplasma in South America, possibly with 
the contribution of migratory hosts such as birds and bats. Outside Brazil, the predominant species 
depends on the region. We confirm that histoplasmosis has significantly broadened its area of 
occurrence, an important feature of emerging pathogens. 
Conclusion: From a practical point of view, our data point to the emergence of histoplasmosis caused 
by a plethora of genotypes and will allow the proposal of public policies to contain the spread of 
histoplasmosis. Furthermore, with the description of such diversity, we open avenues for future 
comparative genomic studies, which will allow progress toward a consensus taxonomy, improve 
understanding of the presence of hybrids in natural populations of medically relevant fungi, test 
reproductive barriers and explore the significance of these variations. 
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Objectives: Pulmonary tuberculosis is one of the most important health concerns. Pulmonary fungal 
infections have clinical and radiological characteristics similar to tuberculosis which may be easily 
misdiagnosed as tuberculosis. This study aimed to evaluate Mycobacterium tuberculosis (MTB) and 
other non-tuberculous mycobacteria (NTM) with coinfection of fungal infections in patients, during 
last 2 years. 
Methods: Microbiological and clinical reports of 149 patients with confirmed mycobacteria have been 
analyzed. Detection and identification of mycobacteria were performed by the standard culture 
method using the BACTEC MGIT 960 system (BD) and Lowenstein–Jensen medium. Identification 
of positive Mycobacterium tuberculosis complex (MTBC) was based on positive acid-fast bacilli 
microscopic smear (Ziehl–Neelsen and fluorochrome), positive niacin accumulation, MALDI-TOF 
and . Mycobacteria PCR. TB isolates were also tested for their sensitivity toward first-line anti-MTB 
drugs. 
Results: Between April 2017 and April 2019, at 149 patients were detected Mycobacterial infections 
(MTB 64%, NMT 36%). Mycological tests are not required in 36 24% patients. Mycological tests are 
required in 113 76% patients. The majority of patients had isolated several types of fungi, 160 
episodes. The patients 113 were isolated yeasts, opportunistic and saprophytic molds (54%, 16%, 
28%). Frequent Candida were C. albicans, C. dubliniensis, C. parapsilosis and C. glabrata respectively. 
Frequent Aspergillus were A. niger, A. fumigatus and A. flavus respectively. In addition to Aspergillus, 
small number of patient had Fusarium, Rhizopus and Pseudallescheria boydii. Saprophytic molds were 
confirmed in 28% of patients. 
Conclusion: Our findings showed the co-infection of fungi agents in patients with tuberculosis that 
should be considered. Clinical data must be analyzed to be able to distinguish infections, 
colonization, or part of normal flora. 
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Objectives: Pulmonary Aspergillosis is a world-widely distributed disease. The prevalence of 
Aspergillus infection in patients with delay resolution community acquired pneumonia (DR-CAP) or 
lower respiratory tract infection (LRTI) had not been investigated in Taiwan. The aims of the study 
was prospectively evaluate the prevalence of Aspergillus infection by serological testing and 
microbiological evidence in high risk patients presented with DR-CAP or LRTI. 
Methods: Patients presented with LRTI or DR-CAP were prospectively enrolled. Patients with 
underling chronic pulmonary disease (CLD), active tuberculosis (TB), collagen fiber disorders were 
study groups, and others who were healthy without underling disorders except DR-CAP or LRTI. 
Delay resolution of community acquired pneumonia (DR-CAP) was defined as clinical diagnosis 
with community acquired pneumonia not significantly getting resolution after 3-4 weeks of 
appropriate anti-bacterial antibiotics. Serum gamma-immunoglobulin (IgG) concentration for 
Aspergillus niger (A. niger) and Aspergillus fumigatus (A. fumigatus) were measured by ELISA method. 
Positive results were recorded by the cut-off-value provided by the company (ImmunoCAP@, 
ThermoFisher Scientic Inc.). Microbiological evidence for mold infection was record according to the 
results of fungus culture from sputum, bronchioalveloar lavage fluid (BALF), or nasal/throat swab. 
Patients were excluded for pulmonary malignancy by diagnostic approach such as bronchoscopic 
and transthoracic lung biopsy. 
Results: From 2018 April to 2019 Jan, a total of 99 patients were enrolled. Overall, 38.3%, 25.1%, and 
11.1% of patients were with CLD, collagen fiber disorders, and active TB or old TB with complete 
anti-TB therapy (ATT), respectively. There were 19% of patients were healthy but presented with 
LRTI not response to anti-bacterial antibiotics. Overall, seroprevalence for A. niger and A. fumigatus 
were 32.3% and 22.9%, and the patients with CLD had a highest seroprevalence with 35.4% and 
36.6%, respectively. In combination of microbiological and serological results, the prevalence for 
mold infection was 59%, and CLD remained a highest-risk disorder (48.7%). Overall, concordance 
between microbiological results for fungus culture and positive serological results for A. niger and A. 
fumigatus were 69.6% and 60%, respectively. 
Conclusion: Both the serological and microbiological evidence for mold or Aspergillus infection in 
high-risk patients with DR-CAP or LRTI were high in Taiwan. We also firstly reporeted the 
seroprevalence for Aspergillus spp. around 10% in patients without underling high-risk disorders, that 
indicate the populational seroprevalence in north Taiwan. 
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Objectives: Candida glabrata was formerly classified in the Torulopsis genera, but it is currently 
considered to belong to the Candida genus. Evidence showed that it is the second causative agent of 
nosocomial candidiasis, alone or coexisting with other yeasts, particularly other Candida species. The 
reason for this association is often unknown and some have suggested a synergistic pathogenesis. 
Due to the increasing resistance of C. glabrata to many common antifungal drugs, treatment in 
patients is also accompanied by some problems. Therefore, identification of co-infection in patients 
and the modification of therapeutic protocols is essential. 
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Methods: This descriptive laboratory-based surveillance study was investigated the incidence of 
nosocomial candiduria and it determined their etiologic agents in 555 hospitalized patients in two 
hospitals (253 hemodialysis patients in Hospital hemodialysis center of Amol city and 305 
hospitalized patients with heart failure in Heart center of Sari city), Mazandaran province, Iran. The 
patients’ urine samples were cultured in mycological culture media and colony counts >104 CFU/ml 
were considered significant for candiduria. Species identification was done based on color of colony 
on CHROMagar Candida and PCR-RFLP method, by ITS region and the MspI restriction enzyme 
and PCR amplification of HWP1 gene. 
Results: We found 40(15.8%) positive candiduria in hemodialysis patients and 58(18.8%) in heart 
failure patients. C. glabrata(47.1%), C. albicans(17.6%), C. tropicalis(15.7%), C. parapsilosis(15.7%) and C. 
kefyr(0.4%) were identified as candiduria agents in hemodialysis patients and C. glabrata(40.3%), C. 
albicans(40.3%), C. tropicalis(7.5%), C. parapsilosis(7.5%) and C. krusei(4.4%) were candiduria agents in 
heart failure patients. C. glabrata, alone as a single-species candiduria agent was detected in many 
patients. However, in these two patient groups, it has associated with other Candida species as mix-
infection. Nine hemodialysis patients had mix-infection by C. glabrata associated with other Candida 
species (7 cases C. glabrata + C. albicans, 2 cases C. glabrata + C. albicans + C. kefyr) and 9 heart failure 
patients had mix-infection by C. glabrata associated with one other species too (4 cases C. glabrata + C. 
albicans, 2 cases C. glabrata + C. tropicalis, 2 cases C. glabrata + C. parapsilosis and 1 case C. glabrata + C. 
krusei). 
Conclusion: Studies indicate increasing azole antifungal prophylaxis treatment and invasive 
application lead to an increase in low susceptibility to azoles non albicans species, and C. glabrata 
became second causative nosocomial infection agent now. The data suggest that the growth of other 
Candida species was stimulated by the presence of C. glabrata and this species in the biofilms more 
active than other species that produce biofilms with more biomass. Although, C. glabrata is generally 
considered a species of low virulence, mortality rate of patients with candidiasis caused by this 
species is higher than C. albicans because of complicates the treatment. Given the prevalence of C. 
glabrata and other candida species co-infection, it is necessary to understand the mechanisms used by 
C. glabrata in collaboration with them and the use of rapid identification methods for candidiasis 
agents can be a great help to treat these patients, more effectively. 
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Objectives: Publications about “real life” using of anidulafungin are limited. Study of anidulafungin 
for the treatment of invasive candidiasis (IC) in actual clinical practice in Russia. 
Methods: The primary endpoints were global response (clinical + microbiological response) at end 
of treatment (EOT), and the 30 days overall survival rate. For diagnosis of invasive candidiasis (IC) 
we used criteria EORTS/MSG, 2008. 
Results: In 2015-2017 yy. in a prospective multicenter (n = 23) study included 300 adult patients who 
were treated with anidulafungin. Men were 57%, median age – 49 y (from 18 to 98). All examined 
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patients had risk factors for IC. In 85% patients, a fever resistant to the use of broad-spectrum 
antibacterial drugs for ≥ 4 days was noted. Median APACHE II at the start of anidulafungin therapy 
was 18.8. Anidulafungin was used for the empirical therapy of IC in 82% patients. Global response 
at EOT was 79%, the 30 days overall survival rate was 78%. Anidulafungin was generally well 
tolerated with few treatment-related adverse events (hypokalemia – 1%, angioedema – 0.5%), which 
were not the cause of drug withdrawal. IC was laboratory confirmed in 25% patients. Candida non-
albicans (57%) prevailed among IC pathogens. In patients with proven IC the 30 days overall survival 
rate was 66%, which is significantly higher than in the earlier multicenter study in Russia (43%). 
Conclusion: The overall efficacy of anidulafungin was high (79%), the 30 days overall survival rate 
was 78%. Adverse events occurred in 1,5% cases and were not the cause of drug withdrawal. In 82% 
patients anidulafungin was used for empiric therapy. In patients with proven invasive candidiasis 
the 30 days overall survival rate was 66%. 
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Case Report: Introduction: Pseudomembranous Aspergillus Tracheobronchitis (PMAT) is an 
uncommon manifestation of invasive pulmonary aspergillosis (IPA). Patients are typically 
immunocompromised although sporadic cases have been reported in previously immunocompetent 
individuals.1Aspergillus flavus is the second most frequent Aspergillus species causing 
bronchopulmonary disease and isolates typically display MICs to amphotericin B (amB) which are 
two-fold dilution steps higher than A.fumigatus.2 Although the clinical significance of in vitro 
antifungal susceptibility is debated, there is evidence to suggest that A. flavus isolates demonstrating 
resistance to amB are associated with increased mortality.3 We present two cases of A. flavus PMAT 
with raised MICs to amB and contrasting host risk-factors. Methods: Susceptibility testing was 
performed using E-test on RPMI agar and confirmed at a reference laboratory using broth-
microdilution in accordance with CLSI methodology. As no species-specific breakpoints have been 
established for A. flavus, resistance was defined as ≥2mg/L based on expected MIC ranges.3 Results: 
Patient 1: A 39-year-old male was admitted for an Allogeneic Haematopoetic Stem Cell Transplant 
for Acute Lymphoblastic Leukaemia. Post-transplant, his medications included prophylactic 
liposomal amB. On day 4, he became febrile with an undetectable neutrophil count. Therapeutic 
doses of liposomal amB were subsequently added due to persistent fevers. Chest CT showed 
bronchial narrowing suggestive of mucous plugging and bronchoscopy revealed 
pseudomembranous tracheobronchitis. Bronchoalveolar-lavage (BAL) cultured A. flavus with an MIC 
to amB of 4.0mg/L. His antifungal regimen was changed to IV voriconazole and caspofungin. He 
required admission to ICU due to respiratory failure but died at 31 days post-transplant. Patient 2: A 
51-year-old previously immunocompetent male presented to hospital with fevers and progressive 
shortness of breath. Chest X-ray showed patchy infiltrates and he was commenced IV co-amoxiclav, 
clarithromycin and oseltamivir. By day 2, he required admission to ICU due to respiratory failure. A 
nasopharyngeal aspirate PCR returned positive for Influenza A RNA and IV hydrocortisone was 
added as an adjunct to his antiviral therapy. Bronchoscopy showed a pseudomembranous 
tracheobronchitis and brushings cultured A.flavus with an MIC of 2.0mg/L to amB. He received dual 
antifungal therapy with IV voriconazole and amphotericin B but died at 31 days post admission. 
Conclusion: These cases contrast a neutropenic patient with classical risk-factors for IPA with a 
patient who was not immunocompromised but was diagnosed with PMAT following Influenza 
infection. Diagnosis may be delayed by the absence of clearly distinguishable symptoms, laboratory 
parameters or imaging findings, and cases may be refractory to antifungal therapy. Our experience 
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is consistent with evidence demonstrating poor outcomes in patients with A.flavus infections with in-
vitro resistance to amB, and underline the importance of performing susceptibility testing to guide 
antifungal therapy. References: 1. Khalid S et al. Pseudomembranous aspergillar tracheobronchitis in 
a non-neutropenic critically ill patient in the intensive care unit. J Community Hosp Intern Med 
Perspect. March 2017p.43-45 2. Van Der Linden, J. W.M et al. Aspergillus species intrinsically resistant 
to antifungal agents. Medical Mycology,Vol.49, Issue Supplement_1, April 2011,p.S82–S89 3. Inès 
Hadrich et al. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection, 
Medical Mycology, Vol.50, Issue 8, November 2012,p829–834 
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Objectives: Invasive pulmonary aspergillosis (IPA) is an opportunistic fungal infection that often 
affects severely immunocompromised hosts. It has been recently documented as a co-infection in 
critically ill patients with severe viral influenza infection, although the exact risk rate is less well 
determined. To study the prevalence of IPA in critically ill patients with severe influenza in 
Evangelismos General Hospital, Greece. 
Methods: We retrospectively reviewed all the ICU records for the 2018-2019 influenza season. 
Influenza was diagnosed using the polymerase chain reaction. Co-infection had to be confirmed 
using standard bacteriological tests. 28-day ICU and hospital mortality was calculated. 
Results: Of the 69 patients diagnosed with influenza (34 H1NH, 31 Influenza A, 1 H1N2, 1 H1N3, 1 
H1N4) in our 1000-bed tertiary hospital, 9 patients where admitted to the ICU (5 H1N1, 1 Influenza 
A, 1 H1N3, 1H1N4). Two patients had a co-infection (2,9% of the hospitalized patients with influenza 
and 22% of influenza patients admitted to the ICU). 3 ICU patients suffering influenza were severely 
immunocompromised but none of them developed IPA. Underlying medical conditions included 
hematology malignancy (3), diabetes mellitus (2), chronic renal failure (2). IPA was confirmed by 
histopathological findings in one patient and in combination of clinical, microbiological and 
radiological criteria in both. The galactomannan test in BAL was positive only in the patient with 
endobronchial bulky disease. Microbiology BAL cultures were Aspergillus spp positive both (A. 
Fumigatusand A. Nigerrespectively). Both patients were treated with isavuconazole (6 and 12 weeks 
respectively) and were completely cured. The 28-days ICU mortality was 22,2% in influenza ICU 
patients group. 90-day hospital mortality was 44,4%. None of the 2 patients with IPA co-infection has 
died. 
Conclusion: IPA co-infection in critically ill patients with severe influenza has been increasingly 
reported worldwide in recent years. Infection with influenza may increase the risk of invasive 
aspergillosis by breaking down the bronchial mucosa facilitating Aspergillus invasion, inducing 
immunomodulatory effects. Aspergillus infection should be considered as a possible cause of 
persistent or progressing respiratory failure in immunocompetent critically ill patients suffering from 
influenza. The diagnosis of IPA requires awareness in order to conduct timely and appropriate 
testing. Microbiology laboratories also need to be aware of the suspicion of IPA. IPA is a rapidly 
progressive disease with high mortality rates up to 90%. Mortality can be reduced with prompt 
initiation of effective antifungal therapy. Isavuconazole has shown promising results in our clinical 
setting, for the primary treatment of IPA, especially in patients with endobronchial bulky disease and 
chronic renal failure. 
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Case Report:  
Objectives: Candida auris was first identified and described in 2009 in Japan. Genomic analysis has 
shown that C. auris emerged in at least 3 different continents, including the Middle-East, almost 
simultaneously. Here we report the first case of C. auris infection in Egypt.  
Methods: We present the first case of C. auris fungemia from a patient in Egypt.  
Results: A 53-year-old male was admitted in December 2017 to a hospital in Cairo just after returning 
travelling from Saudi Arabia. He suffered from vomiting, abdominal pain, bone aches and muscle 
weakness. Further investigations showed a positive C-ANCA and in a renal biopsy, small vessel 
vasculitis consistent with Wegeners granulomatosis. He received steroids and endoxane after which 
he improved temporarily. However, he became more ill and was transferred to ICU where he was 
intubated and received plasmapheresis. Due to kidney failure he required hemodialysis during his 
ICU admission. On day 40 of hospitalization he was transferred to a tertiary care facility in Alexandria 
with cardiovascular, respiratory and renal failure. He appeared septic with leukocytosis and elevated 
C-reactive protein of 223. Peripheral blood cultures were obtained and broad-spectrum empirical 
therapy with iv meropenem, colistin and caspofungin was started. Bronchoalveolar cultures showed 
growth of multidrug resistant Pseudomonas aeruginosa (only colistin and amikacin susceptible) and 
blood cultures showed the growth of yeasts which were identified as C. auris with the VITEK2 with 
updated database (version 8.01) and confirmed with MALDITOF. Despite the early proper empiric 
treatment with caspofungin the patient passed away on day 4 after admission. Urine cultures were 
negative for yeasts. After diagnosis, strict contact precautions were installed and no further C. auris 
cultures were identified in our healthcare facility in the past year. CLSI antifungal susceptibility 
testing showed resistance to fluconazole (64 mg/L), a higher MIC of amphotericin B (1 mg/L) and low 
MICs of echinocandins (0.063 mg/L). AFLP and MLVA genotyping showed that the isolate clustered 
with the south-Asian C. auris Clade.  
Conclusion: We report the first case of C. auris (south-Asian clade) bloodstream infection in Egypt. 
Since the patient resided shortly before in Saudi Arabia it is highly likely that he was colonized while 
staying abroad and that his fast progressing illness predisposed for this fatal outcome of C. auris 
fungemia. In the year after discovery no secondary cases were detected in our healthcare facility. 
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Objectives: Invasive pulmonary aspergillosis (IPA) in patients with influenza is increasingly being 
identified in recent years. Cases of influenza-associated IPA with high mortality have been reported 
from several developed countries with a reported incidence between 19-28 % (1, 2). So far no 
significant data is available from developing countries. The aim was to determine the incidence and 
outcome of IPA in patients with severe influenza pneumonia admitted in an intensive care unit (ICU) 
of a developing country. 
Methods: This was an observational study on confirmed influenza patients with respiratory failure 
admitted to the Aga Khan University hospital (AKUH) ICU from November 2018- March 2019. 
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Patients older than 18 years, acute respiratory failure, pulmonary infiltrates on imaging, and a 
confirmed influenza infection based on a positive influenza PCR were included. The diagnostic 
criteria used for IPA was based on suggestive clinical signs and symptoms, radiological findings and 
mycological data (2). Like other studies, we have also not included the host factors as this criterion 
was largely created for immunosuppressed hosts, and influenza‐related aspergillosis may occur in 
previously normal hosts (2). The clinical characteristics, radiology, laboratory data and outcome were 
recorded on a predesigned performa. 
Results: A total of 92 patients with confirmed influenza were admitted at AKUH during study 
period. Of these 16/92 (17.02%) were admitted in ICU due to respiratory failure. Among these 16 
patients, IPA was diagnosed in 5 patients, giving an incidence of 31.25%. The mean age of IPA 
patients was 61.2 (±5.02) years (Range 53-65 years) and 60% were female. Three (60%) patients had 
non H1N1 Influenza A and 2 (40%) had H1N1 Influenza A infection. Three (60%) patients had 
underlying diseases (diabetes, hypertension and ischemic heart disease) and one patient was 
immunosuppressed. Systemic steroids were used after ICU admission in all patients. On admission 
3 (60%) patients had acute kidney injury and 2 (40%) had deranged liver enzymes. Invasive positive 
pressure ventilation (IPPV) was required in 04 (80%) patients and one patient was managed on 
noninvasive ventilation (NIV). The average duration of IPPV use was 10.8 (range: 5‐24) days. All 5 
patients had received voriconazole after diagnosis of IPA. The overall mortality rate of influenza 
patients admitted in ICU was 50% and in patients with IPA was 60%. The causes of death were ARDS 
and multisystem organ failure. 
Conclusion: High incidence (31.25%) of IPA was found in influenza patients requiring ICU 
admission and was associated with high (60%) mortality. High index of suspicion, early diagnosis 
and appropriate treatment can improve outcome in these patient. Future large multicenter studies 
are required to assess the risk factors and role of antifungal prophylaxis to improve the outcome of 
influenza-associated aspergillosis. References: Schauwvlieghe A, Rijnders BJA, Philips N, Dutch-
Belgian Mycosis study group et al. Invasive aspergillosis in patients admitted to the intensive care 
unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018. Huang L, Zhang N, 
Huang X, et al. Invasive pulmonary aspergillosis in patients with influenza infection: A retrospective 
study and review of the literature. Clin Respir J. 2019 Apr;13(4):202-211. 
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Objectives: HELICAS (HELlenic Invasive CAndidiasis Study) was a prospective non-interventional 
study aiming to compare the cost of treatment of documented invasive candidiasis (IC) by C. albicans 
and C. non-albicans species, in 18 Greek intensive care units (ICUs). As part of this study, isolated 
Candida species were collected and analyzed. Additionally, the epidemiology of IC by C. albicans and 
C. non-albicans, was evaluated by collecting retrospective data from participating ICUs for an at least 
3-month period. 
Methods: A total of 100 adult subjects (49% C. albicans, 51% C. non-albicans) were enrolled according 
to a pre-specified sample size, for both C. albicans and C. non-albicans cases. Demographics, days of 
ICU stay, antifungal and concomitant medications, hospital supplies, laboratory investigations and 
treatment patterns, as well as patient outcomes and survival were documented. Eighty-two of the 
collected Candida isolates (39 C. albicans, 43 C. non-albicans) were sent to the Department of 
Microbiology, Athens Medical School, for further investigation. Candida isolates were identified by 
conventional, biochemical tests (CHROMagarCandida Medium, Becton Dickinson; API 32C, 
BioMérieux), supplemented with mass spectrometry (Vitek MS, BioMérieux), if the identification 
score was < 95%. Antifungal susceptibility testing for amphotericin B, 5-flucytocine, itraconazole, 
fluconazole, voriconazole, posaconazole, micafungin, caspofungin, and anidulafungin was 
performed with the broth microdilution method (MICRONAUT-AM MHK 2, MERLIN Diagnostika 
GmbH), according to CLSI 2012 M27-A3 document. Revised CLSI M27-S4 species–specific clinical 
breakpoints were applied. 
Results: Eighty-two strains were studied, the majority isolated from candidemia cases; 39 (47.6%) C. 
albicans, 26 (31.7%) C. parapsilosis, 9 (11.0%) C. tropicalis, 6 (7.3%) C. glabrata, 1 (1.2%) C. kefyr, and 1 
(1.2%) C. lusitaniae. All strains showed low MICs to amphotericin B, with MIC values ranging from 
0.0625 to1 μg/ml. Sixteen isolates were resistant to fluconazole: 15 C. parapsilosis (MIC range 8-32 
μg/ml) and 1 C. albicans (MIC ≥ 128 μg/ml), while 13 isolates exhibited dose-dependent susceptibility: 
6 C. glabrata, 4 C. parapsilosis, 2 C. tropicalis and 1 C. albicans. Only 2 isolates, i.e.1 C. albicans (MIC ≥ 
128 μg/ml) and 1 C. parapsilosis, were resistant to voriconazole, while 3 C. parapsilosis and 1 C. tropicalis 
exhibited dose-dependent susceptibility. Resistance to echinocandins was not detected in any strain. 
Intermediate susceptibility was demonstrated in 2 C. tropicalis to caspofungin and anidulafungin, and 
in 2 C. glabrata to caspofungin. Based on the epidemiology data, extrapolated to one year, the majority 
(64.3%) of IC cases in the participating ICUs were caused by C. non-albicans spp. (C. parapsilosis: 
45.7%), with the remaining 35.7% being due to C. albicans. 
Conclusion: Epidemiological patterns of IC reveal a predominance of C. non-albicans spp.in Greek 
ICUs, especially C. parapsilosis. Since 15/26 (57.7 %) of C. parapsilosis isolates were resistant to 
fluconazole, this observation raises concerns, as fluconazole has traditionally been considered the 
first-line choice for C. parapsilosis. In vitro antifungal susceptibility testing should be performed to 
assist in the selection of the most appropriate antifungal therapy, and in monitoring the development 
of resistance. 
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Species distribution and antifungal susceptibility patterns of Candida isolated from a Tunisian 
burn intensive care unit 
S. Cheikhrouhou1,2, D. Aloui1,2, M. Bouchekoua1,2, A. Messadi2,3, L. Thabet2,3, S. Trabelsi1,2, S. Khaled1,2 
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burn center, Tunis, Tunisia, Ben Arous, Tunisia 
Objectives: The objective of this study was to analyze the species distribution of Candida isolates from 
a Tunisian burn intensive care unit and their antifungal susceptibility patterns. 
Methods: We performed a retrospective review of 35 severely burned patients admitted to the burn 
intensive care unit of Ben Arous Trauma and Burn Center with one or more positive culture sites for 
Candida, during the 28-month period from January 2017 to April 2019. The susceptibility for 6 
antifungal drugs (5-fluorocytosine, fluconazole, ketoconazole, micronazole, itraconazole, 
amphotericin B) was determined using the Fungitest®  broth dilution method for patients with 
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infected normally sterile body sites or a Candida colonization index superior or equal to 0.4. 
Voriconazole and caspofungine were tested when needed. 
Results: A total of 74 Candida isolates were obtained. Positive urine cultures yielded 30% of Candida 
isolates. The rectal site represented 15% of colonized body sites, followed by nasal and oral sites 
(13,5% each), axillary (9,4%), ocular (8%) and cutaneaous and auricular sites (5,4% each). Candida 
albicans was the predominant species (43.2%), followed by C. glabrata (31%), C. tropicalis (17,5%), C. 
parapsilosis (3%), C. colliculosa (3%) and C. sake (1%). Among the strains whose antifungal 
susceptibility were determined, the majority of Candida isolates were susceptible to fluconazole 
(64%), 20,5% of the isolates were intermediate and 15,4% were resistant to this antifungal drug, 
mainly C. tropicalis and C. glabrata. There was a high rate of strains with intermediate susceptibility 
to itraconazole (46%), miconazole (50%) and ketoconazole (23%). Only one strain was resistant to 
amphotericin B which was C. tropicalis. 
Conclusion: Although the prevalence of non-albicans species has increased over recent years, C. 
albicans remains the most frequent species in burn unit-acquired candidiasis. Our antifungal 
susceptibility test results did not exhibit significant levels of resistance, but non-albicans species must 
be taken into consideration when choosing antifungal agents for calculated therapy. 
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Objectives: Invasive candidiasis (IC), including candidemia episodes, is a considerable cause of 
morbidity and mortality in immunocompromised critically ill patients. Studies have been reported 
that early diagnosis of IC is crucial for an appropriate treatment and successful outcome of patients. 
Analyses using serum levels of the β-D-glucan (BDG) biomarker have shown promising results for 
the early diagnosis of IC/candidemia. This study aimed to evaluate the performance of the BDG assay 
as a diagnostic tool for candidemia detection in ICU adult patients with risk factors for IC. 
Methods: Thirty-nine patients admitted to five ICU from two tertiary hospitals were enrolled, being 
11 with proven candidemia (at least one blood culture positive for Candida) and 28 patients with 
negative bloodstream cultures but clinical findings consistent with candidemia (probable 
candidemia). Blood samples for cultures and BDG testing were collected before administration of 
antifungal therapy. Candida spp. were isolated from blood by using the Bactec™ system and 
identified by VITEK®  MS which uses MALDI-TOF technology. BDG serum concentrations were 
measured using the Fungitell®  assay following the standard operating procedures. All samples were 
tested in duplicate. The analyses were performed using SPSS Statistics version 24.0. 
Results: All patients with proven candidemia presented positive results with significantly higher 
BDG values than those with probable candidemia (median 437.7 vs. 70.6 pg/ml, p <0.001). Among the 
probable candidemia patients, four (14.3%) showed positive BDG results (ranging from 85 to 276.5 
pg/ml), two of them had proven bacteremia, and three patients (10.7%) presented indeterminate 
values (≥ 60 and ≤ 80 pg/ml). Seven patients of the probable candidemia group (negative bloodstream 
cultures) presented positive cultures for Candida spp. in blood samples harvested from central venous 
catheter. These seven patients showed significantly higher BDG values when compared to patients 
with no positive cultures at all (median 151.4 vs. 51.7 pg/ml, p< 0.007). 
Conclusion: We presented preliminary results from a prospective study for early laboratory 
diagnosis of candidemia in ICU adult patients at high risk of this systemic infection. Patients with 
proven candidemia had significantly higher BDG levels than those patients in whom the bloodstream 
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Candida infection could not be demonstrated. The BDG positive values observed in patients with 
positive blood catheter cultures signal that these patients might have true candidemia in spite of 
negativity of blood cultures. By the other hand, the possibility of false-positive results in this group 
should be considered and in this scenario another non-culture based methodology, such as real time 
PCR technique would be required to firmly establish the diagnosis of candidemia. 
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Objectives: Beyond the classical neutropenic hosts, invasive pulmonary aspergillosis (IPA) is 
increasingly reported in non-neutropenic critically ill patients. Influenza A H1NI infection is one 
among those emerging non-classical risk factors. In a multicentre prospective observational study on 
invasive mould infections (IMIs)in Indian ICUs, we identified 12 cases of IPA associated with 
influenza H1N1 [1]. Here, we analysed those influenza associated aspergillosis (IAA) cases to 
evaluate its epidemiology in Indian ICUs. 
Methods: The study captured all cases of IMIs at 11 ICUs across India during April 2016 through 
September 2017. IMI was diagnosed as proven, probable and possible based on the EORTC-MSG 
criteria in the classical immunosuppressed subjects (2), the criteria proposed by Bulpa et al. in subjects 
with COPD (3), and Vandewoude et al. in non-COPD subjects admitted to the ICU (4). Demographic, 
clinical presentation, laboratory investigations, treatment and management of proven and probable 
IMIs were collected using predesigned proforma (1). The present study is the subgroup analysis of 
clinical and laboratory variables and management of 12 patients diagnosed as IAA. 
Results: During the study period 135 IPA cases (proven and probable) were reported, 37 (27.5%) had 
classical risk factor and 98 (72.5%) non-classical risk factors. Among non-classical risk factors 12 
patients had IAA; one patient was proven and 11 cases were probable IPA. Those patients were from 
four centres of India (north-1, south -2, and west-1) and majority (58.3%) cases from a single centre at 
Delhi. 10/12 cases occurred in summer. The mean age of those patients was 56.8 ± 12.34 years with 
equal distribution of sex. The mean APACHE score was 18.41 ± 4.56. The diagnosis of IPA was made 
at a mean of 3.83 ± 2.94 days after ICU admissions. The solid organ malignancies were co-morbidities 
in two patients, eight patients were on ventilator. Aspergillus species was isolated from ten cases 
(Aspergillus flavus-5, A. fumigatus -2, Aspergillus spp. – 2 and A. flavus+A fumigatus -1). Serum and/or 
BAL galactomannan was positive in eleven patients. Radiological evidence in the form of opacity (10 
cases), cavity (1 case), nodules (5 cases), infiltrates (2 cases), consolidation (7 cases) or pleural effusion 
(3 cases) was noted in those patients. None of them had classical air crescent or halo sign. The patients 
were treated with voriconazole (8 cases) or voriconazole + amphotericin B deoxycholate (1 case), 
voriconazole + caspofungin (1 case) and liposomal amphotericin B (1 case). But, the 42-day or 84-day 
mortality remained at 58.3% despite targeted antifungal therapy. 
Conclusion: The study emphasizes that influenza H1N1 is an emerging risk factor for IPA in Indian 
ICUs. Unlike other reports of A. fumigatus, A. flavus is the predominant causative agent in Indian 
scenario. During influenza season, critically ill patients should be thoroughly investigated for IPA. 
Early diagnosis and prompt therapy may reduce high mortality rate of IAA cases. References 
Chakrabarti et al. (2019). J Crit Care 51, 64–70. De Pauw B et al (2008). Clin Infect Dis 46:1813–21. 
Bulpa P(2007) Eur. Respir. J. 30:782–800. Blot SI et al (2012) Am J Respir Crit Care Med: 186:56–64 
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Objectives: Early detection of candida in blood using lateral flow assays and candida mannan assay 
in ICU patients at risk of invasive candidiasis selected by candida scoring and to compare the results 
with the Gold standard blood culture method. 
Methods: Patients having an ICU stay of > 7 days were taken up. Candida scoring was done and 33 
patients who had scored >3 were considered for the study. Patients Age, gender, clinical 
presentations at admission, severity scores including Acute Physiological and Chronic Health 
Evaluation II ( APACHE II), co- morbid medical conditions, surgical and invasive procedures, 
exposure to antibiotics, corticosteroids, antifungals, secondary bacterial infections, antifungal 
treatment instituted in the ICU and final outcome were recorded.Patients were divided into 2 groups 
based on the presence or absence of candida. The blood samples were collected at the onset of sepsis 
and assays were performed. The samples were tested for the presence of IgM and IgG antibodies 
specific for candida using lateral flow assay kits and mannan antigen using candida mannan assay 
kit ( Dynamiker Biotechnology (Tianjin) Co., Ltd ) which would provide early detection of candida in 
blood and thus facilitating in early start of suitable antifungal therapy and a favorable outcome. 
Results: A total of 33 patients admitted to the ICU from Jan 2019-April 2019 based on candida scoring 
were considered for the study. Of the 33 patients, six were proven cases of candidemia and the 
remaining 27 were did not grow candida in blood culture. The mean age of the patients who had 
candidemia ranged from 45-82yrs. Among the candidemia patients the male female ratio was equally 
distributed. The duration of stay in ICU was more for candidemia patients (median days 15). The 
APACHEII scoring was high among candidemia patient (median 54.5) compared to non candidemia 
patients (median 36.5). Also the candida scoring among candidemia patients was found to be high 
(median 4.5). The analysis of the results for the presence of IgG, IgM antibodies specific for candida 
and mannan antigen will be done and compared with gold standard blood culture method.
 
Conclusion: The three methods will be compared so that we don’t have to rely always on culture to 
start the treatment. Development of diagnostic and predictive tests will probably lead to increased 
use of preemptive therapy. The presence of biomarkers is an indicator to assist in decision to start or 
stop antifungal treatment. In case of positivity of fungal biomarker, it recommends to initiate 
preemptive therapy. In case of negativity of fungal biomarker, it suggests to stop empiric therapy. 
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Objectives: Management of invasive candidiasis (IC) in ICU patients is challenging since traditional 
diagnostic methods and prediction scores have limited sensitivity and specificity. Non-culture-based 
biomarkers could potentially improve diagnosis and antifungal treatment (AFT), enabling safer 
discontinuation of unneeded therapy. We evaluated a new antifungal stewardship programme 
(AFSP) including T2Candida and Candida mannan antigen (MAg) screening of high-risk ICU 
patients. 
Methods: 
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Patients in two ICU’s (abdominal/general and thoracic, respectively) at a tertiary university hospital 
were eligible. The Figure and Table summarise inclusion criteria, AFSP algorithm and IC 
classification criteria. The diagnostic value of T2Candida and MAg in relation to traditional methods 
were evaluated. Consumption of antifungals during the AFSP and the preceding 2 years was 
compared. 
Results: 219 patients with 504 T2Candida/MAg samples were included. Median age was 63 years, 
median ICU stay was 19 days, 45% were receiving renal-replacement-therapy; 29% TPN, 22% 
underwent acute surgery and the overall in-hospital mortality was 42%. At inclusion, 32% of patients 
had received AFT for >3 days. 30 patients had positive T2Candida; 24 positive MAg and 18 had 
positive blood cultures (BC). IC was classified as proven in 29, likely in seven and possible in 10 
patients. Defining IC as proven/likely versus unlikely, sensitivity/specificity/NPV values were 
47%/100%/91% for BC; 56%/97%/90% for T2Candida; and 39%/96%/88% for MAg. MAg identified 
five patients with IC, in whom T2Candida or BC were negative. Of these, one had proven C. lusitaniae 
IC and four had possible IC (colonizing isolates without species-identification). The best diagnostic 
performance was the combination of T2Candida&MAg taken <3 days after AFT: 
sensitivity/specificity/PPV/NPV of 70%/90%/ 63%/93%, versus 61%/93%/63%/ 92% for all patients, 
respectively. Overall, similar performance was observed if IC was defined as proven/likely/possible. 
The use of T2Candida/MAg contributed to 15% of patients receiving early (<3 days) AFT after a 
positive test, 25% of patients having early AFT discontinuation and 24% of patients being managed 
without AFT. No reduction or overall change in use of echinocandin or azole treatment was observed 
at the two ICU’s in the study period compared to the two previous years. 
Conclusion: Introduction of an AFSP based on T2Candida and MAg screening of high-risk patients 
contributed to reducing unnecessary treatment but not overall AFT use. The diagnostic performance 
of T2Candida for IC was higher than for BC and MAg, but lower than initially reported. T2Candida 
detects cell-associated Candida DNA and thus depend on circulating Candida cells. A significant 
proportion of our patients were already on antifungal therapy at the time of sampling or suffered 
from BC-negative IC thus likely representing patients with a low number of circulating Candida cells. 
Moreover, a significant proportion of patients were only tested once or twice. Taken together, our 
J. Fungi 2019, 5, 95 320 of 464 
 
study suggests that the combination of T2Candida and MAg improved diagnostic performance 
compared to T2Candida alone with a sensitivity of 70% and NPV of 93% in patients with ≤3 days 
AFT. This combination may contribute to improved management of IC in the setting of an AFSP 
particularly if initiated before AF prescription and with strict adherence to the AFSP. 
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Objectives: To evaluate the incidence, etiology and outcome of candidemia in ICU from our city 
Methods: We retrospectively analyzed all cases of candidemia diagnosed based on patients files, 
considering only the first episode/patient. We included non-neutropenic patients from 5 ICU from 
our city (1pediatric ICU, 1 medical ICU and 3 surgical ICU) during 6 years (Jan 2007- Dec 2012). We 
evaluated: demographic data, etiology, antifungal treatment and outcome. 
Results: There were 107 patients, average age 44.5 (median age 55, min 1 day, max 85 years, median 
age for PICU patients was 1.4 months), 50 female (46.73%). The incidence was 25.8/1000 admission in 
PICU and 2.8/1000 admission in SICU. The etiology was represented by Candida albicans in 53 (48%) 
patients, Candida parapsilosis in 31 (29%), Candida glabrata in 7 (6%) and other species in 15 patients. 
Candida parapsilosis was the most frequent etiology of candidemia for children (45%). Crude mortality 
rate was 59.8%, higher in adults and in patients infected with Candida glabrata (5/6) and Candida 
tropicalis (5/5). 55 patients were treated with fluconazole, 14 with caspofungin, 3 with voriconazole, 
10 with ketoconazole and 25 patients did not receive any antifungals. Resistance to fluconazole was 
23.36% (24.48% for Candida albicans). 
Conclusion: Candidemia was a frequent situation in ICU non-neutropenic patients. The involvement 
of Candida albicans and Candida non-albicans was almost equal but significantly different in adults and 
children. Fluconazole was the most used antifungals but the resistance to Fluconazole was high. The 
mortality rate was very high, significantly higher in adults than in children and in Candida sp. other 
than Candida parapsilosis. 
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A Native Human Burn Infection Model of Candidiasis 
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Objectives: A tenfold rise in fungal burn wound infections (BWI) has been observed globally since 
the 1960s due to the introduction of broad spectrum antimicrobial agents (Sarabahi et al, 2012). The 
fungal opportunistic pathogen Candida albicans is a common isolate from BWI (Branski, Al-Mousawi 
et al. 2009). Systemic candidiasis originating from burn wounds can result in up to 70% mortality 
rates, yet nothing is known about the biology of infection. The objective of this study was to develop 
a reliable model of infection. Current animal models such as murine, rat and porcine have major 
differences in skin biology and inflammatory responses compared to human and are ethically 
questionable. Therefore, we have developed a novel ex vivo human skin model of burn wound C. 
albicans infection and examined the role of key fungal virulence determinants and host responses 
throughout the progression of infection. 
Methods: NativeSkin®  human tissue (Genoskin, France) was burned with a 350°C soldering iron for 
15 sec, debrided and infection was initiated with 1x105 cells of C. albicans wild-type SC5314 strain 
expressing luciferase. The progress of infection was measured by bioluminescence at 1 and 6 days 
after burn induction, followed by sample fixation for further histological analysis and 
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immunofluorescence staining. Immune cell populations were analysed by flow cytometry and media 
was measured for the presence of proinflammatory cytokines and lactate dehydrogenase (LDH), a 
cytotoxicity marker. In some experiments, we supplemented the media with 2x106 
polymorphonuclear neutrophils (PMNs) to observe tissue infiltration and effects on healing of the 
burn. 
Results: The protocol proved to reliably cause third degree burn wounds in an operator independent 
manner. Staining for high mobility group box 1 protein (HMGB1) showed that while the unburned 
skin retained viability after 6 days, the burned skin samples had marked necrosis. Histological 
analysis showed reduced depth of burn and area of burn injury at day 6 compared to day 1, indicative 
of tissue regeneration. Flow cytometry analysis of immune cell populations present in control 
(unburned) skin detected CD1a+ and CD207+ cells, indicating populations of viable langerhans and 
dendritic cells. Further, staining for neutrophil elastase (NE) showed the presence of PMNs at the 
edge of the burn. Levels of cytokines IL-1β, IL-6 and Il-8 were variable between skin donors and 
experimental conditions, with the highest concentration found in burned and infected samples. BWI 
with C. albicans resulted in prominent tissue penetration, especially following debridement of the 
burn. 
Conclusion: A reliable and ethical human skin ex vivo model for fungal BWI has been established 
and various analyses methods were tested. Genoskin NativeSkin®  samples exhibit good healing 
potential, have viable immune cell populations and allow supplementation with PMNs and other 
cells/factors, thus representing an excellent model for BWI candidiasis. The outlook includes testing 
key virulence determinants for candidiasis, including dual transcriptional profiling; mixed bacterial 
and fungal infections, and alterations of approved treatment regimes. Such a model may shed light 
on early signs and symptoms of candidiasis in the burn population, which could help to develop 
guidelines in patient care. 
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Objectives: Invasive fungal infections play an important role as severe infection, constantly rising in 
the services in charge of patients at risk. Diagnosis and treatment are difficult because of the absence 
of pathognomonic signs and symptoms. The delay in diagnosis leads to delayed treatment and thus 
worsened prognosis The objective of this study is to identify the place of laboratory tools applied in 
the diagnosis of deep candidiasis, Cryptococcosis, Pneumocystosis and invasive aspergillosis. 
Methods: This is a descriptive prospective study spanning 07 years (2010-2016) and having respective 
998 samples from patients from several medical services: intensive care, Internal Medicine, major 
burned, Onco-Hematology, infectious diseases, Cardiology, Gastroenterology, Nephrology and 
Pediatrics. The seach of the mannan antigen for the diagnosis of invasive candidiasis and 
galactomannan antigen for the diagnosis of invasive aspergillosis occurs by Enzyme Linked 
ImmunoSorbent Assay . The search for the capsular antigen of Cryptococcus held by slide 
agglutination and Pneumocystis spp. by DFA. The search for antibody anti-Candida and anti-
Aspergillus occurs by Enzyme Linked ImmunoSorbent Assay. Blood cultures and device samples are 
also studied for these patients. 
Results: Among the 371 sera studied for suspected invasive candidiasis, 53 were positive (14.28%) 
and among 286 sera investigated for suspected invasive aspergillosis, 22 were positive (7.69%). Four 
cases of Cryptococcosis were confirmed and three cases of Pneumocystosis. Specie isolated from 
Blood cultures, device and peripheral samples were 93 % C. albicans , 1,5 % were other species : C. 
parapsilosis, C.zeylanoides, C. glabrata, C.krusei. 
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Conclusion: Invasive fungal infections remain under-diagnosed clinically and therefore 
mycologically. The mycological diagnosis associated with sero-immunological diagnosis is a decisive 
contribution in these conditions. A delay in diagnosis worsens the prognosis of these violations where 
the interests of a multidisciplinary proper care. 
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Objectives: Cryptococcal meningitis (CM) is a rare infection in autoimmune diseases (AIDs) patients. 
CM complicated with AIDs is more common in women. The aims of this study were to describe the 
differences of female CM patients with and without AIDs. 
Methods: We retrospectively compared the differences between 21 non-HIV female CM with AIDs 
and 23 non-HIV female CM without AIDs from 2011 to 2018. Their demographic data, clinical 
manifestations, cerebrospinal fluid (CSF) and MR features were analysed. 
Results: We found that female CM with AIDs had lower CSF pressure, higher CPR and ESR than 
female CM without AIDs when admitted to the hospital. There was no statistical difference in clinical 
and MRI features between two groups. After antifungal therapy, headache, fever, mRs scores and 
some CSF index were significantly improved in both groups. In female CM with AIDs, mRs was 
positively correlated with India ink Cryptococcus count and had no correlation with CSF pressure. 
But in female CM without AIDs, we found that mRs was positively correlated with CSF pressure and 
had no correlation with India ink Cryptococcus count. 
Conclusion: Our data suggested that SLE was the most common in female CM with AIDs, and 
revealed for the first time a difference between female CM with and without AIDs. Although 
presenting symptoms of female CM patients with AIDs are usually unspecific. But it is curable if 
timely make the diagnosis and treatment. 
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Objectives: Analysis of underlying diseases, risk factors, etiology, clinical features, treatment and 
survival rates in HIV-positive patients with IA. 
Methods: Retrospective analysis of the register of patients with IAin 1998-2018 yy. For diagnosis IA 
we used criteria EORTS/MSG, 2008. 
Results: In group I we included 12 HIV-positive adult patients with IA from 25 to 52 years old, 
median – 34,males – 58%. The control group consisted of 545 adult patients withhematological 
malignancies, from 18 to 78 years old, median - 47, males – 58%. The study of risk factors showed 
significant differences between these groups. Lymphocytopenia was detected predominantly in HIV-
positive patients 75% vs 56%, duration 35 vs 14,5 days, (p = 0.006), while agranulocytosis in this group 
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was observed less frequently – 58% vs 81%, p = 0.008, duration 8 vs 13 days (p = 0.01). Among the 
HIV+ patients there were no recipients of allogeneic stem cell transplants (0% vs 19%, p = 0.001) and 
patients receiving immunosuppressive therapy (0% vs 29%, p = 0.02). The main sites of infection were 
lungs - 100% vs 98%, however hemoptysis and dissemination of infection more often registered in 
HIV+ patients – 17% vs 6% (p = 0.03)and 17% vs 8% (p = 0.04), respectively.Galactomannan test in 
BAL was positive in 42% vs 75% cases. Aspergillusspp. were isolated in 42% vs 44%, in all HIV+ 
patients the main etiological agent of IA was A.fumigatus - 100% vs 45% (p = 0.001). Mixed fungal 
infection was detected in 33% vs 11% (p = 0,001). «Proven» IA was diagnosed in 17% vs 7% (p = 0.02). 
Antifungal therapy was used in 100% vs 99% of patients; the most commonly used drug was 
voriconazole (58% vs 77%). Twelve weeks overall survival rate was 80% vs 81%. 
Conclusion: The features of invasive aspergillosisin HIV-positive patientswere:prolonged 
lymphocytopenia (75%),agranulocytosis was a rare risk factor (58%), more frequent mixed infection 
- 33%, and high frequency of dissemination of aspergillosis – 17%.The overall 12-week survival did 
not differ in the studied groups (82% vs 79%). 
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Invasive aspergillosis in patients with multiple myeloma. 
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Volkova4, E. Desyatik5, Y. Borzova5, S. Ignatyeva5, T. Bogomolova5, L. Zubarovskaya4, B. Afanasyev4, 
N. Vasilyeva5, N. Klimko1 
1Department Of Clinical Mycology, Allergy And Immunology, North-Western State Medical 
University named after I.I.Mechnikov, St. Petersburg, Russian Federation, 2N.N. Petrov National 
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4I.Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation, 
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Objectives: Identification offeatures of invasiveaspergillosis (IA)in patients with multiple 
myeloma(MM). 
Methods: Retrospective analysis of 337 adult hematological patients with IA. In the main group were 
included 39 patients with MM, median age – 56 years (41 - 79), females - 59%. The control 
groupincluded 298 hematological patients (acute leukemia – 45%, lymphoma – 36%; chronic 
leukemia – 13%, myelodysplastic syndrome – 5%; other – 1%), median age – 53 years (40 - 78), females 
– 56%. The EORTS/MSG 2008 criteria were used for IA diagnosis and assessment of response of 
therapy. 
Results: The main risk factorsfor IA were steroid use (87.5% vs 59.5%, p = 0.03), severe neutropenia 
(51% vs 76%, p = 0.03; median 14 vs 18 days), lymphocytopenia (33% vs 53%, median 10 vs 12.5 days), 
auto-HSCT (28% vs 4%, p = 0.01), and allo-HSCT (8% vs 13%). The main sites of infection were lungs 
(97,4% vs 97,3%), usually bilateral (69% vs 77%). The main clinical symptoms were fever (80% vs 
78%), cough (69% vs 61%),chest pain (16% vs 5%, p = 0.03), and hemoptysis (0% vs 6.4%, p = 0.001). 
Aspergillus spp. positive culture was received in 69% vs 46% patients. The etiology of IA in patients 
with MM: A. niger– 45%, A. fumigatus– 35%, A.flavus– 10%, A. candidus– 5%, A. ochraceus– 
5%.Antifungal therapy (voriconazole – 68,2% vs 64%) was used in 100% MM and 98% control group 
patients. The overall 12-weeks survival rate was 96% vs 80%, p = 0.01. 
Conclusion: The typical risk factors for invasive aspergillosis in multiple myeloma patients were 
steroids use (87,5%), and auto-HSCT (28%). The main sites of infection were lungs (97,4%). The main 
etiological agents were A. niger(45%) and A. fumigatus(35%). In multiple myelomapatients the overall 
12-weeks survival rate was significantly higher compared to the control group (96%vs 80%, p = 0.01). 
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Objectives: Retrospective analysis of the autopsy data of HIV-infected patients with invasive 
mycoses (IM). 
Methods: In retrospective analysis were included 18 HIV-infected patients at the AIDS stage, who 
were hospitalized in 2018 in the Saint-Petersburg Botkin’s hospital. The median age of patients was 
38 years (28 - 67), men – 83%. 
Results: The duration of HIV infection before the IM development was > 10 years in 44% patients, 5-
10 years - 17%, < 5 years – 11%. IM developed before the antiretroviral therapy in 28% patients. Viral 
hepatitis was concomitant infection in 56% patients, other viral infections (cytomegalovirus, Epstein-
Barr and herpes zoster) – 61%, bacterial diseases – 44% (pneumonia – 39%, sepsis – 5%), pulmonary 
tuberculosis – 11%, toxoplasmosis – 11%. Chronic renal failure was comorbid pathology in 33% 
patients. The main risk factors of the IM development were CD3+CD4+ <200 cells/mcl – 100%, 
intensive care unit stay – 67%, and glucocorticosteroid therapy > 21 days (median - 29 days) – 17%. 
Pneumocystis jiroveciipneumonia (PjP) was diagnosed in 67% patients, cryptococcal meningitis – 28%, 
combination of PjP and cryptococcosis – 5%. PjP was diagnosed ante mortem in 77% patients. 
Therapeutic doses of co-trimoxazole were used in 60% PjP patients, low doses – 40%. Cryptococcosis 
was diagnosed ante mortem in 83% patients. Amphotericin B 50 mg/d was used in 67% of these 
patients(the median duration – 3,5 days (1 - 9), fluconazole 600–800 mg/d – 23%. The overall 14 days 
survival rate of patients with IM was 39%, 30 days – 28%, 12 weeks – 5,5%. 
Conclusion: The main risk factor of invasive mycoses (P. jirovecii pneumonia – 67%, cryptococcosis – 
28%, combination – 5%) in HIV-infected patients was a decrease of CD3 + CD4 + < 200 cells/mcl 
(100%). The overall 12-weeks survival rate on patients with invasive mycoses was 5,5%. 
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Fatal case of Cryptococcus albidus fungaemia in an elderly immunocompromised woman 
presented with pleural effusion 
G. Rodríguez-Leguizamón1, E. Coque-Burgos2, O. Espitia-Castro1, C. Firacative3 
1Hospital Universitario Mayor - Méderi, Bogota, Colombia, 2Compensar, Bogota, Colombia, 3School 
Of Medicine And Health Sciences, Universidad del Rosario, Bogota, Colombia 
Case Report: Cryptococcosis is an important opportunistic fungal infection that occurs globally and 
in the vast majority of cases is caused by Cryptococcus neoformans, a basidiomycetous encapsulated 
yeast. Although this mycosis presents most frequently as meningitis or meningoencephalitis, 
pulmonary disease is an underdiagnosed clinical presentation, mainly due to nonspecific symptoms 
and broadly categorized findings. Similarly to C. neoformans, Cryptococcus albidus is a free-living, 
encapsulated yeast that resides in the environment, but that has been rarely recognized as a human 
pathogen, as is the case for other non-neoformans cryptococci, and whose clinical relevance remains 
unknown. Here we describe a fatal case of C. albidus fungaemia in an 85-year old woman from 
Colombia, who presented with pleural effusion. The patient had an underlying condition of type 2 
diabetes mellitus (T2DM) and arterial hypertension and was admitted to the hospital for 
hyperglycemia, presenting fatigue, polyuria, polydipsia, and nocturia. On day 4 after admission, she 
had an episode of atrial fibrillation. A computed tomography (CT) scan of the head showed an old 
lacunar infarction on the left superior cerebellar artery and chronic ischemic microangiopathy. On 
day 7, hypoxia (85%) and another episode of atrial fibrillation occurred. Chest radiography showed 
opacification of the left hemithorax, cardiac silhouette was not visible, and prominent pulmonary 
hilar vessels with atelectasis on the apical right lobe were observed. A chest and an abdominal CT 
scans confirmed left-sided pleural effusion and showed an abdominal mass, which suggested a 
metastatic pleural neoplasm. The condition of the patient deteriorated and she died after 21 days of 
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admission. C. albidus was recovered from blood culture post-mortem and identified with VITEK® 2 
YST ID card and confirmed by MALDI-TOF MS. This is the first report to describe a fatal case of 
cryptococcemia caused by a non-neoformans species, C. albidus, in a non-HIV, yet 
immunocompromised female patient, who presented with pleural effusion. Not only are 
cryptococcal infections of the pleura unusual amongst the pulmonary manifestations but, 
interestingly, such infections caused by a non-neoformans species are even rarer. With an incremental 
rise in the number of at-risk patients having predisposing factors such as T2DM, the incidence of 
cryptococcal infection due to non-neoformans species has also increased, with C. albidus and C. laurentii 
accounting for 80% of reported cases. Although bloodstream and central nervous system are the most 
common sites of infection of these infrequent pathogens, cases of pulmonary infection are also 
present and are mostly manifested as chronic, indolent illnesses and pulmonary involvement that 
includes pneumonia, lung abscess and empyema, which may appear as pulmonary nodules, masses 
or infiltrates, mediastinal lymphadenopathy or, less frequently, pleural effusions. Among the few 
cases of cryptococcal pleural effusion that have been reported, only one was caused by a non-
neoformans species, specifically C. laurentii. This case of lethal fungaemia in an elderly woman 
highlights the importance of considering not only the advanced age and the underlying diseases of 
the patient, but also the emergence of new pathogens, including fungal species, in order to give an 
appropriate and prompt diagnostic. 
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Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute 
Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective 
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Masarova1, M. Konopleva1, Z. Estrov1, K. Takahashi1, M. Yilmaz1, C. Rausch1, K. Marx1, W. Qiao1, X. 
Huang1, C. Bivins1, S. Pierce1, H. Kantarjian1, D. Kontoyiannis1 
1Ut Md Anderson Cancer Center, 1515 Holcombe, Houston, United States of America, 2Pharmacy, 
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Objectives: Mold-active antifungal prophylaxis (ppx) is recommended in neutropenic pts with newly 
diagnosed AML or MDS. ISAV is an extended spectrum triazole with superior tolerability, reliability 
of absorption, fewer drug-drug interactions, lack of QTc prolongation or need for therapeutic drug 
monitoring, approved for the treatment of invasive aspergillosis (IA) and mucormycosis. 
NCT03019939 is an investigator-initiated, phase 2 trial of PAP with ISAV in pts with AML/MDS. 
Methods: Treatment-naïve adult pts with AML or MDS initiating remission-induction chemotherapy 
(RIC) received ISAV per the dosing recommendations in the US label until recovery from neutropenia 
(neutrophils (ANC) ≥ 0. 5 x 109/L) and attainment of complete remission (CR), occurrence of proven 
or probable invasive fungal infection (IFI, EORTC/MSG criteria), or for a maximum of 12 weeks. The 
primary endpoint was incidence of proven/probable IFI during the study period (up to 30 days from 
the last dose of ISAV). 
Results: 67 pts were enrolled (April 28, 2017 to February 14, 2019) and 60 pts were eligible for 
assessment (median age 67 years, 57 pts with AML, median ANC on enrollment was 660). Reasons 
for study completion were achievement of CR with ANC recovery (n = 35), completion of 12 weeks 
of PAP (n = 9), possible IFI (n = 7), investigator decision (n = 3), death (n = 2, 1 disease progression, 1 
cardiac arrest), proven/probable IFI (n = 3), and mild transaminitis, possibly ISAV-related (n = 2). The 
median durations of neutropenia and ISAV ppx were 33 (7-86) and 31 (7-86) days, respectively. One 
microbiologically-proven (gluteal abscess due to Candida glabrata) and 2 cases of probable 
breakthrough IFIs (probable IA with positive galactomannan) occurred (IFI incidence 5%). ISAV 
trough serum concentrations were available in 31 pts on both day 8 (median 3. 74 µg/mL, 2. 03-7. 65) 
and day 15 (median 4. 10 µg/mL, 2. 17-9. 25), and were not significantly different. 
Conclusion: ISAV is a safe and effective alternative for PAP in pts with newly diagnosed AML/MDS 
undergoing RIC, with a breakthrough (proven/probable) IFI rate of 5%. ISAV serum levels were 
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adequate in pts with AML/MDS undergoing RIC. Pharmacological features make ISAV attractive for 
PAP in the era of recently approved or emerging small-molecule AML therapies. 
 
P302 
Retrospective analysis of invasive aspergillosis in pediatric patients with acute myeloid leukemia 
Y. Dinikina1, O. Shadrivova2, M. Belogurova1, S. Ignatyeva2, T. Bogomolova2, S. Khostelidi2, E. 
Boichenko3,4, N. Klimko2 
1Department Of Chemotherapy And Bone Marrow Transplantation For Children, Almazov National 
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Objectives: To examine the epidemiological, clinical, and therapeutic features of invasive 
aspergillosis cases in children with acute myeloid leukemia. To underline the necessity of early 
recognition and initiation of antifungal treatment for the infection control and possibility to continue 
anticancer treatment. 
Methods: Retrospective analysis of IA cases in pediatric patients with AML without stem cell 
transplantation (SCT) registered from 1997 to January 2019. For the probable and proven IA diagnosis 
EORTC / MSG, 2008 criteria were used. 
Results: 46 pediatric patients with malignancies were included, median age - 8 years (1 -18), males – 
69,5%. Hematological malignancies were underlying diseases in 39 patients (84,7%), solid tumors – 7 
(15,2%). Most frequent hematological diagnoses were myeloid leukemia - 16 (34,7%) and acute 
lymphoblastic leukemia (34,7%). Median age of pts with AML – 11 years, males – 62,5%. IA was 
diagnosed after cytostatic chemotherapy in 13 patients (81,3%), prior to chemotherapy in 3 (18,7%) 
pts. Median number of chemotherapy courses before IA manifestation was 3. Two pts were without 
neutropenia at AML and IA presentation. Risk factors were: prolonged neutropenia – 81,3%, median 
- 43,9 days, and lymphocytopenia – 81,3%, median – 27,4 days. Severe bacterial infections were 
diagnosed in 37,5% and cytomegalovirus infection in 18,7%. Main signs of IA were fever (93,7%), 
cough (75%), respiratory failure (33,4%). Main site of IA were lungs (93,7%). Disseminated IA was 
diagnosed in 2 pts (12,5%), endophthalmitis - 1 case (6,25%). Typical findings on chest CT scan 
included the halo sign – 37,5%. Bronchoscopy with bronchoalveolar lavage was performed in 7 
(37,5%) pts. Aspergillus spp. were isolated in culture in 12,5%: Aspergillus fumigatus – 6,25%, A.niger – 
6,25%. Galactomannan test was positive in 92,8%. According received results “probable IA” was 
diagnosed in 87,5% of pts and “proven” in 12,5%. Antifungal treatment received 100% of patients, 
with voriconazole only – 50%. Surgical treatment (splenectomy) was performed in 1 patient with 
disseminated IA. Combined antifungal therapy received 33,3% of pts. Overall 12-week survival was 
87,5%. In all cases of IA before chemotherapy after infection control anticancer therapy was 
continued. 
Conclusion: Among children with IA and malignancies, the AML patients without SCT account for 
34%. The main risk factors of IA were prolonged neutropenia (81,25%) and lymphocytopenia 
(81,25%). The main sites of IA were lungs. 12-weeks overall survival was 87,5%. There were no 
contraindications for anticancer therapy resumption after infection control. 
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Objectives: To identify by molecular method Candidaisolates recovered from liver transplant patients 
with oral candidiasis and to determine the antifungal susceptibility profile. 
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Methods: In a prospective cohort study, 97 liver transplant patients from a hospital in southern Brazil 
were followed up from June 2016 to September 2018. On clinical examination of oral cavity 15 of them 
presented oral candidiasis and were included in this study. Two oral swabs were collected from these 
15 patients with interval of 6 months apart (collections 1 and 2) to detect the presence of 
infection/colonization by Candidaspp. Patients who had candidiasis were treated with topical nystatin 
for 30 days. The swabs were cultured on CHROMagar®  Candidaand the yeast colonies were 
genotypically identified by sequencing the intergenic transcribed sequence (ITS region) of ribossomal 
DNA. The susceptibility test was performed with the following antifungal agents: Fluconazole, 
Amphotericin B and Micafungin using broth microdilution method for yeasts recommended by 
Clinical and Laboratory Standards Institute (CLSI), document M27-A3. 
Results: Among fifteen patients included in this study, eight(53.4%) presented oral candidiasis 
episodes in Collection 1 and seven (46.7%) in Collection 2. In fact, all these patients had isolates 
recovered in both collections, isolates from patients without clinical manifestation were classified as 
colonization. Of those, eight patients who presented oral candidiasis in the Collection 1, five were 
atrophic candidiasis (AC) caused by Candida glabrata(n = 3), C. albicans(n = 1) and C. tropicalis(n = 1), 
and threepseudomembranous candidiasis (PC) caused by C. albicans(n = 2) and C. tropicalis(n = 1). In 
the Collection 2, seven patients presented oral candidiasis, five were AC, caused by C. albicans(n = 4) 
and C. dubliniensis(n = 1); two patients had PC caused by C. albicans. The yeasts classified as colonizers 
were C. albicans(n = 9), C. glabrata(n = 3), C. dubliniensis(n = 2) and C. tropicalis(n = 1). None of the 
patient had infection or colonization by more than one Candidaspecies. Regarding fluconazole 
susceptibility, 10 of 15 Candidaisolates recovered from patients with infection were susceptible (S), 4 
isolates were susceptible-dose dependent (SDD) and 1 resistant (R). Of those recovered from 
colonized patients 12 were S, 2 were SDD and 1 was R (table 1). All isolates studied were susceptible 
to amphotericin B and micafungin.  
 
Conclusion: The main type of oral candidiasis identified in hepatic transplant patients was AC. 
Candida albicans was the most prevalent species identified in this study. The presence of Candidaspp. 
was constant in the oral cavity regardless clinical manifestation. Most isolates were susceptible to 
antifungal agents, however, one C. tropicalisisolate and one C. albicanswere resistant to fluconazole. 
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Objectives: Central nervous system (CNS) aspergillosis is a rare form of invasive aspergillosis. The 
objective of this study is to describe the clinical, mycological, radiological features and outcomes of 
the patients with of CNS aspergillosis. 
Methods: A multicenter, retrospective study was performed involving adults and children with a 
diagnosis of proven or probable cerebral aspergillosis according to the European Organization for 
Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions of invasive 
fungal infections (IFI) published in 2008, modified by adding diabetes to the host criteria, between 
January 2006 and September 2018. 
Results: 119 patients with CNS aspergillosis (54 proven, 65 probable) were included in 20 French 
hospitals. Sixty-six percent were men and the median age was 58 years [48-66]. Hematologic 
malignancies (39.5% of the patients), solid organ transplantation (28.6%), diabetes (8.4%), 
autoimmune diseases requiring steroid or immunosuppressive treatment (7.6%), cirrhosis (2.5%) and 
a history of neuro or sinus surgery (2.5%) were the predominant comorbid conditions. Eleven 
patients (9.2%) had no identified risk factors of IFI. Fever was present in 40.3% of the patients and 
88% of them had an abnormal neurological examination. Only 23.5% of the patients had a history of 
neutropenia in the month preceding the diagnostic. Infection of the CNS occurred by hematogenous 
dissemination from an extracerebral site in 77 patients (64.7%) and direct extension from the 
paranasal sinuses in 27 patients (22.7%). Fifteen patients had no obvious primary organ involvement. 
Hematogenous dissemination was more frequent in patients with hematologic malignancies (68% of 
the patients) and solid organ transplantation (79%) whereas contiguous extension was more common 
in patients with diabetes (60%, p = 0.01). Sensitivity of β-D-glucan, galactomannan and aspergillus 
PCR in sera were 83.3%, 63.5% and 55.1% respectively. Galactomannan was positive in 68.9% of the 
cerebrospinal fluids tested. A fungal co-infection was diagnosed in 10.9% of the patients. Seventy-
two percent of the patients were treated with voriconazole alone or in dual therapy as a first line 
treatment. Twenty-one patients underwent neurosurgical procedures, including abscess resection or 
drainage of abscesses and ventricular shunt. Forty-three percent of the patients presented a 
complication of the surgery such as edema, bleeding or nosocomial infection. Overall survival was 
48.3% at 3 months and 37.7% at 12 months. Contiguous infection of the CNS was associated with a 
lower sensitivity of galactomannan antigen, a higher frequency of vascular complication and a better 
outcome. Patients with hematologic malignancy had a poorer survival (p = 0.04). Although a selection 
bias should be considered, the sub-group of patients who had had neurosurgery had a better survival 
(p = 0,003). 
Conclusion: CNS aspergillosis should be considered in patients with hematologic malignancies and 
solid organ transplantation with or without neutropenia but also in patients with less (such as 
diabetes or cirrhosis) or no known immunosuppression. Mortality among CNS aspergillosis patients 
remains high. When feasible, neurosurgical procedures may improve prognosis although with 
significant morbidity. 
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12Division of Hematology, San Giovanni Addolorata Hospital, Rome, Rome, Italy, 13Division of 
Hematology, San Camillo Hospital, Rome, Rome, Italy, 14Division of Hematology, University of 
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Objectives: Acute myeloid leukemia (AML) patients are at high risk of invasive aspergillosis (IA) 
and required a mould active antifungal prophylaxis during induction chemotherapy (CHT). 
Although IA risk factors have been identified, few data are available on impact of IA, occurring 
during first remission induction phase, on overall AML outcome. 
Methods: The primary endpoint of this prospective, multicentric, case-control study, was to evaluate 
if IA, occurring during first remission-induction CHT, can affect treatment schedule and, 
consequently, patient overall survival (OS). We identified 40 AML patients (cases) who developed 
IA during induction phase, 31 probable (67%) and 9 proven (33%) IA. These cases were matched with 
a control group (80 AML) without IA, balanced according to age, type of induction CHT, AML 
characteristics and cytogenetic-molecular risk factors. The overall response rate to induction CHT 
was the same in the 2 groups. 
Results: In the 40 cases with AI, the overall response rate (ORR) to antifungal treatment was favorable 
(ORR 80%) but it was significantly affected by the achievement of leukemia complete remission (CR) 
with induction CHT. In fact, in cases with AML responsive to induction CHT, complete responses of 
IA to antifungal therapy were 96% compared to 21% in cases of AML not responsive to induction 
CHT (p <0.0001). The adherence to schedule and full doses of CHT was reported in 35% of 
cases (14/40) and in 76% of controls (61/80) (p = 0.0001). After induction CHT a significant higher 
number of cases (15/40; 37.5%) compared to controls (21/80; 26%) could not receive additional cycles 
of CHT (p = 0.01). The IFI related mortality was 22.5%. Comparing OS of 40 cases with the OS of the 
80 controls, the median OS of cases was significantly worse with a difference of 12.3 months (12.1 vs 
24.4 months, p = 0.04-Figure 1A). However, the occurrence of IA during induction phase did not have 
a significant impact on the OS of cases who achieved a CR with induction CHT which are able to 
proceed, despite the IA, with their intensive therapeutic program, achieving the same OS as the 
control group with an AML in CR (p = ns-Figure 1B).  
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Conclusion: These data showed that IAs during induction CHT can delay the subsequent therapeutic 
program and has a significant impact on OS of AML, specifically in those patients with IA occurring 
during induction phase who did not achieved a CR of AML with the first course of CHT (Figure 1C). 
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Case Report: Invasive pulmonary infection by Syncephalastrum: two case reports Memoona 
Irshad; Nosheen Nasir; Urooj Haider Hashmi; Joveria Farooqi; Syed Faisal Mahmood ABSTRACT 
Mucormycosis also known as Zygomycosis is a class of fungi including three orders. The largest order 
is Mucorlaes. Most common species of this order are Rhizopus and Mucor but there are certain rare 
species such as Syncephalastrum spp. These are often responsible for opportunistic fungal infections 
in immunocompromised patients. Syncephalastrum racemosum is the species of the genus 
Syncephalastrum and is potentially fatal to human beings. Although usually results in cutaneous 
infections and onychomycosis, there have been few cases reports of respiratory and CNS infections 
in immunocompromised hosts. Since this is a rare entity, so hardly any data is available on treatment 
response to different antifungal agents. However recent improvements in diagnostic strategies result 
in early identification and treatment. Amphotericin B is the drug of choice due to its low MIC. 
Objective: To describe the clinical manifestations of the rare fungal species Syncephalastrum 
Methods: Two cases of this rare fungus presented with respiratory complaints during 2019 Case 
presentation 1: A 55 years old gentleman recently diagnosed with Acute Myeloid Leukemia and not 
on treatment, presented with severe shortness of breath in emergency. Patient was provisionally 
diagnosed with hospital acquired pneumonia in view of recent hospitalization and was started on 
empirical treatment with intravenous piperacillin tazobactam and vancomycin. However his 
symptoms progressively worsened. Sputum cultures of this patient showed Methicillin resistant 
Staphylococcus aureus and Syncephalastrum spp in a good quality specimen. Patient was continued 
on intravenous vancomycin and started on intravenous conventional amphotericin B. Case 
presentation 2: 73 years old gentleman with known comorbid of chronic obstructive pulmonary 
disease for which he was on long term systemic and inhaled steroids, presented with shortness of 
breath in emergency room. Chest radiograph showed bilateral infiltrates with left sided cavity 
formation. Patient was started on empirical treatment for hospital acquired pneumonia in view of his 
recent hospitalization. Sputum cultures of this patient showed methicillin resistant Staphylococcus 
aureus, Aspergillus flavus and Syncephalastrum spp in a good quality specimen. Patient was started on 
intravenous conventional amphotericin B along with vancomycin and voriconazole. However he 
developed amphotericin induced nephrotoxicity and doses were renally adjusted Result: Both cases 
were started on amphotericin B, case 1 continued to deteriorate rapidly and expired after 12 days of 
therapy. However case 2 is under treatment, patient developed amphotericin induced nephrotoxicity 
so he is currently on renal adjusted dose of amphotericin B and is currently doing well so we had 
different outcomes in two different patients on same treatment. Conclusion: Invasive pulmonary 
infection by Syncephalastrum species is a rare entity. It is usually identified and reported as an 
environmental contaminant but when identified as a pathogen it can have fatal outcome in 
immunocompromised patients. Due to rarity of this infection its course and treatment response are 
not completely understood. 
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Case Report: Talaromyces marneffei is a dimorphic fungus predominantly endemic in Southeast Asia. 
After effective antiretroviral treatment, the incidence of T. marneffei infection in HIV-infected 
individuals has been decreasing. However, the rate of T. marneffei infection is rising among non-HIV 
immunodeficient persons, particulary patients with anti-interferon-gamma autoantibodies. Of these, 
T. marneffei usually causes invasive and disseminated infection including fungemia. T. marneffei 
pharyngo-laryngitis is a very rare manifestation of talaromycosis. Herein, we demonstrate a case of 
T. marneffei pharyngo-laryngitis in a patient who had underlying anti-interferon-gamma 
autoantibodies. Case report A 52-year-old Thai woman has been diagnosed anti-interferon-gamma 
(IFN-ɣ) autoantibodies for 4 years. Last 4 years, she presented with prolonged fever, weight loss 10 
kilograms, and multiple cervical lymphadenopathies. Tissue biopsy from left cervical lymph node 
grew Mycobacterium abscessus. Accordingly, disseminated M. abscessus infection was diagnosed. She 
denied using illicit drugs, herbal medicines, or corticosteroids. Immunological studies including anti-
HIV testing were all negative, but anti-IFN-ɣ autoantibodies was highly positive. She received 
intravenous imipenem 2 g/day and amikacin 750 mg/day for a primary anti-mycobacterial therapy, 
later they were switched to oral clarithromycin 1,000 mg/day and linezolid 600 mg/day for a 
maintenance therapy. Following the treatment, she was in remission, and still has been receiving the 
oral maintenance therapy. Before this admission, she had sore throat, particularly more painful at 
right side of pharynx, and hoarseness for 3 weeks. She also had febrile and lost her weight 5 
kilograms. She received oral amoxicillin 1.5 g/day from a primary physician, but her symptoms did 
not resolve. She denied foreign body sensation, and had no dysphagia, stridor, or difficult breathing. 
Physical examination revealed marked swelling and hyperemia of both sides of tonsils including 
uvula and palatal arches, and a single left submandibular lymph node, sized 1 cm. was identified. 
Indirect laryngoscopy demonstrated moderate swelling of epiglottis, arytenoid, and vocal cord with 
normal airway opening. There were no skin nodules or hepatosplenomegaly found. Blood 
chemistries including plain chest radiography were unremarkable. The patient was performed right 
tonsillar biopsy at 1 day following the admission. The tissue biopsy Gram’s stain including the 
pathological sections exhibited few oval and elongated yeast-like organisms with some central 
transverse septum seen, and it subsequently grew few mold colonies with diffusible red-colored 
pigment on fungal cultures suggestive of T. marneffei. An amphotericin B deoxycholate 45 mg/day 
was commenced as a primary therapy for 1 weeks, followed by an oral itraconazole 400 mg/day. Four 
weeks after the treatment, the swelling of pharynx and larynx were markedly reduced. She had 
continued itraconazole for 4 months, later the dose of 200 mg/day has been using for secondary 
prophylaxis. Her symptoms completely resolved without complication. Conclusion In patients with 
anti-IFN-ɣ autoantibodies, T. marneffei can rarely cause a local infection involving pharynx and 
larynx. Fungal culture and pathological examination are warranted for diagnosis T. marneffei 
pharyngo-laryngitis. This condition requires a long term antifungal therapy. 
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Retrospective analysis of single nucleotide polymorphisms (SNPs) on TLR-4, PTX-3, Dectin-1 
genes and the association with the development of invasive fungal infections among 
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A. Kalkanci1, E. Tug2, I. Fidan1, O. Guzel Tunccan3, Z.N. Ozkurt4, Z.A. Yegin4, E.A. Sahin1, Z. Kuralay1 
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Objectives: Candida and Aspergillus are the two most common causes of invasive fungal infections 
after stem cell transplantation. The development of fungal infections can be associated with several 
risk factors however, it is still difficult to predict why certain individuals develop severe infections, 
while others, under similar conditions, do not. Genetic polymorphisms are recognized as potential 
factors that could affect in the progress of the infectious disease. Pattern recognition receptors (PRR) 
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are germline encoded receptors that recognise a variety of pathogen associated molecular patterns 
(PAMPs) expressed by an invading microorganism. Single nucleotide polymorphisms (SNPs) on 
coding genes of PRRs; Toll like receptor-4 (TLR-4), dendritic cell-associated C-type lectin-1 (Dectin-
1) as a C-type lectin receptor (CLR) and among signaling molecules; Pentraxin-3 (PTX-3) in the 
complement activation cascade were analysed in order to show associations with the development 
of invasive fungal infections (IFIs) among hematopoietic stem cell transplant recipients with 
hematological conditions. 
Methods: In this case control study, a cohort of 62 patients with hematological malignancies were 
assigned by the EORTC-MSG criteria. There were 9 proven, 7 probable,13 possible, total 29 IFI 
patients and 33 patients with no evidence of fungal disease included in this study from 2008 to 2018 
in Hospital of Gazi University. DNA and RNA were isolated from deposited bone marrow samples 
of the patients, using DNA and RNA Isolation kit (SNP Biotechnology, Turkey), respectively. 
Expression levels of TLR4, Dectin-1 and PTX-3 genes were determined by normalized to the Actin 
gene using the One-run RT-PCR kit (SNP Biotechnology, Turkey). The polymorphisms of TLR4 
(rs4986790, rs4986791), Dectin-1 (rs16910526, rs7309123) and PTX-3 (rs2305619, rs3816527) were 
determined by RT-PCR. Continuous variables are reported as means ± standard error mean (SEM), 
while categorical variables are reported as frequencies and percentages (%). The odds ratios (ORs) 
and corresponding 95% confidence intervals (CIs) were calculated by unconditional logistic regres-
sion analysis. The homozygote for the most frequent allele was regarded as the reference group. SPSS 
statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows was used for statistical 
analyses. All p values was considered to be statistically significant when p< 0.05. 
Results: TLR-4, PTX-3, Dectin-1 genes were down-regulated in IFIs group when compared to patients 
with no evidence of fungal disease in the group of hematological conditions. A higher expression of 
TLR-4 was revealed in controls (0.0626±0.032) compared to IFI patients (0.0077±0.014), significantly 
different (p = 0.026), as well as PTX-3 in controls (0.5265±0.0043) compared to patients (0.0043±0.004), 
(p = 0.035). Dectin-1 expression was down-regulated in IFI group (0.1887±0.072 & 0.0655±0.010), 
however, not statistically significant (p>0.05). Conditional logistic regression analyses indicated that 
the GT genotype of rs16910526 polymorphism in Dectin-1 gene was associated with lower risk of IFIs. 
(Odds ratio = 3.635, 95% confidence interval = 0.690-3.138, p = 0.04 
Conclusion: Our study continues to highlight the important role of the host’s underlying genetic 
profile in determining susceptibility to IFIs. Selective genetic immunodeficiencies stratify “at-risk” 
patients to specific pathogens. Dissecting the contribution that host genetic variation has on the 
susceptibility to fungal infection will be principal for personalizing medicine in infectious diseases. 
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Cell wall composition of Mucorales during spore germination : towards better understanding of 
host-pathogen interactions. 
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Objectives: The molecular composition and structural organization of the cell wall of filamentous 
fungi underlie the ability of the host to sense them as pathogen (Gow et al. 2017). Although the 
organization of the fungal cell wall, composed of 90% of polysaccharides (PS), is similar from one 
fungi to another, their expression on the cell wall may condition their ability to trigger pattern 
recognition receptors. Deciphering cell wall polysaccharide composition of filamentous fungi of 
medical concern can lead to a better understanding of mechanisms governing their pathogenicity. 
Those patterns of PS could also serve as biomarkers for the diagnosis of invasive fungal infections. 
Because the incidence of Mucormycosis, an emerging life-threatening infection due to Mucorales, is 
rising worldwide (Prakash and Chakrabarti 2019), we intend in this study to characterize the 
structure of cell wall of Lichtheimia corymbifera (one of the most clinically important mucorales) and 
how this fungus is able to interact with the host’s immune system. 
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Methods: Two strains of L. corymbifera were used, one reference strain - IHEM 21658 - and one strain 
isolated from skin lesions in burn patient. Spores and germ tubes were obtained from cultures on 
SDA-amikacin and liquid medium with yeast extracts, mannitol and glucose, respectively. 
Monosaccharides composition (MC) analysis of the cell wall was conducted on spores and germ 
tubes, on alkali-insoluble and alkali-soluble fractions through gas-chromatography using flame - 
ionisation detector. The same analysis was also performed on secreted extracellular polysaccharides 
obtained after an 8-day culture in YNB with glucose. Determination of the glycosidic linkages was 
performed on soluble oligosaccharides isolated sequentially after zymolyase and chitinase digestion. 
Confocal microscopy after immunofluorescence staining with two lectins (Con-A and WGA, binding 
mannose and N-acetyl-glucosamine -GlcNAc-, respectively), and one anti-β-1,3-glucan monoclonal 
antibody (1A5), was performed to determine the parietal remodeling during germination. THP-1- 
derived macrophages stimulated by various fungal fractions were used to assess fungi-host 
interaction in terms of Toll-like receptor and cytokine expression. 
Results: MC of both strains showed a large amount of glucose (69.9%) with smaller amounts of 
mannose (16.5%) and GlcNAc (12.8%) and traces of glucuronic acid (0.9%) in spores. Enrichment 
using alkalino-treatment showed the presence of glucuronic acid and galactose in the alkali-soluble 
fraction. Fucose appeared in germ tubes. Analysis of extracellular polysaccharides showed the 
presence of fucose, glucose, mannose, galactose and GlcNAc. Tagging the spores with Con-A and 
WGA revealed the presence of mannose around spores, whereas mannose was spread more evenly 
in germ tubes. Chitin emerged along the germ tube and β-1,3-glucan was present in swollen conidia. 
Conclusion: During the first hours of L. corymbifera germination, fungal cells synthetize 
polysaccharides composed chiefly by glucose, GlcNAc and mannose, and to a lesser extent by 
galactose, glucuronic acid and fucose. The role of these latter carbohydrates remains uncertain 
(Bartnicki-Garcia 1968). Confocal microscopy suggests that the emergence of these carbohydrates 
leads to a parietal reorganization of the cell wall. In the near future, data from the in-vitro model could 
help us to understand the impact of these changes on the primary immune response. 
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France, 3National Reference Center For Invasive Mycoses & Antifungals, Molecular Mycology Unit, 
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Objectives: Objectives: Saprochaete clavata is a rare pathogenic yeast that has been involved in 
invasive fungal infection outbreaks in immunocompromised patients especially in patient with 
haematological malignancies. From January 2016 to January 2018, infections due to S. clavata were 
diagnosed in nine patients at a cancer center in Marseille, France raising the question of a common 
source and of the mode of transmission. 
Methods: Methods: We retrospectively reviewed patients' files to assess risk factors, hospitalization 
units and treatments, and carried out an environmental survey (59 samples collected). Whole genome 
sequencing (WGS) was performed for 17 clinical isolates collected during (n = 15) or before (n = 2) the 
outbreak and 10 environmental isolates. The type strain (CBS425.71) and representative clinical 
isolates related (clade A) or unrelated (clade B) to the French national outbreak in 2012 (Vaux et al., 
2014) were used as reference. 
Results: Results: All nine patients were hospitalized at the stem-cell transplant or hematological 
intensive care units. The median age was 58 years (range: 38 to 68) and six (67%) were male. The most 
common underlying disease was acute myeloid leukemia (56%) and 67% of patients were treated 
with cytarabine. A total of 40 samples were found positive for S. clavata: blood (n = 35, 1 to 9 /8 
patients), bronchoalveolar fluid or tracheal aspirates (n = 5), and fecal swab (n = 1). The case fatality 
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rate at day 60 was 44%; death occurred at a median of 9.5 days after diagnosis. Saprochaete clavata was 
also cultured from 10 environmental samples including one from a surface in a patient's room, 5 from 
the dishwasher (water outlet, inside and door seal) made available to patients and families, and 4 
others from pitchers (lids and inside of 2 milk and coffee thermos). In order to control the outbreak, 
all the contaminated materials were replaced and the dishwasher was discarded. No new case was 
reported after the implementation of corrective actions. Phylogenetic analysis based on WGS data 
showed that all clinical and environmental isolates from Marseille belong to the same clade which 
was unrelated to clades A and B previously identified in France. Of note, attempt to grow S. clavata 
failed at temperatures above 48°C. 
Conclusion: Conclusion: Our results place the dishwasher as the source of the transmission of S. 
clavata and suggest that its heating system may have been deficient. Whether the source of S. clavata 
was a diary product as in previously reported outbreaks remains unclear. Vaux, S., Criscuolo, A., 
Desnos-Ollivier, M., et al. (2014). Multicenter outbreak of infections by Saprochaete clavata, an 
unrecognized opportunistic fungal pathogen. MBio, 5(6), e02309-14. 
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Objectives: Chronic disseminated candidiasis (CDC) occurs after profound and prolonged 
neutropenia, and consists in persistent fever and multiple abscesses in liver and/or spleen. 
International guidelines recommend protracted course of antifungal therapy, although there is some 
evidence that CDC belongs to spectrum of immune reconstitution inflammatory syndromes. The aim 
of this study was to assess 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography (PET/CT) in the diagnosis and follow-up of CDC. 
Methods: A pilot prospective study was conducted in 38 French centers from November 2013 to 
March 2017 (NCT01916057). Hematological adult patients having experienced febrile profound 
(neutrophils <100/mm3) and prolonged (≥10 days) neutropenia, and suspect for CDC on imaging (<10 
mm multiple nodules on liver and/or spleen) were included. PET/CT and abdominal conventional 
imaging (CT or MRI) were performed initially and at 3 months (M3). MSG/EORTC criteria were 
adapted to assess response to treatment. At M3, clinical success was defined by resolution of fever 
attributable to CDC, complete biological response was defined by normal liver enzymes and CRP ≤20 
mg/L, and complete radiological response by disappearance of lesions compared to initial imaging. 
The primary endpoint was the global response to antifungal treatment at M3 defined by clinical 
success and extinction of hepatosplenic metabolic uptake on PET/CT. 
Results: A total of 52 cases were included; 6 were secondarily excluded for alternative diagnosis and 
2 for absence of PET/CT at diagnosis. Among the 44 remaining cases, CDC was proven in 7 (6 
candidemia, 1 positive culture of liver biopsy), probable in 13, possible in 24. Patients were mostly 
male (55%), with a median age of 46 y.o. (IQR 32-62). Among 43 underlying hematological disease, 
there were 46% acute myeloid leukemia, 30% acute lymphoid leukemia, 17% allogenic and 2% 
autologous stem cell transplantation, and 5% lymphoma. One patient had a solid cancer. 
Corticosteroids were prescribed in 47% of patients ≤ 1 month before CDC diagnosis, growth factors 
in 68%, antifungal prophylaxis in 64%. Patients were colonized with ≥1 Candida species in 75% of 
cases before CDC diagnosis, mainly C. albicans. At diagnosis, fever and liver enzyme abnormalities 
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were present in 81% and 82% of cases, respectively. C-reactive protein was elevated in 85%. All 
patients were treated with antifungal drugs, combined with corticosteroids in 41%. At M3, 25% (8/32) 
of evaluable patients met the primary endpoint criteria. However, among 35 patients who had clinical 
success, 77% (27/35) had complete biological response, but 83% (29/35) failed to respond on 
conventional imaging. Among these patients, extinction of hepatosplenic metabolic uptake on 
PET/CT was observed in 17% (5/29). 
Conclusion: Clinical improvement of CDC occurs before radiological normalization. In patients with 
clinical success at M3, PET/CT could be more helpful than conventional imaging to guide antifungal 
duration. 
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Case Report: Isavuconazole is the most recent antifungal azole available to treat invasive fungal 
disease (IFD) and has been approved as first line treatment for invasive aspergillosis (IA) and as 
alternative treatment for mucormycosis. We present two cases of IFD with isavuconazole treatment 
failure in acute myeloid leukemia (AML) patients with prolonged neutropenia 100 days after 
hematopoietic stem cell transplantation (SCT) and severe digestive graft-versus-host disease 
(GVHD). The first patient was diagnosed with a probable invasive aspergillosis and a TR34/L98H 
azole resistant Aspergillus fumigatus and the second patient was diagnosed with a mixed Aspergillus 
fumigatus-Rhizomucor sp co-infection.The IFD were diagnosed using a combination of fungal 
biomarkers, applied systematically and including the galactomannan antigen (GM) detection and 
fungal qPCRs, targeting both A. fumigatus and Mucorales; this strategy proved to be optimal. These 
cases highlight the interest of applying a close surveillance using fungal biomarkers in very 
immunocompromised patients under antifungal treatment. Interestingly, the fungal biomarkers 
were alternatively positive. Moreover, these cases also raise several questions such as for example 
the influence of severe digestive GVHD on isavuconazole levels. 
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Objectives: Mucorales infections are life-threatening, with mortality rates approaching 100% in 
disseminated cases. ESCMID/ECMM guidelines strongly recommend surgical debridement, 
liposomal amphotericin B, L-AmB (≥5 mg/kg/day), and reversal of predisposing conditions. We 
introduced a multidisciplinary and aggressive management approach for invasive mucormycosis. 
Here we present data on six patients managed by this approach, whom all had a successful outcome. 
Methods: Management principle: repeated surgical debridement until biopsies taken from the 
resection margins were clean, defined by negative Blankophor microscopy, Mucorales specific PCR 
(both reported within 24h) and cultures. Cultured isolates underwent ITS sequencing for species 
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identification and EUCAST E.Def 9.3.1 susceptibility testing. Targeted antifungal therapy 
(mono/combination) combined with topical therapy (when possible) was given according to the MIC 
(mg/L) and severity of infection. High trough azole levels above MIC were ensured by therapeutic 
drug monitoring (TDM) (mg/L). Fungal free survival was evaluated by case record review. 
Results: 
 
Demographic, microbiological, management and outcome data for the six patients are summarised 
in the Table. All were neutropenic after chemotherapy except patient #5 at time of diagnosis. Patient 
#1 developed Lichtheimia ramosa/corymbifera infection in the liver (PCR). Management included 
isavuconazole and surgery. Patient #2 developed sino-orbital Rhizopus microsporus infection. The 
patient had smoked cannabis. Therapy included surgery, L-AmB and isavuconazole. Isavuconazole 
MIC: 1 mg/L. Patient #3 developed Rhizopus arrhizus infection extending extensively from the hard 
palate (picture). The patient had smoked marihuana. Treatment consisted of unilateral 
hemimaxillectomy followed by frequent supplementary debridements guided by PCR of resection 
margins. The exposed bone was covered during palatal reconstruction with a free flap after several 
mycosis negative debridements. Antifungal therapy included L-AmB and isavuconazole (target TDM 
initially: >2 mg/L, then >6-8 mg/L until negative diagnostics followed by maintenance >2 mg/L 
(isavuconazole MIC: 1 mg/L). Patient #4 developed Rhizopus arrhizus sinuses infection during 
posaconazole prophylaxis. Management included L-AmB and surgery, followed by isavuconazole 
(isavuconazole MIC: 2 mg/L). Patient #5 developed disseminated Rhizomucor pusillus (lumbar 
spondylitis, a subdiaphragmatic and a lung abscess). Surgical debridement including removal of 
vertebrae L4 in toto and surrounding muscle and soft tissue. The spine was then stabilized with cage 
and pedicle screws. PET-CT afterwards showed regression of the spondylitis. Target TDM for 
isavuconazole >2 mg/L. Patient #6 developed Lichtheimia corymbifera sinus infection. Despite targeted 
posaconazole oral solution aiming a target for TDM >2 mg/L (MIC: 0.25 mg/L), the infection 
progressed to nasopharynx, orbit and brain. The patient recovered after surgical and triple-
compound systemic and amphotericin B intrathecal antifungal therapy1. Outcome: At follow-up 6-70 
months after diagnosis, patient #1-4 and #6 were cured of infection, and patient #5 has had no sign of 
relapse (7 months follow-up). 
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Conclusion: Our data suggest improved outcome of Mucorales infections by a multidisciplinary 
approach including: 1) Repeated (except patient #5) biopsy-controlled surgery until resection 
boarders are negative, 2) Systemic and in most cases combination, TDM-adjusted high dose systemic 
antifungal therapy, and 3) Topical therapy when possible to improve antifungal exposure in tissue 
not sufficiently perfused due to the angioinvasive pathology of the infection. 1Jensen, TSR et al. J 
Pediatr Hematol Oncol. 2017;39(4):211-215. 
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Case Report:  
Introduction: Trichophytum rubrum is a filamentous fungus, with worldwide distribution, that 
usually causes superficial infections of skin and nails, namely tinea pedis, tinea corporis, tinea cruris and 
onychomycosis. Rarely, severe dermatophytosis can occur, presenting as deep dermatophytosis, 
Majocchi’s Granuloma or extensive dermatophytosis.  
Objectives and Methods: Case report of Majocchi’s Granuloma in a kidney transplant patient.  
Results: A case of a 55-year-old woman who underwent a kidney transplant 7 months before, under 
immunosuppressive therapy with tacrolimus and mycophenolate mofetil. She attended a 
Dermatology consultation to clarify skin lesions that appeared 6 months earlier. The skin exam 
revealed hard and painful plaque lesions on both legs, with an ulcer on the left leg lesion, violaceous 
papular lesions on the dorsum of the left foot and toes and a hard consistency nodule on the left leg. 
Some of the toe nails presented dystrophy or onycholysis. The patient denied any previous trauma 
or contact with plants or soil. Biopsies of lesions of the left leg and foot dorsum where sent for 
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histology and mycological culture and toe nails for mycological culture. The histological 
examinations showed, in the reticular dermis and reaching the hypodermis, suppurative granulomas 
with multinucleated giant cells and areas of necrosis. PAS (Periodic Acid-Schiff) and GMS (Grocott’s 
Methenamine Silver) staining revealed multiple spores and septate hypha within the granulomas but 
not in the stratum corneum. No remnants of hair follicles where found. Culture of skin biopsies were 
positive for Tricophytum rubrum but nails  ́culture was negative. Identification was further confirmed 
by sequencing of ITS region of ribosomal DNA (GenBank accession number MK967277). Oral 
Itraconazole 100mg bid and topic Sertoconazole where initiated. The patient was observed one month 
after and reported general malaise, tiredness, exertional dyspnea, whitish stools and increased 
abdominal volume. The physician chose to discontinue itraconazole and initiate oral terbinafine 
250mg id. After two months on oral terbinafine, there was regression of the legs  ́and left foot lesions 
with ulcer healing and disappearance of the left leg nodule. Conclusion: Diagnosis of deeper 
dermatophytosis is difficult, in part because there is no specific clinical presentation and, in many 
cases, it is even polymorphic. However, especially in patients with immunodeficiency, this 
hypothesis should be weighed. Confirmation is achieved by finding hyphae compatible with 
dermatophytes in the dermis and a positive culture for a dermatophyte. Treatment should include 
systemic antifungal agents, to which topical medication may be associated. Multiple therapeutic 
regimens have been proposed, but randomized trials or large case series are lacking. Antifungal 
therapy should be continued until the lesions are completely resolved. Surgical treatment has been 
reported as an option for highly localized lesions. 
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Clinical Characteristics and Outcomes of Lomentospora prolificans Infections in Fungiscope™ 
Registry 
J. Jenks1, D. Seidel2, O.A. Cornely3, C. Kauffman4, M. Miceli5, M. Slavin6, S. Chen7, S. Mehta1, S. Reed1, 
M. Hoenigl1 
1Medicine, University of California San Diego, San Diego, United States of America, 2Department I 
Of Internal Medicine, Ecmm Excellence Centre Of Medical Mycology, Cologne Excellence Cluster On 
Cellular Stress Responses In Aging-associated Diseases (cecad), University Hospital Cologne, 
Cologne, Germany, 3Department I Of Internal Medicine, Ecmm Excellence Centre Of Medical 
Mycology, Cologne Excellence Cluster On Cellular Stress Responses In Aging-associated Diseases 
(cecad), German Centre For Infection Research, Partner Site Bonn-cologne, Clinical Trials C, 
University Hospital Cologne, Cologne, Germany, 4University of Michigan, Ann Arbor, United States 
of America, 5Medicine, University of Michigan, Ann Arbor, United States of America, 6Medicine, 
University of Melbourne, Parkville, Victoria, Australia, 7Medicine, The University of Sydney, 
Camperdown, New South Wales, Australia 
Objectives: Lomentospora prolificans are filamentous fungi commonly found in soil and polluted 
waters and are emerging opportunistic pathogens in immunocompromised individuals, accounting 
for 2.4% and 11.1% of non-Aspergillus invasive fungal infections (IFIs) in haematopoietic stem cell 
transplant (HSCT) and solid organ transplant (SOT) infections, respectively. The objective of this 
study was to describe clinical manifestations, treatment and outcomes of patients with L. prolificans 
infections causing IFI in cases documented in Fungiscope™ - A Global Emerging Fungal Infection 
Registry, created in 2003. 
Methods: We performed a retrospective review of medical records of all patients with IFIs caused by 
L. prolificans in Fungiscope™ between 01/01/2008 - 12/31/2017 (10 year period). Infections were 
determined to be disseminated if L. prolificans was isolated from the blood or two non-contiguous 
anatomic sites. The study was approved by the UCSD Human Research Protection Program (IRB 
#181119). 
Results: A total of 37 cases with IFIs caused by L. prolificans, including 7 cases from the University of 
California San Diego, were identified (Table 1). In all but one case (36/37, 97.3%), a risk factor for IFI 
was found, including hematologic malignancy (20/37, 54.1%), solid organ transplant (SOT) (3/37, 
8.1%), ICU stay or trauma (6/37, 16.2%). The majority of infections were diagnosed based on positive 
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culture (35/37, 94.6%) or histopathologic findings plus culture (5/37, 13.5) and most patients had signs 
of IFI on CT scan (15/20, 75%), MRI (1/2, 50%), or CXR (1/2, 50%). At final assessment, 19/37 (51.3%) 
were deceased, 8/37 (21.3%) had complete cure, and 8/37 (21.6%) and partial resolution or stable 
disease. Of those who received antifungal therapy following diagnosis and had an evaluable outcome 
(31/37, 84%), the majority were treated with combination antifungal therapy (24/31, 77%; 54% 
survived). Most antifungal regimens included voriconazole (VRC; 28/31, 90%; 54% survived) and/or 
terbinafine (TRB; 19/31, 61%; 63% survived). Among those receiving a combination of both VRC and 
TRB (+/- other antifungal agents) 11/17 (65%) survived, while 5/14 (36%) survived among those 
receiving other treatments (p = 0.11). Overall, 7/37 patients (18.9%) received surgery, including 5/7 
enucleation or vitrectomy and two extensive debridement (1 died, 5 survived, 1 with unknown 
outcome). Table 1.  
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Conclusion: In this study, the majority of patients had a significant underlying risk factor for 
infection including hematologic malignancy, SOT, ICU admission, or preceding trauma. Despite the 
use of combination antifungal therapy, the overall mortality rate from invasive L. prolificans infection 
was 51%, with a trend towards lower infection-related mortality (35%) in those receiving a 
combination treatment including both VRC and TRB. 
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Making continuous prospective surveillance of invasive mold diseases real-time in hospitals 
using artificial intelligence 
M. Ananda-Rajah1,2, J. Seah2, M. Liu3, G. Haffari3, C. Bergemeir3, T. Peel1 
1Infectious Diseases, Alfred Health, Melbourne, Australia, 2Alfred Health, Melbourne, Australia, 3It, 
Monash University, Clayton, Australia 
Objectives: Surveillance, audit and feedback of invasive mold diseases (IMD) is fundamental to 
antifungal stewardship (AFS) but current methods are inefficient and restrictive. Continuous 
prospective surveillance of IMD in all haematology patients has not been possible because the 
majority of these infections present as a culture negative pneumonia. Artificial intelligence (AI) 
targeting medical imaging provides an opportunity to identify fungal pneumonia in real-time in 
order to present actionable data at the point of care. Here we report preliminary results of real-world 
prospective validation of deep learning based natural language processing (NLP) of chest imaging 
reports for real-time detection of IMD in haematology patients that is part of a multicentre clinical 
trial (Clin Trials.gov NCT03793231). Objective:To validate NLP of chest computed tomography 
reports for prospective surveillance of IMD in all hospitalised haematology patients. As a validation 
study, NLP alerts are not being fedback to clinicians but rather the machine is being validated against 
human surveillance. Presented here are preliminary results from one activated site, Alfred Health, a 
major quaternary Australian transplant centre. 
Methods: Prospective active manual and electronic surveillance of invasive fungal diseases (IFD) 
among hospitalised patients under the haematology service commenced on 1 December 2018. 
Hospitalised patients with IFD were identified by research coordinators through active case finding 
every week. All suspected IFD cases were reviewed again at 30 days and data collected to determine 
if they met internationally accepted criteria for IFD diagnosis (EORTC/MSG 2008 definitions). Chest 
CT reports were prospectively processed by NLP hosted on the hospital server and predictions were 
compared to IFD cases detected by active surveillance. 
Results: From 1 December 2018 to 31 April 2018, there were 8 patients with suspected IFD identified. 
Of these, one case was excluded because it did not meet internationally accepted criteria for IFD, 
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resulting in 7 patients with confirmed IFD associated with the following characteristics: all had IMD; 
all had pulmonary site of infection; 2 cases were probable/proven; 2 possible cases had a positive 
Aspergillus PCR on bronchoalveolar lavage. There were 6 cases of breakthrough IMD on antifungal 
prophylaxis involving posaconazole in 4, liposomal amphotericin in 1 and fluconazole in 1 case. Of 
90 chest CT reports screened by fungalAi-NLP over the study period, 6 of the 7 IFD patients were 
correctly flagged. The case missed by NLP was an intubated patient with probable pulmonary 
invasive Aspergillosis associated with isolation of A. terreus. The NLP output in this case had 
probabilities of 37.8% and 41.0% on serial reports which was below the 50% threshold for triggering 
a positive alert. The radiologist’s conclusion was not definitive in either report. There were 10 (11%) 
false positive reports. NLP is tuned for fungal pneumonia so may miss extra-pulmonary sites. False 
positives could be minimised with multimodal analysis combining other sources of data. 
Conclusion: Real-time, embedded, NLP of chest imaging reports facilitates surveillance of 
diagnostically challenging IMD for an entire haematology population. NLP utilises diagnostic 
imaging readily available in hospitals rather than the electronic medical record. Generalisability of 
NLP will be enhanced by our multicentre clinical trial. 
 
P317 
The case of successful treatment of disseminated cryptococcosis in a patient with Non-Hodgkin's 
lymphoma 
J. Melekhina1, Y. Borzova2, S. Ignatyeva2, E. Desyatik3, T. Bogomolova4, I. Ziuzgin5, N. Vasilyeva2, N. 
Klimko1 
1Department Of Clinical Mycology, Allergology And Immunology, North-Western State Medical 
University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2Kaschkin Research 
Institute Of Medical Mycology. Department Of Medical Microbiology, North-Western State Medical 
University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 3Kashkin Research 
Institute Of Medical Mycology, North-Western State Medical University named after I.I.Mechnikov, 
St. Petersburg, Russian Federation, 4North-Western State Medical University named after I.I. 
Mechnikov, St. Petersburg, Russian Federation, 5FSBI «Petrov Research Institute of Oncology» of the 
Ministry of Healthcare of the Russian Federation, Saint-Petersburg, Russian Federation 
Case Report: Objectives. Clinical case of successful treatment of disseminated cryptococcosis in 
patient with Non-Hodgkin's lymphoma. Methods. The EORTC/MSG 2008 diagnostic criteria were 
used. Results. Patient B., 32-year-old, was hospitalized in a city hospital in June 2016. Non-Hodgkin's 
lymphoma was diagnosed. He received 8 cycles of R-CHOP therapy, two cycles of R- DHAP with 
peripheral blood stem cell transplantation, one cycle of GDP protocol and after achieving partial 
remission, the patient was consolidated with peripheral blood stem cell transplantation using the 
BEAM conditioning regime. In September 2017, hematological remission was achieved. In October 
2018 an infiltrate 17x12 mm in the right lung S4 was revealed on computed tomography (CT) scan. 
Surgical removal the lung lesion was performed. Histological examination revealed granulomatous 
inflammation, and culture was positive with Cryptococcus neoformans. Positive “Crypto +” test in 
blood serum and cerebrospinal fluid was detected and diagnosis disseminated cryptococcosis was 
established. The patient was treated with amphotericin B 50 mg/day for 14 days, followed by 
fluconazole 800 mg/day with positive effect. In February 2109 the decrease of infiltration and the 
reduction of the cavity were detected on chest CT scan. Cryptococcal antigen test was negative in the 
blood serum and in the cerebrospinal fluid. The total duration of antimycotic therapy was six months. 
Conclusion. Disseminated cryptococcosis is possible in patients with Non-Hodgkin's lymphoma. 
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Comparison of fluconazole and posaconazole based antifungal prophylaxis in patients with 
newly diagnosed acute myeloid leukemia 
O. Kandemir1, A. Tombak2, M. Bakır Koyuncu3, S. Şahinoğlu3, A. Türker3, E. Sahin Horasan4 
1Infection Dieseases, Mersin University, mersin, Turkey, 2Hematology, mersin university, MERSIN, 
Turkey, 3Mersin University, MERSIN, Turkey, 4Infection Diseases, mersin university, mersin, Turkey 
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Objectives: Antifungal prophylaxis with posaconazole during remission induction chemotherapy of 
patients with newly diagnosed acute myeloid leukemia has been shown to decrease invasive fungal 
infections (IFI) and increase overall survival. However, real-life studies about this issue is not much. 
Methods: This was a retsopective cohort study incluiding a total of 58 patients with acute myeloid 
leukemia who were received intensive remission induction therapy. 27 patients received fluconazole 
prophylaxis between January 2013 and January 2015, 31 patients received posaconazole prohylaxis 
between February 2015 and February 2017. 
Results: 
  
Demographic characteristics of the patients were similar in both groups (Table-1). At day 100, 
patients receiving posaconazole had a significantly lower incidence of possible IFIs (45.2% vs 74.1%, 
p = 0,026). There was no significant difference in 100-day overall mortality (32.3% in the posaconazole 
group vs. 25.9 % in the fluconazole group, p = 0,597), breakthrough IFIs (31.3% in the posaconazole 
group vs. 29.6 % in the fluconazole group, p = 0,829) and death during active treatment (44.4% in the 
posaconazole group vs. 32.3% in the fluconazole group, p = 0,340) (Table-2). 
Conclusion: Posaconazole prophylaxis decreased the incidence of IFIs but did not improve short-
term overall survival. 
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B-1 cell deficiency decreases the population and function of dendritic cells in murine 
encephalitozoonosis 
A. Pereira1, D. Langanke Dos Santos2, A. Alvares-Saraiva2, E. Hurtado2, J. Alvarez2, M. Lallo2 
1Biomedicina, Centro Universitário São Camilo, São Paulo, Brazil, 2Post-graduation Program In 
Environmental And Experimental Pathology, Paulista University, São Paulo, Brazil 
Objectives: Microsporidia are obligate intracellular pathogens belonging to the kingdom Fungi, 
relatively common enteric microorganisms that usually result in self-limited or asymptomatic 
infections in humans. Although protection against microsporidia is predominantly dependent on the 
onset of a strong T cell response, dendritic cells (DCs) play a critical role in stimulating T cell response 
through pattern recognition receptors. Previous studies have suggested that DCs can regulate B cell 
activity and Encephalitozoon intestinalis infection blocks the differentiation of DCs, thus compromising 
the immune response against the pathogen, characterizing an evasion mechanism. The present study 
aimed to evaluate the relation between B-1 cells and DCs of Peyer's patches (PPs) in mice infected 
with Encephalitozoon cuniculi, a species of microsporidia. 
Methods: BALB/c mice, BALB/c Xid mice (deficient in B-1 cells) and Xid+B-1 (B-1 cells adoptive 
transfer to mice) were infected or not with E. cuniculi orally and the same immunosuppressed with 
cyclophosphamide (Cy) because it is an opportunistic pathogen. After 21 days of the infection, the 
DCs of PPs were quantified by flow cytometry. 
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Results: Infected mice had a lower population of DCs on PPs than uninfected animals (fig. 1). This 
result suggests the ability to block DC differentiation for the pathogen E. cuniculi. The BALB/c mice, 
with higher resistance to E. cuniculi infection, had the highest DCs populations when compared to 
the other groups (Fig.1). Xid animals showed the smallest populations of DCs, with the exception of 
the Xid animals that received B-1 cell transfer. MHC II expression decreased in Xid animals. Cy 
induced an increase in the DCs population in PPs from uninfected BALB/c mice in relation to the 
other uninfected groups, indicating an immunomodulatory effect of the drug. 
 
Figure 1. Evaluation of dendritic cells present in the Peyer's Patches from BALB/c, BALB/c XID and 
XID+B-1 mice inoculated (+) or not (-) with E. cuniculi. A) Percentage of CD11c+ dendritic cells in non-
treated mice. B) Geometric mean of the fluorescence intensity of the MHC II molecule in dendritic 
cells CD11c+. C) Percentage of CD11c+ dendritic cells.Two-way ANOVA analysis with Tukey post-
test revealed # statistically significant differences and p <0.05*, versus BALB XID and versus XID+B-
1, respectively (A). Data were transformed for statistical analysis, analysis of two-way ANOVA with 
Tukey test post revealed p <0.05* versus BALB c. 
Conclusion: These data suggest that B-1 cell deficiency compromises the population and the DCs 
response of PPs in E. cuniculi infection. 
P320 
Evaluation of the Wako™ β-D-Glucan assay in Patient Serum for the Diagnosis of Invasive 
Aspergillosis. 
F. Hegarty 
Microbiology, Mater Misericordiae University Hopsital, Dublin, Ireland 
Objectives: Invasive Aspergillosis is a fungal disease that can carry a high morbidity and mortality, 
especially in those patients who are immunosuppressed. Early diagnosis of Invasive Aspergillosis 
(IA) is key to implementing early treatment and improve patient prognosis. Currently in MMUH, 
serum β-D-Glucan (BDG) is available as an external referral test only (average TAT 109.5 days). 
Expanding our current repertoire of tests to include BDG, would greatly aid in the early diagnosis of 
IA. Delay or misdiagnosis of IA can result in drug toxicity due to inappropriate treatment, high 
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medical expenses and mortality. Given the complexity of invasive fungal diseases a number of tests 
are required for correct diagnosis. Therefore implementation of another test that can quickly and 
accurately aid in the diagnosis of IA would have great benefits for overall patient care, whilst limiting 
unnecessary use of antifungal therapy within the hospital. Aim: To evaluate the Wako™ β-D-Glucan 
assay in the laboratory and its’ implications for clinical practice. To assess the contribution this test 
can make to patient care 
Methods: Fifty-one random patient samples (serum) were used to complete this pilot study. Samples 
included ICU, lung transplant and haematology patients. Positive and negative controls were 
included weekly. The Wako™ β-D-Glucan was evaluated as per the manufacturer’s guidelines 
Results: The results obtained from the BDG were compared to external referral results. They were 
also analysed in conjunction with previous microbiological cultures, galactomannan, OLM™ lateral 
flow device calcofluor/KOH results, histological specimens, radiological imaging and clinical details 
where applicable. EORTC criteria were used to categorise patients into proven, probable or possible 
IA. BDG results demonstrated 83% sensitivity and 100% specificity as well as a positive predictive 
value of 100% and a negative predictive value of 88%. 
Conclusion: Based on results of this study, Wako™ β-D-Glucan will be introduced in MMUH, for 
patients with suspected IA, or those severely immune-suppressed. 
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Evaluation of the Wako™ β-D-Glucan assay in Patient Serum for the Diagnosis of Invasive 
Aspergillosis. 
F. Hegarty 
Microbiology, Mater Misericordiae University Hopsital, Dublin, Ireland 
Objectives: Invasive Aspergillosis is a fungal disease that can carry a high morbidity and mortality, 
especially in those patients who are immunosuppressed. Early diagnosis of Invasive Aspergillosis 
(IA) is key to implementing early treatment and improve patient prognosis. Currently in MMUH, 
serum β-D-Glucan (BDG) is available as an external referral test only (average TAT 109.5 days). 
Expanding our current repertoire of tests to include BDG, would greatly aid in the early diagnosis of 
IA. Delay or misdiagnosis of IA can result in drug toxicity due to inappropriate treatment, high 
medical expenses and mortality. Given the complexity of invasive fungal diseases a number of tests 
are required for correct diagnosis. Therefore implementation of another test that can quickly and 
accurately aid in the diagnosis of IA would have great benefits for overall patient care, whilst limiting 
unnecessary use of antifungal therapy within the hospital. Aim: To evaluate the Wako™ β-D-Glucan 
assay in the laboratory and its’ implications for clinical practice. To assess the contribution this test 
can make to patient care 
Methods: Fifty-one random patient samples (serum) were used to complete this pilot study. Samples 
included ICU, lung transplant and haematology patients. Positive and negative controls were 
included weekly. The Wako™ β-D-Glucan was evaluated as per the manufacturer’s guidelines 
Results: The results obtained from the BDG were compared to external referral results. They were 
also analysed in conjunction with previous microbiological cultures, galactomannan, OLM™ lateral 
flow device calcofluor/KOH results, histological specimens, radiological imaging and clinical details 
where applicable. EORTC criteria were used to categorise patients into proven, probable or possible 
IA. BDG results demonstrated 83% sensitivity and 100% specificity as well as a positive predictive 
value of 100% and a negative predictive value of 88%. 
Conclusion: Based on results of this study, Wako™ β-D-Glucan will be introduced in MMUH, for 
patients with suspected IA, or those severely immune-suppressed. 
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Evaluation of OLM™ Lateral Flow Device (LFD) in Bronchoalveolar Lavage for the Diagnosis of 
Invasive Aspergillosis 
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F. Hegarty 
Microbiology, Mater Misericordiae University Hopsital, Dublin, Ireland 
Objectives: Invasive Aspergillosis is a fungal disease that can carry a high morbidity and mortality, 
especially in those patients who are immunosuppressed. Early diagnosis of Invasive Aspergillosis 
(IA) is key to implementing early treatment and improve patient prognosis. While respiratory 
samples may culture Aspergillus, it is essential to differentiate between active infection verses 
colonisation of the lung. This differentiation can often be difficult as well as time consuming. This 
potential for delay in treatment commencement could contribute to a poor outcome, or if treated 
incorrectly may expose the patient to unnecessary antifungal therapy. Therefore utilisation of a test 
that can reliably differentiate between colonisation and active infection would have benefits for 
patient care. Aim: To evaluate the OLM™ LFD in the laboratory and implications for clinical practice. 
To assess the contribution this test can make to patient care 
Methods: Twenty random patient samples (bronchoalveolar lavage) were used to complete this pilot 
study. Nine samples were Aspergillus culture positive, fifteen samples were Aspergillus culture 
negative and two samples NEQAS controls; Aspergillus sp. and Trichophyton sp. culture positive. The 
OLM™ LFD was evaluated as per the manufacturer’s guidelines, which included the pre-treatment 
steps as required 
Results: The results obtained from the LFD analysed in conjunction with previous microbiological 
cultures, calcofluor/KOH results, histological specimens, radiological imaging and clinical details 
where applicable. LFD results demonstrated 100% sensitivity and 85% specificity as well as a positive 
predictive value of 71% and a negative predictive value of 100%. The LFD detected the presence of 
Aspergillus in three samples which was missed in the previously carried out culture and 
calcofluor/KOH. In this instance, Aspergillus infection was suspected from patient scans, which nicely 
correlated with the LFD result. 
Conclusion: Based on results of this study, OLM™ LFD will be introduced in MMUH, for patients 
with suspected IA, or those severely immune-suppressed. 
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The first case of invasive candidiasis caused by two pathogens (Candida albicans and Candida 
glabrata) in a patient with Hodgkin's lymphoma 
E. Shagdileeva1, O. Shadrivova1, J. Chudinovsky2, M. Motalkina2, I. Zyuzgin2, T. Bogomolova3, I. 
Vybornova3, I. Ryabinin3, A. Hohlova2, A. Artemeva2, N. Klimko1 
1North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian 
Federation, 2N.N. Petrov National Medical Research Centre of Oncology, Saint Petersburg, Russian 
Federation, 3Kashkin Research Institute Of Medical Mycology, North-Western State Medical 
University named after I.I.Mechnikov, St. Petersburg, Russian Federation 
Case Report: Woman with HL, 32 years old, in severe condition was admitted to the Petrov Oncology 
National Medical Medical Research Centre for cytotoxic chemotherapy on 23.01.2019. Risk factors for 
IC were central venous catheter (CVC), broad-spectrum antibacterial drugs therapy, prolonged 
neutropenia, and glucocorticosteroids treatment. The patient didn't receive antifungal prophylaxis. 
Clinical manifestation of IC was body temperature > 38°С, refractory to antibiotic use. Diagnosis of 
invasive candidiasis was confirmed with blood culture – C.albicans with susceptibility to fluconazole 
and voriconazole in vitro. Pathogen identification was determined by MALDI-TOF mass 
spectrometry. In the first 24 hours after diagnosis antifungal therapy (caspofungin) was used, and 
CVC was removed. Anaphylactic reaction with angioedema developed after caspofungin 
administration, and liposomal amphotericin B (7 days), then fluconazole (7 days) and amphotericin 
B deoxyholate (6 days) were used. Death was caused by septic shock after 20 days of antifungal 
therapy. On the autopsy IC with lungs, liver, spleen, and skin involvement was found. Culture from 
the autopsy materials was identified as C.glabrata with dose-dependent susceptibility to fluconazole 
in vitro. Conclusion. In the treatment of invasive candidiasis in immunocompromised patients, the 
possibility of several pathogens should be considered. 
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Pulmonary aspergillosis in patient with autoimmune hepatitis: the report of unusual case 
A. Antonets1, O. Kit2, O. Kutsevalova3, N. Panova3, D. Miroshnichenko4, E. Popovyan5, O. Homenko6 
1Laboratory Of Molecular Oncology, Rostov Research Institute of Oncology, Rostov-on-Don, Russian 
Federation, 2Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation, 3Laboratory 
Of Clinical Microbiology, Rostov Research Institute of Oncology, Rostov-on-Don, Russian 
Federation, 4Clinical Pharmacology Department, Rostov Rostov Regional Clinical Hospital №2, 
Rostov-on-Don, Russian Federation, 5Pulmonology Department, Rostov Rostov Regional Clinical 
Hospital №2, Rostov-on-Don, Russian Federation, 6Hepathology Department, Central City Hospital 
№1 named N.A. Semashko, Rostov-on-Don, Russian Federation 
Case Report: Objectives: To present the case of immunocompromised patient who was diagnosed 
with рulmonary aspergillosis in a short period of time after established diagnosis of autoimmune 
hepatitis. Methods: We examined 69-year-old man who had spitting blood, cough, signs of abscess 
pneumonia in x-ray examination after 5 weeks of immunosuppressive therapy with decreasing dose 
of glucocorticoids that was prescribed after the second episode of bilirubinemia when diagnosis of 
autoimmune hepatitis was established after scrutinizing diagnostic search. Sputum was analyzed 
with standard and fluorescent microscopy with white calcofluor and cultural method. Standard 
methods were applied to exclude tuberculosis and aspergillosis. Galactomannan (GM) detection was 
performed with immunoenzymatic assays XEMA GaIMAg EIA kit (Russia). Positive level of GM 
accounted for ≥0.59 OD (optical density). Results: Cultural methods revealed the presence in sputum 
E.coli (107) and A.flavus (105) (pic.1).  
 
GM level initially was positive in blood (0.73 OD). Antifungal voricоnazol therapy was started 
immediately. Оne week after starting treatment the second cultural testing of nose crust showed 
A.flavus (104) (pic.2); 
 
GM was negative in blood and urine (0.41 OD and 0.14 OD respectively), and positive in 
bronchoalveolar lavage fluide (BALF) accounting for 2.34 OD. Futher cultural testing did not detect 
A.flavus. GM level was positive only in BALF. Spiral computed tomography revealed several 
aspergillomas, the size of the largest one was 70x50 mm. The patient did not have leukopenia at any 
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time from the first episode of hepatitis, however slight lymphopenia was observed. Оne month after 
diagnosis of pulmonary aspergillosis pneumothorax and secondary bacterial complications occurred. 
Despite this the patient has demonstrated positive clinical effect continuing antifungal and antibiotic 
therapy (in accordance with the sensitivity of microorganisms) with accompanying therapy by the 
third month since the diagnosis of aspergilllosis. The remission of autoimmune hepatitis has been 
observed. Conclusion. It should be taken into consideration that immunocompromised patients even 
without leukopenia/agranulocytosis and short period of immunosuppressive therapy are at risk of 
development fungal infection. GM testing demonstrates its usefulness for early diagnosis Aspergillus 
spp. A comprehensive approach to diagnosis and alertness of doctors for fungal infection can improve 
the detection of cases of aspergillosis. 
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Challenges in the management of fusariosis in oncology patients: a single-centre series of 27 cases 
R. Ito1, K. Ibrahim1, P. Bonazzi1, J. De Almeida Junior2, M. Santiago1, A.C. Da Silva1, M. Vieira1, M. 
Freire1, D. Silva3, M. Martins3, M. Szeszs3, L. Bonfietti3, J. Pereira1, V. Rocha2, M.D.P. Diz1, P. Hoff1, M. 
Melhem3, E. Abdala1 
1Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil, 2Hospital da Clinicas da Universidade 
de Sao Paulo, Sao Paulo, Brazil, 3Instituto Adolfo Lutz, Sao Paulo, Brazil 
Objectives: This study aims to describe clinical, epidemiological and laboratorial aspects of fusariosis 
in cancer patients. 
Methods: We retrospectively identified patients from an oncology hospital with proven fusariosis, 
according to the EORTC/MSG modified criteria, since January 2011 to January 2018. Demographic, 
clinical and laboratorial data from patients were obtained. Mortality rates at 30 and 90 days were 
evaluated. 
Results: Twenty-seven cases were identified. Median age was 55 years and 15 were female. Most 
patients had haematological malignancies (81.5%) and neutropenia (88.9%). All patients received 
chemotherapy and/or corticosteroids in the last 3 months. Eighteen had disseminated disease, 7 had 
fungaemia alone and 2 had localized skin infection. Out of 18 patients with disseminated fusariosis, 
13 had skin involvement, 8 had pulmonary disease and 5 had sinusitis. Fourteen patients received a 
lipid formulation of amphotericin B and voriconazole, 10 amphotericin B alone and 3 died before 
treatment. Species identification was performed in 10 isolates, and all of them were from F. solani 
species complex. Six isolates had susceptibility profile to antifungals and all had MIC ≥8 mg/L to 
azoles; two isolates had MIC ≥2 mg/L to amphotericin. Mortality rates at 30 and 90 days were 51.9% 
and 63.0%, respectively. At 90 days, no patients with solid tumor or fungaemia had survived 
Conclusion: Haematological malignancies, neutropenia, and the use of immunosuppressive 
therapies were the conditions most associated to fusariosis in cancer patients. Disseminated disease 
was the most common clinical presentation. Most patients received combined therapy, once the best 
therapeutic option has not yet been defined, and due to identification of isolates with high MICs to 
azoles and amphotericin. Mortality rates were higher in solid tumor patients and those with 
fungaemia alone. 
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Objectives: Pneumocystis jirovecii pneumonia (PCP) is caused by the fungus Pneumocystis jirovecii 
(PJ) and is almost exclusively diagnosed in severely immunocompromised patients. While in the 
recent past the vast majority of PCP-cases were diagnosed in patients with HIV, this is no longer the 
case in resource-rich countries with unrestricted access to HIV care. The benefit of prophylaxis 
against PJ has been convincingly demonstrated for patients with HIV and a CD4 T-cell count <200 
cells/mm but the benefit of prophylaxis is less well established for other patient groups. This study 
aimed to describe the epidemiology of PJP in recent years and assess how many patients with PCP 
did or did not receive appropriate prophylaxis in the months preceding the infection. 
Methods: A multicenter retrospective study was performed in 3 Belgian and Dutch tertiary care 
centers: Erasmus MC, University Medical Center in Rotterdam, AZ Sint-Jan in Bruges and UZ Gent 
in Ghent. A list of patients that underwent broncho-alveolar lavage sampling for PCP testing with an 
in-house PJ PCR was retrieved from the 3 microbiology labs. An in-house PJ PCR was used in each 
of the centers with a cycle threshold (Ct) value of <29 (Rotterdam and Bruges) or <31 (Ghent) 
considered a probable PCP. For patients with a positive PJ PCR but above this threshold a predefined 
case definition was used to classify patients as follows: a possible case of PCP had to fulfill all 3 of 
the following criteria; 1. PCR Ct value <35 and 2. Clinico-radiological diagnosis compatible with PCP 
and 3. Patient died or patient received PCP therapy and survived. Patient files from all PCR+ patients 
were reviewed to determine whether the patient fulfilled the PCP case definition and if antimicrobial 
prophylaxis had been provided prior to PCP. Disease specific guidelines (NIH AIDS, ECIL, ASOT, 
local hospital guidelines) were used to evaluate if prophylaxis was indicated. Fisher’s exact test, t-
test or Mann-Whitney U tests were used as appropriate. 
Results: From 2012 to 2018, 482 patients with positive PCR PJ of respiratory samples were reviewed. 
278 were excluded mostly because CT value was>35 (n = 247). Other reasons were age<18, insufficient 
clinical data available, other respiratory sample than BAL. Of the remaining 204, 153 had a probable 
(n = 90) or possible (n = 63) PCP. The remaining 51 were considered colonized (table 1). PCP patients 
were HIV negative in 74%. Only 11 (7%) of PCP cases had received prophylaxis, despite that 133 
(87%) had an indication for prophylaxis according to guidelines. 
J. Fungi 2019, 5, 95 350 of 464 
 
  
J. Fungi 2019, 5, 95 351 of 464 
 
Conclusion: The vast majority of patients diagnosed with PCP had not received prophylaxis and 
therefore the infection could be considered at least partially preventable. In regions where HIV 
testing and treatment is available without restrictions, PCP is mainly diagnosed in non-HIV 
immunocompromised patients. Strategies to improve awareness of and compliance with 
antimicrobial prophylaxis guidelines in immunocompromised patients are urgently needed. 
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Prospective evaluation of Mucorales DNA qPCR detection in serum for early diagnosis of 
mucormycosis: First results from the ModiMucor study 
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Objectives: Early initiation of specific treatment is essential to improve prognosis of mucormycosis. 
Several retrospective studies have reported that qPCR detection of Mucorales DNA in serum could 
anticipate the diagnosis of mucormycosis by an average of 8 days in hematological patients and in 
critically ill burn patients1-4. Modimucor is a French prospective multicentre study (9 university 
hospitals) that aims to assess the performance (sensitivity, specificity, positive and negative 
predictive values and likelihood ratios) of the circulating DNA detection test for the diagnosis of 
mucormycosis in comparison to CT scan imaging, histopathology, microscopy and culture. 
Methods: Patients with risk factors for invasive mold infection (IMI) such as patients with 
hematological diseases, burns diabetes, solid organ transplantation, trauma, or diabetes, and patients 
diagnosed with mucormycosis were enrolled prospectively. Serum samples were collected twice-a-
week, and Mucorales PCR were performed at the time of serum sampling, in each center, as 
previously described1. Clinical data and biological data were collected up to 6 months after 
enrollment. An interlaboratory quality control was done to ensure uniformity of the assays. Data 
analysis was performed using STATA 14 software. 
Results: Were included 250 patients with suspicion of invasive fungal infection from January 2015 to 
June 2017 (Strasbourg n = 156 ; Dijon n = 39 ; Besançon n = 21 ; APHP Saint Louis n = 10 ; APHP Necker 
n = 9 ; Nantes n = 9 ; APHP Mondor n = 3 ; Amiens n = 2 ; Lyon n = 1). Classification of patients 
according to EORTC/MSG criteria was as follows: 47 probable (n = 13) or proven (n = 34) 
mucormycoses, 64 probable or proven aspergilloses, 5 other probable or proven IMI (fusariosis n = 2; 
scedosporiosis n = 2 ; histoplasmosis n = 1). A very low interlaboratory variation of the Mucorales 
PCR results was observed (SD = 1,8 cycles [range 1.3 ; 2.9]). At least one serum with positive 
Mucorales PCR was found for 35/47 patients with proven or probable mucormycosis. Among the 12 
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PCR-negative patients, 4 were given liposomal amphotericin B for more than 10 days at the date of 
serum sampling, and 3 patients had only a positive direct examination, without positive culture. 
Twenty-two patients with possible IMI had at least one positive Mucorales PCR. Sensitivity, 
specificity, positive and negative predictive values were 74.5% (35/47), 89.2% (181/203), 61.4% (35/57) 
and 93.8% (181/193), respectively. In addition, positive and negative likelihood ratios were 6.8 and 
0.28, respectively. The first PCR-positive sample was observed in average 6.5 days [range 0-22; 
median = 4] before the sampling date of the first mycological positive specimen, and 7 days [range 0-
44; median = 4] before the first imaging criteria. 
Conclusion: This prospective study confirms the good performance of serum Mucorales PCR for 
early diagnosis of mucormycosis. This assay with an acceptable time frame and a reasonable cost 
helps to anticipate the diagnosis of mucormycosis and is becoming essential in the clinical diagnosis 
of mucormycosis. 1.Millon L. Clin Infect Dis, 2013 ; 2.Millon L. Clin Microbiol Infect 2016 ; 3.Caillot 
D. Open Forum Infect Dis, 2016 ; 4.Legrand M. Clin Infect Dis 2016 
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Objectives: Cryptococcosis occurs in man and animals in almost all the regions of the world. People 
with AIDS are particularly vulnerable to this infection. In particular, a higher mortality due to the 
infection is said to be associated with a CD4+ count less than 200cells/μL. Although Nigeria has the 
second highest number of people living with HIV globally, there is paucity of data on the prevalence 
of cryptococcal infections among this people. This study aimed to determine the burden of 
cryptococcal infections among HIV/AIDS patients accessing highly active antiretroviral therapy 
(HAART) treatment in Ibadan as well as determine the CD4+ count associated with cryptococcal 
infections in this locality. 
Methods: Adult male and female HIV/AIDS patients accessing HAART treatment at the President’s 
Emergency Plan for AIDS Relief (PEPFAR) clinic in Ibadan with CD4+ count less than 200cells/μL 
were enrolled into the study. Other HIV/AIDS patients with CD4+ count higher than 200cells/μL but 
who had a high index of cryptococcal meningitis were screened at the attending physician’s request. 
A cryptococcal antigen test was performed on blood samples from patients with CD4+ count less 
than 200cells/μL and CSF samples from patients referred by the attending physician. The CSF 
samples were also cultured on Sabouraud Dextrose Agar culture media to isolate the organism. 
Results: 200 HIV/AIDS patients were enrolled in the study. The mean CD4+ count was 145.2cells/μL 
and 49% of participants were newly diagnosed and had not commenced HAART. The overall 
prevalence of cryptococcosis was 2%. All positive samples were from patients referred by the 
attending physician. All positive samples were from patients with CD4+ higher than 200cells/μL. 
100% of patients with cryptococcosis were already receiving HAART. 
Conclusion: Cryptococcosis was found in HIV/AIDS patients with CD4+ count higher than 
200cells/μL. Hence timely and appropriate cryptococcal screening in HIV/AIDS patients could help 
reduce cases of and mortality due to cryptococcal infection and also guide treatment needs. 
Cryptococcal screening should always be implemented for HIV/AIDS patients with low CD4+ counts 
regardless of symptoms or receipt of HAART to identify asymptomatic infected patients. It is also 
important to promptly screen HIV/AIDS patients with CD4+ count higher than 200cells/μL with a 
high index of cryptococcal meningitis. 
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mycology, The Rabta hospital, Tunis, Tunisia, 3Department Of Anatomopathology, The Rabta 
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Case Report: Introduction: The phaeohyphomycosis are superficial or deep mycosis that occur due 
to pigmented frequently opportunistic fungus. We are reporting a case of co-infection, deep 
pheaohyphomycosis and tuberculosis in a 7 months pregnant patient unknowingly 
immunosupressed . Observation : The patient is Mrs Y.S. 24 years old, admitted for convulsions. The 
diagnosis of cerebral and lymph node tuberculosis was held because of right hemi-body convulsions, 
a positive quantiferon, an evocative lymph node aspiration cytology and the presence of 
tuberculomas on the cerebral MRI. The patient received a quadruple antitubercular treatment. In two 
months, there was recurrence of the seizures and persistance of a left abscessed cerebral lesion with 
an important edema contrasting with the disappearance of a big number of tuberculomas in MRI 
control. The examination found a discreet right mowing, no meningeal syndrome and a firm cervical 
lymph node of 1,5 cm. The HIV serology was negative . We have maintained the antitubercular 
treatment and associated a corticosteroid therapy. A complement of surgical exeresis was realised for 
treatment and diagnosis purposes. She developed two cervical renitent lymph nodes and new 
seizures. The CT Scan identified a numerous parenchymal pulmonary nodes some of which are 
excavated, many necrotic cervical lymph nodes and the reappearance of the cerebral lesion at surgical 
site. The lymph node puncture aspirated greyish pus containing mycelian filaments. The molecular 
biology identified Arthrocladium. The anatomopathology study of cerebral abscess confirmed both 
tubercular and mycosic co-infection. We have associated Amphotericin B and Itraconazole. The 
evolution was slowly favorable. Conclusion : phaeohyphomycosis is a rare pathology with a difficult 
diagnosis. The prognosis is dark for the systematic forms. The treatment is medico-surgical. 
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Objectives: Patients receiving Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase (Btk), 
are at increased risk of invasive and disseminated aspergillosis. Given the increasing use of this drug 
as front-line treatment for haematological malignancies, better understanding of the mechanistic 
basis for this risk is urgently required. Whilst Btk is recognised as an important tyrosine kinase in B 
cell receptor signalling pathways, we and others have shown an important role for Btk in 
macrophage-based phagocytic responses to Aspergillus fumigatusand Candida albicans. Furthermore, 
Ibrutinib is also known to inhibit other TEC kinases such as TEC, which is important for macrophage 
responses to Candida albicans. Our objective was to characterise the impact of Ibrutinib on macrophage 
behaviour during A. fumigatusexposure. 
Methods: Human monocyte-derived and alveolar macrophages, or murine J774A.1 macrophages, 
[AB1] were infected with A. fumigatusafter treatment with Ibrutinib and the impact on phagocytosis, 
cell signalling, fungal killing and cell death responses assayed using a combination of imaging, 
western blotting and cell death kinetic assays. Selected findings were confirmed to be Btk-specific by 
siRNA. 
Results: We show that Ibrutinib is a potent inhibitor of both NFAT and NFκB responses in human 
macrophages during infection with A. fumigatus. We show that A. fumigatusinduces human 
macrophage Btk phosphorylation and that Btk depletion impairs NFAT and NFκB responses in 
human macrophages. Furthermore, Ibrutinib strongly inhibited macrophage necrosis in response to 
infection. Our findings in a human in vitro model suggest Btk involvement in a TLR9-dependent 
endosomally driven pathway in accordance with previous findings in our murine model. How this 
mediates fungal dissemination is currently unknown. 
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Conclusion: . These observations suggest that defects in macrophage Btk signalling contribute to 
susceptibility to pulmonary aspergillosis. We are currently developing in vivo models to further 
study the effects of ibrutinib on outcomes from pulmonary aspergillosis. 
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Centro Hospitalar Sao Joao, Porto, Portugal 
Objectives: Posaconazole prophylaxis in patients with acute myeloid leukaemia (AML) changed the 
paradigm of fungal infections (FI). AIMS: Description of FI and analysis of factors that might 
predispose to this type of infection in non-allotransplant AML patients in the posaconazole era. 
Methods: Retrospective analysis of 217 consecutive non-M3 AML patients diagnosed between June 
2008 and June 2018 in a tertiary center and treated with intensive chemotherapy regimens, including 
autologous transplantation when performed in these patients. Posaconazole prophylaxis was 
introduced since January 2009. Multivariate regression analysis was performed to identify 
characteristics related to FI. 
Results: Median age at diagnosis was 51 years [19;71], 52% were females and all patients had an age-
adjusted Charlson score ≤3. Genetic risk group according to the European Leukemia Net 2017 
classification was favourable in 24%, intermediate in 43% and adverse in 22%. Twelve percent of 
patients (n = 26) had secondary AML. Patients were included from completed remission-induction 
intensive therapy up to transplant referral, the latter which occurred in 48% of patients (n = 104), with 
a global median follow-up of 7 months [1;132]. Autologous transplantation was performed in 15% of 
patients (n = 34). Fluconazole prophylaxis was administered in 7 patients, all others received 
posaconazole. There were 20 patients that had episodes of prophylaxis interruption, 14 during auto-
transplantation, 3 due to toxicity and 3 out of our protocol. During treatment, patients with no relapse 
presented a global median time of neutropenia of 69 days [26;421] whereas relapsed patients had a 
median of 104 days [30;356]. Ten percent of patients had >2 episodes of prolonged neutropenia 
(defined as ≥28 consecutive days of <500 neutrophils/microliter). Fungal infections were identified in 
41 patients (19%), 3 of which were in the non-posaconazole group, and classified according to EORTC 
criteria, with 13 proven, 17 probable and 10 possible infections. In 32% of patients FI occurred during 
remission-induction (n = 13) of which 3 were diagnosed in the first week of neutropenia, 19% during 
consolidation treatment in first remission and 49% during relapse treatment (n = 20). Of the confirmed 
infections, 5 were aspergillosis, 3 candidemia, 2 by Fusarium and 1 mucormycosis. Probable infections 
had pulmonary origin with no microbiology isolate or serologic positivity but identified by typical 
radiologic evidence; of these, broncho-alveolar lavage and/or pulmonary biopsy was performed in 6 
patients (35%) with negative results. For possible infections, antifungal therapy was initiated in a pre-
emptive manner for high risk patients with persistent fever despite large spectrum antibiotics. In a 
multivariate analysis for the posaconazole group, patients with FI had a higher odds of having 
relapsed AML, refractory AML at first approach and >2 episodes of prolonged neutropenia during 
treatment (p<0.01, p = 0.01 and p = 0.012, respectively). There was no mortality related to FI in this 
cohort of patients. 
Conclusion: Despite posaconazole prophylaxis, FI is still prevalent in AML patients. Infection during 
salvage treatment for refractory or relapsed disease and >2 previous periods of neutropenia 
exceeding 4 weeks should raise awareness for an increased risk of FI. 
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Objectives: Introduction: Neuromeningeal cryptococcosis (NMC) is a serious infection. Frequently 
described during HIV infection, it can nevertheless occur on any field of cellular immunosuppression 
and even in the immunocompetent. Aim: describe the clinical, para-clinical, therapeutic and 
evolutionary aspects of NMC cases. 
Methods: A descriptive retrospective study carried out at the infectious diseases’ department of La 
Rabta Hospital over 25 years, between January 1993 and December 2018, including all patients 
hospitalized for NMC. 
Results: We collected 30 cases of (NMC). The median age is 34 years old [18-73] with a sex ratio of 
1.7. 76 % of patients were HIV-positive. The average CD4 count was 58.8 cells / μl. Among HIV-
negative patients, 4 patients were followed for lymphoma, one patient was diabetic, one had 
Histiocytosis X and only 1 was immunocompetent. 
The median time of treatment was 6 days [1-75]. The main symptoms were fever (73%) and headache 
(93%). Seizures and signs of localization were present in 1/3 of the cases. A Physical meningeal 
syndrome was noted in 63% of the cases. Cerebrospinal fluid (CSF) analysis revealed a highly variable 
cytology [0-3000], hypoglycorrhachia (69%) and hyperproteinorachia (83%). The dosage of 
cryptococcal antigen in the CSF ranged between 1/64 and 1/25000. The treatment of attack was based 
primarily on Amphotericin B. The mortality was 56%. 
Conclusion: NMC is a life-threatening fungal infection. Only a high level of clinical suspicion, early 
diagnosis and appropriate medical care can improve the prognosis. 
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Objectives: Deep cutaneous mycoses are infections extending throughout the dermis and 
hypodermis, often occurring after inoculation of pathogen fungi. In kidney transplant, deep 
cutaneous mycoses count for up to 5% of all documented infections. The aim of this study was to 
describe the clinical features, histopathological findings and mycological characteristics of deep 
cutaneous fungal infections in renal transplant patients, as well their management and outcome. 
Methods: We performed a retrospective review of cases of proven deep cutaneous mycosis 
(histologically extending to dermis and/or hypodermis with mycological documentation) occurring 
among kidney transplant recipients in our institution since 2011. We studied the type of transplant, 
immunosuppression, histopathology, treatment with prospective follow-up of cutaneous lesions 
Results: Nineteen kidney transplant patients were included; the average age was 41 (range, 28 to 91). 
The immunosuppressive regimens at the time of diagnosis included corticosteroids (n = 19) and anti 
calcineurin (tacrolimus (n = 18), cyclosporin (n = 1)). In 10 and 6 patients a treatment by 
mycophenolate mofetil and azathioprine was associated, respectively. Co-morbidities were frequent: 
diabetes mellitus (n = 12), cancer (n = 2), HIV (n = 1). In 70% of cases a skin cancer was initially 
suspected (epidermoid carcinoma n = 5, kaposi sarcoma n = 6). The skin lesions were solitary in ten 
patients, mainly nodular (84%) and affected the extremities (95%), without fever or fatigue in the 
majority of cases (63%). Histopathologic examination of skin biopsies showed pseudohyphae and/or 
irregularly branched hyphae (n = 16/16, 100%), a granulomatous dermatitis (n = 6/16, 37%), and an 
inflammatory infiltrate (n = 8/16, 50%). Mycological examination of the biopsy showed the presence 
of hyphae on direct examination in 84% of the cases (n = 16/19). Identification was obtained by culture 
and / or molecular biology. Eleven different fungal species were observed, including dematiaceous 
molds (n = 13), hyphomycetes (n = 4), dermatophyte (n = 1), and Mucorale (n = 1). No dissemination 
to other organs was observed. The detection of the fungal (1-3) beta-D-glucan antigen in serum was 
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positive in 100% of the cases (n = 17/17). Fifteen patients received antifungal treatment with azoles 
(posaconazole n = 10, voriconazole n = 3), or liposomal amphotercin B (n = 2) for a mean duration of 
3 months, and surgery was associated in 11 patients. Side effects were common (64%) with mainly 
tacrolimus overdosage (21%) or acute renal failure (50%). 
Conclusion: This work highlights the great diversity of fungal species responsible for deep cutaneous 
mycoses in renal transplant patients. The mycological documentation is necessary to adapt the 
antifungal treatment according to the sensitivity to antifungal agents of the isolated species. Drug 
interactions between antifungals and immunosuppressive treatment require appropriate monitoring. 
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Objectives: Neutrophils are innate immune cells and the first line of defense against a variety of 
invading pathogens including yeast and mold species. While low circulating neutrophils numbers 
(neutropenia) is a clear risk factor for developing invasive fungal infections (IFI), there is lacking 
evidence if neutrophil dysfunction contributes to infectious risk. In this study, we profiled circulating 
neutrophil anti-Candida fungicidal activity from high-risk patients at our tertiary care hospital, 
specifically transplant recipients compared to healthy controls. 
Methods: Solid-organ (SOT) and stem cell transplant (SCT) patients were identified and consented 
from September 2018 until April 2019. Healthy control patients (HC) were identified at primary care 
clinics. EDTA-anticoagulated peripheral blood was obtained from healthy and transplant patients 2-
4 months post-transplant. Neutrophils were isolated by negative selection. C. albicans was co-
incubated for 2 hours with and without human neutrophils at a multiplicity of infection (MOI) of 1, 
5 and 10. Following neutrophil cell lysis, percent remaining live Candida was measured using a 
viability dye. In addition, growth inhibition of yeast by neutrophil swarming to C. albicans spotted 
onto glass slide arrays was also assessed by live-cell imaging. 
Results: 22 SOT (15 kidneys, 7 livers), 20 SCT (allograft) and 22 HC were enrolled. Neutrophils from 
SCT and SOT had lower C. albicans killing percentages compared to HC at MOI 10 (HC: 47%, SOT: 
29%, SCT 24% p = 0.0041); MOI 5 (HC: 72%, SOT: 35%, SCT 38% p < 0.0001) and MOI 1 (HC: 91%, 
SOT: 48%, SCT: 45% p < 0.0001). Neutrophil swarming and fungal control of C. albicans spots were 
significantly inhibited by neutrophils from SCT when compared to SOT and controls (p <0.0001). 
Analysis of medications, including tyrosine kinase inhibitor (TKI) use, did not demonstrate 
significant differences in a specific drug class when patient groups are compared (SCT versus SOT). 
Conclusion: This study indicates that neutrophils from patients with SOT and SCT have a decreased 
ability to kill C. albicans, despite normal circulating numbers. There were no medications or 
laboratory values that predicted a functional neutrophil outcome. These data strongly support the 
use of functional neutrophil profiling to risk stratify those individuals at higher risk for invasive 
fungal infections, although additional studies are required to determine if PMN dysfunction results 
in increased clinical infection. These findings will inform us of potential therapeutic interventions for 
restoring immune function and preventing invasive fungal infections in high-risk transplant patients. 
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Objectives: To investigate the etiology, risk factors, clinical manifestations, clinical features, and 
results of treatment of invasive candidiasis (IC) in neonatal patients in St. Petersburg, Russia. 
Methods: A prospective study was conducted from January 2015 to February 2019. We evaluated 
neonates with clinical manifestations of infection and a confirmed diagnosis of IC. The EORTC/MSG 
2008 criteria were used for IC diagnosis and evaluation of the effectiveness of therapy. 
Results: “Proven” IC was detected in 29 neonates patients, girls – 62%. Premature neonates were 
86%, twins – 21%. Median birth weight was 1280 g (560 – 4000 g), median gestational age at birth – 
30 weeks (23 – 40). IC developed on the 5 – 88 days of hospitalization (median – 20). The main 
underlying conditions: premature neonates – 86%, intraamniotic infections – 72%, HIV – 7%. Broad-
spectrum antibacterial drugs were prescribed for 100% patients, mechanical ventilation – 97%, central 
venous catheter (CVC) use – 93% (median time – 9,5 days, 4 -25 days), parenteral nutrition – 69 %. 
Antifungal prophylaxis with fluconazole received 93% patients. The main clinical variants of IC were 
candidemia – 97%, chorioretinitis – 6%, meningitis – 3%, and hepatitis – 3%. Candida spp. were 
isolated from CVC in 86% of patients, blood – 41%, cerebrospinal fluid – 3%. The pathogens of IC 
were C.albicans – 38%, C.parapsilosis – 32%, C.famata – 14%, С.pelliculosa – 7%, C.tropicalis – 3%, 
C.guiliermondii – 3%, Candida sp. – 3%. In vitro to voriconazole were resistant 3% Candida spp., 
fluconazole – 3%, dose-dependent susceptibility to fluconazole – 7%. In the first 24 hours after 
diagnosis antifungal treatment was used in 100% patients: fluconazole (100%), micafungin (38%), 
amphotericin B deoxycholate (14%), and voriconazole (14%). The median duration of treatment was 
20 days (1 - 54). The overall 30-day survival rate was 86%. 
Conclusion: IC developed in premature neonates (86%), the median gestational age at birth was 30 
weeks, the median birth body weight - 1280 g. Risk factors for IC were broad-spectrum antibacterial 
drugs therapy (100%), mechanical ventilation (97%), and central venous catheter (93%). Main etiology 
agents were C. albicans – 38% and C. parapsilosis (32%). The main clinical variant of IC was candidemia 
(97%). Antifungal treatment was used in 100% patients, fluconazole – 100%, micafungin – 38%. The 
overall 30-day survival rate was 86% 
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AIRE and STAT1 gene mutations in Children with Chronic Mucocutaneous Candidiasis in Saint-
Petersburg, Russia 
O. Kozlova1, N. Isaeva1, E. Frolova1, T. Bogomolova1, E. Suspitsin2, T. Gabrusskaia3, N. Klimko1 
1Department Of Clinical Mycology, Allergology And Immunology, North-Western State Medical 
University n.a. I.I. Mechnikov, Saint-Petersburg, Russian Federation, 22St. Petersburg State Pediatric 
Medical University, Saint-Petersburg, Russian Federation, 3Saint-Petersburg State Pediatric Medical 
University, Saint-Petersburg, Russian Federation 
Objectives: Publications on AIRE and STAT1 gene mutations in children with chronic 
mucocutaneous candidiasis (CMC) are limited. 
Methods: Molecular genetic studies were performed with multigenic targeted sequencing (MiSeq, 
Illumina, USA). 
Results: In prospective single center study included 11 patients with CMC. Median age was – 7.5 y, 
range - 6 to 13 y, males - 92%. Molecular genetic study has shown heterozygous mutation in the 
STAT1 gene in 4 patients and mutations in autoimmune regulator (AIRE) in 7 patients. CMC started 
between 2 months - 4 years (median – 2 y). Sites of CMC were oral mucosa – 100 %, skin – 64%, 
esophagus - 36%, and nails – 36%. Candida albicans was isolated in all patients. Recurring CMC was 
diagnosed more than 4 times per year in all patients. Endocrine disorders were present in patients 
with AIRE syndrome: primary adrenal insufficiency – 71%, hypoparathyroidism - 71%, autoimmune 
thyroiditis with hypothyroidism - 29%; autoimmune disorders: autoimmune gastritis – 71%, alopecia 
– 29%, and hemolytic anemia – 14%. Patients with impaired STAT1 did not have endocrine disorders 
and autoimmune gastritis was in one patient (29%). 
Conclusion: In 100% patients CMC with mutations in autoimmune regulator AIRE endocrine system 
disorders and autoimmune diseases. STAT1 gene autoimmune diseases diagnosed in 29% patients. 
This work was supported by Russian Scientific Fund grant 18-15-00256 
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Pneumocystis jirovecii pneumonia associated with severe viral infection in children 
O. Kozlova1, E. Mironuk2, V. Kapilov2, A. Ustinova2, P. Muratov2, E. Serikova2, M. Pinevskaia2, S. 
Ignatyeva1, N. Klimko1 
1Department Of Clinical Mycology, Allergology And Immunology, North-Western State Medical 
University n.a. I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2Children's City 
Multidisciplinary Clinical Center for High Medical Technologies. K.A. Rauffusa, Saint-Petersburg, 
Russian Federation 
Objectives: As an opportunistic infection, Pneumocystis jirovecii pneumonia (PjP) is a severe and life-
threatening complication in immunocompromised patients. Publications on PjP associated with 
severe viral infection in children are limited. 
Methods: We report the 2 cases of PJP associated with severe viral infection in children. 
Results: A 13-year-old girl admitted in children’s hospital with interstitial pneumonia, sepsis, and 
respiratory and cardiovascular failure. 7 days before, she presented with the history of fever and dry 
cough. The patient is diagnosed with influenza. She was in acute respiratory distress and required 
immediate intubation and transfer to the intensive care unit. On examination, she was hypoxic with 
SaO2 70-82 % despite 100% flow oxygen. Despite empiric intravenous therapy with ceftriaxone, 
amikacin, meropenem and vancomycin, she remained hypoxic. Lymphopenia (1,0 × 109/l) was in 
blood analysis. HIV testing was negative. The chest CT scan showed bilateral interstitial infiltrates. 
MONOFLUO™ KIT P. jirovecii test and PCR test for P. jirovecii were positive in BAL. Intravenous 
trimethoprim–sulfamethoxazole (TMP–SMX) (12 mg/kg TMP) and prednisone 0.5 mg/kg twice daily 
were initiated, which resulted in improvement in respiratory status and weaning of respiratory 
support over 15 days (SatO2 - 88-92%, PO2 - 46-52%). A 16-year-old boy was diagnosed with chronic 
bronchiolitis, secondary arterial hypertension, and secondary asymmetric hypertrophic 
cardiomyopathy. 3 month before, he presented with the history of high fever and maculopapular 
rashes, spots Koplika and cough. Vaccination details were not available. The patient received several 
courses of antibiotic therapy and prednisone for a long time at a dose of 2.5-7.5 mg/kg without 
positive dynamics. Due to the development of severe respiratory failure, the patient was hospitalized. 
The patient had dyspnea of mixed character (SpO2 - 70-80%). The patient was immunocompetent 
(CD4 = 2,130*109/l) HIV testing was negative. The serology for measles was positive. The CT showed 
bilateral interstitial infiltrates. MONOFLUO™ KIT P. jirovecii test was positive in BAL. Intravenous 
TMP–SMX (12 mg/kg TMP), which resulted in improvement in respiratory status and weaning of 
respiratory support over 7 days. 
Conclusion: Severe viral infection associated with several weeks of immune suppression with the 
consequence may be the cause of secondary infections. 
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The first case of successful treatment of invasive mycosis caused by Candida guiliermondii and 
Exophiala dermatitidis in a neonatal patient 
E. Shagdileeva1, S. Vorobeva2, N. Kotina2, T. Bogomolova3, I. Vybornova3, N. Klimko1 
1North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian 
Federation, 2City Children's Hospital № 1, St. Petersburg, Russian Federation, 3Kashkin Research 
Institute Of Medical Mycology, North-Western State Medical University named after I.I.Mechnikov, 
St. Petersburg, Russian Federation 
Case Report: Newborn girl on the 2nd day of life was admitted to the City Children's Hospital № 1 
on 25.01.2019. Birth weight was 3050 g, gestational age at birth – 40 weeks. Mother 43 years old: 
pregnancy - 8, childbirth - 6, HIV since 2014. The underlying condition was early hemorrhagic disease 
of the newborn, gastric bleeding. Result of HIV-1 DNA PCR test was negative, and antiretroviral 
prophylaxis (zidovudine) was used. Risk factors for IM were prolonged central venous catheter 
(CVC) use and broad-spectrum antibacterial therapy. Clinical manifestation of IM was body 
temperature > 38°С, refractory to broad-spectrum antibacterial therapy. A patient was treated 
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empiricaly with fluconazole. Diagnosis of IM was confirmed with positive blood culture: resistant to 
fluconazole in vitro C. guiliermondii and E.dermatitidis. Antifungal treatment was changed to 
micafungin. Clinical condition was improved and results of multiple blood cultures were negative. 
The total duration of micafungin treatment was 30 days. Conclusion. In the treatment of invasive 
mycosis in neonatal patients, the possibility of several pathogens should be considered. 
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Invasive Fungal Infections in a Paediatric Haematological-Oncological centre: a retrospective 
study of 15 years. 
A. Tragiannidis1, A. Giantsidi2, D. Kotsos2, E. Tsotridou2, A. Saranti2, V. Antari2, E. Hatzipantelis2, T.-
A. Vyzantiadis3 
1Hematology Oncology Unit, 2nd Pediatric Deparment, Aristotle University of Thessaloniki, AHEPA 
Hospital, Thessaloniki, Greece, 2Hematology Oncology Unit, 2nd Pediatric Deparment, Aristotle 
University of Thessaloniki, AHEPA Hospital, THESSALONIKI, Greece, 3First Department Of 
Microbiology, MEDICAL SCHOOL, ARISTOTLE UNIVERSITY OF THESSALONIKI, 
THESSALONIKI, Greece 
Objectives: Despite the major progress made in the last few years regarding the prevention, 
diagnosis and treatment of invasive fungal infections (IFIs), they still represent an important cause of 
morbidity and mortality in paediatric patients with malignancies and those undergoing HSCT. The 
aim of this retrospective study was to collect data of the incidence and outcome of IFIs in children 
with haematological malignancies and solid tumors in a Paediatric Hematology Oncology Unit. 
Additionally, specific data on diagnostics, predisposing factors and treatment was also collected 
Methods: Data was collected retrospectively from patients with an IFI (proven, probable, possible), 
who were diagnosed between January 1, 2003 and December 31, 2017 with haematological 
malignancies and solid tumors in the Haematological-Oncological Unit of the 2nd Department of 
Paediatrics, AHEPA University Hospital. By reviewing the patients’ records, information regarding 
gender, age at the time of the diagnosis of the IFI, underlying disease, treatment phase, the presence 
of neutropenia and its duration (> or < 10 days) as well as severity (< or > 500/mm3) and the site of the 
fungal infection was obtained. Last follow-up was performed after 12 months after the end of 
chemotherapy and included the status of disease, cause of death and in case of the occurrence of an 
IFI, the outcome of the infection. 
Results: Eleven out of the twenty-six children enrolled in the study were males. The underlying 
disease was ALL for 19 patients (73%) and AML for 6 (23%). Twenty of them were under parenteral 
nutrition during the manifestation of the IFIs and 20 of the patients were presented with neutropenia 
(ANC<500/mm3). The most common location of the IFIs were the lungs and the most common 
pathogen was Aspergillus spp. According to the revised criteria of the European Organization for 
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National 
Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) for the diagnosis 
of IFSs, 5 of the diagnoses were classified as proven, of which two patients developed zygomycosis, 
one chronic disseminated candidiasis, one cryptococcosis and one systematic aspergillosis. Out of the 
rest 21 patients, 12 were classified as being affected by probable and 9 as being affected by possible 
IFIs. Eleven patients received a combination of antifungal drugs, whereas the rest of them were 
treated with monotherapy. Twenty received liposomal amphotericin B (LAMB), eleven voricanazole, 
two caspofungin, two micafungin and one fluconazole. IFI was lethal in 9 out of the 26 patients (34%). 
Patients with zygomycosis were successfully treated with surgical excision of the lesion combined 
with high dose of LAMB. 
Conclusion: The results of this study suggest that, despite the progress regarding the diagnosis and 
treatment of IFIs with use of new antifungal drugs, mortality remains high. Therefore, it becomes 
obvious that early suspicion as well as prophylactic and empirical therapy are significant factors 
contributing in the improvement of the outcome of IFIs. 
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Candida sepsis successfully treated with micafungin add-on therapy in extremely preterm infants: 
report of two cases. 
C.S. Kim 
Department Of Pediatrics, Keimyung University School of Medicine, Daegu, Korea, Republic of 
Case Report: Objectives: Candida sepsis is a common hospital-acquired infection in the neonatal 
intensive care unit and occurs usually in extremely preterm infants. Echinocandine is a new drug 
with a different mechanism of action from existing antifungal agents which induces fungal cell wall 
damage, and is mainly used in adults, and neonatal applications are extremely rare. Case 1: A female 
infant was born by an emergent Cesarean section with fetal distress at the gestational age 27 weeks. 
The birth weight was 720 g. After birth, the baby received intensive care for respiratory distress and 
feeding difficulties, including mechanical ventilation, central venous catheterization, and parenteral 
nutrition. On the 16th day of admission, the patient was suspected of sepsis and Candida parapsilosis 
was detected in the culture of both blood and central venous catheter specimens. Initially, 
amphotericin-B (initial dose: 0.5 mg/kg/day, maintenance dose: 1-1.5 mg/kg/day) was administered 
but fungemia persisted after 10 days of treatment. Thereafter, micafungin (therapeutic dose: 15 
mg/kg/day) was added and administered concurrently. After 4 days of the combination therapy, CRP 
was decreased, and candida was no longer detected in blood samples. The patient was treated with 
amphotericin-B for 19 days and micafungin for 8 days, and there was no recurrence of fungal 
infection. There were no adverse effects of antifungal agents in laboratory findings at the end of 
treatment. Case 2: A female infant was born with vaginal delivery at the gestational age 26 weeks 
and 2 days. The birth weight was 750 g. After birth, the baby received neonatal intensive care, 
including mechanical ventilation and parenteral nutrition. On the 13th 15th day of hospitalization, C. 
parapsilosis was consecutively detected in blood samples of the patient. Initially, amphotericin-B was 
administered, but fungemia and elevated titers of CRP were persisted after 10 days of treatment. 
Thereafter, micafungin was added. Candida was no longer detected in the blood samples after 7 days 
of the combined therapy. The patient was treated with amphotericin-B for 25 days and micafungin 
for 14 days, and there was no recurrence of fungal infection. In addition, there were no adverse effects 
of antifungal agents in laboratory findings at the end of treatment. Conclusion: I report two cases of 
extremely preterm infants with Candida sepsis successfully treated with micafungin add-on therapy 
that did not resolve with amphotericin-B alone. 
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Invasive Aspergillosis in a Paediatric Haematological-Oncological center: a retrospective study of 
15 years 
A. Tragiannidis1, A. Saranti2, A. Giantsidi2, D. Kotsos2, E. Tsotridou2, M. Papambougiouki2, E. 
Hatzipantelis2, T.-A. Vyzantiadis3 
1Hematology Oncology Unit, 2nd Pediatric Deparment, Aristotle University of Thessaloniki, AHEPA 
Hospital, Thessaloniki, Greece, 2Hematology Oncology Unit, 2nd Pediatric Deparment, Aristotle 
University of Thessaloniki, AHEPA Hospital, THESSALONIKI, Greece, 3First Department Of 
Microbiology, MEDICAL SCHOOL, ARISTOTLE UNIVERSITY OF THESSALONIKI, 
THESSALONIKI, Greece 
Objectives: Invasive aspergillosis (IA) represents an important cause of morbidity and mortality in 
patients with primary and secondary immunodeficiencies and them undergoing Hematopoietic Stem 
Cell Transplantation (HSCT). In particular, Aspergillus spp. constitute the second most frequent 
cause of fungal infections in immunosuppresed patients, while IA seems to be responsible for higher 
mortality rates in comparison with candidiasis. 
Methods: Retrospective case study of IA managed and treated in the Hematological-Oncological Unit 
between 2001 and 2016. The study included in total 16 children with possible, probable and proven 
IA according to the European Organization for Research and Treatment of Cancer/Invasive Fungal 
Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses 
Study Group (EORTC/MSG) Consensus Group criteria. 
J. Fungi 2019, 5, 95 361 of 464 
 
Results: Among the 16 children included in the study, there were 6 boys. The underlying condition 
was acute lymphoblastic leukaemia (ALL) in 10 patients (62.5%) and acute myeloid leukaemia (AML) 
in 6 (37.5%). Out of the 16 patients, 13 were neutropenic with an absolute neutrophilic count lower 
than 500/mm3 at the time of diagnosis. According to the revised criteria of the EORTC/MSG for the 
diagnosis of IFIs came up that in 1 patient the diagnosis was proven, the diagnosis of 9 patients was 
classified as probable and finally in 6 as possible. Combined antifungal treatment was administered 
in 4 patients, while 12 patients received a single antifungal agent. Liposomal amphotericin B (LAMB) 
was administered in 10/16 patients, voriconazole in 7/16, caspofungin in 1/16 (as combined treatment) 
and micafungin in 1/16 patients (as combined treatment). Six out of the 16 patients (37.5%) died due 
to the IFI. 
Conclusion: According to the above findings there was concluded that despite the progress that was 
made regarding the diagnosis and treatment of IA with the use of newer formulations of antifungal 
agents, morbidity is still high. High suspicion and prompt initiation of empiric and prophylactic 
antifungal treatment in selected cases constitute significant factors for the improvement of the 
outcome of IA. 
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Thoracic actinomycosis mimicking tumor in a children 
O. Kozlova1, I. Suslova2, Y. Avdeenko2, Y. Borzova2, N. Klimko3 
1Department Of Clinical Mycology, Allergology And Immunology, North-Western State Medical 
University n.a. I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2North-Western State Medical 
University n.a. I.I. Mechnikov, Saint-Petersburg, Russian Federation, 3Department Of Clinical 
Mycology, Allergy And Immunology, North-Western State Medical University named after 
I.I.Mechnikov, St. Petersburg, Russian Federation 
Objectives: Thoracic actinomycosis is rare and publications are limited. 
Methods: Prospective, single-center study of 186 patients with different clinical forms of 
actinomycosis (2005 – 2017 yy.). Pulmonary actinomycosis was in 9% (n = 17) cases of them there were 
two children. We present two cases successful treatment of thoracic actinomycosis in children 
without risk factors whose initial diagnosis was malignancy. 
Results: 14-year-old boy, previously healthy, was admitted with a history of continuous chest pain 
during the past three weekes, fever, dry cough and hemoptysis. He was referred to the oncology 
center with the hypothesis of malignant disease. Weight and height of the patient was appropriate 
the age and sex. Respiratory sounds were decreased in the right lower field. Laboratory findings 
demonstrated slight anemia (hemoglobin of 110 g/l) and elevated inflammatory markers, such as 
white blood cell count (leukocyte count of 16 * 109/l) and C-reactive protein (25.5mg/dL). Tuberculin 
test was negative. A chest CT scan revealed a consolidation (70*40 mm) with spiculated margins and 
areas of ground-glass attenuation in the right lower lung. A percutaneous thoracoscopic biopsy of 
right lower lobe was performed. Histological examination revealed the presence filamentous 
organisms and sulfur granules, without evidence of malignancy. The thoracic actinomycosis was 
diagnosed. The patient received penicillin 15000000 units/day) during three weeks, followed by 5 
months of amoxicillin (40mg/kg/day). During the first month of treatment, he showed clinical and 
radiograph improvement. He was followed up every 2 months until completing oral antibiotic 
therapy and remained asymptomatic year after the end of the treatment. Previously healthy 14-year-
old girl was admitted with a history of hemoptysis during the past month, continuous chest pain, 
and fever. Respiratory sounds were decreased in the right lower lobe, the patient's oxygen saturation 
was 96% while breathing ambient air. CT showed dense consolidation in the right lower lobe. The 
disease was initially interpreted as the malignant disease. A lobectomy was performed. Histological 
evaluation of surgical specimens with hematoxylin and eosin staining shows classic sulfur granules 
consistent with actinomycosis. She was started on intravenous sodium penicillin 8 000 000 units/day 
during two weeks, followed by 3 months of amoxicillin (40mg/kg/day), resulting in a rapid clinical 
response with the disappearance of all symptoms. General state of health was satisfactory, indicators 
of clinical and diagnostic studies within the normal range. CT imaging was normal. 
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Conclusion: Actinomycosis is an uncommon disease in children. Thoracic actinomycosis should be 
considered in the differential diagnosis of neoplasia. 
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Coccidioidomycosis disseminated disease in pediatric patient 
V. Lora-Téllez, M.F.D.C. Lara-Hernández, A. Bonifaz-Trujillo, G. Rodríguez-Coello 
Mycology Laboratory, Hospital para el Niño Poblano, Puebla, Mexico 
Case Report: Objective. To describe the clinical manifestations of the disease and laboratory 
diagnosis. Methods. Clinical characteristics, symptoms, direct examination of the pathological 
material, culture and biology molecular methods. Results. 11 years old female patient with 
malnutrition, who lives in semiarid region in the south-east of Mexico. 3 months of clinical evolution 
Fever 38°C Multiple lesions such as subcutaneous nodes tissue with localization in back, ilium region, 
knee, and feet. Without pleuritic, aching chest pain and cough. Subcutaneous abscesses at computer 
assisted tomography suggests with sarcoma diagnosis. Pathological material biopsy for laboratory 
diagnosis by Hematoxylin Eosin, Periodic Acid-Schiff stains, KOH 10% solution, culture on fungal 
media. Direct microscopic observation of the histopathological sections demonstrated the 
inflammatory response contained granulomatous elements, collections of neutrophils, areas of 
caseous necrosis and mature, ruptured spherules. The mature spherules measure 30 to 60 µm, with 
double walls up to 2 µ m in thickness. Inside of the mature spherules multiple endospores measure 2 
to 5 µm containing. The growth of colonies white and floccose at first 3 days was evident by culture 
methods. Coccidioidomycosis for diagnosis of the disease by the direct examination of the 
pathological material was enough. The fungal therapy with amphotericin B was successful. The 
molecular biology method by polymerase chain reaction in real time technique (PCR-rt) match with 
Coccidioides posadasii by the examination of the in vitro fungal growth. Conclusion. 
Coccidioidomycosis is usually acquired through inhalation of arthroconidia and the disease is known 
to be endemic to the United States, Mexico restricted to the semiarid and desert regions. It is also 
found in a lesser degree in Central and South America. At present, the etiological agents of 
coccidioidomycosis in man are Coccidioides immitis and Coccidioides posadasii. Although the both 
etiological agents have equal phenotypic characteristics and produced the same disease, there are 
differences between them, such as the geographic distribution and genetic characteristics. 
Coccidioides immitis is located in the north region of Mexico, whereas Coccidioides posadasii is 
located in the south region of the country. It is important to known the specific etiological agent for 
epidemiological reasons. Lesions of skin and subcutaneous tissue are among the most common 
manifestations of hematogenous dissemination. The usual dissemination as a complication of 
primary infection it was because malnutrition and the endemic region habitat. 
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Zygomycosis in pediatric patients and laboratory diagnosis. 
V. Lora-Téllez, M.L. Pérez-Ricardez, M.F.D.C. Lara-Hernández, G. López-Hernández 
Mycology Laboratory, Hospital para el Niño Poblano, Puebla, Mexico 
Case Report: Objective. To describe the distribution of the clinical manifestations and the etiological 
agents of zygomycosis identification in pediatric patients. Methods. Various clinical forms 
description in four pediatric patients with underlying condition. Etiological agent identification by 
direct examination and culture on Sabouraud Dextrose Agar of the pathological material. Results. 
Female 7 years old, acute lymphocytic leukemia as underlying condition. Sites of the infection were 
paranasal sinuses, eye ś orbital section, palate and face. Paranasal sinuses biopsy was selected as 
pathological material for direct examination and fungal culture. Aseptate hyphae branching at angle 
of 90 degrees approximately was observed by hematoxylin eosin and periodic acid-Schiff stains by 
direct examination. The etiological agent was Lichthiemia spp by fungal culture. Female 7 years old, 
acute lymphocytic leukemia as underlying condition. Site of the infection was paranasal sinuses. In 
the paranasal sinuses biopsy was observed aseptate hyphae 10 µm measure. Fungal culture on 
Sabouraud Dextrose Agar at 25°C, after 4 days a woolly colony growth was observed. Microscopic 
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morphology of the colony was identified Mucor spp as etiological agent. Male 8 years old, burn 
trauma as underlying condition. Sites of the infection were legs, arms and hands. Tissue debridement 
was observed by direct examination with potassium hydroxide KOH 40% solution, and cultured on 
fugal media. A white-gray woolly colony growth was observed after 2 days on Sabouraud Dextrose 
Agar at 25°C, after 4 days incubation, the surface of the colony was covered with dark spots like a 
“salt – and- pepper” appearance. At microscope examination, the differential characteristics of the 
Rhizopus were observed, such as a single umbrached sporangiophore, a globose sporangia, 
sporangiospores and rhizoids. Microscopic morphology of the colony was identified Rhizopus spp. 
Female 1 month old, gastric perforation as underlying condition. At computer assisted tomography 
examination a mass like a tumor was observed in the gastric cavity. Gastric mucosa biopsy by direct 
examination multiple aseptate and very broad hyphae were observed. Histopathological 
examination of the gastric mucosa biopsy demonstrated the vascular invasion by hyphae, leading to 
thrombosis and infarction of tissue. Rhizopus spp as etiological agent by fungal culture examination. 
Conclusion. Zygomycosis is characterized by vascular invasion with hyphae, infarction, and necrosis 
of tissue and by an acute or subacute course. Zygomycosis caused by Rhizopus, Lichtheimia, 
Rhizomucor and Mucor has a wide geographic distribution. The distribution of the clinical 
manifestations was usual sites of infection because underlying condition such as acute lymphocytic 
leukemia with neutrocytopenia, and burn trauma. But gastric cavity was uncommon as site of 
infection due was introduced by oral-gastric catheter. Because the hallmark of Zygomycosis is 
vascular invasion by hyphae, leading to thrombosis and infarction of tissue, the antifungal therapy 
with Amphotericin B was successful while is delimited the original site of the infection, such as 
paranasal sinuses, before it presents in contiguous structures of the orbit, palate, face, nose, or brain. 
The early diagnosis as much as the site of infection contributed for a good clinical evolution. 
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Spectrum of invasive yeast infections in children in Pakistan over the last five years: 2015-2019 
J. Farooqi1, S. Memon2, S. Laiq1, F. Naqvi1, K. Iqbal1, S. Tariq1, A. Zafar3, K. Jabeen4 
1Pathology And Laboratory Medicine, Aga Khan University, Karachi-KHI, Pakistan, 2Microbiology, 
Karachi University, Karachi, Pakistan, 3Pathology And Laboratory Medicine, Aga Khan University, 
Karachi, Pakistan, 4Pathology And Laboratory Medicine, Aga Khan University, Karachi, Pakistan, 
Pakistan 
Objectives: We aim to describe here the changing spectrum of invasive yeast infections in children 
in the last 5 years in Pakistan, using retrospective laboratory data from 2015-May 2019 
Methods: Records of archived yeast isolates from Jan 2015-May 2019 kept at the Aga Khan University 
Clinical Laboratories, section of Microbiology in Karachi, were retrieved for analysis. A total of 1119 
non-duplicate isolates were identified, of which 992 were invasive specimens from blood (833), CSF 
(51), wounds (47), intraabdominal collections (36), Central venous lines (17) and other sterile fluids 
(8). The patients were divided into neonates (259), paediatric age group (253) and adults (477). 
Frequencies of different Candida and non-Candida species isolated over the last 5 years were computed 
and compared for age groups using chi-square test. Hypothesis of a change in the spectrum over the 
years among each age group was also tested. 
Results: Candida species made up 87.4% and 86.6% of all invasive yeasts in neonates and children, 
respectively. The most common group in neonates was a diverse group of rare Candida species 
(including C. lusitaniae, C. guilliermondii and C. pelliculosa to name a few) at 45.4%, followed by C. 
tropicalis (24%) and C. parapsilosis (15.7%); Ustilago species were the most common non-Candida yeasts 
at 9.2%. In children, the most common species was C. tropicalis (32%), followed by rare Candida species 
as described above (22.8%) and C. albicans (15.1%). Ustilago was again the most common non-Candida 
yeast at 11.1%. There was a statistically significant difference in the distribution of invasive yeasts 
between neonatal and paediatric age groups (p<0.001). The change in spectrum of invasive yeast over 
the years was significant for infants and children (p = 0.035) and adults (p = 0.029); however, we could 
not demonstrate a significant difference in neonatal (p = 0.096) and elderly (p = 0.270) spectrum of 
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invasive yeast infections over the years. Fluconazole resistance in yeasts isolated from neonates was 
found to be 8.2% while it was 22.8% in infants and children, possibly due to an emergence of C. auris 
infections in children (12.8%) versus neonates (1.3%). 
Conclusion: We conclude that it is essential to monitor the spectrum of yeast infections in neonates 
and children as they are the population where there is greatest diversity of invasive species, not 
limited to Candida species. Emerging pathogens are most likely to arise from this population, 
including resistant strains, hence, it is also important to monitor resistance trends. 
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1Depatment For Clinical And Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, 
Croatia, 2Department Of Pediatrics, University Hospital Center Zagreb, Zagreb, Croatia, 3Department 
Of Intensive Therapy And Care Pediatrics Clinic, University Clinical Center Tuzla, Tuzla, Bosnia and 
Herzegovina, 4Department Of Pediatrics, Neonatal Intensive Care Unit, University Hospital Osijek, 
Osijek, Croatia, 5Depatrtment Of Pediatric, University Hospital centre Rijeka, Rijeka, Croatia, 
6Department Of Pediatrics, University Hospital Centre Split, Split, Croatia, 7Department Of 
Pediatrics, Nicu, University Hospital Centre Split, Split, Croatia, 8Department Of Pediatrics, 
University clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina, 9Department Of Pediatrics, 
Childrens Hospital Zagreb, Zagreb, Croatia, 10Department Of Pediatrics, university Hospital Centre 
Maribor, Maribor, Slovenia 
Objectives: Invasive Candida infections are considered as very important cause of morbidity and 
mortality in neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU). Although 
C.albicans is the most commonly isolated species from invasive candida infections the frequency of 
non-albicans candida has increased. Geographical differences in epidemiology, and even more 
important changes in susceptibility patterns have been described. It is very important to know the 
epidemiology in order to recognize patients in risk and to start the appropriate empirical therapy and 
improve patient outcome. The aim of this study was to determine changes in Candida infections 
epidemiology in NICU and PICU from three countries. 
Methods: We included the data from three neighboring countries: Croatia, Bosnia and Herzegovina 
and Slovenia (10 centers altogether), during the two year period. We collected data about species of 
Candida causing infection, site of infection and antifungal susceptibility of strains. In first year, overall 
65 patients with invasive fungal infection (IFI) (25 from NICU and 40 from PICU), and in second year 
107 patients with IFI (59 from NICU and 48 from PICU) were enrolled in the study. 
Results: During the first year of surveillance in NICU, Candida albicans was the most frequent isolate 
in IFI patients in 4 centers and Candida parapsilosis in one center. According to collected data, Candida 
tropicalis, Candida krusei and Saccharomyces cerevisiae were observed as rare and sporadic causes of IFI. 
During the second year of surveillance we observed the shift of species as leading cause of IFI 
between centers: C. parapsilosis was most frequent isolate and C albicans was less frequent. In some 
centers C. famata, C. glabrata, C krusei, C. guillermondii was reported, sporadically. In PICUs, during 
first year C. albicans was most common in four centers followed by C. parapsilosis except in one center 
where C. lusitaniae and C. krusei were recorded. C. glabrata and C. guillermondii were recorded, 
sporadically. In second year, we also noted the shift of species as leading cause of IFI: the number of 
C. albicans decreased and number of C. parapsilosis increased in 4 centers. It is important to emphasize 
that 60% of C. parapsilosis in second year were susceptible only to amphotericin B (resistant to 
fluconazole ad intermediate to echinocandins according to the EUCAST interpretation breakpoints). 
C. glabrata, C. tropicalis, C. famata, Crytococcus laurentii and C. lusitaniae were reported, sporadically. 
Conclusion: The results of this observational study indicate the changing epidemiology of IFI 
pointing to differences in fungal isolates as leading causes of IFI between centers and in the same 
centers, during observational period of two years. In addition, this study noted the increase of MICs 
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for some antifungals and shift in susceptibility of fungi, addressing the importance of monitoring and 
optimization of therapeutic guidelines of IFI in NICU and PICU. 
 
P355 
Liposomal Vaccine Containing Aspergillus Proteins Protects Immunosuppressed Male and 
Female Mice Against Pulmonary Aspergillosis Caused by Azole Resistant or Sensitive Strains of 
Aspergillus fumigatus 
M. Slarve1, N. Holznecht2, J. Adler-Moore2, S. Ho3, G. Fuji3 
1Biology, Cal Poly Pomona, Riverside, United States of America, 2Biology, Cal Poly Pomona, Pomona, 
United States of America, 3Molecular Express, Inc, San Dominguez, United States of America 
Objectives: This study tested the efficacy of an immunotherapeutic liposomal Aspergillus vaccine 
(VesiVax®  LAsV), with or without additional antifungal drug treatment. The vaccine contained 
Aspergillus proteins Aspf3 and Aspf9, and the adjuvant lipidated tucaresol (LT1). LAsV was tested in 
female mice challenged with two azole resistant strains of Aspergillus fumigatus (V29 and V80), and 
in male mice with an azole sensitive strain of A. fumigatus (ATCC#13073). 
Methods: Six week old Swiss Webster mice were vaccinated with LAsV (Molecular Express, Inc.) at 
7.5 µg Aspf3/dose,7.5 µg Aspf9/dose and 5 µg LT1/dose, subcutaneously on d0, with intranasal 
boosts on d21 and d42. Control mice were given phosphate buffered saline (PBS). Prior to challenge, 
spleens and blood were collected (n = 5/group) for ELISpot cytokine analysis and anti-spore antibody 
agglutination assays. On d53, d55, and d57, vaccinated mice were immunosuppressed 
intraperitoneally with 28 mg/kg triamcinolone acetonide. On d56, mice were intranasally challenged 
with A.fumigatus conidia (2-2.8 X 10ex7/mouse depending on fungal strain). Some vaccinated groups 
were also given a short course of 7.5 mg/kg liposomal amphotericin B (AmBisome® , AmBi, Gilead 
Sciences Inc.) intravenously at 12h, 36h, and 60h post-challenge. Lungs were collected (n = 7/group) 
3 days post challenge for fungal burden, and remaining mice (n = 9/group) were monitored for 
survival to d77. 
Results: LAsV vaccinated male and female mice had reduced lung fungal burdens compared to PBS 
control mice regardless of the strain of A. fumigatus challenge. Female mice vaccinated with LAsV, 
challenged with strain V29 or V80, and then given subsequent AmBi treatment, had higher survival 
than PBS control mice (V29 = 79% vs 21%; V80 = 57% vs 25%) and the vaccine alone also yielded some 
protection when mice were challenged with V29 (55% survival). Non-vaccinated female mice given 
AmBi alone had only 37% survival following V29 challenge, and 22% survival with V80 challenge. 
Results in male mice vaccinated with LAsV and given AmBi after challenge, were similar to the 
female mice, yielding 55% survival following A fumigatus challenge (#13073) versus 22% survival for 
mice given AmBi alone or PBS. ELISpot cytokine analysis showed that LAsV vaccinated female and 
male mice had a significantly higher number of IL-4 than IFN-γ secreting splenocytes following 
incubation with Aspf3 and Aspf9 (p = 0.0178 for males, p = 0.0290 for females), which is characteristic 
of a Th2 response. Anti-spore antibody agglutination titers demonstrated that LAsV vaccinated mice 
also had increased anti-A.fumigatus spore antibodies in the serum than PBS control mice (p = 0.0009 
for males, p<0.0001 for females). 
Conclusion: Prophylactic LAsV vaccination of immunocompetent female or male mice, which were 
then immunosuppressed prior to Aspergillus challenge, followed by a short course of AmBi 
treatment, provided more protection against pulmonary aspergillosis than AmBi treatment alone 
whether the infection was caused by azole resistant or sensitive strains of A.fumigatus. Elevated levels 
of anti-A.fumigatus spore antibody titers correlated with protection, serving as a possible biomarker 
to indicate protective immune responsiveness to the vaccine. The LAsV has the potential to be used 
as an immunomodulatory treatment to further enhance the efficacy of antifungal drugs. 
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Anti–interferon-γ autoantibodies underlie disseminated Talaromyces marneffei infection 
C. Cao 
Dermatology, The first affiliated hospital of Guangx medical university, Nanning, China 
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Objectives: Anti–interferon-γ autoantibodies underlie disseminated Talaromyces marneffei infection 
Obsjects: T. marneffei causes life-threatening opportunistic infections, mostly in Southeast Asia and 
South China. Most T. marneffei infections occur in patients infected with human immunodeficiency 
virus (HIV), but this infection can, nevertheless, occur in HIV-negative individuals in the absence of 
immunosuppression. We investigated the role of anti-interferon (IFN)-γ autoantibodies in severe T. 
marneffei infection in HIV-negative patients. 
Methods: Anti–interferon-γ autoantibodies underlie disseminated Talaromyces marneffei infection 
Obsjects: T. marneffei causes life-threatening opportunistic infections, mostly in Southeast Asia and 
South China. Most T. marneffei infections occur in patients infected with human immunodeficiency 
virus (HIV), but this infection can, nevertheless, occur in HIV-negative individuals in the absence of 
immunosuppression. We investigated the role of anti-interferon (IFN)-γ autoantibodies in severe T. 
marneffei infection in HIV-negative patients. Method: We enrolled 58 HIV-negative adults who 
developed T. marneffei severe infections but were otherwise healthy in this study. We evaluated the 
presence of anti-IFN-γ autoantibodies and their neutralizing activity. 
Results: The prevalence of neutralizing anti–IFN-γ autoantibodies was high (94.8%) in these 
previously healthy adults suffering from severe T. marneffei infections. The presence of anti–IFN-γ 
autoantibodies was strongly associated with HLA-DRB1*16:02 and DQB1*05:02 in these patients. 
Conclusion: Adult-onset acquired immunodeficiency due to autoantibodies against IFN-γ is the 
major cause of severe T. marneffei infection in HIV-negative patients in the regions in which this 
fungus is endemic. The high prevalence of pathogenic HLA class II DRB1*16:02 and DQB1*05:02 
alleles, which are strongly associated with anti-IFN-γ autoantibodies, may account for the restriction 
of severe T.marneffei infection to Southeast Asia. Our findings clarify the pathogenesis of T. marneffei 
infection and pave the way for the development of novel treatments. 
 
P358 
Phagocytic activity and cytokines production by murine RAW-264.7 macrophages in response to 
Microsporum canis 
J. Neves1, F. Konno1, M. Lallo1, A. Alvares-Saraiva2, E. Hurtado1, J. Alvarez1, S.D.A. Coutinho1 
1Post-graduation Program In Environmental And Experimental Pathology, Paulista University, São 
Paulo, Brazil, 2Institute Of Physical Activity And Sports Sciences, Cruzeiro do Sul University, São 
Paulo, Brazil 
Objectives: Dermatophytes are important fungi for public health, as they are transmitted between 
animals and humans causing zoonoses. The innate immune system plays an important role in the 
establishment of dermatophytic infection; however, there are few studies on the relationship between 
innate immune response and Microsporum canis. Thus, the aim of this work was to evaluate the 
response in vitro of macrophages challenged with Microsporum canis microconidia. We evaluated the 
ability of macrophages stimulated or not with LPS, to phagocytize, to produce nitric oxide and 
cytokines, and the cell viability. 
Methods: Murine Raw-264.7 macrophages were cultivated overnight on glass coverslips in a 24 well 
plates. Macrophages were infected with M. canis (ATCC-36299) in the ratio of 0.25:1 
(microconidia/macrophages) and incubated at 37˚C with 5% CO2 for 30 min, 1 h, 3 h and 6 h. After 
incubation intervals, glass coverslips were collected and submitted to Giemsa stain. Two hundred 
cells were counted and calculated the percentage of macrophages that internalized at least one spore. 
LPS (1mcg/mL) was added to the macrophages 24 h prior M. canis infection in one group. 
Supernatants were collected for detection of nitric oxide and cytokine levels, and to check the cell 
viability. 
Results: The phagocytic index showed an increase in phagocytosis over time (Fig. 1 and 2), reaching 
the maximum at 6 h. The percentage of non-LPS stimulated macrophages that phagocytosed M. canis 
microconidia was 28.0%, 33.5%, 62.5% and 71.5%, respectively in 30 min, 1 h, 3 h and 6 h (Fig. 1). In 
macrophages stimulated with LPS the phagocytic index was 34.5%, 47.5%, 67.0%, and 74.0%, 
respectively in 30 min, 1 h, 3 h and 6 h (Fig. 1). It was observed similar nitric oxide production in 
both, macrophages challenged and not with M. canis. Levels of TNF-α have increased over time in 
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macrophages challenged with M. canis stimulated or not with LPS when compared with 
macrophages non-infected (statistically significant). Higher levels of IL-6 were produced by 
macrophages stimulated with LPS and infected with M. canis at 1 h (statistical difference). Cell 
viability decreased over time, with the peak of macrophages killing at 6 h. Microbicity test showed 
that, even after phagocytosis, spores of M. canis remained viable inside macrophages.  
 
Conclusion: Raw-264.7 macrophages showed high phagocytic activity against M. canis, which 
increased when macrophages were previously stimulated with LPS. LPS stimulation also influenced 
the production of cytokines, which suggests greater modulation in the response to infection. 
Increased production of the pro-inflammatory cytokines TNF-α and IL-6, which are important in the 
recruitment of new phagocytic cells and in the resolution of the disease, have been found in 
macrophages challenged with M. canis. The results suggest that, although macrophages present 
phagocytic activity and cytokine production when challenged with M. canis, their viability and 
microbicidal activity are impaired. 
 
P359 
Importance of using media with physiologic glucose concentration for studying host defence 
against C. albicans in vitro 
S. Kenno, V. Harpf, G. Rambach, C. Speth, R. Würzner 
Div Hygiene & Med. Microbiology, Med. Univ. Innsbruck, Innsbruck, Austria 
Objectives: Candida albicans is a clinically important opportunistic yeast and has evolved different 
immune evasion molecules on its cell surface. In the study on the role of one of these, the 
transmembrane protein “High affinity glucose transporter 1” (Hgt1p), involved in glucose 
metabolism, but also high-jacking the complement regulator factor H (FH) from host serum, we have 
used different media, one of them the commonly used YPD medium (yeast extract 1%, peptone 2% 
and dextrose 2%) to study the role of this evasion molecule in immune defence. 
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Methods: C. albicans strains (SC5314 und others) were opsonized with human serum and incubated 
with anti-FH and anti-complement C3b/iC3b antibodies; their deposition on the cell wall surface was 
assessed by fluorescence-activated cell sorter (FACS). In parallel, C. albicans strains were co-cultured 
with fresh human polymorphonuclear neutrophils (PMNs). All these experiments were done at 
different glucose concentrations, mainly because a glucose transporter was involved. 
Results: Candida wild type strain SC5314 showed a clear FH deposition on its cell wall at the 
physiological glucose concentration of 0.1%, but this was completely higher and thus overestimated 
when using the two high glucose (0.3%, 2%) containing media. Consequently, the resulting low 
C3b/iC3b deposition at 0.1% was even lower at the unphysiologically high glucose levels. Also the 
thus impaired phagocytosis, observable at 0.1%, appeared much more dramatic at glucose levels 
which are not achievable in vivo. 
Conclusion: The main events in immune defence, such as opsonisation by C3b/iC3b and 
phagocytosis by PMNs and the counteracting evasion strategy by Candida to high-jack FH are all 
highly dependent on the glucose concentration and all experimental data are thus completely 
misleading, if media with unphysiological glucose concentration are employed, such as the 
commonly used YPD. 
 
P360 
Immune response in C57BL mice in Encephalitozoon cuniculi infection 
A. Miyuki Hidifira1,2, A. Pereira1,2, A. Alvares-Saraiva1, E. Hurtado1, F. Konno1, J. Alvarez1, M. Lallo1,2 
1Post-graduation Program In Environmental And Experimental Pathology, Paulista University, São 
Paulo, Brazil, 2Biomedicina, Centro Universitário São Camilo, São Paulo, Brazil 
Objectives: Encephalitozoon cuniculi is a microorganism belonging to the phylum Microsporidia and 
to the kingdom Fungi, considered an opportunistic and obligatory intracellular pathogen. The first 
line of defense against E. cuniculi is the innate immune response through the action of phagocytic 
cells and production of cytokines that are responsible for the activation of T lymphocytes. The 
immune response against E. cuniculi has not been fully elucidated and further studies are needed to 
understand the involvement of cell types such as macrophages in the role of microsporidiosis. This 
study evaluated the populations of macrophages and lymphocytic cells in E. cuniculi infection in 
C57BL/6 mice. 
Methods: SPF C57BL/6 mice were used and divided in 4 groups: uninfected, infected, uninfected-
immunosuppressed and infected-immunosuppressed. Immunosuppression was made by 
intraperitoneal injection of cyclophosphamide and euthanasia was performed by anesthetic 
deepening to collect the peritoneal lavage and remove the spleen. Lymphocytes and macrophages 
(F4/80) were identified by cell surface markers using flow cytometry. 
Results: The results of the evaluation of spleen and peritoneal cells indicate that in the peritoneum 
there was an increase in CD8+ T cells in infected group in relation to the uninfected and infected-
immunosuppressed groups and a decreased in CD4+ T population in infected-immunosuppressed 
group. The B cells populations were decreased in both groups infected (immunosuppressed and non-
immunosuppressed). In the spleen, there was an increase of CD8+ T cells and B cells in infected-
immunosuppressed mice and a decrease in CD4+ T in the same groups evaluated. Macrophage 
markers analysis revealed expression of F4/80+ CD80/86high MCHIIhigh in both infected animals 
(immunosuppressed and non-immunosuppressed) in the peritoneal lavage and in the spleen these 
cells were increased only in infected-immunosuppressed group. 
Conclusion: The results of this study help to understand the involvement of cells as macrophages in 
the E. cuniculi infection in C57BL/6 mice. 
 
P361 
Level of Mannose binding Lectin protein in dermatophytic patients and its correlation with MIC 
values 
V. Hemanth1, A.J. Kindo2, A. Subramanian3, A. Krishnan3 
1Microbiology, Sri Ramachandra Medical college and Research Institute, chennai, India, 
J. Fungi 2019, 5, 95 369 of 464 
 
2Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India, 
3Dermatology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India 
Objectives: 1.Speciation of dermatophytes from the clinical isolates 2.To study the antimicrobial 
pattern of frequently used antifungal agents 3.To determine the serum MBL levels in patients with 
dermatophytosis 4.To compare MIC levels with serum MBL levels 
Methods: METHODS: Clinically diagnosed dermatophytic patients were sampled for microscopy 
and culture, grown dermatophytes was subjected to phenotypic identification by conventional 
method. Antifungal susceptibility testing was done by broth microdilution method according to CLSI 
M38-A2 document guidelines. Trichophyton mentagrophytes ATCC 4439 was included in each run of 
susceptibility testing as a quality control. Final drug concentrations in the microdilution plates ranged 
from 64 to 0.25 µg/ml for fluconazole and AmphotericinB and from 16 to 0.25 µg/ml for 
Itraconazole,Voriconazole,Terbinafine and Griesofulvin. This is an ELISA based assay performed in 
microwells coated with a monoclonal antibody against the MBL carbohydrate- binding domain. 
Bound MBL is detected with the same antibody that has been labeled with biotin,followed by 
development with horseradish peroxidase (HRP)-conjugatedstrepavidin and incubation with a 
chromogenic substrate.Reading was taken at 620nm. 
Results: Out of the 100 clinical isolates tested, 58 of them were identified as Trichophyton 
mentagrophytes , 40 were Trichophyton rubrum. and the remaining two isolates were identified as 
Epidermophyton Floccosum and Microsoprum nanum Antifungal susceptibility testing was carried out 
for 100 isolates of Trichophyton species against 6
 
antifungal agents. All isolates showed detectable growth after 4-5days of incubation. MICS for 
Trichophyton mentagrophytes ATCC 4439 were within the established range. Mannose Binding Lectin 
ELISA: Results awaited for ELISA Assay. 
Conclusion: In this study Trichophyton mentagrophytes was the most common cause of 
dermatophytosis .The findings of this study showed that the patients with dermatophytosis have 
higher MBL serum levels, the acute phase protein plays a role in dermatophyte infections. It is well 
known that mutations in MBL genes are associated with reduced serum levels, which is a risk factor 
for infection. In this study, the high level of MBL levels could be used as prognostic marker for 
dermatophytic infections. Further studies with larger samples have to be under taken to come to 
definite conclusion. 
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Aspergillus infection in STAT3-deficient patients is associated with defective interferon-gamma 
and Th17 responses 
F. Danion1, V. Aimanianda2, J. Bayry3, A. Duréault1, M.-E. Bougnoux4, C. Tcherakian5, M.-A. 
Alyanakian6, H. Guegan7, A. Puel8, C. Picard9, O. Lortholary1, F. Lanternier1, J.-P. Latgé2 
1Infectious Diseases, Necker hospital, Paris, France, 2Institut Pasteur, Paris, France, 3Equipe-
immunopathologie Et Immunointervention Thérapeutique, INSERM, Paris, France, 4Parasitology 
Mycology, APHP Hôpital Necker-Enfants-Malades, Paris, France, 5Pneumology, Hopital Foch, Paris, 
France, 6Immunology, AP-HP Necker Hospital, Paris, France, 7Laboratoire De Parasitologie-
mycologie, CHU de Rennes, Rennes, France, 8Inserm U1163, Institut Imagine, Paris, France, 9Centre 
D’étude Des Déficits Immunitaires (cedi), AP-HP Necker Hospital, Paris, France 
Objectives: Signal transducer and activator of transcription 3 (STAT3)-deficient patients are highly 
susceptible to many bacterial and fungal infections including aspergillosis, although its pathogenesis 
remains largely unknown. Objective: To investigate the immune responses of STAT3-deficient 
patients against Aspergillus fumigatus infection 
Methods: Phagocytic and killing efficiencies as well as cytokine responses of mononuclear cells and 
neutrophils of STAT3-deficient patients were investigated against A. fumigatus. 
Results: We compared results among three groups, STAT3 deficient patients with or without 
aspergillosis and healthy controls. STAT3-deficient patients with aspergillosis showed elevated titers 
of A. fumigatus specific IgE and IgG compared to STAT3-deficient patients without aspergillosis as 
well as healthy controls. A. fumigatus conidial phagocytic and killing efficiencies of monocytes and 
neutrophils from STAT3-deficient patients with or without aspergillosis were similar to those from 
healthy controls. When stimulated with A. fumigatus conidia, peripheral blood mononuclear cells 
from patients with STAT3-mutation showed reduced levels of secreted (pg/mL) and intracellular (%) 
cytokines compared to healthy controls (IFN-γ: 1836 vs 3248 pg/mL and 3.7% vs 11.4%; IL-17: 16 vs 
80 pg/mL and 2.6 vs 7.0%; IL-22: 64 vs 170 pg/mL). In addition, there were significantly lower levels 
of IFN-γ and TNF-α in STAT3-deficient patients with aspergillosis compared to those without 
aspergillosis (IFN-γ: 683 vs 3420 pg/mL; TNF-α: 779 vs 4743 pg/mL). In the STAT3-deficient cohort, 
three patients with aspergillosis were treated with IFN-γ in addition to antifungals; two of them 
showed favorable outcome. 
Conclusion: STAT3-deficiency leads to defects in adaptive immune responses against A. fumigatus, 
particularly with a low IFN-γ response in those with aspergillosis, suggesting potential therapeutic 
benefit of recombinant IFN-γ in these patients. 
 
P363 
Functionality of neutrophils against Aspergillus fumigatus in patients with alcoholic cirrhosis 
M. Blaize1, D. Blez1, P. Lebray2, A. Meghraoui-Keddar1, C. Combadière1, A. Boissonnas1, M. Rudler2, 
A. Fekkar1 
1Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, 
F-75013, PARIS, France, 2AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service d'Hépato-Gastro-
Entérologie, F-75013, Paris, France 
Objectives: Patients with liver cirrhosis are at risk of developing bacterial or fungal infections. The 
incidence and severity of these infections depend on the stage of the disease. Severe alcoholic 
hepatitis, the most serious stage of liver failure in patients with alcohol abuse and chronic liver 
disease, has been associated with the development of many cases of invasive aspergillosis and is now 
considered a risk factor for it. A dysfunction of the immune system, namely systemic inflammation 
and immunodeficiency, is described in cirrhosis with, in particular, an alteration of the phagocytic 
and oxidative capacities of neutrophils. The latter is known to be the main immune effector against 
Aspergillus. Therefore, we aim to study neutrophil’s responses from patients with alcoholic cirrhosis 
at different stages of their disease against Aspergillus fumigatus. 
Methods: To achieve this objective, we conducted a prospective monocentric study involving 23 
patients and 12 healthy controls. Patients were divided into 4 groups: stable cirrhosis (n = 5), 
decompensated cirrhosis without severe alcoholic hepatitis (n = 3), decompensated cirrhosis with 
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severe alcoholic hepatitis (n = 11) and decompensated cirrhosis with severe alcoholic hepatitis after 7 
days of steroid treatment (n = 4). Interactions between neutrophils and Aspergillus hyphae were 
analyzed by video microscopy, while the oxidative burst of neutrophils before and after fungal 
stimulation and cytokine production was determined by flow cytometry and enzyme immunoassay 
(EIA). 
Results: Compared to healthy controls, patients with severe alcoholic hepatitis had an increase in the 
production of reactive oxygen species by their neutrophils (1727 versus 2545, expressed as mean 
fluorescence intensity, p = 0.041). An increase in plasma IL-8 levels (95 versus 378 ng/mL respectively, 
p = 0.006) was also observed between these groups. Also among patients with severe alcoholic 
hepatitis, the production of reactive oxygen species decreased after 7 days of corticosteroids 
compared to other patients, both under basal conditions (937 versus 2545; expressed as mean 
fluorescence intensity, p = 0.011) or after stimulation with germinating conidia (2031 versus 9272; 
expressed as mean fluorescence intensity, p = 0.014). In addition, video microscopy experiments 
(Figure 1) showed that an alteration in the ability of neutrophils to kill A. fumigatus hyphae appears 
in the severe alcoholic hepatitis group after 7 days of corticosteroid therapy compared to patients 
sampled before corticosteroid therapy began (12% of mortality versus 46% respectively, p = 0.03) 
(Figure 2). 
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Conclusion: In conclusion, a pro-inflammatory state is present in patients with severe alcoholic 
cirrhosis as well as in patients with stable cirrhosis. The introduction of corticosteroids as a treatment 
for severe alcoholic hepatitis quickly leads to a dramatic decrease in the inflammatory environment 
and the neutrophil's ability to kill Aspergillus fumigatus. 
 
P364 
Impact of mould exposure on the immune response in the course of chronic obstructive pulmonary 
disease (COPD) 
E. Frealle1,2, M. Pichavant1, O. Le Rouzic3, G. Reboux4, N. Bautin3, M.-C. Willemin3, J. Delourme3, B. 
Sendid2, S. Nseir5, S. Fry3, P. Gosset1 
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1Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR8204 - CIIL - Center for 
Infection and Immunity of Lille, Lille, France, 2Parasitology-mycology, CHU Lille, Lille, France, 
3Clinique Des Maladies Respiratoires, CHU Lille, Lille, France, 4Mycology - Umr6249 Cnrs Chrono-
environnement, University Hospital Besançon, Besançon, France, 5Pôle De Réanimation, CHU Lille, 
Lille, France 
Objectives: Chronic obstructive pulmonary disease (COPD) is a complex chronic respiratory disease 
which affects 8% of subjects over 45 years-old in France. It is mainly caused by cigarette smoke, which 
induces chronic lung inflammation and is considered a key etiological factor in the development and 
pathogenesis of COPD. Other environmental factors, such atmospheric pollution, can also be 
involved in the evolution of the disease, modulating inflammation and promoting exacerbations. 
Here, we assessed the contribution of domestic mould exposure to lung and systemic inflammation 
in COPD patients, during exacerbation or at stable state. 
Methods: Sixty-two COPD patients were recruited during severe acute exacerbation requiring 
hospitalization between August 2011 and November 2015 in Lille University Hospital. Mycological 
analysis of sputa and anti-Aspergillus antibodies detection was performed in order to assess 
Aspergillus colonization and sensitization status. CXCL8, TNFα (recruiting/activation of monocytes 
and neutrophils), IL-1β, IL-6, IL-17, IL-22 (Th17 response) and CXCL4, CD62P, CD40L (platelet 
activation) levels were measured in the sputum and in the serum. The inflammatory response was 
compared at inclusion (exacerbation) and after an 18-months follow-up (at stable state) between (i) 
Aspergillus fumigatus colonized or non-colonized patients, (ii) Aspergillus sensitized or non-sensitized 
patients, and (iii) patient with or without mould exposure, which was assessed using electrostatic 
dust collectors (EDCs) that were exposed during 10 weeks in the patient’s home. 
Results: A. fumigatus colonization was detected in 16.9% of patients at inclusion (during exacerbation) 
and 4% of patients at stable state. Anti-Aspergillus antibodies detection was positive in 32.2% of 
patients at inclusion and 36.4% after the 18-months follow-up. No significant differences were found 
between the cytokine levels during exacerbation or at stable state when A. fumigatus colonized or 
non-colonized patients, and Aspergillus sensitized or non-sensitized patients were compared. 
However, during exacerbation, patients with mould exposure showed significantly higher levels of 
serum CXCL8 (19.6±41.2 pg/mL vs <7 pg/mL for non-exposed patients, P = 0.001). Furthermore, at 
stable state, mould exposure was associated with significantly higher levels of serum IL-6 (28.9±87.9 
pg/mL vs <2 pg/mL, P = 0.016), and significantly lower levels of serum IL-22 (86.8±31.6 pg/mL vs 
285.8±363.3 pg/mL, P = 0.0008). 
Conclusion: These data suggest that domestic mould exposure could contribute to the alteration of 
the inflammatory response in the course of COPD. Funding: Conseil Régional Hauts-de-France, Gilead, 
MSD, Pfizer 
 
P365 
Effects of ibrutinib treatment on neutrophil response against A. fumigatus 
M. Blaize1, D. Blez1, C. Soussain2, A. Boissonnas1, A. Meghraoui-Keddar1, N. Menezes3, A. Portalier4, 
C. Combadière1, V. Leblond4, D. Ghez5, A. Fekkar1 
1Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, 
F-75013, PARIS, France, 2Hématologie, Institut Curie - Site de Saint-Cloud, 35 rue Dailly, F-92210, 
Saint-Cloud, France, 3AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie-
Mycologie, F-75013, Paris, France, 4AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service 
d'Hématologie, F-75013, Paris, France, 5Département d'Hématologie, Gustave Roussy, 114 rue 
Edouard Vaillant, F-94805, Villejuif, France 
Objectives: Ibrutinib, a small irreversible Bruton’s tyrosine kinase (Btk) inhibitor has become a 
leading therapy against chronic lymphoid leukemia and has significantly improved patient care. 
Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular 
invasive aspergillosis. This observation was surprising because patients with lymphoid malignancies 
are at low-risk of invasive aspergillosis. The mechanisms underlying the increased susceptibility to 
fungal infections associated with ibrutinib exposure are currently unknown. Polymorphonuclear 
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neutrophil is the cornerstone of anti-Aspergillus immunity. However, since the potential effect of 
ibrutinib on the antifungal capacities of neutrophils has been studied to a very limited extent, we 
decided to do so in more detail. 
Methods: To answer this question, we studied the consequences of in vivo and in vitro ibrutinib 
exposure on the neutrophil’s anti-Aspergillus responses. Thirty-three patients receiving ibrutinib for 
lymphoid malignancies were included. A total of 63 blood samples were collected from patients at 
different time points: just before ibrutinib treatment initiation (n = 23) then approximately 1 month 
(n = 22) and 3 months later (n = 18). Both flow cytometry and video-microscopy approaches were 
used to analyze neutrophils’ cell surface molecule expression, cytokine production, oxidative burst 
and killing activity against Aspergillus. 
Results: We observed different alterations between the patient group at 1 month of treatment and 
the untreated group, as a decrease in the CD11b (major receptor for beta-glucan) expression or IL8 
production. Above all, we observed a decrease in the production of reactive oxygen species (ROS) by 
neutrophils, both in the basal state (2333 versus 1131, expressed as mean fluorescence intensity, 
p<0,05) or after stimulation by Aspergillus germinating conidia (9330 versus 4569; p<0,05). Among the 
interactions observed between germinating conidia and neutrophils in 16-hours video microscopy 
co-cultures experiments, we focus on the engulfment and destruction of fungus by cells. A decrease 
in the ability of neutrophils to spread over the fungus was observed between treated and untreated 
patient groups (Figure1). Regarding the destruction of Aspergillus by neutrophils, we observed a 
dramatic decrease with 50% of germinating conidia killed by neutrophils in the untreated group 
compared to only 1% in the group after one month of treatment and 0.8% in the group after 3 months 
of treatment (p<0.01) (Figure2). The results were confirmed by the analysis of healthy neutrophils 
(from blood donors) exposed (or not) in vitro to ibrutinib.  
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Conclusion: Ibrutinib is associated, both in vitro and in patients receiving this treatment, with several 
functional defects in neutrophils, including a decrease in the production of reactive oxygen species, 
a decrease in their ability to engulf the fungus and an inability to effectively kill Aspergillus hyphae. 
Our results provide a plausible explanation for the emergence of invasive aspergillosis in patients 
receiving ibrutinib. Further work is needed to understand the exact mechanisms underlying this 
effect, particularly if it is caused by inhibition of the Btk itself in neutrophils or by an off-target effect. 
On May 2019, part of the data has been provisionally accepted for publication in Haematologica 
journal. 
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Host innate immune response to echinocandins-resistant Candida glabrata clinical isolates: 
impact on the management of candidemia 
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Objectives: Candida glabrata (C. glabrata) is a commensal yeast of the mucosal surfaces in humans. 
Incidence of invasive candidiasis due to this species has recently increased. Thus the high level of 
resistance that this species can present to different classes of antifungals, including echinocandins is 
of major concern. Nowadays, the impact of resistance acquisition in this opportunistic pathogen to 
the immune response of the host remains poorly understood. Knowing the mechanisms by which 
Candida's intrinsic and adaptive resistance to antifungals can modulate (i.e. 'escape to' or 'recognition 
by’) the immune system of the host is crucial. Indeed, most of the antifungal resistance mechanisms 
causes a direct or indirect modification of the fungal cell-wall. In addition, by establishing the first 
contact with the host tissues, the fungal cell-wall is involved in the recognition of C. glabrata by the 
host cells through interactions with Pattern Recognition Receptors (PRRs). We hypothesize that 
changes in the fungal cell-wall, as a result of resistance, could alter the recognition of C. glabrata by 
PRRs and thus trigger a different immune response, from a qualitative (i.e. cytokines production and 
immune cell recruitment) or quantitative (i.e. amplitude and duration of the immune response) point 
of view. The purpose of this study was (i) to characterize the cell wall modifications associated with 
resistance to echinocandins in C. glabrata and then (ii) to investigate the impact of such modifications 
on the virulence of the fungus and the host immune response. 
Methods: Clinical isolates of C. glabrata included in the study displayed echinocandins’ resistance for 
which the mechanisms of resistance were molecularly characterized. The virulence of these clinical 
isolates was performed using two in vitro models of interaction of the fungus with the host compared 
to the ATCC reference strain: (i) the Yeast-to-Enterocyte interaction model and (ii) the Yeast-to-
Macrophages interaction model. Cell wall characterization of the clinical isolates of C. glabrata was 
performed using microscopy and flow cytometry. 
Results: Data support a change in the virulence and recognition by the host of echinocandins-
resistant C. glabrata clinical isolates compared to the ATCC reference strain. 
Conclusion: This study will allow (i) to better understand the prevalence of echinocandins-resistant 
C. glabrata isolates in high-risk patients, (ii) to specify whether high levels of in vitro resistance 
correlate or not to in vivo therapeutic failure and (iii) to establish effective immunotherapeutic 
strategies to combat Candida resistance to antifungals. 
 
P367 
Gene variants of key TH-1 adaptive immune response proteins as predictors of invasive 
aspergillosis in oncohematological patients 
A. Taraskina1, O. Shadrivova1,2, I. Boyko1, E. Frolova1, A. Uchevatkina1, L. Filippova1, N. Vasilyeva1 
1Kashkin Research Institute Of Medical Mycology, North-Western State Medical University named 
after I.I. Mechnikov, Saint-Petersburg, Russian Federation, 2Department Of Clinical Mycology, 
Allergy And Immunology, North-Western State Medical University named after I.I.Mechnikov, St. 
Petersburg, Russian Federation 
Objectives: Fungi of the genus Aspergillus are widely distributed in nature and are relevant 
opportunistic pathogens for immunocompromised patients, causing a life-threatening infectious 
fungal complication — invasive pulmonary aspergillosis (IPA). Disruption of immune barriers 
associated with suppressive therapy, such as cytostatic polychemotherapy, can affect both the 
mechanisms of the innate immune response and acquired, in particular, the differentiation of T-
helper cells (Th). The regulation of T-cell effector functions occurs due to cytokine-induced 
intracellular signaling and transactivation of transcription factors. Single nucleotide polymorphisms 
(SNPs) of cytokine genes that direct T cell differentiation can lead to their different expression and / 
or affinity for complementary receptors on immune cells, increasing the risk of infectious processes 
The aim of this study was to investigate gene variants of key protein-inductor of Th1 adaptive 
immune response as biomarkers of IPA and effect on expression of IP-10 in serum in 
oncohematological patients. 
Methods: 178 oncohematological patients on the background of cytostatic polychemotherapy with 
symptoms of lung injury were recruited. 86 oncohematological patients (44,5%) either developed 
proven or probable IPA as defined by criteria of EORTC/MSG 2008 (median age 43y ±14, range [22-
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77y], 57% males) whereas controls (92 oncohematological patients (55,5%) without IPA comparable 
in age and sex) did not fulfill these criteria. Polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) was used to determine the SNPs of rs458917, rs56061981 CXCL10 gene, 
rs1800629 TNFα gene and rs2430561 INFγ gene. Chemokine IP-10 amount was determined by the 
enzyme-linked immunosorbent assay with the use of commercial ELISA kit sets (Cloud-Clone Corp, 
USA) and is presented in ng/ml serum. Statistical analysis was performed using SPSS21 (IBM, USA). 
Results: The genotype and allele distribution of the study SNPs were no significant differences 
between oncohematological patients with probable IPA and without IPA. In the study we found that 
allele variants of G-135A (rs56061981) do not appear to affect serum IP-10 levels although the 
presence of allele A is associated with a slight increase in serum chemokine, while the presence of 
minor allele-1447G (rs4508917) is associated with significantly higher concentrations of IP-10 in 
serum. 
Conclusion: The presence of the CXCL10 -1447G allele in serum of oncohematological patients was 
associated with increased IP-10 protein expression. The expansion of the studied groups of patients 
will allow making conclusions about the prospect of typing SNPs as a predictive marker of the risk 
of pulmonary mycosis development. 
 
P368 
In vitro phagocytosis of Aspergillus fumigatus conidia by chicken thrombocytes and heterophils 
P. Bigeard, C. Filleul, T. Vahsen, L. Zapata, F. Botterel, J. Guillot, P. Arné, V. Risco 
Ea Dynamyc Upec, Université de Créteil, Créteil, France 
Objectives: Avian respiratory diseases can be responsible for substantial economic losses to the 
poultry industry. This is particularly true for aspergillosis, which is pervasive in both domestic and 
wild avian communities, and is a common cause of respiratory distress and morbidity. Mammal 
immune response against pulmonary aspergillosis is characterized by an early interaction of 
Aspergillus conidia with phagocytic cells such as macrophages and neutrophils, but knowledge 
remains limited regarding the avian immune response after inhalation of Aspergillus conidia. Avian 
thrombocytes and heterophils (homologues to mammal neutrophils) are known for their phagocytic 
activity, but nothing has been described so far regarding their potential role during Aspergillus 
infection in birds. This study aimed to investigate the phagocytic activity of chicken thrombocytes 
and heterophils against Aspergillus conidia. 
Methods: We used filtered GFP- or DsRed-expressing A. fumigatus conidia to inoculate primary 
cultures of heterophils or thrombocytes previously purified by Percoll’s discontinuous gradient 
density from whole blood of chicken. Cultures and conidia inoculation were performed on poly-L 
lysine treated Labtek®  slides or in suspension. When slides were used, cultures were fixed at different 
time points to measure internalization rates by immunolabeling with goat anti-chicken CD45 
(leucocytes) and anti-chicken CD41 (thrombocytes) antibodies. When cells were in suspension, they 
were inoculated with Aspergillus conidia for 30 min, fixed and analyzed by flow cytometry (BD 
Accuri®  C6) using the antibodies above described. Finally, activation of phagolysosomal acidification 
was evaluated by lysosome staining using the Lysotracker®  method. 
Results: We obtained cultures with up to 95.3% pure thrombocytes while heterophils purification 
was less efficient (<50%) because of heterophil layer contamination with erythrocytes and 
thrombocytes during the purification and heterophil aggregation during culture. Nevertheless, 
identification of avian heterophils by morphology and CD45+ labeling demonstrated conidial 
internalization as soon as 15 min after culture inoculation. Conidial internalization rate reached its 
peak 30 min after inoculation, with 22-28% of thrombocytes containing at least one conidia, while 
heterophils showed up to 93% of internalization. Eight hours after inoculation, conidial swelling and 
germination was observed in almost all thrombocytes while internalized conidia in heterophils 
remained quiescent. Lysotracker®  staining confirmed phagolysosome fusion in heterophils but not 
in thrombocytes containing conidia. 
Conclusion: The results of the present study confirm for the first time the phagocytic capacity of both 
chicken heterophils and thrombocytes to A. fumigatus conidia, and suggest differences in 
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internalization efficacy between these phagocytic cells. In thrombocytes, phagocytic activity was 
lower than that detected in heterophils, which allowed conidia swelling and germination inside the 
cells. Further studies shall determine whether survival inside thrombocytes might be used by 
Aspergillus as a strategy to ensure dissemination in birds. 
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Evaluation of the liposome properties in the development of immune response during an 
immunization protocol with C. albicans proteins loaded on DODAB:MO liposomes 
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Objectives: Candida albicans is a normal colonizer of the human body, persisting in a harmless state 
most of the time. However, given the opportunity, this species becomes one of the most important 
opportunistic pathogens, which increases the risk of developing systemic candidiasis. A promising 
antifungal strategy is the use of liposomal vaccine delivery systems. Previous studies reported that 
cationic liposomes prepared with DODAB:MO (1:2) and loaded with C. albicans cell wall surface 
proteins (CWSPs) were stable, non-cytotoxic and avidly phagocytized by macrophages. However, 
standardizing these liposomal formulations is challenging and complicated, since their wide range 
of characteristics must be taken into consideration according to the application we desire and the 
performance we expect. The liposome preparation method greatly influences these characteristics. 
Our main objective was to analyze the implications of the liposome preparation method on the 
biophysical properties of the DODAB:MO liposomes loaded with C. albicans proteins and evaluate 
the consequences at the immune response level, in order to develop a formulation that could be used 
in vaccination strategies against systemic C. albicans infections. 
Methods: CWSPs from Candida albicans SC5314 were encapsulated in DODAB:MO (1:2) liposomes. 
The DODAB:MO liposomes were prepared using the thin lipid-film hydration method. The lipid film 
was hydrated with ultrapure water (1º experiment) or with HEPES-buffer and sonicated to reduce 
the vesicles’ size (2º experiment). For both, the final concentration of CWSPs was 50 μg/mL in 25mM 
of HEPES-buffer and the final total lipid concentration was 888 µg/mL. The mean size (nm), 
polydispersity (PDI) and surface charge (ζ-potential) were evaluated with the Malvern ZetaSizer 
Nano ZS (Malvern, UK) particle analyzer and the immunization procedure was carried as previously 
reported (Carneiro et al., 2015). The production of IFN-γ, IL-17, IL-4 and IL-10 in splenic CD4+ T cells 
was evaluated through flow cytometry. “ex vivo” cytokine production was evaluated through re-
stimulation of the splenocytes with CWSPs and CWSP-specific antibodies were quantified by ELISA. 
Results: Liposomes from the first experiment had a size around 666.23 ± 91,31 nm, with a PDI of 0.36 
± 0.08, and a ζ-potential of -2.30 ± 0.31 mV. Changing the liposome preparation method, we obtained 
smaller liposomes (249.69 ± 29.34 nm), with a PDI of 0.20 ± 0.06 and a ζ-potential of -8.53 ± 0.66. While 
IL-4 was the prevailing cytokine when taking into consideration the liposomes from the first 
experiment, the liposomes from the second experiment led to much higher production of IFN-γ and 
IL-17, which clearly shifted the immune response from a Th2 to a Th1/Th17 response. The liposomes 
from the second experiment also demonstrated a significant increase (10x) in CWSP-specific 
antibodies. 
Conclusion: Our results indicate that the biophysical properties of DODAB:MO liposomes are 
important in the type of adaptative cellular response, and that in reducing significantly these 
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liposomes sizes a shift from a Th2 to a Th1/Th17 response was observed, which is known to be more 
protective against systemic candidiasis. Therefore, with this liposome system, the liposome size has 
a huge impact in the immune response. 
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Objectives: Calcineurin inhibitors substantially contribute to the risk for opportunistic fungal 
infections in patients after allogeneic transplantation (HSCT). It is well known that the nuclear factor 
of activated T cells (NFAT) is an important transcription factor downstream of calcineurin especially 
in T cells. However, NFAT also seems to play a role in innate antifungal immune responses by 
polymorphonuclear neutrophils (PMN), as well as in regulation of myelopoiesis and myeloid 
differentiation. 
Methods: Firstly, isolated PMN from CsA-treated patients after allogeneic HSCT (n = 17) and healthy 
donors (n = 8) were analyzed were analyzed in vitro and ex vivo regarding their different effector 
functions. Secondly, we used a murine IPA model (C57BL/6) and treated CsA-treated or LysM-
specific NFATc1 knockout (NFATc1LysM) mice with Aspergillus fumigatus intratracheally. PMN 
recruitment to the lungs and pulmonary fungal clearance were examined by analyzing 
bronchoalveolar lavages (BAL) and peripheral blood (PB) using flow cytometry and cytometric bead 
array and murine lungs by fungal culture assays and histopathologic examination. Furthermore, 
survival was studied with neutropenic animals serving as positive controls. In addition, we 
investigated myelopoiesis and myeloid differentiation by quantifying bone marrow derived myeloid 
progenitor cells from CsA treated or NFATc1LysM mice using flow cytometry and simultaneously 
counting PMN in PB under steady state conditions. 
Results: CsA significantly enhanced phagocytosis of PMN in vitro and ex vivo in patients’ blood 
samples. Moreover, PMNs migratory capabilities were reduced in vitro, whereas other effector 
functions or release of IL-8 were rather unaffected. PMNs of CsA-treated patients showed increased 
activation, degranulation and production of inflammatory mediators, but production of ROS was 
slightly decreased. In our in vivo model, IPA was lethal in neutropenic mice whereas solely CsA or 
vehicle treated mice survived the infection. CsA treatment resulted in enhanced PMN recruitment in 
BAL by trend, while pulmonary inflammation and PMN counts in PB remained stable. Indeed, fungal 
clearance was clearly constrained in CsA treated animals. In our murine knockout model, 
NFATc1LysM mice infected with Aspergillus fumigatus showed unimpaired survival without displaying 
detectable differences in PMN recruitment or fungal clearance. However, pulmonary inflammation 
and PMN counts in PB seemed to be more pronounced in knockout mice. Interestingly, BALs of CsA 
treated mice showed increased levels of IL-6 by trend but decreased levels of MCP-1 and TNF-α. In 
contrast, MCP-1, RANTES and TNF-α were enhanced by trend in BALs of NFATc1LysM mice, while 
IL-6 was reduced compared to wild type controls. PMN counts in PB were unaffected in NFATc1LysM 
mice but distribution of bone marrow derived murine myeloid progenitor cells was significantly 
impaired especially in megakaryocyte-erythroid progenitor cells, whereas solely CsA treatment had 
no influence. 
Conclusion: Results from our in vitro and ex vivo studies on patients’ blood samples as well as from 
our murine in vivo IPA model indicate that NFAT regulates not only myelopoiesis, but also PMN 
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functionalities in mice and humans. Nevertheless, these interactions are obviously multidimensional 
and potentially derive from involvement of different pathways. The underlying molecular 
mechanisms and clinical relevance of our findings in HSCT remain to be determined. 
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Novel assay for sterol 24-C-methyltransferase enzymatic activity, a primary antifungal target of 
Abafungin 
H. Naruse, T. Ito, E. Noshi, Y. Tanaka, H. Maki 
SHIONOGI & CO., LTD., Osaka, Japan 
Objectives: Abafungin is a broad-spectrum antifungal agent. It has been presumed that abafungin 
inhibits sterol 24-C-methyltransferase (SMT) from the report that abafungin decreased L-[Methyl-
14C]methionine incorporated intracellular sterol. SMT is one of the enzymes involved in ergosterol 
biosynthesis pathway which is well-known antifungal target (e.g. azoles). As erg6 gene encoding SMT 
is conserved in many fungal species, SMT could be a promising drug target. However, it is not known 
whether abafungin actually inhibits SMT enzymatic activity, and there is no high throughput SMT 
enzyme assay for drug discovery. Therefore, we developed a novel SMT enzymatic assay by 
homogeneous time-resolved FRET (HTRF). We also evaluated the effects of SMT inhibition on 
antifungal activity. 
Methods: HTRF is based on a competitive immunoassay between SAH, byproduct of SMT reaction, 
and d2 labelled SAH (SAH-d2) towards Lumi4-Tb cryptate labelled anti-SAH antibody. A. fumigatus 
SMT and its substrates, lanosterol and SAM, were mixed and incubated at room temperature, then 
SAH-d2 and anti-SAH antibody were added. After incubation at room temperature, HTRF signal was 
measured. The HTRF ratio was calculated as a two-wavelength signal ratio (665 nm/620 nm). SMT 
inhibitory activity of abafungin and its derivatives were calculated as IC50 values. MICs of these 
compounds against A. fumigatus and C. albicans were measured according to the method of the CLSI. 
Results: SAH was detected by 0.001 μM to 0.1 μM in the optimized condition and SMT produced 
SAH in a dose dependent-manner. SMT of microsomal fraction indicated 3-fold higher enzymatic 
activity than that of cytoplasmic fraction. In this HTRF assay abafungin inhibited SAH production 
and exhibited IC50 of 0.21 μM. The MICs of abafungin against A. fumigatus and C. albicans were 2 
μg/ml and 0.0625 μg/ml, respectively. The derivatives without SMT inhibitory activity didn’t exhibit 
antifungal activity against A. fumigatus and C. albicans. 
Conclusion: We established a novel assay to evaluate A. fumigatus SMT activity. Abafungin was 
revealed to inhibit SMT enzymatic activity, which led to antifungal activity. This result would help 
us develop new antifungals targeting SMT. 
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Metagenomic analysis and culture-dependent diagnosis of cystic fibrosis patient airways 
M.R. Von Zeska Kress1, L. Tonani1, L.M. Fonseca1, O.G.G. Almeida1, C.P.D.C. Capizzani1, E.C.P. De 
Martinis1, L.A.G.M.M. Torres2 
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SP, Brazil, 2Faculdade De Medicina De Ribeirão Preto, Universidade de São Paulo, Ribeirao Preto-SP, 
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Case Report: Cystic fibrosis (CF) is a debilitating autosomal recessive disease in which the patient 
carries a mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, which 
encodes a chloride channel involved in electronic exchanges through the plasma membrane of 
epithelial cell types. Consequently, a defective lung mucociliary clearance occurs, producing thick 
and sticky bronchial mucus, suitable for entrap airborne bacteria and fungi. The culture-dependent 
diagnostics of CF patients airways show the frequent colonization by Haemophilus influenzae, 
Staphylococcus aureus, Pseudomonas aeruginosa,Burkholderia cepaciacomplex and atypical mycobacteria. 
Additionally, prolonged antibiotic treatments contribute to the colonization by multidrug-resistant 
pathogens such as Achromobacter xylosoxidansand Stenotrophomonas maltophilia. On the other hand, 
culture-independent technologies, as the metagenomic approach, revealed that the CF patients 
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airways are not inhabited by these few pathogens, but by complex polymicrobial communities. 
Fungal species are usually found colonizing the CF patients airways (e.g.Aspergillus fumigatus 
andCandida albicans), however, few metagenomics studies are reported in the literature. Here, we 
show the culture-dependent identification and metagenomic approach (16S ribosomal DNA and the 
internal transcribed spacers (ITS) of the nuclear ribosomal DNA) of CF patient sputum. The detailed 
description of the CF lung microbiome is presented and compared with culture-dependent 
identification. The isolation of microorganisms on media culture from the sputum of the CF patient 
revealed the bacteria Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Achromobacter xylosoxidans 
andStaphylococcus aureus, and the fungiAspergillus fumigatus and Candida albicans. The identification 
was performed by classical and molecular methods, respectively. As the culture-based identification, 
the 16S and ITS metagenome revealed the bacteria Stenotrophomonassp., Pseudomonas putida, 
Achromobactersp. and Staphylococcus aureus, and the fungi Aspergillus fumigatus and Candida albicans. 
But metagenome additionally identified Streptococcussp., Neisseriasp. and Saccharomyces cerevisiaein 
high relative abundance, and Tectona grandis, Actinobacillussp., Schizophyllum commune, Agaricales 
order and Halosphaeriaceaefamily in intermediate and low relative abundance. Thus, the culture-based 
analyses correlated qualitatively with the relative abundance of data on obtained bacterial and fungal 
taxa. However, additional identifications were obtained by metagenome data. Here we observed that 
the taxonomic identification by Regarding 16S and ITS metagenome to the species level were not 
achieved for the fungal kingdom and the estimation of the relative abundance of species in the 
community is imprecise. This is justified by the primer-based amplicons sequencing method which 
has a limited ability to resolve this taxonomic identification. Thus, although we have identified 
several species colonizing the CF patients airways, the metagenome shotgun approach is indicated 
to provide information about the composition of the community up to the level of clonal complexes. 
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Mechanisms of resistance to elevated copper in the pathogenic mold Aspergillus fumigatus 
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Osherov1 
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Objectives: Aspergillus fumigatus is the most common opportunistic mold pathogen in the growing 
immunocompromised population. Patients with weak immune systems are at risk to develop 
Invasive Aspergillosis (IA), a deadly type of infection with high mortality rates caused by A. 
fumigatus. Fungi use unique pathways to control the levels of essential metals inside the cell. Copper 
is a transition metal essential for all living systems and its homeostasis in A. fumigatus under copper 
excess is dependent on the copper sensing transcription factor AceA and its downstream target, the 
copper transporter CrpA. Studies suggest that genes participating in copper homeostasis can be 
promising drug targets. Our goals were to reveal the detailed function of the copper transporter CrpA 
and to identify and characterize additional participants acting in the Cu-resistance pathway of A. 
fumigatus and assess their relevance to virulence. 
Methods: To achieve these goals we constructed a model structure of A. fumigatus CrpA, in 
collaboration with Prof. Nir Ben-Tal, and identified evolutionarily conserved fungal-specific domains 
in the protein. We generated GFP-tagged CrpA and studied its subcellular localization. We 
performed RNAseq analysis of A. fumigatus exposed to high copper levels and deleted selected 
upregulated genes. Finally, we performed a screen to identify genes that provide Cu-resistance when 
overexpressed. 
Results: Significant progress was made in the localization of CrpA protein. We located the protein 
mostly in the ER but also in the membrane. We also created an inducible overexpression strain of 
CrpA using the xylose-inducible promoter xylP and showed that CrpA overexpression confers 
increased copper resistance when exposed to copper in vitro but not in vivo. We generated deletion 
strains for six genes that were up-regulated in WT vs AceA-null strains following exposure to copper 
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as identified by RNA-seq. These genes are chaperones and metal-binding proteins that may 
participate in A. fumigatus copper resistance. The phenotypes of these deletion strains will be 
described. We performed a genetic screen using an overexpression library in which A. nidulans was 
transformed with the AMA-1-based overexpression genomic library and plated on excess Cu. We 
found four new genes that confer resistance to A. nidulans 
Conclusion: Our results provide a more detailed picture of copper resistance in A. fumigatus, 
indicating that is dependent on the combined activities of the CrpA copper exporter, Cu-chaperones 
and accessory stabilizing proteins. 
 
P378 
Genotyping of Cryptococcus spp. isolated from HIV-negative patients with Neurocryptococcosis 
E. Nascimento1, P.H.G. Barião2, M. Von Zeska Kress2, R. Martinez1 
1Department Of Internal Medicine, Medical School /University Of Sao Paulo/Ribeirao Preto, Ribeirão 
Preto, Brazil, 2school Of Pharmaceutical Sciences Of Ribeirao Preto, University Of Sao Paulo, Ribeirão 
Preto, Brazil 
Objectives: The aim of this study was to determine the species and molecular types of Cryptococcus 
spp. isolates from patients not co-infected with HIV from the Medical Hospital of Ribeirao Preto - 
Medical School of Ribeirão Preto - University of Sao Paulo – Brazil, from 2000 to 2017, and correlate 
with the comorbidity of the patients. 
Methods: A total of 43 strains of Cryptococcus spp. isolated from 43 patients not co-infected with HIV 
were genotyped. The species were determined by PCR with the primers CN70 and CN49. The 
molecular types C. neoformans VNI, VNII, VNIII and VNIV, and C. gattii VGI, VGII, VGIII and VGIV 
were determined by PCR-RFLP with the amplification of the URA5 gene and subsequent enzymatic 
restriction with HhaI and Cfr13I. The identification of C. gattii and C. laurentii was confirmed by the 
sequencing of the rDNA ITS regions. 
Results: From a total of 43 clinical isolates, 28 were identified as C. neoformans, 13 as C. gattii and 2 as 
C. laurentii. Among C. neoformans clinical isolates, 27 were identified with the molecular type VNI and 
1 VNII. Additionally, 2 C. gattii VGI and 11 C. gattii VGII were identified. The correlation between 
species and patient comorbidity revealed 28 clinical cases (Group 1) of patients not coinfected with 
HIV but with other underlying diseases (e. g. diabetes, adenocarcinoma, chronic lung disease, 
transplants, systemic lupus erythematosus and others ) and 15 clinical cases (Group 2) of 
immunocompetent patients. Most of the isolates identified in Groups 1 were C. neoformans (75%) and 
in Group 2 were C. gattii (47%). C. laurentii were isolated from the Group 2. 
Conclusion: Most of the clinical isolates were identified as C. neoformans and were more present in 
individuals not co-infected with HIV but who had another underlying disease. On the other hand, C. 
gattii is more frequent in the group of immunocompetent patients. The molecular types VNI and VGII 
were the most identified in our study, which corroborate with other studies carried out in Southeast 
Brazil. 
 
P379 
Classification of dermatophytes by a multilocus phylogenetic approach based on Tef-1α, beta 
tubulin and ITS genes. 
R. Sacheli1, C. Tomé1, C. Adjetey1, R. Darfouf1, L. Palmeira2, M.-P. Hayette1 
1Clinical Microbiology- Nrc For Mycoses, University Hospital of Liège, Liège, Belgium, 2Human 
Genetics, University Hospital of Liège, Liège, Belgium 
Objectives: Identification of dermatophytes to the species level is epidemiologically, ecologically and 
therapeutically significant. The use of phylogenetic species concepts based on rDNA internal 
transcribed spacer (ITS) regions have improved the taxonomy of dermatophytes. However, it has 
been shown that for some species, confirmation and refinement using other genes are needed. Indeed, 
there are problems with accurate definition and characterization of dermatophytes especially among 
the Trichophyton mentagrophytes series. Intra- and interspecies variations of the translation elongation 
factor 1-α (Tef-1α) gene were evaluated as a new identification marker in a wide range of 
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dermatophytes. The aim of this study was to evaluate the discriminatory power of a phylogenetic 
tool based on concatenated sequences of three genomic regions including Tef-1α, ITS (ITS1 to ITS2) 
and beta-tubulin to differentiate: 1/ the anthropophilic Trichophyton interdigitale species from the 
zoophilic Trichophyton mentagrophytes 2/ the two closely related African anthropophilic species 
Trichophyton violaceum from Trichophyton soudanense. 
Methods: 26 well characterized strains of T. interdigitale/mentagrophytes have been selected including 
3 IHEM reference strains; 30 well characterized strains of T. soudanense/T.violaceum including 2 IHEM 
reference strains were also included. All strains were submitted to ITS, beta-tubulin and Tef-1α 
PCR/sequencing. Moreover, identification was completed by real time PCR DermaGenius®  
(PathoNostics). Alignments were performed using MUSCLE in Seaview. The alignments for each of 
the three genes were then concatenated together based on the name of the sample and gaps were 
added between genes. Phylogenies were then inferred on the concatenated alignment using PhyML. 
Results: After generation of the phylogenetic tree by concatenation of the three sequence genes, the 
differentiation between T. interdigitale and T. mentagrophytes was clear. The 16 strains of T. interdigitale 
were well classified into one distinct group on the dendrogram. The 10 strains of zoophilic T. 
mentagrophytes were well distinct of the anthropophilic group and defined by another clade on the 
dendrogram. Reference strains were correctly classified into the two previously defined groups. 
Regarding the differentiation between T. soudanense and T. violaceum, the concatenation permitted to 
define two well distinct clades on the dendrogram. One clade containing the 10 T. violaceum tested 
and the other containing the 20 T. soudanense included in the study. Reference strains were correctly 
classified into each corresponding clade. 
Conclusion: The concatenation of ITS, beta-tubulin and Tef-1α genes sequences allows the generation 
of a discriminating dendrogram between the zoophilic T. mentagrophytes and the anthropophilic T. 
interdigitale and between the two closely related African anthropophilic species T. violaceum and T. 
soudanense. These species are not clearly well defined by ITS analysis only. This multilocus 
phylogenetic approach allows to better define the species boundaries between these dermatophytes 
species and facilitates the molecular characterization of these species in routine diagnostic. 
 
P380 
Pulmonary mycobiome of patients with suspicion of respiratory fungal infection – an exploratory 
study 
M. Oliveira1,2, M. Pinto3, C. Verissimo4, R. Sabino2 
1Animal Biology Department, Faculty of Sciences of the University of Lisbon, Lisbon, Portugal, 
2Reference Unit For Parasitic And Fungal Infections, Infectious Diseases, National Health Institute 
Dr. Ricardo Jorge, Lisbon, Portugal, 3Bioinformatics Unit, Infectious Diseases, National Health 
Institute Dr. Ricardo Jorge, Lisbon, Portugal, 4Infectious Diseases, Reference Unit for Parasitic and 
Fungal Infections, National Health Institute Dr. Ricardo Jorge, Lisbon, Portugal 
Objectives: This pilot study aimed to characterize the pulmonary mycobiome of patients with 
suspicion of fungal infection of the respiratory tract as well as to identify potentially pathogenic fungi 
colonizing/infecting their lungs. 
Methods: A cohort of 10 patients was analyzed, including HIV+ patients and patients with active 
infection caused by Mycobacterium species. Their respiratory samples (bronchoalveolar lavage fluid/ 
bronchial secretions) were pre-treated with lyticase and proteinase K; DNA was extracted using the 
High Pure PCR Template Preparation kit following the manufacturer’s instructions. The internal 
transcribed spacer region 1 (ITS1) and calmodulin gene were amplified by PCR and the resulting 
amplicons were sequenced using the Illumina MiSeq platform with pair-end reads of 150 bp. The 
obtained results were analyzed using the PIPITS pipeline as described by Gweon et al. [1]. 
Operational taxonomic units (OTU) to which less than 0.1% of the total reads attributed were 
disregarded. 
Results: Thirty-seven different OTU were identified from which two belonged to the Plantae 
kingdom, 11 had less than the 0.1% threshold of the total reads and were therefore disregarded. The 
remaining 24 different OTU (grouped in 17 phylotypes), were considered as part of the pulmonary 
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mycobiome of patients. Two phyla were identified: Basidiomycota (33.3%) and Ascomycota (54.2%). 
Regarding the Basidiomycota phylum, reads were classified in three classes (Agaricomycetes, 
Tremellomycetes and Walleomycetes), while for the Ascomycota phylum four different taxonomical 
classes were identified: Pneumocystidomycetes, Dothideomycetes, Eurotiomycetes and 
Saccharomycetes, with the latter being the most frequent class. Twelve fungal genera were identified, 
being Candida the most frequently detected. The median number of fungal genera detected in 
patients’ pulmonary mycobiome was six (ranging from two up to nine). The genus Papilotrema and 
the potentially pathogenic genera Cryptococcus and Pneumocystis were exclusively found in the 
pulmonary mycobiome of HIV+ patients. Other potentially pathogenic fungi such as Aspergillus spp., 
Trichosporon spp., Saccharomyces spp. and Schizophyllum spp. were also detected. 
Conclusion: This pilot study illustrates how the pulmonary mycobiome is rich and highly variable 
in patients with fungal infections. The obtained results suggest that the described metagenomic 
analysis may possess a great ability to quickly and effectively detect potentially pathogenic fungi in 
the mycobiome of patients, making it a promising future diagnostic tool. Thus, further optimization, 
standardization and clinical validation of these NGS methodologies should be warranted in the 
future. Reference: Gweon HS, Oliver A, Taylor J, Booth T, Gibbs M, Read DS, Griffiths RI, Schonrogge 
K. PIPITS: an automated pipeline for analyses of fungal internal transcribed spacer sequences from 
the Illumina sequencing platform. Methods Ecol Evol. 2015 Aug;6(8):973-980. 
 
P382 
Comparative genomic analysis of Scedosporium species and identification of pathogenicity 
determinants. 
L. Duvaux1,2, J. Shiller3, P. Vandeputte2, M. Bahut4, C. Lemaire1, W. Meyer5, L. Hibrand Saint Oyant4, 
J.P. Renou3, B. Le Cam1, J.-P. Bouchara2, A. Gastebois2 
1Irhs-ecofun, INRA, Beaucouzé, France, 2Geihp, Université d'Angers, Angers cedex, France, 3Irhs-bio-
info, INRA, Beaucouzé, France, 4Sfr-quasav-anan, Université Angers, Beaucouzé, France, 5Molecular 
Mycology Research Laboratory, University of sydney, Sydney, Australia 
Objectives: Objectives Scedosporium species are soil saprophytes that may cause a large variety of 
infections in human. Especially, some of them are capable to chronically colonize the lungs of patients 
suffering from cystic fibrosis (CF) which constitutes a major risk of disseminated infection in case of 
lung transplantation. Molecular and biochemical analysis revealed that the genus Scedosporium 
comprises at least ten distinct species with differences in their susceptibility to antifungals and in 
their pathogenicity. Among them, three species, S. boydii, S. apiospermum and S. aurantiacum are 
predominant in CF patients, while other species like S. minutisporum are occasionally encountered in 
this clinical context. Conversely, S. dehoogii has never been reported from respiratory secretions of CF 
patients whereas some environmental studies revealed its common occurrence in soils where it 
accounts for up to 40% of all Scedosporium isolates. The aim of our project was to identify by a 
comparative genomic approach, regions of the genome or genes that might be responsible for the 
ability of Scedosporium species to establish within the respiratory tract of CF patients and to cause 
chronic colonization of the airways. 
Methods: Methods Five clinical or environmental isolates from each of the five species S. boydii, S. 
apiospermum, S. aurantiacum, S. minutisporum, and S. dehoogii were sequenced. To identify candidate 
proteins that may enable Scedosporium species to establish within the respiratory tract of CF patients, 
we first searched clusters of orthologous proteins conserved in all isolates of the pathogenic species, 
but absent in S. dehoogi isolates. Genomic data were also analyzed searching for genes present in all 
pathogenic species, as well as in S. dehoogii, but exhibiting in this last species point mutations 
potentially leading to a loss of function. 
Results: Results At the beginning of the project, the whole genome of a first strain of S. apiospermum 
sensu stricto (Vandeputte et al., 2014) and of S. aurantiacum (Pérez-Bercoff et al., 2015) were already 
available. The whole-genome sequencing project allowed us to obtain a total of 2.4-8.9 mega-reads 
per isolate which permitted good quality draft genome assemblies. For 3 species, we did de novo 
sequencing, genome assembly and performed comparative genomic analysis with the 25 strains. 
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Finally, comparative genomics allowed us to identify a series of 134 genes lost or with a potential loss 
of function in S. dehoogii but still functional in all other species. 
Conclusion: Conclusion This comparative genomic analysis of the main Scedosporium species 
allowed us to identify a set of candidate genes potentially involved in the adaptative mechanisms 
developed by pathogenic Scedosporium species to establish within the respiratory tract of patients 
suffering from CF. Functional genomic approaches focused on the genes here identified will now be 
developed to elucidate their role in pathogenesis. Acknowledgment This project was financed by 
Angers University with the AAP-CS program. 
 
P383 
Molecular phylogenetic study of strains morphologically identified as Exophiala dermatidis from 
clinical and environmental specimens in Japan 
Y. Alimu, R. Tanaka, S. Ban, T. Yaguchi 
Division Of Bio-resource, Medical Mycology Research Center, Chiba University, Chiba, Japan 
Objectives: With support from the National Bio-Resource Project, at the Medical Mycology Research 
Center (MMRC), Chiba University, the collection, storage and distribution of pathogenic fungi are 
carried out mainly on clinical isolates. The molecular phylogenetic position of the isolates, the 
mycological characterization, the genomic and the clinical information are managed and added to 
the database to increase the value of the stock and lead to an increase in the number of aliquots. Since 
old isolates are morphologically identified and conserved, their identifications are reviewed as 
needed based on the base sequence of the ITS region of rDNA. We report here on Exophiala 
dermatitidis, which is an important pathogen of deep-skin dermatomycosis, it has been reconfirmed 
with identification and fitted with the latest classification. E. dermatitidis has been reported to have a 
molecular phylogenetically polymorphism in strains from South America. However, the 
investigation of the distribution in Japan has not been reported. The aims of this study, is investigate 
the phylogenetic distribution of E. dermatitidis in Japan. 
Methods: In this investigation, we examined 66 clinical and environmental isolates morphologically 
identified and conserved as E. dermatidis previously, which were stocked in Bioresource Management 
Office in MMRC. The identification based on the ITS region. The sequences were aligned and 
compared through neighbor-joining phylogenetic tree analyses on the ITS1 region, using the 
Molecular Evolutionary Genetics Analysis (MEGA) version 7.0.26 software package. Furthermore, 
the strains of different gene types will test for mycological characterization such as the growth 
temperature, the growth rate, and the drug sensitivity. 
Results: The examined 66 clinical and environmental isolates were composed of 47 ones from Japan, 
4 ones from USA, 5 ones from Brazil, 6 ones from Venezuela and 4 ones from China. According to 
establish a phylogenetic tree for the ITS1 region, we knew that 45 of 47 isolates from Japan, 2 of 4 
ones from China, 2 of 6 ones from Venezuela and all of 4 ones from the USA were classified to the 
gene type A1. Only 2 of Japan and China`s isolates belonged to the gene type A2, respectively. 
Interestingly, all of the isolates from Brazil were part of the gene type B and most of the Venezuela 
samples were close to the gene type C. The relationship between the types and their mycological 
characterizations was examined. 
Conclusion: In our study, it is confirmed that, in South American strains, polymorphisms were found 
molecularly within species, and molecular phylogenetic diversity of the isolates in Japan was 
relatively uniform. 
 
P384 
Investigation of the impact of amino acid changes in the substrate binding site of fungal sterol 
14α-demethylase on protein structure and function using Saccharomyces cerevisiae as an 
expression model. 
M. Lackner1, M.V. Keniya2, B. Monk2 
1Division Of Hygiene And Medical Microbiology, Medical University of Innsbruck, Innsbruck, 
Austria, 2Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand 
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Objectives: Mucormycetes are intrinsically short-tailed azoles resistant. We used the high resolution 
X-ray crystal structure of S. cerevisiae lanosterol 14α-demethylase (LDM) in complex with 
voriconazole (VCZ) to postulate that the amino acid substitution Y129F in Rhizopus arrhizus LDM 
(RaLDM) F5 is associated with their intrinsic resistance. Our aim was to experimentally test this 
hypothesis. 
Methods: Full-length recombinant C-terminal hexahistidine-tagged LDM (F1 and F5) of R. arrhizus 
were overexpressed from the PDR5 locus in a S. cerevisiae host lacking 7 drug efflux pumps. Their 
cognate NADPH-cytochromeP450 reductase (RaNCP) was overexpressed from the PDR15. 
Phenotypic and biochemical analysis were used to determine structural and functional features of 
RaLDMF1, RaLDMF5, without and with co-expression of RaNCP. 
Results: RaLDMF1 and F5 were functionally overexpressed in S. cerevisiae. RaLDMF5 appeared to be 
the major contributor to azole resistance, with its expression resulting in a 32x higher VCZ minimal 
inhibitory concentration (MIC) than the recipient strain. Co-expression of RaLDMF5 with NCP 
resulted in additional 4-fold increase of VCZ MIC when compared with RaLDMF5 single expression. 
MICs for long-tailed azoles were unaffected by the LDM supplementation. S cerevisiae co-expressing 
RaLDMF1 with NCP had similar MIC values as the recipient strain. Azole-susceptibility patterns of 
S. cerevisiae co-expressing RaLDMF5 and RaNCP closely matched those of R. arrhizus. Phenotypic 
analysis of recombinant LDMs expressed in S. cerevisiae provides insights on the relevance of 
mutations located in the substrate binding pocket. This system allows assessment of effects on the 
drug target without interference from drug efflux pathways. 
Conclusion: LDMF5 was found to be the dominant isoform in R. arrhizus that confers short-tailed 
azole resistance. Biochemical and structural analysis of the purified protein are expected to provide 
deeper understanding of the observed phenotypes. 
 
P385 
A metagenomic and whole genome sequencing comparative approach to study the impact of azole 
therapy on chronic colonisation with Aspergillus fumigatus during cystic fibrosis. 
J.P. Gangneux1, L.-E. Vandenborght2, B. Bidon3, C. Belleguic4, E. De Neuville4, H. Guegan1, S. Leroy5, 
B. Laviolle4, A. Horsley6, D. Denning7, C. Cuomo8, J.-P. Bouchara3, L. Delhaes9, N. Papon10 
1Laboratoire De Parasitologie-mycologie, CHU de Rennes, Rennes, France, 2Genoscreen, Lille, France, 
3CHU d'Angers, Angers, France, 4CHU de Rennes, Rennes, France, 5CHU de Nice, Nice, France, 
6University Hospital of South Manchester, Manchester, United Kingdom, 7University of Manchester, 
Manchester, United Kingdom, 8Broad Institute of MIT and Harvard, Cambridge, United States of 
America, 9Parasitology Mycology, Univeristy of Bordeaux, Centre de Recherche Cardio-Thoracique 
de Bordeaux, U1045, F-33000, Bordeaux, France, Bordeaux, France, 10Ea Geihp, UFR Pharmacie 
d'Angers, Angers, France 
Objectives: The impact of early azole therapy during cystic fibrosis (CF) remains debated. The ATCF 
(Antifungal Therapy during Cystic Fibrosis) is a longitudinal phase III study with the following 
objectives: - to assess the microbiological and clinical effects of azole therapy: negativation of sputum 
cultures for Aspergillus, course of FEV1, clinical signs and quality of life, and the impact on co-
prescription of antibiotic courses and/or steroid therapies. - to study the genomic impacts of azole 
treatment on the evolution of micro- and mycobiota and on genomic evolution of Aspergillus isolates. 
Methods: The ATCF study followed CF patients with a chronic colonisation with A. fumigatus and 
randomized to receive an early oral azole therapy with itraconazole (ITRA) or voriconazole (VORI) 
for 4 to 6 months in a phase III study. A long-term follow-up was conducted until 2 months after end 
of treatment (EOT). All sputa were submitted to DNA extraction for further metagenomic approach 
to determine the fungal (ITS2) and bacterial (16S) microbiota. Besides, twenty isolates of Aspergillus 
fumigatus recovered before and after treatment were sequenced with a shotgun strategy. 
Results: Eleven patients were included and followed until 2 months after EOT. All assessable patients 
had a successful outcome, with a negativation of sputa, an increase in FEV1 and a decrease in the 
number of antibiotic/steroids co-prescriptions. However, 2 months after EOT, most of clinical 
assessment criteria were similar to the baseline values. Fungal diversity increased under treatment 
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with a large decrease of the more abundant fungal taxa, particularly Aspergillus. However, 2 months 
after EOT the fungal diversity returned to baseline values and Aspergillus reappeared, mostly in a 
larger proportion. Besides, Streptococcus, Pseudomonas and Staphylococcus were the main genera 
detected and their proportion increased under azole therapy. The bacterial communities were similar 
after EOT compared to before. The analysis of micro – and mycobiota must be further documented. 
All SNPs and InDels variants were determined for 20 isolates. Isolates from a single sputum and more 
generally from a single patient during treatment were closely related. By contrast, isolates obtained 
2 months after EOT were far different suggesting reinfections with new genotypes. In particular, one 
azole resistant A. fumigatus was recovered with a TR34/L98H mutation of the CYP51A gene, 
suggesting an environmental origin rather than an acquired resistance under azole drug pressure. 
Conclusion: When a chronic colonisation with A. fumigatus is associated with clinical deterioration, 
EOT can temporarily reduce airway infection and inflammation, and extend periods of stable disease 
status. While only a limited number of patients were included, the longitudinal phase III design of 
ATCF study combined to a genomic approach underlines the need for azole therapy rationalization 
during CF. Indeed, the reversible effects 2 months after the EOT and the limited tolerance of both 
ITRA and VORI encourages short courses of therapy driven by the clinical improvement. The 
longitudinal changes of the mycobiota were restored 2 months after EOT and genetic characterization 
of isolates showed that reinfection with new genotypes is more frequent than Aspergillus in host 
evolutions under azole treatment. 
 
P386 
Role of Candida glabrata candidate genes in echinocandin tolerance and resistance development 
R. Garcia-Rubio1, A. Clear1, K.R. Healey2, E. Shor1, D.S. Perlin1 
1Center For Discovery And Innovation, Hackensack Meridian Health, Nutley, United States of 
America, 2Department Of Biology, William Paterson University, Wayne, United States of America 
Objectives: Candida glabrata is the second most prevalent bloodstream fungal pathogen in North 
America and Europe, and its prevalence is rising. Echinocandin class compounds are first-line agents 
for the treatment of these infections, but therapeutic failures are increasingly encountered. However, 
the reasons why C. glabrata shows elevated potential to develop echinocandin resistance, relative to 
other Candida sp., are currently not well understood. Although echinocandins are fungicidal drugs, 
multiple cellular mechanisms can stabilize C. glabrata during drug exposure and promote drug 
tolerance, allowing cells to survive long enough to acquire mutations leading to stable clinical drug 
resistance. Interestingly, genomic analyses of different C. glabrata clinical isolates have revealed a 
high level of genetic diversity both within the same MLST sequence type (ST) clade and between 
them. Depending on the population subset, genomic plasticity may be responsible for differences in 
tolerance phenotype. The objective of our research is to elucidate the factors involved in promoting 
echinocandin drug tolerance in C. glabrata. 
Methods: Because echinocandins target the fungal cell wall, we have focused on interrogating the 
role of cell wall integrity pathway components in promoting echinocandin tolerance. We have used 
an in vitro killing assay developed in our group to measure tolerance over a range of micafungin 
concentrations (0.016-32 µg/ml). Multiple knock-out mutants (∆slt2, ∆snf1, ∆rlm1, ∆sbe2, ∆mid2, 
∆cka1, ∆cbk1, ∆ypk2, ∆slg1, ∆yps1, ∆ada2, ∆mot3, ∆gas1, ∆rta1, ∆chs5, ∆crz1, ∆pdr1, ∆ssd1, ∆sbe22, 
∆chs3) were tested in this assay looking for significant changes in tolerance phenotypes. Additionally, 
to identify genetic polymorphisms that may be influencing echinocandin tolerance, we have 
sequenced some of the most relevant cell wall integrity pathway genes, particularly focusing on those 
whose deletion was found to affect drug tolerance in the killing assay. 
Results: Most of the knock-out mutants showed no or minor changes in echinocandin tolerance. 
However, three mutants – ∆yps1, ∆ypk2 and ∆slg1 – resulted in significantly reduced tolerance to 
micafungin. These genes were sequenced in a number of C. glabrata echinocandin sensitive clinical 
isolates. Different polymorphism combinations were found in these strains, with specific 
polymorphisms being characteristic of particular STs. Several of these genetic polymorphisms 
resulted in amino acid changes. 
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Conclusion: Changes in micafungin tolerance phenotype were found in mutants lacking certain cell 
wall integrity pathway genes, implicating them in promoting drug tolerance in C. glabrata and 
representing potential targets to limit development of antifungal drug resistance. Further studies will 
evaluate whether polymorphisms in these genes are responsible for variation in drug tolerance 
among clinical strains. 
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Genetic modification of opportunistic pathogenic Mucoromycotina species using a plasmid free 
CRISPR/Cas9 system 
G. Nagy1,2, C. Szebenyi1,2, A. Vaz1,2, O. Jáger1,2, S. Ibragimova1, Y. Gu3, A.S. Ibrahim3, C. Vágvölgyi1, T. 
Papp1,2 
1Deapartment Of Microbiology, University of Szeged, Szeged, Hungary, 2MTA-SZTE “Lendület” 
Fungal Pathogenicity Mechanisms Research Group, Szeged, Hungary, 3Los Angeles Biomedical 
Research Institute at Harbor-UCLA Med Center, Torrance, United States of America 
Objectives: Most fungal species, which can cause human infections belong to the genera Candida and 
Aspergillus, but in the recent years, the number of infections caused by Mucoromycotina species (e.g., 
Rhizopus oryzae, Lichtheimia corymbifera and Mucor circinelloides) has significantly increased. The 
properties and potential virulence factors that make the Mucoromycotina species enable to cause 
disease (mucormycosis) in patients, are not known. Potential virulence factor genes may play role in 
fungal dimorphism, proteolytic enzyme production, iron uptake, and production of cell surface 
proteins. 
Methods: Genetic manipulation of Mucoromycotina species, based on homologous recombination 
still can be a great challenge. In this study, a plasmid free CRISPR/Cas9 system was used for the 
genetic manipulation of Mucor, Lichtheimia and Rhizopus species. PEG-mediated protoplast 
transformation was used to introduce the Cas9 enzyme and the synthesized gene-specific gRNA with 
or without a deletion cassette into the fungus. 
Results: In case of Lichtheimia and Rhizopus, the plasmid free CRISPR/Cas9 system was successfully 
used to disrupt the pyrG gene by NHEJ. Our results suggested that the disruption of the pyrG gene 
has no effect on the growth of fungal strains. These strains and the developed methods will be 
suitable for further transformation procedure in the future. 
Conclusion: Based on the potential virulence factor genes (cotH, svf, cyp51, hsbA), a mutant library 
has been constructed from M. circinelloides. We have started to analyse the function of these genes in 
the pathogenesis and azole resistance of Mucor. This study was supported by the “Lendület” Grant 
of the Hungarian Academy of Sciences (LP2016-8/2016) and the Hungary grant 20391-
3/2018/FEKUSTRAT of the Ministry of Human Capacities. 
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Mycobiome and microbiome in chronic fungal rhinosinusitis 
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Créteil, Créteil, France, 3Ent, HEGP, Paris, France, 4Microbiology, HEGP, Paris, France, 
5Microbiology, Hôpital Henri-Mondor, Créteil, France 
Objectives: Fungal ball rhinosinusitis is the main type of non-invasive fungal rhinosinusitis, 
presenting as a dense mass of mycelium obstructing the sinus. Despite fungal hyphae being observed 
on direct examination of biopsy samples, culture remains negative in more than 60% of cases.1 The 
aim of this study was to evaluate the performances/efficacy of targeted metagenomics to describe 
and analyze bacterial and fungal microbiota in fungal balls compared to other types of sinusitis and 
find possible microbial co-occurrence/associations intra or extra kingdom. 
Methods: A total of 46 sinus biopsies were studied from 46 patients who underwent surgery for 
chronic rhinosinusitis from 2015 to 2017 in Paris, France. Direct examination of biopsies was 
performed by calcofluor and culture was performed on Sabouraud media. DNA was extracted and 
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fungal ITS1 and ITS2 loci and bacterial V3-V4 16S ribosomal DNA locus were amplified and 
sequenced (MiSeqTM Illumina, V2 kit, 500 cycles). To analyze the microbial diversity, operational 
taxonomic units were defined via QIIME and assigned to SILVA and UNITE databases for 16S and 
ITS, respectively. Statistical analyses were performed using SHAMAN. These data were compared 
to microbiological and clinical data. 
Results: Among these 46 patients, 38 had fungal balls and 8 had non-fungal chronic rhinosinusitis 
and were considered as controls. Among the 38 fungal balls, direct examination and culture were 
positive for fungi in 95% and 30% of biopsies, respectively. By contrast, targeted metagenomic 
analysis of the 38 fungal balls yielded one or more fungal genera in 100% of cases, with Aspergillus 
spp. alone or in combination with other fungi in 92.1% (35/38) of patients. Control samples (n = 8) 
generated only a limited number of fungal reads, mainly from the genus Malassezia (4/8). Overall, the 
main bacterial genera found by targeted metagenomics were Haemophilus (20.1%), Staphylococcus 
(14.6%), Pseudomonas (7.66%) and Enterobacter (5.84%). Using principal coordinate analysis (Bray-
Curtis distance; permanova test), we found significantly different bacterial and fungal metagenomic 
profiles in patients with fungal balls compare to controls (p = 0.047 and p<0.001, respectively) (Figure 
1). One bacterial taxon, Haemophilus, was significantly over-represented in patients with fungal balls 
compared to controls (p<0.001). 
 
Conclusion: Targeted metagenomics allowed identification of fungal genera responsible for chronic 
rhinosinusitis when the culture remains negative. Aspergillus was the most commonly fungus 
identified. The genus Haemophilus appeared statistically associated with fungal balls. Fungal balls 
pathogenesis could result from microbial interactions between fungi and bacteria in mixed biofilm-
like structure. 1. Jiang, R.-S., Huang, W.-C. & Liang, K.-L. Characteristics of Sinus Fungus Ball: A 
Unique Form of Rhinosinusitis. Clin Med Insights Ear Nose Throat (2018). 
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From swollen to germination; a transcriptomic approach in Aspergillus fumigatus 
U. Perez-Cuesta, X. Guruceaga, A. Ramirez-Garcia, A. Abad-Diaz-De-Cerio, F.L. Hernando, A. 
Rementeria 
Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), Leioa, 
Spain 
Objectives: The germination is the first adaptive process that Aspergillus fumigatus must overcome to 
colonize the environment or infect animals. The A. fumigatus germination process involves a first step 
known as swollen and the subsequent hyphae elongation. Morphologically, both are well-
characterized processes but molecularly there are only a few studies describing the transition from 
swollen to germination in the literature. This study, therefore, focuses on the transcriptomic analysis 
of the genes differently expressed between swelling conidia and early hyphae output to understand 
the mechanisms involved in these steps. 
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Methods: The A. fumigatus reference strain Af293 was incubated at 37°C without agitation in RPMI 
supplemented with 5% fetal bovine serum for 4.5 and 6 hours to obtain swelling conidia or early 
hyphae respectively. Total RNA was extracted and maintained in RNA later until use. Finally, RNA 
samples were studied using the AWAFUGE microarray (Agilent Whole A. fumigatus Genome 
Expression 44K v.1) designed by our research group. 
Results: The transcriptomic analysis detected 158 and 256 genes overexpressed in the swelling and 
early hyphal stages, respectively. GO enrichment analysis showed that transport (13.2%), organelle 
organization (11.9%) and regulation (10.7%) were the most common categories in the swelling stage, 
and transport (10.2%), regulation (10.2%) and filamentous growth (7.4%) in early hyphal stage. 
Unfortunately, only 36% and 53.5% of the overexpressed genes had known molecular function in 
swelling or hyphal stages, respectively. Among them, the oxidoreductase (17.6%), hydrolase (8.8%) 
and transferase (8.8%) were the most usual activities detected in swelling stage, while hydrolase 
(14.1%), oxidoreductase (10.2%) and transferase (6.3%) activities were the most abundant in early 
hyphal stage. According to component ontologies, the most overexpressed genes in the swelling 
conidia codified proteins located in mitochondrion (24.5%), membrane (23.3%) and nucleus (13.8%), 
while the ones in the early hyphae stage codified proteins of the membrane (13.7%), extracellular 
region (5.9%) and plasma membrane (4.7%). On the one hand, in the swelling step highlights the 
primary metabolism being the production of energy the principal priority. In addition, the regulation 
of glutamate homeostasis as well as the iron metabolism may also play a crucial role. On the other 
hand, in hyphal output, an overexpression of genes implicated in vitamins and cofactors production, 
calcium regulation and cell wall were detected. 
Conclusion: This work might enable a better understanding of the germination process of Aspergillus 
fumigatus from a transcriptomic point of view. This project could involve important advances in the 
knowledge of the ecology and the mechanisms of adaptation of the fungus that could be exploited 
by both the biotechnological and the biosanitary sector. 
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Genotyping of azole resistance in Candida auris 
J. Li1, A.T. Coste1, D. Bachmann1, D. Sanglard1, F. Lamoth2 
1Microbiology Institute, University Hospital Lausanne, University of Lausanne, Lausanne, 
Switzerland, 2Infectious Diseases Service, CHUV, Lausanne, Switzerland 
Objectives: Since 2009, Candida auris has emerged as a multidrug-resistant yeast pathogen in all 
continents. Its ability to cause nosocomial outbreaks with high mortality rate has attracted worldwide 
attention. Four distinct geographic and genetic clades have been described: I: South Asia (India, 
Pakistan), II: East Asia (Japan, South Korea); III: South Africa; IV: South America (Venezuela, 
Colombia). Remarkably, rapid development of fluconazole resistance is a hallmark of most C. auris 
isolates. However, mechanisms of azole resistance and type of genetic mutations still remain unclear. 
Hotspot mutations in the target gene (ERG11) are classical cause of azole resistance in Candida spp, 
but other mechanisms exist, such as overexpression of drug transporters induced by gain-of-function 
mutations in transcription factors like TAC1 and MRR1, both of which are important regulators of 
efflux systems in Candida albicans. Nevertheless, TAC1 and MRR1 have not been studied in C. auris 
yet. The objective of the study was to analyze the genotype of these genes in C. auris isolates from 
different clades and with different levels of azole resistance. 
Methods: Twenty-two C. auris strains from India, Japan, Israel, Colombia and Switzerland were 
collected. Susceptibility to fluconazole (FLC) and voriconazole (VOR) was tested according to CLSI 
protocol. Minimal inhibitory concentration (MIC) thresholds for resistance were defined according 
to arbitrary cut-offs previously reported by Lockhart et al.: MIC ≥32 μg/mL for FLC and ≥2 μg/mL for 
VOR. Entire sequencing of ERG11, TAC1 and MRR1 was performed for all 22 isolates. 
Results: By antifungal susceptibility testing, 2 isolates were classified as azole susceptible (MIC FLC 
4 μg/mL and VOR ≤1 μg/mL), 13 as resistant to FLC only and 7 as resistant to both FLC and VOR. 
ERG11 sequencing revealed three hotspot mutations that have already been described in C. auris 
(F126T, Y132F and K143R). These isolates (n = 8) exhibited high level resistance to FLC and variable 
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VOR susceptibility. In addition, we identified two new hotspot mutations: V125A from Israeli and 
Swiss strains (n = 3) with high resistance to both FLC and VOR, and F444L from Colombian strains 
(n = 4) with high resistance to FLC and variable VOR susceptibility. Putative TAC1(QG37_07465) 
sequencing uncovered twenty mutations possibly associated with azole resistance (i.e. present in 
azole-resistant isolates, but not in susceptible ones): S89Y, E200K, F214L/S, R215K, K225N, K247E, 
I268V, Q298K, T346I, Q503R, F580L, P595H, P607S, S611P, A640V, Y647C, I772-, N773- and L774M. 
Compared to ERG11 mutants exhibiting high FLC MIC (≥64 μg/mL) and relatively high VOR MIC 
(≥1 μg/mL), ERG11 wild-type isolates harboring TAC1 mutations exhibited intermediate level of FLC 
resistance (MIC: <64 µg/mL) and low VOR MIC (<1 µg/mL) . Putative MRR1(QG37_07783) 
sequencing unveiled three mutations: N167K, G280R and N647T. MRR1 mutations were always 
associated with ERG11 mutations and their role in azole resistance thus remains unclear. 
Conclusion: Overall, we identified two new mutations in ERG11 (V125A and F444L) within 
conserved hotspot regions. Moreover, we identified twenty mutations in TAC1-like that were 
associated with intermediate level of fluconazole resistance in the absence of ERG11 mutations. Their 
putative role in azole resistance deserves further investigations. 
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Comparison of phenotypic and genotypic methods of speciation and gene sequencing of 
Malassezia from the skin samples in a tertiary care hospital 
N. Romald1, A.J. Kindo2, M. Veeraragavan3 
1Department Of Microbiology, Sri Ramachandra Institute of Higher Education and Research, 
Chennai, India, 2Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, 
Chennai, India, 3Dermatology, Sri Ramachandra Medical College and Research Institute, Chennai, 
India 
Objectives: Speciate Malassezia phenotypically. Confirm the phenotypic identification through 
molecular method of speciating Malassezia by PCR and Gene Sequencing. Comparison between 
phenotypic and genotypic result. 
Methods: Malassezia species was isolated from the skin scrappings of patients with hypo/hyper 
pigmented lesions .Microscopic Examination was done with 10%KOH. Samples showing meat ball 
and spaghetti appearance were cultured onto Sabourauds Dextrose Agar (SDA), SDA with olive oil 
overlay (SDA-O) and Modified Dixon’s agar (MDA) containing chloramphenicol and incubated at 
32o C upto 3 weeks. Phenotypic Identification Was done based on the colony growth characteristics, 
gram staining, urease test, catalase test, bile esculin with tween 60 hydrolysis and tween assimilation. 
Molecular Identification The isolates which were cultured and identified by phenotypic methods were 
confirmed by Molecular methods DNA was extracted by Phenol: Chloroform method. Extracted 
DNA was amplified by Polymerase chain reaction (PCR) using thermocycler Primers used Pan-fungal 
PCR primers:- PCR amplification of ITS1 and ITS4 regions ITS1 5΄ TCC GTA GGT GAA CCT GCG G 
3΄ and ITS4 5΄ TCC TCC GCT TAT TGA TAT GC 3΄ Malassezia specific nested primers Pan fungal 
PCR positive samples were subjected to species specific nested PCR using Malassezia specific primer 
ITSIF-N 5΄GGATCATTAGTGATTGCCTTTATA 3΄ and ITS4-R 5΄ TCCTCCGCTTATTGATATG 3΄ 
Agarose Gel Electrophoresis was done and band obtained PCR products were sequenced by 
Sanger’s sequencing and NCBI blast was done and species identified. 
Results: Phenotypic method of speciation of Malassezia Out of 31 samples 7 isolates were Malassezia furfur 
12 isolates were Malassezia sympodialis 9 samples grew Malassezia globosa 3 samples grew Malassezia 
obtusa MOLECULAR IDENTIFICATION Pan-fungal PCR PCR by Pan fungal primers ITS 1 and ITS 4 
shows band between 600-1000bp (fig). All samples showing positive band was subjected to Malassezia 
specific nested PCR. Malassezia specific nested PCR Malassezia specific nested PCR using Malassezia 
specific primers showed band at 200-300bp.(fig) Sequence result(table) 
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Conclusion: Phenotypic speciation showed Malassezia sympodialis as the predominant species 
Genotypic speciation showed Malassezia furfur as the predominant species and the least was 
Malassezia sympodialis. Genotypic speciation is more confirmatory than phenotypic method 
Speciation of Malassezia is important because of variation in resistant pattern to anti-fungals among 
different species. 
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First molecular characterization of Uruguayan Cryptococcus spp clinical isolates. 
E. Cabeza, Z. Arteta, L. Betancor 
Montevideo, Hygiene institute, Faculty of medicine, University of the Republic, Montevideo, 
Uruguay 
Objectives: To characterize Uruguayan Cryptococcus spp isolates from meningoencephalitis by PCR 
fingerprinting and MLST. 
Methods: Clinical isolates Our laboratory receives clinical samples from fungal infections. From the 
analyzed period, between 1th of January of 2000 and 31th of december of 2015, 55 strains of 
Cryptococcus spp were selected to be studied. Phenotypic identification was performed in all cases. 52 
C. neoformans complex and 3 C.gattii complex, were recovered from cerebrospinal fluid (CSF) samples 
(n = 51), bornquioloalveolar lavage (n = 2), blood culture (n = 1) and pleural effusion (n = 1). 
Characterization by PCR fingerprinting Molecular type was determined by PCR fingerprinting as 
previously described (Meyer 1993). The specific sequence used was the one from wild-type M13 
minisatelite phage (5-GAGGGTGGCGGTTCT-3). PCR fingerprint patterns were assigned according 
to the main bands of the band pattern of the reference strains. MLST (Mutilocus sequence type) and 
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phylogenetic analysis. MLST analysis was performed by the individual application of the six 
housekeeping genes CAP59, GPD1, LAC1, PLB1, SOD1 and URA5 along with the IGS1 region 
according as previously described (Meyer 2009). The allele types and the sequence type (ST) were 
identified via sequence comparisons with the Cryptococcus MLST database. The allelic profile of the 
strains and the global dataset were applied to the goeBURST algorithm in PHILOVIZ software. Clona 
complex (CC) was defined when the strain had no more than one difference in housekeeping gene 
allele. Statistical analysis X2 and Fischer's exact test were performed for categorical variables and 
student's T test for continuous variable. 
Results: Molecular types Of a total of 55 clinical isolates, molecular types were identified in 50, in the 
5 remaining the pattern of bands is reproducible but not concordant with the patterns of the 
references strains. Three of them corresponded to C.gattii complex. 28 (56,0%) isolates were 
C.neoformans var grubii, VNI (now C. neoformans), 16 (32,0%) were C.neoformans var neoformans, VNIV 
(now C. deneoformans), 6 (12 %) were VNIII AD hybrids. The strains that were not identified by PCR 
fingerprinting were studied by MLST. MLST (Mutilocus sequence type) and phylogenetic analysis. 
20 strains selected by their genetic variability and phenotipic characterization were analyzed by 
MLST. 7 different allele were identified for CAP59, 4 for GPD1,11 for LAC1, 7 for PLB1, 5 for SOD1, 
7 for URA5 and 8 for IGS1 region. A total of 16 ST were observed, 13 C. neoformans complex isolates 
and 3 STs for 3 C. gattii complex isolates (Table 1). Of the 13 STs corresponding to C. neoformans complex, 
8 were not reported until now and were included in the database (ST605, ST606, ST607, ST608, ST609, 
ST610, ST611 and ST612). The more frequent ST were ST32 (n = 3), ST23 (n = 2), ST63 (n = 2). 
 
 
Conclusion: This is the first molecular characterization of Uruguayan isolates of Cryptococcus spp 
from cases of meningoencephalitis. We demonstrated the great genetic variability of circulating 
Cryptococcus spp strains in our environment that cause meningoencephalitis. The new STs reported 
are closely related with each other and with the rest of the STs, although they did not belong to the 
same CC. 
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Identification of genetic mediator of fluconazole tolerance in Candida albicans 
E. Delarze1, E. Trachsel1, L. Brandt1, C. D'Enfert2, D. Sanglard1 
1Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, 
Switzerland, 2Pasteur Institute, Paris, France 
Objectives: Fluconazole (FLC) resistance in Candida albicans has long been reported and is 
involving several well described molecular resistance mechanisms. FLC resistance is based on 
measurement of MIC values and threshold values have been provided to distinguish between wild-
type susceptible isolates and resistant isolates. Another phenomenon, called FLC tolerance (known 
also as “trailing effect” is susceptibility assays) is characterized by the ability of C. albicans to grow 
persistently at supra-MIC drug concentrations without acquisition of drug resistance. Little is known 
about molecular mechanisms behind FLC tolerance and we aimed here to undertake identification of 
genetic mediators of FLC tolerance. 
Methods: We used in this study a collection of 579 C. albicans strains, each of which could 
overexpress a specific C. albicans gene in a tetracycline-dependent manner and was tagged by a 
distinct sequence barcode. The whole collection was pooled in RPMI and, after repeated subcultures 
under FLC pressure at 32 µg/ml for 5 consecutive days in RPMI with 2% glucose, the relative 
population of each barcode was determined by barcode sequencing. In addition, each barcoded strain 
was subjected to single tolerance assays yielding tolerance indexes reflecting relative growth of 
strains at a single drug concentration (8 µg/ml FLC) after 24 h growth in RPMI in 2% glucose (growth 
conditions similar to EUCAST susceptibility assays). 
Results: Combining this genetic selection with single isolates testing, two transcription factors 
(CRZ1 and GZF3) and a protein kinase (YCK2) were confirmed to be positive mediators of FLC 
tolerance when overexpressed. CRZ1 s part of the calcineurin pathway that is known critical for C. 
albicans in response to antifungal stress, while GZF3 and YCK2 are less well characterized. Using 
overexpression of these genes in deletion mutants, we showed that GZF3 acts probably upstream of 
CRZ1. CRZ1 and GZF3 were deleted in azole-susceptible clinical strains but exhibiting different 
levels FLC tolerance. Our results demonstrate that CRZ1 plays a critical role in FLC tolerance in 
these strains while GZF3 deletion has minor effects. Consistent with these data, transcriptional 
profiles of clinical strains in the presence of FLC at supra-MIC drug concentrations was reminiscent 
of a calcineurin-like transcriptional response. 
Conclusion: A genetic screen permitted the identification of mediators of FLC tolerance, one of which 
(CRZ1) is known to be part of the calcineurin pathway. FLC tolerance of clinical strains is dependent 
on the presence of at least CRZ1. The precise mechanisms of FLC tolerance mediated by CRZ1 and 
the other identified genes still need further investigations. 
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Genotypic characterization of Trichosporon sp. from a Tertiary care centre in South India 
T. Premamalini1, S.V. Rajyoganandh2, H. Veena2, R. Vijayakumar2, A.J. Kindo2, S.K.M. Rungmei3, K.S. 
Sridharan2, B. Vijayalakshmi4 
1Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, chennai, India, 
2Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India, 
3Microbiology, SG-PGI Lucknow, Lucknow, India, 4Infecious Disease Consultant, SIMS, Chennai, 
India 
Objectives: To determine the species distribution of the Trichosporon sp. based on genotypic 
characterization. To assess the genetic relatedness of the most commonly isolated Trichosporon asahii 
strains using RAPD primers GAC1 and M13. 
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Methods: Seventy two Trichosporon clinical isolates recovered from patients of SRMC & RI, a few 
hospitals in Chennai, and a hospital in Lucknow, were considered for the study. PCR was performed 
initially with Trichosporon genus specific primers to double check for accurate identification of this 
genus. Genotypic characterization was done by PCR amplification of rRNA gene sequences by T. 
asahii specific primers which identified only T. asahii isolates. Species confirmation was done by IGS1 
sequencing and phylogenetic analysis. Maximum parsimony clustering was used for construction of 
phylogenetic tree. Its stability was assessed by parsimony bootstrapping with 1,000 pseudo 
replications. Phylogenetic analysis was done by comparing the obtained nucleotide sequences with 
the nucleotide sequences of Trichosporon reference strains obtained from the GenBank database. DNA 
fingerprinting of the T. asahii isolates was carried out by RAPD analysis, using primers GAC-1 and 
M13. 
Results: Distribution of sample source of the 72 isolates were as follows: 43 (59.7%) urine, 12 (16.7%) 
blood, 7 (9.7%) Percutaneous nephrostomy (PCN) tube, 5 (6.9%) respiratory isolates, 4 (5.6%) pus, 
and 1 (1.4%) peritoneal dialysate fluid. Trichosporon specific PCR confirmed all the 72 isolates as 
belonging to this genus. Trichosporon asahii specific PCR identified 65 isolates as T. asahii (Fig. 1). The 
remaining 7 isolates were identified further by phylogenetic analysis of the IGS1 sequences. In 
phylogenetic analysis, six representative T. asahii clinical isolates clustered together with T. asahii 
KR265116.1 and T. asahii KR872659.1 (bootstrap >95), confirming the molecular identification results. 
One isolate identified as Trichosporon species clustered in the same clade (bootstrap >79) was found 
to be closely related to T. ovoides. All these isolates belonged to the Ovoides clade. Two isolates 
clustered along with T. loubieri AB066428 & T. loubieri KT936593.1 (bootstrap >99). They belonged to 
the Gracile clade. The remaining 4 isolates clustered together in Cutaneum clade along with T. 
cutaneum AB 066415.1 (bootstrap >47) (Fig. 2). Finally, the 72 Trichosporon clinical isolates were 
identified as 65 Trichosporon asahii, 4 Trichosporon cutaneum, 2 Trichosporon louberi and one Trichosporon 
sp. closely related to T. ovoides. DNA fingerprinting of the mostly commonly isolated T. asahii (64/72) 
isolates carried out by RAPD analysis, identified more heterogeneity among the T. asahii isolates by 
GAC1 than M13 primer. 
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Conclusion: Trichosporon asahii is the most common species causing human trichosporonosis, though 
other members of the genus may also be involved. The members of the genus Trichosporon are most 
frequently under-reported due to inconsistency of the phenotypic methods used routinely in most 
laboratories. Trichosporon infections when treated with fluconazole or caspofungin, which is 
commonly used to treat yeast infections, results in poor clinical outcome. Hence, correct identification 
of the Trichosporon species using molecular methods, helps the clinician in providing appropriate 
treatment. 
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The lung mycobiome and the domestic environment 
E. Rubio-Portillo1, D. Orts2, E. Llorca2, C. Fernández3, C. Ferrer4, B. Gálvez5, V. Esteban6, E. Revelles4, 
C. Pérez-Martín4, E. Gómez-Imbernón4, J. Adsuar4, P. Piqueras4, B. Amat5, J. Antón1, M.F. Colom4 
1Physiology, Genetics And Microbiology, University of Alicante, San Vicente del Raspeig, Spain, 
2Pneumology, Hospital General Universitario de Elda, Elda, Spain, 3Pneumology, Hospital General 
Universitario de Alicante, Alicante, Spain, 4Medical Mycology Lab, University Miguel Hernandez, 
Sant Joan d'Alacant, Spain, 5Pneumology, Hospital Universitario del Vinalopó, Elche, Spain, 
6Pneumology, Hospital Clínico Universitario de Valencia, Valencia, Spain 
Objectives: The goal of the study was to assess the relationship between the fungal mycobiome 
detected in samples from the Lower Respiratory Tract (LRT) of non -infectious patients, and the 
mycobiota detected in the air and dust of their dwellings. 
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Methods: The mycobioma of the LRT was analysed by the study of Bronchoalveolar Lavage (BAL) 
samples taken from patients with indication of bronchoscopy. After informing and getting their 
consent for the study, they were asked about the possibility of a domestic sampling that was 
scheduled. Negative controls were included for every laboratory procedure and samples from the 
bronchoscopes were also taken as controls. All samples were processed for DNA extraction and for 
cultures. The fungal Internal Transcribed Spacer (ITS2) of the extracted DNA was amplified and 
sequenced by the illumina system. Results of the massive sequencing were analyzed by QIIME 1.8.0 
and compared with the ones in the UNITE Database. NCBI nucleotide database was also used for 
identification. Cultures of samples were incubated at room temperature and 37ºC and the fungal 
isolates were studied for identification. 
Results: Forty-six BAL, 4 samples from bronchoscope and 19 domestic environmental (MA) samples, 
together with a negative control from the PCR were submitted to massive sequencing analysis 
(Solexa/Illumina system). The first results yielded over 7000000 sequences (5060431 from BAL, 108178 
from bronchoscopes and 10861275 from MA samples). In order to filter contaminants, we used a 
negative control from PCR and three negative controls from each sequencing run. Samples were 
clustered in different fungal Operational Taxonomic Units (OTUs) at 99% identity and sequences 
clustered in OTUs present in control samples were remove from the analysis. After contaminant 
filtering, we obtained 2840808 clean sequences belonging to 122 different fungal Operational 
Taxonomic Units (OTUs) at 97% identity. The similarity among different microbial communities was 
assessed using phylogenetic information. Among the fungal species detected by massive sequencing, 
6 OTUs were detectable in more than 75% of the BAL and 75% of the MA samples. These sequences 
corresponded to Cladosporium angustisporum; Candida orthopsilopsis; Rhodotorula mucilaginosa; 
Cryptococcus neoformans sensu stricto; Naganishia liquefaciens and Malassezia restricta. Most of these 
species could be detected also by culture in the domestic environment, but almost none in BAL 
samples cultures. When comparing the mycobiome of the LRT of patients with the one of their 
domestic environment, important coincidences can be seen for specific species of Candida, 
Cryptococcus and Malassezia. 
Conclusion: The results show an important similarity between the mycobiota of the environment 
and the mycobiome of the LRT samples of the patients. Most of the fungal species detected in both 
environments correspond to fungi which are important opportunistic pathogens like Cryptococcus 
neoformans and Candida orthopsilosis. 
 
P396 
Identification of Mycotoxigenic Fungi from Grains in a Nigerian Region Using the Modern 
Polyphasic Methodology. 
O.F.I. Okeke1, S.O. Fapohunda2, C. Soares3, N. Lima4, G.M. Ayanbimpe1 
1Medical Microbiology, University of Jos, Plateau State, Nigeria, 2Bioscience And Biotechnology, 
Babcock University, Ogun State, Nigeria, 3Centre Of Biological Engineering, Micoteca da 
Universidade do Minho, University of Minho, Campus of Gualtar,, Braga, Portugal, 4Centre Of 
Biological Engineering,, Micoteca da Universidade do Minho, University of Minho, Campus of 
Gualtar, Braga, Portugal 
Objectives: Mycotoxins are poisonous substances produced by mycotoxigenic fungi which 
contaminate agricultural commodities. Many foods and feeds can become contaminated with 
mycotoxins since they can form in commodities before harvest, during the time between harvesting 
and drying, and in storage. Mycotoxins may also be carried over to animal products due to 
consumption of contaminated feed. Maize (Zea mays) and guinea corn (Sorghum bicolor) form a major 
staple of the study area and are high risk commodities for contamination with mycotoxigenic fungi. 
This study was carried out to identify mycotoxigenic fungi from maize and guinea corn in Plateau 
state, north-central of Nigeria. 
Methods: In a multistage sampling technique, markets for the study were selected. Using simple 
random sampling method, 270 samples were collected from various sampling points within selected 
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markets where these grains are sold. Isolation and identification of the mycotoxigenic fungi 
employed the modern polyphasic methodology for filamentous fungi identification. 
Results: The mycotoxigenic fungi Aspergillus, Fusarium, and Penicillium were isolated. Further work 
on these mycotoxigenic fungal genera identified them as follows: A. niger, A. aculeatus, A. tamari, A. 
flavus, F. verticillioides and F. equiseti. The Penicillium isolate was identified to belong to the section 
Sclerotiora and closely related to P. malochii. Aspergillus accounted for 75% of all mycotoxigenic fungi 
isolated while Fusarium and Penicillium accounted for 23% and 2% respectively. 
Conclusion: Further work is also ongoing to determine if our strain of Penicillium is a P. malochii or 
an entirely novel species. Our findings indicate contamination of maize and guinea corn in the study 
area with mycotoxigenic fungi which may pose serious health risks for the human and animal 
population and also have implications for food safety and public health in Nigeria. In view of this, 
further investigation is necessary to assess the health risks linked with the consumption of these 
grains. Key words: Mycotoxigenic fungi, grains, Nigeria 
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Regulation of DNA repair machinery and Ras pathway in Paracoccidioides brasiliensis during 
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W. Batista1, M. Navarro2, D. Castilho2, J. Calado2, P. Conceição1, B. Castro1, R. Silva2, A. Chaves2 
1Pharmaceutical Sciences, Universidade Federal de São Paulo, São Paulo, Brazil, 2Microbiologia E 
Imunologia, UNIFESP, São Paulo, Brazil 
Objectives: Paracoccidioidomycosis is a granulomatous disease caused by fungi of the genus 
Paracoccidioides and widely distributed in Latin America. The disease has high disabling potential and 
yet is still absolutely neglected. These fungi undergo cell differentiation induced by changes in 
temperature and this event is critical to the ability to cause disease. The knowledge of which 
molecular patterns of the fungus may be true virulence factors is still limited by the difficulties 
inherent to genetic manipulation of these fungi. Studies that have tried to understand these molecular 
aspects rely on the method of transformation mediated by Agrobacterium tumefaciens. To overcome 
these barriers, we need to understand the mechanisms of DNA repair used by the fungus. This is 
because the establishment of a knockout strain depends on the occurrence of homologous 
recombination events. The aim of the present communication was to evaluate the role of the DNA 
repair machinery of P. brasiliensis in response to oxidative stress. 
Methods: P. brasiliensis yeast cells were treated with different concentrations of H2O2, in the presence 
or absence of pharmacological inhibitors (Ras, Hog-1 or DNA ligase 4 pathways). We used the RBD-
GST (Ras Binding Domain fused with GST) probe to detect the Ras activation and western blot to 
evaluate the Hog-1 phosphorilation levels. Gene expression was analyzed by qRT-PCR. Cell viability 
were assessed by MTT assay or cell counting. 
Results: The double-strand breaks repair pathways communicate with the Ras GTPase and Hog1 
Map kinase pathways. The genes PbRAD51 and PbRAD52 are active elements during DNA repair 
and participate in the response to oxidative stress in P. brasiliensis. In addition, inhibition of the non-
homologous end joining (NHEJ) mediated repair pathway has been observed to provide a protective 
response to P. brasiliensis yeasts during a normally lethal oxidative stress condition for the fungus. 
Perhaps, this event is related to the greater efficiency of the repair by homologous recombination 
induced by the inhibition of NHEJ. Finally, it was observed that the combination of the damping of 
the NHEJ pathway, through the inhibition of DNL4 or GSK3, together with the induced oxidative 
stress do increase the efficiency of transformation processes in yeasts of P. brasiliensis. Indeed, 
inhibitors of NHEJ pathway caused a protective effect on yeast cells challenged with high 
concentration of H2O2. This effect correlates with an increase in expression of scavenger genes like 
catalase and superoxide dismutase. 
Conclusion: Taken together, our results indicate that there is a significant crosstalk between two 
major cellular damage response pathways, ROS signaling and DNA repair, for P. brasiliensis survival. 
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Matched-paired analysis of patients treated for invasive mucormycosis - standard treatment vs. 
posaconazole new formulations (MoveOn) 
J. Salmanton-Garcia1, D. Seidel1, P. Köhler1, S. Mellinghoff1, H. Wisplinghoff2, J.-J. Vehreschild1, O.A. 
Cornely1, M.J.G.T. Vehreschild1 
1Department I Of Internal Medicine, University Hospital of Cologne, Cologne, Germany, 2Antibiotic 
Resistance, Molecular Epidemiology, Labor Wisplinghoff, Cologne, Germany 
Objectives: Current first-line (1st) antifungal treatment for invasive mucormycosis (IM) consists of 
liposomal amphotericin B (AMB). Salvage (SAL) treatment options are limited and often based on 
posaconazole oral suspension (POSsusp). However, with the approval of posaconazole new 
formulations (POSnew), patients could benefit from improved pharmacokinetics, safety and 
tolerability. Therefore,our aim is to assess the effectiveness of POSnew as first-line and SAL 
treatments for IM. 
Methods: We performed a case-matched analysis with proven or probable IM patients from the 
FungiScope®  Registry. 1st-POSnew and 1st-AMB+POSnew cases were matched with 1st-AMB-based 
treatment controls, and SAL-POSnew cases were matched with SAL-POSsusp controls. Each case was 
matched with up to three controls based on severity, haematological/oncological malignancy, surgery 
and/or renal dysfunction. 
Results: Five patients receiving first-line POSnew alone, 18 receiving first-line POSnew combined with 
AMB, and 22 receiving salvage POSnew were identified. By day 42, favourable response was reported 
for 80.0% (n = 4/5) of patients receiving first-line POSnew, for 27.8% (n = 5/18) receiving first-line 
POSnew plus AMB, and for 50.0% (n = 11/22) receiving salvage POSnew. Day-42 all-cause mortality 
of patients receiving POSnew was lower compared to mortality in their respective controls (20.0% (n 
= 1/5) in 1st-POSnew vs. 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew vs. 52.0% 
(n = 26/50) in 1st-AMB; 0.0% (n = 0/22) in SAL-POSnew vs. 4.4% (n = 2/45) in SAL-POSsusp). 
Conclusion: In the observed patients, POSnew was effective in terms of treatment response and 
associated mortality of IM. POSnew may be an alternative for treatment of IM. 
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Efficacy of Celecoxib solely or in combination with Itraconazole in the treatment of murine 
paracoccidioidomycosis 
E. Burger1, L.A. Santos1, J.C. Grisolia1, N.A. Dias1, F.B.D.A. Paula2, A.M. De Oliveira3, A.M. 
Rodrigues4, Z.P.D. Camargo4 
1Department Of Microbiology And Immunology, Federal University of Alfenas, Alfenas, Brazil, 
2Department Of Clinical And Toxicological Analysis - Pharmaceutical Sciences Faculty, Federal 
University of Alfenas, Alfenas, Brazil, 3Laboratory Of Pathology - José Do Rosário Vellano University, 
UNIFENAS, Alfenas, Brazil, 4Department Of Microbiology, Immunology And Parasitology, Federal 
University of Sao Paulo, Sao Paulo, Brazil 
Objectives: Our objective is to evaluate the effectiveness of Celecoxib, of Itraconazole and both, as a 
combined treatment for paracoccidioidomycosis, a highly prevalent granulomatous mycosis in Latin 
America using a murine model. 
Methods: Mice were intraperitoneally infected with a virulent P. brasiliensis isolate and three days 
later, daily administration by gavage of either 3mg/mL Itraconazole (I), or 6mg/mL Celecoxib (C) or 
both 3mg/mL Itraconazole and 6mg/mL Celecoxib (I+C) was initiated and kept for 15 days. Controls 
included infected, non-treated mice (Pb) and non-infected mice. Body weight and survival rate were 
monitored daily. At 7 and 15 days of infection, delayed type hypersensitivity (DTH) was evaluated 
and serum was obtained for specific anti-P. brasiliensis IgG antibody determination. At the last day of 
treatment, the mice were sacrificed and spleen, lungs, liver and epiploo/pancreas were collected and 
their macroscopic characteristics were analyzed. Following, the organs were either processed and 
stained with H/E for general histology, or macerated, for quantification of viable fungi. 
Results: There was no difference in the body weight of infected, treated or uninfected controls and 
there were no deaths registered during this early phase of the infection in mice from any group. In 
all experimental groups, DTH decreased from day 7 to day 15 and, in contrast, specific IgG titers 
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increased from day 7 to day 15. But At 15 days, both, DTH reactivity and IgG titers were the highest 
in the Pb group, lower in the I group and in the C group, and the lowest in the I+C group. This 
decrease in both cellular and humoral specific immunity in the groups most treatment-covered may 
be explained by the elimination of viable P. brasiliensis by the drugs, rendering a full immune 
response less necessary. The histological aspects demonstrated that treatment with I+C was the one 
that reduced the most the number of lesions and the severity of the granulomatous response in all 
organs. When analyzing the control of fungal growth in the tissues, both mice from the I and from 
the C groups showed less fungi scattered in the tissue than mice from the Pb group; however the 
lowest numbers of fungi were found in mice from the I+C group. In the epiploo, which is the organ 
of shock for this model of P. brasiliensis infection, the animals of the I+C group had the fewest fungi 
with preserved morphology. The same was found in terms of viable fungi, as the number of CFUs 
was lower in all organs of treated mice, and more markedly in those receiving the combined I+C 
therapy. 
Conclusion: We showed the effect of the antifungal drug Itraconazole and also of the anti-
inflammatory drug Celecoxib at the tissue level. This is the first report of the direct effect of Celecoxib 
on P. brasiliensis as well as in combination with Itraconazole. Our results suggest that this combined 
treatment employing an antifungal and an anti-inflammatory drug may constitute a new efficient 
therapeutic strategy. Grants: CNPq 305216/2016-3 and FAPEMIG APQ 012941-16. L.A. Santos and 
J.C. Grisolia are recipient of CAPES scholarships. 
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Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the 
Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI study 
G. Thompson1, D. Angulo2 
1Infectious Disease, University of California at Davis, Davis, United States of America, 2SCYNEXIS, 
Inc., Jersey City, United States of America 
Case Report: Objectives: Intraabdominal candidiasis is the second most common Candida infection 
after candidemia. Candida albicans is the predominant cause of these infections, with non-albicans 
Candida becoming more frequently observed in this clinical setting. Echinocandins are the 
recommended treatment for intraabdominal Candida infections but have varied clinical response. 
This is postulated to be based on poor drug levels in tissue and abscesses. Ibrexafungerp (formerly 
SCY-078) is a novel IV/oral glucan synthase inhibitor (triterpenoid) antifungal with activity against 
Candida, Aspergillus and Pneumocystis. A Phase 3 open-label, single-arm study of oral ibrexafungerp 
(FURI; NCT03059992) is ongoing for the treatment of patients intolerant of or with fungal disease 
refractory to standard antifungal therapy. We present a patient case of retroperitoneal abscess caused 
by Candida krusei from the FURI study. Methods: A 71 year old male patient with ischemic stroke, 
pulmonary edema, and tracheostomy was being treated for a retroperitoneal abscess, a complication 
of a perforated duodenal ulcer. Candida krusei was isolated in peri-duodenal drain cultures and the 
patient was initiated on micafungin therapy for 21 days. During micafungin therapy, cultures from 
the peri-duodenal drain on three occasions remained positive for Candida krusei. The patient 
underwent abscess drainage and was enrolled into the FURI study due to micafungin treatment 
failure and was treated with oral ibrexafungerp 750mg BID for two days followed by 750mg daily. 
Results: The patient was treated with oral ibrexafungerp therapy for 21 days. Clinical improvement 
was observed during therapy. At End of Treatment visit, the clinical signs and symptoms of fungal 
disease were considered by the investigator to be resolved and the physical exam noted minimal 
discharge from the patient’s retroperitoneal drain. As of the 6-week follow-up visit, clinical signs and 
symptoms of infection were still resolved. No drug-related adverse events were reported. 
Conclusion: This case report shows the potential of oral ibrexafungerp to treat intraabdominal 
infections caused by Candida krusei in patients who fail echinocandin therapy. Continued enrollment 
in the FURI study is warranted. 
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In vitro study of Antifungal Biopharmaceutical Dectin1-Fc 
L. Lim 
Bioprocessing Technology Institute/National University of Singapore, Singapore, Singapore 
Objectives: Invasive fungal infections are a neglected category of disease that has a high mortality 
and implicated in immunocompromised patients. Dectin-1 (CLEC7A) is a type II transmembrane C-
type lectin pattern recognition receptor expressed on cells of the innate immune system like 
macrophages, monocytes and neutrophils that recognizes β-glucans through its single C-type lectin-
like domain at its extracellular region. It functions by binding to cell walls of different fungal species, 
such as Saccharomyces cerevisiae, Candida albicans, Pneumocystis carinii, Coccidioides posadasii, and 
Aspergillus fumigatus; triggering immune cell responses like phagocytosis and cytokine production. 
The absence of β-glucans in human cells presents the opportunity to exploit Dectin-1 as therapeutic 
vehicle to enhance immune response during a fungal infection. This project aims to develop 
recombinant Dectin1-Immunoglobulin G1 Fc fusion protein as a potential biopharmaceutical for 
passive immunization to aid the innate immune system against Candida albicans fungal infection. 
The in vitro properties of the recombinantly expressed fusion protein are examined in this study. 
Methods: The fusion protein was expressed in DG44 Chinese Hamster Ovarian (CHO) cells and 
amplified with methotrexate. The fusion protein was extracted from culture supernatant via GE 
Histrap histag affinity and purified with GE Superdex 200 size exclusion chromatography on a GE 
Akta Purifier FPLC. Immunofluorescence imaging with anti-Fc Alexa Fluor 568 conjugated antibody 
from ThermoFisher Scientific was used to assay binding of the fusion protein to unicellular or hyphae 
Candida albicans. Binding affinity of the Fc fusion protein versus a human IgG1 to Fcγ receptors from 
R&D Systems were screen by surface plasmon resonance on a GE Biacore T200. 
Results: Immunofluorescence imaging shows the fusion protein capable of binding to Candida 
albicans both in the unicellular and hyphae morphology. Surface plasmon resonance study of the Fc-
fusion protein versus a IgG1 control reveal that the fusion protein binds to FcγRI, FcγRIIIa and FcRn. 
However, the binding constants for the Fc-fusion is generally weaker than a full fledge IgG1 antibody. 
Activity testing of the fusion protein using THP-1 monocytes against unicellular Candida albicans in 
a 1 hr phagocytosis assay shows a dose response. For the highest dose of 100μg/ml of fusion protein, 
a reduction of greater than 50% of surviving Candida albicans cells compared to the untreated control 
was observed. 
Conclusion: The in vitro results reveal that the respective domains of the Fc-fusion protein function 
as intended though binding to the Fc receptors are not as strong as an antibody. This in turn may 
affect the efficacy of the drug. Further testing with primary immune cells would be appropriate to 
study the full therapeutic potential of this fusion protein. In addition, in vivo studies with an 
appropriate mouse model will give a better picture of the performance of the Fc-fusion protein drug. 
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The in vitro effect of farnesol on the activity of voriconazol and amphotericin B against 
Aspergillus isolates 
Y. Oz1, S. Onder2, G. Durmaz2 
1Department Of Microbiology, Division Of Mycology, Eskisehir Osmangazi University Medical 
Faculty, Eskisehir, Turkey, 2Department Of Microbiology, Eskisehir Osmangazi University Medical 
Faculty, Eskisehir, Turkey 
Objectives: Although new antifungal agents are being developed, there is an increasing resistance to 
standard antifungal therapy, and no new classes of antifungal agents have been approved for a long 
time. Currently, three antifungal drug classes including triazoles, polyenes and echinocandins are 
available to use in treatment of IFIs. However, treatment is often complicated due to their high 
toxicity, low tolerability, drug interactions and limited spectrums of activities. Therefore, the 
requirement of new drug or treatment alternatives especially those with a wider spectrum, lower 
toxicity and cheaper are increasing day by day. Farnesol is an extracellular quorum-sensing molecule 
producing by C.albicans and inhibits the yeast-to-hypha transition in C.albicans and blocks biofilm 
formation. FAR is also a sesquiterpene alcohol existing in many herbal products and exogenously 
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FAR inhibits the conidiation in Aspergillus niger and the germination of macroconidia in Fusarium 
graminearum. However, the number of studies assessing the antifungal efficacy of FAR with 
standardised methods is limited. In this study, we investigated the contribution of farnesol on the 
activity of antifungals such as voriconazole and amphotericin B against clinical Aspergillus isolates. 
Methods: Clinical Aspergillus isolates, A.fumigatus (n = 30) and A.flavus (n = 15), were included in this 
study. The MIC values of antifungal drugs and farnesol were determined against all Aspergillus 
isolates using reference broth microdilution method (CLSI M38-A2). The interactions of farnesol with 
voriconazole and amphotericin B were investigated by the checkerboard method and evaluated 
based on the fractional inhibitor concentration index (FICI). The FICI was obtained by summing the 
FIC values of each drug; the FIC was calculated for each agent by dividing the inhibitory 
concentration of each antifungal or compound when used in combination by its MIC. Synergy was 
defined as a FICI of ≤ 0.5; no interaction was defined as a FICI > 0.5 but < 4; and antagonism was 
defined as a FICI ≥ 4. 
Results: The MIC ranges of farnesol, voriconazole and amphotericin B were 1500-6000 µM, 0.125-1 
µg/mL and 0.125-0.5 µg/mL against A.fumigatus isolates, 3000->6000 µM, 0.125-0.5 µg/mL and 0.25-2 
µg/mL against A.flavus isolates, respectively. The most common interaction in combination tests was 
“no interaction” and synergistic interaction was not detected in any combination. The combination 
of farnesol with voriconazole had antagonistic activity against 13 of 31 A.fumigatus isolates with FICI 
values of 4.01 to 8.5, and 4 of 14 A.flavus isolates with FICI values of 4.03 to 5. Similarly, the 
combination of farnesol with amphotericin B had antagonistic activity against 7 of 31 A.fumigatus 
isolates with FICI values of 4.01 to 8.03, and 5 of 14 A.flavus isolates with FICI values of 4.5 to 10. 
Conclusion: Antifungal activity of farnesol and synergistic interaction when it was combined with 
antifungal drugs have been reported against Candida spp and its biofilm. However, farnesol did not 
produce any significant inhibitor activity alone or any synergistic interaction in combination with 
voriconazole or amphotericin B against Aspergillus isolates in this study. Conversely, considerably 
antagonistic interaction was observed; 38% for farnesol with voriconazole combination, 27% for 
farnesol with amphotericin B combination. 
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Olorofim is potent against Madurella mycetomatis – the most common causative agent of 
Eumycetoma 
W. Lim1, M. Konings1, B. Rijnders1, A.H. Fahal2, M. Birch3, W. Van De Sande1 
1Department Of Microbiology And Infectious Diseases, Erasmus Medical Center, Rotterdam, 
Netherlands, 2Mycetoma Research Center, University of Khartoum, Khartoum, Sudan, 3F2G Ltd, 
Manchester, United Kingdom 
Objectives: Madurella mycetomatis is the main causative agent of eumycetoma, a chronic 
granulomatous infection of the subcutaneous tissue. Currently, the only antifungal agents with 
activity against M. mycetomatis are agents acting on ergosterol in the fungal cell membrane. 
Itraconazole is currently the drug of choice, but the duration of treatment is long and therapeutic 
failure is common. Therefore, there is an urgent need to identify more potent antifungal agents with 
activity against M. mycetomatis. One of the novel classes of antifungal agents are the orotomides and 
olorofim is the leading representative of this class. It inhibits fungal pyrimidine biosynthesis and it is 
currently being evaluated for invasive fungal infections in patients lacking treatment options. To 
determine if olorofim has in vitro activity against M. mycetomatis, we carried out MIC determinations 
against 21 M. mycetomatis clinical isolates with different genetic and geographical background and 
compared the results to those obtained for itraconazole. 
Methods: Minimal inhibitory concentrations (MIC) were determined for Olorofim and Itraconazole 
against 21 M. mycetomatis clinical isolates from Sudan (14), Algeria (1), Mali (1), India (1), Chad (1), 
the Netherlands (1) and also from an unknown origin (2). The filamentous nature of M. mycetomatis 
necessitates the need for homogenization of inoculum by sonication to obtain a standardized 
inoculum for testing. This creates turbidity in the wells in an MIC test which complicates visual 
reading of the antifungal activity, tests were therefore read using XTT as a colorometric agent to 
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indicate growth. MICs was performed using our CLSI-based in vitro susceptibility testing method 
with XTT reading at 450nm at the end after a 7-day incubation period at 37˚C. As a number of M. 
mycetomatis isolates produces pigments that influences colour intensity and the endpoint reading, an 
80% reduction in viable fungal mass was determined instead of a 100%. 
Results: We showed that olorofim was highly active against all tested M. mycetomatis isolates. MICs 
obtained for olorofim ranged from <0.004 μg/ml to 0.125 μg/ml and 0.06 μg/ml olorofim was needed 
to inhibit 90% of the isolates (see results in Table). Olorofim MICs were consistently one-dilution 
more potent than the MIC values for itraconazole. For itraconazole, MICs ranged from 0.008 µg/ml 
to 0.25 μg/ml and 0.125 μg/ml was needed to inhibit 90% of the isolates. 
 
Conclusion: Our study showed that M. mycetomatis can also be inhibited with antifungal agents with 
a different mode of action to the azoles. Olorofim from the novel antifungal class of orotomides 
showed potent in vitro activity against all tested M. mycetomatis isolates and had MICs similar to or 
slightly lower than those for itraconazole - the current drug of choice for therapy. Further studies, 
including in vivo models are warranted to determine if olorofim would be a suitable alternative to 
itraconazole therapy. 
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Inhibiting fungal BET protein: a new hope to treat systemic fungal infections 
S. El Kennani1, S. Picaud2, M. Champleboux1, J. Marais1, M. Courçon3, M. Arlotto1, G. Rabut4, P. 
Filippakopoulos2, J. Govin1 
1Signaling Through Chromatin, INSTITUTE FOR ADVANCED BIOSCIENCES, GRENOBLE, France, 
2Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of 
Oxford, Oxford, United Kingdom, 3Biologie à Grande échelle, CEA, Grenoble, France, 44. Institute of 
Genetics and Development, Rennes, France 
Objectives: Invasive fungal infections kill an estimated 1.6 million people each year – as many deaths 
as are caused by tuberculosis or malaria. Currently, only four drug classes are available to treat these 
infections (polyenes, azoles, flucytosine and echinocandins). This limited repertoire of antifungal 
drugs, combined with an alarming rise in drug-resistant fungal strains, has created an urgent need 
for novel therapeutic agents. In the developed world, the most common fungal disease among 
hospitalized patients is invasive candidiasis. Among Candida species, C. albicans and C. glabrata rank 
first and second in isolation frequency, respectively, accounting for ~70% of all systemic candidiasis. 
This project investigates new antifungal strategies that target the BET family of transcriptional 
regulators in these Candida species. The fungal BET protein Bdf1 contains two bromodomains (BDs) 
and an extra-terminal domain (ET). We recently established the proof of concept that small-molecule 
inhibition of Bdf1 BDs compromises the viability and virulence of C. albicans (Mietton et al., Nature 
Communications 2017). 
Methods: This project focuses on the ET domain and is based on a combination of genetics, medicinal 
chemistry, structural biology and biochemistry studies. 
Results: It shows that the ET domain is essential for the survival of C. albicans and C. glabrata in vitro. 
Furthermore, we identified a specific groove on the ET domain and demonstrate that it is also 
essential for growth, paving the way for the potential discovery of selective inhibitors. 
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Conclusion: To conclude, epigenetic targets remain largely unexplored in the fungal infection field. 
Our investigation of Bdf1 as a therapeutic target represents a novel and highly promising area of 
exploration in the antifungal field. 
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Efficacy of intravenous posaconazole for the treatment of azole-resistant invasive aspergillosis 
A. Seyedmousavi1, J. Kwon-Chung2, R.J.M. Brüggemann3, P.E. Verweij4 
1Department Of Laboratory Medicine, Microbiology Service, National Institutes of Health Clinical 
Center, Bethesda, United States of America, 2Laboratory Of Clinical Immunology And Microbiology, 
National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America, 
3Pharmacy, RadboudUMC, Nijmegen, Netherlands, 4Medical Microbiology, RadboudUMC, 
Nijmegen, Netherlands 
Objectives: Azole antifungals play a prominent role in the management of patients with invasive 
aspergillosis (IA). However, azole resistance is a growing problem in patients with aspergillus 
infection , which translates into treatment failure. Alternative treatments with new formulations of 
azolesmay improve therapeutic outcome in IA even for the clinical cases caused by strains with low 
susceptibility to currently available azoles. 
Methods: The in vivo efficacy of 0.25, 1, 4, 16 and 64 mg/kg/day recently introduced intravenous 
formulation of posaconazole (POS)was assessed in mice (CD-1 strain) infected with a wild type (POS 
MICEUCAST, 0.031mg/L) and azole-resistant Aspergillus fumigatus(POS MICEUCAST, 0.5 mg/L) harboring 
TR34/L98H mutation in Cyp-51A gene. Efficacy of POS treatment was assessed by tissue 
histopathology 3 days post infection and monitoring of survival for 14 days following intravenous 
inoculation. 
Results: The survival curves for all control groups receiving 0.9% saline intravenously showed 100% 
mortality. The efficacy of POS treatment at the dosing regimens ≤4 mg/kg/day depended on the MIC 
of each isolate. However,the maximum effect (100% survival at day 14 post infection) was achieved 
with a POSdose of ≥ 16 mg/kg for both wild-type and TR34/L98H mutant isolates, and 
histopathological slides revealed limited number of inflammatory foci with or without detectable 
fungal elements in the Kidneys. The Hill-type model with a variable slope fitted the relationship 
between the dose and 14-day survival well, with R2values of 0.99 for the wild type, and 0.95 for the 
TR34/L98Hisolate. The 50% effective dose (ED50) based on survival was 0.89 mg/kg (95% confidence 
interval [CI], 0.59 to 1.4 mg/kg) for the wild type, and 4.5 (95% CI, 2.1 to 7.6 mg/kg) for the 
TR34/L98Hisolate. 
Conclusion: Overall, treatment with intravenous formulation of POS improved the survival of the 
mice in a dose-dependent manner. A dose-response relationship was observed regardless of the 
underlying azole-resistance mechanism. These results show intravenous formulation of POS to be a 
promising therapeutic agent for treatment of azole-resistant IA. 
 
P409 
Anti-Candida activities of carvacrol, cinnamaldehyde, citral and thymol liposomes 
K. Miranda-Cadena1, M. Dias2,3, A. Costa-Barbosa2,3, T. Collins2,3, C. Marcos-Arias1, E. Eraso1, G. 
Quindós1, P. Sampaio2,3 
1Inmunología, Microbiología Y Parasitología, Universidad del País Vasco/Euskal Herriko 
Unibertsitatea UPV/EHU, Bilbao, Spain, 2Centre Of Molecular And Environmental Biology (cbma), 
Department Of Biology, University of Minho, Braga, Portugal, 3Institute Of Science And Innovation 
For Bio-sustainability (ib-s), University of Minho, Braga, Portugal 
Objectives: To develop and characterize carvacrol, cinnamaldehyde, citral and thymol-loaded 
DODAB:MO nanoparticles, to test their cytotoxicity on murine macrophages and to evaluate their 
anti-Candida activities in vitro. 
Methods: Encapsulation was made using monoolein-based liposomes of DODAB:MO in a 1:2 molar 
ratio. DODAB:MO liposomes were prepared using thin lipid-film hydration method Concentrations 
tested were 32, 64 and 128 mg/L of carvacrol and thymol; 16, 32 and 64 mg/L of cinnamaldehyde and 
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64, 128 and 256 mg/L of citral. Mean size (nm), polydispersity (PDI) and surface charge (ζ-potential) 
were evaluated with Malvern ZetaSizer Nano ZS particle analyser (Malvern, UK). Encapsulation 
efficiency (%EE) was determined by HPLC-DAD, after separation by ultacentrigugation. Antifungal 
activities of encapsulated and non-encapsulated phytocompounds (Sigma-Aldrich, USA) was 
evaluated by microdilution against eight Candida albicans, one Candida auris, Candida dubliniensis, 
Candida tropicalis and C. albicans reference strain SC5314. Cytotoxicity was assayed on murine 
macrophage-like cell line RAW 264.7 by detection of cell metabolic activity by the reduction of MTT 
to formazan and lactate dehydrogenase activity (LDH) assay. 
Results: Nanoparticles of 128 mg/L of carvacrol and thymol presented high %EE (70.8 and 69.1%, 
respectively) without loss of anti-Candida activity. Geometric means of MICs of carvacrol and thymol 
nanoparticles were 101.6 mg/L and 71.8 mg/L, respectively. Nanoparticles of 256 mg/L of citral 
presented the best %EE (83.3%), but they did not present antifungal activity. Cinnamaldehyde 
nanoparticles presented the lowest %EE (20.6 to 44.1%) and maintained their antifungal activity. All 
nanoparticles were stable during four weeks stocked at 4 ºC, with PDI values < 0.6 and ζ-potential 
among + 46.9 to + 55.6 mV. Thymol nanoparticles were the biggest with a particle size of 580.3 ±17.4 
nm, followed by cinnamaldehyde, carvacrol and citral nanoparticles (567.9 ± 13.9, 510 ± 9.6 and 497.6 
± 13.8 nm, respectively). Non-encapsulated 32 µg/mL of thymol and carvacrol showed less 
cytotoxicity levels (76.5% and 74.8% cell viability by MTT assay, respectively; and ≥ 80% by LDH 
assay), followed by citral 64 µg/mL with 68% by MTT assay and 92.9% by LDH. Thymol and carvacrol 
nanoparticles were the best tolerated by macrophages with a higher cell viability by MTT assay (83.5-
112.8% for thymol nanoparticles and 101-137% for carvacrol nanoparticles) when incubated with 18, 
36 and 72 µg/mL of thymol nanoparticles and 18 and 36 µg/mL of carvacrol nanoparticles. 
Conclusion: Monoolein-based liposomes of DODAB:MO (1:2) loaded with 128 µg/mL of carvacrol 
or 128 µg/mL of thymol can be a promising alternative of treatment of candidiasis, due to their 
striking physicochemical properties, appropriate encapsulation efficiencies, stability, reduced 
cytotoxicity and preserved anti-Candida activities. Work supported by Gobierno Vasco-Eusko 
Jaurlaritza (GIC15/78 IT-990-16) and the Federation of European Microbiological Societies by 
Research and Training grant (FEMS-GO-2017-020). 
 
P410 
In vitro antifungal effect of plant-based compound CIN-102 on filamentous fungi 
M. D'Agostino 
laboratoire SIMPA, Vandoeuvre-lès-Nancy, France 
Objectives: Today the increase of invasive fungal infections due to the rise of immunosuppressive 
therapies is a real problem especially in hospitals. Moreover, the emergence of resistant strains 
induces a therapeutic failure. Face to this issues, new classes of antifungals are expected. The plant 
kingdom thus represents an immense potential of natural resources to exploit for these purposes. The 
SEPTEOS company has recently developed the CIN-102 compound, by using cinnamaldehyde and 
potentiating compounds from two synergic essential oils of cinnamon. Cinnamaldehyde has already 
been describe to kill bacteria, yeast and molds growth in both growing and non-growing state (not 
published). The objective of this study is to determine the spectrum of activity of CIN-102 on the main 
genus or species of filamentous fungi involved in human pathology. 
Methods: The activity of CIN-102 product and its main constituent (cinnamaldehyde / CIN) are tested 
against a representative panel of strains of filamentous fungi (Aspergillus (n = 39), Fusarium (n = 19) 
and Scedosporium n = 21)) of clinical importance. Clinical and reference strains have been studied, 
comprising isolates characterized by innate or acquired antifungal resistance patterns. A 
determination of MICs (minimum inhibitory concentrations) was performed using the M38-A2 CLSI 
reference method. The observed antifungal effect was then characterized by determining an 
inoculum effect. 
Results: The MIC of CIN-102 determined for the different strains studied is mainly between 62 (n = 
28) and 125 (n = 30) ug / ml, similar to the MIC determined for main active. Strains of the genus 
Aspergillushave on average a slightly higher MIC compared to the genus Fusariumand Scedosporium: 
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MIC mainly to 125 μg / ml for Aspergillus (n = 23), and 62 μg / ml for Fusarium (n = 12) and 
Scedosporium(n = 12). Acquired resistance against azole antifungals (Aspergillus fumigatusTR46, TR34 
and G54E resistant strains) or innate (naturally antifungals resistant Scedosporium strains) do not 
seem to impact the effect of the compound CIN-102 and cinnamaldehyde. The inoculum as well as 
the time and dose dependent effect of CIN-102 and cinnamaldehyde will also be characterized. 
Conclusion: Although the MICs alone do not provide an opinion on the efficacy of CIN-102, these 
results already show the antifungal effect of the compound. The current results for CIN-102 are very 
close to those determined for cinnamaldehyde in our study but also in the literature (Homa et al., 
2015)(Essid et al., 2017). Further studies will then be conducted, notably on the structural aspect and 
the mechanism of action, to complete the knowledge on this new molecule. Moreover, an in vivo 
model of invasive fungal infection is studied to develop our knowledge about this new molecule. 
 
P411 
New strategies based on antifungal antibodies for the treatement of aspergillosis 
D. Chauvin1, M. Hust2, M. Schütte2, A. Chesnay1,3, C. Parent1, G.M.S.G. Moreira2, J.F. Arroyo4, A.B. 
Sanz4, P. Martineau5, M. Pugnière5, E. Bailly1, J. Chandenier1,3, N. Heuzé-Vourc'H1, G. Desoubeaux1,3 
1Cepr Inserm U1100, Université de Tours, Tours, France, 2Institut Für Biochemie, Biotechnologie und 
Bioinformatik, Technische Universität Braunschweig, Braunschweig, Germany, 3Parasitology - 
Mycology - Tropical Medicine, Hôpital Bretonneau, TOURS, France, 4Microbiología Y Parasitología, 
Universidad Complutense, Madrid, Spain, 5Institut De Recherche En Cancérologie De Montpellier, 
Université de Montpellier, Montpellier, France 
Objectives: Aspergillus fumigatus is an airborne opportunistic fungal pathogen responsible for severe 
infections. For instance, invasive pulmonary aspergillosis is a serious threat for individuals suffering 
from severe immunosuppression, with mortality rates > 50%. In parallel, allergic bronchopulmonary 
aspergillosis frequently encountered in cystic fibrosis patients, is also a comorbidity factor. In 
addition to diagnostic means lacking specificity, current treatments present a high toxicity which 
prevents their use in weakened subjects, resulting in impaired prognostic. Because of their low 
toxicity and high specificity, anti-infectious therapeutic antibodies could be a new alternative to 
conventional therapeutics. In this study, we investigated the potential of Chitin Ring Formation cell 
wall transglycosylases of A. fumigatus to be therapeutic targets for therapeutic antibodies. 
Methods: In vitro neutralization test, in vitro cultures, fluorescence and confocal microscopy, DNA 
sequencing, as well as flow cytometry and animal models were used. 
Results: We demonstrated that the Crf target was highly conserved, regardless of the 
pathophysiological context; whereas the CRF1 gene was found to be 100% conserved in 92% of the 
isolates studied, Crf proteins were expressed in 98% of the strains. In addition, we highlighted the 
role of Crf proteins in fungal growth, using a deletion mutant for CRF1 gene, for which a growth 
decrease of 23.6% was observed after 48 h. It was demonstrated that anti-Crf antibodies neutralized 
the enzymatic activity of recombinant Crf protein, and delayed fungal growth by 12.3% in vitro when 
added to spores. In a neutropenic rat model of invasive pulmonary aspergillosis, anti-Crf antibodies 
elicited a significant recruitment of neutrophils, macrophages and T CD4 lymphocytes but it was not 
correlated with a decrease of fungal burden in lungs and improvement in survival. 
Conclusion: Overall, our study highlighted the potential relevance of targeting Crf cell wall protein 
with therapeutic antibodies. 
 
P412 
Olorofim EUCAST susceptibility testing of contemporary moulds: in vitro activity and improved 
reproducibility 
M.C. Arendrup1,2,3, R. Datcu1, R. Hare1, K.M. Jørgensen1 
1Unit Of Mycology, Statens Serum Institut, Copenhagen, Denmark, 2Dept. Of Clinical Microbiology, 
Rigshospitalet, Copenhagen, Denmark, 3Dept. Of Clinical Medicine, University of Copenhagen, 
Copenhagen, Denmark 
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Objectives: Olorofim is a novel antifungal orotomide compound for which we previously 
demonstrated good in vitro activity against various moulds. This study sought to (a) investigate 
whether MIC variation observed for A. fumigatus (unimodal range <0.004–0.25 mg/L) was due to 
inherent MIC variation or true differences in susceptibility and (b) present EUCAST MICs for clinical 
mould isolates from 2018. 
Methods: MICs (mg/L) of olorofim were determined by EUCAST E.Def 9.3 using A. fumigatus ATCC 
204305 for QC. MIC variability study: Fifteen A. fumigatus strains were selected from the prior study, 
as follows: five low MIC isolates: MIC = ≤0.002 (n = 2) and MIC = 0.004 (n = 3); five middle MIC 
isolates: MIC = 0.03 (n = 2) and MIC = 0.06 (n = 3); and five high MIC isolates: MIC = 0.125 (n = 1) and 
MIC = 0.25 (n = 4). MICs were determined visually by two-three observers blinded to the original 
MIC. MICs against 365 clinical mould isolates were determined during 2018. For A. fumigatus 
olorofim activity was evaluated individually for itraconazole susceptible (MIC≤1) and non-
susceptible organisms (MIC>1). The ECOFFinder programme was used for determining statistical 
wildtype upper limits (highest MIC for organisms without phenotypically detectable acquired 
resistance mechanisms, WT-ULs) using 95%, 97.5% and 99% subset endpoints. For Fusarium isolates 
the 50%-MIC was also determined spectrophotometrically using 50% growth inhibition. 
Results: Repetitive testing of low, medium and high MIC A. fumigatus isolates resulted in MICs, 
which for 14/15 isolates fell within two dilutions, whereas 1/10 MICs for isolate #12 and 1/80 MICs 
for the control strain fell one dilution below the two-dilution range when read by observer 1. The 
modal MIC for low/middle/high MIC isolates were as follows for repeated testing: Observer 1 and 2: 
0.03/0.03/0.016 and for observer 3: 0.03/0.03/0.03. Routine testing during 2018 for species represented 
by ≥15 isolates generated uniform Gaussian MIC distributions spanning ≤5 dilutions with modal 
MICs = 0.03-0.06 for all isolates except non-proliferatum Fusarium spp. (n = 10) (Table). Modal MIC/WT-
UL for A. fumigatus was 0.06/0.125 and was unaffected by itraconazole susceptibility and choice of 
ECOFFinder endpoint. Olorofim displayed MICs ≤0.25 against less common Aspergillus spp. except 
A. montevidensis (n = 1) as well as against dermatophytes and other moulds including: Microsporum 
gypseum (n = 1), T. interdigitale (n = 1), T. rubrum (n = 12), Rasamsonia aegroticola (n = 1), Rasamsonia 
argillacea (n = 1), Scedosporium apiospermum (n = 3), Scedosporium boydii (n = 2). 50%-MICs for Fusarium 
were as follows: F. dimerum >8 (n = 2), F. oxysporum 0.06 (n = 1), F. solani complex MIC range 0.25-1, 
modal MIC 1 (n = 7), and F. proliferatum 0.03 (n = 1). 
 
Conclusion: Upon repeated testing of A. fumigatus isolates with initially low/medium/high MICs, no 
differences were observed. This suggests that the initial distribution observed can be explained by 
technical variation and that olorofim has similar and uniform activity against all isolates within the 
wild-type population. This was confirmed when evaluating results for routine MIC testing during 
2018. In conclusion, olorofim displayed promising in vitro activity against most moulds included in 
this study independent of azole susceptibility. 
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EUCAST susceptibility testing of manogepix and six comparative agents against contemporary 
Danish mould isolates 
M.C. Arendrup1,2,3, K.M.T. Astvad1, K.M. Jørgensen1 
1Unit Of Mycology, Statens Serum Institut, Copenhagen, Denmark, 2Dept. Of Clinical Microbiology, 
Rigshospitalet, Copenhagen, Denmark, 3Dept. Of Clinical Medicine, University of Copenhagen, 
Copenhagen, Denmark 
Objectives: The new antifungal fosmanogepix (APX001) is a first-in-class drug candidate and the 
methyl phosphate prodrug of the active moiety manogepix (APX001A). Manogepix targets the 
conserved fungal inositol acyltransferase enzyme Gwt1, thereby preventing GPI-anchored protein 
maturation and compromising fungal growth. Fosmanogepix is currently in Phase 2 clinical trials. 
Here we compared the in vitro activity of manogepix and six comparators against contemporary 
clinical mould isolates received for identification and EUCAST susceptibility testing. 
Methods: A total of 163 clinical mould isolates obtained Aug 2016 to Sep 2017 were included. 
Aspergillus isolates were identified to the species complex level except A. fumigatus that was identified 
sensu stricto using thermotolerance. EUCAST E.Def 9.3.1 reference method using cell-culture treated 
microtitre plates (Nunc, ThermoFisher Scientific, cat. no. 167008) were prepared using serial two-fold 
dilutions of manogepix, amphotericin B, isavuconazole, voriconazole, itraconazole and 
posaconazole. The plates were stored at -80°C for ≥24 h prior to inoculation. Susceptibility endpoints 
were determined visually as MECs for manogepix (the lowest concentration resulting in aberrant 
growth) as complete visual or 50% spectrophotometric growth inhibition were not observed (data 
not shown). For the comparators MICs were read visually according to the EUCAST definition at the 
lowest concentration giving complete growth inhibition. The ECOFFinder programme was used for 
determining a statistical single-centre manogepix wild-type upper-limit for A. fumigatus. 
Results: The manogepix MEC and comparator MICs are shown as modes (not done (ND) for isolates 
represented by five or fewer isolates) and ranges in the Table. Manogepix MECs were ≤0.125 mg/L 
against all Aspergillus and the two Fusarium isolates but no activity could be detected against the 
dermatophyte and three mucorales isolates included at the concentrations tested (MICs >0.5 mg/L). 
Manogepix in vitro activity remained the same against A. fumigatus isolates resistant to itraconazole 
(Table). Using the ECOFFinder programme, a single-centre wild-type upper-limit of 0.125 mg/L was 
determined for A. fumigatus (applying a 97.5% cut-off). 
 
Conclusion: Manogepix displayed uniform and potent in vitro activity against the different 
Aspergillus species and Fusarium isolates included in the study as determined by MECs. The in vitro 
activity was unaffected by acquired resistance in A. fumigatus. Thus, fosmanogepix appears to be a 
promising therapeutic against these pathogens, many of which are difficult to treat. 
 
P414 
Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST 
Antifungal Susceptibility Testing 
K.M. Jørgensen1, R. Hare1, A. Chowdhary2, M.C. Arendrup1,3,4 
1Unit Of Mycology, Statens Serum Institut, Copenhagen, Denmark, 2Department Of Medical 
Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India, 3Dept. Of Clinical 
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Microbiology, Rigshospitalet, Copenhagen, Denmark, 4Dept. Of Clinical Medicine, University of 
Copenhagen, Copenhagen, Denmark 
Objectives: Candida auris is a multidrug-resistant yeast rapidly emerging as a significant cause of 
nosocomial infections. Ibrexafungerp is a novel oral synthetic enfumafungin derivative inhibiting 
glucan synthase. It is active in vitro and in animal models against Candida, Aspergillus and 
Pneumocystis and is currently in clinical development for mucocutaneous and invasive fungal 
infections. Here, we investigate the susceptibility of C. auris to ibrexafungerp (formerly SCY-078) 
compared to that of eight comparators and compared to the activity against C. albicans and C. glabrata. 
Methods: EUCAST AFST according to E.Def 7.3.1 was performed for ibrexafungerp (Scynexis, Jersey 
City, NJ, USA) against 122 clinical C. auris isolates (from India (n = 120) and Oman (n = 2)) and three 
C. auris control strains JCM15448, KCTC17809 and KCTC17810. Sixteen Danish clinical C. albicans and 
16 C. glabrata isolates and the control strains C. albicans ATCC64548, C. krusei ATCC6258 and C. 
parapsilosis ATCC22019 were included as comparators and controls. Cell-culture treated microtitre 
plates (Nunc, Thermo Fisher Scientific, cat. no. 167008) were prepared using the ISO method. The 
ibrexafungerp MICs were compared to previously published MICs for anidulafungin, micafungin, 
amphotericin B, fluconazole, isavuconazole, itraconazole, posaconazole and voriconazole. 
Results: The in vitro activity of ibrexafungerp (IBX) against C. auris was uniform with MICs 
displaying a Gaussian distribution spanning 0.06-2 mg/L suggesting an equal efficacy across the 122 
isolates (Table). The modal MIC and MIC50 were 0.5 mg/L. For the C. auris reference strains, the MICs 
were 0.06 mg/L, 0.125 mg/L and 0.5 mg/L, respectively. The MIC ranges for nine repetitive MIC 
determinations of the control strains MICs were as follows: C. albicans ATCC 64548: 0.06 mg/L, C. 
krusei ATCC 6258: 0.5-1 mg/L and C. parapsilosis ATCC 22019: 0.125-0.5 mg/L respectively. In contrast, 
MIC distributions for anidulafungin (ANF), micafungin (MCF), isavuconazole (ISA), voriconazole 
(VOR), itraconazole (ITR) and posaconazole (PRC) against C. auris were wide (spanning 10-13 two-
fold dilutions) suggesting differential activity against the isolates. Of note, ibrexafungerp MICs 
remained low (MICs of 0.25 mg/L and 0.5 mg/L) for the isolates resistant to anidulafungin and 
micafungin (MICs >32 mg/L). Finally, fluconazole (FLU) MICs for all but one isolate were 16- >256 
mg/L suggesting almost universal fluconazole resistance whereas the amphotericin B (AMB) MICs 
clustered close to the non-species specific breakpoint of 1 mg/L. Next, ibrexafungerp activity was 
compared for C. albicans, C. glabrata and C. auris. MIC50, (range) were 0.06 mg/L (0.03-0.125 mg/L), 
0.25 mg/L (0.25-0.5 mg/L) and 0.5 mg/L (0.06-2 mg/L), respectively. 
 
Conclusion: Ibrexafungerp shows promising in vitro activity against C. auris suggesting it may be a 
welcomed therapeutic against this emerging threat with few treatment options. Ibrexafungerp’s 
MICs were in general one step higher against C. auris than against C. glabrata and, notably, remained 
unchanged against C. auris isolates with antifungal resistance to the comparator drugs, including 
those highly echinocandin-resistant. 
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In vivo efficacy of olorofim against systemic infection caused by Scedosporium apiospermum, 
Pseudallescheria boydii, and Lomentospora prolificans in neutropenic CD-1 mice 
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A. Seyedmousavi1, Y.C. Chang2, D. Law3, M. Birch3, J. Rex3, J. Kwon-Chung4 
1Department Of Laboratory Medicine, Microbiology Service, National Institutes of Health Clinical 
Center, Bethesda, United States of America, 2Laboratory Of Clinical Immunology And Microbiology, 
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United 
States of America, 3F2G Ltd, Manchester, United Kingdom, 4Laboratory Of Clinical Immunology And 
Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United 
States of America 
Objectives: Clinically relevant memebrs of the Scedosporium/Pseudallescheria species complex and 
Lomentospora prolificansare generally resistant to currently available systemic antifungal agents and 
the infection due to these species is difficult to treat. Alternative treatments with new classes of 
antifungals may improve therapeutic outcomes of the disease caused by these difficult to treat 
moulds. 
Methods: We studied the in vivoefficacy of olorofim (formerly F901318), a new fungicidal agent that 
prevents growth of manyascomycetous mold speciesvia inhibition of de novo pyrimidine 
biosynthesis, against scedosporiosis caused by three species in neutropenic CD-1 mice. 
Cyclophosphamide immunosuppressed mice infected by Scedosporium apiospermum, Pseudallescheria 
boydiiand Lomentospora prolificans(tail vein infection) were treated by intraperitoneal administration 
of olorofim (15 mg/kgevery 8 h for 9 days). The efficacy of olorofimtreatment was assessed by 
survival rate 10 days post infection, and tissue histopathology 3 days post infection. 
Results:In the neutropenic CD-1 mice,olorofim therapy significantly improved survival compared to 
the untreated controls; 80 %, 100 % and 100 % of treated mice survived infection by Scedosporium 
apiospermum, Pseudallescheria boydii, Lomentospora prolificans, respectively while less than 20% of the 
control mice (PBS-treated) survived at 10 days post infection. Furthermore, histopathological slides 
of kidneys revealed no detectable fungal elements in the olorofim-treated mice, whilst numerous 
fungal hyphae were present in control mice. 
Conclusion: Overall, treatment with olorofimimproved the survival of the mice infected with all 
three species causing scedosporiosis and showed rapid clearance of fungi from the kidney by 
histological staining. These results show olorofim to be a promising therapeutic agent for systemic 
scedosporiosis, a difficult disease to treat with currently available antifngals. 
 
P416 
APX001 (Fosmanogepix) is Effective in an Immunosuppressed Mouse Model of Fusariosis 
T. Gebremariam1, S. Alkhazraji1, Y. Gu1, A. Alqarihi1, Z. Mamouei1, K.J. Shaw2, A.S. Ibrahim1 
1Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, United States 
of America, 2Amplyx Pharmaceuticals, San Diego, United States of America 
Objectives: Fusariosis has high mortality rates. Owing to its rarity, comparative clinical trials are 
hard to perform. Animal models are an appropriate complementary avenue for evaluating antifungal 
therapy. Thus APX001 (fosmanogepix) was evaluated in an immunosuppressed murine model of 
hematogenously disseminated fusariosis. 
Methods: The minimum effective concentration (MEC) of APX001A (manogepix, the active moiety 
of APX001) was determined against a Fusarium solani clinical isolate using CLSI M38 method. ICR 
mice were immunosuppressed with cyclophosphamide and cortisone acetate on days -2, and +3, 
relative to intravenous infection with 7.5×104 cells of F. solani. For survival studies, treatment with 
placebo (diluent control), APX001 (78 or 104 mg/kg, PO), liposomal amphotericin B (LAmB, 15 mg/kg, 
IV), or voriconazole (Vori, 40 mg/kg, PO) began 16 h post-infection and continued for 8 days for 
APX001 or Vori and 4 days for LAmB. To extend the half-life of APX001, mice were administered 50 
mg/kg of the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) 2 h prior to APX001 
administration. Grapefruit juice in drinking water (50%) was given to Vori-treated mice to enhance 
the drug’s half-life. To assess tissue fungal burden, mice were sacrificed on Day +4 and organs 
processed for conidial equivalent (CE) by qPCR. 
Results: The APX001A MEC value for the tested F. solani strain was 0.03 μg/mL. Treatment with 
APX001 or LAmB enhanced median survival time vs. placebo (12, and 10 days for 78, and 104 mg/kg 
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of APX001, respectively vs. 10 days for LAmB treatment, vs. 8 or 7 days for Vori or placebo, 
respectively, P <0.01). Further, APX001 and LAmB treatments equally enhanced overall survival by 
day 21 when the experiment was terminated (40% for LAmB or APX001 at 78 mg/kg, and 20% for 
APX001 at 104 mg/kg, vs. 0% for placebo or Vori treatment). APX001 or LAmB treatments, but not 
Vori, resulted in ~2-3 log reduction in kidney, and brain CE vs. placebo. 
Conclusion: APX001A showed significant antifungal activity against F. solani in vitro which 
translated to in vivo efficacy. APX001 was as effective as LAmB in this mouse model of fusariosis. 
Continued investigation of APX001 as a novel antifungal agent against this difficult to treat infection 
is warranted. 
 
P417 
Evaluation of the In vitro Activity of Olorofim Against Fusarium Species 
N. Wiederhold1, H. Patterson1, M. Birch2, D. Law2, J. Rex2 
1Fungus Testing Laboratory, The University of Texas Health Science Center at San Antonio, San 
Antonio, United States of America, 2F2G Ltd, Manchester, United Kingdom 
Objectives: Invasive infections caused by Fusarium species are often associated with significant 
morbidity and mortality in highly immunocompromised patients, and treatment options are limited. 
Several species are often resistant to treatment with clinically available antifungals. Olorofim 
(formerly F901318; F2G Ltd.) is a member of the orotomide class of antifungal agents that inhibits 
fungal pyrimidine biosynthesis and has potent activity against a variety of filamentous fungi. We 
evaluated the in vitro activity of olorofim against a selection of various Fusarium isolates. The in vitro 
activity was also measured for the clinically available antifungals amphotericin B, posaconazole, and 
voriconazole. 
Methods: Clinical isolates (n = 111) of Fusarium species in the collection of the University of Texas 
Health Science Center Fungus Testing Laboratory were used. Susceptibility testing was performed 
by broth microdilution according the CLSI M38 reference standard. MICs for olorofim were 
determined after 48 hours of incubation using the 50% and 100% inhibition endpoint, while those of 
the control agents (amphotericin B, posaconazole, and voriconazole) were determined using the 100% 
inhibition endpoint. 
Results: Olorofim demonstrated in vitro activity against F. oxysporum (MIC range 0.125-0.25 mg/L 
and 0.5 – 1 mg/L at the 50% and 100% endpoints, respectively), F. fujikuroi (<0.015 mg/L and <0.015-
0.125 mg/L), F. verticillioides (0.06-0.125 mg/L and 0.06-0.25 mg/L), and F. proliferatum (<0.015->8 mg/L 
and 0.06->8 mg/L) (Table). At the 50% inhibition endpoint, olorofim demonstrated in vitro activity 
against some isolates of the F. solani species complex (FSSC, now members of the genus Neocosmospora 
0.5->8 mg/L) and the F. incarnatum-equiseti species complex (FIESC, 0.25->8mg/L). In contrast, when 
the 100% inhibition endpoint was used, limited to no in vitro activity was observed against these 
species complexes (4->8 mg/L), nor was activity observed against F. dimerum using either endpoint 
(>8 mg/L). Olorofim activity against some of the rarer species of Fusarium was mixed, with the growth 
of some species being inhibited at low MICs (i.e., F. brachygibbosum, F. decemcellulare, F. redolens, and 
F. thapsinum; 0.06-0.25 mg/L at 50% inhibition and 0.25-0.5 mg/L at 100% inhibition). In contrast, 
limited to no activity was also observed against other rarer species (i.e., F. delphinoides, F. nygamai, F. 
pallidoroseum, F. petroliphilum, and P. pseudensiforme; 0.25-8 mg/L at 50% inhibition and >8 mg/L at 
100% inhibition). The MIC ranges for the control agents were also wide and differed across Fusarium 
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species. The most consistent activity was observed with amphotericin B. 
 
Conclusion: Olorofim demonstrated in vitro activity against some clinical isolates of Fusarium species. 
This activity appeared to be species-dependent, and was also dependent on the endpoint used (50% 
vs. 100% inhibition of growth). Further worked is needed to determine how the in vitro activity 
observed against Fusarium species in this study may translate into in vivo efficacy, especially for more 
common species for which there were differences between the activity of olorofim at the different of 
growth inhibition endpoints. 
 
P419 
Nanoparticles as antimicrobial agent against Scytalidium hyalinum and Neoscytalidium 
dimidiatum 
B. De Almeida1, T. Lemes1, M. Almeida2, D. Volanti1 
1Unesp, São José do Rio Preto, Brazil, 2FAMERP, São José do Rio Preto, Brazil 
Objectives: The present study aimed to evaluate the antifungal activity of silver-based 
nanocomposites (NCs) deposited in hydroxyapatite (HAP), after synthesis by microwave, against 
clinical strains of Scytalidium hyalinum and Neoscytalidium dimidiatum. 
Methods: The analysis was performed with Ag/HAP NCs (4 and 8% Ag) and pure Ag to evaluate the 
minimum inhibitory concentration to kill Scytalidium hyalinum and Neoscytalidium dimidiatum, 
according to CLSI M27-S4 with modifications considering, in triplicate. The fungi strains were 
maintained in RPMI broth culture media after overnight incubation at 37°C, and each inoculum 
adjusted according to 0.5 MacFarland standard tube. In 96-well plates, 100 µL of RPMI with fungal 
inoculum was added and NCs were dispersed into the 10% dimethyl sulfoxide (DMSO) - ranging 
from 1000 to 7.8 µg/mL. The plates were incubated for 24 hours. After growth, the cell viability was 
conducted by enzymatic reduction using triphenyl tetrazolium chloride (TTC). 
Results: The highest antifungal activity was seen for 8% Ag/HAP NCs against Scytalidium hyalinum 
and Neoscytalidium dimidiatum with MIC 250 µg/ml. In addition, the pure Ag showed the worst 
antifungal activity with a MIC 1000 µg/mL for Scytalidium hyalinum and MIC 250 µg/mL for 
Neoscytalidium dimidiatum. 
Conclusion: This study contributes to the knowledge of interactions between nanocomposites and 
fungal cell, as potential target of control infection caused by Scytalidium hyalinum and Neoscytalidium 
dimidiatum. It is clear the occurrence of the synergistic effect of Ag/HAP NCs in relation to pure Ag, 
event that must be considered, once HAP is biocompatible and could reduce the toxicity of Ag. 
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APX001 (Fosmanogepix) is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae 
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1Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, United States 
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Objectives: Mucormycosis is a life-threatening infection that predominantly occurs in 
immunocompromised hosts. The antifungal APX001A (manogepix) inhibits Gwt1, an enzyme 
required for the conserved glycosylphosphatidyl inositol (GPI) post-translational modification in 
eukaryotes. We previously reported the activity of APX001 (fosmanogepix, the prodrug of APX001A) 
against Rhizopus delemar (minimum effective concentration [MEC] = 0.25 µg/mL). Here we assessed 
the activity against R. oryzae, which has an elevated MEC value. 
Methods: R. oryzae 99-892 MIC and MEC values were 0.125 µg/mL and 4.0 µg/mL for isavuconazole 
(ISAV) and APX001A, respectively. ICR mice were immunosuppressed with cyclophosphamide (200 
mg/kg) and cortisone acetate (500 mg/kg) on Days -2, +3, and +8 relative to intratracheal infection 
with 2.5 x 105 cells of R. oryzae 99-892. For survival studies, treatment with 104 mg/kg APX001 was 
compared to ISAV (110 mg/kg TID). Oral treatment started on Day +1 through Day +7, relative to 
infection for survival studies, and through Day +4 for tissue fungal burden studies (assessed by 
conidial equivalent [CE] using qPCR). Placebo mice received vehicle control. To extend the half-life 
of APX001, mice were administered 50 mg/kg of the cytochrome P450 inhibitor 1-aminobenzotriazole 
(ABT) 2 h prior to APX001 administration. 
Results: APX001 and ISAV equally prolonged median survival time of mice (n = 20) versus placebo 
(12 and 14 days for APX001 and ISAV, respectively, vs. 8 days for placebo). Further, APX001 and 
ISAV treatment both resulted in 30% 21-day survival versus 0% survival of placebo mice (P <0.05 by 
Log Rank test). Both drug treatments resulted in ~1.5 log10 reduction in lung and brain CE vs. placebo-
treated mice (n = 10, P <0.005 by Wilcoxon Rank Sum). 
Conclusion: Despite a higher MEC value, APX001 showed significant efficacy against R. oryzae that 
was as protective as ISAV in immunosuppressed mice. Given the previously reported activity of 
APX001 against a strain of R. delemar with a lower MEC value, APX001 has now been shown to be 
efficacious against both species of Rhizopus, which together are responsible for ~60-70% of isolates 
causing lethal mucormycosis. Thus, continued investigation of APX001 against mucormycosis is 
warranted. 
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S. Alkhazraji1, T. Gebremariam1, A. Alqarihi1, Y. Gu1, K.J. Shaw2, A.S. Ibrahim1 
1Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, United States 
of America, 2Amplyx Pharmaceuticals, San Diego, United States of America 
Objectives: Scedosporiosis has high mortality rates. Owing to its rarity, comparative clinical trials 
are hard to perform. Animal models are an appropriate complementary avenue for evaluating 
antifungal therapy. Thus, APX001 was evaluated in an immunosuppressed murine model of invasive 
scedosporiosis. 
Methods: The minimum effective concentration (MEC) of APX001A (the active moiety of APX001) 
was determined against 9 clinical isolates of Scedosporium apiospermum, S. boydii and Lomentospora 
prolificans using CLSI M38 methodology. ICR mice were immunosuppressed with cyclophosphamide 
and cortisone acetate on days -2, and +3, relative to intratracheal infection with 3.0×107 cells of S. 
apiospermum. For survival studies, treatment with placebo (diluent control), APX001 (26, 52, 104, or 
156 mg/kg, po), or liposomal amphotericin B (LAmB, 10 mg/kg, iv) began 16 h postinfection and 
continued for 7 or 11 days for APX and 4 days for LAmB. To extend the half-life of APX001, mice 
were administered 50 mg/kg of the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) 2 h prior 
to APX001 administration. To assess tissue fungal burden, mice were sacrificed on Day +4 and organs 
processed for conidial equivalent (CE) by qPCR. 
Results: The APX001A MEC value for all tested isolates was 0.03 μg/mL. Treatment with ABT alone 
or LAmB, did not enhance survival of mice infected with S. apiospermum vs. placebo mice (n = 20 or 
30). Treatment with APX001 at 26, 52, 104 or 156 mg/kg for 7 days enhanced median survival time vs. 
placebo (10, 12, 11, and 15 days for 26, 52, 104, and 156 mg/kg arms, respectively vs. 7 days for placebo, 
P<0.001). Further, APX001 treatment enhanced overall survival by day 21 when the experiment was 
terminated (30%, 40%, and 40%, respectively for 26, 52 or 156 mg/kg vs 10% for placebo). Survival 
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after treatment with APX001 for 7 days or 11 days was not different. All APX001 treatments resulted 
in ~2 log reduction in lung, brain and kidney CE. 
Conclusion: APX001A is cidal against S. apiospermum, S. boydii and L. prolificans in vitro. APX001 
protected immunosuppressed mice from scedosporiosis due to S. apiospermum. Continued 
investigation of APX001 as a novel antifungal agent against scedosporiosis is warranted. 
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1Biotechnology Institute, Universidad Nacional de Colombia, Bogotá D.C., Colombia, 2Biological 
Sciences, Universidad de los Andes, Bogotá D.C., Colombia, 3Chemical Engineering, Universidad de 
los Andes, Bogotá D.C., Colombia 
Objectives: Malassezia pachydermatis is a lipophilic and lipid-dependent yeast, that is part of the 
microbiota in domestic and wild animals’ skin. However, it could be associated with otitis in canines 
and bloodstream infections in humans. Diseases caused by M. pachydermatis frequently exhibit 
chronic and recurrent clinical course, and the current antifungal therapy based on azoles is associated 
with increased resistance as well as significant side effects. Genome sequencing, metabolic network 
reconstruction, and gene essentiality analyses have been performed, allowing to identify fifteen 
candidates as therapeutic targets such as homoserine dehydrogenase (HSD), homocitrate synthase 
(HCS) and saccharopine dehydrogenase (SDH). These enzymes participate in the pathways of L-
lysine or L-threonine biosynthesis, which have been reported as antibacterials and with antifungal 
effect. To assess the impact of these amino acids over the growth of Malassezia pachydermatis we 
evaluated the inhibition of HCS and SDH by L-lysine and HSD by L-threonine based on the feedback 
control, we additionally conducted in vitro susceptibility tests. 
Methods: Recombinant proteins were expressed in Escherichia coli and purified to determine 
enzymatic activity through spectrophotometry detection of corresponding cofactors. Moreover, in 
vitro susceptibility tests using a modified CLSI M27-A3 method and agar diffusion assays were 
performed. The concentrations tested were (μg/ml) from 1500 to 4000 using Sabouraud dextrose 
broth (SDB) with tween 40 and tween 60. 
Results: Therefore, the results of our study showed L-lysine 1 mM and 75 mM were able to inhibit 
the enzymatic activity of HCS and SDH, respectively while L-threonine 1 mM inhibited the activity 
of HSD. Lysine and threonine showed to be competitive inhibitors affecting the substrate-enzyme 
complex (SE) formation. For L-lysine reduction in turbidity was observed at 3100 µg/mL by 
microdilution method. In addition, agar diffusion showed a diameter of inhibition of 13 mm using 
50 mg/mL. On the contrary, L-threonine did not display inhibitory activity in M. pachydermatis at 50 
mg/mL as the maximum allowed concentration to be evaluated. 
Conclusion: This study provides evidence that these three enzymes are efficiently regulated by the 
feedback of the final product of their corresponding metabolic pathway. L-lysine is a potent inhibitor 
for M. pachydermatis, possible for saturation of metabolic pathways and accumulation of high levels 
of L-lysine that generate toxicity and amino acids starvation in the cell. L- lysine will be considered 
as a potential antifungal/fungal static candidate. For L-threonine it is necessary to evaluate higher 
concentrations. 
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The effect of the orotomide antifungal olorofim on the growth and viability of Scedosporium and 
Lomentospora species. 
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Objectives: Olorofim is the first member of the new orotomide class of systemic antifungals acting 
through inhibition of fungal DHODH. Olorofim is active against all species of Aspergillus tested to 
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date including cryptic species. In addition, there is activity against a wide range of filamentous fungi 
including Scedosporium, Paecilomyces and endemic moulds. Scedosporium and Lomentospora species 
represent some of the most clinically challenging fungal infections often showing resistance to 
currently available antifungal agents. Previously olorofim has been shown to be highly active in vitro 
against a range of Scedosporium species and the closely related multidrug-resistant species 
Lomentospora prolificans (Wiederhold et al 2017, Biwas et al 2018). In this study we examined the effects 
of olorofim on isolates from the Scedosporium complex at a cellular level using microscopy and 
viability dyes. 
Methods: In vitro MICs were undertaken using standard CLSI methodology. Images of the bottom 
of each well were obtained using a Leica SP8X confocal microscope. Studies on viability were carried 
out by allowing conidia to germinate for 8h and then exposing to olorofim at the MIC concentration 
for up to 120h. The viability dye DiBAC was used to determine cell death following exposure to 
olorofim over time. 
Results: Olorofim MICs for S. apiospermum 451 and L. prolificans 206 were both determined to be 0.25 
µg/mL. Imaging of microtitre wells above and below this MIC value showed that olorofim 
dramatically reduced growth of both S. apiospermum 451 and L. prolificans 206 at concentrations 
several dilutions below the MIC value. DiBAC staining was conducted with one of the study strains 
(L. prolificans 206) and showed that hyphae began to take up the dye after 24h and that the uptake 
increased steadily over time. When observations were stopped at 120h, >90% of hyphae had taken up 
DiBAC and were non-viable. 
Conclusion: Olorofim demonstrated time-dependent killing of L. prolificans hyphae, consistent with 
previous observations with Aspergillus spp. Microscopic analysis of olorofim treated S. apiospermum 
and L. prolificans cultures, demonstrated profound effects on growth even at concentrations below 
the MIC level. 
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Objectives: Current antifungal agents cover a majority of opportunistic fungal pathogens; however, 
breakthrough invasive fungal infections continue to occur and increasingly involve relatively 
uncommon yeasts and/or moulds that tend to exhibit decreased susceptibility to current agents. 
APX001A (manogepix) is a first-in-class small molecule inhibitor of the fungal Gwt1 enzyme that is 
required for acylation of inositol during glycosylphosphatidylinositol (GPI) anchor biosynthesis. It is 
active against the major fungal pathogens: Candida (except C. krusei), Aspergillus, and hard-to-treat 
moulds, including Fusarium and Scedosporium. In this study, we tested APX001A, anidulafungin 
(ANF), micafungin (MCF), fluconazole (FLU), and others against 1,706 contemporary clinical fungal 
isolates collected worldwide during 2017. 
Methods: A total of 1,706 non-duplicate fungal isolates were collected from 68 medical centers in 
North America (37.3%), Europe (43.4%), Asia-Pacific (12.7%), and Latin America (6.6%). Among the 
isolates tested, 78.5% were Candida spp, 3.9% were non-Candida yeasts, including 30 Cryptococcus 
neoformans var. grubii (1.8%), 14.7% were Aspergillus, and 2.9% were other moulds. All isolates were 
tested by CLSI reference broth microdilution methods. 
Results: APX001A (MIC50/90, 0.008/0.06 µg/mL) was the most active agent tested against Candida 
isolates (Figure); corresponding ANF, MCF, and FLU MIC90 values were 16- to 64-fold higher. 
Similarly, APX001A (MIC50/90, 0.25/0.5 μg/mL) was ≥8-fold more active than ANF, MCF, and FLU 
against C. neoformans var. grubii. Against Aspergillus, AXP001A (MIC50/90, 0.015/0.03 µg/mL) was 
comparable in activity to ANF and MCF. APX001A (MIC90, 0.06 μg/mL) was ≥128-fold more active 
than ANF and MCF against Scedosporium isolates. 
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Conclusion: APX001A demonstrated potent in vitro activity against 1,706 fungal isolates, including 
echinocandin- and fluconazole-resistant strains. The extended spectrum of APX001A was also 
notable for its potency against many less common, yet antifungal-resistant, strains such as Candida 
auris, A. lentulus, A. ustus, Fusarium solani species complex, and Scedosporium. Further studies are 
needed to demonstrate the utility of APX001A in difficult-to-treat resistant fungal infections. 
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Objectives: Rezafungin is a novel echinocandin with favourable safety and pharmacokinetic 
characteristics, which allows for high drug exposures and once-weekly dosing. Epidemiological cut-
off values (ECOFFs) of rezafungin have not yet been established. We determined the in vitro activity 
of rezafungin and four comparators against contemporary Nordic clinical isolates of Candida and 
other yeasts and established single centre wildtype upper limits (WT-UL). Subsequently, these WT-
UL were used to evaluate rezafungin susceptibility for clinical isolates from the completed part A of 
STRIVE, the phase 2 trial of rezafungin for treatment of candidaemia and invasive candidiasis 
(NCT02734862). 
Methods: 1,249 clinical isolates (19 Candida, 13 other yeast species) from Denmark, Norway and 
Sweden received at the Danish mycology reference laboratory in 2017-18 were identified using 
CHROMagar, matrix-assisted laser desorption ionization–time of flight mass spectrometry and, 
when needed, internal transcribed spacer sequencing. EUCAST E.Def 7.3.1 susceptibility testing 
included rezafungin, anidulafungin, micafungin, amphotericin B and fluconazole. WT-UL were 
established following EUCAST principles for visual and statistical ECOFF value setting for 
rezafungin and for comparators against species without EUCAST ECOFFs, allowing classification as 
wildtype or non-wildtype. The FKS target genes were sequenced for echinocandin non-wildtype 
isolates. 
Results: Rezafungin MIC distributions for the most common Candida species and modal MICs for 
rezafungin and comparators are shown in Table 1. Rezafungin had species-specific in vitro activity 
similar to that of anidulafungin and micafungin. At a mg/L basis rezafungin was overall less active 
(modal MICs ≥ 2 two-fold dilutions higher) than anidulafungin and micafungin, but equally or more 
active than fluconazole and amphotericin B, except against C. parapsilosis, other Candida 
(amphotericin B only) and other yeasts. Rates of rezafungin non-wildtype isolates among the most 
common Candida species were <3%, only marginally higher than for amphotericin B and lower than 
for fluconazole, anidulafungin and micafungin (Table 2). We identified 27 (2.0%) echinocandin non-
wildtype isolates: C. albicans (n = 11, 1.9%), C. glabrata (n = 11, 3.3%), C. tropicalis (n = 2, 2.7%), C. 
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dubliniensis (n = 2, 2.9%) and C. krusei (n = 1, 1.2%). Alterations in Fks1 and/or Fks2 hot-spots (or within 
±3 amino acids) were found in 20 of 25 sequenced non-wildtype isolates: Fks1: C. albicans: D648Y, 
P1354P/S (2), P1354S (3), R1361R/S, R1361G; C. tropicalis: F650S and S654P; C. dubliniensis: S645P (2); 
C. krusei: S659F. Fks2: C. glabrata: S663P (2), S663F (3). Fks1+Fks2: C. glabrata: S663F/L630Q and 
L664Q+Y658N+premature stop-codon. The rezafungin MICs for non-wildtype isolates were 0.25–2 
mg/L. Rezafungin susceptibility testing of 95 Candida blood isolates from the STRIVE trial yielded 
MIC distributions comparable to those for the Nordic clinical isolates (Table 1). One C. rugosa isolate 
had an MIC of >8 mg/L, suggesting intrinsic resistance, and one C. glabrata isolate had an MIC of 0.5 
mg/L, but no mutations in FKS target genes. 
Conclusion: Rezafungin displayed broad in vitro activity with a species-specific susceptibility pattern 
similar to that of other echinocandins. WT-UL were suggested for the most common species. Few 
non-wildtype strains with alterations in FKS target genes or reduced susceptibility to rezafungin were 
identified among clinical Candida isolates from Nordic surveillance and the STRIVE trial. 
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An evaluation of the safety and efficacy of nebulised amphotericin B deoxycholate (Fungizone) 
for treatment of pulmonary aspergillosis 
P. Langridge, A. Otu, D. Denning 
National Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, United 
Kingdom 
Objectives: We evaluated the safety and efficacy of nebulised Fungizone in the long-term treatment 
of various forms of pulmonary aspergillosis 
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Methods: This was a retrospective service evaluation of 177 patients with various forms of 
pulmonary aspergillosis attending the National Aspergillosis Centre in Manchester. Due to risk of 
intolerance/bronchospasm, patients first received a challenge test with nebulised Fungizone in the 
hospital setting with spirometry pre/ post Fungizone. To improve tolerability, nebulised short acting 
beta agonist was given prior to administration of Fungizone (10mg in 4ml water for injection). 
Results: The baseline FEV1 and FVC of the patients ranged from 0.94-2.97L and 13.3-5.15L 
respectively. 66% (117) were able to tolerate their first test dose, of whom 26 (21%) stopped using the 
nebulised therapy before their next clinic visit. Reasons cited for Fungizone intolerance included 
increased breathlessness (8), wheeze (7), bronchospasm (6), sore throat/voice (4), coughing (4), chest 
tightness (3), light-headedness/dizziness (2), diarrhoea (2), fatigue (2), mouth blisters/ulcers (2), 
headaches (2) ,nausea/vomiting (2) in addition to other symptoms. Eighteen continued nebulisation 
of Fungizone 10mg twice a day for >3 months. Eleven had allergic bronchopulmonary aspergillosis 
(ABPA), 4 had severe asthma with fugal sensitization (SAFS), 2 had Aspergillus bronchitis and 1 had 
Aspergillus sensitisation with cavitating nodules. Treatment courses ranged from 4months to 4years. 
At their first clinic follow-up, there were reported benefits with sputum production (7), sinus 
symptoms (2), dyspnoea (2), exercise tolerance (2), reduction in prednisolone maintenance dose (1) 
and one demonstrated radiologic improvement. Three had interruptions to their Fungizone 
treatment which had to be restarted following clinical deterioration off therapy (2 of whom had dose 
change to once daily 12.5mg). Five patients have remained on treatment with sustained benefit (e.g. 
clinical stability, marked reduction in frequency of chest infections, reduction in Aspergillus specific 
IgE and increased exercise tolerance). Four patients discontinued therapy as there was no perceived 
clinical benefit. Aspergillus PCR on sputum at first repeated measure following initiation of 
Fungizone treatment changed from positive to negative in 7 and stayed negative in 7. No pre-
treatment PCR tests were done in 5 patients and no follow-up PCR tests were performed in 6 patients. 
Fungal cultures of sputum went from positive to negative after >3 months treatment in 6 patients, 
remained positive in 3 patients, remained negative in 4 patients and became positive in 2 patients. 
 
Conclusion: Nebulised Fungizone is a poorly tolerated treatment for pulmonary Aspergillosis with 
high dropout rates. There appears to be both clinical and serologic benefits following sustained 
treatment with nebulised Fungizone in some patients 
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In-Silico and In-Vitro Evaluation of Anticandidal Activity of Cinnamaldehyde 
G. Uttam1, K. Singh1, D. Katiyar2 
1Animal Mycology Laboratory,zoology, Mmv, Banaras Hindu University, Varanasi, India, 
2Chemistry, Mmv, Banaras Hindu University, Varanasi, India 
Objectives: Candida albicans is a common commensal which resides in human body and causes 
invasive fungal infections especially in immunocompromised hosts. This study aims to evaluate the 
anticandidal activity of cinnamaldehyde through in-silico approach and in-vitro methods. 
Methods: Interactions between cinnamaldehyde and potential drug targets of C. albicans was 
elucidated using in-silico approach which was further validated by determination of minimum 
inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) of cinnamaldehyde 
using broth microdilution method recommended by CLSI 2009 for yeast (M27-A2). The effect of 
cinnamaldehyde on micromorphology of C. albicans was studied. Sorbitol Assay (effect on cell wall) 
and Ergosterol Binding Assay of C. albicans were also performed. Time-kill curve was conducted 
using cell viability testing. 
Results: In-silico studies revealed that cinnamaldehyde showed good binding affinity with potential 
targets of C. albicans such as ergosterol, N-myristoyl transferase and Secreted aspartic proteinase 5. 
MIC and MFC of cinnamaldehyde were found to be 8.2 μg/ml and 16.4 μg/ml respectively. In the 
morphological interference assays, it was observed that the cinnamaldehyde inhibited 
pseudohyphae, blastospores and chlamydospores formation. The time-kill curve of cinnamaldehyde 
showed that it required only few hours of exposure to effectively kill >90% of the inoculum. 
Conclusion: Cinnamaldehyde showed good in-vitro antifungal potential against C. albicans. 
However, evaluation of pharmacodynamics and pharmacokinetics studies is desirous for complete 
elucidation of its action as a therapeutic which will be helpful for mankind. 
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Antifungal Activity of Cinnamaldehyde against Some Human Pathogenic Fungi 
K. Singh, A. Kumari, G. Uttam, N. Srivastava 
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India 
Objectives: Despite the availability of effective antifungals, the morbidity and mortality of fungal 
infections has remained high especially in individuals with impaired immunity. The limited targets 
of existing antifungals may be one of the reasons for the emergence of drug-resistant strains. In this 
regard, the anti-fungal potential of cinnamaldehyde, a plant product and active constituent of 
cinnamon was tested through in-silico approach which was further validated by in-vitro methods. 
Methods: Antifungal activity of cinnamaldehyde was tested against Cryptococcus neoformans (ATCC 
6352), Candida albicans (MTCC 3017), Aureobasidium pullulans var. pullulans (CBS 577.93), Aspergillus 
terreus, Alternaria alternata and Fusarium oxysporum (MTCC 2773) using broth micro-dilution methods 
recommended by CLSI (2009) for yeasts and moulds. Further, PDB structures of drug targets of said 
fungus species were downloaded or molleded (if not available) and their interactions with 
cinnamaldehyde were elucidated in-silico using RCSB Protein databank, PHYRE2 and PatchDock 
servers. 
Results: Cinnamaldehyde showed potent anti-fungal activity against all the fungal pathogens 
screened. However, Cryptococcus neoformans (ATCC 6352) was found highly susceptible against it 
with the MIC value 1.367±0.260 mg/ml. In-silico interaction between targets of Cryptococcus neoformans 
(lanosterol 14-alpha demethylase), Candida albicans (ergosterol, N-myristoyl transferase and Secreted 
aspartic proteinase 5), Aureobasidium pullulans (chitinase), Aspergillus terreus (chitinase), Alternaria 
alternata (ornithine descarboxylase) and Fusarium oxysporum (Thiamine thiazole synthase) with 
cinnamaldehyde exhibited high binding energies and hydrogen bonds. 
Conclusion: Cinnamaldehyde possesses broad spectrum and potential anti-fungal activity. Being a 
plant product, it also has advantage for structural diversity and therefore, could be a potential drug 
candidate for the treatment of fungal diseases. However, its drug likeness properties should be 
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evaluated by ex-vivo and in-vivo studies.
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Assessment of anti-Candida activity of Benzo(a)phenoxazines 
J.I. Carvalho-Pereira1,2, M.S. Gonçalves3, M.J. Sousa1,2, P. Sampaio1,2 
1Centre Of Molecular And Environmental Biology (cbma), Department Of Biology, University of 
Minho, Braga, Portugal, 2Institute Of Science And Innovation For Bio-sustainability (ib-s), University 
of Minho, Braga, Portugal, 3Centre Of Chemistry, University of Minho, Braga, Portugal 
Objectives: Fungal infections represent a major health problem due to their prevalence, increasing 
number of cases and high complexity of the etiological agents involved. Candida species are the most 
common and clinically important being able to cause from less-severe superficial lesions to life-
threatening disseminated mycosis. C. albicans remains the most common species isolated, however, 
infections caused by non-albicans species, such as C. auris, are increasing. Current treatments for 
fungal infections are not 100% effective due to the drug toxicity, pathogen resistance, low drug 
bioavailability and late diagnosis. At the moment, few groups of antimycotics are available to deal 
with these infections. The loss of clinical efficacy of these drugs creates a potential risk of spreading 
of resistant strains through the emergence of clones with high pathogenic potential. This illustrates 
that the development of new antimicrobials is crucial. Phenoxazine derivatives, namely 
benzo(a)phenoxazines have been shown to present good antifungal properties. Thus, in this work we 
evaluated the antifungal activity of five benzo(α)phenoxazin derivatives, against distinct Candida 
species and selected the most promising to develop an effective antifungal nanoformulation. 
Methods: The revised European Committee on Antimicrobial Susceptibility Testing (EUCAST) protocol 
was used to determine the minimum inhibitory concentrations (MICs) of five benzo(α)phenoxazines 
against seven Candida species, namely C.albicans, C.glabrata, C.parapsilosis, C.tropicalis, C.krusei, 
C.bracarensis and C.auris. The most effective compounds were selected for the development of 
formulations based on DODAB:MO liposomes. All formulations were evaluated regarding the mean 
size, polydispersity index, surface charge, liposome stability and encapsulation efficiency. The most 
stable formulations were selected for antifungal activity re-evaluation against all seven Candida 
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species and for cytotoxicity assessment with different cell lines and using both the MTT and the 
lactate dehydrogenase (LDH) release assays. 
Results: demonstrated that all five benzo(α)phenoxazin derivatives tested presented antifungal 
activity against all seven Candida species, with MICs between 3.75 to 60 μM. Two of these 
benzo(a)phenoxazin derivatives presented MICs of 3.75-15 μM against all species tested, being 
selected to develop DODAB:MO formulations. The liposomal formulations were positively charged, 
presenting mean sizes between 300-500nm and polydispersity indexes of 0.4-0.5. The encapsulation 
efficiency was between 80-95% for both benzo(α)phenoxazin derivatives tested. The activity of 
formulation against all seven Candida species were evaluate with the liposomal formulations. Results 
demonstrated that empty liposomes did not affect Candida growth and that the encapsulation of 
benzo(α)phenoxazins increased their activity against Candida species. The cytotoxicity of the 
promising formulations was tested using different cell lines and the non-toxic formulations were 
selected. 
Conclusion: The results obtained demonstrated that benzo(α)phenoxazins derivatives could be 
potential antifungal drugs since present activity against all Candida species tested, including the 
multidrug resistant C. auris. Moreover, the encapsulation of the benzo(α)phenoxazin derivatives 
increase the antifungal activity and reduce the cytotoxicity of compounds. 
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Inhibitory effect of a curcumin-based compound against Epidermophyton floccosum clinical 
isolates 
V. Camilo Pattini1, C.R. Polaquini1, T. Lemes1, N. Brizzotti2, J.P. Siqueira2, M. Almeida2, L.O. Regasini3 
1São Paulo State University - Institute of Biosciences, Humanities and Exact Sciences (UNESP - 
IBILCE), São José do Rio Preto, Brazil, 2FAMERP, São José do Rio Preto, Brazil, 3Chemistry And 
Environmental Sciences, UNESP (Sao Paulo State University), São José do Rio Preto, Brazil 
Objectives: The present study aimed to evaluate the antifungal activity of a curcumin-based 
compound against clinical strains of Epidermophyton floccosum isolated from dermatomycoses. 
Methods: For this study, the curcumin-based compound was obtained from the Laboratory of 
Antibiotics and Chemotherapeutics – LAQ, of the Institute of Biosciences, Letters and Exact Sciences 
(IBILCE, Unesp São José do Rio Preto). This new compound is a hybrid curcumin compound with 
substitutions to make the substance more stable and active. The clinical strains were from the culture 
collection of the Laboratory of Microbiology of the Medical School in São José do Rio Preto 
(FAMERP), Brazil. Susceptibility tests were performed for two E.floccosum strains (6069 and 6113), 
using the Clinical and Laboratory Standards Institute M38-A2 guidelines as reference. Percentage of 
inhibition was calculated by spectrophotometry using the : I = 1 - (AbsT-AbsCT / AbsCC) × 100; 
where: I = percentage of inhibition; AbsT = absorbance of the inoculum plus the compound solution; 
AbsCT absorbance of sterility control; AbsCC = absorbance of growth control. The curcumin 
(Merck® ) was used as a control. 
Results: The minimum inhibitory concentration (MIC) obtained for the curcumin-based compound 
against E.floccosum 6069 and 6113 strains was 15.62μg/mL, inhibiting 80 and 87% the growth of the 
strains, respectively. On the other hand, pure curcumin(Merck® ) exhibited no activity at the 
concentrations tested. 
Conclusion: The curcuminoid showed potent antifungal activity against E. floccosum strains, higher 
than pure curcumin (Merck® ), showing a potential alternative against E. floccosum. In the future, 
toxicity tests will be performed allowing new therapeutic approaches in the treatment of 
dermatomycoses. 
 
P432 
Antifungal activity of Kombucha Hibiscus sabdariffa infusion extract against Trichophyton 
mentagrophytes and Trichophyton rubrum. 
V. Camilo Pattini1, N. Brizzotti2, T. Lemes1, J.P. Siqueira2, M. Marques2, M. Caetano3, T. Maschio-
Lima3, B. De Almeida3, L. Bianco1, C. Silva2, C.R. Polaquini1, L.O. Regasini4, E. Castilho2, M. Almeida2 
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1São Paulo State University - Institute of Biosciences, Humanities and Exact Sciences (UNESP - 
IBILCE), São José do Rio Preto, Brazil, 2FAMERP, São José do Rio Preto, Brazil, 3São Paulo State 
University - Institute of Biosciences, Humanities and Exact Sciences (UNESP - IBILCE), São José do 
Rio Preto, Brazil, 4Chemistry And Environmental Sciences, UNESP (Sao Paulo State University), São 
José do Rio Preto, Brazil 
Objectives: The present study aimed to explore the antifungal potential of Kombucha infusion 
extracts on planktonic cells of potentially pathogenic fungal isolates, as an alternative to synthetic 
drugs. 
Methods: Firstly, a SCOBY (Symbiotic Culture of Bacteria and Yeast), obtained from a local natural 
products store, was placed in 1 liter of distilled water with 20g of sucrose weekly for 30 days to 
remove any previous residues. The Hibiscus sabdariffa infusion (HI) was prepared with four grams of 
leaves/flowers boiled in 450 mL of sterile mineral water for 5 minutes and filtered on filter paper. The 
initial fermentation was obtained by mixing 20 g of SCOBY and 80 g of sucrose to the infusion, and 
the final volume was adjusted to 800 mL with sterile mineral water. The culture was then incubated 
at 25 °C for 20 days. The experiment was carried out in triplicate. After incubation, the solution was 
filtered in the MILLIPORE®  System with 0.2 μm membrane. The chemical compounds of the filtrate 
were extracted using ethyl acetate. To obtain the dry and purified extract of the chemical compounds, 
the acetate phase was placed on a rotary evaporator. Minimal inhibitory concentrations (MIC) and 
minimal fungicide concentrations (MFC) of Kombucha HI extract against Trichophyton rubrum and 
Trichophyton mentagrophytes clinical isolates were investigated by the microdilution method, using as 
reference the document M38-A2 of the Clinical and Laboratory Standards Institute. 
Results: The results obtained for the MIC of Kombucha HI extract against the T. mentagrophytes and 
T. rubrum strain were 125 μg/mL and 62.5 μg/mL, respectively. For the MFC, values observed were 
250 μg/mL for T. mentagrophytes and 125 Oμg/mL for T. rubrum. 
Conclusion: Kombucha HI extract showed antifungal activity against T. mentagrophytes and T. 
rubrum. In the future, isolation and identification of the extract compounds may allow new 
therapeutic approaches in the control of fungal infections. 
 
P433 
Characterization of the specificity of the Ca37 monoclonal antibody and its protective role against 
Candida albicans infection 
A. Antoran1, L. Aparicio-Fernandez1, I. Buldain1, L. Martin-Souto1, M. Areitio1, A. Rementeria1, M.A. 
Ghannoum2, B.B. Fuchs3, E. Mylonakis3, F.L. Hernando1, A. Ramirez-Garcia1 
1Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), Leioa, 
Spain, 2Dermatology, Case Western Reserve University, Cleveland, United States of America, 
3Division Of Infectious Diseases, Rhode Island Hospital and Alpert Medical School of Brown 
University, Providence, United States of America 
Objectives: Candida albicans is a commensal yeast of mucosal surfaces of human body. However, 
when the host is immunocompromised, this yeast can cause invasive infections, that present an 
unacceptably high mortality rate (up to 50%). Therefore, looking for alternative treatments, we have 
focused on monoclonal antibodies. Alcohol dehydrogenase (Adh) protein was selected for antibody 
development, due to its role in carcinogenic acetaldehyde production, its surface location and its 
immunogenicity potential. The objective of this work was to characterize the specificity of this Ca37 
monoclonal antibody against Candida albicans and its ability to interfere with yeast infection. 
Methods: Adh1 protein was cloned in Escherichia coli. This recombinant protein was used for mice 
immunization and Ca37 monoclonal antibody development. Proteomic analysis by two dimensional 
(2-DE) western blotting and LC-MS/MS identification, in yeast and hyphal fractions, were performed 
in order to identify the proteins detected by Ca37 and to determine its specificity against Adh1 
protein. Indirect immunofluorescence was carried out to study surface location of the protein. In this 
case, sodium metaperiodate treatment was used for surface carbohydrate removal. Effect of Ca37 on 
yeast germination, growth and interaction with antifungals was studied. Galleria mellonella in vivo 
model infection, using an ΔADH1 mutant and parental strains was used to study the effect of ADH1 
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gene loss on virulence, and for testing Ca37 antibody role as therapeutic agent against C. albicans 
infection. 
Results: The 2-DE western blot performed on cell wall-associated protein fraction showed that Ca37 
detected Adh1 protein in yeast and Adh2 in hyphal cells. Immunofluorescence results indicated that 
the epitope recognized by the Ca37 was partially covered by carbohydrates, as antibody only bound 
to fungal cells after sodium metaperiodate treatment, or after long incubation times. Yeast 
germination was slightly inhibited, but growth inhibition reached up to 90%. The antibody also 
showed an additive effect with amphotericin B and fluconazole antifungals. Finally, in Galleria 
mellonella infection, we detected a higher survival when using the ΔADH1 strain, and the same level 
of survival using fluconazole or Ca37 treatment. 
Conclusion: The Ca37 monoclonal antibody is specific for Adh proteins, which are located at fungal 
cell surface, partially hidden by carbohydrates, and seem relevant for virulence in vivo. Moreover, 
Ca37 is effective against yeast growth, provides an additive effect with antifungal drugs, and confers 
protection in vivo. Altogether, Adh proteins seem interesting targets against Candida albicans 
infections. Financial support: This study was founded by a grant of UPV/EHU (PPG17/41). LA-F is recipient 
of a PhD grant of UPV/EHU and LM-S of the Basque Government. 
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Rezafungin Clinical Safety and Efficacy in the Treatment of Candidemia and/or Invasive 
Candidiasis: Combined Results from the STRIVE Phase 2 Trial Parts A and B 
G.R. Thompson1, P.M. Honore2, J.P. Horcajada3, J. Fortun4, M. Hites5, M. Bassetti6, K. Mena7, L. 
Navalta7, R. Viani7, T. Sandison7, P. Pappas8 
1University of Davis Medical Center, Davis, United States of America, 2Brugmann University 
Hospital, Brussels, Belgium, 3Hospital del Mar, Barcelona, Spain, 4University Hospital Ramon y 
Cajal, Madrid, Spain, 5Erasme Hospital, Brussels, Belgium, 6Dept Of Medicine, University of Udine, 
Udine, Italy, 7Cidara Therapeutics, San Diego, United States of America, 8University of Alabama at 
Birmingham, Birmingham, United States of America 
Objectives: Rezafungin (RZF) is a novel echinocandin designed to have next-generation properties, 
such as increased stability and safety and novel pharmacokinetics/pharmacodynamics (PK/PD), 
distinct from other systemic antifungals. The PK profile of RZF includes a prolonged half-life and 
front-loaded plasma exposure that allow for once-weekly therapy, as well as maximized 
pharmacometrics of antifungal efficacy. STRIVE is a global, double-blind, randomized, clinical trial 
that compared the safety and efficacy of RZF once-weekly to caspofungin once-daily in patients 
with candidemia and/or invasive candidiasis (IC). After successful completion of STRIVE Part A 
(Thompson et al, 2018), a second randomization (Part B) was conducted. Combined results from 
Parts A and B are presented herein. 
Methods: Adults (≥18 y) with systemic signs and mycological confirmation of candidemia and/or 
IC were randomized to RZF once-weekly or standard of care (SOC) with caspofungin for ≥14 days 
(up to 4 weeks) (Figure 1). Efficacy was assessed by overall response (resolution of clinical signs of 
infection + mycological eradication) at day 14 (primary endpoint) and PI assessment of clinical 
response at day 14 and all-cause mortality at day 30 (secondary endpoints). Safety was evaluated by 
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adverse events (AEs) and mortality. 
 
Results: Of 207 patients enrolled, 183 patients were included in the microbiological intent-to-treat 
population. Treatment groups were well balanced and matched in demographics and baseline 
characteristics. Patients with IC comprised ~21% of the combined population. RZF 400 mg/200 mg 
demonstrated greater efficacy than SOC, with the highest rates of overall success and clinical cure 
and the lowest rate of 30-day all-cause mortality of all 3 groups (Table 1). The rate of all-cause 
mortality through follow-up in the pooled RZF group was 15.6% (19/122) and 19.7% (12/61) for 
SOC. No concerning safety trends were observed. The incidence of ≥1 treatment-emergent adverse 
event (TEAE) related to study drug was 13/134 (9.7%) among RZF-treated patients (pooled) and 
9/68 (13.2%) with SOC. Between the pooled RZF and SOC groups, rates of study drug–related 
TEAEs leading to study discontinuation (2.2% and 1.5%, respectively) and serious AEs (1.5% and 
2.9%, respectively) were comparable. 
 
Conclusion: RZF was safe and efficacious in the Phase 2 trial of RZF treatment in patients with 
candidemia and/or IC. RZF 400 mg/200 mg, the dosing regimen used in the ongoing Ph 3 study, 
demonstrated greater efficacy than SOC and the most favorable efficacy of all groups. No 
concerning trends in TEAEs were observed and, again, the RZF 400 mg/200 mg once weekly group 
demonstrated the most favorable safety outcomes in terms of TEAEs related to study drug. The 
recently completed Part B of STRIVE, combined with the previous success of STRIVE Part A, 
demonstrates the safety and efficacy of RZF treatment and supports its Phase 3 development. 
 
P440 
Invasive aspergillosis in adult non-hematologic patients 
O. Shadrivova1, M. Tonkoshkur1, E. Desyatik2, A. Volkova3, M. Popova3, S. Ermolova4, T. 
Bogomolova2, S. Ignatyeva2, L. Zubarovskaya3, B. Afanasyev3, N. Klimko1 
1Department Of Clinical Mycology, Allergy And Immunology, North-Western State Medical 
University named after I.I.Mechnikov, St. Petersburg, Russian Federation, 2Kashkin Research 
Institute Of Medical Mycology, North-Western State Medical University named after I.I.Mechnikov, 
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St. Petersburg, Russian Federation, 3I.Pavlov First Saint Petersburg State Medical University, St. 
Petersburg, Russian Federation, 4Department Of Pulmonology, 3Leningrad Regional Clinical 
Hospital, St. Petersburg, Russian Federation 
Objectives: To investigate the features of invasive aspergillosis (IA) in non-hematologic patients. 
Methods: Retrospective analysis of clinical data of adult non-hematologicpatients with IA. The 
EORTS/MSG 2008 criteria were used for IA diagnosis and assessment of response of therapy. 
Results: In the study were included 46 non-hematologic patients with IA, median age – 48 years (19 
- 99), females – 57%. The background conditions were autoimmune diseases – 24%, kidney diseases 
with acute or chronic renal failure – 20%, oncology – 15%, heart and vascular diseases – 11%, severe 
viral-bacterial pneumonia – 8%, HIV infection – 7%, lung pathology – 7%, severe influenza H3N2 – 
4%, other – 4%. The risk factors of IA were glucocorticosteroid therapy – 50%, prolonged 
lymphocytopenia (<1,0 х109/l, median – 18 days) – 48%, immunosuppressive therapy – 35%, ICU stay 
– 30%, precede surgical treatment – 28%, organs transplantation – 20%, severe neutropenia (median 
– 10 days) – 13%, diabetes – 11%, allogeneic hematopoetic stem cells transplantation (HSCT) – 2%, 
autologous HSCT – 2%. The main sites of infection were lungs – 85%, central nervous system (CNS) 
– 11%, and paranasal sinuses – 9%. Disseminated (≥2 organs) IA was in 17% patients. Clinical signs 
of IA were fever (≥ 38,50C) – 79%, cough – 76%, respiratory failure – 59%, chest pain – 26%, and 
hemoptysis – 22%. CT scan signs were bilateral lesions – 56%, air crescent sign – 12%. The main 
etiological agents were A.fumigatus (62%), A.niger (14%), A.flavus(14%), A.ustus (5%) and A.ochraceus 
(5%). «Proven» IA was diagnosed in 28% patients, «probable» – 72%. Antifungal therapy was used 
in 93% patients, surgical treatment – 7%. Overall 12-weeks survival of patients was 76%. 
Conclusion: Invasive aspergillosisdeveloped in non-hematologic patientsusually with autoimmune 
(24%), renal (20%) or oncology diseases (15%). The main risk factors were glucocorticosteroid therapy 
(50%), lymphocytopenia (48%), immunosuppressive therapy (35%), organs and hematopoetic stem 
cells transplantation (24%). The main etiological agents were A.fumigatus (62%), A.niger (14%), and 
A.flavus(14%). The main sites of infection were lungs (85%), disseminated (≥2 organs) infection was 
in 17% patients. Overall 12-weeks survival of patients was 76%. 
 
P441 
A plea to preserve fungal pathogens in public microbial resource centres 
D. Stubbe1, M. Hendrickx2, P. Becker2 
1Mycology & Aerobiology, Bccm/ihem Collection, Sciensano, Brussels, Belgium, 2Mycology, 
Sciensano, BCCM/IHEM, Brussels, Belgium 
Objectives: Open science aims at sharing scientific outputs in order to maximize the impact of 
research. This allows follow-on studies, facilitates new discoveries, improves reproducibility of 
experiments and favours transparency of results. Although open data is becoming a well-known 
concept, less attention is given to the availability of research materials. In medical sciences, public 
culture collections represent an historical example of open science, thanks to their longstanding 
experience in the preservation of living microorganisms and their distribution for further scientific 
investigations or development. These microbial resource centres provide well-characterized, quality-
controlled and authenticated strains and associated data. In medical mycology, the diversity of fungal 
pathogens is important and needs to be secured following (inter)national legislations for future basic 
and applied health questions. We wish to promote the deposit of isolates in public collections. 
However, the responsibility to make fungal strains available is shared by researchers, funding 
agencies and publishers. 
Methods: We made a random selection of articles in the field of medical mycology to check whether 
or not studied isolates were deposited and made available in public collections. 
Results: A random selection was made of 90 articles issued between 2017 and 2019 in seven journals 
specialized in medical mycology. Out of them, only 13 (less than 15%) mentioned the deposit of the 
strains. 
Conclusion: Medical mycologists need to be more aware towards strain conservation. Governmental 
funding policies should request the deposit of strains isolated during financed projects. Regarding 
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publishers, most journals encourage authors to make biological material available but few specifically 
require deposit and most isolates investigated in publications are not preserved. Editors should 
therefore implement mechanisms for active agreement by authors to deposit strains when submitting 
an article. Such mechanisms could follow Transparency and Openness Promotion guidelines1 for 
journals that include a standard for research materials. Two level of stringency are proposed for this 
standard: (1) the article states whether strains are available and, if so, where to access them and (2) 
the mandatory deposit of the strains in a trusted repository. 
 
P442 
Fungicidal and Yeasticidal activity of chemical disinfectant and antiseptic products: European 
standards & Real hospital life - How to be successful? 
S. Loeffert-Frémiot 
Microbiology Laboratory, Member Of Wg 1 Of The Cen, Laboratoires ANIOS, LILLE, France 
Objectives: Chemical disinfectants and antiseptic products are a crucial part of the infection control 
strategy in hospital and are upregulated by European standards. If infection control fails, the 
consequences could be severe especially for immunocompromised. This is why it is important that 
testing procedures of chemical chemical disinfectants are sufficient and well understand to ensure 
that disinfectants for the medical area are reliable. The aim of this work is to help users to understand 
where, when and how to use these products and to make and update of the conception and evolution 
of these standards following what is happening in real work. 
Methods: Explain the European Standards to which products have to conform in order to support 
the claims for Fungicidal and yeasticidal activity. This include the description of EN 14885 “Chemical 
disinfectants and antiseptics – Application of European Standards for chemical disinfectants and 
antiseptics” (2018) requirements and the tests conditions of the EN 13624 “Chemical disinfectants and 
antiseptics – Quantitative suspension test for the evaluation of fungicidal or yeasticidal activity in the 
medical area -Test method and requirements (phase 2, step 1)” (2013). In order to adapt the European 
standards to what happen in medical area, standards are systematically revised by group of expert 
members of the Working Group 1 of the European Comission of standardization (Commission 
Europeenne de Normalisation :CEN). 
Results: It is known that some strains could be challenging for healthcare workers by their emerging 
character or by the apparition/ evolution of their resistance in different part of European country. 
Therefore, European standards need to continuously follow and adapt to the field situation. The 
choice of test organisms and conditions of EN 13624 is under discussion to see their relevance. It is a 
critical point that need to be raised and share with expert people of the field. 
Conclusion: European Standards requirements must be continuously revised to be suitable for 
effective infection strategy in medical area and particularly in healthcare settings.These standards are 
more often not really known by healthcare people working on the field, fighting everyday against 
resitant pathogens. They need to have all the keys to ensure a reliable startegy against these 
pathogens. 
 
P443 
Comparing the efficacy of three adsorbents, bentonite, activated charcoal and fuller’s earth on the 
detoxification of aflatoxin-contaminated feeds. 
A. Mgbeahuruike 
Department Of Veterinary Pathology And Microbiology, Faculty Of Veterinary Medicine,, University 
of Nigeria, Nsukka, Nsukka, Enugu, Nigeria 
Objectives: To test the ability of three low-cost and locally available adsorbents (activated charcoal, 
bentonite and fuller’s earth) to detoxify poultry feeds contaminated with aflatoxin. 
Methods: Mould growth was induced on poultry feeds by sprinkling water on the feeds until the 
feed was fully wet, the feed was packed in dark nylon bags and covered tightly. The bags were stored 
in dark environments for 3 weeks. The feeds were divided into 4 groups, Contaminated but 
untreated, Contaminated but treated with bentonite, Contaminated but treated with Activated 
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charcoal and contaminated but treated with Fuller's earth. Aflatotoxin concentration in the feeds was 
measured using reverse phase HPLC. Fungal contaminants in the feeds were isolated and 
molecularly identified. Phylogentic analysis was reconstructed using MEGA 5.0. Measurement of 
performance indices of the birds like heamatological and serum biochemical parameters were carried 
out and analysed statistically using Minitab. 
Results: Bentonite was the most effective adsorbent and lowered the total aflatoxin concentration 
from 120 ± 38 µg/kg to 15 ± 5.0 µg/kg, while the concentration was reduced to 20 ± 6.5 µg/kg in feed 
treated with fuller’s earth. The three adsorbent treatments resulted in 63-100% weight increase of the 
birds, compared with birds fed the untreated, aflatoxin-containing feed. Based on sequencing of the 
internal transcribed spacer and phylogenetic analysis, 86% of the identified fungal contaminants 
were Aspergillus species, with Aspergillus tamarii and A. nominus being the most prevalent with a 
frequency of occurrence of 21% each. The number of white blood cells in blood samples was increased 
by 13-17% in birds that consumed adsorbent-treated feed, compared with the untreated, aflatoxin-
contaminated feed. Serum biochemical analysis further showed that aspartate amino transferase 
activity was 2.3 to 2.6 fold higher in birds that consumed the contaminated but untreated feed, 
compared with feed treated with adsorbents. Hepatic lesions were also prominent in the liver of the 
birds fed contaminated but untreated feed but were reduced in the group that were fed the adsorbent-
treated feeds, especially in the bentonite-treated feed. 
Conclusion: Conclusively, the adsorbents were able to reduce the concentration of aflatoxin in the 
feed and this reflected positively on the general performance of the birds. 
 
P444 
Evaluation of the growth of Sporothrix schenckii and Sporothrix brasiliensis when exposed to the 
iron element 
M.L. Scroferneker1, A.H. Da Silva Hellwig2, H. Klein De Abreu2, A. Carvalho Ribeiro1, H. Tedesco De 
Oliveira1, E. Heidrich Pezzi1, R. Adriel Zanette3 
1Department Of Microbiology, Immunology And Parasitology, Universidade Federal do Rio Grande 
do Sul, Porto Alegre, Brazil, 2Postgraduate Program In Medicine: Medical Sciences, Universidade 
Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Postgraduate Program In Biological Sciences: 
Pharmacology And Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil 
Objectives: The aim is to evaluate the viability of Sporothrix spp. when exposed to iron, using 11 
isolates of S. schenckii and 10 isolates from S. brasiliensis. 
Methods: All the samples used were previously analyzed by molecular methods. Conidia were 
collected from cultures with seven days of growth in potato dextrose agar medium and suspended 
in 0.85% saline solution. Each suspension was standardized in a Neubauer chamber, adjusted to the 
concentration of 106 conidia / ml, and inoculated at the center of petri plates containing potato 
dextrose agar plus the following iron concentrations (FeCl3): 0.0625%; 0.125%; 0.25%. The isolates 
were also inoculated into plates containing potato dextrose agar pure or added with 1 mM ascorbic 
acid and 1 mM ferrozine to eliminate traces of iron present in the medium. Plates were incubated in 
triplicates at 35 ° C for 28 days to measure the mean diameter of colonies (mm) and perform analysis 
of variance followed by the Tukey post-hoc test in the GraphPad Prism statistical program, with 
significance p < 0.05. 
Results: It has been found that high iron concentrations are toxic to Sporothrix spp., as seen in the 
concentration of 0.25% FeCl3, where there was no growth of the isolates. In addition, medium with 
absence of iron also had to lower growth of Sporothrix spp. when compared to the potato dextrose 
agar medium and the medium plus 0.0625% and 0.125% FeCl3. 
Conclusion: It is possible to conclude that the viability of Sporothrix schenckii and Sporothrix brasiliensis 
is affected by iron, which is an important element for its biological activity. 
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The interaction between Sporothrix schenckii sensu sctricto and Sporothrix brasiliensis with 
Acanthamoeba castellanii 
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M.L. Scroferneker1, P. Lemos Tavares2, F. Kercher Berte1, A. Carvalho Ribeiro1, M. Brittes Rott1 
1Department Of Microbiology, Immunology And Parasitology, Universidade Federal do Rio Grande 
do Sul, Porto Alegre, Brazil, 2Postgraduate Program In Medicine: Medical Sciences, Universidade 
Federal do Rio Grande do Sul, Porto Alegre, Brazil 
Objectives: The aim of our study was to verify the profile of interaction between S. schenckii sensu 
stricto and S. brasiliensis and A. castellanii by an in vitro model of coculture as a modulator factor of 
both microorganisms intrinsic characteristics. 
Methods: For this purpose the phagocytosis index of S. schenckii sensu stricto and S. brasiliensis by A. 
castellanii was evaluated; the S. schenckii sensu stricto and S. brasiliensis viability after contact with A. 
castellanii; the amoeba viability after contact with the fungus; and the influence of S. schenckii sensu 
stricto and S. brasiliensis in encystment process of A. castellanii were performed. The analyses indicated 
that S. schenckii and S. brasiliensis have suffered phagocytic events by A. castellanii and this index is 
significantly higher for S. schenckii in the first two hours compared to S. brasiliensis. 
Results: Our results showed a significant increase in conidia and hyphae count after 72h of coculture 
of S. brasiliensis and lysis of amoebae occurred after fungal internalization. 
Conclusion: S. schenckii sensu stricto and S. brasiliensis probably used amoebae as nutritional source. 
Our results were obtained in vitro and may not demonstrate the same behavior in vivo, being required 
in vivo studies with co-infection in order to have a thorough understanding of this relationship. 
 
P446 
Estimation of fungal risk in cystic fibrosis: lessons from the MucoFong prospective project 
L. Delhaes1, F. Francis2, R. Enaud3, P. Soret4, M. Consortia5, S. Bui3, M. Fayon3, R. Thiebaut2 
1Parasitology Mycology, Univeristy of Bordeaux, Centre de Recherche Cardio-Thoracique de 
Bordeaux, U1045, F-33000, Bordeaux, France, Bordeaux, France, 2CHU Bordeaux, Department of 
Public Health, Bordeaux, France, 3University of Bordeaux, Centre de Recherche Cardio-Thoracique 
de Bordeaux, U1045, CHU de Bordeaux, CRCM Pédiatrique, CIC 1401, Bordeaux, France, 4University 
of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, INRIA SISTM Team, 
Bordeaux, France, 5The Mucofong Investigation Group, Bordeaux, France 
Objectives: Beside the main objectives of the multicentric project "MucoFong" (PHRC-19021906) that 
evaluated the respiratory fungal composition in CF and provided the first French guidelines for 
mycological analysis of CF sputum, data collected during this two-year follow-up of 299 CF patients 
(3 visits per patient including biological, radiological, and clinical data) were analyzed to assess 
associations between the microorganisms identified in the sputum and the clinical evolution. 
Methods: Relations between microorganisms identified in the sputum and clinical course of patients 
were longitudinally analyzed taking as output variable FEV1 (Forced Expiratory Volume in 1s 
expressed as percent of predicted value). As data were collected several times throughout the follow-
up, a mixed-model analysis was performed to evaluate the effect of a sporadic or chronic colonization 
with bacteria and/or fungi at the inclusion on the evolution of lung function over two years. 
Univariate plus multivariate analysis were achieved. A sensitivity analysis was performed to identify 
interactions between microbes. 
Results: P. aeruginosa, A. xylosoxidans, S. maltophilia, and C. albicans were associated to a more 
significant decrease in FEV1 during the two-year follow-up, adjusted on age, gender, hospital centre, 
BMI, and gastrooesophageal reflux disease. Unexpectedly, FEV1 evolution was lower of 11.26% in 
patients presenting an intermittent colonisation with non-pneumoniae Streptococcus than others. 
Conclusion: To conclude, these results were in agreement with data recently published, and 
provided new insights into the bacterial but also the fungal colonization as a key factor in assessing 
and predicting lung function evolution in CF patients. The Mucofong Investigation Group: Marc 
Pihet, Emilie Fréalle, Yolande Lemeille, Claudine Pinel, Hervé Pelloux, Gilles Gargala, Loic Favennec, 
Isabelle Accoceberry, Isabelle Durand-Joly, Frédéric Dalle, Frédéric Huet, Annlyse Fanton, Amale 
Boldron, Guy-André Loeuille, Philippe Domblides, Bérengère Coltey, Isabelle Pin, Catherine Llerena, 
Françoise Troussier, Christine Person, Christophe Marguet, Nathalie Wizla, Caroline Thumerelle, 
Dominique Turck, Anne Prévotat, Benoit Wallaert, Sylvie Leroy, Jean-Philippe Bouchara Grant: 
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Project MucoFng 2.0 (RF20160501626/1/1/275) from Vaincre la Mucoviscidose (VLM) 
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Evaluation of metabolic adaptations of Fonsecaea pedrosoi using tricyclazole and FTIR 
M.L. Scroferneker1, A. Koehler2, V. Corbellini3 
1Department Of Microbiology, Immunology And Parasitology, Universidade Federal do Rio Grande 
do Sul, Porto Alegre, Brazil, 2Postgraduate Program In Medicine: Medical Sciences, Universidade 
Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Department Of Chemistry And Physics, 
Universidade de Santa Cruz do Sul, Santa Cruz do Sul, Brazil 
Objectives: Evaluating the metabolic adaptations of Fonsecaea pedrosoi when exposed to tricyclazole 
using Fourier Transform Infrared Spectroscopy (FTIR). 
Methods: Twelve isolates of F. pedrosoi from the collection of the Pathogenic Fungi Laboratory, 
Department of Microbiology, ICBS, UFRGS, were cultivated for 14 days at 30ºC in Petri dishes with 
Sabouraud agar. For each isolate were used two plates with 4 µg/mL or 16 µg/mL of tricyclazole. The 
spectra were acquired through attenuated total reflection (ATR) using fragments of the cultures on 
dehydrated agar. Five spectra were recorded from 4000 to 650 cm-1 for each isolate. The data set was 
preprocessed and normalized by amplitude. The Pirouette®  software was used to perform the 
Principal Component Analysis (PCA) and the Partial Least Squares Discriminant Analysis (PLS-DA) 
using the first derivative and an orthogonal signal correction. These analyzes were perfomed to verify 
if it was possible to separate the classes (growth with 4 or 16 µg/mL) through the spectra, showing if 
there are metabolic adaptations of F. pedrosoi when exposed to tricyclazole. 
Results: The PCA didn’t allowed class differentiation due to irrelevante background information. 
With PLS-DA, using only one component, the minimum error of class prediction was about 0.001, 
with Bayes limit between classes close to 0.5 and 100% of accuracy in the identification of the cultures 
in 4 or 16 µg/mL of tricyclazole. The results show that the metabolic adpatations are reproducible, 
but discrete, and the regions of the spectra that most contributed to the differentiation were the bands 
of 989 cm-1 and 1086 cm-1 (sugars); 1508 cm-1 (proteins) and 1617 cm-1 (unsaturated carbon bonds, 
evidence of the formation of the 1,8-dihydroxynaphtalene (DHN) melanin precursors). 
Conclusion: There are metabolic adaptations of F. pedrosoi with the exposition to tricyclazole. These 
adaptations can be evaluated through FTIR, which is relevant for the development of techniques to 
make correlations with models of virulence and pathogenicity of these fungi. 
 
P449 
Bridging the knowledge gap on mycoses in Africa; setting up a Pan-African Mycology Working 
Group 
R. Oladele1, I. Akase2, A. Fahal3, N. Govender4, M. Hoenigl5, J.-P. Gangneux6, T. Chiller7, O.A. 
Cornely8, D. Denning9, A. Chakrabarti10 
1Medical Microbiology & Parasitology, College of Medicine of University of Lagos, Lagos, Nigeria, 
2Internal Medicine, Lagos University Teaching Hospital, Lagos, Nigeria, 3Mycetoma Research Centre, 
Kartoum, Sudan, 4National Institute for Communicable Diseases, Johannesburg, South Africa, 
5Division of Infectious Diseases, Department of Medicine, UCSD, San Diego, United States of 
America, Austria, United States of America, 6Universite de Rennes, Rennes, France, 7Mycotic 
Division, Centre for Disease Control, Atlanta, United States of America, 8Department I of Internal 
Medicine, University Hospital of Cologne, Cologne, Germany, Cologne, Germany, 9Global Action 
Fund for Fungal Infections, Geneva, Switzerland, 10Medical Microbiology, Postgraduate Institute of 
Medical Education and Research,, Chandigarh, India 
Objectives: The African continent has an estimated population of 1.3 billion people accounting for 
roughly about a quarter of the world’s population and has an estimated 700,000 fungal related deaths 
in the setting of HIV infections. From the data generated by GAFFI; an estimated 47,643,919 Africans 
suffer from fungal diseases, of which 1,728,657 suffer from a serious fungal infection annually (GAFFI 
Factsheet). This is a course for concern considering the fact that this is data from only 15 (out of 57) 
African countries (Table 1). Almost all African countries lack a surveillance system for fungal 
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infections,; the only exception is South Africa. Interestingly, only South Africa has a reference 
mycology laboratory. Also, there is a pervasive picture of inadequate/poor diagnostic capacity, low 
level of awareness/ index of suspicion among health care workers and policymakers, unavailability, 
and non-accessibility to antifungal medications. Most African countries have poorly funded and 
overburdened health systems. Additionally, a high prevalence of HIV in Sub-Saharan Africa 
contributes to a high burden of opportunistic fungal infections. Recently, the African sub-region 
developed a network of mycology experts whose goal is to provide a common platform for a 
compressive discussion and collaboration on fungal infections. 
Methods: Recent outreach efforts of ISHAM and also the European Confederation of Medical 
Mycology (ECMM) aimed to increase the involvement of African countries and experts in e.g. the 
“One World One Guideline” initiative and also the ECMM Academy. The Medical Mycology Society 
of Nigeria with support from ISHAM and ECMM held its first international conference on March 
2019, which cumulated with the establishment of the PanAfrican Mycology Working Group 
(PAMWG). 
Results: PAMWG will organize and engage African leaders in the field of mycology in the African 
sub-region linked to ISHAM. The aim is is to provide better interaction&synergy among regional 
leaders in order to develop educational programs for capacity building to aid in the diagnosis and 
care of patients with fungal infections. It will also encourage countries' initiatives to develop clinical 
guidelines for the clinical management of fungal infections and support the need for the 
establishment of reference mycology laboratories. Objectives The ISHAM-PAMWG aims to provide 
a platform for all the leaders in the field on mycology from different African countries in order to 
initiate epidemiological studies, regional guidelines, and educational programs to increase the 
capacity/ expertise of African specialists in the early detection and treatment of fungal infections. 
These activities will be achieved via the following: Education and training programs for health care 
workers involved in the care and evaluation of patients with fungal infections. South-south, and 
north-south collaborations and partnership. Organization of regional collaborative studies. 
Participation in the ECMM One World One Guideline program. Encourage all PAWG members to 
affiliate with ISHAM Organize local meetings in African countries in collaboration with ISHAM and 
ECMM Participation of leading centers in Africa in the ECMM Excellence Center program To 
advocate the recognition of neglected fungal diseases in Africa. 
Conclusion: Meeting the objectives listed above will generate the needed data for advocacy needed 
to drive government commitment to allocate the resources required. 
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P450 
Importance of Sphingolipid Biosynthetic Pathway for Growth, Biofilm Formation and Membrane 
Integrity of the Pathogenic Fungus Scedosporium boydii 
R. Rollin Pinheiro1, V. Pereira Rochetti1, M.I.D.S. Xisto1, B. Bastos2, A. Rella3, S. Rozental2, M. Del 
Poeta3, E. Barreto-Bergter1 
1Instituto De Microbiologia Paulo De Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 
Brazil, 2Instituto De Biofísica Carlos Chagas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 
Brazil, 3Department Of Molecular Genetics And Microbiology, Stony Brook University, Stony 
Brook/New York, United States of America 
Objectives: Scedosporium boydii is a worldwide emerging pathogen able to cause a wide-spectrum 
infection ranging from mycetoma to invasive infections in immunocompromised patients. It is also 
considered the second more frequent pathogenic fungus associated to cystic fibrosis patients. 
Sphingolipids are abundant components of membranes in fungal cells, playing a variety of roles such 
as heat stress response, signal transduction, hyphal growth, endocytosis and apoptosis. Particularly, 
glucosylceramides (GlcCer) have been studying by our group during the last decades in 
Scedosporium/Lomentospora complex, being associated to fungal growth and pathogenesis. This study 
aims to evaluate the sphingolipid synthesis during the germination process, as well as the importance 
of different sphingolipids for fungal growth, membrane integrity using some inhibitors of the 
biosynthetic pathway. 
Methods: S. boydii conidia were treated with Myriocin, a serine palmitoyltransferase inhibitor, or 
PPMP (1-phenyl-2-palmitoylamino-3-morpholino-1-propanol), a glucosylceramide synthase 
inhibitor, and the results were compared to the non-treated control. Sphingolipid synthesis was 
evaluated by mass spectrometry of lipids extracted by fungal cells treated or not with the inhibitors. 
The effect of the inhibitors on fungal growth was analyzed by germination assay, colony forming 
units (CFU) quantification and biofilm formation. Filipin staining, checked by fluorescence 
microscopy, was performed to evaluate the accumulation of membrane microdomains on hyphal 
tips. Membrane integrity was analyzed by transmission electron microscopy (TEM) and fungal 
susceptibility to membrane stressors, such as SDS and NaCl. Susceptibility to antifungal agents in the 
presence of Myriocin and PPMP was evaluated through the checkerboard method. 
Results: S. boydii treated with Myriocin and PPMP displayed decreased sphingolipid production and 
showed a reduced growth, forming less CFU and biofilms compared to the control. Additionally, the 
germination process was impaired, since treated cells formed short germ tubes compared to mature 
hyphae in the control. It was confirmed with filipin staining, in which lipid raft accumulation in 
hyphal tips, essential for hyphae elongation, was not observed in treated cells. Analysis by TEM 
revealed the presence of regions with loss of membrane integrity, what was confirmed through the 
increase in membrane susceptibility to SDS and NaCl in treated cells. Myriocin-treated cells became 
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more susceptible to different classes of antifungal drugs, suggesting that sphingolipids on the 
membrane could interfere in drug susceptibility. 
Conclusion: Sphingolipids have been considering a potent target for the develop of new antifungal 
drugs. Thus, the study of these molecules in pathogenic fungal becomes a useful approach in medical 
mycology. The present data highlight the participation of sphingolipids in different fungal cell events 
that are crucial for fungal growth, virulence and drug resistance. Hyphae elongation and biofilm 
formation are important processes for mold proliferation and host tissue invasion. In addition, 
membrane integrity, especially regarding lipid raft areas, is essential for signal transduction, stress 
resistance and a variety of other physiological processes in fungal cells. For these reasons, the use of 
sphingolipid inhibitors helped to show how these molecules are promising targets for new drugs 
against Scedosporium/Lomentospora infections. 
 
P451 
Studying the unknown: implementation of two recognized protocols to characterize lipid droplets 
in Malassezia pachydermatis 
M. Mantilla1, G. Ariza1, C. Cabrera2, S. Restrepo1, A.M. Celis Ramírez1 
1Biological Sciences, Universidad de los Andes, Bogotá D.C., Colombia, 2Chemistry, Universidad de 
los Andes, Bogotá D.C., Colombia 
Objectives: Malassezia pachydermatis is a lipid-dependent yeast that is part of animal skin mycobiota 
and is associated with otitis externa and dermatitis in animals, as well as fungemia in humans. The 
lipid metabolism of this yeast is of high relevance because it may play an essential role during 
pathogenesis; however, these processes are yet to be well understood. Lipid droplets (LD) have 
become a subject of study in Malassezia, as they are known to store lipids and proteins in other 
biological models such as Mycobacteria, Hepatitis B virus, Saccharomyces cerevisiae and, mammal 
eukaryotic cells. Therefore, this study aims to standardize for the first time two protocols for the 
analysis of LD in Malassezia pachydermatis: The first one to characterize their structure by observation 
under a laser scanning confocal fluorescence microscopy; and the second one for the extraction and 
purification of LD for future lipidomic analysis. 
Methods: Here we standardized two protocols to describe LD: the first one to characterize the 
structure is based on co-staining yeast cells and LDs with different fluorochromes: Nile Red (Sigma-
Aldrich), LipidTox red neutral (Invitrogen) and BODIPY 493/503 (Invitrogen), in combination with 
calcofluor white (Sigma-Aldrich). The first three fluorochromes bind to neutral lipids present in the 
LD and calcofluor binds to the cellulose and chitin in the fungal cell wall. The second protocol to 
extract and purify LD induces yeast cell lysis by a combination of chemical and physical techniques, 
followed by the modification of the density of the solution with different buffers to allow the 
extraction and purification of LD. 
Results: We standardized a protocol to optimize LD fluorescent staining to characterize their 
structure under confocal microscopy. We found that the optimal steps are as follows: 1) Preparation 
of the staining solution with a mixture of 4% formaldehyde and the three neutral lipid fluorophores. 
2) Incubation at room temperature of LipidTox and Nile Red for 2 hours, and BODIPY for 30 minutes. 
3) Double washing with PBS, resuspension in 4% formaldehyde and mounting on microscope slides. 
4) Addition of calcofluor white, and 0.01% and 10%(v/v) KOH to the slide. We also optimized the 
protocol to get the of rupture M. pachydermatis cells for the extraction and purification of LDs. We 
found that the optimal conditions are: 1) Enzymatic digestion with Trichoderma harzianum enzymes 
(Sigma-Aldrich) for 2 hours at 47ºC. 2) Mechanical disruption by adding 0.5 mm zirconium pearls to 
the sample and ten cycles of 1 minute of a vortex and 30 seconds on ice. In addition, cell wall removal 
by stroking the sample 10 times with a Dounce homogenizer. 3) Finally, several ultracentrifugation 
cycles in buffers containing Ficoll 400 (Sigma-Aldrich) to separate the LDs in the supernatant from 
the organelles that stay in the pellet. 
Conclusion: Improving and standardizing these protocols can contribute to the study of the 
morphology, structure and, in the future, the lipid composition of LD in Malassezia pachydermatis. 
This study also could disclose clues about the lipid metabolism field in this yeast. 
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Characterization of the local inflammatory reaction after inhalative infection of 
immunocompromised mice with the mucormycete Rhizopus arrhizus 
C. Speth1,2, J. Marcabruni1, N. Parth1, F. Koci1, C. Lass-Flörl2, H. Maier3, G. Rambach4 
1Div Hygiene & Med. Microbiology, Med. Univ. Innsbruck, Innsbruck, Austria, 2Christian Doppler 
Laboratory for Invasive Fungal Infections, Innsbruck, Austria, 3Institute Of Pathology, INNPATH, 
Innsbruck, Austria, 4Div Hygiene & Med. Microbiology, Med. Univ. Innsbruck, Medical University 
of Innsbruck, Austria 
Objectives: The mucormycete species Rhizopus arrhizus mainly enters the body of 
immunosuppressed patients via inhalation of the spores. The local pathogenesis of inflammatory 
processes in the lung is poorly understood. For that reason we investigated the inflammatory reaction 
and the antifungal immune reaction in the lung of Rhizopus-infected mice. 
Methods: Mice treated with cortisone or cyclophosphamide were intravenously infected with a high 
dose of Rhizopus arrhizus spores. For comparison mice with selective deficiency in neutrophils, 
alveolar macrophages or complement were used. Lung parameters were investigated by histology 
and by isolation of bronchoalveolar lavage (BAL). Immune processes were quantified in blood 
samples taken from the animals. 
Results: Lack of neutrophils as well as treatment with cyclophosphamide were the most prominent 
risk factors for a lethal outcome after Rhizopus infection; in contrast, depletion of alveolar 
macrophages or cortisone treatment represented only moderate risk factors. Interestingly, 
complement deficiency even ameliorated the outcome, presumably due to a reduced inflammatory 
process. Lack of macroscopic organ abnormalities beside the lung indicated that fungal infection was 
mainly limited to the lung. BAL analyses revealed clear signs of excessive inflammation such as 
presence of erythrocytes, massive infiltration of granulocytes and high levels of the marker 
haptoglobin. Furthermore, macrophages in the lung were significantly augmented and these immune 
cells were highly activated. Most spores found in BAL were bound to or phagocytosed by neutrophils 
and macrophages and only few fungal hyphae were visible. 
Conclusion: Inflammatory processes in the lung after inhalation of Rhizopus arrhizus are the main 
reason for fatal outcome; fungal growth and/or dissemination plays a minor role. 
 
P453 
Pathogenesis and amphotericin B treatment of Lichtheimia corymbifera infection in a murine 
model 
G. Rambach1,2, J. Marcabruni1, N. Parth1, C. Lass-Flörl1,2, C. Speth1,2 
1Div Hygiene & Med. Microbiology, Med. Univ. Innsbruck, Innsbruck, Austria, 2Christian Doppler 
Laboratory for Invasive Fungal Infections, Innsbruck, Austria 
Objectives: Immunocompromised individuals are the main risk group for invasive mucormycosis, 
but the relevance of the precise nature of immunodeficiency is insufficiently investigated. 
Furthermore, only limited information exists about differences in the efficiency of amphotericin B 
(AmB) therapy in various patient groups. For that purpose we aimed to study pathogenesis and AmB 
treatment of inhalative Lichtheimia corymbifera infection and to compare the susceptibility of 
pancytopenic mice versus mice with selective defects in innate immunity. 
Methods: Mice treated with cyclophosphamide or cortisone or selectively deficient in neutrophils, 
alveolar macrophages or complement, were inhalatively infected with Lichtheimia corymbifera. Half of 
the animals received therapy with liposomal AmB. Survival, clinical status and immunological 
processes were monitored. 
Results: Immunosuppression of the animals with cyclophosphamide represented the most relevant 
risk factor for fatal outcome of Lichtheimia infection, followed by treatment with cortisone. Although 
neutropenia is assumed to be the correlate for susceptibility against fungal infection, selective 
depletion of neutrophils predisposed only moderately for severe disease and mortality. Interestingly, 
neither complement deficiency nor depletion of alveolar macrophages represented major risk factors 
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for the animals. Various clinical parameters such as body temperature and weight loss as well as 
immunological parameters confirmed these results. For those animals dying from invasive 
Lichtheimia infection, neurological symptoms were the second most reason for scarifying the mice. 
Treatment with liposomal AmB successfully improved the outcome in the animal groups with 
neutropenia, cortisone acetate and cyclophosphamide with the most prominent effect in the cortisone 
group. 
Conclusion: Affectation of several immune cell types is necessary to make the animals susceptible 
for invasive mucormycosis by Lichtheimia corymbifera, whereas selective loss of neutrophils or alveolar 
macrophages have only minor effects. 
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The role of Aspergillus fumigatus fumagillin in fungal virulence. 
X. Guruceaga1, U. Perez-Cuesta1, A. Pellon2, B. Uribe3, O. Gonzalez3, N. P. Keller4, F.L. Hernando1, J. 
Anguita2, R.M. Alonso3, A. Ramirez-Garcia1, A. Rementeria1 
1Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), Leioa, 
Spain, 2Inflammation And Macrophage Plasticity Laboratory, CIC bioGUNE, Derio, Spain, 
3Department Of Analytical Chemistry, University of the Basque Country (UPV/EHU), Leioa, Spain, 
4Department Of Medical Microbiology And Immunology, University of Wisconsin, Madison, United 
States of America 
Objectives: Aspergillus fumigatus is a saprophytic fungus capable to cause pulmonary infections in 
immunosuppressed patients. We have previously demonstrated an overexpression of 67% of the 
genes involved in the fumagillin metabolic pathway during experimental infection of 
immunosuppressed mice. The aim of this work was to demonstrate the implication of this molecule 
in fungal pathogenesis. 
Methods: We performed a set of in vitro experiments using commercial toxin preparations to first 
standardize the UHPLC-PDA analytical method and then identify its toxic effects on macrophages 
(RAW 264.7), melanome (B16-F10), and the lung epithelial (A549) cell lines. Moreover, we carried out 
fungus-host cell co-incubation assays using murine primary bone marrow derived macrophages 
(BMMs). Finally, in vivo assays were performed by intranasal infection of immunosuppressed Swiss 
mice treated with 100 mg/kg of cyclophosphamide intraperitoneally every 72 h, starting four days 
before the infection. The mice, in group on 10, were infected with, the non-fumagillin producer 
mutant strain, ΔfumR, as well as the wild type (WT), ΔakuBku80, and the complemented strains. All the 
experiments were repeated at least thrice. 
Results: The UHPLC-PDA method assay showed that A. fumigatus WT strain is able to produce the 
toxin at a 1.31 μg/ml growing in RPMI during 24 h at 37°C. Furthermore, when we incubated the cell 
lines in the presence of 1 μg/ml of commercial toxin for 24 h, eighty percent of the toxin disappeared 
from the media of A549 cultures, 58% in the case of B16-F10 melanome and only 4% in cultures with 
RAW 264.7 cells. However, the viability of the A549 cells was not significantly affected, while B16-
F10 and RAW264.7 cells showed a significant reduction in their viability compared to. untreated cells. 
Assays in vitro showed that the null strain, ΔfumR, was significantly more susceptible to phagocytosis 
by the BMMs than the complemented or WT control strains. On the other hand, no differences in 
germination were observed during the co-incubation with BMMs, but ΔfumR showed a significant 
increase in the percentage of double branches conidia compared to the other two strains. Indeed 
around 25% of the germinated ΔfumR conidia showed two branches after 8 hours of co-incubation. 
The in vivo study did not show any significant differences in mice survival between the groups 
infected with the ΔfumR and the WT strains. In contrast, mice infected with the complemented strain 
showed a higher mortality rate, maybe due to the increase secretion of fumagillin by complemented 
strain, as we showed in the in vitro assays. 
Conclusion: This study shows that A. fumigatus is able to secrete the mycotoxin fumagillin, a toxin 
that penetrates inside the cells causing cell death. Furthermore, this toxin could be a fungal defense 
factor against phagocytosis and may play an important role during A. fumigatus pulmonary infection. 
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Establishment of an experimental protocol of chronic tobacco exposure to study its effects on a 
mice model of pulmonary paracoccidioidomycosis 
R. Buccheri1,2, A. Nunes Duarte Neto1, F.L. Batista Da Silva2, G.O. Marques Haddad Carvalho2, L. 
Buffoni Roque Da Silva3, R. Soares De Azevedo Neto1, C.P. Taborda3, G. Benard4 
1Department Of Pathology, Medical School, University of São Paulo, São Paulo, Brazil, 2Laboratório 
De Investigação Médica Lim53, Insituto de Medicina Tropical, São Paulo, Brazil, 3Laboratório De 
Fungos Dimórficos Patogêncios, Biomedical Sciences Institute, University of São Paulo, São Paulo, 
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Medicina da Universidade de São Paulo, São Paulo, Brazil 
Objectives: Paracoccidioidomycosis (PCM) is caused by Paracoccidioides spp, and the most important 
systemic mycosis in non-immunosuppressed patents in Latin America. It has two major clinical 
presentations, the acute/subacute, more rare (≤5% of the cases) form (AF), and the more prevalent, 
chronic form (CF). In the AF, the phagocytic-mononuclear system is predominantly affected, while 
the lung is the target organ in the CF. The AF in general develops some time (weeks to months) after 
exposure to Paracoccidioides spp. and the CF develops from reactivated quiescent foci many years or 
decades after the initial exposure. However, we still do not know the factors that trigger the 
reactivation of the fungus and the development of the CF. Of note is the observation that most (>90%) 
CF patients refer tobacco smoking. It is well known that chronic tobacco exposure leads to imbalance 
of the pulmonary immune responses, and has a role in the development of other chronic pulmonary 
infections such as tuberculosis. We therefore aimed to develop a protocol of chronic tobacco exposure 
to study its effects on an experimental mice model of pulmonary PCM. We present here the 
preliminary results of this protocol. 
Methods: C57BL/6 animals were exposed to cigarette smoke for 120 minutes (equivalent to ~16 
cigarettes) twice/day, 5 days/week, for a total of 20 weeks, using a previously described device [Biselli 
PJC et al. Braz J Med Biol Res. 2011;44:460-468]. Three groups of animals were studied: an 
infected/exposed group, inoculated intra-tracheally with 102 P. brasiliensis yeast cells 2 weeks prior to 
initiation of tobacco exposure, an infected only group, and an exposed only group. The tobacco 
exposure protocol was adjusted to result in carboxyhemoglobin (COHb) levels of 10-15% after the 
daily first exposure, and 15-20% after the second exposure, to simulate the levels observed in chronic 
moderate smokers [Stewart RD et al. JAMA. 1974;26:1187-95]. Animals were sacrificed at weeks 4, 12 
and 20 and their lungs examined for colony forming units, area involved by the granulomatous 
inflammation and histological assessment of the effects of tobacco exposure. 
Results: The tobacco exposure protocol was successful in mimicking the effect of chronic tobacco 
smoking in humans: a) the mean level of COHb after the first tobacco exposure (measured monthly) 
was 15,5% (range 10,9-16,1%), and of 20,5% (range 15,9-21,1%) after the second exposure, while in the 
no-exposed infected group it was 0,1% (range 0-0,3%); b) By week 20 there were moderate dysplasia 
of the columnar epithelium, increased mucous production, alveolar septum destruction and focal 
areas of bronchiolitis. Preliminary data showed that tobacco exposure increased both the CFU and 
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the area involved by the granulomatous inflammation as shown below. 
 
Conclusion: These preliminary results indicate that: 1) We were able to establish a protocol of tobacco 
exposure mimicking that observed in patients with chronic form paracoccidioidomycosis. 2) Tobacco 
exposure impacts the pulmonary disease in a mouse model of PCM. Financial support: Fapesp 
#2016/08730-6 and #2017/12374-3. CPT and GB receive a senior researcher fellowship from CNPq 
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1Immunology, Microbiology And Parasitology, University of the Basque Country (UPV/EHU), Leioa, 
Spain, 2Department Of Clinical Pharmacy And Translational Science, University of Tennessee Health 
Science Center (UTHSC), Memphis, United States of America 
Objectives: Invasive aspergillosis is the most dangerous disease produced by Aspergillus fumigatus. 
To identify genes important for host-pathogen interactions, we analyzed fungal gene expression in 
contact with macrophages and lung epithelium cell lines, as well as during an in vivo infection in 
immunosuppressed mice and detected multiple genes overexpressed in all the situations. One of 
these genes, maiA, is involved in the Tyrosine metabolic pathway and could be an important gene for 
energy production during host-pathogen interactions. For that, the aim of this work was to 
characterize a mutant strain deficient in maiA gene. 
Methods: The loss of function mutant strain was built by CRISPR-Cas9 technology using the A. 
fumigatus genetic background Af-293. The transformation method was carried out using a standard 
protocol. For the phenotypic spot characterization assays, we used Glucose minimal medium (GMM) 
agar plates supplemented with Congo red (80 µg/ml), Calcofluor white (80 µg/ml), Voriconazole (0,5 
µg/ml), Caspofungin (4 µg/ml) or Anidulafungin (4 µg/ml) and minimal medium supplemented with 
L-tyrosine (10 mM) or Phenylalanine (10 mM) as the sole carbon source. Antifungal susceptibility 
tests using Voriconazole, Itraconazole, Isavuconazole, Posaconazole, Caspofungin and 
Anidulafungin were carried out following the EUCAST method. Finally, glucan quantification, 
following the Aniline blue assay, and pyomelanin quantification, using GMM broth and GMM broth 
supplemented with L-Tyrosine (10mM) or Phenylalanine (10mM), were also performed. All the 
assays were performed in triplicate. 
Results: The CRISPR-Cas9 technique provided a gene-targeting efficiency of 60% (3 out of 5 colonies) 
using the A. fumigatus genetic background Af-293. After spot dilution assays analysis, differences in 
the fungal growth between the wild type and the mutant strain were not found in presence of 
Calcofluor white, Voriconazole, Caspofungin or Anidulafungin. In contrast, ΔmaiA was 
hypersusceptible to Congo red despite a lack of significantly different amounts of glucan per 
milligram of mycelia. Furthermore, no significant differences were observed in the MIC or MEC for 
the triazoles or the echinocandins, respectively. However, ΔmaiA was unable to use either L-tyrosine 
or Phenylalanine as the sole carbon source and pyomelanin production by the mutant strain was 
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significantly higher than the wild type when GMM broth was supplemented with L-tyrosine or 
Phenylalanine. In GMM broth non-supplemented, both the wild type and ΔmaiA showed the same 
pyomelanin production pattern. 
Conclusion: CRISPR-Cas9 is an accurate technique that allowed us to generate the mutant strain 
ΔmaiA using the A. fumigatus genetic background Af-293 with a great efficiency. This mutant was not 
able to grow in presence of Congo red or to use L-Tyrosine or Phenylalanine as a sole carbon source. 
Pyomelanin production was higher for ΔmaiA in the presence of both amino acids, which is consistent 
with results published using other mutants of the Tyrosine degradation pathway. Future studies will 
explore in deep the role of maiA in animal models of IA. Acknowledgement. This study was funded 
by a grant of UPV/EHU (PPG17/41). EMBO Short-Term Fellowships and pre-doctoral grants of the 
UPV/EHU have supported XG and UPC respectively. 
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Objectives: Scedosporium species are filamentous fungi which commonly colonize the airways of 
patients with cystic fibrosis (CF). Nevertheless, there is only scarce information on their virulence 
mechanisms. Iron acquisition is crucial for the survival of nearly all microorganisms and is implicated 
in virulence of numerous pathogens that chronically inhabit the CF lung. Several genes relevant for 
siderophore-mediated iron uptake were previously identified in Scedosporium apiospermum genome, 
notably an orthologue of sidD, a non-ribosomal peptide synthetase (NRPS) gene that was 
demonstrated to drive the production of the extracellular hydroxamate-type siderophore fusarinine 
C (FsC) in Aspergillus fumigatus. Here, we aimed to determine the chemical structure of the 
siderophore produced by S. apiospermum sidD gene and to assess its role in fungal growth. 
Methods: First, sidD gene was disrupted in a wild-type (WT) strain after previous disruption of the 
gene ku70 encoding one of the components of the DNA repair system. Next, siderophore analysis 
was performed on lyophilized filtrates from WT and ΔsidD strains grown in minimal Yeast Nitrogen 
Base (YNB) medium for 48 h at 37°C. WT strain was cultured in YNB supplemented or not with 100 
µM bathophenantroline disulfonate (BPS), while the mutants (n = 3) were grown in YNB without BPS 
only. The impact of sidD deletion was then studied by cultivating the fungus on yeast extract-
peptone-dextrose-agar (YPDA) plates containing BPS and supplemented with culture filtrates from 
either WT or mutant strains. Finally, the ability of S. apiospermum to assimilate iron from 
xenosiderophores was assessed by using iron-saturated ferrichrome, ferrioxamine or pyoverdine (20 
µM each) as sole source of iron. 
Results: Analysis of the extracellular siderophores by high-resolution mass spectrometry performed 
on culture filtrate from WT strain yielded a molecular mass of m/z (M-2H + Fe)+ = 794.314 for the iron-
saturated siderophore, perfectly matching Nα-methylcoprogen B. This compound was absent in all 
ΔsidD mutant strains, indicating that sidD gene is essential for its synthesis. Other siderophores like 
FsC or TAFC were not found in any sample. Moreover, the disruption of sidD resulted in the lack of 
growth under iron-restricted conditions, and growth could be restored by supplementation of the 
culture medium (YPDA+BPS) with a culture filtrate from the WT strain. Conversely, incorporation of 
lyophilized filtrates from mutant strains in the culture medium did not rescue growth, corroborating 
the biochemical analyses. Interestingly, the use of iron-saturated ferrichrome or ferrioxamine as sole 
source of iron permitted a normal growth of all strains, indicating their direct assimilation by the 
fungus independently of siderophore production. Conversely, pyoverdine supported growth of the 
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WT strain only, suggesting that N-methylcoprogen B is important for iron acquisition from 
pyoverdine. 
Conclusion: Our results revealed that the S. apiospermum sidD gene drives the synthesis of a unique 
extracellular siderophore, Nα-methylcoprogen B, that is essential for fungal growth. This compound 
seems important for iron acquisition from pyoverdine, which might explain why S. apiospermum and 
Pseudomonas aeruginosa are rarely found concomitantly in the CF lungs. Works are in progress to 
determine the contribution of sidD in the virulence of S. apiospermum. 
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Objectives: Candida albicans is an opportunistic pathogenic fungus usually present in different areas 
of the human body such as mouth and gut. Under certain circumstances, this yeast is able to reach 
the bloodstream causing disseminated candidiasis. Therefore, C. albicans is in close relationship with 
human cells, being in constant contact with them. This microorganism has been related to cancer and 
metastasis through different mechanisms such as carcinogenic product synthesis and induction of 
pro-metastatic microenvironment. Among the types of cancer studied in relation to C. albicans are 
oral malignancies and melanoma metastasis. Hence, this work aims to determinate whether the 
exposure to C. albicans is able to change tumor cells phenotype, increasing their aggressiveness. 
Methods: Three tumor cell lines were used for this study: murine melanoma cells (B16M), human 
oral squamous cell carcinoma (H357) and murine colon carcinoma cells (C26). First, an adhesion assay 
was performed to test the effect of Candida albicans on tumor cells. Then, cancer cell lines were 
stimulated with antibiotic-inactivated fungus and conditioned media of the fungus, and wound 
healing assay was performed to measure migration activity of tumor cells. Afterwards, RNA was 
extracted from tumor cells to examine the expression of cancer-related genes by RT-qPCR and the 
supernatant was collected to measure the level of pro-inflamatory and cancer-related cytokines by 
ELISA. 
Results: First, we observed that C. albicans was able to adhere to the three tumor cell lines. Then, 
wound healing assays with both antibiotic-inactivated C. albicans and conditioned media of C. albicans 
showed an increase in migration capacity of the different cell lines in comparison with the control, 
which indicates that the exposure to this fungus can induce a phenotypical change in tumor cells. 
The pro-tumor microenvironment was also altered, being the expression of different studied 
cytokines and cancer-related genes increased in presence of the fungus. 
Conclusion: These results suggest that exposure to C. albicans induce alteration or changes in tumor 
cells and the related microenvironment that can lead to an increased malignancy. Acknowledgement: 
This study was funded by a grant of UPV/EHU (PPG17/41). Pre-doctoral Grants of Basque Government and 
UPV/EHU have supported LMS and LAF respectively. 
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Objectives: Therapeutic drug monitoring for posaconazole (POS) tablet and isavuconazole (ISA) is 
still under debate and target trough concentrations (Cmin) need to be specified. We aimed to 
investigate the pharmacokinetic-pharmacodynamic relationship of POS and ISA, using a bioassay 
approach as surrogate marker of antifungal activity, in order to refine the therapeutic Cmin of both 
antifungals. 
Methods: A bioassay using a cellulose disk diffusion method was performed to determine the growth 
inhibition zone (GIZ) of POS and ISA on A.fumigatus (POS and ISA) and C. parapsilosis (ISA only). 
GIZs of plasma from patients undergoing routine TDM for POS (n = 136) or ISA (n = 40) were 
determined. 
Results: GIZs of plasma patients and antifungal Cmin were highly correlated both for ISA (A fumigatus: 
rho = 0.942, p<0.0001; C. parapsilosis: rho = 0.949, p<0.0001) and POS (rho = 0.922, p<0.0001), and these 
relationships were represented with a Michaelis-Menten model. Based on this modeling, the 
recommended thresholds of 0.7, 1, and 1.25 mg/L for the POS Cmin corresponded to 50.1, 55.2, and 
59.1% of the maximal GIZ, respectively. We propose an upper threshold of 4.8 mg/L for the POS Cmin 
and a lower threshold of 2.0 mg/L for the Cmin of ISA, as they respectively corresponded to 
concentrations leading to 90 % and 50 % of the maximal GIZ on A.fumigatus. 
Conclusion: The determination of antifungal activity using this bioassay allowed refining target Cmin 
for both POS and ISA, especially the upper threshold of POS (4.8 mg/L) and the lower threshold of 
ISA (2.0 mg/L). 
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Tronche, France, 7Centre de ressources biologiques, CHU Grenoble Alpes, GRENOBLE Cedex , 
France, 8Univ. Grenoble Alpes, CHU Grenoble Alpes, TIMC-Therex, Grenoble, France 
Objectives: Voriconazole (VRC) exhibits a highly variable pharmacokinetics which is partly related 
to genetic polymorphisms affecting activities of cytochromes (CYP) 2C19 and 3A. This prospective 
observational study aimed to evaluate the impact of a previously described genetic score combining 
CYP2C19 and CYP3A genotypes (Gautier-Veyret, AAC 2015) to predict infratherapeutic plasma VRC 
trough concentration (Cmin) (defined as VRC Cmin < 1mg/L) in order to individualize VRC dose. 
Methods: CYP2C19, CYP3A4 and CYP3A5 genotypes were determined in hematological patients 
treated by VRC and who benefited from longitudinal therapeutic drug monitoring in Grenoble 
University Hospital between January 2016 and December 2018. The genetic score was determined for 
each patient and patients were classified according to their genetic score ≤ or > 2. The higher the 
genetic score, the faster the metabolism of the patient. Statistical analyzes were performed on VRC 
Cmin adjusted on dose (VRC Cmin/D), considering either the initial VRC Cmin/D or all VRC Cmin. 
Results: Forty-three patients (43 % of female, median age [Q1-Q3]: 57 [45-67] years) were included 
and 127 VRC Cmin analyzed. Ninety five percent of patients (41/43) received VRC for curative 
treatment of invasive aspergillosis (22 possible, 17 probable and 2 proven). Median initial VRC Cmin 
was 2.2 [1.1-4.3] mg/L and 21 % of patients (n = 9/43) had infratherapeutic initial VRC Cmin. Sixty-
three percent of patients had at least one genetic variant for CYP2C19, 3A4 or 3A5, with 8 patients 
with a genetic score <2. Among 9 patients with infratherapeutic initial VRC Cmin, 8 (89%) had a 
genetic score ≥ 2. In univariate analysis, initial VRC Cmin/D, as well as all VRC Cmin/D was not 
influenced by genetic score, but significantly associated with advanced age, increased CRP and 
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bilirubin levels. Multivariate analysis performed in all VRC Cmin/D identified CRP (p<0.0001), 
bilirubin (p = 0.01) and age (p = 0.007) as independent determinants of VRC Cmin/D, while genetic 
score had no impact. Genetic score was significantly associated with VRC Cmin/D only in the 
subgroup of VRC Cmin (n = 51) determined in absence of severe inflammation (defined by CRP level 
< median CRP of 65 mg/L). 
Conclusion: Our genetic score that combined genetic variants of CYP2C19, 3A4 and 3A5 seems 
interesting to predict subtherapeutic VRC Cmin, but its impact is suppressed by severe inflammation. 
Strategies for individualization of VRC dose must integrate pharmacogenetics variants, but also the 
inflammatory status of patient. 
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Objectives: The use of posaconazole as prophylaxis for influenza-associated aspergillosis is currently 
investigated in critically ill patients. An important subset of patients admitted to the intensive care 
unit (ICU) for influenza is undergoing extracorporeal membrane oxygenation (ECMO) for severe 
acute hypoxemic respiratory failure. Little is known on the exposure to posaconazole in this 
population. This study presents the pharmacokinetics (PK) of seven ICU patients treated with 
intravenous posaconazole while on ICU undergoing ECMO. 
Methods: All but one of the included patients were participating in the posaconazole-arm of the 
ongoing multicenter Posa-Flu study (NCT03378479), assessing the efficacy of a 7-day prophylactic 
intravenous treatment with posaconazole in ICU patients admitted for severe influenza. The 
additional patient was a lung transplant recipient treated with posaconazole for invasive 
aspergillosis. Blood samples were collected at an early (day 2-3) and late (day 5-7) time point, using 
a full (predose, 1.5,2,3,4,6,8,10,12,18,24h) or limited (predose, 1.5-3, 4-8, 8-12, 12-24h) sampling 
scheme. Trough concentrations were collected on all other days. All patients received an intravenous 
loading dose of 300 mg BID followed by a maintenance dose of 300 mg QD. Written informed consent 
was obtained from the patients or their relatives. PK parameters were estimated in Excel® . 
Results: All patients received veno-venous ECMO and two patients were supported by continuous 
veno-venous hemodialysis (CVVH). The median area under the curve (AUC0-24), clearance (CL) and 
volume of distribution (Vd) were 35.69 mg.h/L, 8.42 L/h and 421.0 L, respectively. Exposure 
documented in the ECMO patients is shown in Table 1, along with the results previously documented 
in healthy volunteers, patients with hematological disease and critically ill patients. As shown in 
Figure 1, all trough concentrations (Cmin) were above 0.7 mg/L, which is the suggested threshold for 
prophylaxis in patients with hematological disease, and 71% of the Cmin were also ≥ 1 mg/L, which is 
the suggested hematological threshold for treatment of invasive aspergillosis (ECIL-6 and ESCMID-
ECMM-ERS 2017). The median average concentration (Cavg) of both exposure days, i.e. 1.49 mg/L, 
was within the European Medicines Agency (EMA) target range (0.5-2.5 mg/L). The targeted 
posaconazole AUC0-24 of 20.87-22.5 mg.h/L for a MIC value of 0.125 mg/L (DRU 2014), was also 
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achieved. 
 
Conclusion: Posaconazole exposure was similar compared to that documented in hematology 
patients but higher than in ICU patients without ECMO. The lower limit for prophylaxis, as 
recommended in patients with hematological malignancies, is attained in all patients. This should be 
interpreted with caution as the optimal exposure to ensure prophylactic efficacy might be different 
in critically ill patients admitted for severe influenza. This optimal exposure is currently being 
investigated in the Posa-Flu trial. Based on this limited dataset, ECMO does not seem to influence 
posaconazole exposure. An a priori dose adjustment does not seem to be necessary but therapeutic 
drug monitoring is recommended to confirm the exposure. Despite the fact that this observation 
should be established in a larger number of patients, these results suggest that posaconazole exposure 
is maintained in critically ill patients undergoing ECMO. Hence we recommend the standard dosing 
regimen. 
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Objectives: One in five individuals will be obese in 2025. Obesity is associated with underdosing of 
antimicrobial drugs for prophylaxis and treatment of (life-threatening) infections. Posaconazole is a 
broad-spectrum triazole antifungal drug frequently used for prophylaxis and treatment of mold 
infections. There is anecdotal evidence that posaconazole exposure is impacted by weight resulting 
in suboptimal target attainment. We performed a prospective clinical trial to investigate the effect of 
body size in obese subjects and determined the probability of reaching the target trough 
concentration for prophylaxis (>0.7mg/L) and therapy (>1.0mg/L). 
Methods: Obese subjects (BMI above 35 kg/m2) undergoing bariatric surgery and normal-weight 
subjects (BMI 18.5-25 kg/m2) were included in an open-label, single-dose, multicenter, 
pharmacokinetic study. Obese subjects were randomized to receive either 300 or 400 mg 
posaconazole IV while normal-weight subjects all received 300 mg posaconazole IV. Blood samples 
were collected at nine time points up to 24 hours after start of infusion. Statistical analysis and 
population pharmacokinetic modeling was performed using R and NONMEM 7.3. 
Results: 8 obese subjects on 300 mg, 8 obese subjects on 400 mg and 8 normal-weight subjects on 300 
mg were included. Weight [range] was 129 kg [109-190]), 144 kg [107-175]), 72.3 kg [61.4-85.4] 
respectively. The observed geometric mean [range] AUC0-24h in normal-weight versus obese subjects 
receiving 300 mg posaconazole was 21.4 mg*h/L [15.6-29.1] versus 13.1 mg*h/L [9.1-18.5] (p<0.05). 
Obese subjects receiving 400 mg posaconazole had an AUC0-24h of 16.8 mg*h/L [12.2-25.6].A two-
compartment model with first-order elimination, a proportional residual error model and inter-
individual variability on the central compartment best described the data. Total body weight was the 
best predictor of variability of clearance and the central and peripheral compartment. Simulations 
demonstrated that a 300 mg dose results in a >90% PTA in patients up to 190kg for prophylaxis. For 
treatment, a 300 mg dose is sufficient up to 120 kg after which a dose increase to 400 mg daily should 
result in a >90% PTA up to 170 kg. 
Conclusion: We found that obese individuals have a significant lower exposure to posaconazole 
compared to normal-weight individuals even when using a 400 mg dose. Nevertheless, PTA (at 0.7 
mg/L) was high using the IV formulation. In the treatment setting higher dosages are warranted. 
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Objectives: Cytochrome P450 (CYP) 2C19 genetic polymorphism contributes to variability of 
voriconazole pharmacokinetics. Supra-therapeutic voriconazole trough concentrations have been 
correlated with hepatotoxicity. This study aims to establish the effects of CYP2C19 profile on 
voriconazole troughs and hepatotoxicity. 
Methods: A prospective, observational study was done to determine voriconazole trough 
concentrations at pre-steady state (day 2 to 4 of therapy) and steady state (day 6 onwards). Blood 
sampling was repeated weekly until week 12 of recruitment or death. The CYP2C19 genotype was 
also identified for patients on voriconazole. 
Results: 11 patients were analyzed for CYP2C19 polymorphism: 1*/1* normal metabolizers (n = 5, 45 
%), 1*/2* intermediate metabolizers (n = 3, 27 %) and 2*/2* poor metabolizers (n = 3, 27 %), 
respectively. 4 out of 6 patients were intermediate or poor metabolizers whom had supra-therapeutic 
voriconazole concentrations (trough > 5.5 mg/L). All poor metabolizers developed abnormal liver 
function tests (range of ALP: 230 to 630). 
Conclusion: Knowledge of CYP2C19 profile would allow pre-emptive dose adjustments during the 
first week of voriconazole therapy and thus reduce the incidence of hepatotoxicity. 
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Objectives: In 2014, approximately 11% of adult men and 15% of adult women were obese 
worldwide, a number that is increasing. Like other patients, obese patients may be confronted with 
invasive fungal disease and require treatment with antifungal agents such as liposomal amphotericin 
B (L-AmB, Ambisome® ). We performed a pharmacokinetic study in morbidly obese individuals to 
define the optimal dose of L-Amb by quantifying the impact of obesity on the pharmacokinetics of 
L-AmB. 
Methods: In this open-label study, morbidly obese but otherwise healthy subjects (BMI > 40 kg/m2) 
received L-AmB received a single dose of 1 or 2 mg/kg (n = 8+8) the day before undergoing 
laparoscopic bariatric surgery. Each subject was intensively sampled (n = 9) up to 48 hours to 
determine amphotericin B plasma concentrations. The following information was collected: body size 
descriptors (e.g. total body weight [TBW], lean body weight, BMI, ideal body weight calculated 
according to Janmahasatian et al., body surface area), age and sex. Population pharmacokinetic 
analyses was performed in NONMEM 7.3 with PsN 4.7. For the covariate analyses the relationships 
between empirical Bayes estimates and covariates were investigated in scatter plots. The final model 
was used to simulated AUC0-24h and Cmax in steady state conditions in 10.000 subjects with body 
weights uniformly distributed between 60 and 180 kg. Each virtual subject < 100 kg received a daily 
3 mg/kg L-AmB infusion in one hour, subjects ≥100 kg received either 3 mg/kg or a fixed 300 mg dose 
as a one hour infusion. 
Results: 16 morbidly obese subjects with median [range] BMI of 45.9 [40.2-52.1] kg/m2 and a total 
body weight of 137 [104-177] kg were included. A two-compartment model best explained the data. 
There was no relationship between clearance of L-AmB and any of the body size descriptors. A linear 
relationship was found between the central volume of distribution (Vc) and TBW. Simulations show 
that the AUC0-24 increases with weight when patients are dosed on a mg per kg basis. ). In parallel, 
Cmax also increases with body weight when L-AmB is dosed on a per kg basis. This phenomenon is 
primarily driven by the absolute increase in the dose with a clearance that does not change with 
weight. When using a dose cap of 300 mg for patients > 100 kg the AUC would remain similar across 
weight while a similar Cmax (13% lower) in a 140 kg patient compared to a 70 kg patient will be 
obtained. 
Conclusion: Based on our results we see limitations to using a mg per kg dose regime for adult 
patients as clearance and therefore exposure to AmB is not affected by body weight. In addition, body 
weight derived dosing might lead to an increased risk of toxicity in heavy patients since toxicity is 
associated with AUC. A fixed dose regimen would not only be more appropriate but also more 
practical for clinicians. In obese patients specifically, we recommend using the licensed 3 mg/kg dose 
and cap the dose at a maximum weight of 100 kg resulting in a 300 mg fixed dose. 
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Objectives: Candida auris has recently emerged as a cause of nosocomial outbreaks. The health alert 
caused by this pathogen is related to the difficulty of a proper identification, its persistence in the 
hospital environment and multidrug resistance. Antifungal combination therapy may allow to 
overcome this multiresistance. Despite their relevance, research about the activity of antifungal drug 
combinations against C. auris is still scarce. The objective of this study was to evaluate the activity of 
the combinations of amphotericin B with anidulafungin or caspofungin against C. auris clinical 
isolates by time-kill curves. 
Methods: In vitro static time-kill curves experiments were performed in duplicate in microtitre plates 
in RPMI-1640 medium with six C. auris clinical blood isolates (Hospital La Fe, Valencia, Spain). 
Inoculum size ranged from 1 to 5 x 105 CFU/mL and concentrations assayed in combination 
experiments were 0.5 and 1 mg/L for amphotericin B and 0.25, 0.5, 1 and 2 mg/L for anidulafungin 
and caspofungin. Samples for viable counts were taken at 0, 2, 4, 6, 8, 24 and 48 h. Plots of averaged 
colony counts (log CFU/mL) versus time were constructed for data analysis. The first-order killing 
rate constant K (h-1) obtained after fitting an exponential equation to the data and time to achieve the 
fungicidal endpoint t99.9% (h) were calculated to assess antifungal activity and to compare different 
combinations between them. Fungistatic or fungicidal activities, and synergistic, antagonist or 
indifferent interactions between these drugs were considered according to published definitions [1]. 
Results: Combinations of 0.5 mg/mL of amphotericin B with 0.5, 1 and 2 mg/mL of anidulafungin or 
caspofungin were synergistic ( >2 log reduction compared to the drug with greater activity) and 
fungistatic. However, combinations of 1 mg/mL of amphotericin B with 0.25 and 0.5 mg/mL of 
anidulafungin or caspofungin were additive (<2 log reduction) and fungicidal. There were not 
significant differences between the use of anidulafungin or caspofungin in combinations with 
amphotericin B. 
Conclusion: Combination of amphotericin B with anidulafungin and caspofungin showed promising 
results. Combinations of 0.5 mg/L of amphotericin B with low doses of echinocandins were 
synergistic, whereas the interaction with 1 mg/mL of amphotericin B was additive but exerted 
fungicidal activity. This is a remarkable finding, specially if we take into account that echinocandins 
do not show fungicidal behaviour against C. auris. The results could support the use of these 
antifungal combinations for treating C. auris deep infections. Funding: This study was partially 
financed by GIC 15/78 IT-990-16 (Gobierno Vasco-Eusko Jaurlaritza), PI17/01538 (FIS,Spain) and 
SAF2017-86188-P (MINECO, Spain). Unai Caballero has received a grant by the University of the 
Basque Country (UPV/EHU) [1] Serena C et al., In vitro interactions of micafungin with amphotericin 
B against clinical isolates of Candida spp. Antimicrob Agents Chemother. 2008; 52(4):1529-32 
 
P472 
Time-kill Studies of Caspofungin in an Ex vivo model in Relation to Plasma Protein Levels: Is the 
Protein Binding Less Than Expected? 
S. Kurland1, M. Furebring1, A. Shams1, E. Chryssanthou2, J. Sjölin1, E. Löwdin1 
1Section Of Infectious Diseases, Department Of Medical Sciences, Uppsala University, Uppsala, 
Sweden, 2Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden 
Objectives: The echinocandin caspofungin is used as first-line therapy in candidemia, the most 
common invasive candida infection. The protein bound fraction of caspofungin is 96.5% (in healthy 
volunteers). In our recent study on critically ill patients treated with caspofungin, a median AUC in 
plasma of 58 (range 44-113) mg*h/L was reported, corresponding to an average plasma concentration 
of 2.4 (1.8-4.7) mg/L. This would result in a free unbound concentration of 0.08 (0.06-0.16) mg/L, 
concentrations equivalent to the MIC distribution for wild type Candida glabrata. For fungicidal effect 
higher free concentrations would be needed. In critically ill patients the plasma protein level is 
habitually reduced. The objectives of this study were to determine the killing effect of caspofungin 
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on C. glabrata with clinically relevant concentrations of caspofungin in an ex vivo model using human 
plasma and furthermore to study the efficacy in relation to different plasma protein levels. 
Methods: The efficacy of caspofungin on four blood isolates of C. glabrata was determined by time-
kill studies performed in plasma from healthy blood donors. In order to investigate the significance 
of the protein level on the killing effect of caspofungin, C. glabrata with an inoculum of 5x10⁴ CFU/ml 
was added to plasma, plasma diluted with 50% Ringer ś Acetate (Ri-Ac) and plasma diluted with 
75% Ri-Ac. The MIC values for the isolates were determined by Sensititre Yeast One method and 
were 0.06, 0.12 and 1 mg/L, respectively. The caspofungin concentrations investigated were 1, 2, 5 
and 9 mg/L. CFU/ml were determined at 0, 2, 6 and 24 hours. 
Results: The results showed a higher reduction in CFU/ml than expected based on MIC and the 
calculated unbound caspofungin concentration. There was a ≥ 2 log reduction in log CFU/ml with a 
concentration of 1 mg/L (corresponding to 0.035 mg/L free drug/unbound concentration) for the two 
strains with MIC 0.06 mg/L. For the strain with MIC 0.12 mg/Lthe corresponding reduction was 
approximately 1 log CFU/ml. Furthermore, there was a limited but significant decrease in CFU/ml in 
the time-kill studies performed in plasma with reduced levels of protein in comparison with plasma 
with normal protein level. For the strain with MIC 1 mg/L there was no reduction in CFU/ml in 
plasma. Although, there was a killing with the concentrations 5 and 9 mg/L in the experiments in 
plasma diluted with 75% Ri-Ac. 
Conclusion: The killing of C. glabrata with caspofungin in plasma was higher than expected based on 
MIC and the reported amount of unbound caspofungin in normal plasma. At lower protein levels 
this killing was augmented which is consistent with an increased concentration of free caspofungin. 
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Subcutaneous nodule caused by Phaeoacremonium fuscum in a non-immunocompromised patient. 
S. Colman, L. Cattoir, A. Boel 
Microbiology, OLV Hospital, Aalst, Belgium 
Case Report: Introduction Phaeohyphomycosis (PHM) is a chronic infection caused by dematiaceous 
fungi which usually involves the skin and subcutaneous tissue. As a result of the use of molecular 
diagnostic techniques, previously unrecognized causative agents of phaeohyphomycosis have been 
discovered. Here we report the first case of phaeohyphomycosis caused by Phaeoacremonium fuscum 
in an immunocompetent patient. Case presentation A 60 year old Filipino male presented with 
rotator cuff pathology to the orthopedics consultation. On physical examination a painless, soft, 
subcutaneous mass above the right patella was noted, which didn’t cause the patient any complaints. 
The suprapatellar nodule had been growing slowly for 3 years. The patient denied any apparent 
antecedent trauma, arthropod bite, family history or contact with a person with similar lesions. The 
man still visits the Philippines on an infrequent basis. He had no fever, weight loss or other 
symptoms. Detailed physical examination further revealed a 4x3 cm, immobile, non-pulsatile light 
red mass. There were no other signs of inflammation of the skin. A serous effusion was aspirated 
from the mass. Fungal culture of the aspirated fluid showed growth of a filamentous fungus on 
chocolate blood agar and Sabouraud's dextrose agar. Molecular identification was performed by 
sequence analysis of the internal transcribed spacer region 2 (ITS2). BLAST search revealed a 
similarity of 100% with Phaeoacremonium fuscum.  The antifungal susceptibility profile was established 
by EUCAST broth microdilution: itraconazole >16 mg/L, posaconazole 0.25 mg/L, amphotericin B 
0.50 mg/L, voriconazole 0.50 mg/L. This susceptibility profile is similar to those previously published. 
A wide local excision of the lesion was performed a couple of weeks later. The patient had an 
uneventful postoperative recovery. No antifungal therapy was started postoperatively since the 
patient was not immunocompromised and there was lack of reimbursement. Histopathological 
examination of the specimen showed fibrous tissue with a mixed cellular infiltrate including 
lymphocytes, plasma cells, macrophages and neutrophils. Periodic acid-schiff stain and Grocott stain 
showed evidence of branching septate hyphae. Discussion PHM is caused by brown pigmented fungi 
containing melanin in their cell wall. Phaeoacremonium species are known as vascular plant 
pathogens, responsible for wilting and dieback of woody plants. They are also opportunistic 
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pathogens in humans, mainly causing cutaneous or subcutaneous PHM. However, sporadic cases of 
respiratory tract infection, septic arthritis and disseminated infection are described. The true 
prevalence of Phaeoacremonium species is probably underestimated due to the asymptomatic nature 
of most subcutaneous lesions and the difficult identification. There is no standard antifungal regimen 
or evidence regarding the necessity for antifungal treatment as concomitant with surgery for 
localized infections. Long courses of antifungals, such as voriconazole treatment, are often employed 
to reduce the risk of recurrence. Case reports suggest that surgery can be curative if the infection is 
localized and adequately removed, as was the case in our patient. Regardless of the immune status 
of the patient, clinicians should consider the possibility of a fungal infection when they encounter 
chronic subcutaneous nodules without major symptoms. 
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Belgian national survey on tinea capitis: epidemiology and molecular investigations. 
R. Sacheli1, X. Menatong1, C. Labarbe1, C. Crutzen1, S. Harag2, J. André2, S. Evrard3, K. Lagrou4, K. 
Laffineur5, D. Rousseaux6, L. Detollenaere1, C. Adjetey1, L. Seidel7, M.-P. Hayette1 
1Clinical Microbiology- Nrc For Mycoses, University Hospital of Liège, Liège, Belgium, 
2Dermatology, CHU St Pierre, Brussels, Belgium, 3Clinical Microbiology, CHR Citadelle, Liège, 
Belgium, 4Clinical Bacteriology And Mycology, Katholieke Universiteit Leuven, Leuven, Belgium, 
5Clinical Biology, Clinique St Luc Bouge, Bouge, Belgium, 6Clinical Biology, Centre Hospitalier 
Chretien Heusy, Verviers, Belgium, 7Statistics, University Hospital of Liège, Liège, Belgium 
Objectives: Tinea capitis (TC) is a superficial infection of the scalp caused by dermatophyte fungi 
which affects mainly prepubescent children. This last decade, a huge increase of African 
anthropophilic strains causing tinea capitis, has been observed in Europe, probably due to 
immigration waves from African countries. The Belgian National Reference Center for Mycosis 
(NRC) has conducted a surveillance study about TC in 2018. This work presents final results of the 
study for the epidemiological part and preliminary results for the molecular part. 
Methods: Belgian laboratories were invited to send all dermatophytes strains isolated from the scalp 
from January to December 2018. Dermatologists were involved and were asked to fill a form 
containing several epidemiological information about the patient. Strains identification was 
confirmed by ITS sequencing. A multiplex pan-dermatophyte real time PCR assay (DermaGenius® , 
PathoNostics) was applied if necessary. Typing of the M.audouinii strains was done using rep-PCR 
method (Diversilab, BioMérieux). 
Results: A total of 337 strains have been collected from 337 patients. The main population concerned 
by TC was children from 5-9 years (165/337, 49,01%). Males (214/337, 63,5%) were more affected than 
females (123/337, 36,5%), the sex ratio M/F was of 1,74. The majority of the strains was collected in 
Brussels area (181/337, 53,8%), followed by Liege area (73/337; 21,7%). Other Belgian cities were less 
concerned by TC. Among known ethnical origins (n = 119), African people (114/119, 96,2%) were 
more concerned by TC than European people (5/119, 3,8%), (p<0,0001). The majority of patients were 
from Guinea (26/119, 21,8%), followed by Cameroun (14/119, 11,8%) and RDC (14/119, 11,8%), many 
other African nationalities were represented (12 different countries, all over Africa). The main 
transmission mode of TC was the familial way (83,3% among known cases n = 126, 105/126). The 
major etiological agent was Microsporum audouinii (118/337, 35%) followed by Trichophyton soudanense 
(83/337, 24,6%), T. tonsurans (27/337, 17%), M. canis (36/337, 10,7%), T. violaceum (28/337, 8,3%), T. 
benhamiae (7/337, 2,1%), T. mentagrophytes (5/337, 1,48%) and M. incurvatum (1/337, 0,3%). This last 
rare dermatophyte has never been reported as responsible for TC in Belgium before. M. audouinii 
strains have been genotyped by rep-PCR and three genotypic variants have been characterized, one 
of them circulating mainly in Brussels area. No link with a particular ethnical origin could be found 
among genotypic groups. 
Conclusion: African anthropophilic dermatophytes such as M.audouinii and T. soudanense are mainly 
responsible for tinea capitis in Belgium. Large cosmopolitan cities like Brussels and Liege are the 
most concerned. People from African origin are mostly affected by TC. Among the M. audouinii 
strains circulating in Belgium, a genotypic diversity has been characterized. 
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Identification of dermatophytes isolated from tinea capitis infections using a liquid media 
MALDI-TOF MS protocol 
P. Lecerf1, Y. Jazaeri1, M. Hendrickx2, B. Richert1, A. Packeu3 
1Faculty Of Medecine, Université Libre de Bruxelles, Brussels, Belgium, 2Mycology, Sciensano, 
BCCM/IHEM, Brussels, Belgium, 3Mycology & Aerobiology, Sciensano, Brussels, Belgium 
Objectives: Tinea capitis is a common childhood superficial infection of the scalp caused by 
dermatophytes. Conventional methods based on morphological characteristics to identify theses 
fungi are time-consuming and complex, requiring expert mycological knowledge. Recently, MALDI-
TOF MS has become a powerful tool in clinical microbiology for rapid identification of these 
microorganisms. In the present study, a liquid media MALDI-TOF MS protocol was developed and 
validated for the fast and accurate identification of dermatophytes species responsible for tinea capitis 
infection, using both dermatophytes from reference strains and clinical isolates. The main purpose 
was to work with primary isolates in order to avoid the culture step and lead to a faster diagnosis. 
Identification techniques (conventional identification and MALDI-TOF MS based on liquid and solid 
culture) were evaluated and compared for their rate of correct identification and turnaround time.for 
the fast and accurate identification of dermatophytes species responsible for tinea capitis infection, 
using both dermatophytes from reference strains and clinical isolates. The main purpose was to work 
with primary isolates in order to avoid the culture step and lead to a faster diagnosis. Identification 
techniques (conventional identification and MALDI-TOF MS based on liquid and solid culture) were 
evaluated and compared for their rate of correct identification and turnaround time. 
Methods: The in-house BCCM/IHEM database made from references strains on solid culture was 
used. First, the liquid media MALDI-TOF MS protocol was validated using references strains. 
Secondly, the same protocol was applied on clinical isolates collected from Saint-Pierre University 
Hospital and paralleled with solid media MALDI-TOF MS protocol. 
Results: The use of the liquid media MALDI-TOF MS protocol resulted in a rate of 100% of correct 
identification at the species level for reference strains and 78,8% for clinical isolates. The protocol was 
statistically significantly faster than the conventional method. The results of the different methods 
disagreed for 17 isolates. The complete extraction from the solid media MALDI-TOF MS gave the 
highest correct species identification with the highest mean of log-scores. 
Conclusion: The liquid media MALDI-TOF MS technique is an accurate method for the correct 
identification of dermatophytes at the species level and is much faster than the conventional 
technique. The main advantage lies in not needing a culture step for primary isolates, thus leading to 
a faster diagnosis. For the identification of closely related species, the complete extraction from solid 
media MALDI-TOF MS protocol remains the most reliable technique. 
 
P478 
Dermatophytes’ identification by Matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS) - the experience of a clinical laboratory 
C. Verissimo, H. Simões, R. Sabino, D. Simões 
Infectious Disease, National Health Institute, Lisbon, Portugal 
Objectives: Dermatophytes are a challenging group of fungi that infect the keratinized tissues. The 
taxonomy of these fungi has changed recently with the reclassification of some species and 
description of new ones. However, many clinical laboratories still base the identification of 
dermatophytes on their phenotype. Since dermatophytes are very pleomorphic, macro and 
micromorphology are often insufficient to reach a correct classification and may lead to 
misidentifications. The identification based on MALDI-TOF relies on the protein profile of the 
microorganism. Thus, this study aims to summarize our current laboratorial experience of 
dermatophyte identification using MALDI-TOF MS. 
Methods: From january to april 2018, 95 dermatophytes isolates, collected from human keratinized 
samples and also from quality control programs were characterized by phenotypic analysis, and by 
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VITEK MS V3.2 bioMerieux. Before identification procedure, isolates were inoculated on Sabouraud 
Dextrose agar plates and incubated at 27°C during 5 to 10 days. Species were identified taking into 
account clinical features, as well as cultural, microscopic and physiological characteristics. Prior to 
MALDI-TOF MS analysis, the samples were pre-treated according to the manufacturer’s protocol for 
filamentous fungi. Molecular identification by sequencing of the internal transcribed spacer 1 (ITS1) 
was performed in 34 of those isolates 
Results: Through phenotypic analysis eight different species were identified (54 Trichophyton 
rubrum; 4 T.soudanense; 22 T.interdigitale; 1 T.mentagrophytes; 3 T.tonsurans; 7 Microsporum canis; 
3 M.audouinii; 1 Microsporum spp.- (non canis or audouinii). MALDI-TOF analysis showed an 
identification agreement in 80 cases (84,2%) with a confidence level of 99,9%. Eight isolates showed 
divergent identification results: three T.rubrum were identified as T.violaceum, three T.soudanense 
were identified as T.rubrum, one T.mentagrophytes was identified as T.interdigitale and one 
T.tonsurans was identified as T.rubrum. In four cases MALDI-TOF analysis did not get a profile. The 
ITS sequencing analysis of discrepant results corroborated the MALDI-TOF identification in five of 
them. On the other hand, T.soudanense was only identified by phenotypic analysis since MALDI-
TOF and ITS sequencing result was T.rubrum. MALDITOF identification of T.violaceum was not 
confirmed by ITS sequencing that identified T. rubrum instead, in accordance with the phenotypic 
identification. 
Conclusion: Correct identification of dermatophytes to species level requires sequencing of the ITS, 
LSU, and/or beta-tubulin regions. The implementation of this methodology in a clinical laboratory is 
expensive and time consuming. MALDI-TOF identification is a good option for dermatophytes’ 
identification performed in laboratory routine, since costs of consumables as well as time of sample 
preparation are lower than for PCR analysis and doesn’t require long training period as phenotypic 
identification does. In this study, however, both methods failed to identify some species variants like 
Trichophyton soudanense or T. violaceum. The combined use of both MALDI-TOF and phenotypic 
methods seems to be the better approach for dermatophytes’ identification since some species show 
significant phenotypic and clinical differences. 
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A retrospective study of dermatophyte infections caused by Tricophyton rubrum and T. 
interdigitale in the County of Stockholm, Sweden. 
L. Vargas, E. Alvarado, C. Stenström, S. Forsblom, B. Girestam, G. Loko, E. Chryssanthou 
Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden 
Objectives: Dermatophytosis is a common fungal infection caused by keratinophilic fungi that are 
capable of invading nail, hair and superficial layers of the skin of humans and animals. The aim of 
this study was to determine the epidemiologic profile of the most frequent dermatophytosis such as 
Tinea unguium and T. pedis caused by Tricophyton rubrum or T. interdigitale in Stockholm, Sweden. 
Methods: In 2015 we developed and validated a rapid and sensitive real-time PCR method for 
detection of the two most prevalent dermatophytes in Northern Europe. Fungal DNA was extracted 
directly from clinical samples (toe or finger nail and skin scrapings from the feet) by using proteinase 
K and heat as pre-lysis step, followed by automated DNA extraction on the PSH/MagNA Pure 96 
Compact. Real-time PCR was performed using pan-dermatophyte primers for detection of all 
dermatophytes and specific primers for identification of T. rubrum and T. interdigitale. Specimens 
from finger nails were also cultured on Chrom agar plates for detection of onychomycosis caused by 
yeasts. 
Results: Laboratory records comprising PCR results of 13,683 specimens (3,304 skin respective 10,379 
nail fragments) collected from May 2015 through March 2019 were retrospectively analyzed. 
Tricophyton rubrum (42%) was the predominant pathogen identified from these cases, followed by T. 
interdigitale (4,9%). In contrast, 2% of the samples were positive for pan-Derm indicating the 
prevalence of infections caused by other pathogens distinct to T. rubrum or T. interdigitale. Sex 
distribution analysis of the patients showed that males (40%) were more susceptible to suffer 
dermatophyte infections compared to females (21,9%). (Furthermore, the prevalence of 
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onychomycosis in finger nails caused by yeasts were also evaluated in this study.) Culture analysis 
from total 941 finger nails showed that 25% were positive for yeast infection. Candida parapsilosis 
(52%), followed by C. albicans (35%) and C. guilliermondii (6%) were the predominant species isolated 
in such cultures. 
Conclusion: The findings presented in our study are in concordance with previous studies where T. 
rubrum is the most frequent dermatophyte species isolated in the general population of industrialized 
countries. Detection of dermatophytes using real-time PCR represents a faster and sensitive method 
to evaluate large volume of clinical samples. 
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Evaluation of Diafactory tinea unguium®, a new rapid immunochromatographic test for the 
diagnostic of onychomycosis 
E. Rupin, H. Pelloux, H. Fricker-Hidalgo, M.-T. Leccia, O. Cognet 
Parasitology-mycology, Grenoble Alps University Hospital, GRENOBLE, France 
Objectives: Suspected nail onychomycosis remains a frequent and still increasing problem despite 
therapeutic advances. Based on clinical features the diagnosis of onychomycosis is confirmed by 
direct examination and culture. Direct examination can be done on the same day but cultures 
required several weeks what delays diagnosis and therapy. Furthermore, direct examination and 
culture have low sensitivity. Diafactory tinea unguium® , a new rapid immunochromatography test 
was recently developed. The aim of this study was to compare this new test to conventional methods 
(direct examination and culture) in suspected tinea unguium. 
Methods: Diafactory tinea unguium®  (Biosynex, France) detects dermatophytes by using monoclonal 
antibodies that react specifically with polysaccharide present in the cell wall of dermatophytes. Direct 
microscopic examination was performed using KOH enhanced with chlorazol black E and dimethyl 
sulfoxide. Cultures were carried out on Sabouraud medium with or without cycloheximide 
(bioMérieux, France), incubated at 25°C. The three methods were evaluated on nails samples (n = 70) 
collected from patients (n = 50) with suspected nail mycosis infection in the Grenoble Alps University 
Hospital. 
Results: Among the 70 samples, cultures were positive in 53 nails. Dermatophytes were isolated in 
40 samples (Trichophyton rubrum n = 35, Trichophyton interdigitale n = 3, Trichophyton tonsurans n = 2), 
yeasts in 8 samples (Candida parapsilosis n = 6, Candida albicans n = 2), and moulds in 5 samples 
(Scopulariopsis spp. n = 4, Fusarium spp. n = 1). The results were positive with Diafactory tinea 
unguium®  in 48 samples, correlated with direct microscopy (i.e. presence of filamentous fungal 
elements) in 36 samples and with cultures in 39 samples. In one case, the result of Diafactory tinea 
unguium®  was negative and the culture was positive (T. rubrum). In three cases, the result of 
Diafactory tinea unguium®  was negative and the direct examination was positive. In the 13 cases of 
moulds or yeasts isolation, the immunochromatographic test was negative. The positive and negative 
predictive value of Diafactory tinea unguium®  were respectively 75% and 86%. 
Conclusion: In order to reinforce the importance of confirmation in the diagnosis of mycological 
onychomycosis, Diafactory tinea unguium®  provides a reliable, convenient and quick method (5 to 
30 minutes). Because of its good detection capacity, this device improved the accuracy of diagnosis 
of tinea inguium in complement of conventional fungus testing methods. 
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Molecular identification of Dermatophytes from clinical samples 
Z. Gazit1, S. Gefen-Halevi2, N. Belausov1, N. Keller1, G. Smollan1 
1Clinical Microbiology, Sheba medical center, Ramat Gan, Israel, 2Clinical Microbiology, Sheba 
medical center, ramat gan, Israel 
Objectives: Dermatophytes are fungi that can invade and infect the keratinized layers of skin, hair, 
and nails. Three genera of fungi, Trichophyton (T), Microsporum (M), and Epidermophyton (E), 
account for most Dermatophytic infections and cause a pathology called tinea (ringworm fungi). The 
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gold-standard method for dermatophyte identification is microscopy and culture. Microscopy has 
low specificity and culture has low 
Methods: (1) The gold-standard methods routinely used in the laboratory were microscopy using 
30% KOH and culture using DTM (dermatophyte test medium) agar incubated at 28OC for up to 4 
weeks. For 12 months, from 1.1.2016 until 31.12.2016 samples from skin, nail and hair from patients 
with suspected tinea were analyzed using the gold-standard methods. (2) A new Israeli commercial 
molecular kit called DERMADYN Dermatophyes detection test V.01 (Dyn R&D) kit that identifies 7 
dermatophytes; T. rubrum complex, T. tonsurans, T. violaceum, M. gypseum, E. floccosum, M. canis and 
T. mentagrophytes complex was evaluated compared to the gold-standard on 103 samples. (3) From 
1.8.18 until 31.12.18, 1179 samples were analyzed for the presence of Dermatophytes using the 
molecular kit only. 
Results: Using the gold-standard only 480 (23.6%) samples were positive for dermatophytes with a 
distribution of 462 (23%), 12 (0.6%), 2 (0.1%), 2 (0.1%) 1 (0.05%), 1 (0.05%) positive for T. rubrum 
complex, T. mentagrophytes complex, M. canis, Scopulariopsis brevicaulis, T. tonsurans, and M. gypseum, 
respectively. Discrepancies between microscopy and culture were found in 27% of the samples. (2) 
There was an agreement between the gold-standard and the molecular kit in 60 out of the 103 samples 
tested (58%), a complete disagreement in 9 (9%) and a partial disagreement in 34 (33%) of them. (3) 
Using the molecular approach 578 (49%) samples were positive for dermatophytes with the 
distribution of 551 (46.7%), 2 (0.2%), 8 (0.7%), 6 (0.5%), 1 (0.08%) and 10 (0.85%) positive for T. rubrum 
complex, T. mentagrophytes complex, M. canis, T. tonsurans, M. gypseum and E. floccosum, respectively. 
Conclusion: Twice the number of dermatophytes were identified using the molecular approach 
compared to the gold-standard with a similar distribution of species having T. rubrum complex the 
main pathogen. The molecular assay has a much shorter training period, a high capacity of 
performance and high sensitivity. Although the kit contains only 7 dermatophytes, these are the most 
prevalent species in Israel. As discrepancies between microscopy and culture is a common problem 
and as culture has low sensitivity Labs should consider evaluating a molecular based diagnostic 
method for dermatophyte identification to increase detection rates. 
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In the Aspergillus section Nigri, Aspergillus welwitschiae is more often responsible for otomycosis 
than Aspergillus tubingensis and Aspergillus niger 
M. Gits-Muselli1,2, S. Hamane2, B. Verillaud3, E. Cherpin2, N. Guigue2, D. Garcia-Hermoso1, A. 
Alanio4, S. Bretagne4 
1Molecular Mycology, Institut Pasteur, PARIS, France, 2Parasitology-mycology Laboratory, 
Lariboisière Saint-Louis Fernand Widal Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 
PARIS, France, 3Ent Department, Lariboisière Saint-Louis Fernand Widal Hospital, Assistance 
Publique-Hôpitaux de Paris (AP-HP), PARIS, France, 4Paris-diderot, Sorbonne Paris Cité University, 
Institut Pasteur, Molecular Mycology Unit, Cnrs Cmr2000, Parasitology-Mycology Laboratory, 
Lariboisière Saint-Louis Fernand Widal Hospitals, Assistance Publique-Hôpitaux de Paris, Paris, 
France 
Objectives: Fifteen percent of external otitis are otomycosis (Ninkovic et al. 2008). Aspergillus section 
Nigri are the most frequent molds isolated from external ear conduct (EEC) samples followed by 
Aspergillus section Flavi (R. Sarvan et al. 2012). Aspergillus section Nigri include several cryptic species 
difficult to differentiate using phenotypic features. We wondered whether some species of the Nigri 
section could be more frequently observed in some specific anatomical sites. 
Methods: We identified at the species level all the isolates of Aspergillus section Nigri consecutively 
collected between 2010 and 2017 in our laboratory and stored frozen at -20 C°. After thawing and 
subculture on Sabouraud medium, DNA was extracted using a MagnaPure DNA extractor and 
species identification was performed upon the partial sequence of the calmodulin gene. The two 
primers used for amplification of the targeted gene were CMD5 (CCGAGTACAAGGARGCCTTC) 
and CMD6 (CCGATRGAGGTCATRACGTGG) (Hong et al. 2005). The sequences were compared to 
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the Mycobank database. The sequences obtained were aligned to build a phylogenic tree using 
Geneious software. 
Results: A total of 186 strains were sequenced: 75 EEC (64 patients), 78 respiratory samples (78 
patients), and 33 air environmental isolates. When considering the first strain per patient, we 
identified by decreasing frequency: Aspergillus tubingensis (78/175; 45 %), Aspergillus welwitschiae 
(59/175; 34 %), Aspergillus niger (34/175; 19 %), Aspergillus luchuensis (2/175; 1%), and Aspergillus 
japonicus (2/175; 1%). When several isolates were available for a given patients, the following isolates 
belonged to the same species. The species repartition was statistically different when comparing EEC 
samples to respiratory and air samples with A. welwitschiae overrepresented in otomycosis (53% 
34/64) (p<0.001). In contrast, the distribution of the species was not different between respiratory and 
air samples, with 46% and 61% A. tubingensis respectively (Figure 1). \
 
Inside each species, the sequence identity was high (96.5% for A. tubingensis, 99.3% A. welwitschiae, 
and 99.4% A. niger isolates) with no difference according to the isolation site. The phylogenetic tree 
based on the calmodulin gene partial sequences showed a stackable organization to the tree 
generated using whole genome sequencing (Vesth et al. (2018)), with Aspergillus luchuensis included 
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within the A. tubingensis clade, and A. welwitschiae closed to the A. niger clade (Figure 2). 
 
Conclusion: Among the 175 Aspergillus species belonging to the Nigri section, A. welwitschiae was 
found significantly associated with otomycosis whereas the species distribution was similar between 
respiratory and environmental isolates. This finding suggests specific physical properties of A. 
welwitschiae to thrive in the external ear. One hypothesis could be a better fitness to infect EEC 
containing different lipids linked to the ear-wax. 
 
P484 
Fungal necrotizing external otitis 
D. Aloui1, M. Tbini2, H. Jaafoura2, S. Cheikhrouhou1, M. Bouchekoua1, S. Trabelsi1, M. Ben Salah2, S. 
Khaled1 
1Laboratory Of Parasitology And Mycology, Charles Nicolle Hospital, tunis, Tunisia, 2Oto-rhino-
laryngology, Charles Nicolle Hospital, tunis, Tunisia 
Objectives: Malignant otitis externa is an uncommon, but potentially fatal, complication of otitis 
externa affecting immunocompromised and elderly patients, particularly those with diabetes. Fungal 
infection is rare, severe and the clinical presentations pose significant problems in diagnosis and 
treatment. The purpose of our study is to report the diagnostic and therapeutic difficulties of fungal 
necrotizing external otitis. 
Methods: It is a retrospective study spread over 5 years conducted between January 2012 and 
December 2017. It included patients with documented diagnosis of fungal necrotizing external otitis. 
Results: There were eight men and three women, all diabetic with a mean age of 64 years. The reason 
for the consultation was treatment-resistant otalgia and otorrhea. The clinical examination and the 
TDM (tomodensitometry) were in favor of a necrotizing external ear infection. All patients were 
treated with antipyocyanic therapy antibiotic (ceftazidime and ciprofloxacin) for an average duration 
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of one month. A swab of the infected ear was taken for mycological examination and a mycosic agent 
was revealed within an average of 45 days. Candida albicans was isolated in four cases and Candida 
parapsilosis in one case. Concerning molds, Aspergillus flavus was isolated in four cases, Aspergillus 
fumigatus and Rhizopus spp in one case respectively. Treatment was based on Amphotericin B in two 
cases and on Amphotericin B followed by Voriconazole in the other cases. The average duration of 
treatment was four months. Seven patients evolved well, two were lost to follow-up and two died. 
The average follow-up period was 11 months. 
Conclusion: When a necrotizing external ear infection, occurs in an immunocompromised patient, 
with no response to antibiotic therapy, a fungal infection should be suspected and treated early and 
effectively to ensure a better prognosis. 
 
P485 
Chromagars for differentiation between Trichophyton benhamiae, Microsporum canis and M. 
audouinii 
E. Alvarado Ramirez, L. Vargas, C. Stenström, S. Forsblom, B. Girestam, G. Loko, E. Chryssanthou 
Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden 
Objectives: Objective: Trichophyton benhamiae has increasingly been isolated in Europe during the 
last years. In culture, this dermatophyte is difficult to differentiate macroscopically from immature 
colonies of Microsporum canis and sometimes from non‐sporulating form of M. audouinii. Here we 
have used different culture conditions aiming to establish the macroscopic differences between these 
species, which could be useful for identification. 
Methods: Method: T benhamiae (6 isolates), M. canis (8 isolates), and M. audouinii (5 isolates) were 
cultured at 28 °C on Trichophyton agars for nutritional requirements (5 d), urease (5 d), Chromagar 
CandiSelect™ (BioRad) (7-10 d) and CHROMAgar™Candida (CHROMAgar) (7-10 d). Identification 
of T. benhamiae, M. canis and non-sporulating form of M. audouinii were confirmed by ITS sequencing. 
Results: Results: Five of 6 T. benhamiae isolates had requirement for vitamins (inositol and thiamine) 
and had positive urease test after 5 days incubation at 28 °C. M. canis and M. audouinii isolates showed 
no vitamin requirements. M. audouinii showed weak or negative urease test. The tested dermatophyte 
species could be differentiated by colony colour on Chromagar CandiSelect™: T. benhamiae presented 
turquoise diffuse pigment, meanwhile M. canis had light yellow and M. audouinii purple pigment 
around the colony. On CHROMAgar™Candida the colonies showed macroscopical differences: T. 
benhamiae had colonies with white centre and yellow margin, and the other two dermatophytes had 
brownish colonies. 
Conclusion: Conclusion: Identification and differentiation between T. benhamiae, M.canis (immature 
colonies) and M. audouinii (non-sporulating form) by conventional methods is difficult. Using 
biochemical tests like vitamin requirements, urease and Chromagars, may be helpful for 
identification. 
 
P487 
First results in the study of mycetoma in Turkana (Kenya) 
M.F. Colom1, C. Ferrer1, S. Leting2, L. Ramírez1, J. Ekai2, C. Hernández3 
1Medical Mycology Lab, University Miguel Hernandez, Sant Joan d'Alacant, Spain, 2Medical 
Diagnosis Laboratory, Lodwar County Referral Hospital, Lodwar, Kenya, 3General Surgery, Hospital 
Clínico San Carlos, Madrid, Spain 
Objectives: The aim of the study was to assess the prevalence of mycetoma in the county of Turkana 
(Northwest Kenya), as well as to describe the main causative agents involved in the disease and their 
possible environmental origin, using simple methods that can be applied locally. 
Methods: Based on the data collected by the team of cooperative medicine Cirugia en Turkana, a 
specific study for mycetoma was started during the 16th campaign of that team in February 2019. 
Patients with suspected mycetoma were studied at the Lodwar County Referral Hospital (LCRH). 
After informing the patient and getting their consent, the lesions were examined and sampled 
(mainly by biopsy) and clinical data were recorded. Samples were washed in sterile saline solution 
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and cut in fragments. Some of these were inoculated in Sabouraud Dextrose Agar and Malt Extract 
Agar plates. One fragment of each sample was used for DNA extraction. The DNA and the rest of the 
fragments of samples were kept at -20ºC. Environmental samples were also taken from soils, trees 
and shrubs in different locations of the county. These samples were also fragmented and inoculated 
in the same culture media. All cultures were incubated at room temperature at the LCRH laboratory. 
The DNA obtained from clinical samples was submitted to PCR amplification of the ITS-5.8S and the 
V4-V5 16S rRNA gene region, for the detection and identification of fungi and bacteria respectively. 
Results: In this 2019 campaign 11 patients were studied. All were men between 13 and 70 Yo (mean 
age 34). Ten of them were shepherds and one worked as a builder. Lesions were mainly located at 
the feet (91%). Three of them referred black grains in the exudate and 6 yellow or cream coloured. 
Culture of clinical and environmental samples yield 5 and 24 fungal colonies respectively. For clinical 
samples, most of cultures were negative. From environmental samples, fungi morphologically 
compatible with Madurella mycetomatis and Trematosphaeria grisea were obtained as well as other 
mycetoma-related genera (Alternaria and Aspergillus). Molecular identification of showed Aspergillus 
terreus, Aspergillus flavus, and Paecilomyces formosus in the environment. Cellulosimicrobium cellulans, 
an actinobacteria that has not been previously reported as causative agent of mycetoma, was detected 
in two of the clinical samples, Alternaria sp. in one and Penicillium spp in 5 (P. glabrum, P. spinulosum, 
P. corylophilus). After DNA amplification, three samples remained negative. 
Conclusion: The detection of Cellulosimicrobium cellulans could be a significative result of this study. 
Nevertheless, it should be confirmed in more samples and patients. For Alternaria sp, and Aspergillus 
sp, they had been reported as mycetoma agents previously. The lack of results from some of the 
yellow grain mycetomas could be since some patients were under antibiotic treatment and, for the 
black grain ones, this is probably due to the low sensitivity of the method in the detection of these 
fungi. The isolation of mycetoma agents from the environmental samples confirms that not only 
Acacia thorns, but also other vegetal products, can be the origin and vehicle of inoculation of the 
pathogens 
 
P488 
Examining the efficacy of Origanum heracleoticum essential oil against fungal pathogens of the 
nails: preliminary results. 
K. Samaras, A.-M. Markantonatou, T.-A. Vyzantiadis 
First Department Of Microbiology, Medical School, Aristotle University of Thessaloniki, 
Thessaloniki, Greece 
Objectives: Fungal infections of the nails (onychomycoses) are very common and often need long 
term treatments, not always effective. In addition to the available chemical antifungal agents, natural 
products have been used as well. Scope of this study was to test the possible efficacy of commercial 
antifungal regimens based on Origanum heracleoticum essential oil as well as the efficacy of their main 
antifungal substance, carvacrol, against common fungal pathogens of the nails. 
Methods: Three different regimens were tested. Regimen (A), contains Origanum heracleoticum 
essential oil (purity>99%, carvacrol >86%), whereas regimen (B) contains the essential oil (28% v/v) in 
combination with other natural essential oils. Both formulations are suitable for external use. The 
antifungal activity of pure carvacrol was also tested. Possible indication of the aforementioned 
regimens (A and B) is the treatment of microbial pathogens of the nails. The proposed dosage for 
regimen (A) is 4-6 drops (20 μL per drop) oregano essential oil diluted in a teaspoon (5 mL) of another 
oil (for example olive oil), which is equivalent to carvacrol concentration of approximately 13.76-20.64 
mg/ml. Regimen (B) is proposed to be used undiluted (carvacrol concentration approximately 240 
mg/ml). In order to demonstrate their possible antifungal activity, serial dilutions of regimens (A), 
(B) and pure carvacrol from 1,024 mg/L to 0.031 mg/L were tested against dermatophytic 
(Trichophyton rubrum and Trichophyton interdigitale) and non dermatophytic isolates (Candida albicans, 
Candida parapsilosis, Candida glabrata and Scopulariopsis brevicaulis) which are all common causes of 
onychomycoses. The fungal strains were examined also for their sensitivity in fluconazole and 
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itraconazole. The susceptibility testing was performed according to the proposed EUCAST 
methodology (microdilution method). 
Results: All tested regimens exhibited antifungal activity in high concentrations. Depending on the 
fungal strain the range of MICs was 64-256 mg/L for regimen (A), 64-512 mg/L for regimen (B) and 
64-512 mg/L for pure carvacrol. The ranges of MICs were 0.063-4 mg/L for itraconazole and 0.5-64 
mg/L for fluconazole. 
Conclusion: The results of the study demonstrate that the regimens tested may have antifungal 
activity against both dermatophytic and non dermatophytic isolates, although in much higher 
concentrations than the commonly used antifungal drugs. However, being substances of only local 
use on the fungal lesions, there is the probability that the above mentioned concentrations could be 
achieved on the nail application. Further experimental data and studies of clinical use are required 
in order to specify potential benefit, duration of treatment and possible toxicity. 
 
P489 
Cutaneous ulcer due to Candida parasilosis associated with skin trauma in an adult patient with 
psoriasis vulgaris 
G. Ge1, D. Shi2 
1Jining Medical University, Jining, China, 2Jining No. 1 People's Hospital, Jining, China 
Case Report: The Candida parapsilosis (C. parapsilosis) family has emerged as a major opportunistic 
and nosocomial pathogen. It causes multifaceted pathology in immuno-compromised and normal 
hosts. Common symptoms of Candida skin infections include thickening of the skin, hyperkeratosis, 
and erythema. C. parapsilosis rarely induced the skin ulcer without assistance from other pathogens. 
Here, we present 27-year-old female with cutaneous ulcer on her left foot due to C. parapsilosis after 
trauma. She has a 6-month history of psoriasis vulgaris without treatment. C. parapsilosis was isolated 
from skin lesion for several times and was confirmed by morphological and cultural characteristics 
as well as by DNA molecular analysis. Patient was successfully treated with oral itraconazole in 200 
mg daily for seven weeks. To our knowledge, it was the first report that C. parapsilosis induced 
cutaneous ulcer in a patient with psoriasis; Cutaneous candidiasis maybe associated with the skin 
barrier damage (the trauma) or psoriasis. 
 
P490 
Two genetic lines of Trichophyton rubrum population in Russia 
I. Pchelin, Y. Mochalov, G. Chilina, N. Vasilyeva, A. Taraskina 
Kashkin Research Institute Of Medical Mycology, North-Western State Medical University named 
after I.I. Mechnikov, Saint Petersburg, Russian Federation 
Objectives: Trichophyton rubrum is the most prevalent agent of onychomycosis and tinea pedis in 
most countries, including Russia. However, data on its population structure remain controversial, 
with some studies reporting the absence of the structure and others reporting bipartite structure. We 
aimed at studying T. rubrum population by microsatellite analysis and typing of TERG_02941 locus. 
Methods: The study included 59 clinical isolates of T. rubrum from Saint Petersburg and 
Yekaterinburg, Russia. Species identification was done by ITS rDNA region sequencing. Typing was 
performed by real time PCR of the locus TERG_02941 and microsatellite analysis of 12 loci, including 
4 original ones. The data were processed in the R software using the polysat and poppr packages. 
Genetic distances were calculated by Bruvo method. 
Results: Ribosomal ITS region sequencing revealed nucleotide sequence, identical to that one, 
deposited under KT285224 accession in all but two isolates. Real-time PCR of the TERG_02941 locus 
revealed one SNP at position 793. At this position, adenine was found in 59% of isolates and guanine 
was found in 34% of isolates. The scatterplot, based on the results of the analysis of the lengths of 
microsatellite loci by the method of principal components, contained two separate clouds of points. 
One of the clouds was formed by isolates with TERG_02941 793A genotype, the other — by 793G 
isolates (Fig. 1). The value of the Simpson index, calculated for equal samples, was not significantly 
different for TERG_02941 genotypes. The association index, rˉd = 0.02483, was calculated using the 
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Multilocus Style Permutation method after deleting one non-informative locus and performing clonal 
correction. The value laid beyond the right boundary of the distribution of expected frequencies. The 
probability rˉd was estimated as 0.002, which made it possible to reject the null hypothesis of the 
absence of connections between the markers. The χ2 test showed no connection between the 
TERG_02941 isolate genotype and the localization of the lesion on the patient’s body. 
Conclusion: Microsatellite analysis with an extended set of loci confirms the presence of two genetic 
lines of the fungus T. rubrum in the territory of the Russian Federation, with the same diversity. In 
the population of the fungus there is a significant deviation from the Hardy-Weinberg equilibrium. 
 
P491 
Comparison of three skin sampling methods and two media for culturing Malassezia yeast 
A. Abdillah1, S. Khelaifia2, D. Raoult2, F. Bittar3, S. Ranque1 
1Vitrome, Aix Marseille Univ, IRD, AP-HM, SSA, Marseille, France, 2Culturomics, IHU Méditerranée 
Infection, Marseille, France, 3Mephi, Aix Marseille Univ, IRD, AP-HM, SSA, Marseille, France 
Objectives: Malassezia species are lipid-dependent basidiomycetous yeast. They are resident 
commensals of the human skin but also cause common skin diseases, such as pityriasis versicolor, 
seborrheic dermatitis, etc. Whether they are associated with other human diseases remains an open 
question, partly because of the lack of efficient medium to culture these fastidious yeast. Besides, the 
absence of a standardized skin sampling technique introduces a major bias in culture-based 
descriptive studies. The objectives of this study were: 1) to compare three methods of skin sampling 
for the detection of Malassezia yeast and 2) to evaluate the performances of « FastFung » a new culture 
medium based on the Schæ dler agar, for the growth of Malassezia spp. by culture compared to the 
reference Dixon medium. 
Methods: A total of 10 healthy volunteers were included in this study. Fifteen skin samples were 
collected at 5 different body sites for each participant using three sampling methods: a) dry cotton 
swabs, b) swabs in a liquid transport medium « Transwab® », and c) a sterile gauze. The three 
methods were applied successively in a random order, which was noted, at each sampling site. Each 
skin sample was then plated in parallel, in a random order on both Dixon and FastFung media. All 
plates were incubated aerobically at 30°C and cultures were examined each day for one week for 
Malassezia spp. growth. 
Results: Malassezia yeast grew in 93/300 (31%) culture plates, corresponding to 150 samples. A total 
of 1 082 Malassezia spp. colonies were isolated and identified by MALDI-TOF Mass Spectrometry, of 
which 455 (42%) were M. globosa, 424 (40%) M. sympodialis, and 203 (18%) M. restricta. Multivariate 
statistical analysis found a significant independent effect (P<10-3) of the sampling methods. Of the 93 
positive culture, 62 (67%) were sampled using a sterile gauze, 17 (18%) with Transwab® , and 14 (15%) 
with the dry cotton swab. We also found a statistically significant independent effect (P = 0.003) of 
the culture medium, with the FastFung and Dixon media yielding 58 (62%) and 35 (38%) positive 
culture, respectively. Interestingly, the majority of the fastidious M. globosa and M. restricta species 
were isolated on the FastFung medium. 
Conclusion: Our findings demonstrate that sterile gauze is the most efficient and reliable skin 
sampling technique to culture Malassezia yeast; and that the novel FastFung culture medium is 
suitable, and more efficient than the Dixon medium for Malassezia spp. culture. We propose 
implementing sterile gauze skin sampling and the FastFung culture medium in the routine Malassezia 
spp. cultivation procedures. 
 
P495 
Morphological and molecular characterization of the T. benhamiae isolates. 
A. Packeu1, F. Baert1, K. Goens1, S. Roesems1, D. Stubbe2, M. Hendrickx3 
1Mycology & Aerobiology, Sciensano, Brussels, Belgium, 2Mycology & Aerobiology, Bccm/ihem 
Collection, Sciensano, Brussels, Belgium, 3Mycology, Sciensano, BCCM/IHEM, Brussels, Belgium 
Objectives: Dermatophytes are keratinophilic fungi responsible for causing dermatophytosis in both 
man and animals. Recently, several genera were (re)introduced in addition to Epidermophyton, 
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Microsporum, and Trichophyton and depending on their primary habitat, divided into geophilic, 
zoophilic and anthropophilic species. Due to the fact that they are affecting more than 20-25% of the 
world’s population, able to affect healthy individuals and in some cases are communicable makes 
this specific group of fungi of great importance for public health. Recent taxonomical changes (de 
Hoog et al., 2017) proposed an increase in the number of genera, simplifying identification of 
dermatophytes in routine diagnostics. The implementation of these changes necessitated a taxonomic 
re-evaluation of the dermatophytes within the Belgian BCCM/IHEM culture collection. And 
furthermore, an evaluation of such a large dataset leads to further insights in the taxonomy of this 
specific group of dermatophytes. 
Methods: In the present study, the members of the T. benhamiae and T. bullosum clade were evaluated, 
using different molecular methods (sequencing and MALDI-TOF MS). The obtained results were 
coupled with conventional physiological, morphological, clinical, and geographical data of the 
strains in order to obtain a correct nomenclature for each analysed isolate. As proposed by de Hoog 
et al., T. benhamiae strains can be categorized into two subclades: the T. bullosum clade and the T. 
benhamiae clade. The T. bullosum clade comprises the type strain of this zoophilic species isolated from 
cutaneous lesion of a horse described for the first time in 1933 by Lebasque. The T. benhamiae clade 
comprises isolates from the zoophilic species T. benhamiae, T. erinacei, T. verrucosum and T. eriotrephon 
and the anthropohilic T. concentricum species. However, in both clades delineation of the different 
species still remains unclear. Especially for T. benhamiae a lot of confusion still exists, where 2 different 
phenotypes (white and yellow) have been described. 
Results: Preliminary molecular results (ITS and BT), obtained with the BCCM-IHEM isolates, point 
to the existence of only one T. benhamiae clade with well supported clades for the species T. erinacei, 
T. verrucosum and T. eriotrephon. The remaining species are, however, not well resolved. While most 
T. benhamiae strains clustered together with T. concentricum as a subclade in the ITS+BT phylogeny, 
some strains clustered with T. bullosum forming a highly supported clade. 
Conclusion: In order to better delineate the different taxonomic entities and to define criteria for their 
identification, a combining of all results obtained via the proposed polyphasic approach will be 
primordial. 
 
P496 
Phenotypic and phylogenetic characterization of malbranchea-like isolates from clinical 
specimens in United States 
J.F. Cano-Lira1, E. Rodriguez-Andrade1, N. Wiederhold2, A. Stchigel1 
1Mycology, Universitat Rovira i Virgili, Reus, Spain, 2Pathology, The University of Texas Health 
Science Center at San Antonio, San Antonio, United States of America 
Objectives: The main objective of this work was to identify phenotypically and molecularly twenty-
two strains from clinical specimens in USA, preliminary classified as Malbranchea spp. 
Methods: For cultural characterization, the strains were grown onto potatoes extract agar (PDA), 
phytone yeast extract agar and oatmeal agar, and the colonies measured and described after two 
weeks at 25°C. Vegetative and reproductive structures were observed and documented from slide 
cultures mounted on water and 60% lactic acid by a BH1 Olympus microscope. Photo micrographs 
were taken using a Zeiss Axio-Imager M1 light microscope with a DeltaPix Infinity X digital camera 
using Nomarski differential interference contrast. For phylogenetic analysis, total DNA was 
extracted from colonies after 7-10 days of growth on PDA at 25 °C. DNA was used to amplify and 
to sequence a fragment of the 28S nrRNA gene (LSU) using the primer pair LR0R and LR5, and the 
ribosomal internal transcribed spacers (ITS) by using the primer pair ITS5 and ITS4. A preliminary 
molecular identification was performed with ITS and LSU sequences using the Basic Local 
Alignment Search Tool (BLAST; https://blast.ncbi.nlm.nih.gov/Blast.cgi). A maximum level of 
identity of ≥ 98% respect to the sequences of type or reliable reference strains deposited in the 
GenBank/EMBL database, and the phenotypic characteristics, were used for identification at 
species-level. LSU sequences generated by us were aligned with other from known taxa belonging 
to the order Onygenales by ClustalW application of MEGA v. 6.06. The phylogenetic tree was built 
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using maximum-likelihood (ML) and Bayesian-inference (BI) methods with RAxML v. 8.2.10 and 
MrBayes v3.2.6 computer programs, respectively. Oidiodendron truncatum and Myxotrichum deflexum 
(Myxotrichaceae family) were used as outgroup. 
Results: Hitherto, taking into account the phylogenetic data and the phenotypic features, eleven 
strains were identified at species level. We report the finding of Auxarthron alboluteum (two strains), 
A. conjugatum (two strains), A. umbrinum (three strains) and A. zuffianum (one strain); and of 
Malbranchea aurantiaca (two strains) and M. flocciformis (one strain). One strain of Arachnomyces, two 
of Auxarthron, one of Malbranchea and two of Spiromastigoides could not be identified at species-
level. In addition, two strains did not matched at genus-level. 
Conclusion: The phenotypic characterization and the phylogenetic analysis carried out by us only 
allowed us to identify at species-level 11/19 strains previously identified as Malbranchea spp. Most 
of these strains finally resulted known species of the genus Auxarthron, and only three of them 
could be identified as Malbranchea species. This indicates that the presumptive morphological 
identification is unreliable, and molecular data are needed for the correct identification of this sort 
of fungi. Surprisingly, eight of nineteen strains were identified at genus-level or not identified, 
which suggests that these malbranchea-like fungi could be putatively new taxa 
 
P497 
Fast mold identification with MALDI-TOF MS: The importance of the spectra acquisition method 
K. Mucek, T. Maier, M. Timke, M. Kostrzewa 
Research And Development, Microbiology And Diagnostics, Bruker Daltonik GmbH, Bremen, 
Germany 
Objectives: Invasive fungal infections are a major cause for morbidity and mortality in ill, 
immunocompromised and paediatric patients [1, 2]. Clinical diagnosis of mold infections and 
identification of fungal contamination is often based on morphological criteria which encounter 
issues like robustness of phenotypic procedures, often sporulation as a prerequisite for identification 
and very few skilled mycologists that are capable of differentiating molds in the medical 
environment. In order to solve this situation one of the most promising alternative to identify 
clinically and environmental relevant molds is MALDI-TOF MS. Through the generation of protein 
spectra and the comparison with a reference library, molds can be identified fast and reliable. 
However, in some cases the acquisition of mass spectra particular from filamentous fungi is 
challenging since the frond mycelium often results in reduced spectra quality. 
Methods: A minimum about 56 filamentous fungi was measured with MALDI-TOF in duplicates 
with at least two different operators. Each strain was cultivated on Sabouraud agar for 24 – 48 h, front 
mycel was smeared on a MALDI target plate. One of two spots was pre-treated with formic acid 
before all spots were overlaid with HCCA matrix and the measurement started. Two different 
acquisition methods were applied. The Bruker ‘standard’ method and the ‘filamentous fungi’ method 
was compared. Subsequently all spectra were matched against the Filamentous Fungi Library 3.0. 
Results: After cultivation of filamentous fungi biological material could be transferred successfully 
to a MALDI-TOF target plate in duplicates for each strain. The results showed that the rate of spectra 
acquisition by using the filamentous fungi method was significant higher (about 25%) compared to 
the standard acquisition method. It could be shown additionally that the acquired spectra resulted in 
an increased identification rate. 
Conclusion: The MALDI Biotyper Filamentous Fungi Module with adapted acquisition settings for 
filamentous fungi improves the identification rate for molds. MALDI-TOF based differentiation is 
less error prone and faster compared to classical identification. Results can be easily obtained in one 
hour from cultivation plate. Moreover, the adapted filamentous fungi method compared to the 
standard spectra acquisition method is a vast advantage. Time consuming repetition of target 
preparation and re-measurement is reduced as well as previous protein extraction for MALDI-TOF 
measurement. Thus, mold infections like aspergillosis or mucormycosis or fungal contaminations are 
identified more reliable and faster. [1] Prattes, J., Heldt, S., Eigl, S. et al. Curr Fungal Infect Rep (2016) 
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Trichophyton mentagrophytes – a new genotype in Cambodia 
S. Uhrlass1, M. Sithach2, D. Koch1, F. Wittig1, H. Muetze1, C. Krueger1, P. Nenoff1 
1Partnership Dr. C. Krueger & Prof. P. Nenoff, Laboratory of medical microbiology, Roetha OT 
Moelbis, Germany, 2Department Of Dermatology, Preah Kossamak Hospital, Phnom Penh, 
Cambodia 
Objectives: According to the currently suggested classification and new taxonomy of the 
dermatophytes, the former Trichophyton mentagrophytes (TM)-complex is now differentiated in TM 
(zoophilic strains) and Trichophyton interdigitale (TI, anthropophilic strains). 
Methods: Mycological diagnostics was done during a survey of superficial dermatophytoses in 
Cambodia. 
Results: 1) The new genotype „Cambodia“ of TM (strain 201341/18) was found in a 8 years old male 
child with skin lesions starting already 3 months ago, prior the dermatology consultation. 
Inflammatory papules on the right part of the scalp were to be seen. 2) A 31 years old male suffered 
from a tinea cruris. The dermatophyte isolate was found to be the new TM genotype Cambodia (strain 
218292/17). 3) A 26 years old male farmer showed lesions appearing since one year, started with scaly 
pruriginous plaques on both hips. Clinical diagnosis was tinea corporis. By mycological diagnostics, 
from skin scrapings, a dermatophyte was isolated. By sequencing of the DNA it was identified as TM 
genotype VIII India (strain 218294/17). 4) A one-year-old male was diagnosed as tinea corporis. The 
dermatophyte which was growing from skin scrapings of the baby ś cutaneous lesions was identified 
as T. interdigitale (TI strain 250037/18 genotype II* - mixed type between TI and TM). 
Conclusion: Today, due to sequencing of the ITS region of the rDNA, at least 10 genotypes of TM 
and TI are known. These genotypes are mostly associated to the geographic origin or to the source of 
infection. Currently, two genotypes of TI (ITS Type I [Europe] and ITS Type II [Cosmopolite]), were 
described. TM, however, comprises the common zoophilic “German” ITS Type III (Europe) and III* 
(Cosmopolite), genotype IV (UK, USA, South Africa and Feancde), V (Asia, Egypt, Iran, Iraq and 
Japan), VI (Europe, Russia and Finland), VII (from Thailand originating isolates in Switzerland and 
Germany, USA, Australia, Georgia, Russia, and Vietnam), VIII (Asia, India, Iran, Oman, Australia), 
and last but not least the Australian genotype (ITS Type IX). Based on results of sequencing preferably 
of the ITS region of the rDNA, we are able to demonstrate that 2 out of 3 TM strains in Cambodia 
represent a new, until now not described, ITS genotype which is called now the “Cambodian” 
genotype of TM. Surprisingly, we found one additional TM strain of the Indian genotype VIII. An 
association between this dermatophytosis in Cambodia and the current Indian outbreak of superficial 
dermatophytosis can only be suspected. The fourth here isolated dermatophyte belongs to the until 
now very rarely described genotype TI II*. Phylogenetic, this genotype is the so called mixed type 
between anthropophilic TI and zoophilic TM. Each genotype of the TM/TI complex seems to be 
specific for e.g. a geographic area, for a country, or for a distinct animal which represents the source 
of infection, speaking for a special way of transmission of the infection. 
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Case Report: Title: Novel Cunninghamella species causing mucormycosis in an apparently 
immunocompetent individual Mucormycosis due to Cunninghamella spp. is extremely rare clinical 
entity. We report here a case of mucormycosis due to Cunninghamella sp. in an apparently 
immunocompetent individual. Material & Methods: Patient & microbiological methods: Tissue 
biopsy from the lesion was subjected to histopathology, and culture. Formalin fixed paraffin 
embedded tissue (FFPE) and culture were sent to Mycology Reference Laboratory at PGIMER 
Chandigarh for species identification & susceptibility testing. Molecular identification: DNA was 
extracted from FFPE tissue and cultures as described previously by Rickerts et. al( 1) & Prakash et.al. 
(2) DNA from FFPE tissue was PCR amplified using mucoromycetes specific primers. The ITS and 
26s genes of ribosomal DNA of the isolate were amplified using pan fungal primers. Consensus 
sequences obtained from amplified products were analyzed using the National Center for 
Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST). Phylogenetic 
characterization: The 26S rDNA and ITS sequences of different Cunninghamella were retrieved from 
NCBI nucleotide database. Phylogenetic analysis was performed as per Prakash et.al.(2) 
Results: Patient & microbiological methods: A 26-year-old healthy man presented with slowly 
progressive swelling on the left cheek for 2 years and ulceration over the swelling for two months. 
Laboratory investigations revealed a normal blood sugar, hemogram, CD4 counts, liver and renal 
function tests. He was non-reactive for HIV. Contrast enhanced computed tomography scan of the 
head and neck showed mild enhancing lesions on left side of the face along with thickening of floor 
of maxilla. Biopsy from the lesion showed focal areas of chronic inflammation with multinucleated 
giant cells containing broad aseptate fungal hyphae. A rapidly growing white mould with aseptate 
hyphae & erect sporangiophores ending in a swollen vesicle, with 1-spored sporangiola suggestive 
of Cunninghamella was isolated. The isolate had minimum inhibitory concentrations (MICs) of 4µg/ml 
for amphotericin B, itraconazole, and posaconazole; and 3µg/ml for Terbinafine as per CLSI M38A2. 
He was managed with repeated debridement over 7.5 months, amphotericin B and posaconazole for 
1.5 months & 6 months respectively. As there was no improvement, he was finally treated with oral 
Itraconazole. At present the ulcer has healed, but the swelling is still persisting. Molecular 
identification: The fungus was identified as Cunnighamella sp. by analysis of DNA sequence of the 
FFPE tissue. ITS sequences of the isolate showed 97.54% base identity with uncultured 
Cunninghamella spp. (MG571234.1) isolated from Thailand. Phylogenetic analysis: Phylogenetic 
analysis of ITS and 26s regions of all known Cunninghamella species with the present isolate suggested 
that the isolate may be a new or undefined species under genus Cunninghamella. Conclusion: We 
report recalcitrant mucormycosis due to a Cunninghamella sp., which is phylogenetically different 
from other described species in this genus. Further molecular characterization is essential to identify 
the species. References: Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):8-13. Med Mycol. 2016 Aug 
1;54(6):567-75. doi: 10.1093 
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Charles University, Prague, Czech Republic 
Objectives: Species of Trichophyton benhamiae complex have a worldwide distribution and their host 
range includes many pet and livestock animals. Nowadays, this complex has become very important 
due to epidemic spread of T. benhamiae complex species in children and their pet animals in Europe. 
No causal mechanism has been found that would explain this increase. Moreover, the incidence of 
several other species from this complex is also increasing in Europe due to higher interest of people 
in pet hedgehogs (host of T. erinacei), insufficient prophylactic vaccination (T. verrucosum) or 
increasing use of molecular methods in the dermatological diagnostics leading to more accurate 
identification (T. bullosum, T. eriotrephon). A considerable genetic and phenotypic variability has been 
revealed in these emerging pathogens, but the species limits are not always clearly defined. 
Therefore, the aim of this study was to elucidate species boundaries and phylogenetic relationships 
between species belonging to the T. benhamiae complex. 
Methods: A total of 352 clinical isolates from T. benhamiae complex associated with human and animal 
dermatophytoses were analysed using molecular markers (DNA sequence data and microsatellites), 
and morphological and physiological methods. 
Results: Members of the T. benhamiae complex were resolved into three major clades (designated T. 
benhamiae, T. erinacei and T. africanum clades). All analyses supported delimitation of four species in 
the T. benhamiae clade, i.e., T. benhamiae, T. concentricum, and two novel species, T. europaeum and T. 
japonicum. In contrast to DNA sequence and based phylogeny, the population genetic and phenotypic 
data distinguished North American strains of T. benhamiae (mostly isolated from dogs) and emerging 
European strains associated with quinea pigs. The status of new variety, T. benhamiae var. luteum, is 
proposed for these strains. The T. erinacei clade consisted of three species, namely T. erinacei, T. 
verrucosum and T. eriotrephon. Trichophyton bullosum and one new species, T. africanum (previously 
African race of Arthroderma benhamiae) together with T. bullosum formed the T. bullosum clade 
Conclusion: Species boundaries in the T. benhamiae clade were resolved by using polyphasic 
approach. This approach supported recognition of nine species, including three new zoophilic 
species. Trichophyton benhamiae was split into two varieties; T. benhamiae var. luteum is currently 
responsible for the European outbreak of zoonotic infections. 
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Subcutaneous nodule caused by Phaeoacremonium fuscum in a non-immunocompromised patient 
S. Colman, L. Cattoir, A. Boel 
Microbiology, OLV Hospital, Aalst, Belgium 
Objectives: Phaeohyphomycosis (PHM) is a chronic infection caused by dematiaceous fungi which 
usually involves the skin and subcutaneous tissue. As a result of the use of molecular diagnostic 
techniques, previously unrecognized causative agents of phaeohyphomycosis have been discovered. 
Here we report the first case of phaeohyphomycosis caused by Phaeoacremonium fuscum in an 
immunocompetent patient. 
Methods: Case presentation A 60 year old Filipino male presented with rotator cuff pathology to the 
orthopedics consultation. On physical examination a painless, soft, subcutaneous mass above the 
right patella was noted, which didn’t cause the patient any complaints. The suprapatellar nodule had 
been growing slowly for 3 years. The patient denied any apparent antecedent trauma, arthropod bite, 
family history or contact with a person with similar lesions. The man still visits the Philippines on an 
infrequent basis. He had no fever, weight loss or other symptoms. Detailed physical examination 
further revealed a 4x3 cm, immobile, non-pulsatile light red mass. There were no other signs of 
inflammation of the skin. A serous effusion was aspirated from the mass. 
Results: Fungal culture of the aspirated fluid showed growth of a filamentous fungus on chocolate 
blood agar and Sabouraud's dextrose agar. Molecular identification was performed by sequence 
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analysis of the internal transcribed spacer region 2 (ITS2). BLAST search revealed a similarity of 100% 
with Phaeoacremonium fuscum.  The antifungal susceptibility profile was established by EUCAST 
broth microdilution: itraconazole >16 mg/L, posaconazole 0.25 mg/L, amphotericin B 0.50 mg/L, 
voriconazole 0.50 mg/L. This susceptibility profile is similar to those previously published. A wide 
local excision of the lesion was performed a couple of weeks later. The patient had an uneventful 
postoperative recovery. No antifungal therapy was started postoperatively since the patient was not 
immunocompromised and there was lack of reimbursement. Histopathological examination of the 
specimen showed fibrous tissue with a mixed cellular infiltrate including lymphocytes, plasma cells, 
macrophages and neutrophils. Periodic acid-schiff stain and Grocott stain showed evidence of 
branching septate hyphae. 
Conclusion: PHM is caused by brown pigmented fungi containing melanin in their cell wall. 
Phaeoacremonium species are known as vascular plant pathogens, responsible for wilting and 
dieback of woody plants. They are also opportunistic pathogens in humans, mainly causing 
cutaneous or subcutaneous PHM. However, sporadic cases of respiratory tract infection, septic 
arthritis and disseminated infection are described. The true prevalence of Phaeoacremonium species 
is probably underestimated due to the asymptomatic nature of most subcutaneous lesions and the 
difficult identification. There is no standard antifungal regimen or evidence regarding the necessity 
for antifungal treatment as concomitant with surgery for localized infections. Long courses of 
antifungals, such as voriconazole treatment, are often employed to reduce the risk of recurrence. Case 
reports suggest that surgery can be curative if the infection is localized and adequately removed, as 
was the case in our patient. Regardless of the immune status of the patient, clinicians should consider 
the possibility of a fungal infection when they encounter chronic subcutaneous nodules without 
major symptoms. 
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Trichosporon diagnosis- The Right path 
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1Microbiology, Sri Ramachandra Medical College and Research Institute, SRIHER, Chennai, India, 
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Objectives: To discuss about the correct path in identifying Trichosporon sp. To emphasize the 
importance of performing conventional laboratory diagnostic methods like microscopy, along with 
molecular methods in the diagnosis of Trichosporon sp. 
Methods: Yeast-like colonies were observed for microscopic characteristics by Gram staining. The 
isolates which showed the presence of budding yeast cells, pseudohyphae and arthroconidia were 
tested for production of the enzyme urease. Urease positive test isolates were provisionally identified 
as belonging to the genus Trichosporon. To confirm the identity of all phenotypically identified 
Trichosporon isolates, Trichosporon genus specific colony PCR was performed. This pair of primer is 
Trichosporon specific and it amplified part of the nucleotide sequences of the rDNA small subunit 
(18S). 
Results: The study of colony morphology of the Trichosporon isolates on SDA at 25oC after 10 days of 
incubation revealed varied colony morphology. Most commonly, they may appear as white to cream, 
farinose or cerebriform colonies, with furrows. The important characteristic feature of this yeast is 
the production of arthroconidia and enzyme urease. Performing Gram stain or Dalmau technique to 
search for arthroconidia is a very useful tool for screening of Trichosporon spp. Finally, the accurate 
identification of this yeast was done using DNA based methods like Trichosporon genus specific 
colony PCR. The members of the genus Trichosporon produced DNA bands of approximately 170 bp. 
Conclusion: Trichosporon sp. has been so far reported as the second most common cause of 
disseminated yeast infections in humans, next to the genus Candida. They are emerging opportunistic 
pathogens causing disseminated infections in immunocompromised patients. Such infections are 
usually difficult to diagnose, do not respond to treatment with routinely used antifungal agents, and 
are associated with high mortality rates. Hence, correct identification of Trichosporon sp. helps the 
clinician in providing appropriate treatment. This also applies for other emerging yeast infections, 
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where combination of conventional and molecular methods may help in timely and accurate 
diagnosis. 
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Disseminated rhinosporidiosis with different morphological lesions involving various 
anatomical sites. 
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Objectives: Rhinosporidiosis is a chronic granulomatous disease caused by Rhinosporidium seeberi, 
which is a taxonomically debated endosporulating aquatic eukaryotic organism since long. 
Rhinosporidiosis predominantly involves the mucous membranes of the nose and eyes mainly 
conjunctiva. In recent past, giant lesions and disseminated type of disease, has also been reported in 
some of the clinical settings. This disease is hyperendemic in the Indian subcontinent, particularly in 
Sri Lanka and southern India. However, sporadic cases have occasionally been reported from other 
continents. 
Methods: A case report of rare disseminated rhinosporidiosis with varied morphological lesions 
involving simultaneously three anatomical sites i.e. nasal, cutaneous and bones in a hepatitis B virus 
surface antigen (HBsAg) positive patient. A 35-years old male, resident of district Madhubani, Bihar, 
fisherman by occupation presented with complaints of left sided nasal obstruction, insidious in onset, 
gradually progressive and associated with change in voice since the last 6 years. Also, there was 
slowly progressive swelling over medial aspect of left ankle for the last 1 year and a similar looking 
swelling, smaller in size also appeared in the left post-auricular region four months back and has 
gradually increased in size.On examination, a polypoidal fungating mass was present over left 
medial aspect of foot which was non-tender, highly vascular, large, hemi-spherical in shape and bled 
on touch. On anterior rhinoscopy, a warty, irregular, non-tender mass, not bleeding on touch, 
occupying whole of left nasal cavity was seen. Oral cavity showed bulging soft palate and a bilobed 
pale polypoidal mass with smooth surface hanging from nasopharynx to oropharynx. There was a 
solitary ovoid growth measuring 2 x 2 cm with normal appearing overlying skin in the left upper 
post-auricular region. Serum of the patient on testing for HBsAg was positive. The patient was known 
chronic alcoholic and smoker. 
Results: A wedge biopsy of the lesion when examined in normal saline showed sporangia of 
R.seeberiin different stages of development. Routine haematoxylin and eosin (H & E) staining, 
periodic acid-Schiff (PAS) staining as well as mucicarmine staining of the tissue also revealed 
findings of rhinosporidiosis with many sporangia and scattered endospores seen in a background of 
inflammatory infiltrate composed of polymorphs, lymphocytes and plasma cells including the bony 
involvement. A final diagnosis of disseminated rhinosporidiosis presenting simultaneously with 
three different kinds of lesions; nasal, cutaneous and osteomyelitis of medial malleolus and distal end 
of tibia was made. The patient was treated surgically by performing below knee amputation; 
transnasal and transoral excision with electrocoagulation as well as excision of postauricular mass 
was also performed. Histopathology of the excised bone and other growths was consistent with the 
preoperative diagnosis. The patient was discharged and advised dapsone therapy 100 mg bd to 
prevent recurrence. Presently, the patient is on follow up and there is no recurrence of the disease. 
Conclusion: This is prudent for clinicians, microbiologists and pathologists to keep rhinosporidiosis 
as a differential diagnosis when managing patients with polypoidal growths even in non-endemic 
areas. In such a background high index of suspecion is the key to reach the final diagnosis. 
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